Institute of Cancer Researchhttps://www.icr.ac.uk/The Institute of Cancer Research is one of the world’s leading cancer research organisations and cancer charities. In partnership with The Royal Marsden NHS Foundation Trust, The ICR specialises in cancer diagnosis, cancer treatment and cancer educationCopyright 2024 ICR. All rights reserved.Tue, 19 Mar 2024 05:17:19 Zhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-ve-been-given-a-second-chance-mark-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-ve-been-given-a-second-chance-mark-s-story“I’ve been given a second chance” – Mark’s storyMark was diagnosed with kidney cancer in April 2021. After surgery to remove the tumour and affected kidney, he was initially told there was no evidence that the disease had spread. However, a biopsy of the tumour showed it was an aggressive type of cancer, prone to returning. https://www.icr.ac.uk/news-archive%2fnew-technique-opens-up-study-of-immune-response-to-cancer-by-releasing-precious-material-locked-in-old-archive-cancer-sampleshttps://www.icr.ac.uk/news-archive%2fnew-technique-opens-up-study-of-immune-response-to-cancer-by-releasing-precious-material-locked-in-old-archive-cancer-samplesNew technique opens up study of immune response to cancer by releasing precious material locked in old archive cancer samplesScientists have developed an improved technique for reading the genetic material associated with the body’s immune response to cancer, making it possible to study tissue samples that have been stored in archives for decades. https://www.icr.ac.uk/news-archive%2ficr-scientists-seek-new-drugs-to-treat-childhood-cancer-as-part-of-global-cancer-grand-challenges-teamhttps://www.icr.ac.uk/news-archive%2ficr-scientists-seek-new-drugs-to-treat-childhood-cancer-as-part-of-global-cancer-grand-challenges-teamICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges teamA global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the challenge of solid tumours in children.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-had-come-to-realise-that-my-research-could-contribute-meaningfully-to-improvements-in-patient-outcomes-developing-tests-that-could-change-clinical-practice-to-personalise-breast-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-had-come-to-realise-that-my-research-could-contribute-meaningfully-to-improvements-in-patient-outcomes-developing-tests-that-could-change-clinical-practice-to-personalise-breast-cancer-treatment“I had come to realise that my research could contribute meaningfully to improvements in patient outcomes” – developing tests that could change clinical practice to personalise breast cancer treatmentPersonalised medicine is increasingly allowing us to provide individuals with the treatments most likely to be effective for them. In some cases, it might even spare people from unnecessary treatment. Isy Godfrey spoke with Dr Maggie Cheang, co-inventor of the Prosigna® Breast Cancer Prognostic Gene Signature Assay, to find out more.https://www.icr.ac.uk/news-archive%2fartificial-intelligence-reveals-prostate-cancer-is-not-just-one-diseasehttps://www.icr.ac.uk/news-archive%2fartificial-intelligence-reveals-prostate-cancer-is-not-just-one-diseaseArtificial Intelligence reveals prostate cancer is not just one diseaseArtificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer which could revolutionise how the disease is diagnosed and treated in the future.https://www.icr.ac.uk/news-archive%2ftargeted-immunotherapy-could-lead-to-pioneering-treatment-for-breast-cancerhttps://www.icr.ac.uk/news-archive%2ftargeted-immunotherapy-could-lead-to-pioneering-treatment-for-breast-cancerTargeted immunotherapy could lead to pioneering treatment for breast cancerA new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumours, according to new research from the ICR.https://www.icr.ac.uk/news-archive%2fnew-drug-could-unlock-benefits-of-immunotherapy-for-more-patientshttps://www.icr.ac.uk/news-archive%2fnew-drug-could-unlock-benefits-of-immunotherapy-for-more-patientsNew drug could unlock benefits of immunotherapy for more patientsA new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-really-save-the-lives-of-children-with-brain-cancer-we-need-to-minimise-morbidityhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-really-save-the-lives-of-children-with-brain-cancer-we-need-to-minimise-morbidityTo really save the lives of children with brain cancer, we need to minimise morbidityA recent review paper led by scientists at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research looks at how the treatment of paediatric brain tumours is evolving to prioritise children’s quality of life. Isy Godfrey spoke with corresponding author Dr Lynley Marshall to find out more.https://www.icr.ac.uk/news-archive%2fher-majesty-the-queen-presents-cancer-researchers-with-prize-at-buckingham-palacehttps://www.icr.ac.uk/news-archive%2fher-majesty-the-queen-presents-cancer-researchers-with-prize-at-buckingham-palaceHer Majesty The Queen presents cancer researchers with prize at Buckingham PalaceEarlier today, researchers from The Institute of Cancer Research, London, received a prestigious Queen’s Anniversary Prize on behalf of the institute, in recognition of its transformational breast cancer research programme. https://www.icr.ac.uk/news-archive%2f%27olive-oil%27-drug-shows-early-promise-for-some-brain-cancer-patientshttps://www.icr.ac.uk/news-archive%2f%27olive-oil%27-drug-shows-early-promise-for-some-brain-cancer-patients'Olive oil' drug shows early promise for some brain cancer patientsA unique drug derived from oleic acid – which naturally occurs in animal and vegetable fats such as olive oil – has shown promise for patients with an advanced form of the most common type of brain cancer, following a study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. https://www.icr.ac.uk/news-archive%2fresearchers-develop-new-approaches-to-live-track-the-production-of-different-types-of-blood-cells-in-micehttps://www.icr.ac.uk/news-archive%2fresearchers-develop-new-approaches-to-live-track-the-production-of-different-types-of-blood-cells-in-miceResearchers develop new approaches to live-track the production of different types of blood cells in mice Scientists have found a way to monitor in real time how bone marrow stem cells produce the different types of cells in the blood – a process called haematopoiesis. https://www.icr.ac.uk/news-archive%2fnew-study-opens-the-door-to-learning-more-about-an-important-driver-of-breast-cancerhttps://www.icr.ac.uk/news-archive%2fnew-study-opens-the-door-to-learning-more-about-an-important-driver-of-breast-cancerNew study opens the door to learning more about an important driver of breast cancerThrough innovative exploratory work, scientists have identified a new way to study proteins that are involved in the development of the majority of breast cancers. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-better-home-for-our-microbes-the-relationship-between-the-microbiome-and-disease-including-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-better-home-for-our-microbes-the-relationship-between-the-microbiome-and-disease-including-cancerMaking a better home for our microbes – the relationship between the microbiome and disease, including cancerTo celebrate Darwin Day, The Institute of Cancer Research, London, invited Professor Martin Blaser to deliver its annual Darwin Lecture on the importance of microbes in a healthy life for humans. Professor Blaser took time to chat with the ICR’s Mark Jones ahead of the lecture.https://www.icr.ac.uk/news-archive%2fnew-ai-collaboration-could-advance-precision-therapy-in-breast-cancerhttps://www.icr.ac.uk/news-archive%2fnew-ai-collaboration-could-advance-precision-therapy-in-breast-cancerNew AI collaboration could advance precision therapy in breast cancerA new collaboration between academic and industry researchers could help to improve clinical decision making for cancer patients – including by potentially guiding the use of immunotherapy to breast cancer patients who could benefit from it.https://www.icr.ac.uk/news-archive%2fscientists-discover-how-some-advanced-breast-cancers-become-resistant-to-hormone-therapyhttps://www.icr.ac.uk/news-archive%2fscientists-discover-how-some-advanced-breast-cancers-become-resistant-to-hormone-therapyScientists discover how some advanced breast cancers become resistant to hormone therapy New research has identified why some advanced oestrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and has identified drugs currently in development that could keep disease stable for longer for these patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-end-of-life-to-full-of-life-how-research-is-helping-people-live-with-cancer-and-hopehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-end-of-life-to-full-of-life-how-research-is-helping-people-live-with-cancer-and-hopeFrom end of life to full of life – how research is helping people live with cancer and hopeCancer research is driving progress in treatment that means more and more people are living well for longer after a diagnosis of advanced cancer. Sarah Lothian spoke to five people who are each responding well to treatment and are now looking to the future, after receiving a devastating diagnosis.https://www.icr.ac.uk/news-archive%2ficr-welcomes-appointment-of-aviva-and-socius-for-new-life-sciences-development-at-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-appointment-of-aviva-and-socius-for-new-life-sciences-development-at-the-london-cancer-hubICR welcomes appointment of Aviva and Socius for new life-sciences development at The London Cancer HubThe Institute of Cancer Research has welcomed the appointment of a new partnership to deliver a major redevelopment project at The London Cancer Hub in Sutton.https://www.icr.ac.uk/news-archive%2ficr-welcomes-recommendation-of-talazoparib-for-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-recommendation-of-talazoparib-for-advanced-breast-cancerICR welcomes recommendation of talazoparib for advanced breast cancerThe Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer.https://www.icr.ac.uk/news-archive%2fwe-must-not-rush-to-implement-new-genetic-screening-programmes-experts-warnhttps://www.icr.ac.uk/news-archive%2fwe-must-not-rush-to-implement-new-genetic-screening-programmes-experts-warnWe must not rush to implement new genetic screening programmes, experts warnThere is a danger that population genetic screening programmes may be introduced without the necessary scrutiny and rigour that is usually applied when screening programmes are put into effect, experts have warned.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-exercise-reduce-cancer-risk-and-support-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-exercise-reduce-cancer-risk-and-support-treatmentCan exercise reduce cancer risk and support treatment?There are many benefits to exercise, including reducing a person’s risk of cancer. Being physically active can also be helpful for many people during and after cancer treatment. Laura-Maria Horga explores some of the links between exercise and cancer by talking to patients, oncologists and researchers at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fscientists-now-able-to-predict-response-to-radium-223-treatment-in-prostate-cancer-bone-metastaseshttps://www.icr.ac.uk/news-archive%2fscientists-now-able-to-predict-response-to-radium-223-treatment-in-prostate-cancer-bone-metastasesScientists now able to predict response to radium-223 treatment in prostate cancer bone metastasesResearchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones.https://www.icr.ac.uk/news-archive%2fprofessor-clare-isacke-wins-prestigious-award-for-women-in-sciencehttps://www.icr.ac.uk/news-archive%2fprofessor-clare-isacke-wins-prestigious-award-for-women-in-scienceProfessor Clare Isacke wins prestigious award for women in scienceProfessor Clare Isacke has been awarded the biennial Women in Science Achievement Award by the Metastasis Research Society (MRS). https://www.icr.ac.uk/news-archive%2fnew-understanding-of-devastating-type-of-breast-cancer-spread-could-lead-to-better-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-understanding-of-devastating-type-of-breast-cancer-spread-could-lead-to-better-treatmentsNew understanding of devastating type of breast cancer spread could lead to better treatmentsA new study has increased the understanding of an increasingly common complication of advanced breast cancer.https://www.icr.ac.uk/news-archive%2fphysical-activity-reduces-a-womans-risk-of-developing-breast-cancer-before-menopausehttps://www.icr.ac.uk/news-archive%2fphysical-activity-reduces-a-womans-risk-of-developing-breast-cancer-before-menopauseLargest study of its kind suggests physical activity reduces a woman’s risk of developing breast cancer before menopauseRegular leisure time physical activity may reduce the risk of breast cancer for women before menopause, according to new research funded by Breast Cancer Now.https://www.icr.ac.uk/news-archive%2fstar-studded-carols-from-chelsea-kicks-off-christmas-season-in-stylehttps://www.icr.ac.uk/news-archive%2fstar-studded-carols-from-chelsea-kicks-off-christmas-season-in-styleStar-studded Carols from Chelsea kicks off Christmas season in styleFamous faces and guests packed the stunning Wren Chapel at the Royal Hospital Chelsea, for the 21st year of Carols from Chelsea, in support of our world-leading research. https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2023https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2023Scientific achievements of 2023We've selected a range of discoveries from the academic year that highlight the quality and breadth of our basic, translational and clinical research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-survived-cancer-as-a-child-and-now-i-m-working-to-defeat-it-andrew-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-survived-cancer-as-a-child-and-now-i-m-working-to-defeat-it-andrew-s-story“I survived cancer as a child and now I’m working to defeat it” – Andrew’s storyAndrew Wicks, a PhD student at The Institute of Cancer Research, knows firsthand what it’s like to face cancer. Diagnosed with acute lymphoblastic leukaemia (ALL) at the age of 12, he went through years of treatment before getting the all-clear. Now, wanting to help others with cancer, he is carrying out research in our Breast Cancer Research Division. Here, he shares his story.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-the-principles-of-evolution-to-defeat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-the-principles-of-evolution-to-defeat-cancerUsing the principles of evolution to defeat cancerThis Evolution Day, we look at how scientists in the Centre for Evolution and Cancer at The Institute of Cancer Research, London, are applying the principles of evolution to their research. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-need-to-stop-other-children-from-having-to-go-through-this---tommy-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-need-to-stop-other-children-from-having-to-go-through-this---tommy-s-story“We need to stop other children from having to go through this” - Tommy’s story Tommy Edwards was just four years old when his parents noticed symptoms suggesting something wasn’t right. Tests revealed he had acute lymphoblastic leukaemia (ALL). Following nearly three years of treatment, Tommy is now looking towards the future. His parents, Chris and Jo Edwards, have set up a charity to fund research into ALL. In this blog, Chris explains how groundbreaking work by scientists at The Institute of Cancer Research is giving them hope for the future. https://www.icr.ac.uk/news-archive%2ftrial-results-support-new-gold-standard-for-head-and-neck-cancer-radiotherapyhttps://www.icr.ac.uk/news-archive%2ftrial-results-support-new-gold-standard-for-head-and-neck-cancer-radiotherapyTrial results support ‘new gold standard’ for head and neck cancer radiotherapyPhase 3 trial results on a precision radiotherapy technique support a ‘new gold standard’ for treating head and neck cancer patients. The research suggests the new approach can reduce the risk of swallowing problems after radiotherapy, without impacting the success of treatment. https://www.icr.ac.uk/news-archive%2fmajor-collaborative-childhood-cancer-research-programme-launched-with-5.5-million-children-with-cancer-uk-and-cancer-research-uk-fundinghttps://www.icr.ac.uk/news-archive%2fmajor-collaborative-childhood-cancer-research-programme-launched-with-5.5-million-children-with-cancer-uk-and-cancer-research-uk-fundingMajor collaborative childhood cancer research programme launched with £5.5 million funding from Children with Cancer UK and Cancer Research UKLeading charities Children with Cancer UK and Cancer Research UK come together to co-fund a second cancer research programme aiming to help treat relapsed childhood cancers through precision medicine. The SMPaeds2 project will be led by Professor Louis Chesler at The Institute of Cancer Research, London.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffda-approval-for-capivasertib-and-our-new-collaboration-opportunities-for-industry-partnershttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffda-approval-for-capivasertib-and-our-new-collaboration-opportunities-for-industry-partnersFDA approval for capivasertib: and our new collaboration opportunities for industry partnersThe US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib, now given the brand name Truqap, as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib?https://www.icr.ac.uk/news-archive%2ficr-welcomes-fda-approval-of-first-in-class-breast-cancer-drughttps://www.icr.ac.uk/news-archive%2ficr-welcomes-fda-approval-of-first-in-class-breast-cancer-drugICR welcomes FDA approval of first-in-class breast cancer drugThe ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals.https://www.icr.ac.uk/news-archive%2ficr-awarded-prestigious-prize-for-transformational-breast-cancer-researchhttps://www.icr.ac.uk/news-archive%2ficr-awarded-prestigious-prize-for-transformational-breast-cancer-researchICR awarded prestigious prize for transformational breast cancer researchThe Institute of Cancer Research, London, has been granted the highest national honour in UK further and higher education for its innovative work on breast cancer - a Queen's Anniversary Prizehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmy-experience-has-highlighted-to-me-just-how-vital-cancer-research-is---erin-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmy-experience-has-highlighted-to-me-just-how-vital-cancer-research-is---erin-s-story“My experience has highlighted to me just how vital cancer research is” - Erin’s storyErin Kennedy MBE is a British Paralympic coxswain. In 2022, at the age of 29, she was diagnosed with triple negative breast cancer, and was successfully treated. She later found she has a mutation in her BRCA1 gene which means she has a higher risk of her cancer returning. In the summer of 2023, she supported our Finish Cancer campaign. Here she tells her story.https://www.icr.ac.uk/news-archive%2fresearch-uncovers-genetic-clues-to-high-rates-of-prostate-cancer-in-men-with-african-ancestry-improving-risk-predictionhttps://www.icr.ac.uk/news-archive%2fresearch-uncovers-genetic-clues-to-high-rates-of-prostate-cancer-in-men-with-african-ancestry-improving-risk-predictionResearch uncovers genetic clues to high rates of prostate cancer in men with African ancestry – improving risk predictionMore equitable testing for prostate cancer risk is on the horizon, as researchers report findings from the largest and most genetically diverse study of prostate cancer genes ever conducted.https://www.icr.ac.uk/news-archive%2fai-twice-as-accurate-as-a-biopsy-at-grading-aggressiveness-of-some-sarcomashttps://www.icr.ac.uk/news-archive%2fai-twice-as-accurate-as-a-biopsy-at-grading-aggressiveness-of-some-sarcomasAI twice as accurate as a biopsy at grading aggressiveness of some sarcomasArtificial intelligence (AI) could be around twice as accurate as a biopsy at grading the aggressiveness of some sarcomas, according to new research from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fharnessing-the-power-of-ai-to-improve-outcomes-for-people-with-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fharnessing-the-power-of-ai-to-improve-outcomes-for-people-with-breast-cancerHarnessing the power of AI to improve outcomes for people with breast cancerScientists at the ICR are investigating how AI can help us improve the lives of people with breast cancer. Here, we learn about the work of Dr Stephen-John Sammut and other researchers who are focusing on this technology.https://www.icr.ac.uk/news-archive%2fhigh-performance-computing-facilitates-new-radiotherapy-approach-that-could-improve-therapy-for-hard-to-treat-cancershttps://www.icr.ac.uk/news-archive%2fhigh-performance-computing-facilitates-new-radiotherapy-approach-that-could-improve-therapy-for-hard-to-treat-cancersHigh-performance computing facilitates new radiotherapy approach that could improve therapy for hard-to-treat cancersResearchers have used methods from high-performance computing to significantly reduce the time it takes to reconstruct images acquired through four-dimensional magnetic resonance imaging (4D-MRI).https://www.icr.ac.uk/news-archive%2ficr-amongst-top-uk-universities-for-industry-and-academic-partnerships-and-public-engagementhttps://www.icr.ac.uk/news-archive%2ficr-amongst-top-uk-universities-for-industry-and-academic-partnerships-and-public-engagementICR amongst top UK universities for industry and academic partnerships and public engagementThe ICR has ranked as one of the UK's best higher education institutions at engaging with industry, academic partners and the wider public, in the Government's latest Knowledge Exchange Framework (KEF).https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-can-t-defeat-cancer-without-acknowledging-the-differences-between-men-and-womenhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-can-t-defeat-cancer-without-acknowledging-the-differences-between-men-and-womenWe can’t defeat cancer without acknowledging the differences between men and womenIsy Godfrey looks at why sex disparities persist in cancer and speaks with Dr Anna Wilkins about her work highlighting the sex gap in bladder cancer survival.https://www.icr.ac.uk/news-archive%2fnew-clinical-trial-guidelines-set-to-increase-transparency-and-support-progress-in-developing-new-therapieshttps://www.icr.ac.uk/news-archive%2fnew-clinical-trial-guidelines-set-to-increase-transparency-and-support-progress-in-developing-new-therapiesNew clinical trial guidelines set to increase transparency and support progress in developing new therapiesNew guidelines have been developed to help researchers ensure that their clinical trial protocols and reports are complete, high-quality and transparent.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fesmo-2023-using-blood-tests-to-help-treat-breast-cancer-more-precisely-professor-nick-turner-on-his-award-winning-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fesmo-2023-using-blood-tests-to-help-treat-breast-cancer-more-precisely-professor-nick-turner-on-his-award-winning-researchESMO 2023: Using blood tests to help treat breast cancer more precisely – Professor Nick Turner on his award-winning researchProfessor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, has received the Translational Research Award by the European Society for Medical Oncology (ESMO). Laura-Maria Horga spoke with him about the remarkable impact he has had in cancer research throughout his career so far.https://www.icr.ac.uk/news-archive%2fscientists-reverse-drug-resistance-in-prostate-cancer-by-targeting-%27hijacked%27-white-blood-cellshttps://www.icr.ac.uk/news-archive%2fscientists-reverse-drug-resistance-in-prostate-cancer-by-targeting-%27hijacked%27-white-blood-cellsScientists reverse drug resistance in prostate cancer by targeting 'hijacked' white blood cellsProstate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature. https://www.icr.ac.uk/news-archive%2ficr-one-of-founding-institutions-of-new-childhood-cancer-non-profit-companyhttps://www.icr.ac.uk/news-archive%2ficr-one-of-founding-institutions-of-new-childhood-cancer-non-profit-companyICR one of founding institutions of new childhood cancer non-profit companyThe Institute of Cancer Research is one of the founding members of a new not-for-profit company that will enable scientists across the world to test cancer drugs in cell and animal models of childhood cancers.https://www.icr.ac.uk/news-archive%2fscientists-uncover-key-mechanism-linking-dna-replication-to-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-uncover-key-mechanism-linking-dna-replication-to-cancerScientists uncover key mechanism linking DNA replication to cancer Researchers have gained a clearer insight into how common alterations to the structure of DNA affect the process of DNA replication. https://www.icr.ac.uk/news-archive%2fimmunotherapy-shows-promise-as-a-kinder-first-line-treatment-for-advanced-head-and-neck-cancershttps://www.icr.ac.uk/news-archive%2fimmunotherapy-shows-promise-as-a-kinder-first-line-treatment-for-advanced-head-and-neck-cancersImmunotherapy shows promise as a kinder first-line treatment for advanced head and neck cancersImmunotherapy can extend the response of some head and neck tumours to treatment, maintaining the anti-tumour effects and preventing them from growing or spreading for longer, a study reports.https://www.icr.ac.uk/news-archive%2fstage-set-for-major-new-life-sciences-redevelopment-at-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fstage-set-for-major-new-life-sciences-redevelopment-at-the-london-cancer-hubStage set for major new life-sciences redevelopment at The London Cancer HubThe ICR has welcomed the news that insurer Aviva and developer Socius have been announced as the preferred bidder for a major life-sciences redevelopment project at The London Cancer Hub in Sutton.https://www.icr.ac.uk/news-archive%2fscientists-identify-11-new-genes-linked-to-aggressive-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-11-new-genes-linked-to-aggressive-prostate-cancerScientists identify 11 new genes linked to aggressive prostate cancer​Researchers have identified 11 new gene alterations that are linked to more aggressive prostate cancer which can be picked up with a simple blood test.https://www.icr.ac.uk/news-archive%2fnew-medtech-firm-expands-liquid-biopsy-research-at-the-london-cancer-hub-s-innovation-gatewayhttps://www.icr.ac.uk/news-archive%2fnew-medtech-firm-expands-liquid-biopsy-research-at-the-london-cancer-hub-s-innovation-gatewayNew MedTech firm expands liquid biopsy research at The London Cancer Hub’s Innovation GatewayVortex Biosciences is expanding its footprint at The London Cancer Hub’s Innovation Gateway in support of its next phase of growth, having opened a new laboratory there earlier this year.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-changing-approach-to-rare-cancers-is-driving-progress-but-we-still-have-further-to-gohttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-changing-approach-to-rare-cancers-is-driving-progress-but-we-still-have-further-to-goOur changing approach to rare cancers is driving progress, but we still have further to goTo mark Rare Cancer Day, Isy Godfrey looks at how we are making progress in this field and speaks with paediatric brain tumour expert Professor Chris Jones about his experiences.https://www.icr.ac.uk/news-archive%2fhigher-doses-of-radiotherapy-cut-treatment-time-by-up-to-75-per-cent-in-localised-prostate-cancer-patients-while-maintaining-high-cure-rateshttps://www.icr.ac.uk/news-archive%2fhigher-doses-of-radiotherapy-cut-treatment-time-by-up-to-75-per-cent-in-localised-prostate-cancer-patients-while-maintaining-high-cure-ratesHigher doses of radiotherapy cut treatment time by up to 75 per cent in localised prostate cancer patients, while maintaining high cure ratesPeople with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-role-of-advocacy-is-extremely-important-improving-treatment-for-the-childhood-cancer-neuroblastomahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-role-of-advocacy-is-extremely-important-improving-treatment-for-the-childhood-cancer-neuroblastoma‘The role of advocacy is extremely important’ – improving treatment for the childhood cancer neuroblastomaMuch of our cutting-edge work is only possible because of the help we receive from our supporters, including our wonderful family charity partners. Dr Sally George, who leads our Developmental Oncology group at the ICR, explains why these partnerships are so important.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-re-all-working-towards-a-future-where-children-don-t-die-from-cancer.-hannah%27s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-re-all-working-towards-a-future-where-children-don-t-die-from-cancer.-hannah%27s-story“We’re all working towards a future where children don’t die from cancer” – Hannah's storyHannah Tarplee was four years old when her parents noticed a lump in her tummy which turned out to be a cancerous tumour. Despite intensive treatment, it became untreatable, and Hannah died just seven months after the lump was discovered. The Little Princess Trust, which was set up in her memory, funds our research, as one of our valued family charity partners. Her mum, Wendy Tarplee-Morris, explains how Hannah’s legacy is now giving hair and hope to thousands of children and young people.https://www.icr.ac.uk/news-archive%2ficr-and-merck-renew-strategic-alliance-in-discovery-and-development-of-innovative-new-small-molecule-cancer-drugshttps://www.icr.ac.uk/news-archive%2ficr-and-merck-renew-strategic-alliance-in-discovery-and-development-of-innovative-new-small-molecule-cancer-drugsICR and Merck renew strategic alliance in discovery and development of innovative new small-molecule cancer drugsThe Institute of Cancer Research, London, and science and technology company Merck have renewed their strategic alliance in the discovery and development of new cancer drugs.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fresearch-is-what-s-going-to-save-these-children-siobhan-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fresearch-is-what-s-going-to-save-these-children-siobhan-s-story“Research is what’s going to save these children” – Siobhan’s story Siobhan Mather was two years old when she became lethargic and didn’t want to eat. Tests revealed she had a tumour above her adrenal gland - it was neuroblastoma. With treatment, Siobhan went into remission and her family and friends raised money to fund a trial abroad. Sadly, the cancer returned, and Siobhan was unable to travel. She passed away in June 2019 when she was four years old. Her parents, Sarah and Antony Mather, explain how they’re using the funds raised to support our research as one of our valued family charity partners.https://www.icr.ac.uk/news-archive%2ficr-strategic-commercial-partner-raises-USD226.5m-in-financinghttps://www.icr.ac.uk/news-archive%2ficr-strategic-commercial-partner-raises-USD226.5m-in-financingICR strategic commercial partner raises $226.5m in financingApollo Therapeutics, a strategic partner of The Institute of Cancer Research, has raised more than $226m from investors to fund its ongoing collaboration with the ICR and other academic partners.https://www.icr.ac.uk/news-archive%2fnew-test-helps-drug-discoverers-identify-future-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-test-helps-drug-discoverers-identify-future-cancer-treatmentsNew test helps drug discoverers identify future cancer treatmentsResearchers have developed an investigative procedure that makes the early stages of drug discovery more efficient. https://www.icr.ac.uk/news-archive%2fsearch-and-destroy-treatment-improves-quality-of-life-for-patients-with-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fsearch-and-destroy-treatment-improves-quality-of-life-for-patients-with-advanced-prostate-cancer ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancerA new radioactive medicine that seeks out tumour cells to deliver a targeted dose of radiation greatly improves quality of life for patients with advanced prostate cancer, a phase III study finds.https://www.icr.ac.uk/news-archive%2fscan-could-guide-use-of-drugs-targeting-tumours-scaffold-to-improve-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fscan-could-guide-use-of-drugs-targeting-tumours-scaffold-to-improve-breast-cancer-treatmentScan could guide use of drugs targeting tumours’ ‘scaffold’ to improve breast cancer treatmentResearchers have found a way to use a simple, non-invasive scan to tell whether an experimental approach to enhance treatment for breast cancer is effective.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-a-game-changer-glenys-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-a-game-changer-glenys-story“Immunotherapy is a game-changer” – Glenys’ story Glenys Gregory recently became a grandmother, but at one point, she’d wondered if she would live to see him born. In January 2020, Glenys was diagnosed with advanced lung cancer after nursing her mother through the same disease. Due to the coronavirus pandemic, she went straight onto immunotherapy and a scan in summer 2023 revealed that she had no evidence of disease. Here she tells her story. https://www.icr.ac.uk/news-archive%2fresearchers-gain-fascinating-new-insights-into-chromosome-shortening-and-identify-new-potential-cancer-drug-targetshttps://www.icr.ac.uk/news-archive%2fresearchers-gain-fascinating-new-insights-into-chromosome-shortening-and-identify-new-potential-cancer-drug-targetsResearchers gain fascinating new insights into chromosome shortening – and identify new potential cancer drug targetsA new study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat cancers – and in the process, uncovered fascinating new information about how cells divide and grow.https://www.icr.ac.uk/news-archive%2fnew-approach-to-screening-has-potential-to-extend-survival-in-glioblastoma-brain-cancerhttps://www.icr.ac.uk/news-archive%2fnew-approach-to-screening-has-potential-to-extend-survival-in-glioblastoma-brain-cancerNew approach to screening has potential to extend survival in glioblastoma brain cancerA new form of screening may improve survival rates among people with a fast-growing type of brain tumour by helping identify those most likely to benefit from certain treatments.https://www.icr.ac.uk/news-archive%2fprofiling-gene-messages-could-guide-chemotherapy-for-triple-negative-breast-cancerhttps://www.icr.ac.uk/news-archive%2fprofiling-gene-messages-could-guide-chemotherapy-for-triple-negative-breast-cancer Profiling gene messages could guide chemotherapy for triple negative breast cancerA new study sheds light on the genetic messages encoded by genes within ‘triple negative’ breast cancers – and poses important questions on how they could be better treated in future.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-researchers-are-shining-a-spotlight-on-rnahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-researchers-are-shining-a-spotlight-on-rnaCancer researchers are shining a spotlight on RNATo mark World RNA Day, Isy Godfrey explores why cancer researchers are increasingly interested in RNA and considers the impact this essential molecule may have on the future cancer treatment landscape.https://www.icr.ac.uk/news-archive%2fexisting-cancer-drugs-have-potential-to-benefit-thousands-more-patientshttps://www.icr.ac.uk/news-archive%2fexisting-cancer-drugs-have-potential-to-benefit-thousands-more-patientsExisting cancer drugs have potential to benefit thousands more patientsExisting targeted cancer drugs could help even more patients, including some with the most common type of breast cancer, scientists have discovered. https://www.icr.ac.uk/news-archive%2fscientists-uncover-the-rosetta-stone-of-sarcoma-research-to-personalise-treatmenthttps://www.icr.ac.uk/news-archive%2fscientists-uncover-the-rosetta-stone-of-sarcoma-research-to-personalise-treatmentScientists uncover the ‘Rosetta stone’ of sarcoma research to personalise treatmentScientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers.https://www.icr.ac.uk/news-archive%2fsporting-champions-greg-rutherford-erin-kennedy-spearhead-race-to-finish-cancerhttps://www.icr.ac.uk/news-archive%2fsporting-champions-greg-rutherford-erin-kennedy-spearhead-race-to-finish-cancer Sporting champions spearhead race to finish cancerOlympic gold medallist Greg Rutherford MBE and Paralympic gold medallist Erin Kennedy MBE launch an inspirational run for the ICR across 100 miles of British coastline – which will see ‘FINISH CANCER’ imprinted 167,000 times in the sand.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-do-we-overcome-treatment-resistance-in-a-sarcoma-cancer-with-already-limited-treatment-optionshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-do-we-overcome-treatment-resistance-in-a-sarcoma-cancer-with-already-limited-treatment-optionsHow do we overcome treatment resistance in a sarcoma cancer with already limited treatment options?Leiomyosarcoma is a type of soft tissue sarcoma that is hard-to-treat and associated with a poor prognosis. Scientists at the ICR are working to better understand the biology of this cancer to develop more targeted and effective treatment options. Elena Daviter-Nowell spoke to Dr Will Kerrison about the future of cancer treatment for patients with leiomyosarcoma.https://www.icr.ac.uk/news-archive%2fprofessor-nicholas-turner-wins-prestigious-esmo-award-for-translational-researchhttps://www.icr.ac.uk/news-archive%2fprofessor-nicholas-turner-wins-prestigious-esmo-award-for-translational-researchProfessor Nicholas Turner wins prestigious ESMO Award for Translational ResearchProfessor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, where he is also Head of the Ralph Lauren Centre for Breast Cancer Research, has received the Translational Research Award by the European Society for Medical Oncology (ESMO).https://www.icr.ac.uk/news-archive%2fnew-ai-drug-discovery-collaboration-aims-to-design-new-precision-cancer-drugshttps://www.icr.ac.uk/news-archive%2fnew-ai-drug-discovery-collaboration-aims-to-design-new-precision-cancer-drugsNew AI drug discovery collaboration aims to design new precision cancer drugsResearchers are set to to combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-the-way-forward---camilla-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-the-way-forward---camilla-s-story“Immunotherapy is the way forward” - Camilla’s storyCamilla Keeling was a month away from celebrating her 61st birthday when she was diagnosed with skin cancer. After having it removed, she thought she was in the clear but not long after, she found out it had spread to her lungs, and later, her brain and bowel. She is now receiving immunotherapy which has seen her tumours shrink and given her renewed hope. Here is her story.https://www.icr.ac.uk/news-archive%2fwe-dance-for-life-film-celebrating-cancer-research-wins-award-at-international-film-festivalhttps://www.icr.ac.uk/news-archive%2fwe-dance-for-life-film-celebrating-cancer-research-wins-award-at-international-film-festival'We Dance for Life' film celebrating cancer research wins award at international film festival'We Dance for Life', a creative film that celebrates scientists from The Institute of Cancer Research, London, and The London Cancer Hub, has won the Best Dance Experimental award at the Experimental, Dance & Music Film Festival in the USA and Canada. https://www.icr.ac.uk/news-archive%2fradiotherapy-boost-cuts-breast-cancer-treatment-time-by-at-least-one-weekhttps://www.icr.ac.uk/news-archive%2fradiotherapy-boost-cuts-breast-cancer-treatment-time-by-at-least-one-weekRadiotherapy boost cuts breast cancer treatment time by at least one weekTreatment times for radiotherapy could be reduced for some early breast cancer patients, according to the IMPORT HIGH trial.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fas-research-tools-improve-our-use-of-them-must-evolve-too-we-re-here-to-helphttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fas-research-tools-improve-our-use-of-them-must-evolve-too-we-re-here-to-helpAs research tools improve, our use of them must evolve too – we’re here to helpProfessor Paul Workman discusses the increased numbers of high-quality chemical tools available to study specific proteins in biomedical research, and what needs to be done to ensure they are used appropriately by biomedical researchers. Chemical probes, usually inhibitors, are getting better and better – and researchers using them need to catch up. https://www.icr.ac.uk/news-archive%2fanimal-kingdom-wide-ai-tool-could-help-unravel-cancer-complexityhttps://www.icr.ac.uk/news-archive%2fanimal-kingdom-wide-ai-tool-could-help-unravel-cancer-complexityAnimal kingdom-wide AI tool could help unravel cancer complexityAn international study led by ICR scientists has accurately categorised tumour and immune cells of non-human animal species by applying an artificial intelligence (AI) algorithm that was trained on human lung cancer samples.https://www.icr.ac.uk/news-archive%2fnext-generation-trial-shows-five-drug-combo-can-keep-ultra-high-risk-bone-marrow-cancer-at-bayhttps://www.icr.ac.uk/news-archive%2fnext-generation-trial-shows-five-drug-combo-can-keep-ultra-high-risk-bone-marrow-cancer-at-bayNext-generation trial shows five-drug combo can keep ‘ultra-high-risk’ bone marrow cancer at bayCombining five existing drugs can keep a highly aggressive type of bone marrow cancer at bay for longer, an innovative trial has shown.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-keeping-me-alive---john-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-keeping-me-alive---john-s-story“Immunotherapy is keeping me alive” - John’s story On his daughter’s second birthday in 2009, John Dabell was diagnosed with advanced head and neck cancer. He went through extensive surgery and treatment and was on the road to recovery when he was diagnosed with cancer again – this time, a tumour in his throat. John was told he didn’t have long to live. But then he started immunotherapy. Here, he talks about its incredible impact and the opportunity it’s given him to spend more time with his wife and daughter.https://www.icr.ac.uk/news-features%2flatest-features%2funtapping-the-full-potential-of-immunotherapies-for-more-people-with-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2funtapping-the-full-potential-of-immunotherapies-for-more-people-with-cancerUntapping the full potential of immunotherapies for more people with cancerImmunotherapy works by sparking the body’s own immune system into action against tumours. It has become a first-choice treatment for some types of cancer, and now there are exciting opportunities to unlock its benefits for more patients through research. Jane Shepley explores the story behind immunotherapy and how we can untap its potential.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchannelling-a-diagnosis-into-change-carols-from-chelsea-chair-reflects-as-she-stands-down-after-seven-yearshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchannelling-a-diagnosis-into-change-carols-from-chelsea-chair-reflects-as-she-stands-down-after-seven-yearsChannelling a diagnosis into change: Carols from Chelsea chair reflects as she stands down after seven yearsChristmas may feel far away, but plans are already underway for this year’s Carols from Chelsea. It’s the flagship fundraising event of the ICR’s calendar, raising almost £2 million for our life-changing research over the 20 years it’s been running. Diana MacKenzie-Charrington recently stepped down as chair of the committee behind the evening, and here she reflects on her experiences and motivations.https://www.icr.ac.uk/news-archive%2fnew-drug-combination-twice-as-effective-for-some-ovarian-cancer-patients-as-next-best-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-drug-combination-twice-as-effective-for-some-ovarian-cancer-patients-as-next-best-treatmentASCO 2023: New drug combination twice as effective for some ovarian cancer patients as next best treatmentA targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a phase II study.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finspiring-tomorrow%27s-leaders-an-education-strategy-for-a-changing-worldhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finspiring-tomorrow%27s-leaders-an-education-strategy-for-a-changing-worldInspiring tomorrow's leaders – an education strategy for a changing worldChief Research and Academic Officer, Dr Barbara Pittam, sets out how we will empower the next generation of cancer researchers by providing the best possible education, training and careers support.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2023-cancer-experts-gather-in-chicagohttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2023-cancer-experts-gather-in-chicagoASCO 2023: Cancer experts gather in ChicagoThis June world-leading cancer researchers from around the globe are getting ready to present and discuss the latest advances in the oncology at the 2023 ASCO Annual meeting in Chicago. Ahead of the meeting, we look at some of the ICR’s research being presented this year.https://www.icr.ac.uk/news-archive%2fdetailed-structure-of-understudied-cell-division-nanomachine-revealedhttps://www.icr.ac.uk/news-archive%2fdetailed-structure-of-understudied-cell-division-nanomachine-revealedDetailed structure of understudied cell division ‘nanomachine’ revealedResearchers have revealed, at high-resolution, the structure of a human protein complex named SIN3B, which is a ‘nanomachine’ involved in regulating cell division – a fundamental process for life which, if it becomes uncontrolled, can lead to cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-m-so-grateful-to-be-here---how-immunotherapy-sparked-graham-s-remarkable-recoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-m-so-grateful-to-be-here---how-immunotherapy-sparked-graham-s-remarkable-recovery“I’m so grateful to be here’’ - How immunotherapy sparked Graham’s remarkable recoveryGraham Bonner was in his early fifties when he went from cycling 100 miles a week to being dependant on oxygen. He'd been diagnosed with kidney cancer in 2020, and later the father-of-three learned it had spread to his lungs, abdomen and lymph glands. But after treatment with immunotherapy, he made what he describes a ‘miraculous’ recovery and his scan showed no evidence of disease. Here he tells his story.https://www.icr.ac.uk/news-archive%2fmajor-study-reveals-how-pancreatic-cancer-changes-its-diet-to-survivehttps://www.icr.ac.uk/news-archive%2fmajor-study-reveals-how-pancreatic-cancer-changes-its-diet-to-surviveMajor study reveals how pancreatic cancer changes its ‘diet’ to survivePancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research reveals.https://www.icr.ac.uk/news-archive%2fengland-s-first-integrated-pathology-unit-focusing-on-clinical-trial-research-will-use-novel-technology-to-diagnose-cancer-faster-and-more-affordablyhttps://www.icr.ac.uk/news-archive%2fengland-s-first-integrated-pathology-unit-focusing-on-clinical-trial-research-will-use-novel-technology-to-diagnose-cancer-faster-and-more-affordablyEngland’s first Integrated Pathology Unit focusing on clinical trial research will use novel technology to diagnose cancer faster and more affordablyEngland’s first centre of its kind is set to make significant improvements in cancer diagnosis and treatment – by combining pioneering digital imaging with artificial intelligence.https://www.icr.ac.uk/news-archive%2fcell-nanobot-breakthrough-shines-light-on-cause-of-aggressive-cancershttps://www.icr.ac.uk/news-archive%2fcell-nanobot-breakthrough-shines-light-on-cause-of-aggressive-cancersCell ‘nanobot’ breakthrough shines light on cause of aggressive cancersScientists have uncovered the inner workings of one of the most important and intricate ‘nanobots’ operating within our cells – using cutting-edge microscopy for visualising molecules almost at an atomic level. Their new study published in Nature has unveiled the critical step that switches on the spliceosome – a piece of cellular machinery that enables cells to build complex proteins.https://www.icr.ac.uk/news-archive%2ficr-s-chief-executive-elected-as-foreign-member-of-the-royal-societyhttps://www.icr.ac.uk/news-archive%2ficr-s-chief-executive-elected-as-foreign-member-of-the-royal-societyICR’s Chief Executive elected as Foreign Member of the Royal SocietyProfessor Kristian Helin, a world-leading cancer researcher and Chief Executive of The Institute of Cancer Research, London, has been elected as a Foreign Member of the Royal Society in recognition of his outstanding contribution to cancer research.https://www.icr.ac.uk/news-archive%2ficr-discovered-drug-to-enter-phase-ii-clinical-trial-in-ovarian-cancer-thanks-to-new-research-collaborationhttps://www.icr.ac.uk/news-archive%2ficr-discovered-drug-to-enter-phase-ii-clinical-trial-in-ovarian-cancer-thanks-to-new-research-collaborationICR-discovered drug to enter phase II clinical trial in ovarian cancer thanks to new research collaborationAn innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.https://www.icr.ac.uk/news-archive%2fai-could-help-doctors-diagnose-lung-cancerhttps://www.icr.ac.uk/news-archive%2fai-could-help-doctors-diagnose-lung-cancerAI could help doctors diagnose lung cancerArtificial intelligence (AI) could help doctors diagnose lung cancer earlier, according to a study led by researchers from The Royal Marsden NHS Foundation Trust in collaboration with The Institute of Cancer Research, London, and Imperial College London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmall-molecules-clinical-trials-and-protein-degradation-our-new-head-of-chemistry-on-25-years-in-cancer-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmall-molecules-clinical-trials-and-protein-degradation-our-new-head-of-chemistry-on-25-years-in-cancer-drug-discoverySmall molecules, clinical trials and protein degradation: our new Head of Chemistry on 25 years in cancer drug discoveryProfessor Swen Hoelder gave his inaugural lecture recently to mark his promotion to Professor at the ICR in 2020 – an event that had been postponed due to the Covid pandemic.https://www.icr.ac.uk/news-archive%2fscientists-create-potent-degrader-of-cancer-driving-proteinhttps://www.icr.ac.uk/news-archive%2fscientists-create-potent-degrader-of-cancer-driving-proteinScientists create potent ‘degrader’ of cancer-driving proteinScientists at The Institute of Cancer Research, London, have created a compound that destroys a protein involved in driving cancers, including B-cell lymphoma.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhacking-students-knowledge-at-the-first-ever-chemical-probes-portal-hackathonhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhacking-students-knowledge-at-the-first-ever-chemical-probes-portal-hackathonHacking students’ knowledge at the first ever Chemical Probes Portal Hackathon The Chemical Probes Portal completed its first ever Probe Hackathon, bringing students and experts together to evaluate the quality of tools for biomedical research and drug discovery.https://www.icr.ac.uk/news-archive%2ficr-saddened-by-death-of-gerry-potterhttps://www.icr.ac.uk/news-archive%2ficr-saddened-by-death-of-gerry-potterICR saddened by death of Gerry PotterFormer colleagues at The Institute of Cancer Research, London, have reacted with great sadness to news of the untimely death of Gerry Potter, at the age of 63.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-cancer-patient-to-marathon-runner---susanna-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-cancer-patient-to-marathon-runner---susanna-s-storyFrom cancer patient to marathon runner - Susanna’s storySusanna Stephenson was diagnosed with breast cancer just three days before her 42nd birthday in 2014. Following treatment, the mum of two has now recovered and is part of our amazing #teamICR runners taking on the 2023 London Marathon.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frunning-the-marathon-in-memory-of-mum-daniel-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frunning-the-marathon-in-memory-of-mum-daniel-s-storyRunning the Marathon in memory of Mum – Daniel’s storyDaniel Davidson’s mum, Amanda Hood, died of cancer during the pandemic, just months after her diagnosis. Now to celebrate her life, he is running the 2023 London Marathon as part of #teamICR. Here Daniel explains why, despite the challenges of working on an oil rig in the North Sea and not being a keen runner, he is determined to take on this gruelling race to raise vital funds for our research.https://www.icr.ac.uk/news-archive%2fart-and-science-collide-in-a-creative-collaboration-between-the-london-cancer-hub-and-the-sutton-communityhttps://www.icr.ac.uk/news-archive%2fart-and-science-collide-in-a-creative-collaboration-between-the-london-cancer-hub-and-the-sutton-communityArt and science collide in a creative collaboration between The London Cancer Hub and the Sutton communityAn inspirational film featuring local dance groups, members of the Sutton community and scientists from The Institute of Cancer Research, London, premiered this month as part of a festival celebrating arts, science and culture in Sutton.https://www.icr.ac.uk/news-archive%2fimmuno-oncology-collaboration-to-develop-innovative-new-type-of-cancer-drughttps://www.icr.ac.uk/news-archive%2fimmuno-oncology-collaboration-to-develop-innovative-new-type-of-cancer-drugImmuno-oncology collaboration to develop innovative new type of cancer drugScientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs.https://www.icr.ac.uk/news-archive%2fnew-study-reveals-key-priorities-to-guide-us-president-biden-s-cancer-moonshothttps://www.icr.ac.uk/news-archive%2fnew-study-reveals-key-priorities-to-guide-us-president-biden-s-cancer-moonshotNew study reveals key priorities to guide US President Biden’s Cancer MoonshotResearchers have revealed a set of recommendations to help reach the US Cancer Moonshot’s target of cutting cancer deaths by half in the next 25 years.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2folaparib-a-story-of-hope-for-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2folaparib-a-story-of-hope-for-cancer-patientsOlaparib – a story of hope for cancer patients In 1995 researchers at The Institute of Cancer Research, London, uncovered the breast cancer susceptibility gene BRCA2. This discovery helped families to assess their cancer risk through genetic testing, enabling them to be closely monitored or take preventative measures.https://www.icr.ac.uk/news-archive%2ficr-hails-momentous-recommendation-of-olaparib-for-breast-and-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ficr-hails-momentous-recommendation-of-olaparib-for-breast-and-prostate-cancerICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancerThe Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.https://www.icr.ac.uk/news-archive%2finnovative-first-in-class-hsf1-pathway-cancer-drug-shows-strong-results-in-new-studyhttps://www.icr.ac.uk/news-archive%2finnovative-first-in-class-hsf1-pathway-cancer-drug-shows-strong-results-in-new-studyInnovative first in class HSF1 pathway cancer drug shows strong results in new studyA new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows.https://www.icr.ac.uk/news-archive%2fbiological-markers-identified-as-powerful-predictors-of-prostate-cancer-relapse-following-radiotherapyhttps://www.icr.ac.uk/news-archive%2fbiological-markers-identified-as-powerful-predictors-of-prostate-cancer-relapse-following-radiotherapyBiological markers identified as powerful predictors of prostate cancer relapse following radiotherapyTwo key proteins linked to cell division can reliably predict disease recurrence in prostate cancer after radiotherapy treatment, according to new research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-1-million-project-designed-to-unravel-the-mystery-of-chameleon-like-childhood-cancer-cellshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-1-million-project-designed-to-unravel-the-mystery-of-chameleon-like-childhood-cancer-cellsNew 1 million pound project designed to unravel the mystery of chameleon-like childhood cancer cellsOur scientists have embarked on pioneering research to find new therapies that will prevent or treat relapse in rhabdomyosarcoma – thanks to a £1 million pound grant from our family charity partner Alice’s Arc.https://www.icr.ac.uk/news-archive%2fcancer-cells-set-to-be-launched-into-space-for-microgravity-experiment-on-the-international-space-stationhttps://www.icr.ac.uk/news-archive%2fcancer-cells-set-to-be-launched-into-space-for-microgravity-experiment-on-the-international-space-stationCancer cells set to be launched into space for microgravity experiment on the International Space StationA pioneering UK research project to study the three-dimensional spread of cancer cells in microgravity is set to take place on the International Space Station.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreaking-down-regulatory-barriers-could-deliver-step-change-improvements-to-prostate-cancer-outcomeshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreaking-down-regulatory-barriers-could-deliver-step-change-improvements-to-prostate-cancer-outcomesBreaking down regulatory barriers could deliver step change improvements to prostate cancer outcomesWe have seen major advances in prostate cancer research, and people with the disease are living longer than ever. However, more needs to be done to harness scientific discoveries and bring innovative drugs to patients. Here we discuss the regulatory landscape and reforms needed to ensure patients can access the most innovative treatments as quickly as possible. https://www.icr.ac.uk/news-archive%2fgenetic-test-can-guide-treatment-for-blood-cancer-to-help-prevent-relapsehttps://www.icr.ac.uk/news-archive%2fgenetic-test-can-guide-treatment-for-blood-cancer-to-help-prevent-relapseGenetic test can guide treatment for blood cancer to help prevent relapseScientists have found a new way to predict which patients with the blood cancer myeloma will benefit the most from a treatment often used to help keep the disease from coming back after a bone marrow transplant.https://www.icr.ac.uk/news-archive%2fnew-scan-measures-tumour-oxygen-levels-in-real-time-to-help-guide-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-scan-measures-tumour-oxygen-levels-in-real-time-to-help-guide-treatmentNew scan measures tumour oxygen levels in real-time to help guide treatmentImaging researchers have taken a major step towards their ultimate goal of identifying cancers that are starved of oxygen so that altered treatment can be used to target them more effectively.https://www.icr.ac.uk/news-features%2flatest-features%2fover-a-decade-of-abiraterone-the-drug-that-revolutionised-advanced-prostate-cancer-carehttps://www.icr.ac.uk/news-features%2flatest-features%2fover-a-decade-of-abiraterone-the-drug-that-revolutionised-advanced-prostate-cancer-careOver a decade of abiraterone: the drug that revolutionised advanced prostate cancer careThis Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer. We share the story of the drug’s discovery, how a landmark trial changed the way advanced prostate cancer is treated today, and what the drug has meant for patients who are currently treated with it.https://www.icr.ac.uk/news-archive%2fcharity-funding-could-help-establish-new-clinical-trials-for-deadliest-of-all-childhood-cancershttps://www.icr.ac.uk/news-archive%2fcharity-funding-could-help-establish-new-clinical-trials-for-deadliest-of-all-childhood-cancersCharity funding could help establish new clinical trials for deadliest of all childhood cancersThe Institute of Cancer Research, London has been awarded £2.5 million by the charity Brain Tumour Research to help find new treatments and pave the way towards a cure for the childhood cancer high grade glioma, a type of brain tumour.https://www.icr.ac.uk/news-archive%2fscientists-discover-a-new-way-to-help-prevent-breast-cancer-time-bombhttps://www.icr.ac.uk/news-archive%2fscientists-discover-a-new-way-to-help-prevent-breast-cancer-time-bombScientists discover a new way to help prevent breast cancer ‘time bomb’ Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep - forming incurable secondary tumours.https://www.icr.ac.uk/news-archive%2falgorithm-offers-new-way-to-spot-patients-likely-to-respond-to-immunotherapyhttps://www.icr.ac.uk/news-archive%2falgorithm-offers-new-way-to-spot-patients-likely-to-respond-to-immunotherapyAlgorithm offers new way to spot patients likely to respond to immunotherapyScientists have developed a new way of using cancers’ DNA to spot cancer patients who may benefit from immunotherapy.https://www.icr.ac.uk/news-archive%2fgene-test-could-guide-use-of-cancer-chemotherapyhttps://www.icr.ac.uk/news-archive%2fgene-test-could-guide-use-of-cancer-chemotherapyGene test could guide use of cancer chemotherapyA gene test already used routinely in the NHS can guide use of chemotherapy in people with bowel cancer by predicting whether or not they will benefit.https://www.icr.ac.uk/news-archive%2fnew-study-unveils-epigenetic-traffic-lights-controlling-stop-and-go-for-gene-activityhttps://www.icr.ac.uk/news-archive%2fnew-study-unveils-epigenetic-traffic-lights-controlling-stop-and-go-for-gene-activityNew study unveils epigenetic ‘traffic lights’ controlling stop and go for gene activityA major new study in the journal Nature reveals a ‘traffic light’ mechanism controlling genetic activity within cells – a system which could potentially be targeted by cancer drugs already in development.https://www.icr.ac.uk/news-archive%2fexpectations-for-population-wide-gene-testing-need-to-be-realistic-say-researchershttps://www.icr.ac.uk/news-archive%2fexpectations-for-population-wide-gene-testing-need-to-be-realistic-say-researchersExpectations for population-wide gene testing need to be realistic, say researchersTesting a population for multiple genes at once will always be limited in its ability to accurately predict disease risk, experts are warning.https://www.icr.ac.uk/news-archive%2fscientists-reveal-how-different-cancer-cells-team-up-to-help-incurable-childhood-brain-tumour-spreadhttps://www.icr.ac.uk/news-archive%2fscientists-reveal-how-different-cancer-cells-team-up-to-help-incurable-childhood-brain-tumour-spreadScientists reveal how different cancer cells ‘team up’ to help incurable childhood brain tumour spreadScientists have shed light on how different types of cancer cells in an aggressive childhood brain cancer interact and work together to spread.https://www.icr.ac.uk/news-archive%2fmolecular-glue-degrader-reaches-cancer-trial-following-icr-research-programmehttps://www.icr.ac.uk/news-archive%2fmolecular-glue-degrader-reaches-cancer-trial-following-icr-research-programme‘Molecular glue degrader’ reaches cancer trial following ICR research programmeThe biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology.https://www.icr.ac.uk/news-archive%2fmeet-our-scientists-at-upcoming-industry-collaboration-eventshttps://www.icr.ac.uk/news-archive%2fmeet-our-scientists-at-upcoming-industry-collaboration-eventsMeet our scientists at upcoming industry collaboration eventsUpcoming events will give industry experts the chance to hear from some of our leading researchers about opportunities to work with them.https://www.icr.ac.uk/news-archive%2furinary-and-sexual-side-effects-less-likely-after-advanced-radiotherapy-than-surgery-for-advanced-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2furinary-and-sexual-side-effects-less-likely-after-advanced-radiotherapy-than-surgery-for-advanced-prostate-cancer-patientsUrinary and sexual side effects less likely after advanced radiotherapy than surgery for advanced prostate cancer patientsMen with prostate cancer are less likely to experience urinary and sexual side effects two years after treatment with an advanced type of radiotherapy than surgery, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fmobile-health-checks-could-speed-up-diagnosis-of-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fmobile-health-checks-could-speed-up-diagnosis-of-prostate-cancerMobile health checks could speed up diagnosis of prostate cancerData from a pilot study suggest​the ‘Man Van’, an innovative targeted outreach programme, could improve healthcare access for men and potentially speed up the detection of prostate cancer. https://www.icr.ac.uk/news-archive%2fstrong-family-history-of-prostate-cancer-linked-to-better-survivalhttps://www.icr.ac.uk/news-archive%2fstrong-family-history-of-prostate-cancer-linked-to-better-survivalStrong family history of prostate cancer linked to better survivalBeing aware of a strong family history of prostate cancer is linked to an increased chance of surviving the disease, new research suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-research-careers-scientists-share-who-inspired-them-to-become-researchershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-research-careers-scientists-share-who-inspired-them-to-become-researchersCancer research careers: Scientists share who inspired them to become researchersWhat did you want to be when you grew up – a singer, a lawyer, a designer? What about a cancer researcher? To mark International Day of Women and Girls in Science, we asked some of our researchers who it was that first inspired them to pursue a career in science.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcommercial-partnering-opportunities-in-oncology-a-new-biomarker-test-to-guide-treatment-for-oestrogen-receptor-positive-breast-cancerhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcommercial-partnering-opportunities-in-oncology-a-new-biomarker-test-to-guide-treatment-for-oestrogen-receptor-positive-breast-cancerCommercial partnering opportunities in oncology: a new biomarker test to guide treatment for oestrogen-receptor positive breast cancerIn the first of a series on exciting opportunities for industry to collaborate with scientists at The Institute of Cancer Research, Andrew Czyzewski looks at a new biomarker test developed by Dr Maggie Cheang and colleagues that could guide breast cancer treatment.https://www.icr.ac.uk/news-archive%2fresearchers-discover-potential-new-series-of-cancer-drugs-targeting-cancer-driving-protein-bcl6https://www.icr.ac.uk/news-archive%2fresearchers-discover-potential-new-series-of-cancer-drugs-targeting-cancer-driving-protein-bcl6Researchers discover potential new series of cancer drugs targeting cancer-driving protein BCL6Scientists have revealed details of the discovery of new inhibitors of the BCL6 protein, which is involved in driving several cancer types including the blood cancer B-cell lymphoma.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fno-one-should-have-to-lose-a-loved-one-due-to-lack-of-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fno-one-should-have-to-lose-a-loved-one-due-to-lack-of-research"No one should have to lose a loved-one due to lack of research"How a family’s devastating loss spurred them to fund research into Gliomatosis Cerebri and other rare and inoperable brain cancers.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-elephants-rarely-get-cancer-how-evolution-is-helping-unlock-nature-s-potential-to-overcome-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-elephants-rarely-get-cancer-how-evolution-is-helping-unlock-nature-s-potential-to-overcome-cancerWhy elephants rarely get cancer – how evolution is helping unlock nature’s potential to overcome cancerEmma Ong spoke to Professor Joshua Schiffman when he visited the ICR to deliver the annual Darwin Lecture. He shared how his research both involves studying elephants and builds on the work of Charles Darwin.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-is-genomics-transforming-cancer-research-and-treatment-seven-lessons-learned-from-the-festival-of-genomics-biodata-2023https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-is-genomics-transforming-cancer-research-and-treatment-seven-lessons-learned-from-the-festival-of-genomics-biodata-2023How is genomics transforming cancer research and treatment? Seven lessons learned from the Festival of Genomics & Biodata 2023 Scientists from around the world, including many ICR researchers, gathered last month at the Festival of Genomics & Biodata in London. Julia Bakker and Diana Cano attended the conference and report back on some of the key take-home messages.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbbc-radio-5-live-drive-shares-message-of-hope-from-icr-s-centre-for-cancer-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbbc-radio-5-live-drive-shares-message-of-hope-from-icr-s-centre-for-cancer-drug-discoveryBBC Radio 5 Live Drive shares message of hope from ICR’s Centre for Cancer Drug Discovery The Institute of Cancer Research, London, hosted a special live broadcast of the BBC 5 Live Drive programme on Monday 30 January from the Centre for Cancer Drug Discovery – dedicated to celebrating advances in cancer research and promoting the new live episode of the 'You, Me & the Big C' podcast. Diana Cano, Laura-Maria Horga and Ichha Khanal attended the broadcast and share some highlights.https://www.icr.ac.uk/news-archive%2fdrug-discovery-researcher-professor-paul-workman-awarded-prestigious-aaas-fellowshiphttps://www.icr.ac.uk/news-archive%2fdrug-discovery-researcher-professor-paul-workman-awarded-prestigious-aaas-fellowshipDrug discovery researcher Professor Paul Workman awarded prestigious AAAS FellowshipProfessor Paul Workman, former Chief Executive and President of The Institute of Cancer Research, London, from 2014 to 2021, has been elected as a Fellow of the American Association for the Advancement of Science (AAAS), one of the most distinguished honours in the scientific community.https://www.icr.ac.uk/news-archive%2fexperts-call-for-better-cancer-tests-to-tailor-treatmenthttps://www.icr.ac.uk/news-archive%2fexperts-call-for-better-cancer-tests-to-tailor-treatmentExperts call for better cancer tests to tailor treatmentGreater use of cancer tests is the key to tailoring use of new treatments for patients more precisely and so increasing their chances of being recommended for use within the NHS, experts say.https://www.icr.ac.uk/news-archive%2ftravel-boost-for-the-london-cancer-hub-as-number-of-trains-set-to-doublehttps://www.icr.ac.uk/news-archive%2ftravel-boost-for-the-london-cancer-hub-as-number-of-trains-set-to-doubleTravel boost for The London Cancer Hub as number of trains set to doubleThe number of trains serving The London Cancer Hub’s local rail station, Belmont, is set to double thanks to £14m from the Government’s Levelling Up Fund.https://www.icr.ac.uk/news-archive%2fcancer-cells-shrink-or-super-size-to-survivehttps://www.icr.ac.uk/news-archive%2fcancer-cells-shrink-or-super-size-to-surviveCancer cells shrink or super-size to surviveCancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered.https://www.icr.ac.uk/news-archive%2fscientists-behind-breast-cancer-gene-discovery-honoured-with-new-plaqueshttps://www.icr.ac.uk/news-archive%2fscientists-behind-breast-cancer-gene-discovery-honoured-with-new-plaquesScientists behind breast cancer gene discovery honoured with new plaquesThe team of scientists who made a ground-breaking gene discovery which transformed the field of cancer research have been celebrated with the unveiling of two commemorative plaques in London today. The plaques pay homage to the 41 scientists who made the landmark discovery of the BRCA2 cancer gene at the ICR in 1995.https://www.icr.ac.uk/news-features%2flatest-features%2fa-challenge-for-a-challenge-meet-the-cyclists-funding-our-secondary-breast-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fa-challenge-for-a-challenge-meet-the-cyclists-funding-our-secondary-breast-cancer-research“A challenge for a challenge”: Meet the cyclists funding our secondary breast cancer researchCyclist Christine O’Connell set up the One More City campaign shortly before she was diagnosed with stage 4 breast cancer in 2018. She and her teammates are now riding to fund a PhD studentship at The Institute of Cancer Research. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit-s-not-just-about-surviving-it-s-about-so-much-more---alfred-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit-s-not-just-about-surviving-it-s-about-so-much-more---alfred-s-story“It’s not just about surviving, it’s about so much more” - Alfred’s storyWhen Alfred Samuels was diagnosed with advanced prostate cancer in 2012, it felt as if his world had fallen apart overnight. Doctors said surgery wasn’t an option for him because the cancer had spread beyond his prostate, and he started to lose hope. But then he joined a clinical trial and began treatment with abiraterone, a drug discovered and developed by our scientists, which is now extending the lives of thousands of men worldwide. Eleven years later, Alfred explains how he wouldn’t be here today without our research.https://www.icr.ac.uk/news-archive%2ftargeting-cancer-supporting-cells-boosts-immunotherapy-in-previously-insensitive-tumourshttps://www.icr.ac.uk/news-archive%2ftargeting-cancer-supporting-cells-boosts-immunotherapy-in-previously-insensitive-tumoursTargeting cancer-supporting cells boosts immunotherapy in previously insensitive tumoursRemoving a single protein from cells that surround tumours can improve the sensitivity of certain cancers to immunotherapy, researchers have found.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-polygenic-risk-scorehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-polygenic-risk-scoreScience Writing Prize 2022 – Polygenic Risk ScoreDr Catherine Huntley explores the clinical potential of cancer risk scores in this piece shortlisted for the 2022 Mel Greaves Science Writing Prize.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-even-in-death-there-can-be-hope-utilising-the-post-mortem-to-advance-brain-tumour-researchhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-even-in-death-there-can-be-hope-utilising-the-post-mortem-to-advance-brain-tumour-researchScience Writing Prize 2022 – Even in death, there can be hope; utilising the post-mortem to advance brain tumour researchDr Matt Clarke presents a case for the need to have difficult conversations with families about post-mortems to inform future medical advances in this winning piece of the 2022 Mel Greaves Science Writing Prize.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-unsealing-the-terrariumhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2022-unsealing-the-terrariumScience Writing Prize 2022 – Unsealing the terrariumDr Vivian Dimou uses a terrarium as a metaphor to describe the cancer ecosystem in this piece shortlisted for the 2022 Mel Greaves Science Writing Prize.https://www.icr.ac.uk/news-archive%2ffirst-uk-proton-beam-therapy-trial-for-breast-cancer-launcheshttps://www.icr.ac.uk/news-archive%2ffirst-uk-proton-beam-therapy-trial-for-breast-cancer-launchesFirst UK proton beam therapy trial for breast cancer launchesThe first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched in the UK. The trial will compare proton beam therapy – which can target radiotherapy beams more precisely – with standard radiotherapy for patients who are at greater risk of long-term heart problems after radiotherapy treatment.https://www.icr.ac.uk/news-archive%2fnew-targeted-therapy-using-armed-antibodies-shows-promise-against-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-targeted-therapy-using-armed-antibodies-shows-promise-against-prostate-cancerNew targeted therapy using 'armed' antibodies shows promise against prostate cancerA new type of treatment strategy targeting a protein found on the surface of the most lethal prostate cancers could hold promise against the disease.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2four-successes-in-partnering-with-industry-in-2022https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2four-successes-in-partnering-with-industry-in-2022Our successes in partnering with industry in 2022!https://www.icr.ac.uk/news-archive%2ftwin-study-confirms-childhood-leukaemia-starts-in-the-womb-and-could-help-guide-screening-when-only-one-twin-is-affectedhttps://www.icr.ac.uk/news-archive%2ftwin-study-confirms-childhood-leukaemia-starts-in-the-womb-and-could-help-guide-screening-when-only-one-twin-is-affectedTwin study confirms childhood leukaemia starts in the womb and could help guide screening when only one twin is affectedBy studying rare cases of identical twins with leukaemia, scientists have shed new light on the origins of the most common type of childhood cancer – confirming it originates in the womb but that events after birth determine whether or not clinical leukaemia develops. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprobing-the-quality-of-compounds-at-the-heart-of-biological-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprobing-the-quality-of-compounds-at-the-heart-of-biological-research‘Probing’ the quality of compounds at the heart of biological researchAlisa Crisp and Professor Paul Workman explore a major online resource that provides biomedical researchers with expert advice on using the best reagents for their experiments. https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ficr-celebrates-innovation-and-commercialisation-at-staff-awardshttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ficr-celebrates-innovation-and-commercialisation-at-staff-awardsICR celebrates innovation and commercialisation at staff awardsA recent staff awards ceremony offered an opportunity to celebrate our entrepreneurial culture.https://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-celebrates-20-years-supporting-our-researchhttps://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-celebrates-20-years-supporting-our-researchCarols from Chelsea celebrates 20 years supporting our researchThe Wren Chapel at the Royal Hospital Chelsea was full of guests and famous faces on 6 December, celebrating the 20th Carols from Chelsea service in support of The Institute of Cancer Research, London.https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-2022https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-2022Scientific achievements of 2022We have picked 10 exciting scientific discoveries from the past academic year that brilliantly showcase the quality, breadth and strategic impact of our research.https://www.icr.ac.uk/news-archive%2fnew-tool-could-help-target-prostate-cancer-testing-at-men-at-greatest-riskhttps://www.icr.ac.uk/news-archive%2fnew-tool-could-help-target-prostate-cancer-testing-at-men-at-greatest-riskNew tool could help target prostate cancer testing at men at greatest riskScientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say will help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.https://www.icr.ac.uk/news-archive%2fnew-targeted-drug-shows-benefit-against-breast-cancer-in-first-phase-iii-trialhttps://www.icr.ac.uk/news-archive%2fnew-targeted-drug-shows-benefit-against-breast-cancer-in-first-phase-iii-trialNew targeted drug shows benefit against breast cancer in first phase III trialA new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.https://www.icr.ac.uk/news-features%2flatest-features%2fcapivasertib-a-huge-success-story-for-uk-sciencehttps://www.icr.ac.uk/news-features%2flatest-features%2fcapivasertib-a-huge-success-story-for-uk-scienceCapivasertib – a huge success story for UK scienceThe latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Henry French gives an update https://www.icr.ac.uk/news-archive%2ficr-remembers-internationally-renowned-haematologist-and-researcher-professor-daniel-catovskyhttps://www.icr.ac.uk/news-archive%2ficr-remembers-internationally-renowned-haematologist-and-researcher-professor-daniel-catovskyICR remembers internationally renowned haematologist and researcher Professor Daniel CatovskyScientists and clinicians at The Institute of Cancer Research, London, and from around the world, have shared their condolences and celebrated the many achievements of Professor Daniel Catovsky, who died last week.https://www.icr.ac.uk/news-archive%2ficr-announces-new-strategic-collaboration-with-apollo-therapeutics-to-develop-novel-cancer-drugshttps://www.icr.ac.uk/news-archive%2ficr-announces-new-strategic-collaboration-with-apollo-therapeutics-to-develop-novel-cancer-drugsICR announces new strategic collaboration with Apollo Therapeutics to develop novel cancer drugsThe Institute of Cancer Research, London, and biopharmaceutical company Apollo Therapeutics have announced a new collaboration that will advance the development of new cancer drugs, combining the strengths and expertise of both organisations. https://www.icr.ac.uk/news-archive%2fdiscovery-could-lead-to-new-drugs-to-block-protein-that-fuels-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fdiscovery-could-lead-to-new-drugs-to-block-protein-that-fuels-bowel-cancerDiscovery could lead to new drugs to block protein that fuels bowel cancerScientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.https://www.icr.ac.uk/news-archive%2fscientists-plot-extinction-of-cancers-by-disrupting-their-ecosystemshttps://www.icr.ac.uk/news-archive%2fscientists-plot-extinction-of-cancers-by-disrupting-their-ecosystemsScientists plot ‘extinction’ of cancers by disrupting their ecosystemsWorld-leading cancer researchers announce plans to create a new generation of treatments that target the ecosystems supporting cancer. Their new strategy sees cancer genetics and evolution within complex ecosystems as keys to creating new targeted drugs and immunotherapies. They aim to double survival for people with advanced cancer within a decade by combining existing treatments and using smart dosing strategies https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-still-have-a-lot-of-living-left-to-do---sue-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-still-have-a-lot-of-living-left-to-do---sue-s-story“I still have a lot of living left to do” - Sue’s story When Sue Vincent learned in 2010 that her ovarian cancer had spread to three different parts of her body and was inoperable, she resigned herself to having only months to live. But then she was offered a place on a clinical trial for a pioneering drug called olaparib, the discovery and development of which was underpinned by our research. 12 years on, Sue is still taking olaparib, and explains how the work of our scientists has given her a quality of life she could only have dreamed about.https://www.icr.ac.uk/news-archive%2fblood-tests-may-prevent-relapse-in-breast-cancer-patientshttps://www.icr.ac.uk/news-archive%2fblood-tests-may-prevent-relapse-in-breast-cancer-patientsBlood tests may prevent relapse in breast cancer patientsAn innovative trial to detect relapse in breast cancer patients with circulating tumour DNA (ctDNA) has opened at our partner hospital, The Royal Marsden NHS Foundation Trust. The TRAK-ER trial, led by researchers at The Royal Marsden and The Institute of Cancer Research, London, will establish a circulating tumour DNA (ctDNA) surveillance programme for over 1,000 patiets with ER positive breast cancer who are currently receiving hormone therapy to reduce their risk of cancer returning.https://www.icr.ac.uk/news-archive%2fnew-personalised-cancer-medicine-company-moves-in-at-the-london-cancer-hub-s-innovation-gatewayhttps://www.icr.ac.uk/news-archive%2fnew-personalised-cancer-medicine-company-moves-in-at-the-london-cancer-hub-s-innovation-gatewayNew personalised cancer medicine company moves in at The London Cancer Hub’s Innovation GatewayPersonalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.https://www.icr.ac.uk/news-archive%2fscientists-uncover-potential-electrical-language-of-cancer-cellshttps://www.icr.ac.uk/news-archive%2fscientists-uncover-potential-electrical-language-of-cancer-cellsScientists uncover potential ‘electrical language’ of cancer cellsBreast cancer cells may be able to communicate with each other using electrical impulses, new research suggests.https://www.icr.ac.uk/news-archive%2ficr-urges-continued-negotiation-after-nice-rejection-of-olaparib-for-early-breast-cancerhttps://www.icr.ac.uk/news-archive%2ficr-urges-continued-negotiation-after-nice-rejection-of-olaparib-for-early-breast-cancerICR urges continued negotiation after NICE rejection of olaparib for early breast cancerThe Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer.https://www.icr.ac.uk/news-archive%2fadvanced-radiotherapy-safely-treats-prostate-cancer-patients-in-a-quarter-of-the-time-of-current-standardhttps://www.icr.ac.uk/news-archive%2fadvanced-radiotherapy-safely-treats-prostate-cancer-patients-in-a-quarter-of-the-time-of-current-standardAdvanced radiotherapy safely treats prostate cancer patients in a quarter of the time of current standardAn advanced radiotherapy technique can be used to safely treat prostate cancer patients in as little as one to two weeks, compared with the current standard, which takes one to two months.https://www.icr.ac.uk/news-archive%2ficr-discovery-club-celebrates-the-second-anniversary-of-the-centre-for-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-celebrates-the-second-anniversary-of-the-centre-for-cancer-drug-discoveryICR Discovery Club celebrates the second anniversary of the Centre for Cancer Drug Discovery Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery. https://www.icr.ac.uk/news-archive%2fbreast-cancer-test-could-guide-treatment-for-more-aggressive-subtypehttps://www.icr.ac.uk/news-archive%2fbreast-cancer-test-could-guide-treatment-for-more-aggressive-subtypeBreast cancer test could guide treatment for more aggressive subtypeA new breast cancer test could detect women who are less likely to respond to a standard breast cancer treatment – and could help improve treatment for these women by giving them other treatment options earlier.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwho-is-terry-foxhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwho-is-terry-foxWho is Terry Fox?While Terry Fox is a household name in Canada, his story may be new to some people in the UK. In this blog, our Digital Communications Officer Laura-Maria Horga shares the story of the Canadian hero whose legacy continues more than 40 years after his death.https://www.icr.ac.uk/news-archive%2flandmark-nature-papers-unveil-dark-matter-shaping-cancer-behaviourhttps://www.icr.ac.uk/news-archive%2flandmark-nature-papers-unveil-dark-matter-shaping-cancer-behaviourLandmark Nature papers unveil ‘dark matter’ shaping cancer behaviourCancers can evolve to become more aggressive without relying only on DNA mutations, two major studies published simultaneously in Nature reveal.https://www.icr.ac.uk/news-archive%2ficr-ranked-amongst-top-uk-universities-for-partnerships-and-public-engagementhttps://www.icr.ac.uk/news-archive%2ficr-ranked-amongst-top-uk-universities-for-partnerships-and-public-engagementICR ranked amongst top UK universities for partnerships and public engagementThe ICR has been rated as one of the UK's top higher education institutions in three categories in the latest Knowledge Exchange Framework (KEF), a Government assessment of universities' influence on society.https://www.icr.ac.uk/news-archive%2fstudy-opens-route-to-overcoming-drug-resistance-in-stomach-cancerhttps://www.icr.ac.uk/news-archive%2fstudy-opens-route-to-overcoming-drug-resistance-in-stomach-cancerStudy opens route to overcoming drug resistance in stomach cancerScientists have shown how stomach cancers can dodge the effects of a promising new experimental treatment – raising the possibility of outsmarting cancer by predicting drug resistance in advance.https://www.icr.ac.uk/news-archive%2fblood-tests-could-offer-smarter-treatment-for-children-s-cancerhttps://www.icr.ac.uk/news-archive%2fblood-tests-could-offer-smarter-treatment-for-children-s-cancerBlood tests could offer smarter treatment for children’s cancerA simple blood test could help guide the treatment of children with the cancer rhabdomyosarcoma, a new study reports.https://www.icr.ac.uk/news-archive%2ftriple-negative-breast-cancer-s-reliance-on-sperm-and-egg-production-proteins-may-offer-new-treatment-pathwayshttps://www.icr.ac.uk/news-archive%2ftriple-negative-breast-cancer-s-reliance-on-sperm-and-egg-production-proteins-may-offer-new-treatment-pathwaysTriple negative breast cancer’s reliance on sperm and egg production proteins may offer new treatment pathwaysScientists have discovered the key role of a series of proteins in the survival of some triple negative breast cancers. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fproud-moments-for-our-postgraduate-students-as-we-celebrate-graduationhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fproud-moments-for-our-postgraduate-students-as-we-celebrate-graduationProud moments for our postgraduate students as we celebrate graduation after three long yearsDr Barbara Pittam, Registrar and Director of Academic Services at The Institute of Cancer Research, London, celebrates the achievements of our students in the month they gathered to receive their degrees in person for the first time since the Covid-19 pandemic.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcracking-on-for-tom-honouring-the-legacy-of-an-inspirational-young-man-lost-to-sarcomahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcracking-on-for-tom-honouring-the-legacy-of-an-inspirational-young-man-lost-to-sarcoma“Cracking on for Tom” – honouring the legacy of an inspirational young man lost to sarcomaTen years ago, 18-year-old Tom Bowdidge was diagnosed with desmoplastic small round cell tumour (DSRCT) – an aggressive type of sarcoma. DSRCT has a very poor prognosis and Tom died in 2013 after several months of “brutal” treatment. The ICR is working in partnership with the foundation set up in his name to find more effective and kinder treatments.https://www.icr.ac.uk/news-archive%2fimmune-targets-for-chemotherapy-resistant-breast-cancers-identifiedhttps://www.icr.ac.uk/news-archive%2fimmune-targets-for-chemotherapy-resistant-breast-cancers-identifiedImmune targets for chemotherapy-resistant breast cancers identifiedResearchers perform a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery - the findings could help tailor pre-surgical treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-research-day-how-international-collaborations-benefit-the-global-cancer-research-communityhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-research-day-how-international-collaborations-benefit-the-global-cancer-research-communityWorld Cancer Research Day: how international collaborations benefit the global cancer research communityThe ICR is one of the world’s most influential cancer research organisations – making discoveries that have benefited many people with cancer in the UK and around the world. Laura-Maria Horga explores how the ICR’s researchers are harnessing international collaborations to help even more people.https://www.icr.ac.uk/news-archive%2fgenetically-modified-herpes-virus-delivers-one-two-punch-against-advanced-cancershttps://www.icr.ac.uk/news-archive%2fgenetically-modified-herpes-virus-delivers-one-two-punch-against-advanced-cancersGenetically modified herpes virus delivers one-two punch against advanced cancersA new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial.https://www.icr.ac.uk/news-archive%2fdeliberately-damaging-dna-could-boost-the-effectiveness-of-immunotherapy-in-kidney-cancerhttps://www.icr.ac.uk/news-archive%2fdeliberately-damaging-dna-could-boost-the-effectiveness-of-immunotherapy-in-kidney-cancerDeliberately damaging DNA could boost the effectiveness of immunotherapy in kidney cancer DNA damage is one of the foundational causes of cancer. But researchers have now found that deliberately causing DNA damage – by delivering additional treatments like radiotherapy – could improve the effectiveness of immunotherapy for some people with kidney cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fknowing-we-helped-that-will-be-ollie-s-legacy-sarah-s-story-of-childhood-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fknowing-we-helped-that-will-be-ollie-s-legacy-sarah-s-story-of-childhood-cancer“Knowing we helped – that will be Ollie’s legacy” – Sarah’s story of childhood cancerThe Ollie Young Foundation, which supports our world-leading research into childhood brain tumours, was set up in memory of Ollie, who died one day before his sixth birthday. Ollie’s mum, Sarah, tells us their story.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffor-abbie-cancer-was-just-her-normal-life-mike-s-story-of-childhood-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffor-abbie-cancer-was-just-her-normal-life-mike-s-story-of-childhood-cancer“For Abbie, cancer was just her normal life” – Mike’s story of childhood cancerMike Shaw tells us about the charity Abbie’s Fund, which supports our research into childhood cancer, and about the girl who inspired it all: Abbie Shaw.https://www.icr.ac.uk/news-archive%2ficr-statement-on-the-death-of-her-majesty-the-queenhttps://www.icr.ac.uk/news-archive%2ficr-statement-on-the-death-of-her-majesty-the-queenICR statement on the death of Her Majesty The QueenIt is with deep sadness that The Institute of Cancer Research, London, marks the death of Her Majesty The Queen.https://www.icr.ac.uk/news-archive%2fprizes-and-celebrations-at-icr-s-biggest-ever-student-graduation-ceremonyhttps://www.icr.ac.uk/news-archive%2fprizes-and-celebrations-at-icr-s-biggest-ever-student-graduation-ceremonyPrizes and celebrations at ICR’s biggest ever student graduation ceremonyAt our annual awards ceremony this week, The Institute of Cancer Research, London, celebrated the hard work of our graduating students and recognised their outstanding achievements.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fesmo-2022---cancer-researchers-rendezvous-in-parishttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fesmo-2022---cancer-researchers-rendezvous-in-parisESMO 2022: Cancer researchers rendezvous in ParisICR scientists will be presenting at this years ESMO annual meeting. We take a look at some of the presentations.https://www.icr.ac.uk/news-archive%2fartificial-intelligence-unlocks-treasure-trove-of-billions-of-cancer-sampleshttps://www.icr.ac.uk/news-archive%2fartificial-intelligence-unlocks-treasure-trove-of-billions-of-cancer-samplesArtificial intelligence unlocks ‘treasure trove’ of billions of cancer samplesScientists have developed an artificial intelligence (AI) method that could unlock a research ‘treasure trove’ of cancer genomes from billions of preserved tissue samples stored routinely at hospitals over decades.https://www.icr.ac.uk/news-archive%2fdame-deborah-james-and-you-me-and-the-big-c-team-awarded-honorary-doctorates-by-leading-cancer-research-institutehttps://www.icr.ac.uk/news-archive%2fdame-deborah-james-and-you-me-and-the-big-c-team-awarded-honorary-doctorates-by-leading-cancer-research-instituteDame Deborah James and You, Me and the Big C team awarded honorary doctorates by leading cancer research instituteDame Deborah James, Lauren Mahon and Steve Bland awarded honorary degrees in recognition of their efforts to raise awareness of the impact of cancer on patients and their loved oneshttps://www.icr.ac.uk/news-archive%2fmhra-approves-olaparib-for-high-risk-early-stage-breast-cancerhttps://www.icr.ac.uk/news-archive%2fmhra-approves-olaparib-for-high-risk-early-stage-breast-cancerMHRA approves olaparib for high-risk, early-stage breast cancerThe Institute of Cancer Research, London, celebrates the news that the precision medicine olaparib has been approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for patients with high-risk, early-stage breast cancer and inherited faults in their BRCA1 or BRCA2 genes.https://www.icr.ac.uk/news-archive%2ficr-criticises-nice-rejection-of-olaparib-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ficr-criticises-nice-rejection-of-olaparib-for-advanced-prostate-cancerICR criticises NICE rejection of olaparib for advanced prostate cancerThe Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer.https://www.icr.ac.uk/news-archive%2flong-term-benefit-of-radiotherapy-confirmed-in-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2flong-term-benefit-of-radiotherapy-confirmed-in-advanced-prostate-cancerLong-term benefit of radiotherapy confirmed in advanced prostate cancerRadiotherapy to the prostate alongside standard treatment can keep some men with advanced prostate cancer alive for longer without detriment to quality of life, long-term study results confirm.https://www.icr.ac.uk/news-archive%2fimmunotherapy-drug-combination-stimulates-immune-system-against-resistant-cancershttps://www.icr.ac.uk/news-archive%2fimmunotherapy-drug-combination-stimulates-immune-system-against-resistant-cancersImmunotherapy drug combination stimulates immune system against resistant cancersA combination treatment of immunotherapy with the experimental drug guadecitabine may reverse a cancer’s resistance to immunotherapy – making it sensitive to treatment again, a new study has found.https://www.icr.ac.uk/news-archive%2ficr-welcomes-mhra-approval-of-%27search-and-destroy%27-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2ficr-welcomes-mhra-approval-of-%27search-and-destroy%27-prostate-cancer-treatmentICR welcomes MHRA approval of 'search and destroy' prostate cancer treatmentThe Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-are-combination-therapies-for-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-are-combination-therapies-for-cancer-treatmentWhat are combination therapies for cancer treatment?Combination therapies combine two or more different types of treatments for cancer patients. Hattie Hayeck interviewed Professor Chris Jones and Professor Udai Banerji to delve into some of the challenges and opportunities of combination therapies.https://www.icr.ac.uk/news-archive%2fskin-cancer-cells-harness-nerve-cell-gene-to-drill-through-and-invade-new-tissueshttps://www.icr.ac.uk/news-archive%2fskin-cancer-cells-harness-nerve-cell-gene-to-drill-through-and-invade-new-tissuesSkin cancer cells harness nerve cell gene to drill through and invade new tissuesMelanoma skin cancer cells harness a gene usually used by growing nerves to escape from their immediate area and spread through tissues, new research has found.https://www.icr.ac.uk/news-archive%2fall-patients-cancers-should-be-genetically-profiled-to-improve-care-say-leading-health-expertshttps://www.icr.ac.uk/news-archive%2fall-patients-cancers-should-be-genetically-profiled-to-improve-care-say-leading-health-expertsAll patients’ cancers should be genetically profiled to improve care, say leading health expertsThe NHS should offer all cancer patients genetic profiling of their cancers at diagnosis and during treatment to shape care and track how the disease evolves, a consensus group of leading experts has concluded.https://www.icr.ac.uk/news-archive%2folaparib-for-high-risk-early-stage-breast-cancer-approved-in-europehttps://www.icr.ac.uk/news-archive%2folaparib-for-high-risk-early-stage-breast-cancer-approved-in-europeOlaparib for high-risk, early-stage breast cancer approved in EuropeThe Institute of Cancer Research, London, strongly welcomes the news that the precision medicine olaparib has been approved in Europe for people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.https://www.icr.ac.uk/news-archive%2flong-term-benefit-of-combining-chemotherapy-and-radiotherapy-in-bladder-cancerhttps://www.icr.ac.uk/news-archive%2flong-term-benefit-of-combining-chemotherapy-and-radiotherapy-in-bladder-cancerLong-term benefit of combining chemotherapy and radiotherapy in bladder cancer Giving people with bladder cancer chemotherapy and radiotherapy at the same time helps stop cancer from coming back, long-term results of a 10-year study confirm.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-want-to-raise-awareness-of-sarcoma-janine-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-want-to-raise-awareness-of-sarcoma-janine-s-story“I want to raise awareness of sarcoma” – Janine’s storyDuring Sarcoma Awareness Month, Janine tells us about her son, Harry, and why raising awareness of rarer cancers is so important.https://www.icr.ac.uk/news-archive%2fnew-study-reveals-how-free-radicals-drive-cell-division-uncovering-a-potential-new-way-to-target-cancerhttps://www.icr.ac.uk/news-archive%2fnew-study-reveals-how-free-radicals-drive-cell-division-uncovering-a-potential-new-way-to-target-cancerNew study reveals how ’free radicals’ drive cell division, uncovering a potential new way to target cancerScientists have discovered how naturally occurring but unstable molecules, known as free radicals, can control the fundamental process of cell division, which, when it goes wrong, can lead to uncontrolled cell growth and cancer.https://www.icr.ac.uk/news-archive%2ficr-s-in-person-business-partnering-events-returnhttps://www.icr.ac.uk/news-archive%2ficr-s-in-person-business-partnering-events-returnICR’s in-person business partnering events return!Our Partnering to Defeat Cancer series of business networking events returned this month, with scientists from The Institute of Cancer Research giving presentations on their work to an audience of industry professionals before a networking reception.https://www.icr.ac.uk/news-archive%2ffirst-medtech-company-moves-in-at-the-london-cancer-hub-s-innovation-gatewayhttps://www.icr.ac.uk/news-archive%2ffirst-medtech-company-moves-in-at-the-london-cancer-hub-s-innovation-gatewayFirst MedTech company moves in at The London Cancer Hub’s Innovation GatewayPrecision medicine start-up enterprise Vesynta has become the first MedTech company to move into a sophisticated laboratory at south London’s newest incubator space, the Innovation Gateway at The London Cancer Hub in Sutton.https://www.icr.ac.uk/news-features%2flatest-features%2fscience-and-medical-imaging-competition-2022https://www.icr.ac.uk/news-features%2flatest-features%2fscience-and-medical-imaging-competition-2022PhD student Rose Foster wins ICR Science and Medical Imaging CompetitionPhD student Rose Foster in the Prostate and Bladder Cancer Team in the Division of Radiotherapy and Imaging has won the ICR Science and Medical Imaging Competition 2022 for her image of a fluorescent image of bladder tumour tissue. https://www.icr.ac.uk/news-archive%2fjunk-dna-could-lead-to-cancer-by-stopping-copying-of-dnahttps://www.icr.ac.uk/news-archive%2fjunk-dna-could-lead-to-cancer-by-stopping-copying-of-dna‘Junk’ DNA could lead to cancer by stopping copying of DNAScientists have found that non-coding ‘junk’ DNA, far from being harmless and inert, could potentially contribute to the development of cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-discovery-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-discovery-scienceWhat is discovery science?When cancer research hits the headlines, it’s often clinical trial results or a potential new test or treatment for patients. However, these breakthroughs would never be possible without earlier fundamental discoveries by scientists in the lab. Hannah Taylor Lewis takes a look at the role of discovery science in cancer research.https://www.icr.ac.uk/news-archive%2fpioneering-icr-scientist-wins-prestigious-translational-cancer-research-awardhttps://www.icr.ac.uk/news-archive%2fpioneering-icr-scientist-wins-prestigious-translational-cancer-research-awardPioneering ICR scientist wins prestigious translational cancer research awardDr George Poulogiannis, leader of the Signalling and Cancer Metabolism Team at The Institute of Cancer Research, London, has received the 2022 British Association of Cancer Research–AstraZeneca Young Scientist Frank Rose Award for his research into the role of metabolism and nutrition in cancer development and therapy response.https://www.icr.ac.uk/news-archive%2fresearchers-call-for-improved-use-of-chemical-tools-to-enhance-biomedical-researchhttps://www.icr.ac.uk/news-archive%2fresearchers-call-for-improved-use-of-chemical-tools-to-enhance-biomedical-researchResearchers call for improved use of chemical tools to enhance biomedical researchExperts in biomedical research are calling for better use of chemical probes to improve our understanding of protein function and the foundations on which much of modern drug discovery and development are based.https://www.icr.ac.uk/news-archive%2fscientists-discover-mechanism-controlling-spread-of-pancreatic-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-discover-mechanism-controlling-spread-of-pancreatic-cancerScientists discover mechanism controlling spread of pancreatic cancerScientists have shown it is possible to reverse a key process that allows pancreatic cancer cells to grow and spread around the body.https://www.icr.ac.uk/news-archive%2ficr-remembers-dame-deborah-jameshttps://www.icr.ac.uk/news-archive%2ficr-remembers-dame-deborah-jamesICR remembers Dame Deborah JamesThe ICR has offered heartfelt condolences to Dame Deborah James' family after the campaigner and podcaster very sadly died - Deborah had been living with bowel cancer for six years.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-giving-hope-to-cancer-patients-like-me-alison-s-story-of-being-on-a-combination-therapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-is-giving-hope-to-cancer-patients-like-me-alison-s-story-of-being-on-a-combination-therapy‘Immunotherapy is giving hope to cancer patients like me’: Alison’s storyAlison, 61, was diagnosed with advanced non-small cell lung cancer in 2018. After four years of treatment on a combination therapy of immunotherapy and chemotherapy, she has no cancer on her scans.https://www.icr.ac.uk/news-archive%2fema-recommends-olaparib-for-treatment-of-high-risk-early-breast-cancerhttps://www.icr.ac.uk/news-archive%2fema-recommends-olaparib-for-treatment-of-high-risk-early-breast-cancerEMA recommends olaparib for treatment of high-risk, early breast cancerThe Institute of Cancer Research, London, strongly welcomes the news that olaparib has been recommended by the European Medicines Agency (EMA) to treat people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.https://www.icr.ac.uk/news-archive%2ficr-among-top-ranked-universities-for-invention-income-for-ninth-consecutive-yearhttps://www.icr.ac.uk/news-archive%2ficr-among-top-ranked-universities-for-invention-income-for-ninth-consecutive-yearICR among top-ranked universities for invention income for ninth consecutive yearThe Institute of Cancer Research, London, has again ranked among the top academic institutions in the UK at generating income from its intellectual property.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fvisiting-st.-jude-children-s-research-hospital-discovering-different-approaches-to-pathology-and-childhood-cancer-researchhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fvisiting-st.-jude-children-s-research-hospital-discovering-different-approaches-to-pathology-and-childhood-cancer-researchVisiting St. Jude Children’s Research Hospital – discovering different approaches to pathology and childhood cancer researchFor National Pathology Week, Dr Matthew Clarke from our Glioma team, and a trainee neuropathologist, shares his experiences of visiting and learning from colleagues at the renowned St. Jude Children’s Research Hospital in the US.https://www.icr.ac.uk/news-archive%2flight-activated-photoimmunotherapy-could-enhance-brain-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2flight-activated-photoimmunotherapy-could-enhance-brain-cancer-treatmentLight-activated ‘photoimmunotherapy’ could enhance brain cancer treatmentAn innovative light-activated therapy developed at The Institute of Cancer Research, London, could help detect and treat an aggressive brain cancer type, a new study shows. https://www.icr.ac.uk/news-archive%2fnew-combination-therapy-exploits-natural-killer-cells-to-destroy-head-and-neck-tumourshttps://www.icr.ac.uk/news-archive%2fnew-combination-therapy-exploits-natural-killer-cells-to-destroy-head-and-neck-tumoursNew combination therapy exploits ‘natural killer’ cells to destroy head and neck tumoursScientists have identified a new treatment combination that is highly effective at suppressing the growth of head and neck tumours.https://www.icr.ac.uk/news-archive%2ficr-discovery-club-showcases-how-we-combine-therapies-to-target-hard-to-treat-cancershttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-showcases-how-we-combine-therapies-to-target-hard-to-treat-cancersICR Discovery Club showcases how we combine therapies to target hard-to-treat cancersDiscovery Club members gathered at the Science Museum in London to learn how our researchers are transforming cancer care for patients with innovative combination therapies.https://www.icr.ac.uk/news-archive%2fasco-2022-%27practice-changing%27-radiotherapy-technique-can-reduce-swallowing-problems-for-cancer-patientshttps://www.icr.ac.uk/news-archive%2fasco-2022-%27practice-changing%27-radiotherapy-technique-can-reduce-swallowing-problems-for-cancer-patientsASCO 2022: 'Practice-changing' radiotherapy technique can reduce swallowing problems for cancer patientsA new precision radiotherapy technique described as ‘practice changing’ has been shown to reduce long-term side effects, including swallowing problems, for patients with head and neck cancer following treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2022-icr-researchers-hit-the-headlines-with-innovative-approaches-to-cancer-treatment-and-carehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2022-icr-researchers-hit-the-headlines-with-innovative-approaches-to-cancer-treatment-and-careASCO 2022: ICR researchers hit the headlines with innovative approaches to cancer treatment and careThe first in-person ASCO conference since the start of the Covid-19 pandemic took place in Chicago over the weekend. Many researchers from the ICR and The Royal Marsden presented their work in the form of talks or posters. Here we look back over some of our highlights of this year’s meeting.https://www.icr.ac.uk/news-archive%2fasco-2022-drug-combination-shows-promise-against-cancer-s-death-star-proteinhttps://www.icr.ac.uk/news-archive%2fasco-2022-drug-combination-shows-promise-against-cancer-s-death-star-proteinASCO 2022: Drug combination shows promise against cancer’s ‘death star’ proteinA drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.https://www.icr.ac.uk/news-archive%2fasco-2022-screening-of-patients-genomes-for-gps-to-assess-disease-risk-is-feasiblehttps://www.icr.ac.uk/news-archive%2fasco-2022-screening-of-patients-genomes-for-gps-to-assess-disease-risk-is-feasibleASCO 2022: Screening of patients’ genomes for GPs to assess disease risk is ‘feasible’Screening people’s genomes as part of routine primary care can spot genetic changes that may have important implications for health, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2022-cancer-researchers-unite-for-in-person-meetinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2022-cancer-researchers-unite-for-in-person-meetingASCO 2022: Cancer researchers unite for in-person meetingWorld-leading cancer researchers will be gathering in Chicago from 3 to 7 June for the ASCO Annual Meeting – the first to take place in person since the Covid-19 pandemic. We look ahead at some of the ICR’s research highlights that will be presented at this year’s meeting.https://www.icr.ac.uk/news-archive%2fcancer-revolution-major-exhibition-opens-at-the-science-museum-showcasing-icr-researchhttps://www.icr.ac.uk/news-archive%2fcancer-revolution-major-exhibition-opens-at-the-science-museum-showcasing-icr-researchCancer Revolution: Major exhibition opens at the Science Museum showcasing ICR researchA new, free exhibition chronicling how science is transforming cancer care opens at the Science Museum in London today – featuring discoveries led by researchers at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fscientists-identify-potential-new-drug-combination-for-some-skin-cancershttps://www.icr.ac.uk/news-archive%2fscientists-identify-potential-new-drug-combination-for-some-skin-cancersScientists identify potential new drug combination for some skin cancersA combination of two existing skin cancer drugs and a third experimental drug could lead to a new strategy for treating patients who do not respond to existing therapies, a new study in mice suggests. https://www.icr.ac.uk/news-archive%2fnew-head-and-neck-cancer-radiotherapy-technique-could-deliver-more-robust-treatment-plan-in-shorter-time-on-mr-linachttps://www.icr.ac.uk/news-archive%2fnew-head-and-neck-cancer-radiotherapy-technique-could-deliver-more-robust-treatment-plan-in-shorter-time-on-mr-linacNew head and neck cancer radiotherapy technique could deliver more robust treatment plan in shorter time on MR LinacNew adaptive radiotherapy technique for head and neck cancer can deliver a more robust treatment plan in a shorter timeframe on MR Linac, compared with the current method used by most radiotherapy centres.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fkaren-s-story-of-living-well-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fkaren-s-story-of-living-well-with-cancer“Seven years ago I was told I had just months to live” – Karen’s story of living well with cancerKaren, 59, was told she only had months to live when she was diagnosed with bowel cancer seven years ago. Now, she lives 'near normal life' on a combination of chemotherapy and the targeted drug cetuximab. Here she tells her story.https://www.icr.ac.uk/news-archive%2fscientists-report-link-between-male-infertility-and-breast-cancer-in-menhttps://www.icr.ac.uk/news-archive%2fscientists-report-link-between-male-infertility-and-breast-cancer-in-menScientists report link between male infertility and breast cancer in menInfertile men may be twice as likely to develop breast cancer than those without fertility issues, according to new research published today. https://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-breast-cancer-radiotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-breast-cancer-radiotherapyOur research impact: breast cancer radiotherapyTo mark our outstanding success in REF2021, Gege Li spoke to two of our researchers here at the ICR who have played central roles in improving the use of radiotherapy in the treatment of breast cancer – transforming the lives of many thousands of patients.https://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-prostate-cancer-radiotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-prostate-cancer-radiotherapyOur research impact: prostate cancer radiotherapyTo mark our outstanding success in REF2021, Gege Li spoke to several of our researchers here at the ICR who have pioneered improved use of radiotherapy in the treatment of prostate cancer.https://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-parp-inhibitorshttps://www.icr.ac.uk/news-features%2flatest-features%2four-research-impact-parp-inhibitorsOur research impact: PARP inhibitorsTo mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.https://www.icr.ac.uk/news-features%2flatest-features%2fakt-inhibitors-a-new-type-of-targeted-cancer-drughttps://www.icr.ac.uk/news-features%2flatest-features%2fakt-inhibitors-a-new-type-of-targeted-cancer-drugAKT inhibitors: a new type of targeted cancer drugTo mark our outstanding success in REF2021, Alison Halliday shares the story of how our researchers revealed the 3D structure of the key cancer protein AKT, catalysing the discovery and development of at least 12 drugs now in clinical trials for a variety of cancers.https://www.icr.ac.uk/news-archive%2ficr-rated-second-in-uk-among-all-higher-education-institutions-in-ref-2021-analysishttps://www.icr.ac.uk/news-archive%2ficr-rated-second-in-uk-among-all-higher-education-institutions-in-ref-2021-analysisICR rated second in UK among all higher education institutions in REF 2021 analysisThe Institute of Cancer Research, London, has rated second in REF 2021 – the Government’s evaluation of university research quality – among all higher education institutions in the UK that submitted at least two units of assessment.https://www.icr.ac.uk/news-archive%2fprofessors-kristian-helin-and-trevor-graham-elected-as-fellows-of-the-academy-of-medical-scienceshttps://www.icr.ac.uk/news-archive%2fprofessors-kristian-helin-and-trevor-graham-elected-as-fellows-of-the-academy-of-medical-sciencesProfessors Kristian Helin and Trevor Graham elected as Fellows of the Academy of Medical SciencesProfessor Kristian Helin, Chief Executive and President at The Institute of Cancer Research, London, and Professor Trevor Graham, Director of the ICR’s Centre for Evolution and Cancer, have been awarded prestigious Fellowships for the Academy of Medical Sciences (AMS). https://www.icr.ac.uk/news-archive%2ficr-saddened-by-death-of-mike-ormerodhttps://www.icr.ac.uk/news-archive%2ficr-saddened-by-death-of-mike-ormerodICR saddened by death of Mike OrmerodThe ICR is saddened to learn of the death of Dr Mike Ormerod, who headed the ICR’s flow cytometry facility in Sutton in the 1980s.https://www.icr.ac.uk/news-archive%2fcommon-genetic-mutation-allows-cancer-cells-to-gain-extra-chromosomes-which-help-them-survivehttps://www.icr.ac.uk/news-archive%2fcommon-genetic-mutation-allows-cancer-cells-to-gain-extra-chromosomes-which-help-them-surviveCommon genetic mutation allows cancer cells to gain extra chromosomes which help them surviveScientists have found a genetic mutation that results in cancer cells being able to tolerate having an abnormal number of chromosomes – a condition which normally kills cells – allowing them to adapt to their environment and continue to grow.https://www.icr.ac.uk/news-archive%2fdrugs-targeting-cell-recycling-could-be-used-to-suffocate-cancer-cellshttps://www.icr.ac.uk/news-archive%2fdrugs-targeting-cell-recycling-could-be-used-to-suffocate-cancer-cellsDrugs targeting cell recycling could be used to suffocate cancer cellsPancreatic cancers recycle resources to fuel their survival and growth, opening up the possibility of new treatments aimed at stopping them from doing so, scientists report.https://www.icr.ac.uk/news-archive%2fnew-3d-structure-could-help-design-future-drugs-against-cancerhttps://www.icr.ac.uk/news-archive%2fnew-3d-structure-could-help-design-future-drugs-against-cancerNew 3D structure could help design future drugs against cancerA team of scientists has created a three-dimensional map showing how a small molecule with anticancer properties – called spliceostatin – can promote the killing of cancer cells.https://www.icr.ac.uk/news-features%2flatest-features%2fa-field-rich-for-discovery-realising-immunotherapy-s-potentialhttps://www.icr.ac.uk/news-features%2flatest-features%2fa-field-rich-for-discovery-realising-immunotherapy-s-potentialA field rich for discovery: realising immunotherapy’s potentialWidely considered a revolutionary treatment, immunotherapy has become a powerful tool against cancer. On the International Day of Immunology, Gege Li looks at the progress we are making in our understanding of the immune landscape of cancer to develop more effective treatments for even more people with cancer.https://www.icr.ac.uk/news-features%2flatest-features%2fdamaged-dna-wielding-a-double-edged-sword-against-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fdamaged-dna-wielding-a-double-edged-sword-against-cancerDamaged DNA – wielding a double-edged sword against cancer This DNA Day, we look at how our scientists are seeking to understand how cells respond to damage to DNA – and the tricks cancer uses to stay alive despite suffering genetic damage.https://www.icr.ac.uk/news-archive%2fai-study-%27exciting-first-step%27-towards-improving-post-treatment-surveillance-of-lung-cancer-patientshttps://www.icr.ac.uk/news-archive%2fai-study-%27exciting-first-step%27-towards-improving-post-treatment-surveillance-of-lung-cancer-patientsAI study 'exciting first step' towards improving post-treatment surveillance of lung cancer patientsArtificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to new research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-can-we-help-scientists-find-the-right-tools-for-their-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-can-we-help-scientists-find-the-right-tools-for-their-researchThe Chemical Probes Portal: helping scientists find the right tools for their researchChemical probes have become increasingly important in understanding protein function and drug discovery, but they vary in quality. Alisa Crisp spoke to the team behind the Chemical Probes Portal, who hope to change how scientists use these essential tools to improve the robustness of cancer research. https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffive-reasons-why-pharma-and-biotech-companies-are-co-locating-with-university-researchers-and-one-more-reason-why-you-should-toohttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffive-reasons-why-pharma-and-biotech-companies-are-co-locating-with-university-researchers-and-one-more-reason-why-you-should-tooFive reasons why pharma and biotech companies are co-locating with university researchers – and one more reason why you should too!https://www.icr.ac.uk/news-features%2flatest-features%2ffrom-bench-to-bedside-and-beyond-the-team-of-scientists-that-transformed-breast-cancer-treatmenthttps://www.icr.ac.uk/news-features%2flatest-features%2ffrom-bench-to-bedside-and-beyond-the-team-of-scientists-that-transformed-breast-cancer-treatmentFrom bench to bedside and beyond: the team of scientists that transformed breast cancer treatmentA group of researchers from The Institute of Cancer Research and The Royal Marsden have won the prestigious AACR Team Science Award for breast cancer research. Hear from the winning team about their pioneering work and its impact.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-unconventional-journey---beginning-a-research-career-later-in-lifehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-unconventional-journey---beginning-a-research-career-later-in-lifeAn unconventional journey - beginning a research career later in lifePaul Eve, a Senior Scientific Officer in Cancer Therapeutics, was 41 when he started his first science job, having previously worked as a chef and a scaffolder. He tells us more about his career, and why he thinks his varied jobs have added to his work.https://www.icr.ac.uk/news-archive%2faacr-2022-new-%27killer%27-immunotherapy-shows-early-promise-in-range-of-solid-tumourshttps://www.icr.ac.uk/news-archive%2faacr-2022-new-%27killer%27-immunotherapy-shows-early-promise-in-range-of-solid-tumoursAACR 2022: New 'killer' immunotherapy shows early promise in range of solid tumoursA new type of immunotherapy making use of the immune system’s ‘natural killer cells’ could offer potential against a range of cancers that can evade current treatments, early results from a phase I trial suggest.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-2022-what-cancer-research-successes-are-we-looking-forward-tohttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-2022-what-cancer-research-successes-are-we-looking-forward-toAACR 2022: Major cancer conference aims to decode cancer's complexityWith the 2022 AACR Annual Meeting kicking off later this week, Alisa Crisp, Diana Cano and Hattie Hayeck look at some of the pioneering research that will be presented by our researchers at the conference.https://www.icr.ac.uk/news-archive%2faacr-2022-team-of-scientists-and-clinicians-wins-global-award-for-transforming-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2faacr-2022-team-of-scientists-and-clinicians-wins-global-award-for-transforming-breast-cancer-treatmentAACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatmentA group of UK clinical and non-clinical scientists working together across different areas of cancer research has won the AACR Team Science Award for work that has transformed treatment for many patients with breast cancer.https://www.icr.ac.uk/news-archive%2fai-test-could-predict-effective-cancer-drug-combinations-in-less-than-two-dayshttps://www.icr.ac.uk/news-archive%2fai-test-could-predict-effective-cancer-drug-combinations-in-less-than-two-daysAI test could predict effective cancer drug combinations in less than two daysScientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours.https://www.icr.ac.uk/news-archive%2fnew-centre-targets-undruggable-cancers-after-major-donationhttps://www.icr.ac.uk/news-archive%2fnew-centre-targets-undruggable-cancers-after-major-donationNew centre targets ‘undruggable’ cancers after major donationThe centre will focus on ‘targeted protein degradation’ – one of the hottest and most promising areas in drug discovery. Scientists aim to hijack normal process of protein destruction to wipe out cancer proteins that traditional targeted drugs cannot block. https://www.icr.ac.uk/news-archive%2fstudy-shows-more-women-with-invasive-lobular-breast-cancer-should-qualify-for-tailored-clinical-trialshttps://www.icr.ac.uk/news-archive%2fstudy-shows-more-women-with-invasive-lobular-breast-cancer-should-qualify-for-tailored-clinical-trialsStudy shows more women with invasive lobular breast cancer should qualify for tailored clinical trialsA new study led by scientists at The Institute of Cancer Research, London, has changed our understanding of invasive lobular breast cancer – and could increase the number of patients who access new treatments via lobular breast cancer specific clinical trials.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-think-the-cancer-is-done-now-gerry-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-think-the-cancer-is-done-now-gerry-s-story“I think the cancer is done now” – Gerry’s storyGerry was diagnosed with prostate cancer in 2000. During Prostate Cancer Awareness Month, he tells us what research has brought him.https://www.icr.ac.uk/news-archive%2ftest-can-personalise-use-of-immunotherapy-and-chemotherapy-for-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2ftest-can-personalise-use-of-immunotherapy-and-chemotherapy-for-head-and-neck-cancerTest can personalise use of immunotherapy and chemotherapy for head and neck cancer Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report.https://www.icr.ac.uk/news-archive%2ficr-welcomes-fda-approval-of-search-and-destroy-treatmenthttps://www.icr.ac.uk/news-archive%2ficr-welcomes-fda-approval-of-search-and-destroy-treatmentICR welcomes FDA approval of ‘search and destroy’ treatmentThe Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers.https://www.icr.ac.uk/news-archive%2flonger-course-of-hormonal-therapy-before-surgery-for-breast-cancer-has-greater-impact-on-tumour-growthhttps://www.icr.ac.uk/news-archive%2flonger-course-of-hormonal-therapy-before-surgery-for-breast-cancer-has-greater-impact-on-tumour-growthLonger course of hormonal therapy before surgery for breast cancer has greater impact on tumour growthTreating some women with higher risk breast cancer with a longer course of hormonal therapy before surgery led to more changes in the genetic makeup of their tumours, some of which were associated with better survival outcomes. https://www.icr.ac.uk/news-archive%2ficr-discovery-club-showcases-how-we-take-new-drugs-to-cancer-patientshttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-showcases-how-we-take-new-drugs-to-cancer-patientsICR Discovery Club showcases how we take new drugs to cancer patientsMembers of the Discovery Club gathered at the Royal Society of Chemistry to hear how our scientists are moving new cancer drugs into the clinic.https://www.icr.ac.uk/news-archive%2f%27man-van%27-launched-to-speed-up-early-diagnosis-of-prostate-cancer-and-improve-healthcare-accesshttps://www.icr.ac.uk/news-archive%2f%27man-van%27-launched-to-speed-up-early-diagnosis-of-prostate-cancer-and-improve-healthcare-access'Man Van' launched to speed up early diagnosis of prostate cancer and improve healthcare access​The 'Man Van', an innovative new outreach programme, has been launched today to provide free health checks for men and boost early diagnosis of prostate and other urological cancers. https://www.icr.ac.uk/news-archive%2fspinal-fluid-analysis-could-speed-up-diagnosis-of-breast-cancer-spreadhttps://www.icr.ac.uk/news-archive%2fspinal-fluid-analysis-could-speed-up-diagnosis-of-breast-cancer-spreadSpinal fluid analysis could speed up diagnosis of breast cancer spreadAnalysing cancer DNA in spinal fluid could speed up and improve the diagnosis of breast cancer which has spread to the brain and spinal cord, according to a new pilot study. https://www.icr.ac.uk/news-archive%2fcancer-research-uk-renew-support-for-convergence-science-centrehttps://www.icr.ac.uk/news-archive%2fcancer-research-uk-renew-support-for-convergence-science-centreCancer Research UK renew support for Convergence Science CentreRenewed Cancer Research UK funding for Convergence Science Centre at the ICR and Imperial will build on existing partnership by uniting cancer researchers with engineers and physical scientists to tackle cancer’s toughest challenges.https://www.icr.ac.uk/news-archive%2fmajor-trial-shows-targeted-drug-improves-survival-in-early-stage-breast-cancer-with-inherited-BRCA1-or-BRCA2-mutationhttps://www.icr.ac.uk/news-archive%2fmajor-trial-shows-targeted-drug-improves-survival-in-early-stage-breast-cancer-with-inherited-BRCA1-or-BRCA2-mutationESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutationThe ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.https://www.icr.ac.uk/news-features%2flatest-features%2fbreakthebias-scientists-showcase-their-lives-outside-the-labhttps://www.icr.ac.uk/news-features%2flatest-features%2fbreakthebias-scientists-showcase-their-lives-outside-the-lab#BreakTheBias: Scientists showcase their lives outside the labWhat do scientists look like? This International Women’s Day, we are introducing some of our researchers to help #BreakTheBias, and showcasing the full lives and passions of our scientists outside the lab – from dancing and baking to running or playing an instrument.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-women-s-day-2022-meet-icr-entrepreneur-in-residence-heather-kinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-women-s-day-2022-meet-icr-entrepreneur-in-residence-heather-kingInternational Women’s Day 2022: meet ICR entrepreneur-in-residence Heather KingHeather King is one of the entrepreneurs-in-residence here at The Institute of Cancer Research. As part of a programme of entrepreneurial activities overseen by our Business and Innovation Office, Heather is working closely with our researchers – ultimately, aiming to help develop more new products, services and companies to benefit cancer patients. For International Women’s Day, she spoke to Rose Wu about her journey in science and industry, and her advice for the women leaders of the future. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeing-diagnosed-with-cancer-changed-the-way-i-work-surinder-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeing-diagnosed-with-cancer-changed-the-way-i-work-surinder-s-story"Being diagnosed with cancer changed the way I work" – Surinder’s storyNurse consultant Surinder tells us how her experience of cancer changed the way she cares for patients.https://www.icr.ac.uk/news-archive%2fnew-home-for-innovative-life-science-companies-opens-at-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fnew-home-for-innovative-life-science-companies-opens-at-the-london-cancer-hubNew home for innovative life-science companies opens at The London Cancer HubA new incubator and collaboration space for innovative life-science companies whose work is relevant to cancer is opening its doors at The London Cancer Hub in Sutton, south London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-reliable-are-direct-to-consumer-genetic-tests-when-interpreting-cancer-riskhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-reliable-are-direct-to-consumer-genetic-tests-when-interpreting-cancer-riskHow reliable are direct-to-consumer genetic tests when interpreting cancer risk?At-home genetic testing has gained a lot of traction in recent years, raising many ethical issues. Diana Cano talked to world-leading cancer genetics expert Professor Ros Eeles to find out more about the promises and dangers of direct-to-consumer tests in helping to manage cancer risk.https://www.icr.ac.uk/news-archive%2fnhs-gene-testing-does-not-detect-half-of-people-at-cancer-riskhttps://www.icr.ac.uk/news-archive%2fnhs-gene-testing-does-not-detect-half-of-people-at-cancer-riskNHS gene testing does not detect half of people at cancer riskNHS guidelines for gene testing miss half of people carrying inherited genetic changes linked to cancer, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-different-point-of-view-finding-new-ways-to-image-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-different-point-of-view-finding-new-ways-to-image-cancerA different point of view: finding new ways to image cancerProfessor James O’Connor and his team work on developing new ways to image cancer, with a particular focus on imaging tumour cells that don’t receive enough oxygen – a phenomenon called hypoxia that can lead to treatment resistance. Céleste Nilges spoke to him to find out more. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-re-giving-lucas-a-legacy-jo-s-story-of-losing-her-son-to-a-brain-tumourhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-re-giving-lucas-a-legacy-jo-s-story-of-losing-her-son-to-a-brain-tumourWhy we’re giving Lucas a legacy – Jo’s story of losing her son to a brain tumourJo Williams and her husband set up the charity Lucas’ Legacy after losing their son, Lucas, to a brain tumour when he was nearly seven years old. Their support has helped fund our life-changing research into childhood brain tumours. Jo shares their story.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcharles-darwins-theories-expose-cancers-secretshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcharles-darwins-theories-expose-cancers-secretsApplying Charles Darwin’s theories to expose cancer’s secretsTo celebrate Darwin Day, we spoke to Professor Trevor Graham who soon joins us as the new Director of our Centre for Evolution and Cancer. Julia Bakker found out more about his research, how he’s inspired by Charles Darwin, and where he hopes to take our Centre in years to come.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-day-of-women-and-girls-in-science-2022-thoughts-from-our-researchers-to-the-next-generationhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-day-of-women-and-girls-in-science-2022-thoughts-from-our-researchers-to-the-next-generationInternational Day of Women and Girls in Science 2022: thoughts from our researchers to the next generationTo mark the International Day of Women and Girls in Science this year, we're sharing some words of encouragement and advice from our scientists to inspire the next generation of young women starting out in STEM. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-exciting-potential-of-radioactive-elements-in-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-exciting-potential-of-radioactive-elements-in-cancer-treatmentThe exciting potential of radioactive elements in cancer treatmentThe element lutetium has made headlines around the world recently. In its radioactive ‘Lu-177’ form, as part of the drug Lu-177-PSMA, it has exciting potential as a cancer treatment – as our researchers here at The Institute of Cancer Research have helped to demonstrate. So how does it work – and what other radioactive elements have been used as cancer treatments?https://www.icr.ac.uk/news-archive%2fnice-misses-golden-opportunity-to-enhance-access-to-innovative-cancer-drugshttps://www.icr.ac.uk/news-archive%2fnice-misses-golden-opportunity-to-enhance-access-to-innovative-cancer-drugsNICE misses golden opportunity to enhance access to innovative cancer drugsCancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs.https://www.icr.ac.uk/news-archive%2ffocused-sound-waves-and-immunotherapy-combination-shows-promise-in-pancreatic-cancershttps://www.icr.ac.uk/news-archive%2ffocused-sound-waves-and-immunotherapy-combination-shows-promise-in-pancreatic-cancersFocused sound waves and immunotherapy combination shows promise in pancreatic cancersCombining targeted, focused ultrasound and immunotherapy drugs could work as a new treatment for pancreatic cancers, a new study has shown.https://www.icr.ac.uk/news-archive%2ficr-ranks-top-in-uk-for-student-satisfactionhttps://www.icr.ac.uk/news-archive%2ficr-ranks-top-in-uk-for-student-satisfactionICR ranks top in UK for student satisfactionStudents on our MSc taught course and postgraduate research degree programmes have again ranked The Institute of Cancer Research, London, top nationally for student satisfaction in their respective surveys.https://www.icr.ac.uk/news-features%2flatest-features%2fworld-cancer-day-how-our-new-virtual-centre-will-enhance-global-cancer-research-and-tackle-inequalityhttps://www.icr.ac.uk/news-features%2flatest-features%2fworld-cancer-day-how-our-new-virtual-centre-will-enhance-global-cancer-research-and-tackle-inequalityWorld Cancer Day: how our new virtual centre will enhance global cancer research and tackle inequalityThe Centre for Global Oncology will help to to connect and develop cancer scientists around the world.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsequencing-drugging-and-interpreting-genomes-where-is-genomics-going-nexthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsequencing-drugging-and-interpreting-genomes-where-is-genomics-going-nextSequencing, drugging and interpreting genomes: Where is genomics going next?The 2022 Festival of Genomics and Biodata took place last week. Our Media Officer Diana Cano reports on some of the talks, with topics ranging from cancer genomics to drug development.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-targeted-prostate-cancer-screening-programme-could-be-possible-in-five-years---what-will-it-look-likehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-targeted-prostate-cancer-screening-programme-could-be-possible-in-five-years---what-will-it-look-likeA targeted prostate cancer screening programme could be possible in five years - what will it look like?The UK began screening for breast cancer nearly 35 years ago but we’re yet to have a screening programme for prostate cancer. Julia Bakker spoke to the UK’s leading expert in prostate cancer genetics, the ICR’s Professor Ros Eeles, about the progress we’re making and when we can expect prostate cancer screening to be a reality.https://www.icr.ac.uk/news-archive%2fstudy-uncovers-how-cancers-resist-targeted-treatmenthttps://www.icr.ac.uk/news-archive%2fstudy-uncovers-how-cancers-resist-targeted-treatmentStudy uncovers how cancers resist targeted treatmentScientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide.https://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-not-to-recommend-olaparib-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-not-to-recommend-olaparib-for-advanced-prostate-cancerICR responds to NICE decision not to recommend olaparib for advanced prostate cancerThe Institute of Cancer Research, London, has expressed disappointment that NICE has decided not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. https://www.icr.ac.uk/news-archive%2ffirst-clinical-trial-of-innovative-drug-targeting-hsf1-pathway-beginshttps://www.icr.ac.uk/news-archive%2ffirst-clinical-trial-of-innovative-drug-targeting-hsf1-pathway-beginsFirst clinical trial of innovative drug targeting HSF1 pathway beginsThe first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.https://www.icr.ac.uk/news-archive%2fabiraterone-could-halve-risk-of-prostate-cancer-death-for-some-patientshttps://www.icr.ac.uk/news-archive%2fabiraterone-could-halve-risk-of-prostate-cancer-death-for-some-patientsAbiraterone could halve risk of prostate cancer death for some patientsAdding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease. https://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-celebrates-festive-season-and-our-world-leading-researchhttps://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-celebrates-festive-season-and-our-world-leading-researchCarols from Chelsea celebrates festive season and our world-leading researchWe welcomed back guests to our flagship annual social and fundraising event, Carols from Chelsea, at the Royal Hospital Chelsea on the 7 December.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frising-to-the-challenge-meet-one-of-our-researchers-applying-expertise-in-breast-cancer-research-to-make-gains-in-childhood-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frising-to-the-challenge-meet-one-of-our-researchers-applying-expertise-in-breast-cancer-research-to-make-gains-in-childhood-cancerRising to the challenge: meet one of our researchers applying expertise in breast cancer research to make gains in childhood cancerJules Bakker spoke to Dr Chiara Gorrini about joining one of the top childhood cancer research labs in the UK. She discusses how her ten years of experience studying breast cancer is helping the lab drive forward discoveries that will lead to smarter and kinder treatments for children with cancer.https://www.icr.ac.uk/news-archive%2fmeet-our-new-team-membershttps://www.icr.ac.uk/news-archive%2fmeet-our-new-team-membersMeet our new team membersNew faces have joined the Business and Innovation Office here at The Institute of Cancer Research, London since our last newsletter. They’re helping us further expand our work with industry and academic partners.https://www.icr.ac.uk/news-archive%2ficr-in-new-collaboration-to-develop-next-generation-immunotherapy-candidatehttps://www.icr.ac.uk/news-archive%2ficr-in-new-collaboration-to-develop-next-generation-immunotherapy-candidateICR in new collaboration to develop ‘next generation’ immunotherapy candidateScientists at The Institute of Cancer Research, London, are working with the Cambridge-based immuno-oncology company Crescendo Biologics on its development of a potential ‘next generation’ immunotherapy.https://www.icr.ac.uk/news-archive%2ftrial-identifies-five-drug-combo-for-ultra-high-risk-bone-marrow-cancerhttps://www.icr.ac.uk/news-archive%2ftrial-identifies-five-drug-combo-for-ultra-high-risk-bone-marrow-cancerTrial identifies five-drug combo for ‘ultra high risk’ bone marrow cancerA combination of five existing drugs keeps cancer at bay for longer in patients with a highly aggressive type of bone marrow cancer, a major new trial reveals.https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2021https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2021Scientific achievements of 2020/2021We've selected a range of discoveries from the academic year that highlight the quality and breadth of our basic, translational and clinical research.https://www.icr.ac.uk/news-archive%2fcancer-trial-recruitment-drops-by-60-per-cent-during-pandemichttps://www.icr.ac.uk/news-archive%2fcancer-trial-recruitment-drops-by-60-per-cent-during-pandemicCancer trial recruitment drops by 60 per cent during pandemicThe number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying the development of cutting-edge drugs and technologies. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-new-guidelines-are-ushering-in-a-new-era-for-breast-cancer-clinical-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-new-guidelines-are-ushering-in-a-new-era-for-breast-cancer-clinical-trialsHow new guidelines are ushering in a new era for breast cancer clinical trialsBreast cancer clinical trials have evolved over the years, and with new ideas came new challenges in reporting their results. Molly Andrews explores the ICR’s role in setting out new guidance for recording results from breast cancer clinical trials. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-was-so-young-when-my-mum-died-danny-s-secondary-breast-cancer-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-was-so-young-when-my-mum-died-danny-s-secondary-breast-cancer-story“I was so young when my mum died” – Danny’s secondary breast cancer storyDanny lost his mum to secondary breast cancer when he was just seven years old. He tells us how he found a community who are helping to fight the disease.https://www.icr.ac.uk/news-archive%2fsleeping-cancer-cells-explain-why-childhood-leukaemia-returns-after-years-of-treatmenthttps://www.icr.ac.uk/news-archive%2fsleeping-cancer-cells-explain-why-childhood-leukaemia-returns-after-years-of-treatment‘Sleeping’ cancer cells explain why childhood leukaemia returns after years of treatmentLeukaemic cancer cells can ‘go to sleep’ and thus avoid the effects of chemotherapy, sometimes for years. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2021-debating-the-future-of-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2021-debating-the-future-of-cancer-treatmentNCRI 2021: Debating the future of cancer treatmentMunro Passmore, Public Engagement Intern at the ICR, reports on a series of discussions at the recent NCRI Festival exploring current issues and opportunities at the heart of cancer research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-personal-source-code-leveraging-personal-proteogenomics-for-targeted-cancer-therapyhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-personal-source-code-leveraging-personal-proteogenomics-for-targeted-cancer-therapyScience Writing Prize 2021 – Personal source code: leveraging personal proteogenomics for targeted cancer therapyDr James Wright covers the evolving field of proteogenomics and its future for targeted cancer therapies in this piece shortlisted for the 2021 Mel Greaves Science Writing Prize.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-the-next-big-thing-diving-into-the-immunoverse-to-create-novel-and-personalised-cancer-therapieshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-the-next-big-thing-diving-into-the-immunoverse-to-create-novel-and-personalised-cancer-therapiesScience Writing Prize 2021 – The next big thing: diving into the ‘immunoverse’ to create novel and personalised cancer therapiesDr Vivian Dimou explores the 'immunoverse' – the interplay between immune cells and their surrounding tissue environment – in this piece shortlisted for the 2021 Mel Greaves Science Writing Prize. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-organoidsationhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2021-organoidsationScience Writing Prize 2021 – OrganoidsationJorge Almagro Santiago draws together differing perspectives on organoid science in this piece which won the 2021 Mel Greaves Science Writing Prize.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fhpv-vaccines-and-the-prospects-for-cancer-preventionhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fhpv-vaccines-and-the-prospects-for-cancer-preventionHPV vaccines and the prospects for cancer preventionFollowing the report that HPV vaccination of teenage girls may reduce the incidence of cervical cancer by around 90%, Professor Sir Mel Greaves discusses the future of cancer prevention.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fembedding-sustainability-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fembedding-sustainability-at-the-icrEmbedding sustainability at the ICRNow world leaders have left COP26 in Glasgow after agreeing measures to help combat climate change, Environmental Sustainability Consultant Peter Watts discusses the steps the ICR is taking to reduce our carbon emissions and to help make our research more sustainable. https://www.icr.ac.uk/news-archive%2ficr-researchers-named-among-world-s-most-influential-scientistshttps://www.icr.ac.uk/news-archive%2ficr-researchers-named-among-world-s-most-influential-scientistsICR researchers named among world’s most influential scientistsSix researchers at the ICR and The Royal Marsden have been named in a list of the world's most influential by the by science analytics company Clarivate.https://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-one-year-at-the-centre-for-cancer-drug-discoveryhttps://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-one-year-at-the-centre-for-cancer-drug-discoveryCelebrating one year at the Centre for Cancer Drug DiscoveryOne year ago we opened the doors to the Centre for Cancer Drug Discovery. To celebrate, we're looking back on the journey to build it, how it has developed over the last year and its exciting future.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-year-2035-what-is-the-future-of-cancer-research-and-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-year-2035-what-is-the-future-of-cancer-research-and-treatmentThe year 2035: What is the future of cancer research and treatment?The Covid-19 pandemic has accelerated many changes in cancer research, and shown we can do things in radically different ways – as we heard at a series of ‘Year 2035’ talks at this year’s National Cancer Research Institute (NCRI) Festival. Here we take a look at three key themes emerging from these talks: the challenges of adapting cancer treatment for an ageing population, the importance of equality and diversity, and clinical trials in a post-Covid world.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-future-of-prostate-cancer-research-what-could-the-next-decade-bringhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-future-of-prostate-cancer-research-what-could-the-next-decade-bringThe future of prostate cancer research: what could the next decade bring?The last decade has brought major advances in the way we diagnose and treat prostate cancer and men with advanced disease are living longer than ever. Diana Cano spoke to our scientists about the most exciting research areas that have the potential to revolutionise prostate cancer treatment in years to come.https://www.icr.ac.uk/news-archive%2fscientists-identify-potential-new-drug-combination-for-children-with-incurable-brain-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-potential-new-drug-combination-for-children-with-incurable-brain-cancerScientists identify potential new drug combination for children with incurable brain cancerCombining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2021-cancer-researchers-reconvene-virtually-for-uk-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2021-cancer-researchers-reconvene-virtually-for-uk-s-largest-cancer-conferenceNCRI 2021: Cancer researchers reconvene virtually for UK’s largest cancer conferenceWe highlight the ICR science being presented at this year’s virtual NCRI Festival. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdigital-pathology-how-our-scientists-are-part-of-a-revolution-in-cancer-diagnosis-and-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdigital-pathology-how-our-scientists-are-part-of-a-revolution-in-cancer-diagnosis-and-treatmentDigital pathology: how our scientists are part of a revolution in cancer diagnosis and treatmentNational Pathology Week celebrates the important contribution pathologists make to healthcare. At The Institute of Cancer Research, we’re pioneers in a new field called digital pathology – that’s set to transform the way cancer is diagnosed and treated, using sophisticated computing tools and artificial intelligence to uncover crucial clues about tumours.https://www.icr.ac.uk/news-features%2flatest-features%2ftaking-a-personalised-approach-to-aggressive-pancreatic-cancershttps://www.icr.ac.uk/news-features%2flatest-features%2ftaking-a-personalised-approach-to-aggressive-pancreatic-cancersTaking a personalised approach to aggressive pancreatic cancersPancreatic cancer is highly aggressive and difficult to treat, but now our scientists are taking a more personalised approach. For Pancreatic Cancer Awareness Month, Gege Li looks at how our researchers are using artificial intelligence to improve treatment.https://www.icr.ac.uk/news-archive%2fliquid-biopsies-one-step-closer-to-entering-the-clinic-to-help-guide-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fliquid-biopsies-one-step-closer-to-entering-the-clinic-to-help-guide-breast-cancer-treatmentLiquid biopsies one step closer to entering the clinic to help guide breast cancer treatmentA simple blood test can identify specific genetic mutations in patients’ breast tumours to help guide their treatment and assess how likely patients are to relapse, a study shows.https://www.icr.ac.uk/news-archive%2fcancer-researchers-reveal-direct-block-to-dna-replicationhttps://www.icr.ac.uk/news-archive%2fcancer-researchers-reveal-direct-block-to-dna-replicationCancer researchers reveal direct block to DNA replicationFor the first time, scientists have shown that a major protein acts as a direct block in multiple stages of DNA replication, improving our understanding of how cancer develops. https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-sir-michael-peckham-1935-2021https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-sir-michael-peckham-1935-2021Professor Sir Michael Peckham, 1935 – 2021Professor Sir Michael Peckham was Professor of Radiotherapy at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust from 1973 to 1985. In this obituary, former colleagues pay tribute to a brilliant scientist, artist and policymaker.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsafeguarding-our-research-for-the-future-how-the-icr-is-greening-its-labshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsafeguarding-our-research-for-the-future-how-the-icr-is-greening-its-labsSafeguarding our research for the future: how the ICR is greening its labsAhead of the UN Climate Change Conference (COP26) in Glasgow, Graham Shaw looks at some of the ways ICR researchers are helping to reduce waste and lower their carbon footprint.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-decades-of-clinical-trials-have-transformed-breast-cancer-radiotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-decades-of-clinical-trials-have-transformed-breast-cancer-radiotherapyHow decades of clinical trials have transformed breast cancer radiotherapyAfter leading numerous practice-changing trials, Professor John Yarnold received a prestigious award at the 2021 ESTRO Congress. For Breast Cancer Awareness Month, Diana Cano looks back at the huge impact he has had in the field of breast cancer radiotherapy.https://www.icr.ac.uk/news-archive%2ficr-research-showcased-in-world-first-exhibition-exploring-cutting-edge-cancer-researchhttps://www.icr.ac.uk/news-archive%2ficr-research-showcased-in-world-first-exhibition-exploring-cutting-edge-cancer-researchICR research showcased in world-first exhibition exploring cutting-edge cancer researchA new world-first exhibition by the Science Museum Group titled Cancer Revolution: Science, innovation and hope features a series of pioneering research projects being carried out at The Institute of Cancer Research, London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fclinical-trial-statistics-so-much-more-than-just-analysishttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fclinical-trial-statistics-so-much-more-than-just-analysisClinical trial statistics: so much more than analysisFor World Statistics Day Graham Shaw spoke to Dr Jan Rekowski from the ICR’s Clinical Trials and Statistics Unit. He shared advice on getting into medical statistics and explained how statistics helps to generate meaningful data and provide far more than just analysis.https://www.icr.ac.uk/news-archive%2ftargeted-prostate-cancer-screening-could-benefit-men-with-inherited-cancer-syndromehttps://www.icr.ac.uk/news-archive%2ftargeted-prostate-cancer-screening-could-benefit-men-with-inherited-cancer-syndromeTargeted prostate cancer screening could benefit men with inherited cancer syndromeMen who inherit an increased risk of cancer through ‘Lynch syndrome’ could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe.https://www.icr.ac.uk/news-archive%2ficr-ranked-as-one-of-world-s-top-research-institutes-for-influence-and-commercial-impacthttps://www.icr.ac.uk/news-archive%2ficr-ranked-as-one-of-world-s-top-research-institutes-for-influence-and-commercial-impactICR ranked as one of world’s top research institutes for influence and commercial impactThe Institute of Cancer Research is one of the top-ranked higher education institutions in the world for academic influence and commercial impact, according to an international assessment.https://www.icr.ac.uk/news-archive%2ficr-discovery-club-returns-in-person-looks-to-the-future-of-treating-children-with-cancerhttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-returns-in-person-looks-to-the-future-of-treating-children-with-cancerICR Discovery Club returns in-person, looks to the future of treating children with cancerMembers of the Discovery Club reunited at the Royal Society in London for an intimate evening with some of our leading childhood cancer scientists. https://www.icr.ac.uk/news-archive%2fresearchers-find-immune-system-link-with-rare-ovarian-cancer-that-could-guide-future-treatmenthttps://www.icr.ac.uk/news-archive%2fresearchers-find-immune-system-link-with-rare-ovarian-cancer-that-could-guide-future-treatmentResearchers find immune system link with rare ovarian cancer that could guide future treatmentImmune-related genes are associated with the development of the rare cancer ovarian clear cell carcinoma (OCCC), new research has found.https://www.icr.ac.uk/news-archive%2fimmunotherapy-combination-could-be-alternative-to-extreme-chemotherapy-in-some-head-and-neck-cancershttps://www.icr.ac.uk/news-archive%2fimmunotherapy-combination-could-be-alternative-to-extreme-chemotherapy-in-some-head-and-neck-cancersESMO 2021: Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancersAn immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblackincancer-reaching-communities-most-affected-by-prostate-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblackincancer-reaching-communities-most-affected-by-prostate-cancer#BlackinCancer: Reaching communities most affected by prostate cancerFor Black in Cancer Week, our Science Communications Officer Juanita Bawagan spoke to Dr Michael Ranes about the importance of diversity in cancer research for science and society.https://www.icr.ac.uk/news-archive%2fthe-princess-royal-officially-opens-pioneering-centre-for-%27darwinian%27-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2fthe-princess-royal-officially-opens-pioneering-centre-for-%27darwinian%27-cancer-drug-discoveryThe Princess Royal officially opens pioneering centre for 'Darwinian' cancer drug discoveryHer Royal Highness The Princess Royal has officially opened the Centre for Cancer Drug Discovery and toured the centre to learn more about its work to overcome cancer’s ability to evolve and become resistant to treatment.https://www.icr.ac.uk/news-archive%2f%27gut-bugs%27-can-drive-prostate-cancer-growth-and-treatment-resistancehttps://www.icr.ac.uk/news-archive%2f%27gut-bugs%27-can-drive-prostate-cancer-growth-and-treatment-resistance'Gut bugs' can drive prostate cancer growth and treatment resistanceCommon gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2funravelling-the-proteome-how-we-can-use-proteomics-to-understand-and-treat-rare-cancershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2funravelling-the-proteome-how-we-can-use-proteomics-to-understand-and-treat-rare-cancersUnravelling the proteome: how we can use proteomics to understand and treat rare cancersDr Paul Huang is using proteomics as part of his ongoing research into sarcomas. Diana Cano talked to him to find out how why it is important to understand the protein machinery that drives this cancer type.https://www.icr.ac.uk/news-archive%2fscientists-use-ai-to-identify-new-drug-combination-for-children-with-incurable-brain-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-use-ai-to-identify-new-drug-combination-for-children-with-incurable-brain-cancerScientists use AI to identify new drug combination for children with incurable brain cancerScientists have used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.https://www.icr.ac.uk/news-archive%2fdrug-combination-shows-promise-in-treatment-resistant-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fdrug-combination-shows-promise-in-treatment-resistant-advanced-ovarian-cancerESMO 2021: Drug combination shows promise in treatment-resistant advanced ovarian cancerA new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.https://www.icr.ac.uk/news-archive%2fabiraterone-keeps-men-with-prostate-cancer-at-risk-of-spreading-alive-for-longerhttps://www.icr.ac.uk/news-archive%2fabiraterone-keeps-men-with-prostate-cancer-at-risk-of-spreading-alive-for-longerAbiraterone keeps men with prostate cancer at risk of spreading alive for longerGiving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer, that has not spread elsewhere in the body, live longer.https://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-courses-for-prostate-cancer-are-well-tolerated-long-term-by-patientshttps://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-courses-for-prostate-cancer-are-well-tolerated-long-term-by-patientsShorter radiotherapy courses for prostate cancer are well tolerated long-term by patients A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblood-cancer-awareness-month-2021-meet-a-blood-cancer-researcherhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblood-cancer-awareness-month-2021-meet-a-blood-cancer-researcherBlood Cancer Awareness Month 2021: Meet a blood cancer researcherWe interview Charlotte Pawlyn, one of our top blood cancer researchers. Find out the ins and outs of the life of a scientist, the latest discoveries in the laboratory, and how patients help direct Charlotte's research into kinder, smarter therapies.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-lost-tribe-improving-the-lives-of-young-adults-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-lost-tribe-improving-the-lives-of-young-adults-with-cancerThe Lost Tribe: Improving the lives of young adults with cancerCaught between child and adult care, young adult cancer patients have been described as a 'lost tribe'. In this blog, Juanita Bawagan speaks to patient and researcher Sam Beardsworth and Staff Scientist Dr Olga Husson about the unique challenges that young adults with cancer face.https://www.icr.ac.uk/news-archive%2fmonte-rosa-therapeutics-lists-on-new-york-stock-exchangehttps://www.icr.ac.uk/news-archive%2fmonte-rosa-therapeutics-lists-on-new-york-stock-exchangeMonte Rosa Therapeutics lists on New York Stock ExchangeMonte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblood-cancer-awareness-month-2021-recent-advances-in-blood-cancer-research-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fblood-cancer-awareness-month-2021-recent-advances-in-blood-cancer-research-at-the-icrBlood Cancer Awareness Month 2021: Recent advances in blood cancer research at the ICRWorldwide, more than one million people are diagnosed with blood cancer each year. For Blood Cancer Awareness Month, our Communications Administrator Molly Andrews looks back at some recent developments in blood cancer research at the ICR.https://www.icr.ac.uk/news-archive%2fcancer-vaccine-could-be-effective-way-to-overcome-treatment-resistancehttps://www.icr.ac.uk/news-archive%2fcancer-vaccine-could-be-effective-way-to-overcome-treatment-resistanceCancer vaccine could be effective way to overcome treatment resistanceA cancer vaccine could be an effective way to prevent cancer from evolving and becoming resistant to treatment, new research suggests.https://www.icr.ac.uk/news-archive%2ficr-comes-top-in-university-invention-income-for-eighth-successive-yearhttps://www.icr.ac.uk/news-archive%2ficr-comes-top-in-university-invention-income-for-eighth-successive-yearICR comes top in university invention income for eighth successive yearThe Institute of Cancer Research, London, has earned the most staff-adjusted invention income of any UK higher education institution for the eighth year in a row.https://www.icr.ac.uk/news-archive%2fshorter-course-of-radiotherapy-safely-delivers-treatment-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fshorter-course-of-radiotherapy-safely-delivers-treatment-for-prostate-cancerShorter course of radiotherapy safely delivers treatment for prostate cancerAdvanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and the ICR.https://www.icr.ac.uk/news-features%2flatest-features%2fa-visionary-research-leader-ally-and-mentor---professor-paul-workman-steps-down-as-ceohttps://www.icr.ac.uk/news-features%2flatest-features%2fa-visionary-research-leader-ally-and-mentor---professor-paul-workman-steps-down-as-ceoA visionary research leader, ally and mentor - Professor Paul Workman steps down as CEOAs Professor Paul Workman steps down as Chief Executive of The Institute of Cancer Research, London, colleagues from the ICR and beyond share memories of and reflections on his impact in cancer research.https://www.icr.ac.uk/news-archive%2finnovative-icr-discovered-drug-to-enter-first-clinical-trial-targeting-hsf1-pathwayhttps://www.icr.ac.uk/news-archive%2finnovative-icr-discovered-drug-to-enter-first-clinical-trial-targeting-hsf1-pathwayInnovative ICR-discovered drug to enter first clinical trial, targeting HSF1 pathwayCancer patients are set to receive, for the first time, a highly innovative investigational drug called NXP800 – which was discovered at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-paul-workman%27s-achievementshttps://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-paul-workman%27s-achievementsCelebrating the ICR’s achievements under Professor Paul Workman’s leadershipProfessor Paul Workman steps down as Chief Executive of The Institute of Cancer Research. Here, we look back at a selection of the many ICR achievements during his leadership.https://www.icr.ac.uk/news-archive%2fnew-brca-targeting-drug-could-offer-hope-in-treating-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-brca-targeting-drug-could-offer-hope-in-treating-advanced-prostate-cancerNew BRCA-targeting drug could offer hope in treating advanced prostate cancerTalazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows.https://www.icr.ac.uk/news-archive%2frecreating-a-signalling-process-in-the-test-tube-provides-clues-to-bowel-cancerhttps://www.icr.ac.uk/news-archive%2frecreating-a-signalling-process-in-the-test-tube-provides-clues-to-bowel-cancerRecreating a signalling process in the test tube provides clues to bowel cancerScientists have, for the first time, recreated an assembly of proteins known as the β-catenin destruction complex in the test tube. This is a long-awaited step in cancer research, as mutations in this destruction complex are found in a large percentage of bowel and other cancers.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2freflecting-on-deepmind-s-alphafold-artificial-intelligence-success-what-s-the-real-significance-for-protein-folding-research-and-drug-discoveryhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2freflecting-on-deepmind-s-alphafold-artificial-intelligence-success-what-s-the-real-significance-for-protein-folding-research-and-drug-discoveryReflecting on DeepMind’s AlphaFold artificial intelligence success – what’s the real significance for protein folding research and drug discovery?In a long read, Professor Paul Workman, Chief Executive and President of the ICR, and also a drug discovery scientist, reflects on the significance of the latest version of AlphaFold – a powerful AI system that has been applied to predict structures for almost 99% of human proteins – for fundamental research and drug discovery.https://www.icr.ac.uk/news-archive%2fcombination-drug-therapy-can-significantly-benefit-patients-with-newly-diagnosed-blood-cancerhttps://www.icr.ac.uk/news-archive%2fcombination-drug-therapy-can-significantly-benefit-patients-with-newly-diagnosed-blood-cancerCombination drug therapy can significantly benefit patients with newly diagnosed blood cancerA four-drug combination therapy that includes the novel drug carfilzomib can slow the progression of the blood cancer myeloma in patients who have been newly diagnosed with the disease, a phase III study has shown.https://www.icr.ac.uk/news-archive%2fscoring-system-predicts-head-and-neck-cancer-patient-response-to-immunotherapyhttps://www.icr.ac.uk/news-archive%2fscoring-system-predicts-head-and-neck-cancer-patient-response-to-immunotherapyScoring system predicts head and neck cancer patient response to immunotherapyA prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.https://www.icr.ac.uk/news-features%2flatest-features%2ftaking-on-the-challenge-of-treating-sarcomashttps://www.icr.ac.uk/news-features%2flatest-features%2ftaking-on-the-challenge-of-treating-sarcomasTaking on the challenge of treating sarcomasIn the UK, sarcoma diagnoses make up more than 1% of all cancer cases. But sarcomas are hard to understand and treat, and outcomes for patients with advanced disease remain poor – they are cancers of urgent unmet need. Sarcomas are a major focus for our scientists, who are forging new collaborations and opening up fresh avenues for research and treatment.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-nice-s-recommendation-not-to-approve-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-nice-s-recommendation-not-to-approve-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerThe ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancerThe Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer.https://www.icr.ac.uk/news-features%2flatest-features%2frace-equality-how-the-icr-is-going-beyond-its-statements-and-taking-real-actionhttps://www.icr.ac.uk/news-features%2flatest-features%2frace-equality-how-the-icr-is-going-beyond-its-statements-and-taking-real-actionRace equality: how the ICR is going beyond its statements, and taking real actionOne year ago the ICR made commitments to tackling racial inequality in our organisation and beyond. To mark the anniversary, Gege Li spoke to some of the people involved in our progress to date and discussed the challenges ahead.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-gift-of-giving-how-your-generosity-can-lead-to-changehttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-gift-of-giving-how-your-generosity-can-lead-to-changeThe gift of giving: how your generosity can lead to changeLara Jukes is the Director of Development at The Institute of Cancer Research, London. As we thank generous donors to our Spring fundraising appeal, she reflects on why giving is an integral part of our culture and how much of a difference it can make to those who need it most. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fambassadors-of-change-how-our-students-are-driving-innovation-and-diversityhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fambassadors-of-change-how-our-students-are-driving-innovation-and-diversityAmbassadors of change: how our students are driving innovation and diversityAs we mark our annual Teaching Week – celebrating our students’ contribution to life here at The Institute of Cancer Research – our Registrar Dr Barbara Pittam describes how our students play a central role in both our world-leading cancer research and creating a diverse, inclusive culture.https://www.icr.ac.uk/news-archive%2fnew-drug-combination-attacks-prostate-cancer-on-two-fronts-to-keep-men-healthy-for-longerhttps://www.icr.ac.uk/news-archive%2fnew-drug-combination-attacks-prostate-cancer-on-two-fronts-to-keep-men-healthy-for-longerNew drug combination attacks prostate cancer on two fronts to keep men healthy for longerMen with particularly aggressive prostate cancers can be treated more effectively by combining an existing targeted medicine, abiraterone, with a new experimental drug to block two of cancer’s growth signals at once, a major new trial shows.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcomplexity-of-cause-in-cancer-or-why-the-frogs-jumphttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcomplexity-of-cause-in-cancer-or-why-the-frogs-jumpComplexity of cause in cancer: or why the frogs jumpOur need to understand the cause or reason for dramatic, natural events is a very ancient and uniquely human urge. Professor Sir Mel Greaves explores the dilemma between our instinctive desire for simple, singular explanations when science is inherently uncertain and complex.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-m-33-years-old-and-there-s-still-so-much-i-want-to-do---kate%27s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-m-33-years-old-and-there-s-still-so-much-i-want-to-do---kate%27s-story“I’m 33 years old, and there’s still so much I want to do” - Kate's storyKate Parker was diagnosed with stage 4 bowel cancer just before her 30th birthday. She tells us what more treatment options mean for her.https://www.icr.ac.uk/news-features%2flatest-features%2fcansar-10-year-anniversaryhttps://www.icr.ac.uk/news-features%2flatest-features%2fcansar-10-year-anniversarycanSAR: The AI ‘knowledgebase’ revolutionising cancer drug discovery Since its release in 2011, canSAR has become the largest, public, cancer drug discovery resource in the world. On the 10-year anniversary of canSAR we take a look at how it’s shaping the future of drug discovery.https://www.icr.ac.uk/news-archive%2fmri-images-reconstructed-by-artificial-intelligence-could-accelerate-and-better-guide-radiotherapyhttps://www.icr.ac.uk/news-archive%2fmri-images-reconstructed-by-artificial-intelligence-could-accelerate-and-better-guide-radiotherapyMRI images reconstructed by artificial intelligence could accelerate and better guide radiotherapyAn artificial intelligence (AI) that reconstructs MRI images of moving tumours can do so in seconds, offering a significant improvement on current methods to optimise radiotherapy treatment in the clinic.https://www.icr.ac.uk/news-archive%2fgenetic-discovery-could-help-guide-treatment-for-aggressive-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-discovery-could-help-guide-treatment-for-aggressive-childhood-cancerGenetic discovery could help guide treatment for aggressive childhood cancerA new study could lead to improved decision making in assigning treatments for children with the aggressive cancer rhabdomyosarcoma after revealing key genetic changes underlying development of the disease.https://www.icr.ac.uk/news-archive%2fearly-promise-for-first-targeted-brain-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fearly-promise-for-first-targeted-brain-cancer-treatmentASCO 2021: Early promise for first targeted brain cancer treatmentA new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease.https://www.icr.ac.uk/news-archive%2fnew-drug-class-could-treat-range-of-cancers-with-faulty-brca-geneshttps://www.icr.ac.uk/news-archive%2fnew-drug-class-could-treat-range-of-cancers-with-faulty-brca-genesNew drug class could treat range of cancers with faulty BRCA genesScientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fhow-we-ranked-amongst-the-country-s-top-universities-in-the-knowledge-exchange-frameworkhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fhow-we-ranked-amongst-the-country-s-top-universities-in-the-knowledge-exchange-frameworkHow we ranked amongst the country’s top universities in the Knowledge Exchange FrameworkDr Angela Kukula, Director of Business of Innovation at The Institute of Cancer Research, reflects on our strong performance in the recent Knowledge Exchange Framework (KEF), highlighting our excellence in translating our research into patient benefit.https://www.icr.ac.uk/news-archive%2fleading-icr-scientists-recognised-by-the-royal-college-of-radiologistshttps://www.icr.ac.uk/news-archive%2fleading-icr-scientists-recognised-by-the-royal-college-of-radiologistsLeading ICR scientists recognised by the Royal College of Radiologists Professor Nick James and Professor Emma Hall were recognised for their contributions to radiology and oncology by the Royal College of Radiologists in a virtual admission ceremony today. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthere-was-a-lot-of-joy-and-a-lot-of-living-got-donehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthere-was-a-lot-of-joy-and-a-lot-of-living-got-done“There was a lot of joy, and a lot of living got done” - Hilary's storyHilary Morgan kindly shared the story of her husband, Tim, to support our bowel cancer fundraising appeal. Tim was diagnosed with advanced bowel cancer at the age of 43. Here, Hilary tells us more about how pioneering treatments gave him a chance to live.https://www.icr.ac.uk/news-archive%2ficr-researchers-reveal-how-they-are-tackling-rare-cancers-at-virtual-discovery-club-eventhttps://www.icr.ac.uk/news-archive%2ficr-researchers-reveal-how-they-are-tackling-rare-cancers-at-virtual-discovery-club-eventICR researchers reveal how they are tackling rare cancers at virtual Discovery Club eventFor our latest Discovery Club, members met virtually with some of our leading scientists, who are using cutting-edge methods to assess and treat rare cancers such as sarcoma and other cancers of unmet need. During the evening, guests learned more about how they helping to find new treatment options for these patients who desperately need them - and why philanthropic support is so vital. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-icr-research-makes-an-impression-at-virtual-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-icr-research-makes-an-impression-at-virtual-cancer-conferenceASCO 2021: ICR research makes an impression at virtual cancer conferenceThe ASCO Annual Meeting took place virtually over the weekend, with many ICR researchers attending and presenting abstracts. Here we look back over some of the highlights of this year’s meeting.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-the-science-behind-olaparib-s-promise-shown-in-the-olympia-trial-for-early-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-the-science-behind-olaparib-s-promise-shown-in-the-olympia-trial-for-early-breast-cancerASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trialThe OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough.https://www.icr.ac.uk/news-archive%2ftrial-shows-benefits-of-targeted-drug-against-early-stage-breast-cancer-with-inherited-brca-mutationhttps://www.icr.ac.uk/news-archive%2ftrial-shows-benefits-of-targeted-drug-against-early-stage-breast-cancer-with-inherited-brca-mutationASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutationWomen with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.https://www.icr.ac.uk/news-archive%2fnew-search-and-destroy-treatment-extends-life-in-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-search-and-destroy-treatment-extends-life-in-advanced-prostate-cancerASCO 2021: New ‘search and destroy’ treatment extends life in advanced prostate cancerA new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports.https://www.icr.ac.uk/news-archive%2ficr-announces-new-chair-of-board-of-trusteeshttps://www.icr.ac.uk/news-archive%2ficr-announces-new-chair-of-board-of-trusteesICR announces new Chair of Board of TrusteesProfessor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-global-cancer-researchers-reunite-virtuallyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2021-global-cancer-researchers-reunite-virtuallyASCO 2021: Global cancer researchers reunite virtually We look ahead at some of the highlights that scientists from The Institute of Cancer Research will be presenting at this year’s virtual edition of the ASCO Annual Meeting.https://www.icr.ac.uk/news-archive%2fstudy-polypharmacology-earlier-in-drug-discovery-say-researchershttps://www.icr.ac.uk/news-archive%2fstudy-polypharmacology-earlier-in-drug-discovery-say-researchersStudy polypharmacology earlier in drug discovery, say researchersPolypharmacology – the ability of a drug to affect more than one protein – should be studied early in the drug discovery pathway, and constantly monitored as the chemical structure is optimised in the design of the clinical candidate, leading researchers believe.https://www.icr.ac.uk/news-archive%2fscientists-make-long-range-weather-forecasts-of-bowel-cancer-s-drug-resistancehttps://www.icr.ac.uk/news-archive%2fscientists-make-long-range-weather-forecasts-of-bowel-cancer-s-drug-resistanceScientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistanceScientists can use genetic ‘weather forecasting’ to predict how long it will take for bowel cancer to evolve resistance to a drug before a patient has even started treatment, a new study has shown.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flisten-to-the-patient-international-clinical-trials-day-2021https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flisten-to-the-patient-international-clinical-trials-day-2021Listen to the patient: International Clinical Trials Day 2021Professor Christina Yap is Team Leader in Early Phase and Adaptive Trials within our Clinical Trials and Statistics Unit (ICR-CTSU). Her work on clinical trial design involves rethinking conventional procedures to make trials more efficient and outcomes more relevant for patients. On International Clinical Trials Day 2021, Gege Li spoke to Professor Yap to find out more about one change that could improve how we uncover adverse symptoms in cancer patients. https://www.icr.ac.uk/news-features%2flatest-features%2ffrom-breakthroughs-to-patient-benefits-inside-the-icr-s-clinical-trials-and-statistics-unithttps://www.icr.ac.uk/news-features%2flatest-features%2ffrom-breakthroughs-to-patient-benefits-inside-the-icr-s-clinical-trials-and-statistics-unitFrom breakthroughs to patient benefits: inside the ICR’s Clinical Trials and Statistics Unit In this feature, Molly Andrews takes a close look at how the ICR’s Clinical Trials and Statistics Unit is turning scientific advances into benefits for patients, through cutting-edge clinical trials.https://www.icr.ac.uk/news-archive%2ficr-among-country-s-top-universities-in-first-knowledge-exchange-frameworkhttps://www.icr.ac.uk/news-archive%2ficr-among-country-s-top-universities-in-first-knowledge-exchange-frameworkICR among country’s top universities in first Knowledge Exchange FrameworkThe Institute of Cancer Research, London, has ranked highly in the UK’s first Knowledge Exchange Framework (KEF), a new Government assessment of universities’ partnerships and their influence on wider society.https://www.icr.ac.uk/news-archive%2fprince-of-wales-visits-the-breast-cancer-now-toby-robins-research-centre-at-icrhttps://www.icr.ac.uk/news-archive%2fprince-of-wales-visits-the-breast-cancer-now-toby-robins-research-centre-at-icrPrince of Wales visits the Breast Cancer Now Toby Robins Research Centre at ICRToday, His Royal Highness The Prince of Wales visited the Breast Cancer Now Toby Robins Research Centre, at The Institute of Cancer Research, London, 21 years after he officially opened it as the UK’s first dedicated breast cancer research centre in 1999. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fshining-new-light-on-immunotherapy-for-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fshining-new-light-on-immunotherapy-for-breast-cancerShining new light on immunotherapy for breast cancerResearch shows some breast cancer types may benefit from immunotherapy, but new trial designs are needed to evaluate this potential.https://www.icr.ac.uk/news-archive%2fleading-breast-cancer-researcher-elected-as-fellow-of-the-academy-of-medical-scienceshttps://www.icr.ac.uk/news-archive%2fleading-breast-cancer-researcher-elected-as-fellow-of-the-academy-of-medical-sciencesLeading breast cancer researcher elected as Fellow of the Academy of Medical SciencesProfessor Nicholas Turner has been recognised with a prestigious Fellowship of the Academy of Medical Sciences for his excellence in breast cancer research and outstanding contribution to the field. https://www.icr.ac.uk/news-archive%2fnew-type-of-treatment-could-reawaken-immune-response-against-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-type-of-treatment-could-reawaken-immune-response-against-prostate-cancerNew type of treatment could reawaken immune response against prostate cancerTargeting a molecule on the surface of immune cells could offer an exciting new way to treat prostate cancer by reawakening the immune response against it.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-medical-physics-week-2021-how-the-icr-has-pioneered-ultrasound-research-to-study-and-treat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-medical-physics-week-2021-how-the-icr-has-pioneered-ultrasound-research-to-study-and-treat-cancerInternational Medical Physics Week 2021 – how the ICR has pioneered ultrasound research to study and treat cancerPhysics plays an important role in cancer research, and in helping to understand and treat the disease. To mark International Medical Physics Week, Graham Shaw discussed pioneering ultrasound research with two of The Institute of Cancer Research’s leading Medical Physicists, Dr Emma Harris and Professor Jeffrey Bamber. https://www.icr.ac.uk/news-archive%2fceo-announcementhttps://www.icr.ac.uk/news-archive%2fceo-announcementICR announces appointment of new Chief ExecutiveProfessor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of The Institute of Cancer Research, London, in September.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdna-day-how-we-re-turning-the-tables-on-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdna-day-how-we-re-turning-the-tables-on-cancerDNA Day: How we’re turning the tables on cancerDNA damage is the underlying cause of cancer – but it is also a key weakness in cancer cells that can be exploited for treatment. This DNA Day, we highlight scientists at the Institute of Cancer Research who are exploring how cancer cells repair damage to their DNA to understand more about how cancers develop, and to uncover new ways to treat the disease.https://www.icr.ac.uk/news-archive%2fovarian-cancer-drug-offers-new-genetically-targeted-approach-against-range-of-cancershttps://www.icr.ac.uk/news-archive%2fovarian-cancer-drug-offers-new-genetically-targeted-approach-against-range-of-cancersOvarian cancer drug offers new genetically targeted approach against range of cancersA type of drug used against ovarian and breast cancers could offer a brand new targeted approach for treating a range of cancers with particular genetic defects, including a common form of kidney cancer.https://www.icr.ac.uk/news-archive%2ffirst-covid-jab-provides-protection-for-most-myeloma-blood-cancer-patientshttps://www.icr.ac.uk/news-archive%2ffirst-covid-jab-provides-protection-for-most-myeloma-blood-cancer-patientsFirst Covid jab provides protection for most myeloma blood cancer patientsA single dose of a Covid-19 vaccine triggers an immune response in around 70 per cent of patients with myeloma – suggesting that it does provide protection against the virus.https://www.icr.ac.uk/news-archive%2fcancer-researchers-work-through-night-as-pandemic-restricts-access-to-labshttps://www.icr.ac.uk/news-archive%2fcancer-researchers-work-through-night-as-pandemic-restricts-access-to-labsCancer researchers work through night as pandemic restricts access to labsThe number of scientists able to access labs dropped by almost 30 per cent when the latest coronavirus lockdown was announced, according to new data released by the ICR. Some 28% are therefore resorting to working in unsociable hours to keep their research going. The ICR is calling for financial support to avert a two-year delay in cancer research advances reaching patients.https://www.icr.ac.uk/news-archive%2ficr-alumni-inspire-the-next-generation-at-the-2021-student-conferencehttps://www.icr.ac.uk/news-archive%2ficr-alumni-inspire-the-next-generation-at-the-2021-student-conferenceICR alumni inspire the next generation at the 2021 Student Conference At this year’s virtual event, our current PhD students had the opportunity to meet with ICR alumni and ask them about their careers.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fuk-life-sciences-are-thriving-despite-covid-19https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fuk-life-sciences-are-thriving-despite-covid-19UK life sciences are thriving despite Covid-19 – but choppy waters lie aheadWe’ve seen a surge in commercial investment in UK life sciences, driven by world-class interactions between academia and industry. But cuts to Government and charity funding for academic research could put that all at risk, says Angela Kukula, Director of Business and Innovation at the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frethinking-immunotherapy-using-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frethinking-immunotherapy-using-radiotherapyRethinking immunotherapy using radiotherapyDr Erik Wennerberg joined the ICR last summer as Team Leader of Radiation-enhanced Immunotherapy. Gege Li spoke to him to about his research on immunotherapy resistance, and how he is looking to novel combinations of cancer therapy to get the maximum benefit for patients. https://www.icr.ac.uk/news-archive%2fadvanced-radiotherapy-must-play-central-role-in-clearing-covid-s-cancer-backloghttps://www.icr.ac.uk/news-archive%2fadvanced-radiotherapy-must-play-central-role-in-clearing-covid-s-cancer-backlogAdvanced radiotherapy ‘must play central role’ in clearing Covid’s cancer backlogUrgent investment is needed in advanced forms of radiotherapy so the high-tech treatment can play a central role in clearing the backlog in NHS cancer care that has built up during the pandemic.https://www.icr.ac.uk/news-archive%2fimmunotherapy-combination-shows-early-promise-in-aggressive-brain-cancershttps://www.icr.ac.uk/news-archive%2fimmunotherapy-combination-shows-early-promise-in-aggressive-brain-cancersAACR Annual Meeting 2021: Immunotherapy combination shows early promise in aggressive brain cancersImmunotherapy together with an experimental cancer drug could offer a new way of treating some patients with aggressive brain cancers, promising early results from a Phase I trial presented at the 2021 AACR conference suggest.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-2021-cancer-discoveries-on-a-virtual-platformhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-2021-cancer-discoveries-on-a-virtual-platformAACR 2021: Cancer discoveries on a virtual platformWith the 2021 AACR Annual Meeting around the corner, Gege Li looks at some of the cutting-edge work being presented by our researchers.https://www.icr.ac.uk/news-archive%2fgene-mutations-linked-with-death-from-infection-in-patients-with-chronic-lymphocytic-leukaemiahttps://www.icr.ac.uk/news-archive%2fgene-mutations-linked-with-death-from-infection-in-patients-with-chronic-lymphocytic-leukaemiaGene mutations linked with death from infection in patients with chronic lymphocytic leukaemiaDeath from infection – the leading cause of death for patients with a common type of leukaemia – is linked to specific gene mutations, a new study has found. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffunding-cuts-create-perfect-storm-that-could-capsize-cancer-research-in-the-ukhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffunding-cuts-create-perfect-storm-that-could-capsize-cancer-research-in-the-ukFunding cuts create perfect storm that could capsize cancer research in the UKThe UK’s science budget faces catastrophic cuts – on top of the alarming impact of Covid-19 on medical research organisations. Professor Paul Workman, Chief Executive of the ICR, warns that without a change in course from the Government, cancer research in the UK is heading for a perfect storm with an impact that could last decades.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fabiraterone-gave-my-husband-time-to-live-life-to-the-fullhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fabiraterone-gave-my-husband-time-to-live-life-to-the-full“Abiraterone gave my husband time to live life to the full” - Sue's storySue’s husband, Philip, was entered onto a clinical trial for abiraterone when his prostate cancer developed resistance to the treatment he was on. She tells us what a difference it made to their lives.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fone-year-on-taking-stock-of-the-cancer-crisishttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fone-year-on-taking-stock-of-the-cancer-crisisOne year on, taking stock of the cancer crisisProfessor Clare Turnbull from The Institute of Cancer Research recently joined an expert panel to reflect on the cancer patient and surgery backlog and discuss what we’ve learnt since the UK went into lockdown one year ago. Julia Bakker summarises the discussion.https://www.icr.ac.uk/news-archive%2fai-analysis-gives-insight-into-how-bacteria-attackhttps://www.icr.ac.uk/news-archive%2fai-analysis-gives-insight-into-how-bacteria-attackAI analysis gives insight into how bacteria attackA new study has helped to uncover how bacterial proteins work as a network to take control of our cells.https://www.icr.ac.uk/news-archive%2fresistance-busting-icr-drug-enters-clinical-trialhttps://www.icr.ac.uk/news-archive%2fresistance-busting-icr-drug-enters-clinical-trialResistance-busting ICR drug enters clinical trialA drug discovered at The Institute of Cancer Research that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust.https://www.icr.ac.uk/news-archive%2fcreation-of-new-innovation-gateway-begins-at-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fcreation-of-new-innovation-gateway-begins-at-the-london-cancer-hubCreation of new Innovation Gateway begins at The London Cancer HubWork has begun to create a new Innovation Gateway – a high-quality incubator space for life-science companies – at the heart of The London Cancer Hub in Sutton, south London.https://www.icr.ac.uk/news-archive%2ffirst-uk-clinical-trial-in-proton-beam-therapyhttps://www.icr.ac.uk/news-archive%2ffirst-uk-clinical-trial-in-proton-beam-therapyFirst UK clinical trial in proton beam therapyThe first proton beam therapy clinical trial in the UK, co-led by The Institute of Cancer Research, London, is now taking place at The Christie NHS Foundation Trust in Manchester.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmother-s-day-the-generations-of-mums-inspiring-their-children-to-become-scientistshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmother-s-day-the-generations-of-mums-inspiring-their-children-to-become-scientistsMother’s Day: The generations of mums inspiring their children to become scientistsMolly Andrews spoke to four of our scientists about the pivotal roles their mothers played in inspiring them to pursue careers in science, some of the barriers mothers face, and the importance of continuing to strive for gender equality in science.https://www.icr.ac.uk/news-archive%2fthree-drug-combination-moves-forward-for-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2fthree-drug-combination-moves-forward-for-advanced-breast-cancerThree-drug combination moves forward for advanced breast cancerA combination of three drugs is safe and shows signs of effectiveness in treating some patients with previously treated advanced breast cancer, a clinical trial shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-women-s-day-2021-what-does-mentorship-look-likehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-women-s-day-2021-what-does-mentorship-look-likeInternational Women’s Day 2021: What does mentorship look like?For International Women’s Day, we're talking about the importance of mentorship — for science, for careers and for life. Juanita Bawagan and Clara May spoke to our researchers about their mentorship journeys and how formal mentoring programmes are supporting women in science.https://www.icr.ac.uk/news-archive%2ftargeted-immunotherapy-could-boost-radiotherapy-responsehttps://www.icr.ac.uk/news-archive%2ftargeted-immunotherapy-could-boost-radiotherapy-responseTargeted immunotherapy could boost radiotherapy responseProfiling the ‘immune landscape’ of patient’s tumours reveals who will most benefit from radiotherapy with potential immunotherapy in bowel cancer. Tumours which are chronically Inflamed before treatment could be made more susceptible using targeted immunotherapieshttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-explores-how-exploiting-cancer-s-dna-weaknesses-can-unlock-new-treatmenthttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-explores-how-exploiting-cancer-s-dna-weaknesses-can-unlock-new-treatmentICR Discovery Club explores how exploiting cancer’s DNA weaknesses can unlock new treatmentFor the second virtual event, Discovery Club members went on a trip back in time and deep inside the cell with Professor Jessica Downs and Dr Navita Somaiah to explore how targeting cancer’s DNA weaknesses can unlock new treatments. https://www.icr.ac.uk/news-features%2flatest-features%2fwhen-the-damage-is-done-how-icr-scientists-tackle-dna-damage-repairhttps://www.icr.ac.uk/news-features%2flatest-features%2fwhen-the-damage-is-done-how-icr-scientists-tackle-dna-damage-repairWhen the damage is done – how ICR scientists tackle DNA damage repairDNA damage is the basic cause of cancer, and understanding how cells repair DNA can help researchers develop the next generation of smarter, kinder treatments. https://www.icr.ac.uk/news-archive%2fnew-cancer-scan-could-guide-brain-surgeryhttps://www.icr.ac.uk/news-archive%2fnew-cancer-scan-could-guide-brain-surgeryNew cancer scan could guide brain surgeryA type of ultrasound scan can detect cancer tissue left behind after a brain tumour is removed more sensitively than surgeons, and could improve the outcome from operations, a new study suggests.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020---pushing-the-frontiers-in-onco-pathology-from-microscopes-to-digital-diagnosticshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020---pushing-the-frontiers-in-onco-pathology-from-microscopes-to-digital-diagnosticsScience Writing Prize 2020 - Pushing the frontiers in onco-pathology: from microscopes to digital diagnosticsNivedita Ravindran examines cutting edge digital pathology in this shortlisted entry for the 2020 Mel Greaves Science Writing Prize. Nivedita is a Higher Scientific Officer in the Division of Breast Cancer Research at the Institute of Cancer Research. https://www.icr.ac.uk/news-features%2flatest-features%2fscience-and-medical-imaging-competition-2021-shortlisthttps://www.icr.ac.uk/news-features%2flatest-features%2fscience-and-medical-imaging-competition-2021-shortlistICR Science and Medical Imaging Competition 2021Six outstanding images have been shortlisted for the ICR’s Science and Medical Imaging competition. Over the next two weeks, we will be sharing our shortlist across the ICR’s social media channels and on our website for a public vote, before we announce the judge’s chosen winner and the public’s choice.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020-a-modern-homo-universalis-is-at-the-forefront-of-science-and-medicinehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020-a-modern-homo-universalis-is-at-the-forefront-of-science-and-medicineScience Writing Prize 2020 – A modern Homo universalis is at the forefront of science and medicineDr Vivian Dimou explores the importance and success of collaboration in research in this piece shortlisted for the 2020 Mel Greaves Science Writing Prize. Vivian is a postdoctoral training fellow in the Division of Cancer Therapeutics.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-the-human-genome-project-shook-the-world-of-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-the-human-genome-project-shook-the-world-of-cancer-researchHow the Human Genome Project shook the world of cancer researchTwenty years ago, a detailed draft and analysis of the human genome was completed. In this feature, Diana Cano Bordajandi looks at the lasting legacy of the Human Genome Project.https://www.icr.ac.uk/news-archive%2fmen-with-early-stage-testicular-cancer-could-avoid-potentially-harmful-monitoring-scanshttps://www.icr.ac.uk/news-archive%2fmen-with-early-stage-testicular-cancer-could-avoid-potentially-harmful-monitoring-scansMen with early stage testicular cancer could avoid potentially harmful monitoring scansMen who have had treatment for early stage testicular cancer could benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging, according to results presented at GU ASCO conference.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-researchers-are-using-ai-to-crack-cancer-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-researchers-are-using-ai-to-crack-cancer-evolutionHow our researchers are using AI to crack cancer evolutionMost advanced cancers undergo genetic changes that enable them to resist the drugs meant to kill them. ICR scientists like Dr Yinyin Yuan are working to better understand why this happens in lung cancer, in an attempt to crack cancer evolution.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevolution-cancer-and-coronavirus-how-biologys-theory-of-everything-is-key-to-fighting-cancer-and-global-pandemicshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevolution-cancer-and-coronavirus-how-biologys-theory-of-everything-is-key-to-fighting-cancer-and-global-pandemicsEvolution, cancer and coronavirus – how biology’s ‘Theory of Everything’ is key to fighting cancer and global pandemicsDarwin day marks the birthday of Sir Charles Darwin, the father of modern biology. Graham Shaw talked to Team Leaders Dr Alejandra Bruna and Dr Marco Bezzi from the ICR’s Centre for Evolution and Cancer, to learn more about how evolution helps us understand cancer and the parallels in the fight against coronavirus. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020---(cell)-death-is-not-the-endhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2020---(cell)-death-is-not-the-endScience Writing Prize 2020 – (Cell) Death is not the end The winner of the Mel Greaves Science Writing Prize for 2020, Dr Arnaud Legrand, explores the life and death of cells in this piece on the theme of 'Barriers and Breakthroughs' in cancer research. Arnaud is a post doctoral fellow in the Division of Breast Cancer Research at the Institute of Cancer Research, London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-splice-of-lifehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-splice-of-lifeThe splice of lifeProfessor Vlad Pena recently joined the Division of Structural Biology at The Institute of Cancer Research. Juanita Bawagan spoke to him about his research on splicing, a vital process in cells that can cause disease when gone awry.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-day-of-women-and-girls-in-science-2020https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-day-of-women-and-girls-in-science-2020International Day of Women and Girls in Science 2020To celebrate International Day of Women and Girls in Science this year, we're sharing some advice from our scientists about pursuing a career in research.https://www.icr.ac.uk/news-archive%2fcommon-antiseptic-could-be-cheap-and-easy-way-to-improve-cancer-radiotherapy-around-the-worldhttps://www.icr.ac.uk/news-archive%2fcommon-antiseptic-could-be-cheap-and-easy-way-to-improve-cancer-radiotherapy-around-the-worldCommon antiseptic could be cheap and easy way to improve cancer radiotherapy around the worldA simple injection of a common antiseptic could boost the cancer-killing effect of radiotherapy for breast cancer and other cancers, an early clinical trial has shown. https://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-course-reduces-risk-of-bladder-cancer-returninghttps://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-course-reduces-risk-of-bladder-cancer-returningShorter radiotherapy course reduces risk of bladder cancer returningGiving people with bladder cancer fewer but larger doses of radiation reduces the risk of their disease returning and should be adopted as the new standard of care, a new study shows. https://www.icr.ac.uk/news-archive%2fexisting-breast-cancer-drug-offers-new-targeted-treatment-for-triple-negative-breast-cancerhttps://www.icr.ac.uk/news-archive%2fexisting-breast-cancer-drug-offers-new-targeted-treatment-for-triple-negative-breast-cancerExisting breast cancer drug offers new targeted treatment for triple negative breast cancerAn already approved breast cancer drug could bring hope to thousands of UK women who have an aggressive form of breast cancer, new research has found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffestival-of-genomics-2021-whats-next-for-AI-precision-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffestival-of-genomics-2021-whats-next-for-AI-precision-cancer-treatmentAI and the genome: What’s next for precision cancer treatment?Statisticians, clinicians and scientists across disciplines will come together virtually for the Festival of Genomics & Biodata from 26-29 January. Juanita Bawagan spoke to the ICR’s Dr Anguraj Sadanandam ahead of his presentation on data, AI and therapeutics for precision oncology.https://www.icr.ac.uk/news-archive%2fpromising-new-treatment-strategy-for-men-with-drug-resistant-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fpromising-new-treatment-strategy-for-men-with-drug-resistant-prostate-cancerPromising new treatment strategy for men with drug-resistant prostate cancerA new experimental drug could offer a promising approach to treating men with advanced prostate cancer which does not respond to existing treatments, or develops resistance to them, researchers report.https://www.icr.ac.uk/news-archive%2fstudy-sheds-light-on-genetic-basis-of-black-men-s-higher-prostate-cancer-riskhttps://www.icr.ac.uk/news-archive%2fstudy-sheds-light-on-genetic-basis-of-black-men-s-higher-prostate-cancer-riskStudy sheds light on genetic basis of Black men’s higher prostate cancer riskBlack men are more likely than their White or Asian counterparts to have a range of genetic changes that increase their risk of developing prostate cancer, a major new study reports.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fthe-trouble-with-chimneys-from-percival-potts-to-archibald-leitchhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fthe-trouble-with-chimneys-from-percival-potts-to-archibald-leitchThe trouble with Chimneys: from Percival Potts to Archibald LeitchWhat, you might ask, could possibly connect Percival Potts, surgeon at St Bartholomew’s hospital in the 1770s, with a pathologist a hundred years ago? The answer is that it is something to do with soot, sweat and scrotums. And chimneys.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeing-told-i-had-the-brca2-mutation-effectively-saved-my-life-tony-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeing-told-i-had-the-brca2-mutation-effectively-saved-my-life-tony-s-story“Being told I had the BRCA2 mutation effectively saved my life” – Tony’s storyAfter both he and his sister were diagnosed with breast cancer, Tony Herbert decided to undergo genetic testing to see if he had a BRCA mutation. Here he talks about how the result may have saved his life.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-brca2-team-the-scientists-behind-the-breast-cancer-gene-discoveryhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-brca2-team-the-scientists-behind-the-breast-cancer-gene-discoveryThe BRCA2 team: Researchers behind the breast cancer gene discovery25 years ago, ICR researchers made a historic discovery. Juanita Bawagan recounts some of their stories.https://www.icr.ac.uk/news-archive%2fnew-collaboration-to-advance-cancer-prevention-research-and-strategieshttps://www.icr.ac.uk/news-archive%2fnew-collaboration-to-advance-cancer-prevention-research-and-strategiesNew collaboration to advance cancer prevention research and strategiesA new unit focusing on cancer prevention research and strategies has launched at The Institute of Cancer Research, London, and Imperial College London.https://www.icr.ac.uk/news-archive%2fnew-3d-structure-could-be-a-treasure-map-guiding-search-for-new-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-3d-structure-could-be-a-treasure-map-guiding-search-for-new-treatmentsNew 3D structure could be ‘a treasure map’ guiding search for new treatmentsScientists have created a three-dimensional map of a complex of molecules that plays a fundamental role in life – and which when it goes wrong is linked to increased sensitivity to viral infections and neurodegenerative diseases.https://www.icr.ac.uk/news-archive%2fsymphony-finished-to-mark-new-era-for-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2fsymphony-finished-to-mark-new-era-for-cancer-drug-discoverySymphony finished to mark new era for cancer drug discoveryThe ICR and Royal Philharmonic Orchestra complete the ‘unfinished symphony’ – to mark the opening of a revolutionary new research centre and a new era for cancer treatment.https://www.icr.ac.uk/news-archive%2fresearchers-target-thyroid-cancer-with-triple-threat-drug-combinationhttps://www.icr.ac.uk/news-archive%2fresearchers-target-thyroid-cancer-with-triple-threat-drug-combinationResearchers target thyroid cancer with triple threat drug combinationCombining a genetically targeted drug, a cancer-bursting virus and a drug that removes the immune system’s brake pedal can tackle thyroid cancer with newfound gusto, research has found. https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ften-lessons-for-the-life-sciences-from-covid-19https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ften-lessons-for-the-life-sciences-from-covid-19Ten lessons for the life sciences from COVID-19Dr Angela Kukula, the ICR’s Director of Business and Innovation, asks what the future holds for the life sciences after the COVID-19 pandemic – and how we can ensure the rapid development of COVID-19 technologies happens in other areas too.https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2020https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2020Scientific achievements of 2020We've selected a range of discoveries from 2019/20 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.https://www.icr.ac.uk/news-archive%2factor-eddie-redmayne-guest-stars-in-virtual-carols-from-chelsea-servicehttps://www.icr.ac.uk/news-archive%2factor-eddie-redmayne-guest-stars-in-virtual-carols-from-chelsea-serviceActor Eddie Redmayne guest stars in virtual Carols from Chelsea serviceWe celebrate the festive season and our world-leading research, with a special virtual Carols from Chelsea concert. For the past 17 years, our flagship annual social and fundraising event has been held at The Royal Hospital Chelsea, but is now shared online for the very first time.https://www.icr.ac.uk/news-archive%2fpandemic-to-delay-cancer-advances-by-nearly-18-months-researchers-fearhttps://www.icr.ac.uk/news-archive%2fpandemic-to-delay-cancer-advances-by-nearly-18-months-researchers-fearPandemic to delay cancer advances by nearly 18 months, researchers fearA survey of more than 200 researchers details impact of the pandemic. The scientists estimate their own research has been put back by six months through loss of access to labs, facilities, trials and samples. But they feel science has now adapted to COVID-19 – and researchers believe donations and Government support could accelerate recovery.https://www.icr.ac.uk/news-archive%2fmolecular-clock-blood-test-could-track-spread-of-breast-cancerhttps://www.icr.ac.uk/news-archive%2fmolecular-clock-blood-test-could-track-spread-of-breast-cancer‘Molecular clock’ blood test could track spread of breast cancerA blood test to watch breast cancer’s ‘molecular clock’ could help track the growth of multiple tumours around the body and monitor how they are responding to treatment, new research suggests.https://www.icr.ac.uk/news-archive%2fvideo-for-schools-shows-how-scientists-create-new-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fvideo-for-schools-shows-how-scientists-create-new-cancer-treatmentsVideo for schools shows how scientists create new cancer treatmentsCancer researchers talk about their pioneering work to discover and develop new drugs in a new video for schools and students designed to bring the GCSE curriculum on the creation of new treatments to life.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flung-cancer-awareness-month-non-small-cell-lung-cancer-and-the-targeted-drug-revolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flung-cancer-awareness-month-non-small-cell-lung-cancer-and-the-targeted-drug-revolutionLung Cancer Awareness Month: Non-small cell lung cancer and the targeted drug revolutionTo mark Lung Cancer Awareness Month, our Communications Administrator Molly Andrews spoke to Dr Paul Huang about how targeted drugs have changed the landscape of non-small cell lung cancer treatment, and the challenges arising as a result of resistance to these drugs. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-steps-to-improve-access-to-cancer-immunotherapieshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-steps-to-improve-access-to-cancer-immunotherapiesFive steps to improve access to cancer immunotherapiesImmunotherapies are some of the most innovative new cancer treatments available to patients, but more needs to be done to get them to as many patients as possible. Policy Officer Aislinn Santoni looks at the barriers to wider access and what we can do to overcome them.https://www.icr.ac.uk/news-archive%2fresearch-begins-at-pioneering-centre-aimed-at-overcoming-cancer-s-ability-to-evolve-resistance-to-treatmenthttps://www.icr.ac.uk/news-archive%2fresearch-begins-at-pioneering-centre-aimed-at-overcoming-cancer-s-ability-to-evolve-resistance-to-treatmentPioneering centre for 'Darwinian' cancer drug discovery opens to researchersA world-first new centre aiming to overcome cancer’s ability to evolve and become resistant to once effective treatments has opened its doors to researchers. Scientists at the new Centre for Cancer Drug Discovery hope their approaches will mean long-term control of cancer, as well as cures.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcovid-19-and-other-experiments-of-naturehttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcovid-19-and-other-experiments-of-natureCOVID-19 and other experiments of natureProfessor Sir Mel Greaves ponders 'experiments of nature' - from the COVID-19 pandemic to the birth of identical twins - and argues that they can give us vital clues to the causes of cancer.https://www.icr.ac.uk/news-archive%2fblood-test-picks-out-cancers-likely-to-benefit-from-targeted-drugshttps://www.icr.ac.uk/news-archive%2fblood-test-picks-out-cancers-likely-to-benefit-from-targeted-drugsBlood test picks out cancers likely to benefit from targeted drugsA simple and inexpensive blood test could pick out patients with stomach or oesophageal cancer who are likely to benefit from targeted treatment, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faccess-routes-and-asking-prices---getting-drugs-to-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faccess-routes-and-asking-prices---getting-drugs-to-cancer-patientsAccess routes and asking prices - getting drugs to cancer patientsToday the ICR and 15 organisations launch a nine point plan on cancer drug pricing and access. Here, our Policy Officer Joanne Duffy speaks to patient advocate Emma Robertson about the recommendations.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-tackling-the-underrepresentation-of-bame-students-in-our-postgraduate-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-tackling-the-underrepresentation-of-bame-students-in-our-postgraduate-researchHow we’re tackling the underrepresentation of BAME students in our postgraduate researchProfessor Bamber, the ICR’s Deputy Dean, sets out how we are promoting diversity and racial equality among our postgraduate students.https://www.icr.ac.uk/news-archive%2fpipette-painting-marks-pioneering-cancer-researchhttps://www.icr.ac.uk/news-archive%2fpipette-painting-marks-pioneering-cancer-researchPipette painting marks pioneering cancer researchStreet artist James Cochran has created a 50,000-dot painting using a lab pipette – to illustrate pioneering new research which will be undertaken in the ICR's new Centre for Cancer Drug Discovery.https://www.icr.ac.uk/news-archive%2fvary-drug-prices-for-different-conditions-say-health-expertshttps://www.icr.ac.uk/news-archive%2fvary-drug-prices-for-different-conditions-say-health-expertsVary drug prices for different conditions, say health expertsThe NHS could improve patients’ access to new cancer treatments by paying different prices for drugs depending on the disease they are used to treat, concludes a group of experts from across academia and industry.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhat-are-the-biggest-issues-in-drug-discovery-and-developmenthttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhat-are-the-biggest-issues-in-drug-discovery-and-developmentWhat are the biggest issues in drug discovery and development?Our programme of expert summits is proposing solutions to some of the biggest issues in drug discovery and development, says Director of Business and Innovation Dr Angela Kukula.https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-targeting-achilles-heel-approved-in-europehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-targeting-achilles-heel-approved-in-europeProstate cancer drug targeting Achilles heel approved in EuropeThe Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in BRCA1 or BRCA2. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frising-to-the-challenge-the-clinical-researchers-who-joined-the-nhs-frontline-against-covid-19https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frising-to-the-challenge-the-clinical-researchers-who-joined-the-nhs-frontline-against-covid-19Rising to the challenge – the clinical researchers who joined the NHS frontline against COVID-19Many of our researchers are clinician scientists – focusing much of their time on scientific work, but often continuing to see patients too. When the COVID-19 pandemic hit the UK in March, many put their research to one side in order to be redeployed or seconded to the NHS front line. Here are some of their stories from the start of the year. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ftrying-to-drug-the-apparently-undruggable-and-what-it-can-teach-ushttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ftrying-to-drug-the-apparently-undruggable-and-what-it-can-teach-usTrying to drug the apparently undruggable, and what it can teach usProfessor Paul Workman reflects in depth on his experience in trying to drug a particularly challenging cancer target, and why it is always important to be clear about the risks and benefits of a drug discovery project – and to share the results with the research community.https://www.icr.ac.uk/news-archive%2fncri-2020-new-bowel-cancer-model-uncovering-how-it-avoids-immunotherapy-drughttps://www.icr.ac.uk/news-archive%2fncri-2020-new-bowel-cancer-model-uncovering-how-it-avoids-immunotherapy-drugNCRI 2020: New bowel cancer model uncovering how it avoids immunotherapy drugScientists at The Institute of Cancer Research, London, have developed a complex model system that mimics the most common form of bowel cancer and is showing how it ‘hides’ from immunotherapy.https://www.icr.ac.uk/news-archive%2flow-cost-test-could-pick-out-breast-cancer-patients-at-increased-risk-of-relapsehttps://www.icr.ac.uk/news-archive%2flow-cost-test-could-pick-out-breast-cancer-patients-at-increased-risk-of-relapseLow-cost test could pick out breast cancer patients at increased risk of relapseTesting women’s response to hormone therapy for breast cancer given around the time of surgery could be a fast and cheap way of predicting how likely the disease is to come back, a major clinical trial has found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2020-the-uk%27s-largest-cancer-conference-goes-virtualhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2020-the-uk%27s-largest-cancer-conference-goes-virtualNCRI 2020: The UK's largest cancer conference goes virtualThis year, the National Cancer Research Institute annual conference is taking place as a virtual event, enabling researchers and clinicians to stay connected despite the disruption caused by the COVID-19 pandemic. As always – although this year from a distance – we will be reporting on innovative ICR science presented at the conference.https://www.icr.ac.uk/news-archive%2ficr-welcomes-nice-s-decision-to-reassess-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-nice-s-decision-to-reassess-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancerThe Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider its decision not to recommend abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer.https://www.icr.ac.uk/news-archive%2fnew-drug-for-difficult-to-drug-cancer-mutation-could-be-key-treatment-for-a-range-of-cancershttps://www.icr.ac.uk/news-archive%2fnew-drug-for-difficult-to-drug-cancer-mutation-could-be-key-treatment-for-a-range-of-cancersNew drug for difficult-to-drug cancer mutation could be key treatment for a range of cancersA new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flooking-back-on-a-distinguished-career-professor-david-dearnaleyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flooking-back-on-a-distinguished-career-professor-david-dearnaleyLooking back on a distinguished career – Professor David DearnaleyAfter an acclaimed career spanning more than 40 years, Professor David Dearnaley, Professor of Uro-Oncology at the ICR and Consultant Clinical Oncologist at The Royal Marsden, has retired. His work has changed best practice on a global level, impacting the lives of an untold number of cancer patients and advancing cancer research.https://www.icr.ac.uk/news-archive%2ficr-calls-for-change-to-bring-immunotherapies-to-more-cancer-patientshttps://www.icr.ac.uk/news-archive%2ficr-calls-for-change-to-bring-immunotherapies-to-more-cancer-patientsICR calls for change to bring immunotherapies to more cancer patientsMajor changes to the way immunotherapy drugs are researched and evaluated are essential if they are to become successful treatment options for many more types of cancers, leading cancer experts are warning.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fclimbing-the-peaks-of-drug-discovery-tackling-the-most-challenging-targets-with-ingenuity-and-realismhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fclimbing-the-peaks-of-drug-discovery-tackling-the-most-challenging-targets-with-ingenuity-and-realismClimbing the peaks of drug discovery – tackling the most challenging targets with ingenuity and realismProfessor Paul Workman argues that creating drugs is a bit like climbing mountains – and as with scaling a craggy slope versus a smooth wall of rock, tackling some disease targets is easier than others.https://www.icr.ac.uk/news-archive%2ficr-is-top-ranked-university-for-invention-income-for-seventh-consecutive-yearhttps://www.icr.ac.uk/news-archive%2ficr-is-top-ranked-university-for-invention-income-for-seventh-consecutive-yearICR is top-ranked university for invention income for seventh consecutive yearThe Institute of Cancer Research, London, has again been the most successful academic institution in the UK at making income from its intellectual property – for the seventh successive year.https://www.icr.ac.uk/news-archive%2ficr-discovery-club-gives-members-a-virtual-glimpse-into-the-cancer-genetics-labhttps://www.icr.ac.uk/news-archive%2ficr-discovery-club-gives-members-a-virtual-glimpse-into-the-cancer-genetics-labICR Discovery Club gives members a virtual glimpse into the cancer genetics labMembers of the ICR’s Discovery Club were given an exclusive insight into how researchers sample, process and analyse tumour cells in the lab, as part of the ICR’s first virtual event for our donors. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-goes-viral-icr-research-on-cancer-killing-viruses-featured-on-bbc-s-the-one-showhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-goes-viral-icr-research-on-cancer-killing-viruses-featured-on-bbc-s-the-one-showImmunotherapy goes viral: ICR research on cancer-killing viruses featured on BBC’s The One ShowBefore lockdown, TV presenter and medical doctor, Kevin Fong, visited The Institute of Cancer Research to find out all about our work on viral immunotherapy for BBC’s The One Show. Senior Media Officer, Sarah Wells, explores how our researchers are using viruses against cancer.https://www.icr.ac.uk/news-archive%2fstudy-seeks-to-find-out-why-black-men-develop-prostate-cancer-at-twice-the-rate-of-other-menhttps://www.icr.ac.uk/news-archive%2fstudy-seeks-to-find-out-why-black-men-develop-prostate-cancer-at-twice-the-rate-of-other-menStudy seeks to find out why black men develop prostate cancer at twice the rate of other menA first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men in the UK.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2finside-story-the-microbiome-and-cancerhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2finside-story-the-microbiome-and-cancerInside story: the microbiome and cancerProfessor Sir Mel Greaves discusses the importance of the human microbiome for health and how it could be harnessed to help improve outcomes in cancer. https://www.icr.ac.uk/news-archive%2fnew-study-sheds-light-on-the-best-drug-choices-for-some-patients-with-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2fnew-study-sheds-light-on-the-best-drug-choices-for-some-patients-with-advanced-breast-cancerNew study sheds light on the best drug choices for some patients with advanced breast cancerPatients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study.https://www.icr.ac.uk/news-archive%2fscientists-reveal-important-role-for-workhorse-of-cell-divisionhttps://www.icr.ac.uk/news-archive%2fscientists-reveal-important-role-for-workhorse-of-cell-divisionScientists reveal important role for ‘workhorse’ of cell division A new study shows how a crucial protein, which acts as trigger for cell division, helps release another key protein from the cell’s ‘control centre’. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbiology-week-2020-zooming-in-on-dna-repairhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbiology-week-2020-zooming-in-on-dna-repairBiology Week 2020: Zooming in on DNA repairDr Basil Greber recently joined the Division of Structural Biology at The Institute of Cancer Research. To mark Biology Week 2020, Céleste Nilges spoke to him about his work on the structural and molecular mechanisms of DNA repair, and how new technology has revolutionised his field.https://www.icr.ac.uk/news-archive%2fnew-drug-targeting-high-risk-children-s-cancer-is-ready-for-trialshttps://www.icr.ac.uk/news-archive%2fnew-drug-targeting-high-risk-children-s-cancer-is-ready-for-trialsNew drug targeting high-risk children’s cancer is ready for trialsA new drug that has passed safety tests in adults shows the potential to be effective against the aggressive childhood cancer neuroblastoma, scientists have found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-icr-is-tackling-race-inequality-in-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-icr-is-tackling-race-inequality-in-scienceHow the ICR is tackling race inequality in scienceNaa-Anyima Boateng is a Higher Scientific Officer and Chair of the Black, Asian and minority ethnic forum at the ICR and The Royal Marsden. This Black History Month, she gives her personal reflections on race equality in science.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgynaecological-cancer-awareness-month-new-trial-offers-hope-for-patients-with-rare-hard-to-treat-gynaecological-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgynaecological-cancer-awareness-month-new-trial-offers-hope-for-patients-with-rare-hard-to-treat-gynaecological-cancerGynaecological Cancer Awareness Month: New trial offers hope for patients with rare hard-to-treat gynaecological cancer Around 21,000 people are diagnosed with a gynaecological cancer in the UK each year. This September - Gynaecological Cancer Awareness Month - our Communications Administrator Molly Andrews spoke to Professor Chris Lord and Dr Susana Banerjee about an important new trial in the gynaecological cancer field. https://www.icr.ac.uk/news-archive%2faggressive-childhood-cancer-could-be-treated-by-combining-dna-damage-targeting-drugshttps://www.icr.ac.uk/news-archive%2faggressive-childhood-cancer-could-be-treated-by-combining-dna-damage-targeting-drugsAggressive childhood cancer could be treated by combining DNA-damage targeting drugsAn aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently used in the treatment of colon and ovarian cancer, a study led by researchers at The Institute of Cancer Research, London, suggests. https://www.icr.ac.uk/news-archive%2fnew-drug-targeting-dna-repair-shows-promise-in-range-of-advanced-cancershttps://www.icr.ac.uk/news-archive%2fnew-drug-targeting-dna-repair-shows-promise-in-range-of-advanced-cancersNew drug targeting DNA repair shows promise in range of advanced cancersA new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-think-therefore-i-am-how-perception-influences-sarcoma-survivors-journeyshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-think-therefore-i-am-how-perception-influences-sarcoma-survivors-journeysI think therefore I am – how perception influences sarcoma survivors’ journeysDelays in cancer diagnosis can have a profound impact on patients, but so too can their perception of the process. New ICR research shows that there is a complex relationship between patient wellbeing and waiting times. Science Communications Officer Joanne Duffy delves in. https://www.icr.ac.uk/news-archive%2ficr-and-cancer-research-uk-spinout-company-monte-rosa-therapeutics-raises-usd96m-in-series-b-financinghttps://www.icr.ac.uk/news-archive%2ficr-and-cancer-research-uk-spinout-company-monte-rosa-therapeutics-raises-usd96m-in-series-b-financingICR and Cancer Research UK spinout company Monte Rosa Therapeutics raises USD96m in ‘Series B’ FinancingMonte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline.https://www.icr.ac.uk/news-features%2flatest-features%2fnavigating-our-way-through-a-new-era-of-fundraisinghttps://www.icr.ac.uk/news-features%2flatest-features%2fnavigating-our-way-through-a-new-era-of-fundraisingNavigating our way through a new era of fundraisingLara Jukes is the Director of Development at the ICR. Here she shares her personal thoughts on the impact the coronavirus pandemic has had on the charity, the life-saving research it supports, and those who benefit from it.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-a-decade-of-research-progress-offers-hope-to-children-with-neuroblastomahttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-a-decade-of-research-progress-offers-hope-to-children-with-neuroblastomaHow a decade of research progress offers hope to children with neuroblastomaResearchers at the ICR are working hard to improve the outlook for children with cancer. Here we look back on a decade of discoveries made possible by the support of the parent-led charity Christopher’s Smile, which was founded just over 10 years ago.https://www.icr.ac.uk/news-archive%2fesmo-2020-two-pronged-attack-using-new-targeted-drug-could-treat-addicted-prostate-cancershttps://www.icr.ac.uk/news-archive%2fesmo-2020-two-pronged-attack-using-new-targeted-drug-could-treat-addicted-prostate-cancersESMO 2020: Two-pronged attack using new targeted drug could treat ‘addicted’ prostate cancersAn experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.https://www.icr.ac.uk/news-archive%2fesmo-2020-research-breakthrough-offers-new-hope-for-high-risk-patients-with-hr-breast-cancerhttps://www.icr.ac.uk/news-archive%2fesmo-2020-research-breakthrough-offers-new-hope-for-high-risk-patients-with-hr-breast-cancerESMO 2020: Research breakthrough offers new hope for high risk patients with HR+ breast cancerA new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who are at a high risk of recurrence has been shown to reduce the risk by 25 per cent in the first two years, according to a new study.https://www.icr.ac.uk/news-archive%2fesmo-2020-breast-cancer-drug-set-to-transform-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fesmo-2020-breast-cancer-drug-set-to-transform-prostate-cancer-treatmentESMO 2020: Breast cancer drug set to transform prostate cancer treatmentA drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.https://www.icr.ac.uk/news-archive%2fesmo-2020-step-forward-in-treatment-for-patients-with-newly-diagnosed-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fesmo-2020-step-forward-in-treatment-for-patients-with-newly-diagnosed-advanced-ovarian-cancerESMO 2020: Step forward in treatment for patients with newly diagnosed advanced ovarian cancerAlmost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years, according to a study led by The Royal Marsden NHS Foundation Trust.https://www.icr.ac.uk/news-features%2flatest-features%2fbringing-precision-medicine-to-children-with-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fbringing-precision-medicine-to-children-with-cancerBringing precision medicine to children with cancerProfessor Louis Chesler is Head of the new Centre for Paediatric Experimental Medicine at the ICR – and leads an ambitious team of researchers who are investigating new targeted treatments that could make a real difference for children with cancer.https://www.icr.ac.uk/news-archive%2fcombining-two-precision-medicines-can-treat-drug-resistant-cancershttps://www.icr.ac.uk/news-archive%2fcombining-two-precision-medicines-can-treat-drug-resistant-cancersCombining two precision medicines can treat drug-resistant cancersLaunching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.https://www.icr.ac.uk/news-archive%2fmathematical-model-maps-out-%27arms-race%27-between-cancer-and-immune-system-and-predicts-effectiveness-of-immunotherapyhttps://www.icr.ac.uk/news-archive%2fmathematical-model-maps-out-%27arms-race%27-between-cancer-and-immune-system-and-predicts-effectiveness-of-immunotherapyMathematical model maps out 'arms race' between cancer and immune system and predicts effectiveness of immunotherapyResearchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fchildhood-brain-tumours-from-tissue-samples-to-new-treatment-optionshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fchildhood-brain-tumours-from-tissue-samples-to-new-treatment-optionsChildhood brain tumours: From tissue samples to new treatment optionsTo mark Childhood Cancer Awareness Month, Diana Martins Carvalho, a post-doctoral training fellow in our Glioma Team, reflects on the vital support of families who generously donate tissue samples and funds, without which her research into childhood brain tumours would not be possible.https://www.icr.ac.uk/news-archive%2fmajor-plasmamatch-trial-uses-blood-test-to-match-women-with-breast-cancer-to-range-of-precision-treatmentshttps://www.icr.ac.uk/news-archive%2fmajor-plasmamatch-trial-uses-blood-test-to-match-women-with-breast-cancer-to-range-of-precision-treatmentsMajor ‘plasmaMATCH’ trial uses blood test to match women with breast cancer to range of precision treatmentsA blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal.https://www.icr.ac.uk/news-archive%2ficr-welcomes-approval-of-immunotherapy-for-head-and-neck-cancer-in-scotland-but-warns-of-home-nations-lotteryhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-approval-of-immunotherapy-for-head-and-neck-cancer-in-scotland-but-warns-of-home-nations-lotteryICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’The ICR has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head and neck cancer.https://www.icr.ac.uk/news-archive%2fchildren-and-young-people-with-cancer-who-have-relapsed-can-get-rapid-access-to-new-treatments-thanks-to-new-clinical-trialhttps://www.icr.ac.uk/news-archive%2fchildren-and-young-people-with-cancer-who-have-relapsed-can-get-rapid-access-to-new-treatments-thanks-to-new-clinical-trialChildren and young people with cancer who have relapsed can get rapid access to new treatments thanks to new clinical trialChildren and young people in the UK with cancers that have come back can now access new personalised treatments quicker than ever before thanks to a national tumour biopsy sequencing platform and clinical trial.https://www.icr.ac.uk/news-archive%2fhard-to-treat-pancreatic-cancer-hijacks-immune-system-and-could-be-targeted-with-immunotherapieshttps://www.icr.ac.uk/news-archive%2fhard-to-treat-pancreatic-cancer-hijacks-immune-system-and-could-be-targeted-with-immunotherapiesHard-to-treat pancreatic cancer hijacks immune system and could be targeted with immunotherapiesScientists have used artificial intelligence to reveal an aggressive form of pancreatic cancer that is more likely to respond to immunotherapy, in the most extensive analysis of the immune landscape of these tumours to date.https://www.icr.ac.uk/news-archive%2fteaching-evolutionary-theory-to-artificial-intelligence-reveals-cancer-s-life-historyhttps://www.icr.ac.uk/news-archive%2fteaching-evolutionary-theory-to-artificial-intelligence-reveals-cancer-s-life-historyTeaching evolutionary theory to artificial intelligence reveals cancer’s life historyScientists have developed the most accurate computing method to date to reconstruct the patchwork of genetic faults within tumours and their history during disease development.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-little-girl-driving-change-how-aoife-s-legacy-will-help-other-childrenhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-little-girl-driving-change-how-aoife-s-legacy-will-help-other-childrenThe little girl driving change: how Aoife’s legacy will help other childrenAfter Aoife Flanagan died of germ cell cancer at the age of three, her mum, Eilish, set up a charity in her daughter’s name to change the future for other children with cancer.https://www.icr.ac.uk/news-features%2flatest-features%2fkick-starting-the-icr-an-interview-with-phd-student-iona-blackhttps://www.icr.ac.uk/news-features%2flatest-features%2fkick-starting-the-icr-an-interview-with-phd-student-iona-blackKick-starting the ICR: an interview with PhD student Iona BlackAs our #KickstartICR appeal draws to a close, we spoke to PhD student Iona Black about her research and the importance of fundraising for cancer research. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-our-students-in-these-extraordinary-timeshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-our-students-in-these-extraordinary-timesSupporting our students in these extraordinary timesOur Registrar and Director of Academic Services, Dr Barbara Pittam, discusses how we are supporting our students as they navigate the impact of Covid-19 pandemic.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcancer-research-resumes-at-the-institute-of-cancer-researchhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcancer-research-resumes-at-the-institute-of-cancer-researchCancer research resumes at The Institute of Cancer ResearchOur Director of Enterprise, Dr Angela Kukula, reflects on how our researchers are adapting to the ‘new normal’ two months after we reopened our laboratories.https://www.icr.ac.uk/news-archive%2ficr-research-ranks-in-top-five-globally-for-academic-influence-collaboration-and-commercial-impacthttps://www.icr.ac.uk/news-archive%2ficr-research-ranks-in-top-five-globally-for-academic-influence-collaboration-and-commercial-impactICR research ranks in top five globally for academic influence, collaboration and commercial impactThe Institute of Cancer Research has again ranked among the top higher education institutions in the world for the impact of our research academically and commercially.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-don-t-know-how-much-time-we-ve-got-left-together-sally-s-melanoma-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-don-t-know-how-much-time-we-ve-got-left-together-sally-s-melanoma-story“We don’t know how much time we’ve got left together” – Sally’s melanoma storyScientists at The Institute of Cancer Research have helped discover and develop many targeted treatments that are enabling cancer patients to live longer and with a better quality of life. Sally Steadman-South explains what these research advances have meant for her and her family, and why she needs this work to continue.https://www.icr.ac.uk/news-archive%2fscientists-discover-three-new-genetic-variants-linked-to-male-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-discover-three-new-genetic-variants-linked-to-male-breast-cancerScientists discover three new genetic variants linked to male breast cancerUK scientists have discovered three new genetic changes that increase the risk of breast cancer in men, in the world’s largest genetic study of the causes of male breast cancer to date.https://www.icr.ac.uk/news-archive%2fcomputer-assisted-ultrasound-imaging-could-help-deliver-more-accurate-radiotherapy-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fcomputer-assisted-ultrasound-imaging-could-help-deliver-more-accurate-radiotherapy-for-prostate-cancerComputer-assisted ultrasound imaging could help deliver more accurate radiotherapy for prostate cancerA computer algorithm which helps radiographers interpret ultrasound images could improve radiotherapy treatment for patients with prostate cancer, a new study suggests.https://www.icr.ac.uk/news-archive%2fimmune-system-could-be-trained-to-spot-drug-resistant-cancershttps://www.icr.ac.uk/news-archive%2fimmune-system-could-be-trained-to-spot-drug-resistant-cancersImmune system could be trained to spot drug-resistant cancersAggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer cells with specific drug resistance-causing mutations, a major new study suggests.https://www.icr.ac.uk/news-archive%2fstudy-strengthens-calls-to-clear-cancer-diagnosis-backloghttps://www.icr.ac.uk/news-archive%2fstudy-strengthens-calls-to-clear-cancer-diagnosis-backlogStudy strengthens calls to clear cancer diagnosis backlogDelays to cancer referral through reduced use of the urgent GP referral pathway during the coronavirus pandemic could result in more than a thousand additional deaths in England, a new study reports.https://www.icr.ac.uk/news-archive%2flong-term-safety-of-radiotherapy-in-fewer-doses-for-patients-with-early-breast-cancer-demonstrated-in-10-year-studyhttps://www.icr.ac.uk/news-archive%2flong-term-safety-of-radiotherapy-in-fewer-doses-for-patients-with-early-breast-cancer-demonstrated-in-10-year-studyLong-term safety of radiotherapy in fewer doses for patients with early breast cancer demonstrated in 10-year study A lower total dose of radiotherapy delivered in fewer but larger doses is as safe in the long term as breast cancer radiotherapy courses giving multiple small doses, according to the final results of a 10-year study.https://www.icr.ac.uk/news-archive%2furgent-call-to-kick-start-life-saving-cancer-research-so-cancer-patients-don-t-get-left-behindhttps://www.icr.ac.uk/news-archive%2furgent-call-to-kick-start-life-saving-cancer-research-so-cancer-patients-don-t-get-left-behindUrgent call to kick-start life-saving cancer research so cancer patients don’t get left behindScientists researching new treatments for cancer patients are calling for urgent support to ensure the disruption caused by the coronavirus crisis does not damage long-term progress to defeat the disease. https://www.icr.ac.uk/news-archive%2fresearchers-reveal-discovery-of-new-cancer-drug-fadraciclibhttps://www.icr.ac.uk/news-archive%2fresearchers-reveal-discovery-of-new-cancer-drug-fadraciclibResearchers reveal discovery of new cancer drug fadraciclibScientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumours.https://www.icr.ac.uk/news-archive%2flung-cancer-in-non-smokers-likely-to-respond-differently-to-treatmenthttps://www.icr.ac.uk/news-archive%2flung-cancer-in-non-smokers-likely-to-respond-differently-to-treatmentLung cancer in non-smokers likely to respond differently to treatmentLung cancer in non-smokers is a biologically distinct disease from that in smokers, according to a new study. Researchers also found it has characteristics that mean it could be targeted with tailored treatments.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-and-covid-19-how-coronavirus-has-delayed-vital-cancer-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-and-covid-19-how-coronavirus-has-delayed-vital-cancer-treatmentsCancer and COVID-19: how coronavirus has delayed vital cancer treatmentsHenry French looks at how an Institute of Cancer Research-led study into the impact of the COVID-19 pandemic on people with cancer helped to start a national debate.https://www.icr.ac.uk/news-archive%2freprogramming-immune-cells-could-switch-defence-into-attack-to-treat-prostate-cancerhttps://www.icr.ac.uk/news-archive%2freprogramming-immune-cells-could-switch-defence-into-attack-to-treat-prostate-cancer‘Reprogramming’ immune cells could switch defence into attack to treat prostate cancerDrugs that can ‘reprogramme’ immune cells from protecting cancer to attacking it could be an effective new treatment for some men with advanced prostate cancer, a new study shows. https://www.icr.ac.uk/news-archive%2fvirtual-terry-fox-run-launches-in-the-uk-in-aid-of-the-icrhttps://www.icr.ac.uk/news-archive%2fvirtual-terry-fox-run-launches-in-the-uk-in-aid-of-the-icrVirtual Terry Fox Run launches in the UK in aid of the ICRA virtual run has been launched in the UK inspired by a prominent Canadian cancer research activist, to raise money for the Institute of Cancer Research, London. https://www.icr.ac.uk/news-archive%2fscientists-expand-understanding-of-how-dna-is-organisedhttps://www.icr.ac.uk/news-archive%2fscientists-expand-understanding-of-how-dna-is-organisedScientists expand understanding of how DNA is organisedScientists at The Institute of Cancer Research have uncovered new information about vital structures inside cells which are responsible for organising our DNA.https://www.icr.ac.uk/news-archive%2fmri-scan-used-for-heart-disease-could-also-pick-out-aggressive-cancershttps://www.icr.ac.uk/news-archive%2fmri-scan-used-for-heart-disease-could-also-pick-out-aggressive-cancersMRI scan used for heart disease could also pick out aggressive cancersA type of smart MRI scan used in people with heart disease could help assess whether children’s cancers are especially aggressive and spot early signs that targeted treatments are working, a new study suggests.https://www.icr.ac.uk/news-archive%2fmen-in-england-and-wales-miss-out-on-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fmen-in-england-and-wales-miss-out-on-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerMen in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancerThe ICR has expressed disappointment at the decision by NICE not to recommend abiraterone as a first-line treatment on the NHS for newly diagnosed, advanced prostate cancer.https://www.icr.ac.uk/news-archive%2fdrug-used-in-breast-and-ovarian-cancer-could-lead-to-safer-more-effective-treatment-for-neuroblastomahttps://www.icr.ac.uk/news-archive%2fdrug-used-in-breast-and-ovarian-cancer-could-lead-to-safer-more-effective-treatment-for-neuroblastomaDrug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastomaA type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma – a common childhood tumour with a low survival rate.https://www.icr.ac.uk/news-archive%2fbreast-cancer-drug-capivasertib-enters-major-trialhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-drug-capivasertib-enters-major-trialBreast cancer drug capivasertib enters major trialA major phase III trial of capivasertib, a cancer drug discovered following collaborative work between The Institute of Cancer Research, London, and partners, has begun in breast cancer.https://www.icr.ac.uk/news-archive%2fnew-class-of-precision-medicine-strips-cancer-of-its-dna-defenceshttps://www.icr.ac.uk/news-archive%2fnew-class-of-precision-medicine-strips-cancer-of-its-dna-defencesNew class of precision medicine strips cancer of its DNA defencesA new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class.https://www.icr.ac.uk/news-archive%2faacr-virtual-annual-meeting-2020-personalised-cancer-vaccine-shows-promise-in-early-trialhttps://www.icr.ac.uk/news-archive%2faacr-virtual-annual-meeting-2020-personalised-cancer-vaccine-shows-promise-in-early-trialAACR Virtual Annual Meeting 2020: Personalised cancer vaccine shows promise in early trialA personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-target-cancer-s-metabolism-by-combining-new-drugs-with-a-fat-free-diethttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-target-cancer-s-metabolism-by-combining-new-drugs-with-a-fat-free-dietCan we target cancer’s metabolism by combining new drugs with a fat-free diet?The ICR’s Dr George Poulogiannis and his team have revealed a metabolic weakness in cancer that could be targeted by combining new drugs with a diet free of omega-6 fats. Our Media Officer Diana Cano Bordajandi explains the research findings and their potential implications.https://www.icr.ac.uk/news-archive%2fcancer-s-reliance-on-fat-could-be-targeted-with-new-drugs-and-diet-treatmenthttps://www.icr.ac.uk/news-archive%2fcancer-s-reliance-on-fat-could-be-targeted-with-new-drugs-and-diet-treatmentCancer’s reliance on fat could be targeted with new ‘drugs and diet’ treatmentCancers are often heavily reliant on breaking down fats for their growth and spread, and could be treated by a highly innovative combination of new drugs and dietary changes, a major new study concludes.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmen-s-health-week-how-our-researchers-are-transforming-prostate-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmen-s-health-week-how-our-researchers-are-transforming-prostate-cancer-treatmentMen’s Health Week: How our researchers are transforming prostate cancer treatmentProfessor Nick James, Chief Investigator of the STAMPEDE trial, joined the ICR in December 2019 and is one of our newest Team Leaders. Diana Cano Bordajandi met him to find out more about his current research and future plans, which will help us answer key questions on how to treat men with prostate cancer.https://www.icr.ac.uk/news-archive%2ficr-ramps-up-lab-research-after-lockdownhttps://www.icr.ac.uk/news-archive%2ficr-ramps-up-lab-research-after-lockdownICR ramps up lab research after lockdownICR researchers are returning to their labs this week as we start to ramp up our pioneering cancer research following the disruption caused by the pandemic.https://www.icr.ac.uk/news-archive%2ficr-and-cancer-research-uk-spinout-company-monte-rosa-therapeutics-launches-with-library-of-anti-cancer-compoundshttps://www.icr.ac.uk/news-archive%2ficr-and-cancer-research-uk-spinout-company-monte-rosa-therapeutics-launches-with-library-of-anti-cancer-compoundsICR and Cancer Research UK spinout company Monte Rosa Therapeutics launches with library of anti-cancer compoundsA company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research, London, has been publicly launched – revealing $32.5m in funding and a library of innovative anti-cancer compounds.https://www.icr.ac.uk/news-features%2flatest-features%2fisabella-s-gift-the-precious-donation-aiding-vital-research-into-childhood-brain-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fisabella-s-gift-the-precious-donation-aiding-vital-research-into-childhood-brain-cancerIsabella’s gift: The precious donation aiding vital research into childhood brain cancerThe parents of Isabella Ortiz, who died from a brain tumour, have highlighted the need for rare tissue donation, to help other children facing the same condition.https://www.icr.ac.uk/news-archive%2ficr-statement-regarding-black-lives-matterhttps://www.icr.ac.uk/news-archive%2ficr-statement-regarding-black-lives-matterICR statement regarding Black Lives MatterAs an organisation that believes passionately in equality, we want to express our solidarity with our Black, Asian and minority ethnic staff following the death of George Floyd. https://www.icr.ac.uk/news-archive%2fmini-tumours-help-predict-how-cancer-handles-the-heat-of-innovative-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fmini-tumours-help-predict-how-cancer-handles-the-heat-of-innovative-cancer-treatmentsMini tumours help predict how cancer handles the heat of innovative cancer treatmentsScientists have shown that therapies which combine heat and radiation have a different effect on lab-grown mini tumours than they do on lab-grown cancer cells grown in a more traditional way in a two-dimensional layer. https://www.icr.ac.uk/news-archive%2fpioneer-in-building-collaboration-across-research-fields-joins-as-scientific-director-of-the-cancer-research-uk-convergence-science-centrehttps://www.icr.ac.uk/news-archive%2fpioneer-in-building-collaboration-across-research-fields-joins-as-scientific-director-of-the-cancer-research-uk-convergence-science-centrePioneer in building collaboration across research fields joins as Scientific Director of the Cancer Research UK Convergence Science CentreThe Institute of Cancer Research, London, and Imperial College London have appointed a leading expert in building interdisciplinary partnerships to head our joint Cancer Research UK Convergence Science Centre.https://www.icr.ac.uk/news-archive%2fasco-2020-uk-first-study-shows-feasibility-of-genetic-screening-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fasco-2020-uk-first-study-shows-feasibility-of-genetic-screening-for-prostate-cancerASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancerGenetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows.https://www.icr.ac.uk/news-archive%2fasco-2020-blood-test-predicts-response-to-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fasco-2020-blood-test-predicts-response-to-prostate-cancer-treatmentASCO 2020: Blood test predicts response to prostate cancer treatmentA new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease.https://www.icr.ac.uk/news-archive%2fasco-2020-new-optimised-precision-radiotherapy-can-reduce-swallowing-difficulties-for-head-and-neck-cancer-patientshttps://www.icr.ac.uk/news-archive%2fasco-2020-new-optimised-precision-radiotherapy-can-reduce-swallowing-difficulties-for-head-and-neck-cancer-patientsASCO 2020: New optimised precision radiotherapy can reduce swallowing difficulties for head and neck cancer patientsA new optimised intensity-modulated radiation therapy (IMRT) could spare head and neck cancer patients’ adverse life-long side effects after treatment, new clinical trial results have shown.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2020-cancer-researchers-get-together-at-a-distancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2020-cancer-researchers-get-together-at-a-distanceASCO 2020: Cancer researchers get together at a distanceAt a time when cancer researchers usually descend on Chicago for the biggest cancer conference of the year, Sarah Wells looks ahead at some of the highlights that researchers from The Institute of Cancer Research will be presenting at this year’s virtual edition of the ASCO Annual Meeting.https://www.icr.ac.uk/news-archive%2fai-could-predict-risk-of-lung-cancer-coming-backhttps://www.icr.ac.uk/news-archive%2fai-could-predict-risk-of-lung-cancer-coming-backAI could predict risk of lung cancer coming backComputer scientists working with pathologists have trained an artificial intelligence (AI) tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment. https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fpressing-a-post-coronavirus-reset-button-on-cancer-researchhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fpressing-a-post-coronavirus-reset-button-on-cancer-researchPressing a post-coronavirus reset button on cancer researchThe global COVID-19 pandemic has ground the world as we know it to a halt – and cancer research is no exception. ICR researcher Professor Udai Banerji reflects on this opportunity to take stock of the challenges faced in cancer research, and restart with ambitious new plans.https://www.icr.ac.uk/news-archive%2fapproval-of-olaparib-offers-men-first-gene-targeted-medicine-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fapproval-of-olaparib-offers-men-first-gene-targeted-medicine-for-prostate-cancerProstate cancer gets first gene-targeted medicinesThe Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.https://www.icr.ac.uk/news-archive%2fthousands-of-lives-could-be-lost-to-delays-in-cancer-surgery-during-covid-19-pandemichttps://www.icr.ac.uk/news-archive%2fthousands-of-lives-could-be-lost-to-delays-in-cancer-surgery-during-covid-19-pandemicThousands of lives could be lost to delays in cancer surgery during COVID-19 pandemicDelays to cancer surgery and other treatment caused by the coronavirus crisis could result in thousands of additional deaths linked to the pandemic in England, a major new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcryo-electron-microscopy-the-coolest-tech-in-the-cancer-toolkithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcryo-electron-microscopy-the-coolest-tech-in-the-cancer-toolkitCryo-electron microscopy – the coolest tech in the cancer toolkitCryo-electron microscopy is an exciting technology that could revolutionise drug design by seeing complex molecules in unprecedented detail. The Institute of Cancer Research has been at the vanguard in applying it to cancer – and now a new collaboration called the London Consortium for Cryo-EM (LonCEM) is using this super-cooled technique to learn more about the mechanisms of life and cancer. https://www.icr.ac.uk/news-archive%2fmapping-how-evolutionary-forces-affect-cancer-growth-could-help-doctors-choose-biopsieshttps://www.icr.ac.uk/news-archive%2fmapping-how-evolutionary-forces-affect-cancer-growth-could-help-doctors-choose-biopsiesMapping how evolutionary forces affect cancer growth could help doctors choose biopsiesA computer model that uses the principles of evolution to map the growth of populations of cancer cells in tumours could help doctors choose where to take biopsies from tumours, improving decisions about treatment.https://www.icr.ac.uk/news-archive%2fnew-life-sciences-incubator-space-plans-announced-for-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fnew-life-sciences-incubator-space-plans-announced-for-the-london-cancer-hubNew life-sciences incubator space plans announced for The London Cancer HubLife-science companies will have the opportunity to work directly alongside world-class scientists from The Institute of Cancer Research, London, after exciting plans were revealed to create a new innovation centre.https://www.icr.ac.uk/news-archive%2fscientists-bring-together-world-s-coronavirus-research-in-%27intelligent%27-online-databasehttps://www.icr.ac.uk/news-archive%2fscientists-bring-together-world-s-coronavirus-research-in-%27intelligent%27-online-databaseScientists bring together world’s coronavirus research in 'intelligent' online databaseScientists have created a dynamic database driven by artificial intelligence which is collecting together the world’s research on coronavirus in a single online space.https://www.icr.ac.uk/news-archive%2fapproval-of-targeted-therapies-first-line-for-prostate-cancer-will-ease-covid-19-pressureshttps://www.icr.ac.uk/news-archive%2fapproval-of-targeted-therapies-first-line-for-prostate-cancer-will-ease-covid-19-pressuresApproval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’The Institute of Cancer Research, London, has broadly welcomed the approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-adapting-a-novel-antibody-technology-to-combat-the-covid-19-coronavirushttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-adapting-a-novel-antibody-technology-to-combat-the-covid-19-coronavirusHow we’re adapting a novel antibody technology to combat COVID-19Henry French introduces a new project at the ICR, where cancer researchers are turning their expertise in the creation of high-affinity antibodies to new approaches to COVID-19 testing and treatment. https://www.icr.ac.uk/news-archive%2fone-week-course-of-radiotherapy-could-benefit-women-with-early-stage-breast-cancer-study-findshttps://www.icr.ac.uk/news-archive%2fone-week-course-of-radiotherapy-could-benefit-women-with-early-stage-breast-cancer-study-findsOne-week course of radiotherapy could benefit women with early stage breast cancer, study finds A one-week course of radiotherapy in fewer but larger daily doses was found to be as safe and effective as standard three-week therapy for women following surgery for early stage breast cancer. The protocol is being eagerly sought by hospitals to help reduce demands on the NHS during the COVID-19 pandemic.https://www.icr.ac.uk/news-archive%2fmajor-trial-shows-breast-cancer-drug-can-hit-prostate-cancer-achilles-heelhttps://www.icr.ac.uk/news-archive%2fmajor-trial-shows-breast-cancer-drug-can-hit-prostate-cancer-achilles-heelMajor trial shows breast cancer drug can hit prostate cancer Achilles heelA drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.https://www.icr.ac.uk/news-features%2flatest-features%2ftraining-for-a-marathon-in-a-pandemic-the-fundraisers-helping-us-finish-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2ftraining-for-a-marathon-in-a-pandemic-the-fundraisers-helping-us-finish-cancerTraining for a marathon in a pandemic: the fundraisers helping us finish cancerAs sports events around the world are put on hold in the midst of the coronavirus crisis, Joanne Duffy finds out how #teamICR have come together to support each other, adapt their training and focus on what really matters to them.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbook-published-in-tribute-to-the-late-dr-susan-lindquist-hsf1-and-molecular-chaperones-in-biology-and-cancerhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbook-published-in-tribute-to-the-late-dr-susan-lindquist-hsf1-and-molecular-chaperones-in-biology-and-cancerBook published in tribute to the late Dr Susan Lindquist – HSF1 and Molecular Chaperones in Biology and CancerWith the publication of a monograph in her honour, in which he contributed an article, Professor Paul Workman celebrates the outstanding scientific achievements of the late Dr Susan Lindquist in the field of protein folding and its application to cancer and neurodegenerative disease. He also explains how her work has underpinned several of his drug discovery projects at the ICR.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcancer-research-collaborations-in-the-era-of-covid-19-force-majeure-home-working-and-supporting-the-nhshttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fcancer-research-collaborations-in-the-era-of-covid-19-force-majeure-home-working-and-supporting-the-nhsCancer research collaborations in the era of COVID-19: force majeure, home working and supporting the NHSOur Director of Enterprise Dr Angela Kukula gives an update on our response to COVID-19, and discusses how it is affecting our partnerships and collaborations. https://www.icr.ac.uk/news-archive%2ficr-supporting-national-coronavirus-responsehttps://www.icr.ac.uk/news-archive%2ficr-supporting-national-coronavirus-responseOur COVID-19 research and how we’re supporting the NHSStaff and students from across The Institute of Cancer Research, London, are using their scientific and clinical expertise as part of the national response to the coronavirus pandemic.https://www.icr.ac.uk/news-archive%2fscientists-enhance-new-way-to-overcome-resistance-to-targeted-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fscientists-enhance-new-way-to-overcome-resistance-to-targeted-cancer-treatmentsScientists enhance new way to overcome resistance to targeted cancer treatmentsResearchers have enhanced a new method for inhibiting the protein HSP72, known to be important in helping cancer cells survive and resist treatment, which will help scientists move closer to discovering a new cancer drug that targets the protein.https://www.icr.ac.uk/news-archive%2fbabies-with-brain-tumours-could-benefit-from-targeted-treatmenthttps://www.icr.ac.uk/news-archive%2fbabies-with-brain-tumours-could-benefit-from-targeted-treatmentBabies with brain tumours could benefit from targeted treatmentBrain cancer in infants is biologically distinct from other childhood brain tumours and could be successfully treated with targeted drugs, a new study has shown.https://www.icr.ac.uk/news-archive%2fmajor-new-cancer-imaging-network-involving-the-icr-and-the-royal-marsden-establishedhttps://www.icr.ac.uk/news-archive%2fmajor-new-cancer-imaging-network-involving-the-icr-and-the-royal-marsden-establishedMajor new cancer imaging network involving the ICR and The Royal Marsden establishedNine world-leading medical imaging centres from across the UK will come together to form an integrated network for standardising and validating the use of cutting-edge imaging techniques in cancer treatment.https://www.icr.ac.uk/news-archive%2flatest-coronavirus-update---25-marchhttps://www.icr.ac.uk/news-archive%2flatest-coronavirus-update---25-marchLatest coronavirus update - 25 MarchThe Institute of Cancer Research, London, has now ceased most of its ‘wet lab’ research as part of a series of measures to safeguard staff and students from coronavirus – but we are proud to be supporting the national effort against the pandemic.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-awareness-month-2020-immunotherapy-state-of-the-art-radiotherapy-olaparib-and-psa-screeninghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-awareness-month-2020-immunotherapy-state-of-the-art-radiotherapy-olaparib-and-psa-screeningProstate Cancer Awareness Month 2020: Immunotherapy, state-of-the-art radiotherapy, olaparib and PSA screeningMarch is Prostate Cancer Awareness Month. Web Editor Dave Morgan reviews four recent news stories covering different types of prostate cancer research taking place at The Institute of Cancer Research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fliving-with-lynch-syndrome-cara-s-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fliving-with-lynch-syndrome-cara-s-storyLiving with Lynch syndrome: Cara’s storyResearch carried out by The Institute of Cancer Research, London, into cancer susceptibility genes has transformed our understanding of the inheritance of cancer risk. Genetic information can be used to help people with cancer and their families by informing them about their risk and guiding decisions over personalised cancer treatment. Cara Hoofe was diagnosed with bowel cancer in 2016. She has the inherited condition Lynch syndrome which means she had an 80% chance of developing bowel cancer and has a higher risk of developing womb and ovarian cancer. Here she explains how living with Lynch syndrome has changed her life.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwill-i-see-them-graduate-one-patient-s-perspective-on-life-with-advanced-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwill-i-see-them-graduate-one-patient-s-perspective-on-life-with-advanced-breast-cancerWill I see them graduate? One patient’s perspective on life with advanced breast cancerMaureen is 56 and is living with advanced, incurable breast cancer. Before the outbreak of coronavirus, she wrote a blog post about why she’s making the most of the life she has now. This is a very difficult time for many, but here at the ICR we’re doing everything we can to ensure our life-saving work continues, so that we can give people like Maureen more time to spend with their loved ones.https://www.icr.ac.uk/news-archive%2flatest-icr-update-concerning-coronavirus---20-marchhttps://www.icr.ac.uk/news-archive%2flatest-icr-update-concerning-coronavirus---20-marchLatest coronavirus update - 20 MarchThe Institute of Cancer Research, London, is putting in place a series of measures to safeguard its staff and students in response to the coronavirus pandemic, while also seeking to minimise the long-term impact upon our life-saving research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmy-treatment-has-given-me-a-new-lease-of-life-rob-s-prostate-cancer-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmy-treatment-has-given-me-a-new-lease-of-life-rob-s-prostate-cancer-story“My treatment has given me a new lease of life” – Rob’s prostate cancer storyHundreds of thousands of men with prostate cancer across the world are now able to live longer and with a better quality of life, thanks to abiraterone. Discovered and developed by The Institute of Cancer Research, the drug was the first treatment shown to be effective in patients with advanced prostate cancer. Rob Lester is one of those patients, and has been on abiraterone for around 8 years.https://www.icr.ac.uk/news-archive%2flatest-icr-update-concerning-coronavirus---march-17https://www.icr.ac.uk/news-archive%2flatest-icr-update-concerning-coronavirus---march-17Latest ICR update concerning coronavirus - 17 MarchThe Institute of Cancer Research, London, is doing everything it can to safeguard its staff and students in response to the coronavirus pandemic while attempting to minimise the inevitable disruption to its life-saving research.https://www.icr.ac.uk/news-archive%2ficr-updates-on-its-response-to-coronavirushttps://www.icr.ac.uk/news-archive%2ficr-updates-on-its-response-to-coronavirusICR updates on its response to coronavirus - 14 MarchThe Institute of Cancer Research, London, is continuing to do its life-saving cancer research in line with Government guidance on coronavirus while making extensive preparations for disruption ahead.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fweighing-in-on-breast-cancer-risk-considering-the-effect-of-weight-gain-before-the-menopausehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fweighing-in-on-breast-cancer-risk-considering-the-effect-of-weight-gain-before-the-menopauseWeighing in on breast cancer risk – considering the effect of weight gain before the menopauseObesity is known to be linked to cancer risk, but new research shows that weight gain is linked to a *lower* risk of breast cancer among women before the menopause. In this blog post, Joanne Duffy takes a closer look at the findings and explains how this contributes to our understanding of breast cancer risk factors.https://www.icr.ac.uk/news-archive%2fweight-gain-linked-to-lower-risk-of-breast-cancer-before-the-menopausehttps://www.icr.ac.uk/news-archive%2fweight-gain-linked-to-lower-risk-of-breast-cancer-before-the-menopauseWeight gain linked to lower risk of breast cancer before the menopauseGaining weight from early adulthood is linked to a lower risk of breast cancer before the menopause, a major global study of more than 600,000 women has found.https://www.icr.ac.uk/news-archive%2ftwo-pronged-attack-on-dna-repair-could-kill-drug-resistant-cancershttps://www.icr.ac.uk/news-archive%2ftwo-pronged-attack-on-dna-repair-could-kill-drug-resistant-cancersTwo-pronged attack on DNA repair could kill drug-resistant cancersLaunching a two-pronged attack on cancer’s ability to safeguard its DNA could offer an effective new way of treating the disease, a new study reports.https://www.icr.ac.uk/news-archive%2ficr-recognised-in-budget-as-world-leading-research-centrehttps://www.icr.ac.uk/news-archive%2ficr-recognised-in-budget-as-world-leading-research-centreICR recognised in Budget as world-leading research centreThe ICR is set to receive extra Government funding after being recognised in the Budget as a world-leading specialist institution. https://www.icr.ac.uk/news-archive%2fgenetic-test-could-pick-out-%27ultra-high-risk%27-bone-marrow-cancer-patientshttps://www.icr.ac.uk/news-archive%2fgenetic-test-could-pick-out-%27ultra-high-risk%27-bone-marrow-cancer-patientsGenetic test could pick out 'ultra high risk' bone marrow cancer patientsA new genetic test could help doctors pick out patients with the bone marrow cancer multiple myeloma who are at ‘ultra high risk’ of their cancer progressing aggressively early on.https://www.icr.ac.uk/news-archive%2ftime-for-family-friends-and-travel-most-valued-by-patients-living-with-cancerhttps://www.icr.ac.uk/news-archive%2ftime-for-family-friends-and-travel-most-valued-by-patients-living-with-cancerTime for family, friends and travel most valued by patients living with cancerSpending time with family is what cancer patients would most value if new treatments allowed them to live for longer, a new YouGov poll reveals.https://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-five-women-leading-the-way-at-the-icr-on-international-women-s-dayhttps://www.icr.ac.uk/news-features%2flatest-features%2fcelebrating-five-women-leading-the-way-at-the-icr-on-international-women-s-dayCelebrating five women leading the way at the ICR on International Women's Day 2020On International Women’s Day 2020, we speak to five women leading the way at the ICR on their journeys in science, their tips for others considering a career in research and the importance of diversity in research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmall-numbers-big-impact-the-unique-challenges-of-studying-rare-cancershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmall-numbers-big-impact-the-unique-challenges-of-studying-rare-cancersSmall numbers, big impact: the unique challenges of studying rare cancersNew results from an ICR-led clinical trial are set to change the outlook for patients with a rare form of kidney cancer. Sarah Wells takes a look at some of the main challenges in studying rare cancers, and how the ICR’s researchers are going about making discoveries to improve the outlook for the one in five cancer patients with a rare cancer.https://www.icr.ac.uk/news-archive%2fchemotherapy-after-surgery-halves-risk-of-rare-kidney-cancer-coming-backhttps://www.icr.ac.uk/news-archive%2fchemotherapy-after-surgery-halves-risk-of-rare-kidney-cancer-coming-backChemotherapy after surgery halves risk of rare kidney cancer coming backChemotherapy halves the risk of a rare form of kidney cancer coming back after surgery, the largest ever trial conducted in the disease worldwide has found.https://www.icr.ac.uk/news-features%2flatest-features%2fobesity-and-tumours-what-s-cancer-eating-for-lunchhttps://www.icr.ac.uk/news-features%2flatest-features%2fobesity-and-tumours-what-s-cancer-eating-for-lunchObesity and tumours: What’s cancer eating for lunch?Obesity is one of the leading factors contributing to cancer development worldwide. In this feature, Joanne Duffy speaks to Dr Barrie Peck about how fat affects cancer on a molecular level, the relationship between obesity and cancer, and why it's all more complicated than it seems.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-genomics-is-transforming-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-genomics-is-transforming-cancer-treatmentHow genomics is transforming cancer treatmentScientists from The Institute of Cancer Research, London, gathered recently at this year’s Festival of Genomics. Diana Cano Bordajandi, Media Officer at The Institute of Cancer Research, reports on the themes that ran through the conference.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2funderstanding-the-off-target-effects-of-cancer-drugs-and-how-they-could-lead-us-to-new-forms-of-treatmenthttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2funderstanding-the-off-target-effects-of-cancer-drugs-and-how-they-could-lead-us-to-new-forms-of-treatmentUnderstanding the off-target effects of cancer drugs – and how they could lead us to new forms of treatmentProfessor Paul Workman explores how an understanding of the 'off-target' effects of drug treatments has the potential to help uncover contributions to both the beneficial action of drugs and also the unwanted side-effects.https://www.icr.ac.uk/news-features%2flatest-features%2fsquaring-up-to-silent-tumours-the-research-burden-of-pancreatic-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fsquaring-up-to-silent-tumours-the-research-burden-of-pancreatic-cancerSquaring up to silent tumours: the research burden of pancreatic cancerThis rare disease day, Joanne Duffy looks at some of the cutting-edge research taking place at the ICR. https://www.icr.ac.uk/news-archive%2fworld-s-largest-sarcoma-research-database-aims-to-revolutionise-sarcoma-treatment-after-multi-million-pound-investmenthttps://www.icr.ac.uk/news-archive%2fworld-s-largest-sarcoma-research-database-aims-to-revolutionise-sarcoma-treatment-after-multi-million-pound-investmentWorld’s largest sarcoma research database aims to revolutionise sarcoma treatment after multi-million pound investmentResearchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, working alongside collaborators from around the globe, are set to begin work on the world’s largest digital hub of sarcoma clinical and research data after receiving a £2.5m grant.https://www.icr.ac.uk/news-archive%2ficr-experts-show-discovery-club-how-to-build-the-cancer-drugs-of-the-futurehttps://www.icr.ac.uk/news-archive%2ficr-experts-show-discovery-club-how-to-build-the-cancer-drugs-of-the-futureICR experts show Discovery Club how to build the cancer drugs of the futureMembers of the ICR’s Discovery Club saw first-hand the delicacy and complexity of techniques used to sculpt new drug molecules, as they learned how our scientists design the cancer drugs of the future.https://www.icr.ac.uk/news-archive%2fscientists-identify-drug-fragments-that-could-lead-to-new-cancer-drugshttps://www.icr.ac.uk/news-archive%2fscientists-identify-drug-fragments-that-could-lead-to-new-cancer-drugsScientists identify drug fragments that could lead to new cancer drugsResearchers have found drug fragments, which could help improve our understanding of the function of a key cancer protein and ultimately lead to new drug treatments.https://www.icr.ac.uk/news-features%2flatest-features%2fcancer-close-up---how-the-latest-imaging-technology-is-helping-us-understand-how-cancer-spreadshttps://www.icr.ac.uk/news-features%2flatest-features%2fcancer-close-up---how-the-latest-imaging-technology-is-helping-us-understand-how-cancer-spreadsCancer close-up – how the latest imaging technology is helping us understand how cancer spreadsCancer’s ability to move and spread around the body is one of its most dangerous aspects. Science Communications Officer, Graham Shaw, spoke with the ICR’s Professor Chris Bakal to learn how cutting-edge imaging is helping him to look at cancer cells in unprecedented detail to understand how they move.https://www.icr.ac.uk/news-archive%2fclinical-trial-leads-the-way-to-side-stepping-side-effects-using-state-of-the-art-radiotherapyhttps://www.icr.ac.uk/news-archive%2fclinical-trial-leads-the-way-to-side-stepping-side-effects-using-state-of-the-art-radiotherapy Clinical trial aims to side-step side-effects with state-of-the-art radiotherapyA major clinical trial has shown that changing the way radiotherapy is delivered could significantly reduce the side effects associated with radiotherapy treatment for prostate cancer. https://www.icr.ac.uk/news-features%2flatest-features%2fthe-art-of-science-cutting-edge-science-and-captivating-imageshttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-art-of-science-cutting-edge-science-and-captivating-imagesThe Art of Science – Cutting edge science and captivating imagesResearchers from the ICR and The Royal Marsden submitted fantastic images to this year’s ICR Science and Medical Imaging competition, with winning images by PhD student Sumana Shrestha showcasing just how captivating scientific and medical images can be.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fageing-cancer-and-evolution-what-darwin-s-great-theory-of-life-means-for-two-unavoidable-aspects-of-livinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fageing-cancer-and-evolution-what-darwin-s-great-theory-of-life-means-for-two-unavoidable-aspects-of-livingAgeing, cancer, and evolution – what Darwin’s great theory of life means for two unavoidable aspects of livingTo celebrate Darwin Day, The Institute of Cancer Research invited world-leading expert on the biology of ageing, Professor Dame Linda Partridge, to talk about how ageing stems from evolutionary processes, and what it means for diseases like cancer.https://www.icr.ac.uk/news-archive%2fgenetic-rewiring-drives-cancer-s-drug-resistancehttps://www.icr.ac.uk/news-archive%2fgenetic-rewiring-drives-cancer-s-drug-resistance'Genetic rewiring' by a microRNA gene drives cancer’s drug resistanceA tiny molecule of RNA – known as ‘microRNA’ – plays a key role in ‘rewiring’ cancer cells so they can resist the effects of chemotherapy, a new study reveals. The discovery opens up the possibility of creating new cancer drugs that target this microRNA molecule, rather than more conventional treatments that block the action of proteins.https://www.icr.ac.uk/news-archive%2fcancer-vaccine-could-boost-the-effectiveness-of-immunotherapyhttps://www.icr.ac.uk/news-archive%2fcancer-vaccine-could-boost-the-effectiveness-of-immunotherapyCancer vaccine could boost the effectiveness of immunotherapySupercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.https://www.icr.ac.uk/news-archive%2fmajor-investment-to-transform-uk-s-leading-cancer-campushttps://www.icr.ac.uk/news-archive%2fmajor-investment-to-transform-uk-s-leading-cancer-campusMajor investment to transform UK’s leading cancer campusA new multimillion investment is to drive forward development of The London Cancer Hub – boosting efforts to turn it into the world’s leading life-science campus focused on overcoming cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fastrazeneca-s-tim-eisen-on-the-importance-of-collaborations-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fastrazeneca-s-tim-eisen-on-the-importance-of-collaborations-in-cancer-researchAstraZeneca’s Tim Eisen on the importance of collaborations in cancer researchICR alumnus Professor Tim Eisen is now Head of Oncology Early Clinical Development at AstraZeneca. We caught up with him at a recent event where he shared his career advice and thoughts about working in industry.https://www.icr.ac.uk/news-features%2flatest-features%2ffit-to-burst-how-cancer-exploding-viruses-are-changing-the-gamehttps://www.icr.ac.uk/news-features%2flatest-features%2ffit-to-burst-how-cancer-exploding-viruses-are-changing-the-gameFit to burst: How cancer-exploding viruses are changing the gameOncolytic viruses are viruses which can burst cancer cells. In this feature, Joanne Duffy takes a look at what ICR researchers are doing in this realm, and how oncolytic viruses can help us target cancer more effectively.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-how-the-icr-is-building-expertise-in-cancer-research-in-nepalhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-how-the-icr-is-building-expertise-in-cancer-research-in-nepalWorld Cancer Day: how the ICR is building expertise in cancer research in NepalOur researchers have been working with oncologists in Nepal since 2017 to share their expertise, and improve research and cancer care in the country.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhat-next-for-uk-cancer-research-in-the-brexit-erahttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhat-next-for-uk-cancer-research-in-the-brexit-eraWhat next for UK cancer research in the Brexit era?Henry French asks how Brexit might affect cancer researchers and their collaborations with life-science companies.https://www.icr.ac.uk/news-archive%2fmri-data-can-predict-patient-response-to-treatment-and-survival-in-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fmri-data-can-predict-patient-response-to-treatment-and-survival-in-advanced-ovarian-cancerMRI data can predict patient response to treatment and survival in advanced ovarian cancer A simple test using an MRI scan can be used to predict how well people with advanced ovarian cancer will respond to treatment, according to the results of a new study.https://www.icr.ac.uk/news-archive%2fmost-innovative-cancer-drugs-facing-delays-in-reaching-patientshttps://www.icr.ac.uk/news-archive%2fmost-innovative-cancer-drugs-facing-delays-in-reaching-patientsMost innovative cancer drugs facing delays in reaching patientsDespite increasing numbers of cancer drugs being licensed, an analysis has found that highly innovative drugs took longer to reach NHS patients than more conventional treatments.https://www.icr.ac.uk/news-archive%2ficr-research-showcased-in-major-new-science-museum-gallery-documenting-history-of-medicinehttps://www.icr.ac.uk/news-archive%2ficr-research-showcased-in-major-new-science-museum-gallery-documenting-history-of-medicineICR research showcased in major new Science Museum gallery documenting history of medicineThe Science Museum's new £24 million medicine galleries showcases pioneering research from The Institute of Cancer Research, London, as part of its story of modern medicine. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-coming-for-cancer-in-the-2020shttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-coming-for-cancer-in-the-2020sWhat’s coming for cancer in the 2020sWe’ve learned a lot about cancer in the last decade, with survival rates better now than ever before. Our Policy Adviser, Roya Ziaie, takes a look at what might be in store over the next ten years in an ever-changing field. https://www.icr.ac.uk/news-archive%2fadding-chemotherapy-to-radiotherapy-for-bladder-cancer-shows-benefits-for-patientshttps://www.icr.ac.uk/news-archive%2fadding-chemotherapy-to-radiotherapy-for-bladder-cancer-shows-benefits-for-patientsAdding chemotherapy to radiotherapy for bladder cancer shows benefits for patientsData from a clinical trial which assessed the benefits of adding chemotherapy alongside radiotherapy for patients with muscle invasive bladder cancer has shown that this treatment can be given without substantially impacting subsequent health related quality of life.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftell-me-more-about-telomeres-how-basic-science-can-help-us-treat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftell-me-more-about-telomeres-how-basic-science-can-help-us-treat-cancerTell me more about telomeres: how ‘basic’ science can help us treat cancerDr Max Douglas recently joined the ICR as leader of the Telomere Biology Team. By rebuilding telomeres in the lab, he aims to unpick how they work to understand their link to cancer. Diana Cano Bordajandi met him to find out more.https://www.icr.ac.uk/news-archive%2fcancers-engaged-in-evolutionary-arms-race-with-immune-systemhttps://www.icr.ac.uk/news-archive%2fcancers-engaged-in-evolutionary-arms-race-with-immune-systemCancers engaged in evolutionary arms race with immune systemAggressive, highly mutated cancers evolve escape routes in response to immune attacks in an ‘evolutionary arms race’ between cancer and the immune system, a new study reports.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-pembrolizumab-as-first-line-treatment-for-advanced-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-pembrolizumab-as-first-line-treatment-for-advanced-head-and-neck-cancerThe ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancerThe ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-approval-of-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer-on-the-nhs-in-scotlandhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-approval-of-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer-on-the-nhs-in-scotlandThe ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in ScotlandThe Institute of Cancer Research, London, strongly welcomes the recommendation by the Scottish Medicines Consortium (SMC) to make the prostate cancer drug abiraterone available to men with advanced prostate cancer as first-line treatment on the NHS in Scotland.https://www.icr.ac.uk/news-archive%2fradiotherapy-can-be-used-in-hard-to-treat-bladder-cancerhttps://www.icr.ac.uk/news-archive%2fradiotherapy-can-be-used-in-hard-to-treat-bladder-cancerRadiotherapy can be used in hard-to-treat bladder cancerMore targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis, according to a new clinical trial.https://www.icr.ac.uk/news-archive%2fscientists-map-cancer-related-proteins-in-unprecedented-detailhttps://www.icr.ac.uk/news-archive%2fscientists-map-cancer-related-proteins-in-unprecedented-detailScientists map cancer-related proteins in unprecedented detailResearchers have gained new understandings of two key complexes of cancer-related proteins by producing the most detailed ever maps of the structures they form when they come together.https://www.icr.ac.uk/news-archive%2fhalf-the-amount-of-chemo-prevents-testicular-cancer-from-coming-back-new-trial-showshttps://www.icr.ac.uk/news-archive%2fhalf-the-amount-of-chemo-prevents-testicular-cancer-from-coming-back-new-trial-showsHalf the amount of chemo prevents testicular cancer from coming back, new trial showsTesticular cancer can be prevented from coming back using half the amount of chemotherapy that is currently used, a new clinical trial has shown.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fcure-or-nothing-doesn-t-capture-the-realities-of-modern-cancer-research-and-treatmenthttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fcure-or-nothing-doesn-t-capture-the-realities-of-modern-cancer-research-and-treatment‘Cure or nothing’ doesn’t capture the realities of modern cancer research and treatmentWhile curing cancer will always be the ultimate goal for the ICR's researchers, Professor Paul Workman argues that it's vital we understand and accept new evolutionary approaches to treatment that can control even advanced cancers long term.https://www.icr.ac.uk/news-archive%2fscientists-identify-potential-drug-target-for-brca-mutated-tumourshttps://www.icr.ac.uk/news-archive%2fscientists-identify-potential-drug-target-for-brca-mutated-tumoursScientists identify potential drug target for BRCA-mutated tumoursA new study has uncovered a previously unknown role for the enzyme EXD2, identifying it as a potential drug target for cancer therapy.https://www.icr.ac.uk/news-archive%2fworld-first-treatment-with-acoustic-cluster-therapy-to-improve-chemotherapy-deliveryhttps://www.icr.ac.uk/news-archive%2fworld-first-treatment-with-acoustic-cluster-therapy-to-improve-chemotherapy-deliveryWorld first treatment with ‘acoustic cluster therapy’ to improve chemotherapy deliveryThe first patient has been treated, as part of a clinical trial, with an innovative new technology called Acoustic Cluster Therapy that uses microscopic clusters of bubbles and liquid droplets to enhance the delivery of chemotherapy drugs to tumours. The new therapy could improve targeting of chemotherapy and reduce doses.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-take-my-pill-every-day-and-i-get-on-with-my-life-christine%27s-breast-cancer-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fi-take-my-pill-every-day-and-i-get-on-with-my-life-christine%27s-breast-cancer-story“I take my pill every day, and I get on with my life” – Christine’s breast cancer storyScientists at The Institute of Cancer Research have already been involved in the discovery and development of many targeted treatments that are helping cancer patients live longer and with a better quality of life. Now we’re taking our research a step further with the world’s first drug discovery programme to tackle the challenge of drug resistance. Christine O’Connell, who is living with advanced breast cancer, explains why it’s so important.https://www.icr.ac.uk/news-archive%2fblood-test-can-quickly-match-advanced-breast-cancer-patients-to-targeted-treatmentshttps://www.icr.ac.uk/news-archive%2fblood-test-can-quickly-match-advanced-breast-cancer-patients-to-targeted-treatmentsBlood test can quickly match advanced breast cancer patients to targeted treatmentsA blood test can help identify rare mutations in advanced breast cancer, which may enable patients to access effective treatment more quickly in the future, a new clinical trial has found.https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-announces-intention-to-step-down-as-icr-ceo-in-around-a-yearhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-announces-intention-to-step-down-as-icr-ceo-in-around-a-yearProfessor Paul Workman announces intention to step down as ICR CEO in around a year Professor Paul Workman has announced his intention to step down as Chief Executive of The Institute of Cancer Research, London, in around a year's time after more than six years in the role. https://www.icr.ac.uk/news-archive%2fcancer-research-offers-more-hope-than-people-thinkhttps://www.icr.ac.uk/news-archive%2fcancer-research-offers-more-hope-than-people-thinkCancer research offers more hope than people thinkThe strong public focus on a ‘cure for cancer’ is masking dramatic progress in extending the lives of patients with advanced cancer and turning it into a manageable disease long term, a YouGov poll of members of the public and cancer patients has found.https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2019https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2019Scientific achievements of 2019We've selected a range of discoveries from 2018/19 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.https://www.icr.ac.uk/news-archive%2fnew-test-predicts-chance-of-living-more-than-a-year-on-targeted-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-test-predicts-chance-of-living-more-than-a-year-on-targeted-breast-cancer-treatmentNew test predicts chance of living more than a year on targeted breast cancer treatmentA new test could pick out women with advanced breast cancer who are likely to benefit from an exciting new targeted therapy for more than a year.https://www.icr.ac.uk/news-archive%2fuk-first-study-to-assess-role-of-whole-genome-screening-in-primary-carehttps://www.icr.ac.uk/news-archive%2fuk-first-study-to-assess-role-of-whole-genome-screening-in-primary-careUK-first study to assess role of whole-genome screening in primary carePeople in the UK will for the first time have their entire genetic code read from samples taken at a GP practice as part of a pioneering study to assess the potential benefits of screening for gene faults that increase the risk of disease.https://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2019-festive-season-begins-in-style-with-carol-service-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2019-festive-season-begins-in-style-with-carol-service-for-cancer-researchCarols from Chelsea 2019: Festive season begins in style with carol service for cancer researchFamiliar faces and voices from stage and screen came together on Tuesday 3 December to celebrate the start of the Christmas season at the 17th annual Carols from Chelsea service in support of The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2folaparib-becomes-first-gene-targeted-medicine-to-show-benefits-in-prostate-cancerhttps://www.icr.ac.uk/news-archive%2folaparib-becomes-first-gene-targeted-medicine-to-show-benefits-in-prostate-cancerOlaparib becomes first gene-targeted medicine to show benefits in prostate cancerA pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-the-case-for-regulatory-innovation-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-the-case-for-regulatory-innovation-in-cancer-researchMaking the case for ‘regulatory innovation’ in cancer researchRegulation of new cancer therapies, whilst crucially important, can become a barrier to innovation. Our Policy Adviser, Roya Ziaie, takes a look at the current regulatory landscape and what is needed in the future to ensure innovative treatments find their way to patients as quickly as possible. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fenhancing-the-selection-and-use-of-chemical-probes-in-cancer-research-using-innovative-data-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fenhancing-the-selection-and-use-of-chemical-probes-in-cancer-research-using-innovative-data-scienceEnhancing the selection and use of chemical probes in cancer research – using innovative data scienceOur former Digital Communications Intern, Bethany Nichols, takes a look at the work scientists at the ICR are leading on to help researchers choose their chemical probes more wisely.https://www.icr.ac.uk/news-archive%2fuse-combined-chemical-probe-resources-to-select-best-tools-for-biomedical-research-and-drug-discovery-scientists-urgehttps://www.icr.ac.uk/news-archive%2fuse-combined-chemical-probe-resources-to-select-best-tools-for-biomedical-research-and-drug-discovery-scientists-urgeUse combined chemical probe resources to select best tools for biomedical research and drug discovery, scientists urgeA new report urges biomedical researchers to use online web resources very carefully, taking into account their complementary benefits and weaknesses, when selecting small-molecule chemical probes to help answer their research questions.https://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-approval-of-palbociclib-for-treating-advanced-breast-cancer-after-hormone-therapyhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-approval-of-palbociclib-for-treating-advanced-breast-cancer-after-hormone-therapyICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapyThe Institute of Cancer Research, London, welcomes the approval by NICE of the innovative targeted cancer treatment palbociclib for women with advanced breast cancer who have already received hormone therapy.https://www.icr.ac.uk/news-archive%2fprostate-cancer-super-responders-live-for-two-years-on-immunotherapyhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-super-responders-live-for-two-years-on-immunotherapyProstate cancer ‘super responders’ live for two years on immunotherapySome men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.https://www.icr.ac.uk/news-archive%2fmajor-trial-backs-immunotherapy-as-standard-first-line-treatment-for-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-trial-backs-immunotherapy-as-standard-first-line-treatment-for-head-and-neck-cancerMajor trial backs immunotherapy as standard first-line treatment for head and neck cancerImmunotherapy is better than standard ‘extreme’ chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmen-s-health-awareness-month-12-months-of-progress-into-male-cancer-research-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmen-s-health-awareness-month-12-months-of-progress-into-male-cancer-research-at-the-icrMen’s Health Awareness Month: 12 months of progress into male cancer research at the ICRNovember is Men’s Health Awareness Month, an important time to raise awareness of male cancers. Our Web Editor, Dave Morgan, looks into six advances made by our researchers into prostate, testicular and urological cancers in the last year.https://www.icr.ac.uk/news-archive%2fadvanced-bowel-cancers-have-very-few-molecular-flags-hindering-immune-recognitionhttps://www.icr.ac.uk/news-archive%2fadvanced-bowel-cancers-have-very-few-molecular-flags-hindering-immune-recognitionAdvanced bowel cancers have very few ‘molecular flags’, hindering immune recognitionAdvanced bowel cancer cells have very few ‘molecular flags’ on their surface, helping to explain why they may be hard for the immune system to detect, a new study has shown.https://www.icr.ac.uk/news-archive%2fscientists-discover-change-in-cell-logistics-that-helps-cancer-become-resistanthttps://www.icr.ac.uk/news-archive%2fscientists-discover-change-in-cell-logistics-that-helps-cancer-become-resistantScientists discover change in cell logistics that helps cancer become resistantResearchers have uncovered a potential cause of sustained resistance to hormone therapy in the most common form of breast cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-what-patients-want-and-new-territory-in-cancer-research-looking-back-over-a-packed-three-dayshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-what-patients-want-and-new-territory-in-cancer-research-looking-back-over-a-packed-three-daysNCRI 2019: What patients want and new territory in cancer research – looking back over a packed three daysIn our closing blog from the 2019 NCRI Cancer Conference, Rose Wu looks back over the Glasgow event, and picks out some highlights. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-treatable-but-not-curable-cancer-as-a-chronic-diseasehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-treatable-but-not-curable-cancer-as-a-chronic-diseaseNCRI 2019: Treatable but not curable – cancer as a chronic disease New treatments and an ageing population are giving rise to a new group of patients who have cancers which are treatable but not curable. Joanne Duffy considers the research and patient perspectives on this growing issue, which were discussed at the 2019 NCRI Cancer Conference. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-thinking-outside-the-box-for-new-cancer-screening-methodshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-thinking-outside-the-box-for-new-cancer-screening-methodsNCRI 2019: Thinking outside the box for new cancer screening methodsScreening and testing for cancer is a huge challenge, and doesn’t always result in fewer people dying of cancer. ICR Science Communications Officer Joanne Duffy discusses an NCRI conference talk on how we can think outside the box when it comes to cancer screening and prevention. https://www.icr.ac.uk/news-archive%2fmen-over-40-with-brca2-gene-fault-should-get-regular-psa-screeninghttps://www.icr.ac.uk/news-archive%2fmen-over-40-with-brca2-gene-fault-should-get-regular-psa-screeningMen over 40 with BRCA2 gene fault ‘should get regular PSA screening’Guidelines should change so that all men over the age of 40 with faults in the BRCA2 gene should be offered regular PSA testing to detect early signs of prostate cancer, experts are urging.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-making-research-count-for-patients-reflecting-on-a-fascinating-first-day-at-the-uk-s-biggest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2019-making-research-count-for-patients-reflecting-on-a-fascinating-first-day-at-the-uk-s-biggest-cancer-conferenceNCRI 2019: Making research count for patients – reflecting on a fascinating first day at the UK’s biggest cancer conferenceBen Kolbington reflects on the first day of the 15th NCRI conference in Glasgow, in which a key theme was turning research advances into practical and affordable solutions for improving patients’ lives.https://www.icr.ac.uk/news-archive%2ficr-and-the-royal-marsden-form-part-of-new-radiotherapy-research-network-after-receiving-major-new-fundinghttps://www.icr.ac.uk/news-archive%2ficr-and-the-royal-marsden-form-part-of-new-radiotherapy-research-network-after-receiving-major-new-fundingICR and The Royal Marsden form part of new radiotherapy research network after receiving major new fundingA new radiotherapy network will unite seven centres across the UK to pioneer the use of the latest technologies, creating a global hub for radiotherapy research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-black-history-month-mean-for-the-institute-of-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-black-history-month-mean-for-the-institute-of-cancer-researchWhat does Black History Month mean for The Institute of Cancer Research? October is Black History Month. Rose Wu, Deputy Chair of the Black, Asian and minority ethnic forum at the ICR and The Royal Marsden, shares some thoughts from the month and the work the forum has been leading on.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthinking-inside-the-box-five-ways-the-icr-is-leading-the-way-with-big-data-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthinking-inside-the-box-five-ways-the-icr-is-leading-the-way-with-big-data-in-cancer-researchThinking Inside the Box: five ways the ICR is leading the way with Big Data in cancer researchArtificial Intelligence is transforming the world in ways once limited to the imaginations of science fiction writers. In this blog, we take a look at how Big Data and AI tools are helping to tackle some of the biggest challenges in cancer research. https://www.icr.ac.uk/news-archive%2ficr-celebrates-major-donation-from-cris-cancer-foundation-at-exclusive-supporter-eventhttps://www.icr.ac.uk/news-archive%2ficr-celebrates-major-donation-from-cris-cancer-foundation-at-exclusive-supporter-eventICR celebrates major donation from CRIS Cancer Foundation at exclusive supporter eventAt our recent Discovery Club event, members thanked CRIS Cancer Foundation for their donation of £1.4 million to support immunotherapy research at the ICR. https://www.icr.ac.uk/news-features%2flatest-features%2fhow-icr-researchers-are-leading-the-way-in-breast-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-icr-researchers-are-leading-the-way-in-breast-cancer-researchHow ICR researchers are leading the way in breast cancer researchIn Breast Cancer Awareness Month, Rose Wu looks at some of the recent research breakthroughs by breast cancer researchers at the ICRhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-medicine-2019-oxygen-sensing-in-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-medicine-2019-oxygen-sensing-in-cancerNobel Prize for Medicine 2019: Oxygen sensing in cancerThe Nobel Prize for Medicine has been awarded to three scientists for discovering how cells respond to changes in oxygen levels. This is how their work has paved the way to a greater understanding of cancer.https://www.icr.ac.uk/news-archive%2fdrug-blocking-blood-vessel-growth-could-treat-rare-sarcomashttps://www.icr.ac.uk/news-archive%2fdrug-blocking-blood-vessel-growth-could-treat-rare-sarcomasDrug blocking blood vessel growth could treat rare sarcomasAn experimental targeted drug could treat a rare type of cancer usually affecting the limbs, a clinical trial led by The Institute of Cancer Research has shown.https://www.icr.ac.uk/news-archive%2ficr-researchers-working-with-imperial-college-london-to-investigate-medical-cannabis-for-cancer-and-acute-painhttps://www.icr.ac.uk/news-archive%2ficr-researchers-working-with-imperial-college-london-to-investigate-medical-cannabis-for-cancer-and-acute-painICR researchers working with Imperial College London to investigate medical cannabis for cancer and acute painImperial College London researchers are trialling cannabis-based medicinal products for the treatment of cancer and acute pain. The researchers are collaborating with medical cannabis company EMMAC Life Sciences and The Institute of Cancer Research, London, to better understand the effectiveness of the products.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhy-the-uk-is-at-the-forefront-of-a-changing-life-sciences-industryhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fwhy-the-uk-is-at-the-forefront-of-a-changing-life-sciences-industryWhy the UK is at the forefront of a changing life sciences industryDr Angela Kukula, Director of the Enterprise Unit at the Institute of Cancer Research, on the reasons for the UK's continuing strength in life sciences.https://www.icr.ac.uk/news-archive%2fimaging-tumour-stiffness-could-help-enhance-treatment-for-breast-and-pancreatic-cancerhttps://www.icr.ac.uk/news-archive%2fimaging-tumour-stiffness-could-help-enhance-treatment-for-breast-and-pancreatic-cancerImaging tumour stiffness could help enhance treatment for breast and pancreatic cancerUsing a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumours, new research shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdebunking-13-common-cancer-mythshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdebunking-13-common-cancer-mythsDebunking 13 common cancer mythsThe ICR’s Science Communications Officer Joanne Duffy took on the Royal Parks Half Marathon to raise money for the ICR’s world-leading research. Here she debunks 13 cancer myths – one for each mile that she ran – and highlights some examples of where the ICR’s scientists are making a real difference for people with cancer. https://www.icr.ac.uk/news-archive%2fnew-athena-swan-silver-recognises-icr-s-work-on-diversity-and-access-to-opportunitieshttps://www.icr.ac.uk/news-archive%2fnew-athena-swan-silver-recognises-icr-s-work-on-diversity-and-access-to-opportunitiesNew Athena SWAN Silver Award recognises ICR’s work on diversity and access to opportunitiesThe ICR is celebrating the work of all our staff and students in creating an open, diverse and fully inclusive environment, with the award of an Athena SWAN Charter Silver Award for 2019-23.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwomen-in-stem-and-how-they-are-pushing-for-access-to-smarter-kinder-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwomen-in-stem-and-how-they-are-pushing-for-access-to-smarter-kinder-treatmentsWomen in STEM and how they are pushing for access to smarter, kinder treatmentsTuesday 8 October marks Ada Lovelace day, which celebrates women in STEM around the world. There are many inspirational female role models at the ICR, and here one of them, Professor Christina Yap, describes how her work as a woman in STEM could improve clinical trials, improving access to smarter, kinder treatments for cancer patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-ct-scans-continue-to-play-a-fundamental-role-in-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-ct-scans-continue-to-play-a-fundamental-role-in-cancer-treatmentHow CT scans continue to play a fundamental role in cancer treatmentCT scans have been used for decades in hospitals all over the world to “see” abnormalities within tissues. We discuss new ways in which they are being combined with other techniques to produce better images of cancer, which could help improve treatment in the future.https://www.icr.ac.uk/news-archive%2fnew-evolution-busting-drug-overcomes-resistance-in-aggressive-breast-cancershttps://www.icr.ac.uk/news-archive%2fnew-evolution-busting-drug-overcomes-resistance-in-aggressive-breast-cancersNew evolution-busting drug overcomes resistance in aggressive breast cancersA new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown.https://www.icr.ac.uk/news-archive%2ficr-forms-collaboration-with-ai-drug-discovery-company-to-develop-new-possible-treatments-in-rare-childhood-cancer-dipghttps://www.icr.ac.uk/news-archive%2ficr-forms-collaboration-with-ai-drug-discovery-company-to-develop-new-possible-treatments-in-rare-childhood-cancer-dipgICR forms collaboration with AI drug discovery company to develop new possible treatments in rare childhood cancer DIPGScientists at The Institute of Cancer Research are working with Healx, a biotech company specialising in artificial intelligence (AI) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), an essentially untreatable brain cancer in children.​https://www.icr.ac.uk/news-archive%2fgut-bacteria-fingerprint-predicts-radiotherapy-side-effectshttps://www.icr.ac.uk/news-archive%2fgut-bacteria-fingerprint-predicts-radiotherapy-side-effectsGut bacteria ‘fingerprint’ predicts radiotherapy side effectsTaking a ‘fingerprint’ of the mix of bacteria in the gut can indicate how susceptible individual cancer patients are to gut damage as a result of radiotherapy for prostate and gynaecological cancers, a new study shows. https://www.icr.ac.uk/news-archive%2fesmo-2019-breast-and-ovarian-cancer-drug-outperforms-targeted-hormone-therapy-in-some-men-with-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fesmo-2019-breast-and-ovarian-cancer-drug-outperforms-targeted-hormone-therapy-in-some-men-with-advanced-prostate-cancerESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancerA drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal. https://www.icr.ac.uk/news-archive%2fesmo-2019-modern-chemotherapy-drug-better-than-second-targeted-hormone-therapy-against-resistant-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fesmo-2019-modern-chemotherapy-drug-better-than-second-targeted-hormone-therapy-against-resistant-prostate-cancerESMO 2019: Modern chemotherapy drug better than second targeted hormone therapy against resistant prostate cancerA modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows.https://www.icr.ac.uk/news-archive%2fscientists-develop-new-way-to-study-spread-of-devastating-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-develop-new-way-to-study-spread-of-devastating-childhood-cancerScientists develop new way to study spread of devastating childhood cancer New research has helped create a mouse model to help study a devastating childhood cancer and understand how it spreads.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-awareness-month-how-we-re-improving-the-lives-of-young-people-with-cancer-through-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-awareness-month-how-we-re-improving-the-lives-of-young-people-with-cancer-through-researchChildhood Cancer Awareness Month: How we’re improving the lives of young people with cancer through researchThe annual Childhood Cancer Conference is an opportunity to hear about the latest scientific developments, and the research and care priorities for young patients and their parents. Sarah Wells went along and heard from one of the world’s leading childhood cancer researchers.https://www.icr.ac.uk/news-archive%2fcombination-immunotherapy-drugs-offer-new-hope-for-melanoma-patientshttps://www.icr.ac.uk/news-archive%2fcombination-immunotherapy-drugs-offer-new-hope-for-melanoma-patientsESMO 2019: Combination immunotherapy drugs offer new hope for melanoma patientsA combination of two immunotherapy drugs, ipilimumab and nivolumab, stops or reverses the progression of advanced melanoma – with long term survival rates hitting an all-time high – according to a study presented at the ESMO Congress.https://www.icr.ac.uk/news-archive%2flargest-ever-trial-in-postoperative-prostate-cancer-patients-confirms-that-men-can-be-spared-radiotherapy-after-surgeryhttps://www.icr.ac.uk/news-archive%2flargest-ever-trial-in-postoperative-prostate-cancer-patients-confirms-that-men-can-be-spared-radiotherapy-after-surgeryESMO 2019: Largest ever trial in postoperative prostate cancer patients confirms that men can be spared radiotherapy after surgeryMen with prostate cancer can be spared radiotherapy after surgery, according to late breaking results from a study presented at the ESMO Congress in Barcelona.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-professor-sir-mel-greaves-and-his-legacy-in-leukaemia-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-professor-sir-mel-greaves-and-his-legacy-in-leukaemia-researchCelebrating Professor Sir Mel Greaves and his legacy in leukaemia researchLeukaemia researchers from around the world gathered at the Royal Society last week to celebrate Professor Sir Mel Greaves and his knighthood for his services to children's leukaemia research. Science Communications Officer Joanne Duffy reports back on the day. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-ways-global-links-help-our-researchers-carry-out-life-changing-research-on-world-cancer-research-dayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-ways-global-links-help-our-researchers-carry-out-life-changing-research-on-world-cancer-research-dayThree ways global links help our researchers carry out life-changing research on World Cancer Research DayCancer research is a team effort that crosses all borders, and on World Cancer Research Day we highlight three ways our researchers contribute to and benefit from these global ties. https://www.icr.ac.uk/news-archive%2fstudy-signals-new-era-of-precision-medicine-for-children-with-cancerhttps://www.icr.ac.uk/news-archive%2fstudy-signals-new-era-of-precision-medicine-for-children-with-cancerStudy signals new era of precision medicine for children with cancerA new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives – signalling a new era of precision medicine for young patients.https://www.icr.ac.uk/news-archive%2fcombination-therapies-could-help-treat-fatal-lung-cancershttps://www.icr.ac.uk/news-archive%2fcombination-therapies-could-help-treat-fatal-lung-cancersCombination therapies could help treat fatal lung cancersCombining a new class of drug with two other compounds can significantly shrink lung tumours in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-technique-could-cut-treatment-time-from-two-months-to-two-weekshttps://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-technique-could-cut-treatment-time-from-two-months-to-two-weeksTargeted prostate cancer radiotherapy technique could cut treatment time from two months to two weeksAdvanced radiotherapy technology could safely deliver curative treatment for some prostate cancer patients in just one or two weeks, according to new research published today.https://www.icr.ac.uk/news-archive%2fincreased-risk-of-prostate-cancer-in-men-with-brca2-gene-faulthttps://www.icr.ac.uk/news-archive%2fincreased-risk-of-prostate-cancer-in-men-with-brca2-gene-faultIncreased risk of prostate cancer in men with BRCA2 gene faultMen with faults in the BRCA2 gene have an increased risk of prostate cancer and could benefit from PSA testing to help detect the disease earlier, according to new research.https://www.icr.ac.uk/news-archive%2fnew-way-to-target-cancer-s-diversity-and-evolutionhttps://www.icr.ac.uk/news-archive%2fnew-way-to-target-cancer-s-diversity-and-evolutionNew way to target cancer’s diversity and evolutionScientists reveal 3D structure of crucial molecule involved in mixing and matching genetic information within cells.https://www.icr.ac.uk/news-archive%2fthree-minute-mri-scan-could-safely-and-effectively-test-new-precision-treatments-for-children-with-neuroblastomahttps://www.icr.ac.uk/news-archive%2fthree-minute-mri-scan-could-safely-and-effectively-test-new-precision-treatments-for-children-with-neuroblastomaThree-minute MRI scan could safely and effectively test new precision treatments for children with neuroblastomaA simple non-invasive MRI scan could play a key role in guiding the delivery of precision medicine to children with neuroblastoma – reducing the need for surgery, a new study has found.https://www.icr.ac.uk/news-archive%2ficr-alumnus-professor-jacques-miller-wins-prestigious-albert-lasker-award-for-pioneering-research-underpinning-modern-immunologyhttps://www.icr.ac.uk/news-archive%2ficr-alumnus-professor-jacques-miller-wins-prestigious-albert-lasker-award-for-pioneering-research-underpinning-modern-immunologyICR alumnus Professor Jacques Miller wins prestigious Albert Lasker Award for pioneering research underpinning modern immunologyProfessor Jacques Miller has been jointly awarded this year’s Albert Lasker Basic Medical Research Award, for his pivotal role in discoveries that laid the foundation for much of the field of modern immunology.https://www.icr.ac.uk/news-features%2flatest-features%2fbeating-melanoma-with-drug-discovery-immunotherapy-and-cutting-edge-sciencehttps://www.icr.ac.uk/news-features%2flatest-features%2fbeating-melanoma-with-drug-discovery-immunotherapy-and-cutting-edge-scienceBeating melanoma with drug discovery, immunotherapy and cutting-edge scienceHenry French introduces some of our research into melanoma, one of the UK’s most common cancers.https://www.icr.ac.uk/news-archive%2finspirational-young-woman-smashes-target-of-raising-21k-for-the-icr-before-21st-birthdayhttps://www.icr.ac.uk/news-archive%2finspirational-young-woman-smashes-target-of-raising-21k-for-the-icr-before-21st-birthdayInspirational young woman smashes target of raising £21K for the ICR before 21st birthdayA determined young woman from Southend-on-Sea has smashed her goal of raising £21,000 for cancer research before her 21st birthday this week. Amy Elvidge set herself the ambitious fundraising challenge after her father was diagnosed and successfully treated for cancer last summer.https://www.icr.ac.uk/news-archive%2fbereaved-parents-visit-icr-lab-supported-in-daughter-s-memoryhttps://www.icr.ac.uk/news-archive%2fbereaved-parents-visit-icr-lab-supported-in-daughter-s-memoryBereaved parents visit ICR lab supported in daughter’s memoryThe parents of Kelly Turner, Linda and Martin, recently visited The Institute of Cancer Research, London, to see the labs doing research into the cancer that took Kelly’s life.https://www.icr.ac.uk/news-archive%2fscientists-talk-medicine-and-engineering-with-potential-future-partners-at-the-harwell-campushttps://www.icr.ac.uk/news-archive%2fscientists-talk-medicine-and-engineering-with-potential-future-partners-at-the-harwell-campusScientists talk medicine and engineering with potential partners at the Harwell campusThe ICR's Enterprise Unit has hosted a networking event alongside the Science and Technology Facilities Council (STFC) at Harwell, a science and technology campus near Oxford.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-immunity-and-beyond-cancer-bursting-viruses-fight-cancer-in-two-wayshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-immunity-and-beyond-cancer-bursting-viruses-fight-cancer-in-two-waysTo immunity and beyond: cancer bursting viruses fight cancer in two waysYour immune system has the power to recognise billions of molecules that cause disease. From structures on the surface of bacterial cells, to poisons and viruses, your body can recognise and fight against it all. https://www.icr.ac.uk/news-features%2flatest-features%2fwithout-research-there-will-be-no-cure-why-parents-fund-vital-research-into-children-s-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fwithout-research-there-will-be-no-cure-why-parents-fund-vital-research-into-children-s-cancer"Without research there will be no cure" – why parents fund vital research into children’s cancer ICR researchers are working hard to improve children’s cancer treatment. This children’s cancer awareness month, our parent-led charity supporters – who fund so much of this crucial work – have shared their inspirational stories with us and explain why they choose to work with the ICR.https://www.icr.ac.uk/news-archive%2fprofessor-to-cycle-60-miles-to-give-back-to-the-newcastle-charity-supporting-her-research-into-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fprofessor-to-cycle-60-miles-to-give-back-to-the-newcastle-charity-supporting-her-research-into-childhood-cancerProfessor to cycle 60 miles to give back to the Newcastle charity supporting her research into childhood cancerA scientist who studies a rare form of childhood cancer is joining a 60 mile cycle ride through Northumberland in support of the charity which has funded her research for more than ten years.https://www.icr.ac.uk/news-archive%2ffirst-degree-relatives-of-blood-cancer-patients-at-increased-risk-major-new-study-revealshttps://www.icr.ac.uk/news-archive%2ffirst-degree-relatives-of-blood-cancer-patients-at-increased-risk-major-new-study-revealsFirst-degree relatives of blood cancer patients at increased risk, major new study revealsPeople with a parent, sibling or child affected by blood cancer are more likely to be diagnosed with the disease, a new study has shown.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-the-dangers-of-colorectal-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-the-dangers-of-colorectal-cancerScience Writing Prize 2019 – The dangers of colorectal cancerThe winning entry in our 2019 Mel Greaves Science Writing Prize is by Dr Maxine Lam. Her thoughtful post shares her own personal experience with colorectal cancer following her father's diagnosis, and examines the reasons why it is so often picked up late.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-ai-and-maths-to-look-at-cancer-through-the-lens-of-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-ai-and-maths-to-look-at-cancer-through-the-lens-of-evolutionUsing AI and maths to look at cancer through the lens of evolutionAt the ICR, scientists are applying Darwin’s theory of evolution to cancer in order to understand how the disease develops and evolves. By combining advanced technologies, mathematics and AI, scientists hope that studying cancer evolution can offer new insight into drug resistance and disease progression. https://www.icr.ac.uk/news-archive%2fpoet-laureate-s-poem-on-a-pill-cuts-cancer-down-to-sizehttps://www.icr.ac.uk/news-archive%2fpoet-laureate-s-poem-on-a-pill-cuts-cancer-down-to-sizePoet Laureate’s ‘poem on a pill’ cuts cancer down to sizeNewly appointed Poet Laureate Simon Armitage has written a poem for The Institute of Cancer Research, London, symbolising the goal of precision science to turn cancer into a manageable disease. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-made-to-order-cancer-treatmentshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-made-to-order-cancer-treatmentsScience Writing Prize 2019 – Made-to-order cancer treatmentsThis highly commended entry for the Mel Greaves Science Writing Prize is by PhD student Nithya Paranthaman. She discusses tumour organoids: lab-grown mini-tumours that mimic cancers in a patient's body. These tumours-in-a-dish could be used to screen drug combinations and tailor treatments to each patient. https://www.icr.ac.uk/news-archive%2fpositive-clinical-trial-results-for-olaparib-in-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fpositive-clinical-trial-results-for-olaparib-in-advanced-prostate-cancerPositive clinical trial results for olaparib in advanced prostate cancerThe preliminary results of a major phase III clinical trial show that the genetically targeted drug olaparib improves outcomes for men with advanced prostate cancer whose tumours have DNA repair faults.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019---sleep-and-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019---sleep-and-cancerScience Writing Prize 2019 - Sleep and cancerThe third runner-up for the Mel Greaves Science Writing Prize is Dr Samantha Nimalasena with a piece which discusses how our sleeping habits or lack thereof may be affecting our health.https://www.icr.ac.uk/news-archive%2fartificial-intelligence-reveals-new-breast-cancer-types-that-respond-differently-to-treatmenthttps://www.icr.ac.uk/news-archive%2fartificial-intelligence-reveals-new-breast-cancer-types-that-respond-differently-to-treatmentArtificial intelligence reveals new breast cancer types that respond differently to treatmentScientists have used artificial intelligence to recognise patterns in breast cancer – and uncovered five new types of the disease, each matched to different personalised treatments.https://www.icr.ac.uk/news-archive%2fpersonalised-liquid-biopsy-could-detect-return-of-breast-cancer-nearly-eleven-months-earlier-than-hospital-scanshttps://www.icr.ac.uk/news-archive%2fpersonalised-liquid-biopsy-could-detect-return-of-breast-cancer-nearly-eleven-months-earlier-than-hospital-scansPersonalised ‘liquid biopsy’ could detect return of breast cancer nearly eleven months earlier than hospital scansMulticentre UK study finds new blood test could detect the return and spread of breast cancer on average 10.7 months before tumours became visible on scans or patients developed symptomshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-therapies-galore-yet-cancer-hasn-t-a-curehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-therapies-galore-yet-cancer-hasn-t-a-cureScience Writing Prize 2019 – Therapies galore, yet cancer hasn’t a cure?PhD student Varun Ramawamy, runner-up for the Mel Greaves Science Writing Prize muses on the search for a cancer 'cure' in the second post of this five part series. https://www.icr.ac.uk/news-archive%2ftumour-liquifying-microbubbles-and-immune-cell-tracking-uk-s-first-convergence-science-centre-officially-launcheshttps://www.icr.ac.uk/news-archive%2ftumour-liquifying-microbubbles-and-immune-cell-tracking-uk-s-first-convergence-science-centre-officially-launchesTumour-liquifying microbubbles and immune cell tracking: UK’s first convergence science centre officially launchesTwo of the UK’s foremost academic research institutions, The Institute of Cancer Research, London, and Imperial College London, are coming together with funding from Cancer Research UK to launch the new £13 million Convergence Science Centre.https://www.icr.ac.uk/news-archive%2ficr-calls-for-wider-gene-testing-in-ovarian-cancer-after-approval-of-olaparib-earlier-in-treatment-for-women-with-brca-mutationshttps://www.icr.ac.uk/news-archive%2ficr-calls-for-wider-gene-testing-in-ovarian-cancer-after-approval-of-olaparib-earlier-in-treatment-for-women-with-brca-mutationsICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutationsThe ICR responds to the approval by NHS regulators NICE for the use of targeted cancer drug olaparib earlier in the course of treatment for women with late-stage ovarian cancer and other gynaecological cancers who have BRCA gene mutations.https://www.icr.ac.uk/news-archive%2fgene-test-picks-out-prostate-cancers-patients-who-could-benefit-from-search-and-destroy-medicinehttps://www.icr.ac.uk/news-archive%2fgene-test-picks-out-prostate-cancers-patients-who-could-benefit-from-search-and-destroy-medicineGene test picks out prostate cancers patients who could benefit from ‘search-and-destroy’ medicineTesting for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-the-war-on-cancer-keep-your-enemies-closehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2019-the-war-on-cancer-keep-your-enemies-closeScience Writing Prize 2019 – The war on cancer: keep your enemies closeIn the first of five blog posts by the winner and runners-up of the Mel Greaves Science Writing Prize, Dr Amit Samani, runner-up, follows cancer research through the last 50 years to the new challenges today.https://www.icr.ac.uk/news-archive%2fdiscovery-club-shows-the-power-of-new-research-in-the-patient-journeyhttps://www.icr.ac.uk/news-archive%2fdiscovery-club-shows-the-power-of-new-research-in-the-patient-journeyDiscovery Club shows the power of new research in the patient journeyMembers of the The Discovery Club gathered at the Royal Society of Chemistry last month to learn how our research is influencing the cancer patient journey.https://www.icr.ac.uk/news-archive%2fcancer-trades-in-sugar-for-fatty-acids-in-order-to-spread-around-the-bodyhttps://www.icr.ac.uk/news-archive%2fcancer-trades-in-sugar-for-fatty-acids-in-order-to-spread-around-the-bodyCancer trades in sugar for fatty acids in order to spread around the bodyScientists have uncovered a crucial change in cancer cells that allows them to spread around the body – by switching from sugar to fatty acids to fuel their growth. https://www.icr.ac.uk/news-archive%2fuk-cancer-treatment-revolution-as-survey-finds-third-of-patients-receiving-modern-precision-treatmentshttps://www.icr.ac.uk/news-archive%2fuk-cancer-treatment-revolution-as-survey-finds-third-of-patients-receiving-modern-precision-treatmentsUK cancer treatment ‘revolution’ as survey finds third of patients receiving modern precision treatmentsOver one-third of surviving cancer patients have received state-of-the-art targeted drug treatment or immunotherapy, reveals a new survey highlighting the ‘revolution’ in cancer treatment over the last decade.https://www.icr.ac.uk/news-archive%2fpairing-targeted-drugs-for-breast-and-lung-cancer-could-overcome-treatment-resistancehttps://www.icr.ac.uk/news-archive%2fpairing-targeted-drugs-for-breast-and-lung-cancer-could-overcome-treatment-resistancePairing targeted drugs for breast and lung cancer could overcome treatment resistanceTargeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows.https://www.icr.ac.uk/news-archive%2ficr-alumni-return-to-inspire-the-next-generation-at-the-2019-student-conferencehttps://www.icr.ac.uk/news-archive%2ficr-alumni-return-to-inspire-the-next-generation-at-the-2019-student-conferenceICR alumni return to inspire the next generation at the 2019 Student Conference At The Institute of Cancer Research’s annual Student Conference, our PhD students had the opportunity to meet with ICR alumni and find out more about their career journeys.https://www.icr.ac.uk/news-archive%2fimmunotherapy-could-work-against-bowel-cancers-resistant-to-important-targeted-treatmenthttps://www.icr.ac.uk/news-archive%2fimmunotherapy-could-work-against-bowel-cancers-resistant-to-important-targeted-treatmentImmunotherapy could work against bowel cancers resistant to important targeted treatmentPatients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.https://www.icr.ac.uk/news-archive%2ficr-recognises-next-generation-of-cancer-researchershttps://www.icr.ac.uk/news-archive%2ficr-recognises-next-generation-of-cancer-researchersICR recognises next generation of cancer researchersA new generation of cancer researchers took to the stage at London’s Guildhall this week as The Institute of Cancer Research, London, held its annual awards ceremony.https://www.icr.ac.uk/news-archive%2ficr-honours-campaigning-parents-and-convergence-scientist-with-honorary-degreeshttps://www.icr.ac.uk/news-archive%2ficr-honours-campaigning-parents-and-convergence-scientist-with-honorary-degreesICR honours campaigning parents and convergence scientist with honorary degreesThe ICR has awarded the founders of the children’s cancer charity Christopher’s Smile and a world-leading expert in convergence science with honorary degrees at this year’s awards ceremony.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-it-like-to-study-at-the-icr-we-speak-to-some-of-our-amazing-students-to-find-outhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-it-like-to-study-at-the-icr-we-speak-to-some-of-our-amazing-students-to-find-outWhat is it like to study at the ICR? We speak to some of our amazing students to find out Our students are an integral part of our mission to 'make the discoveries that defeat cancer' and will form the next generation of cancer researchers. We explore our reputation for academic excellence and speak to several of our students to find out why they chose to study at the ICR.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ftackling-cancer-evolution-and-resistance-in-our-new-centre-for-cancer-drug-discoveryhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ftackling-cancer-evolution-and-resistance-in-our-new-centre-for-cancer-drug-discoveryTackling cancer evolution and resistance in our new Centre for Cancer Drug DiscoveryFiona Want is a second-year PhD student in our Division of Cancer Therapeutics. She is working to understand APOBEC proteins, and help develop what ICR researchers believe will be the world’s first family of drugs to target cancer’s ability to evolve and become resistant to treatment. Fiona will be moving along with her team into the ICR’s new Centre for Cancer Drug Discovery next year, working alongside drug discovery researchers and evolutionary scientists to focus on meeting the pressing challenge of cancer evolution and drug resistance.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-type-matters-zooming-in-on-the-response-to-gene-targeted-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-type-matters-zooming-in-on-the-response-to-gene-targeted-drugsCancer type matters: zooming in on the response to gene-targeted drugsDrugs designed to target particular gene faults can kill cancer cells while leaving healthy cells alone. These kinds of smarter, kinder therapies have revolutionised cancer treatment. But a new study found that the response to drugs targeting the same fault can vary between tumour types. Sarah Wells asks how this news could change the way we think about precision medicine.https://www.icr.ac.uk/news-archive%2fresponse-to-gene-targeted-drugs-depends-on-cancer-typehttps://www.icr.ac.uk/news-archive%2fresponse-to-gene-targeted-drugs-depends-on-cancer-typeResponse to gene-targeted drugs depends on cancer typeCancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finvesting-in-our-future-means-both-great-facilities-and-great-peoplehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finvesting-in-our-future-means-both-great-facilities-and-great-peopleInvesting in our future means both great facilities and great peopleThe ICR is investing £75 million in creating a state-of-the-art Centre for Cancer Drug Discovery on our Sutton site. That presents a huge opportunity to attract the best researchers and students, Registrar and Director of Academic Services Dr Barbara Pittam argues.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fuk-science-needs-a-clear-plan-for-the-futurehttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fuk-science-needs-a-clear-plan-for-the-futureUK science needs a clear plan for the futureIf science in the UK is going to remain world class, it’s crucial that we have a clear plan for the future that secures research funding, ensures freedom for scientists to work across borders, and provides regulatory alignment, argues the ICR’s Chief Executive Professor Paul Workman.https://www.icr.ac.uk/news-archive%2ftwo-in-one-drug-combining-herceptin-with-chemotherapy-keeps-women-s-breast-cancers-at-bayhttps://www.icr.ac.uk/news-archive%2ftwo-in-one-drug-combining-herceptin-with-chemotherapy-keeps-women-s-breast-cancers-at-bayTwo-in-one drug combining Herceptin with chemotherapy keeps women’s breast cancers at bayGuiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmri-is-changing-radiotherapy-and-the-role-of-all-who-deliver-ithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmri-is-changing-radiotherapy-and-the-role-of-all-who-deliver-itMRI is changing radiotherapy – and the role of all who deliver itSophisticated technologies like the MR Linac are targeting radiation precisely at tumours – guided by a new generation of clinicians trained up in the latest research advances. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-scientists-put-melanoma-put-under-the-microscope-for-bbc-documentaryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-scientists-put-melanoma-put-under-the-microscope-for-bbc-documentaryICR scientists put melanoma under the microscope for BBC documentaryEarlier this year, ICR researchers were given a unique opportunity to image a primary tumour from a patient and discuss it with them as part of a documentary for BBC Four, airing on Monday 24 June at 9pm. Here, we show some of the amazing images they produced and explain how their related research is advancing our understanding of melanoma.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdr-gideon-coster-on-cancer-dna-and-why-he-chose-the-icr-to-study-ithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdr-gideon-coster-on-cancer-dna-and-why-he-chose-the-icr-to-study-itDr Gideon Coster on cancer DNA and why he chose the ICR to study itAfter his recent move to the ICR, we spoke to Dr Gideon Coster to find out more about how his research into DNA replication – and when this goes wrong in cancer – could lead to new drug targets.https://www.icr.ac.uk/news-archive%2fcancer-killing-virus-boosts-immunotherapy-in-hard-to-treat-cancerhttps://www.icr.ac.uk/news-archive%2fcancer-killing-virus-boosts-immunotherapy-in-hard-to-treat-cancerCancer-killing virus boosts immunotherapy in hard-to-treat cancerCombining a cancer-killing virus with immunotherapy could effectively treat advanced cancers that affect the limbs, a new study reveals.https://www.icr.ac.uk/news-archive%2ficr-in-top-five-in-the-world-for-academic-influence-and-commercial-impacthttps://www.icr.ac.uk/news-archive%2ficr-in-top-five-in-the-world-for-academic-influence-and-commercial-impactICR in top five in the world for academic influence and commercial impactThe ICR has ranked among the top higher education institutions in the world for the impact of its research academically and commercially.https://www.icr.ac.uk/news-archive%2ficr-appoints-dr-adrian-cottrell-gsk-vice-president-as-chief-information-officerhttps://www.icr.ac.uk/news-archive%2ficr-appoints-dr-adrian-cottrell-gsk-vice-president-as-chief-information-officerICR appoints Dr Adrian Cottrell, GSK Vice President, as Chief Information OfficerThe Institute of Cancer Research, London, today announces the appointment of a leading international expert in research and development IT at GlaxoSmithKline (GSK), to lead its information and communication technologies.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2019-icr-research-makes-waves-at-world-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2019-icr-research-makes-waves-at-world-s-largest-cancer-conferenceASCO 2019: ICR research makes waves at world’s largest cancer conferenceTens of thousands of researchers were in Chicago to hear about the latest developments in cancer treatment – many of them involving the ICR. Sarah Wells looks back at this year’s edition of the biggest event in the cancer research calendar.https://www.icr.ac.uk/news-archive%2fcancer-s-last-notehttps://www.icr.ac.uk/news-archive%2fcancer-s-last-noteCancer's last note – Royal Philharmonic Orchestra create 'unfinished symphony' to support new cancer centreThe Institute of Cancer Research, London and the Royal Philharmonic Orchestra create an ‘unfinished symphony’ for cancer research – to raise funds to complete a revolutionary new research buildinghttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fbio-2019-trends-so-far-at-the-world-s-biggest-life-sciences-partnering-conferencehttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fbio-2019-trends-so-far-at-the-world-s-biggest-life-sciences-partnering-conferenceBIO 2019: Trends so far at the world’s biggest life sciences partnering conferenceHenry French is attending BIO 2019, one of the world’s biggest and most influential annual business partnering conferences in the life sciences, to represent the ICR’s Enterprise Unit and The London Cancer Hub. As <a href=https://twitter.com/search?q=%23BIO2019&src=typd>#BIO2019</a> gets into full swing, he gives his thoughts on the convention so far.https://www.icr.ac.uk/news-archive%2fasco-2019-breast-cancer-drug-effective-in-80-per-cent-of-men-with-brca-mutant-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fasco-2019-breast-cancer-drug-effective-in-80-per-cent-of-men-with-brca-mutant-prostate-cancerASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancerA pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports.https://www.icr.ac.uk/news-archive%2fasco-2019-immunotherapy-better-than-aggressive-chemotherapy-as-first-treatment-option-for-recurrent-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fasco-2019-immunotherapy-better-than-aggressive-chemotherapy-as-first-treatment-option-for-recurrent-head-and-neck-cancerASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancerImmunotherapy used with chemotherapy or on its own is a better first-line treatment for people with head and neck cancer that has returned than standard aggressive chemotherapy, new clinical trial results show. https://www.icr.ac.uk/news-archive%2fasco-2019-new-blood-test-predicts-breast-cancer-s-return-at-start-of-treatmenthttps://www.icr.ac.uk/news-archive%2fasco-2019-new-blood-test-predicts-breast-cancer-s-return-at-start-of-treatmentASCO 2019: New blood test predicts breast cancer’s return at start of treatmentA new blood test for women with breast cancer can predict how well patients will respond to a new drug right at the start of treatment.https://www.icr.ac.uk/news-archive%2fasco-2019-drug-targeting-dna-damage-response-shows-promise-against-cancers-of-anus-and-genitalshttps://www.icr.ac.uk/news-archive%2fasco-2019-drug-targeting-dna-damage-response-shows-promise-against-cancers-of-anus-and-genitalsASCO 2019: ICR-discovered drug shows promise in phase I clinical trialA precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage has shown promising results in two clinical trials.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2019-patients-put-at-the-forefront-for-world-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2019-patients-put-at-the-forefront-for-world-s-largest-cancer-conferenceASCO 2019: Patients put at the forefront for world’s largest cancer conferenceOn 31 May, world-leaders in cancer research will be gathering in Chicago for the 2019 ASCO Annual Meeting. ICR researchers will be amongst those presenting their groundbreaking research at the world’s largest cancer conference, which is focusing on ‘Caring for Every Patient, Learning from Every Patient’.https://www.icr.ac.uk/news-archive%2fscientists-discover-switch-that-helps-breast-cancer-spread-around-the-bodyhttps://www.icr.ac.uk/news-archive%2fscientists-discover-switch-that-helps-breast-cancer-spread-around-the-bodyScientists discover ‘switch’ that helps breast cancer spread around the bodyResearchers have identified a genetic ‘switch’ in breast cancer cells that helps them spread around the body. https://www.icr.ac.uk/news-archive%2fnight-shifts-do-not-increase-breast-cancer-risk-major-uk-analysis-suggestshttps://www.icr.ac.uk/news-archive%2fnight-shifts-do-not-increase-breast-cancer-risk-major-uk-analysis-suggestsNight shifts do not increase breast cancer risk, major UK analysis suggestsWorking night shifts is not linked to an increased risk of breast cancer, a major prospective UK analysis has found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmelanoma-awareness-month-2019-a-personal-look-behind-the-scenes-of-our-melanoma-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmelanoma-awareness-month-2019-a-personal-look-behind-the-scenes-of-our-melanoma-researchMelanoma Awareness Month 2019: A personal look behind the scenes of our melanoma researchPatient advocate Debbie Keynes, who was diagnosed with melanoma in April 2016, visited the ICR to meet with researchers who are developing new techniques to advance the diagnosis of melanoma to help patients and GPs.https://www.icr.ac.uk/ttps%3a%2f%2fwww.icr.ac.uk%2fnews-features%2flatest-features%2fwhen-it-comes-to-cancer-how-can-dna-become-its-own-enemyhttps://www.icr.ac.uk/ttps%3a%2f%2fwww.icr.ac.uk%2fnews-features%2flatest-features%2fwhen-it-comes-to-cancer-how-can-dna-become-its-own-enemyWhen it comes to cancer, how can DNA become its own enemy?Dr Gideon Coster is one of the newest Team Leaders at the ICR. Here we take a look at his research, aiming to understand how DNA can become its own enemy.https://www.icr.ac.uk/news-archive%2fopera-stars-encore-funds-life-saving-cancer-researchhttps://www.icr.ac.uk/news-archive%2fopera-stars-encore-funds-life-saving-cancer-researchOpera stars’ encore funds life-saving cancer researchFour of the UK’s leading opera singers have performed an exclusive recital in support of the ICR.https://www.icr.ac.uk/news-archive%2fnew-barcode-test-divides-bowel-cancer-into-five-diseaseshttps://www.icr.ac.uk/news-archive%2fnew-barcode-test-divides-bowel-cancer-into-five-diseasesNew ‘barcode’ test divides bowel cancer into five diseasesA new test can genetically ‘barcode’ bowel cancer and separate it into five different diseases that could each receive tailored treatment, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-clinical-trials-day-an-inside-look-at-clinical-trials-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finternational-clinical-trials-day-an-inside-look-at-clinical-trials-at-the-icrInternational Clinical Trials Day: An inside look at clinical trials at the ICRToday, on Monday 20 May, scientists around the world are celebrating International Clinical Trials Day. Here we take a look at just a few of the clinical trials being conducted by The Institute of Cancer Research.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-the-icrs-pioneering-drug-research-is-changing-liveshttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-the-icrs-pioneering-drug-research-is-changing-livesHow the ICR’s pioneering drug research is changing livesThe ICR has discovered more new cancer drugs than any other academic institution globally, and led the underpinning science for many more cancer treatments. We have helped lead clinical trials of these drugs and many others – taking them to cancer patients as quickly as possible.https://www.icr.ac.uk/news-archive%2fworld-s-first-darwinian-cancer-drug-programme-aims-to-deliver-step-change-in-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fworld-s-first-darwinian-cancer-drug-programme-aims-to-deliver-step-change-in-cancer-treatmentRevolutionary new Centre for Cancer Drug Discovery aims to deliver step change in cancer treatmentThe world’s first ‘Darwinian’ drug discovery programme specially designed to tackle cancer’s lethal ability to evolve resistance to treatment is to be launched in a state-of-the-art new building in London.https://www.icr.ac.uk/news-archive%2fnew-radiotherapy-system-that-moves-patients-in-sync-with-x-ray-beam-can-deliver-accurate-treatment-for-brain-cancerhttps://www.icr.ac.uk/news-archive%2fnew-radiotherapy-system-that-moves-patients-in-sync-with-x-ray-beam-can-deliver-accurate-treatment-for-brain-cancerNew radiotherapy system that moves patients in sync with x-ray beam can deliver accurate treatment for brain cancerA new way to deliver radiotherapy that rotates patients in sync with the treatment beam could treat patients with brain cancer as accurately and quickly as the most advanced radiotherapy available, scientists at the ICR show.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmental-health-awareness-week-why-a-black-dog-visit-is-making-our-staff-think-about-happiness-and-wellbeinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmental-health-awareness-week-why-a-black-dog-visit-is-making-our-staff-think-about-happiness-and-wellbeingMental Health Awareness Week: Why a black dog visit is making our staff think about happiness and wellbeingThis week is Mental Health Awareness Week. Here at The Institute of Cancer Research, mental health and wellbeing in the workplace has been an important topic of conversation for staff and students over May, as we welcomed the charity SANE’s Black Dog statue campaign to our Sutton and Chelsea campuses as part of a month-long residency.https://www.icr.ac.uk/news-archive%2fnew-treatment-could-become-first-ever-targeted-therapy-designed-for-untreatable-childhood-brain-cancerhttps://www.icr.ac.uk/news-archive%2fnew-treatment-could-become-first-ever-targeted-therapy-designed-for-untreatable-childhood-brain-cancerNew treatment could become first ever targeted therapy designed for ‘untreatable’ childhood brain cancerA new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease. The prototype treatment could also offer hope for patients with the rare and devastating ‘stone man syndrome’ – in which muscles and ligaments turn to bone. https://www.icr.ac.uk/news-archive%2fgene-mutation-discovery-linked-to-very-poor-survival-in-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fgene-mutation-discovery-linked-to-very-poor-survival-in-prostate-cancer-patientsGene mutation discovery linked to very poor survival in prostate cancer patientsScientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival – and which could be used to pick out patients for more intensive treatment.https://www.icr.ac.uk/news-archive%2ficr-is-most-successful-uk-university-for-invention-income-for-sixth-consecutive-yearhttps://www.icr.ac.uk/news-archive%2ficr-is-most-successful-uk-university-for-invention-income-for-sixth-consecutive-yearICR is most successful UK university for invention income for sixth consecutive yearThe Institute of Cancer Research, London has once again earned the most invention income per member of research staff of any UK higher education institution for the past academic year.https://www.icr.ac.uk/news-archive%2ftwo-for-one-molecule-could-target-two-key-drivers-of-aggressive-childhood-cancerhttps://www.icr.ac.uk/news-archive%2ftwo-for-one-molecule-could-target-two-key-drivers-of-aggressive-childhood-cancerTwo-for-one molecule could target two key drivers of aggressive childhood cancerA group of molecules which each simultaneously target two of the most common genetic faults behind an aggressive form of childhood cancer could lead to a potential new drug for the disease, a new ICR study suggests.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fevaluation-and-our-place-in-the-future-knowledge-landscapehttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fevaluation-and-our-place-in-the-future-knowledge-landscapeEvaluation and our place in the future knowledge landscapePart 6 of 6: In this final blog in her series on delivering impact and commercialisation from academic research, Dr Angela Kukula considers how to evaluate the difference knowledge exchange teams are making in a highly complex and collaborative field.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2freaching-potential-licensees-and-investors-six-key-tipshttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2freaching-potential-licensees-and-investors-six-key-tipsReaching potential licensees and investors: six key tipsPart 5 of 6: In the penultimate blog of this series on achieving impact from academic research, Dr Angela Kukula explores how knowledge exchange professionals can help universities and their researchers to reach potential licensees and investors.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fbuilding-an-efficient-skilled-knowledge-exchange-officehttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fbuilding-an-efficient-skilled-knowledge-exchange-officeBuilding an efficient, skilled knowledge exchange officePart 4 of 6: In her latest blog on delivering impact and commercial opportunity from academic research, Dr Angela Kukula reflects on what makes a successful knowledge exchange office.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fhow-to-make-academic-research-count-through-impact-and-commercial-opportunityhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fhow-to-make-academic-research-count-through-impact-and-commercial-opportunityHow to make academic research count through impact and commercial opportunityPart 1 of 6: In a new series of blogs Dr Angela Kukula, Director of Enterprise at The Institute of Cancer Research, London, will be reflecting on how higher education institutions can deliver impact and commercial opportunities from their research. In our first post, she reflects on how impact has risen to the top of the Government’s policy agenda.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ftechnology-evaluation-protection-and-developmenthttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ftechnology-evaluation-protection-and-developmentTechnology evaluation, protection and developmentPart 3 of 6: Dr Angela Kukula continues her series on delivering impact and commercial opportunity through research. In this blog, she outlines some simple steps higher education institutions can take to steer research along the path to commercialisation.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fidentifying-knowledge-capable-of-creating-impacthttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fidentifying-knowledge-capable-of-creating-impactIdentifying knowledge capable of creating impactPart 2 of 6: Dr Angela Kukula continues her series on delivering impact and commercial opportunity through research. In this blog, she looks at how universities can uncover the knowledge within their walls.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2four-manifesto-for-cancer-drug-discovery-and-development-focusing-on-innovation-to-tackle-treatment-resistance-and-meeting-patients-needshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2four-manifesto-for-cancer-drug-discovery-and-development-focusing-on-innovation-to-tackle-treatment-resistance-and-meeting-patients-needsOur manifesto for cancer drug discovery and development – focusing on innovation to tackle treatment resistance and meeting patients’ needsProfessor Paul Workman argues that concerted action is needed to accelerate patients’ access to today’s new treatments – and incentivise creation of the innovative new medicines of tomorrow that will lead to step changes in clinical outcome.https://www.icr.ac.uk/news-archive%2fnew-panel-of-genes-identifies-men-at-highest-risk-of-aggressive-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-panel-of-genes-identifies-men-at-highest-risk-of-aggressive-prostate-cancerNew panel of genes identifies men at highest risk of aggressive prostate cancerA new panel of genes could pick out men at highest risk of developing prostate cancer and pick out those already diagnosed who are likely to have particularly aggressive forms of the disease, a large-scale genetic analysis has found.https://www.icr.ac.uk/news-archive%2fmanifesto-calls-for-action-on-cancer-drug-access-as-survey-shows-patient-delayshttps://www.icr.ac.uk/news-archive%2fmanifesto-calls-for-action-on-cancer-drug-access-as-survey-shows-patient-delaysManifesto calls for action on cancer drug access as survey shows patient delaysOur new 10-point manifesto is calling for action to speed up access to innovative cancer drugs as an accompanying survey of 1,000 cancer patients finds many face barriers in receiving the latest treatments.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-cure-cancer-nine-challenges-scientists-say-we-need-to-overcomehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-cure-cancer-nine-challenges-scientists-say-we-need-to-overcomeCan we cure cancer? Nine challenges scientists say we need to overcomeOur Head of Content and Partnerships, Henry French, introduces some of the issues that cancer researchers are considering in the search for cancer cures.https://www.icr.ac.uk/news-archive%2ftargeted-breast-cancer-drug-olaparib-given-green-light-by-euhttps://www.icr.ac.uk/news-archive%2ftargeted-breast-cancer-drug-olaparib-given-green-light-by-euTargeted breast cancer drug – olaparib – given green light by EUEuropean Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US.https://www.icr.ac.uk/news-archive%2fcancers-change-spots-to-avoid-immunotherapyhttps://www.icr.ac.uk/news-archive%2fcancers-change-spots-to-avoid-immunotherapyCancers ‘change spots’ to avoid immunotherapyCancers can make themselves harder for new immunotherapies to see by ‘changing their spots’ – and switching off a key molecule on the surface of cells that is otherwise recognised by treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbowel-cancer-awareness-month-2019-six-advances-in-bowel-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbowel-cancer-awareness-month-2019-six-advances-in-bowel-cancer-researchBowel Cancer Awareness Month 2019: Six advances in bowel cancer research There are over 40,000 new cases of bowel cancer in the UK each year and April is Bowel Cancer Awareness Month. Our Digital Communications Intern Liz Partridge looks back at six noteworthy advances in bowel cancer research involving the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhen-it-comes-to-cancer-how-does-alcohol-compare-to-smokinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhen-it-comes-to-cancer-how-does-alcohol-compare-to-smokingWhen it comes to cancer, how does alcohol compare to smoking?New research into the link between alcohol consumption and cancer tries out a new way of getting the message to hit home.https://www.icr.ac.uk/news-archive%2fthree-pronged-attack-can-overcome-drug-resistance-in-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fthree-pronged-attack-can-overcome-drug-resistance-in-bowel-cancerThree-pronged attack can overcome drug resistance in bowel cancerResearchers at the ICR show that triple drug combinations could prevent resistance in many cancer types.https://www.icr.ac.uk/news-archive%2fsutton-paul-scully-mp-becomes-cancer-researcher-for-the-day-at-the-icrhttps://www.icr.ac.uk/news-archive%2fsutton-paul-scully-mp-becomes-cancer-researcher-for-the-day-at-the-icrSutton MP – Paul Scully – becomes cancer researcher for the day at the ICRLocal MP Paul Scully donned a lab coat and safety specs to spend a day as a cancer researcher working in the Sutton laboratories of the ICR.https://www.icr.ac.uk/news-archive%2ficr-researchers-among-the-world-s-most-influentialhttps://www.icr.ac.uk/news-archive%2ficr-researchers-among-the-world-s-most-influentialICR researchers among the world’s most influentialResearchers at the ICR and The Royal Marsden have been named in a list of the world's most influential researchers.https://www.icr.ac.uk/news-archive%2fdiscovery-club-members-meet-next-generation-of-cancer-researchershttps://www.icr.ac.uk/news-archive%2fdiscovery-club-members-meet-next-generation-of-cancer-researchersDiscovery Club members meet next generation of cancer researchersA number of up-and-coming cancer researchers from the ICR shared the research challenges they are working on to outsmart cancer at our latest Discovery Club event.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcancer-and-avoiding-the-blame-gamehttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fcancer-and-avoiding-the-blame-gameCancer – and avoiding the blame gameLeading childhood leukaemia researcher Professor Sir Mel Greaves, discusses the difficulties of avoiding blame and responsibility when it comes to cancer. https://www.icr.ac.uk/news-archive%2f3d-printed-tungsten-could-improve-gamma-camera-imageshttps://www.icr.ac.uk/news-archive%2f3d-printed-tungsten-could-improve-gamma-camera-images3D printed tungsten could improve gamma camera imagesA honeycomb of tungsten built using 3D printing could help take better quality images of processes inside the body, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-awareness-month-2019-six-of-the-latest-advances-in-prostate-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-awareness-month-2019-six-of-the-latest-advances-in-prostate-cancer-researchProstate Cancer Awareness Month 2019: Six of the latest advances in prostate cancer researchMarch is Prostate Cancer Awareness Month – and our researchers are renowned for their success in improving treatments for men with prostate cancer. Web Editor Dave Morgan takes a look back at some of the progress made in prostate cancer research at the ICR over the last 12 months.https://www.icr.ac.uk/news-archive%2fnew-version-of-cansar-database-is-more-user-friendly-with-more-data-than-ever-beforehttps://www.icr.ac.uk/news-archive%2fnew-version-of-cansar-database-is-more-user-friendly-with-more-data-than-ever-beforeNew version of canSAR database is more user-friendly, with more data than ever beforeThe world’s largest and most comprehensive resource for cancer drug discovery has been updated to include more data and new tools to make it easier to use than ever before.https://www.icr.ac.uk/news-archive%2fprecision-drugs-could-unmask-cancers-to-the-immune-system-and-boost-the-effects-of-immunotherapyhttps://www.icr.ac.uk/news-archive%2fprecision-drugs-could-unmask-cancers-to-the-immune-system-and-boost-the-effects-of-immunotherapyPrecision drugs could unmask cancers to the immune system and boost the effects of immunotherapyPrecision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-women-in-science-international-women-s-dayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-women-in-science-international-women-s-daySupporting women in science: International Women’s DayThis International Women’s Day, Rose Wu speaks to our researchers to find out more about some of the work taking place across the Institute of Cancer Research to support women across different stages of their research careers.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fovarian-cancer-awareness-month-knowledge-of-brca2-gene-is-powerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fovarian-cancer-awareness-month-knowledge-of-brca2-gene-is-powerKnowledge of BRCA2 gene is powerThis week marks 25 years since our researchers discovered the BRCA2 gene. Our Cancer Stories Officer, Lydia Brain, spoke to Davina Gardner – a survivor of ovarian and breast cancer – about being a BRCA2 gene mutation carrier and how it has affected her and her family.https://www.icr.ac.uk/news-archive%2fnew-cancer-preventing-role-found-for-dna-cable-tiehttps://www.icr.ac.uk/news-archive%2fnew-cancer-preventing-role-found-for-dna-cable-tieNew cancer-preventing role found for DNA ‘cable tie’A ring of proteins that holds our chromosomes together as they replicate also plays a vital role in stopping DNA damage from leading to cancer, according to new research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frare-disease-day-2019-what-makes-a-cancer-rare-and-how-can-research-helphttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frare-disease-day-2019-what-makes-a-cancer-rare-and-how-can-research-helpRare Disease Day 2019: What makes a cancer rare and how can research help?On 28 February organisations around the world will be working to raise awareness of rare diseases for Rare Disease Day. Tilly Haynes looked into what qualifies as a rare cancer, and how researchers at The Institute of Cancer Research, London, are working on some of them. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-summer-with-the-icr-one-student-s-experience-at-the-forefront-of-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-summer-with-the-icr-one-student-s-experience-at-the-forefront-of-cancer-researchA summer with the ICR – one student’s experience at the forefront of cancer researchEvery year the ICR takes on undergraduate students as part of our 2019 Summer Vacation Scholarship Scheme. These summer studentships involve students working in our research labs and contributing to valuable cancer research. Tilly Haynes spoke to one summer student, Isabelle Atkins, about her experience and her success as first author of a paper in Cancer Research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-old-science-to-new-science---110-years-of-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-old-science-to-new-science---110-years-of-cancer-researchFrom old science to new science - 110 years of cancer research The Institute of Cancer Research, London, has been conducting world leading research since we opened our doors as The Cancer Hospital Research in 1909. Our former Digital Communications Intern, Francis Newman, takes a look at five of the major advances that took place here during the 20th century, which now form the basis of much of the work done by modern cancer researchers worldwide. https://www.icr.ac.uk/news-archive%2fcell-death-triggers-keep-cancer-at-bay-in-healthy-cellshttps://www.icr.ac.uk/news-archive%2fcell-death-triggers-keep-cancer-at-bay-in-healthy-cellsCell death triggers keep cancer at bay in healthy cellsTwo molecules with the power of life and death over cells also play a key role in protecting the genome and preventing cancer, a major new study reveals.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fthe-london-cancer-hub-the-story-so-farhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fthe-london-cancer-hub-the-story-so-farThe London Cancer Hub: the story so farHenry French introduces the latest developments at The London Cancer Hub, a major regeneration project in Sutton, south London, which aims to develop the world’s leading cancer-specialist life-science campus. https://www.icr.ac.uk/news-archive%2fnew-organ-sparing-radiotherapy-plan-could-reduce-treatment-side-effectshttps://www.icr.ac.uk/news-archive%2fnew-organ-sparing-radiotherapy-plan-could-reduce-treatment-side-effectsNew organ sparing radiotherapy plan could reduce treatment side effectsA new way to plan radiotherapy could help shape treatment away from sensitive organs near tumours to reduce side-effects, a new study shows. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcuring-brain-cancer-the-challenges-aheadhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcuring-brain-cancer-the-challenges-aheadCuring brain cancer – the challenges aheadResearchers and clinicians from across the world, including our Chief Executive Professor Paul Workman and Professors Raj Chopra and Louis Chesler, have come together to set out how future research can finally deliver major progress against brain cancer in both adults and children. Our Science Communications Officer, Conor McKeever, looks at the group’s recommendations.https://www.icr.ac.uk/ttps%3a%2f%2fwww.icr.ac.uk%2fnews-features%2flatest-features%2fcapturing-cancer-on-the-move-icr-photography-competition-showcases-stunning-images-of-tumour-cells-in-actionhttps://www.icr.ac.uk/ttps%3a%2f%2fwww.icr.ac.uk%2fnews-features%2flatest-features%2fcapturing-cancer-on-the-move-icr-photography-competition-showcases-stunning-images-of-tumour-cells-in-actionCapturing cancer on the move – ICR photography competition showcases stunning images of tumour cells in actionEvery year our researchers submit outstanding pictures to our Science and Medical Imaging Competition – telling a story about our pioneering work and its benefits for patients. Check out the fantastic images selected by our judges, and this year voted for by the public.https://www.icr.ac.uk/news-archive%2ficr-hails-350m-tender-as-major-milestone-for-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2ficr-hails-350m-tender-as-major-milestone-for-london-cancer-hubICR hails £350m tender as ‘major milestone’ for London Cancer HubThe Institute of Cancer Research, London, has welcomed the launch of a £350 million tender to find a commercial development partner for The London Cancer Hub as a major milestone in turning the vision for the project into reality.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdarwin-day-2019-unpicking-cancer-evolution-to-beat-cancer-at-its-own-gamehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdarwin-day-2019-unpicking-cancer-evolution-to-beat-cancer-at-its-own-gameDarwin Day 2019: unpicking cancer evolution to beat cancer at its own gameTo celebrate Darwin Day, the ICR holds an annual lecture to recognise the ongoing relevance of Darwin’s principles of natural selection in cancer research. This year Professor Joel S. Brown from Florida’s the Moffitt Cancer Center will discuss how figuring out cancer’s evolutionary strategies can help us tackle the problem of cancer drug resistance in an era of personalised medicine. The ICR’s Sarah Wells spoke to him to find out more.https://www.icr.ac.uk/news-archive%2ftackling-tumour-scar-tissue-could-be-key-to-treating-pancreatic-cancerhttps://www.icr.ac.uk/news-archive%2ftackling-tumour-scar-tissue-could-be-key-to-treating-pancreatic-cancerTackling tumour scar tissue could be key to treating pancreatic cancerThe first study in the world to take a detailed look at scar tissue in human pancreatic cancer has revealed a range of different scar tissue types that could help clinicians predict which patients will respond best to particular treatments. https://www.icr.ac.uk/news-archive%2fnew-trojan-horse-cancer-treatment-shows-early-promise-in-multiple-tumour-typeshttps://www.icr.ac.uk/news-archive%2fnew-trojan-horse-cancer-treatment-shows-early-promise-in-multiple-tumour-typesNew ‘Trojan horse’ cancer treatment shows early promise in multiple tumour typesA brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwinning-the-war-on-cancer-why-words-matterhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwinning-the-war-on-cancer-why-words-matterWinning the War on Cancer: why words matterProfessor Paul Workman cautions that aggressive military language can be unhelpful in describing some patients’ experience of living with cancer – and oversimplifies the overall challenge of cancer research https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-2019-how-everyone-at-the-icr-helps-play-their-parthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-2019-how-everyone-at-the-icr-helps-play-their-partWorld Cancer Day 2019: how everyone at the ICR helps play their partEveryone at The Institute of Cancer Research, London plays their role in improving the situation for patients with cancer. This World Cancer Day we are joining the conversation about how we are contributing.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-genomes-everywhere-lessons-learned-from-the-festival-of-genomicshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-genomes-everywhere-lessons-learned-from-the-festival-of-genomicsCancer genomes everywhere: lessons learned from the Festival of Genomics Cancer featured prominently as scientists from around the world met recently at the Festival of Genomics conference in London. Dr Keith Bradnam, the ICR’s Digital Strategy Manager, was in attendance to see talks by ICR researchers and find out about the latest developments in cancer genomics. https://www.icr.ac.uk/news-archive%2fkey-signalling-protein-linked-to-aggressive-cancershttps://www.icr.ac.uk/news-archive%2fkey-signalling-protein-linked-to-aggressive-cancersKey signalling protein linked to aggressive cancersScientists have identified a protein which is associated with more aggressive breast, colorectal and ovarian cancers, which could be used to assist the diagnosis and development treatments for these cancers.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fhelping-give-hope-to-patients-with-rare-chordoma-cancershttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fhelping-give-hope-to-patients-with-rare-chordoma-cancersHelping give hope to patients with rare chordoma cancersAn ICR team contributed to a major collaborative study discovering a new treatment approach for chordoma – the disease from which my own mother died.https://www.icr.ac.uk/news-archive%2fpartnering-to-defeat-cancer-babraham-research-campus-hosts-icr-networking-event-for-our-scientists-and-potential-new-commercial-partnershttps://www.icr.ac.uk/news-archive%2fpartnering-to-defeat-cancer-babraham-research-campus-hosts-icr-networking-event-for-our-scientists-and-potential-new-commercial-partnersPartnering to Defeat Cancer: Babraham Research Campus hosts ICR networking event for our scientists and potential new commercial partnersThe Institute of Cancer Research, London’s Enterprise Unit played host to scientists and possible future partners from the commercial sector to discuss opportunities to work together to defeat cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-s-bright-professor-udai-banerji-reflects-on-the-evolution-of-anticancer-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-s-bright-professor-udai-banerji-reflects-on-the-evolution-of-anticancer-drugs“The future’s bright” – Professor Udai Banerji reflects on the evolution of anticancer drugsMarking his promotion to Professor after 18 years at The Institute of Cancer Research, Professor Udai Banerji gave his inaugural lecture to packed lecture theatres across our two sites. Conor McKeever, our Science Communications Officer, was there to hear him talk about his work on the development of new anticancer drugs, and where he sees the field going next.https://www.icr.ac.uk/news-archive%2fhigh-precision-radiotherapy-can-safely-treat-prostate-cancer-spreadhttps://www.icr.ac.uk/news-archive%2fhigh-precision-radiotherapy-can-safely-treat-prostate-cancer-spreadHigh-precision radiotherapy can safely treat prostate cancer spreadMen with ‘high risk’ prostate cancer can safely receive high-dose radiotherapy to kill cancer cells that have spread into neighbouring lymph nodes, a new study reports.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffive-big-challenges-facing-the-life-sciences-biotech-and-pharma-sectors-in-2019https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2ffive-big-challenges-facing-the-life-sciences-biotech-and-pharma-sectors-in-2019Five big challenges facing the life sciences, biotech and pharma sectors in 2019Henry French introduces five challenges for the life sciences this year.https://www.icr.ac.uk/news-archive%2fnew-ai-shapeshift-test-identifies-women-with-very-high-risk-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fnew-ai-shapeshift-test-identifies-women-with-very-high-risk-ovarian-cancerNew AI ‘shapeshift’ test identifies women with ‘very high risk’ ovarian cancerScientists have developed a new test that scans the shapes of tumour cells to pick out women with especially aggressive ovarian cancer, so treatment can be tailored to their needs.https://www.icr.ac.uk/news-archive%2fthe-royal-marsden-s-martin-gore-dies-unexpectedlyhttps://www.icr.ac.uk/news-archive%2fthe-royal-marsden-s-martin-gore-dies-unexpectedlyThe Royal Marsden’s Martin Gore dies unexpectedlyThe ICR is shocked to learn that Professor Martin Gore, former Medical Director at The Royal Marsden, has died suddenly.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-the-nhs-long-term-plan-really-mean-for-childhood-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-the-nhs-long-term-plan-really-mean-for-childhood-cancerWhat does the NHS Long Term Plan really mean for childhood cancer?The NHS released their Long Term Plan this week – and much of the media coverage focused on the news about genetic testing for childhood cancer. We look at the plan and ask whether it will really deliver for children with cancer.https://www.icr.ac.uk/news-archive%2fprotein-found-more-in-advanced-prostate-cancer-could-be-key-to-preventing-drug-resistancehttps://www.icr.ac.uk/news-archive%2fprotein-found-more-in-advanced-prostate-cancer-could-be-key-to-preventing-drug-resistanceProtein found more in advanced prostate cancer could be key to preventing drug resistanceA cancer-driving protein is found in the tumours of men with advanced prostate cancer after treatment with hormone drugs, but rarely found in early-stage disease, a new study shows.https://www.icr.ac.uk/news-archive%2fland-deal-completes-multimillion-pound-investment-to-make-london-cancer-hub-a-realityhttps://www.icr.ac.uk/news-archive%2fland-deal-completes-multimillion-pound-investment-to-make-london-cancer-hub-a-realityLand deal completes multimillion pound investment to make London Cancer Hub a realityPlans to develop a world-leading cancer research hub in south London have taken a major step forward with the completion of the final stage in a £30 million investment in land.https://www.icr.ac.uk/news-features%2flatest-features%2ffocus-on-childhood-leukaemiahttps://www.icr.ac.uk/news-features%2flatest-features%2ffocus-on-childhood-leukaemiaRevolutionising the way we view childhood leukaemiaFor decades, research at the ICR has transformed our understanding of childhood leukaemia and how it is treated. Now, research from Professor Sir Mel Greaves, Director of our Centre for Evolution and Cancer, could once more revolutionise the way we view the disease.https://www.icr.ac.uk/news-archive%2fpioneering-scientist-mel-greaves-is-knighted-after-research-to-unveil-cause-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fpioneering-scientist-mel-greaves-is-knighted-after-research-to-unveil-cause-of-childhood-leukaemiaPioneering scientist Mel Greaves is knighted after research to unveil cause of childhood leukaemiaProfessor Mel Greaves has been knighted in the New Year Honours List for his pioneering and hugely influential research into childhood leukaemia.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-older-mothers-really-at-higher-risk-of-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-older-mothers-really-at-higher-risk-of-breast-cancerAre older mothers really at higher risk of breast cancer?Recent headlines reported that older mothers are at higher risk of breast cancer. But that was just one piece of evidence taken from a large study co-led by the ICR looking at a whole range of pregnancy-related factors and their role in breast cancer risk. The ICR’s Sarah Wells dug into the stats to put the headlines into context.https://www.icr.ac.uk/news-archive%2fbreast-cancer-drugs-could-help-treat-resistant-lung-cancershttps://www.icr.ac.uk/news-archive%2fbreast-cancer-drugs-could-help-treat-resistant-lung-cancersBreast cancer drugs could help treat resistant lung cancersA class of drugs used to treat certain breast cancers could help to tackle lung cancers that have become resistant to targeted therapies, suggests a new study in mice from the Francis Crick Institute and The Institute of Cancer Research, Londonhttps://www.icr.ac.uk/news-archive%2fpractice-changing-clinical-trial-reduces-long-term-radiotherapy-side-effects-in-women-with-breast-cancerhttps://www.icr.ac.uk/news-archive%2fpractice-changing-clinical-trial-reduces-long-term-radiotherapy-side-effects-in-women-with-breast-cancerPractice-changing clinical trial reduces long-term radiotherapy side effects in women with breast cancerTargeting or reducing the dose of radiotherapy for women with breast cancer after surgery can substantially reduce the side effects they experience, a large-scale clinical trial has shown.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbuckingham-palace-and-blue-plaques-icr-s-2018-year-in-reviewhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbuckingham-palace-and-blue-plaques-icr-s-2018-year-in-reviewBuckingham Palace and Blue Plaques: ICR’s 2018 year in reviewIt's been a busy, and exciting, year for the ICR. In this blog post we look back and reflect on some of our highlights that exemplify the broad range of stimulating and thought-provoking work that happens here.https://www.icr.ac.uk/news-features%2flatest-features%2fhifu-using-ultrasound-to-heat-and-destroy-tumourshttps://www.icr.ac.uk/news-features%2flatest-features%2fhifu-using-ultrasound-to-heat-and-destroy-tumoursHIFU: using ultrasound to heat and destroy tumoursUltrasound has been used to detect cancer inside the body for over 70 years. But what if it could be used to treat cancer too? Conor McKeever, our Science Communications Officer, introduces an exciting technology developed by ICR scientists that does just that.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbaroness-tessa-jowell-and-advances-in-brain-cancer-research-celebrated-at-palace-of-westminster-eventhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbaroness-tessa-jowell-and-advances-in-brain-cancer-research-celebrated-at-palace-of-westminster-eventBaroness Tessa Jowell and advances in brain cancer research celebrated at Palace of Westminster event The ICR’s Tilly Haynes attended an event, hosted by The Brain Tumour Charity, in the House of Commons to hear about the latest progress in brain tumour research and treatment, and how the ICR is contributing to achieving the charity’s strategic goal.https://www.icr.ac.uk/news-archive%2ficr-celebrates-royal-society-of-chemistry-blue-plaques-for-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2ficr-celebrates-royal-society-of-chemistry-blue-plaques-for-cancer-drug-discoveryICR celebrates Royal Society of Chemistry blue plaques for cancer drug discoveryThe ICR has been recognised for its many successes in drug discovery through the award of blue plaques in Sutton and Chelsea under the Royal Society of Chemistry’s Chemical Landmark scheme.https://www.icr.ac.uk/news-archive%2fgiving-birth-increases-women-s-breast-cancer-risk-in-the-short-termhttps://www.icr.ac.uk/news-archive%2fgiving-birth-increases-women-s-breast-cancer-risk-in-the-short-termGiving birth increases women’s breast cancer risk in the short termYounger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children.https://www.icr.ac.uk/news-archive%2fimmunotherapy-appeal-raises-over-80-000-for-our-researchhttps://www.icr.ac.uk/news-archive%2fimmunotherapy-appeal-raises-over-80-000-for-our-researchImmunotherapy appeal raises over £80,000 for our researchThanks to the generosity of our donors, we have raised over £80,000 to help fund our cutting-edge work in immunotherapy through a fundraising appeal. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-100-000-genomes-project-has-finished-what-were-the-challenges-and-what-comes-nexthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-100-000-genomes-project-has-finished-what-were-the-challenges-and-what-comes-nextThe 100,000 Genomes Project has finished: what were the challenges and what comes next? This week, the Health Secretary Matt Hancock announced that the 100,000 Genomes Project has reached its goal of decoding 100,000 genomes from NHS patients. We take a look at some of the challenges that had to be overcome to reach this point and ask what happens next?https://www.icr.ac.uk/news-archive%2ftargeted-drug-palbociclib-stops-tumour-growth-in-patients-with-early-breast-cancerhttps://www.icr.ac.uk/news-archive%2ftargeted-drug-palbociclib-stops-tumour-growth-in-patients-with-early-breast-cancerTargeted drug – palbociclib – stops tumour growth in patients with early breast cancerAdding a new targeted therapy to hormone therapy halts the growth of tumour cells in women with early-stage breast cancer, new research shows.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-regulators-must-move-with-the-science-if-we-re-to-get-innovative-new-treatments-to-patients-more-quicklyhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-regulators-must-move-with-the-science-if-we-re-to-get-innovative-new-treatments-to-patients-more-quicklyWhy regulators must move with the science if we’re to get innovative new treatments to patients more quicklyOur CEO, Professor Paul Workman, discusses the findings of the ICR's new drug access report, which asks how we can best harness advances in science to bring innovative drugs to patients.https://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2018-christmas-season-starts-in-style-with-carol-service-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2018-christmas-season-starts-in-style-with-carol-service-for-cancer-researchCarols from Chelsea 2018: Christmas season starts in style with carol service for cancer researchSome famous faces from stage and screen came together to mark the start of the festive season and support the ICR at our exclusive carol service.https://www.icr.ac.uk/news-features%2flatest-features%2fmaking-it-count-the-real-life-stories-of-people-benefiting-from-innovative-new-cancer-treatmentshttps://www.icr.ac.uk/news-features%2flatest-features%2fmaking-it-count-the-real-life-stories-of-people-benefiting-from-innovative-new-cancer-treatmentsMaking it count – the real life stories of people benefiting from innovative new cancer treatments We are in an exciting time in cancer research, with many researchers believing we are at the tipping point in cancer treatment, and moving towards truly personalised treatment plans for patients. https://www.icr.ac.uk/news-archive%2fnew-cancer-drugs-taking-longer-to-reach-nhs-patientshttps://www.icr.ac.uk/news-archive%2fnew-cancer-drugs-taking-longer-to-reach-nhs-patientsNew cancer drugs taking longer to reach NHS patientsNHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a major new analysis of regulatory data reveals.https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2018https://www.icr.ac.uk/news-features%2flatest-features%2fscientific-achievements-of-2018Scientific achievements of 2018We've selected a range of discoveries from 2017/18 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.https://www.icr.ac.uk/news-archive%2fimmunotherapy-keeps-some-patients-with-advanced-head-and-neck-cancer-alive-for-more-than-three-yearshttps://www.icr.ac.uk/news-archive%2fimmunotherapy-keeps-some-patients-with-advanced-head-and-neck-cancer-alive-for-more-than-three-yearsImmunotherapy keeps some patients with advanced head and neck cancer alive for more than three yearsA new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-of-car-t-cell-immunotherapy-in-the-ukhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-of-car-t-cell-immunotherapy-in-the-ukThe future of CAR T cell immunotherapy in the UKCancer research has delivered major breakthroughs in recent years, and CAR T cell therapy is a stand-out example. Dr Claire Hastings went along to an event run by the Financial Times and Gilead Sciences to hear what needs to happen next to ensure this particular breakthrough treatment benefits patients in the UK. https://www.icr.ac.uk/news-archive%2fgene-test-predicts-likelihood-of-stomach-or-oesophageal-cancer-relapsehttps://www.icr.ac.uk/news-archive%2fgene-test-predicts-likelihood-of-stomach-or-oesophageal-cancer-relapseGene test predicts likelihood of stomach or oesophageal cancer relapseA new test could improve care for patients with stomach or oesophageal cancer by predicting their likelihood of relapse after chemotherapy and surgery.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fharnessing-the-power-of-patient-data-and-the-patient-experience-to-improve-cancer-research-and-carehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fharnessing-the-power-of-patient-data-and-the-patient-experience-to-improve-cancer-research-and-careHarnessing the power of patient data and the patient experience to improve cancer research and careThis year’s War on Cancer event – hosted by The Economist – was focused on the technological revolution and the future of patient engagement. Lydia Brain, the ICR’s Cancer Stories Officer, reports back from the conference, where she heard from an impressive range of speakers that included policy makers, industry leaders, scientists and patients. https://www.icr.ac.uk/news-archive%2fweight-loss-drug-could-help-treat-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fweight-loss-drug-could-help-treat-advanced-ovarian-cancerWeight loss drug could help treat advanced ovarian cancerA weight loss drug available over the counter in the UK could help women with treatment-resistant ovarian cancer respond to chemotherapy again, a new study suggests. https://www.icr.ac.uk/news-archive%2fscientists-uncover-why-testicular-cancer-runs-in-familieshttps://www.icr.ac.uk/news-archive%2fscientists-uncover-why-testicular-cancer-runs-in-familiesScientists uncover why testicular cancer runs in familiesTesticular cancer in families is usually caused by the accumulation of minor genetic changes that have only a small effect on their own, but together can add up to a significant risk.https://www.icr.ac.uk/news-archive%2ftargeting-inflammation-could-help-treat-drug-resistant-bowel-cancerhttps://www.icr.ac.uk/news-archive%2ftargeting-inflammation-could-help-treat-drug-resistant-bowel-cancerTargeting inflammation could help treat drug-resistant bowel cancerSome bowel cancers that are resistant to treatment could be re-sensitised using drugs that reduce inflammation, according to new research.https://www.icr.ac.uk/news-archive%2fcall-for-hospitals-to-use-high-tech-scans-to-diagnose-prostate-cancers-when-they-can-still-be-curedhttps://www.icr.ac.uk/news-archive%2fcall-for-hospitals-to-use-high-tech-scans-to-diagnose-prostate-cancers-when-they-can-still-be-curedCall for hospitals to use high-tech scans to diagnose prostate cancers when they can still be curedModern, sophisticated scans should be used in hospitals to pick out men whose prostate cancers have only spread to a limited number of sites, so they can be offered the chance of cure, a new assessment concludes.https://www.icr.ac.uk/news-archive%2fhow-our-supporters-are-helping-us-take-on-stealth-cancershttps://www.icr.ac.uk/news-archive%2fhow-our-supporters-are-helping-us-take-on-stealth-cancersHow our supporters are helping us take on ‘stealth’ cancers Professor Raj Chopra, Head of Cancer Therapeutics, thanked ICR supporters and spoke about his hopes for the future for cancer treatment – made possible by their support. https://www.icr.ac.uk/news-archive%2fpatients-with-hpv-positive-throat-cancer-should-keep-taking-chemotherapyhttps://www.icr.ac.uk/news-archive%2fpatients-with-hpv-positive-throat-cancer-should-keep-taking-chemotherapyPatients with HPV-positive throat cancer should keep taking chemotherapyPatients with human papillomavirus (HPV)-positive throat cancer should carry on receiving chemotherapy rather than switching to a targeted cancer drug, new clinical trial results have shown.https://www.icr.ac.uk/news-archive%2fpublic-private-sector-collaboration-the-theme-as-minister-visits-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fpublic-private-sector-collaboration-the-theme-as-minister-visits-the-london-cancer-hubPublic-private sector collaboration the theme as Minister visits The London Cancer HubBusiness Minister Lord Henley has visited The London Cancer Hub to discuss new opportunities for life-sciences businesses to collaborate with world-leading scientists from The Institute of Cancer Research (ICR), London.https://www.icr.ac.uk/news-archive%2fprofessor-laurence-pearl-awarded-prestigious-novartis-medal-and-prizehttps://www.icr.ac.uk/news-archive%2fprofessor-laurence-pearl-awarded-prestigious-novartis-medal-and-prizeProfessor Laurence Pearl awarded prestigious Novartis Medal and PrizeProfessor Laurence Pearl, Head of the Division of Structural Biology, has been awarded the Novartis Medal and Prize by the Biochemical Society.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2flet-s-celebrate-university-collaboration-with-industryhttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2flet-s-celebrate-university-collaboration-with-industryLet’s celebrate university collaboration with industryDr Angela Kukula, Director of Enterprise at The Institute of Cancer Research, calls on universities and businesses to celebrate the range of different collaborations we make.https://www.icr.ac.uk/news-archive%2ficr-thanks-star-fundraisers-for-their-significant-contributions-to-our-researchhttps://www.icr.ac.uk/news-archive%2ficr-thanks-star-fundraisers-for-their-significant-contributions-to-our-researchICR thanks star fundraisers for their significant contributions to our researchBowel cancer patient and fundraiser Tim Morgan and founder of The Chris Lucas Trust, Lynn Lucas, were thanked at the October meeting of the ICR's Discovery Club for their phenomenal fundraising efforts to support our research.https://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-on-olaparib-for-women-with-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-on-olaparib-for-women-with-advanced-ovarian-cancerICR responds to NICE decision on olaparib for women with advanced ovarian cancerNICE has announced today, its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2freducing-inequalities-immunotherapy-and-quality-of-life-three-key-themes-from-ncri-2018https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2freducing-inequalities-immunotherapy-and-quality-of-life-three-key-themes-from-ncri-2018Reducing inequalities, immunotherapy and quality of life: three key themes from NCRI 2018As the conference stands are packed up and the signs taken down, Lydia Brain reflects back on some of the most commonly recurring topics from the conference.https://www.icr.ac.uk/news-archive%2fclimb-of-life-fundraising-total-hits-1millionhttps://www.icr.ac.uk/news-archive%2fclimb-of-life-fundraising-total-hits-1millionClimb of Life fundraising total hits £1 millionIn its 12th year raising money for The Institute of Cancer Research, London, the Climb of Life has reached the tremendous milestone of raising over £1 million. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-three-new-ways-researchers-are-combatting-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-three-new-ways-researchers-are-combatting-cancerNCRI 2018: Three new ways researchers are combatting cancerAn intriguing session at the NCRI conference gave a glimpse of some novel ways for attacking cancers.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-using-liquid-biopsies-to-understand-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-using-liquid-biopsies-to-understand-cancer-treatmentNCRI 2018: Using liquid biopsies to understand cancer treatmentTesting for cancer cells and DNA in the bloodstream is showing huge promise as a way of monitoring cancers and how they are responding to treatment. At the 2018 NCRI conference in Glasgow, ICR researchers spoke about how these so-called liquid biopsies can guide clinical decisions for cancer patients.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fpresident-trump-the-cancer-moonshot-and-the-new-war-on-drug-pricinghttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fpresident-trump-the-cancer-moonshot-and-the-new-war-on-drug-pricingPresident Trump, the Cancer Moonshot and the new war on drug pricingWhat could the new US administration mean for drug discovery and development – in the US and the UK? Dr Angela Kukula, the ICR's Director of Enterprise, reports back from the world’s biggest life sciences conference, BioWeek SF.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fthe-secrets-of-successful-industry-academic-partnershipshttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fthe-secrets-of-successful-industry-academic-partnershipsThe secrets of successful industry-academic partnershipsThe Institute of Cancer Research, London – the world’s leading academic centre for drug discovery – has announced a major new strategic partnership with science and technology company Merck, and Cancer Research UK. Here Dr Angela Kukula, Director of Enterprise at The Institute of Cancer Research (ICR) – and responsible for its interactions with industry – gives some tips on what makes a good collaboration between industry and academic researchers.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fdo-academic-organisations-make-enough-money-from-their-inventionshttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2fdo-academic-organisations-make-enough-money-from-their-inventionsDo academic organisations make enough money from their inventions?Dr Angela Kukula asks whether academic organisations should gain financially from lucrative discoveries – and proposes some solutions to the high costs of new cancer drugs.https://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2finnovation-in-research-provides-benefits-to-society-and-the-economy-but-how-do-we-measure-ithttps://www.icr.ac.uk/blogs%2fconnections-blog%2fpage-details%2finnovation-in-research-provides-benefits-to-society-and-the-economy-but-how-do-we-measure-itInnovation in research provides benefits to society and the economy… but how do we measure it?Dr Angela Kukula, the ICR’s Director of Enterprise, says that innovation in academic research is key to unlocking benefits to society and the economy – but cautions that measuring it is much trickier than just counting patents or profits.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-world-leading-cancer-researchers-and-clinicians-gather-in-glasgowhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2018-world-leading-cancer-researchers-and-clinicians-gather-in-glasgowNCRI 2018: World-leading cancer researchers and clinicians gather in GlasgowThis year The Institute of Cancer Research, London, is in Scotland to attend the National Cancer Research Institute (NCRI) annual conference. As the UK’s largest platform for cancer researchers, clinicians, industry and patients to showcase the latest advances in cancer research, the ICR will be reporting on the cutting-edge science throughout.https://www.icr.ac.uk/news-archive%2ficr-welcomes-tfl-consultation-on-sutton-tram-extensionhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-tfl-consultation-on-sutton-tram-extensionICR welcomes TfL consultation on Sutton tram extensionThe Institute of Cancer Research, London, has welcomed the opening of a formal planning consultation on new proposals to take the tram to Sutton station as a stepping stone towards extending the tram to The London Cancer Hub site.https://www.icr.ac.uk/news-archive%2fgoodbye-to-one-of-our-most-inspirational-teachershttps://www.icr.ac.uk/news-archive%2fgoodbye-to-one-of-our-most-inspirational-teachersGoodbye to one of our most inspirational teachersOur students have thanked Professor Keith Jones for his support and dedication to training the next generation of cancer researchers as he retires from The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fesmo-2018-immunotherapy-effective-as-first-line-treatment-for-advanced-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fesmo-2018-immunotherapy-effective-as-first-line-treatment-for-advanced-head-and-neck-cancerESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancerImmunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.https://www.icr.ac.uk/news-archive%2fesmo-2018-cancer-trials-shows-treating-the-prostate-directly-with-radiotherapy-improves-survivalhttps://www.icr.ac.uk/news-archive%2fesmo-2018-cancer-trials-shows-treating-the-prostate-directly-with-radiotherapy-improves-survivalESMO 2018: Cancer trial shows treating the prostate directly with radiotherapy improves survivalTreating the prostate with radiotherapy alongside standard treatment led to a 11 per cent increase in survival for some men with advanced prostate cancer, according to a new study.https://www.icr.ac.uk/news-archive%2ffewer-but-larger-radiation-doses-cause-similarly-low-side-effects-as-conventional-breast-cancer-radiotherapyhttps://www.icr.ac.uk/news-archive%2ffewer-but-larger-radiation-doses-cause-similarly-low-side-effects-as-conventional-breast-cancer-radiotherapyFewer but larger radiation doses cause similarly low side-effects as conventional breast cancer radiotherapyWomen who received radiotherapy for early-stage breast cancer in fewer, larger doses experienced similarly low rates of late-onset side-effects as those receiving conventional treatment, results from a 10-year study show.https://www.icr.ac.uk/news-archive%2fesmo-2018-major-trial-shows-targeted-drug-palbociclib-extends-breast-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fesmo-2018-major-trial-shows-targeted-drug-palbociclib-extends-breast-cancer-survivalESMO 2018: Major trial shows targeted drug – palbociclib – extends breast cancer survivalCombining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-the-fda-approval-of-talazoparib-for-women-with-brca-mutant-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-the-fda-approval-of-talazoparib-for-women-with-brca-mutant-advanced-breast-cancerThe ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancerThe ICR strongly welcomes the news that talazoparib (trade name Talzenna) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhere-you-really-can-make-a-difference-professor-chris-lord-looks-back-at-18-years-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhere-you-really-can-make-a-difference-professor-chris-lord-looks-back-at-18-years-at-the-icr“Here you really can make a difference” – Professor Chris Lord reflects on the biggest developments in his career so farProfessor Chris Lord, Deputy Head of the Division of Breast Cancer Research, has given his inaugural lecture to mark his promotion to Professor after 18 years at the Institute of Cancer Research. Conor McKeever, our Science Communications Officer, was there to hear him talk about the biggest developments in his career so far.https://www.icr.ac.uk/news-archive%2fnew-study-discovers-inhibitors-of-protein-linked-to-the-devastating-childhood-brain-cancer-dipghttps://www.icr.ac.uk/news-archive%2fnew-study-discovers-inhibitors-of-protein-linked-to-the-devastating-childhood-brain-cancer-dipgNew study discovers inhibitors of protein linked to the devastating childhood brain cancer DIPGScientists at The Institute of Cancer Research, London in collaboration with a team at the Structural Genomics Consortium in Oxford (SGC) have created a new series of compound that could form the basis for drugs that target the devastating childhood brain cancer diffuse intrinsic pontine glioma, or DIPG.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbiology-week-2018-the-scientists-studying-what-makes-cancer-tickhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbiology-week-2018-the-scientists-studying-what-makes-cancer-tickBiology Week 2018: the scientists studying what makes cancer tickLooking back to the Royal Society of Biology’s 7th annual Biology Week, Sarah Wells met with Professor Jon Pines, Head of the ICR’s Division of Cancer Biology, to find out what the division has been working on, and where he sees our fundamental biology research going next.https://www.icr.ac.uk/news-archive%2fhaving-a-heavier-first-born-child-or-a-shorter-pregnancy-may-increase-a-mother-s-risk-of-breast-cancerhttps://www.icr.ac.uk/news-archive%2fhaving-a-heavier-first-born-child-or-a-shorter-pregnancy-may-increase-a-mother-s-risk-of-breast-cancerHaving a heavier first-born child or a shorter pregnancy may increase a mother’s risk of breast cancerShort first pregnancies and having a heavier first-born child may slightly increase a mother’s risk of breast cancer, a new study has found.https://www.icr.ac.uk/news-archive%2fteamicr-take-on-the-royal-parks-half-marathon-2018https://www.icr.ac.uk/news-archive%2fteamicr-take-on-the-royal-parks-half-marathon-2018#teamICR take on the Royal Parks Half Marathon 201822 members of #teamICR will be running the Royal Parks Half Marathon this Sunday to raise money for cancer research. https://www.icr.ac.uk/news-archive%2ficr-completes-new-deal-with-company-to-develop-ovarian-cancer-drughttps://www.icr.ac.uk/news-archive%2ficr-completes-new-deal-with-company-to-develop-ovarian-cancer-drugICR completes new deal with company to develop ovarian cancer drug CT900The Institute of Cancer Research, London and global healthcare company BTG have successfully concluded negotiations with a biopharmaceutical company, Carrick Therapeutics, to take a promising precision drug discovered at The Institute of Cancer Research into a later-stage clinical trial.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreast-cancer-awareness-month-five-advances-in-breast-cancer-research-in-2018https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreast-cancer-awareness-month-five-advances-in-breast-cancer-research-in-2018Breast Cancer Awareness Month: Five advances in breast cancer research in 2018October is Breast Cancer Awareness Month – an annual international health campaign. Web Editor Dave Morgan rounds up five exciting breast cancer news stories from the ICR in 2018 so far.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-medicine-2018-the-early-research-that-led-to-revolutionary-cancer-immunotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-medicine-2018-the-early-research-that-led-to-revolutionary-cancer-immunotherapyNobel Prize for Medicine 2018: the early research that led to ‘revolutionary’ cancer immunotherapyTwo scientists who made key discoveries about how the immune system is regulated have won the 2018 Nobel Prize for Medicine. Dr Claire Hastings explains how their work led to a revolution in cancer treatment. https://www.icr.ac.uk/news-features%2flatest-features%2fwhat-the-future-holds-for-children-with-brain-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fwhat-the-future-holds-for-children-with-brain-cancerWhat the future holds for children with brain cancerBrain cancer is a devastating disease, particularly when it affects young children, and progress in treatments has been slow. But ICR researchers have made major breakthroughs in recent months, with discoveries that could impact diagnosis, treatment and survival from childhood brain tumours.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdedicated-parents-lead-team-that-raises-over-16-000-for-rhabdomyosarcoma-research-this-childhood-cancer-awareness-monthhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdedicated-parents-lead-team-that-raises-over-16-000-for-rhabdomyosarcoma-research-this-childhood-cancer-awareness-monthDedicated parents lead team that raises over £16,000 for rhabdomyosarcoma research this Childhood Cancer Awareness MonthLooking back on childhood cancer awareness month, our Cancer Stories Officer, Lydia Brain, spoke to Ged and Julie Hussey about why they are fundraising for research into rhabdomyosarcoma as a legacy to their son, Jack. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-precision-medicine-a-reality-for-children-with-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-precision-medicine-a-reality-for-children-with-cancerMaking precision medicine a reality for children with cancerDr Sally George, a Clinical Research Fellow in the <a href=/our-research/research-divisions/division-of-clinical-studies/paediatric-solid-tumour-biology-and-therapeutics>Paediatric Solid Tumour Biology and Therapeutics Team</a>, explains why we are calling for genetic testing to personalise treatment for all children with cancer.https://www.icr.ac.uk/news-archive%2fexperts-call-for-genetic-testing-to-personalise-treatment-for-all-children-assessed-for-new-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fexperts-call-for-genetic-testing-to-personalise-treatment-for-all-children-assessed-for-new-cancer-treatmentsExperts call for genetic testing to personalise treatment for all children assessed for new cancer treatmentsAll children with cancer should have the genetic profile of their tumour comprehensively analysed when being considered for new treatments, say leading childhood cancer experts.https://www.icr.ac.uk/news-archive%2fscientists-make-important-breakthrough-in-understanding-our-immune-systemhttps://www.icr.ac.uk/news-archive%2fscientists-make-important-breakthrough-in-understanding-our-immune-systemScientists make important breakthrough in understanding our immune systemResearchers have discovered how a key element of our body’s response to diseases works, answering a long-standing and important question in the field of studies of the immune system.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2frevolutionising-radiotherapy-with-the-mr-linachttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2frevolutionising-radiotherapy-with-the-mr-linacRevolutionising radiotherapy with the MR LinacJoshua Freedman is a third-year PhD student in our Division of Radiotherapy and Imaging. In this blog post, he describes his research to help develop new approaches to support treatment planning and guidance on the <a href=/news-features/mr-linac>MR Linac</a>, a revolutionary new type of radiotherapy machine which is currently being applied for the first time in the UK on patients. https://www.icr.ac.uk/news-archive%2ffirst-patient-in-the-uk-receives-pioneering-new-form-of-radiotherapyhttps://www.icr.ac.uk/news-archive%2ffirst-patient-in-the-uk-receives-pioneering-new-form-of-radiotherapyFirst patient in the UK receives pioneering new form of radiotherapyThe ICR and the Royal Marsden have delivered the first ever treatment in the UK using a Magnetic Resonance Linear Accelerator (MR Linac) machine.https://www.icr.ac.uk/news-archive%2fcancer-researchers-family-and-friends-gather-to-celebrate-award-of-queen-s-regius-professorship-to-professor-johann-de-bonohttps://www.icr.ac.uk/news-archive%2fcancer-researchers-family-and-friends-gather-to-celebrate-award-of-queen-s-regius-professorship-to-professor-johann-de-bonoCancer researchers, family and friends gather to celebrate award of Queen’s Regius Professorship to Professor Johann de BonoColleagues from across cancer research, family and friends came together to celebrate and mark the achievements of the ICR's Professor Johann de Bono, as he delivered a celebratory lecture to mark his appointment as the ICR's first Regius Professor of Cancer Research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-cancer-in-your-coffeehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-cancer-in-your-coffeeScience Writing Prize 2018 – Cancer in your coffeeThe winner of the Mel Greaves Science Writing Prize 2018, recently graduated PhD student Alice King, looks at whether there is any scientific basis behind media headlines about the causes of cancer.https://www.icr.ac.uk/news-archive%2fhigh-levels-of-fertility-related-hormone-linked-to-increased-breast-cancer-risk-new-study-findshttps://www.icr.ac.uk/news-archive%2fhigh-levels-of-fertility-related-hormone-linked-to-increased-breast-cancer-risk-new-study-findsHigh levels of fertility-related hormone linked to increased breast cancer risk, new study findsHaving high levels of anti-Müllerian hormone (AMH) – a hormone that indicates the size of a woman’s ovarian reserve – before the menopause is associated with an increased risk of breast cancer, research suggests.https://www.icr.ac.uk/news-archive%2fscientists-dig-up-cancer-s-secrets-buried-in-gene-desertshttps://www.icr.ac.uk/news-archive%2fscientists-dig-up-cancer-s-secrets-buried-in-gene-desertsScientists dig up cancer’s secrets buried in ‘gene deserts’Scientists have found a way to uncover the secrets behind the development of cancer hidden away amongst vast ‘gene deserts’ in our DNA.https://www.icr.ac.uk/news-archive%2fgenetic-testing-could-pick-out-people-at-three-fold-increased-risk-of-bone-marrow-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-could-pick-out-people-at-three-fold-increased-risk-of-bone-marrow-cancerGenetic testing could pick out people at three-fold increased risk of bone marrow cancerAssessing DNA for areas of the genome linked to cancer risk could pick out some people with a three-fold increased risk of blood cancer, a new study suggests.https://www.icr.ac.uk/news-archive%2fviruses-show-new-promise-in-treating-cancerhttps://www.icr.ac.uk/news-archive%2fviruses-show-new-promise-in-treating-cancerViruses show new promise in treating cancer Viruses have shown renewed promise in the treatment for cancer, after new research has shown they retain their cancer-killing ability even when injected into the bloodstream.https://www.icr.ac.uk/news-archive%2ficr-supporters-launch-exciting-new-cycling-challenge-ride-of-lifehttps://www.icr.ac.uk/news-archive%2ficr-supporters-launch-exciting-new-cycling-challenge-ride-of-lifeICR supporters launch exciting new cycling challenge – Ride of LifeTop researchers waved off a group of our most dedicated supporters as they embarked on a new cycling challenge, which has already raised over £12,500 for the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-the-research-lab-to-the-clinic-and-back-again-exploring-an-early-career-in-prostate-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-the-research-lab-to-the-clinic-and-back-again-exploring-an-early-career-in-prostate-cancer-researchFrom the research lab to the clinic and back again – exploring an early career in prostate cancer researchThe career path in research can be quite standardised but Dr Adam Sharp took a slightly different route. Ben Kolb spoke with him about his career to date and how a major new funding award from the Prostate Cancer Foundation will help his career progress and, more importantly, help men with prostate cancer.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-when-your-parent-is-diagnosed-with-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-when-your-parent-is-diagnosed-with-cancerScience Writing Prize 2018 – When your parent is diagnosed with cancerHannah Brewer, a PhD student in the Division of Genetics and Epidemiology and runner-up in the Science Writing Prize 2018, shares the story of her mother's cancer diagnosis.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-awareness-month-how-we-re-bringing-genetic-testing-to-children-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-awareness-month-how-we-re-bringing-genetic-testing-to-children-with-cancerChildhood cancer awareness month: how we’re bringing genetic testing to children with cancerTo mark childhood cancer awareness month, Rose Wu introduces one of our pioneering programmes of childhood cancer research.https://www.icr.ac.uk/news-archive%2fimmunotherapy-could-offer-hope-for-some-men-with-aggressive-prostate-cancershttps://www.icr.ac.uk/news-archive%2fimmunotherapy-could-offer-hope-for-some-men-with-aggressive-prostate-cancersImmunotherapy could offer hope for some men with aggressive prostate cancersA group of men with especially aggressive prostate cancer may respond unusually well to immunotherapy, a major new study reports.https://www.icr.ac.uk/news-archive%2fartificial-intelligence-can-predict-how-cancers-will-evolve-and-spreadhttps://www.icr.ac.uk/news-archive%2fartificial-intelligence-can-predict-how-cancers-will-evolve-and-spreadArtificial intelligence can predict how cancers will evolve and spread Scientists have used artificial intelligence to predict how cancers will progress and evolve – so that doctors can design the most effective treatment for each patient. https://www.icr.ac.uk/news-archive%2fgenetic-weather-forecasting-could-predict-bowel-cancer-s-response-to-treatmenthttps://www.icr.ac.uk/news-archive%2fgenetic-weather-forecasting-could-predict-bowel-cancer-s-response-to-treatmentGenetic ‘weather forecasting’ could predict bowel cancer’s response to treatmentBlood tests could predict how long it takes until bowel cancer returns based on the same principle used in forecasting the weather, a new study has found.https://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-about-car-t-immunotherapy-for-non-hodgkin-lymphomahttps://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-decision-about-car-t-immunotherapy-for-non-hodgkin-lymphomaICR responds to NICE decision about CAR T immunotherapy for non-Hodgkin lymphomaThe ICR responds to draft decision not to recommend CAR T cell therapy for two types of non-Hodgkin lymphoma.https://www.icr.ac.uk/news-archive%2ficr-statement-on-allegations-of-bullyinghttps://www.icr.ac.uk/news-archive%2ficr-statement-on-allegations-of-bullyingICR statement on allegations of bullyingThe Institute of Cancer Research, London, is making the following statement regarding an investigation we have conducted into allegations of bullying by a staff member.https://www.icr.ac.uk/news-archive%2fnew-computer-prediction-tool-can-forecast-how-cancer-will-resist-drugs-before-they-are-given-to-patientshttps://www.icr.ac.uk/news-archive%2fnew-computer-prediction-tool-can-forecast-how-cancer-will-resist-drugs-before-they-are-given-to-patientsNew computer prediction tool can forecast how cancer will resist drugs before they are given to patientsSophisticated new computer software can be used to predict how cancers may respond to a new drug before it has ever been given to patients.https://www.icr.ac.uk/news-archive%2fdrug-combination-gives-exciting-results-in-ovarian-and-lung-cancer-in-early-trialhttps://www.icr.ac.uk/news-archive%2fdrug-combination-gives-exciting-results-in-ovarian-and-lung-cancer-in-early-trialDrug combination gives ‘exciting’ results in ovarian and lung cancer in early trialCombining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-eating-our-way-out-of-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-eating-our-way-out-of-cancerScience Writing Prize 2018 – Eating our way out of cancer In the second of our series of blog posts by the winner and runners-up of the Mel Greaves Science Writing Prize 2018, Dr Maxine Lam discusses how diet affects cancer.https://www.icr.ac.uk/news-archive%2fbreast-cancer-vulnerability-could-point-way-to-new-target-treatmentshttps://www.icr.ac.uk/news-archive%2fbreast-cancer-vulnerability-could-point-way-to-new-target-treatmentsBreast cancer vulnerability could point way to new target treatmentsResearchers have identified a vulnerability in some breast cancer cells of a certain type – called triple negative breast cancer – that could be exploited by future targeted drugs.https://www.icr.ac.uk/news-archive%2ftumour-%27diaries%27-track-cancers%27-evolutionary-history-and-predict-the-futurehttps://www.icr.ac.uk/news-archive%2ftumour-%27diaries%27-track-cancers%27-evolutionary-history-and-predict-the-futureTumour 'diaries' track cancers' evolutionary history and predict the futureScientists have developed a complex mathematical model that uses a snapshot of tumours’ genetic code to reach back in time, revealing its evolutionary history.https://www.icr.ac.uk/news-archive%2fdiscovery-club-members-hear-about-how-philanthropy-is-making-a-difference-to-people-with-cancerhttps://www.icr.ac.uk/news-archive%2fdiscovery-club-members-hear-about-how-philanthropy-is-making-a-difference-to-people-with-cancerDiscovery Club members hear about how philanthropy is making a difference to people with cancer Members of the ICR’s Discovery Club, our high-level giving club of visionary supporters, learned about the difference that philanthropy is making to people with cancer at an event in the impressive surroundings of Two Temple Place, in Central London.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-the-human-microbiome-and-cancer-friend-or-foehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fscience-writing-prize-2018-the-human-microbiome-and-cancer-friend-or-foeScience Writing Prize 2018 – The human microbiome and cancer: friend or foe?In the first of four blog posts by the winner and runners-up of the Mel Greaves Science Writing Prize 2018, Dr Samantha Nimalasena, runner-up, writes about how our own microbiomes and immune systems can be used to tackle cancer.https://www.icr.ac.uk/news-archive%2fnew-prostate-cancer-blood-test-detects-early-treatment-failurehttps://www.icr.ac.uk/news-archive%2fnew-prostate-cancer-blood-test-detects-early-treatment-failureNew prostate cancer blood test detects early treatment failureA new prostate cancer blood test can detect early signs that cancer is evolving to become resistant to treatment, a new study has found.https://www.icr.ac.uk/news-archive%2fincreased-risk-of-myeloid-blood-cancers-in-relatives-of-patientshttps://www.icr.ac.uk/news-archive%2fincreased-risk-of-myeloid-blood-cancers-in-relatives-of-patientsIncreased risk of myeloid blood cancers in relatives of patients​The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-will-a-clinical-trial-called-chhip-affect-the-future-of-prostate-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-will-a-clinical-trial-called-chhip-affect-the-future-of-prostate-radiotherapyHow will a clinical trial called CHHiP affect the future of prostate radiotherapy?Men with prostate cancer can now face a much less daunting course of radiotherapy thanks to the CHHiP clinical trial. Our Cancer Stories Officer, Lydia Brain, spoke with Derek Tomlin, a patient whose treatment was influenced by CHHiP, to find out how the trial could improve the experience of prostate cancer patients in the future.https://www.icr.ac.uk/news-archive%2fnew-super-resolution-mri-could-help-plan-radiotherapy-treatment-for-lung-cancerhttps://www.icr.ac.uk/news-archive%2fnew-super-resolution-mri-could-help-plan-radiotherapy-treatment-for-lung-cancerNew ‘super-resolution’ MRI could help plan radiotherapy treatment for lung cancerResearchers have developed a new technique to create high-quality 3D movies of tissues in the body as they move, which could help doctors plan radiotherapy treatment for cancers including lung tumours.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-need-to-recognise-the-full-spectrum-of-research-commercialisation-activities-in-academiahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-need-to-recognise-the-full-spectrum-of-research-commercialisation-activities-in-academiaWhy we need to recognise the full spectrum of research commercialisation activities in academiaThe Institute of Cancer Research is influential on a national scale through its excellence in building partnerships with industry. Science Information and Policy Officer, Roya Ziaie, attended a conference to hear how academics can drive social and economic benefits through these partnerships.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fengaging-the-public-about-the-promise-of-cancer-immunotherapy-at-science-museum-lateshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fengaging-the-public-about-the-promise-of-cancer-immunotherapy-at-science-museum-latesEngaging the public about the promise of cancer immunotherapy at Science Museum LatesOn the scale of hot topics, cancer immunotherapy is arguably the hottest. Interim Head of Editorial Projects, Dr Alison Halliday conveys how ICR scientists engaged a public audience about recent progress in this exciting field at an event at London’s Science Museum.https://www.icr.ac.uk/news-archive%2ficr-top-in-uk-for-commercial-earnings-for-the-second-year-runninghttps://www.icr.ac.uk/news-archive%2ficr-top-in-uk-for-commercial-earnings-for-the-second-year-runningICR top in UK for commercial earnings for the second year runningThe ICR has been ranked as the most successful higher education institution in the country at earning invention income from its research, for the second year running.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbig-bird-gal%C3%A1pagos-and-cancer-how-studying-nature-helps-us-understand-evolution-in-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbig-bird-gal%C3%A1pagos-and-cancer-how-studying-nature-helps-us-understand-evolution-in-cancerBig Bird, Galápagos and Cancer – How studying nature helps us understand evolution in cancerEvolution takes millions of years, except when it doesn’t. Science Communications Officer Graham Shaw considers the story of Darwin’s finches on the Galápagos Islands – a fascinating example of evolution in action, and the forces that also help cancer evade treatment. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fboys-one-step-closer-to-receiving-cancer-protecting-hpv-vaccine-after-committee-approvalhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fboys-one-step-closer-to-receiving-cancer-protecting-hpv-vaccine-after-committee-approvalBoys one step closer to receiving cancer-protecting HPV vaccine after committee approvalAn advisory committee has recommended that the government extend the HPV vaccine to boys in the UK. Dr Claire Hastings explains how HPV can cause cancer, why the recommendation for boys is significant and what still needs to happen before they begin to receive the vaccine.https://www.icr.ac.uk/news-archive%2fscientists-uncover-dna-shield-with-crucial-roles-in-normal-cell-division-the-immune-system-and-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-uncover-dna-shield-with-crucial-roles-in-normal-cell-division-the-immune-system-and-cancerScientists uncover DNA ‘shield’ with crucial roles in normal cell division, the immune system and cancerScientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.https://www.icr.ac.uk/news-archive%2ficr-part-of-major-medtech-commercialisation-programmehttps://www.icr.ac.uk/news-archive%2ficr-part-of-major-medtech-commercialisation-programmeICR part of major MedTech commercialisation programme The ICR is taking part in a major new initiative to drive forward world-class university commercialisation across the country, and encourage collaboration between higher education institutions. https://www.icr.ac.uk/news-archive%2ftiny-changes-in-prostate-cancer-blood-test-could-spot-early-warning-signs-of-treatment-not-workinghttps://www.icr.ac.uk/news-archive%2ftiny-changes-in-prostate-cancer-blood-test-could-spot-early-warning-signs-of-treatment-not-workingTiny changes in prostate cancer blood test could spot early warning signs of treatment not workingA test that can detect trace levels of tumour cells in the blood could help spot early signs of treatment not working for men with advanced prostate cancer.https://www.icr.ac.uk/news-archive%2ficr-holds-first-networking-event-for-scientists-and-commercial-partnershttps://www.icr.ac.uk/news-archive%2ficr-holds-first-networking-event-for-scientists-and-commercial-partnersICR holds first networking event for scientists and commercial partnersThe ICR’s Enterprise Unit has hosted our first ever event for our scientists to meet with possible future partners from the commercial sector.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ftraining-as-an-oncologist-in-a-top-quality-research-environment-an-icr-clinical-student-shares-their-experienceshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ftraining-as-an-oncologist-in-a-top-quality-research-environment-an-icr-clinical-student-shares-their-experiencesTraining as an oncologist in a top-quality research environment: an ICR clinical student shares their experiencesDuring this year's Teaching Week, Dr Sumeet Hindocha, an MSc student in Oncology and an NIHR Academic Clinical Fellow in Clinical Oncology at The Institute of Cancer Research, introduces some of the benefits and challenges of training simultaneously in a clinical and research environment. https://www.icr.ac.uk/news-archive%2ficr-celebrates-a-new-generation-of-cancer-researchershttps://www.icr.ac.uk/news-archive%2ficr-celebrates-a-new-generation-of-cancer-researchersICR celebrates a new generation of cancer researchersThe ICR award ceremony took place yesterday, to celebrate the hard work and achievements of our 2018 student graduates – and future generation of cancer researchers.https://www.icr.ac.uk/news-archive%2fbroadcaster-victoria-derbyshire-and-former-cancer-research-uk-ceo-sir-harpal-kumar-awarded-honorary-doctorateshttps://www.icr.ac.uk/news-archive%2fbroadcaster-victoria-derbyshire-and-former-cancer-research-uk-ceo-sir-harpal-kumar-awarded-honorary-doctoratesBroadcaster Victoria Derbyshire and former Cancer Research UK CEO Sir Harpal Kumar awarded honorary doctoratesThe ICR has invited three individuals to receive Honorary Degrees to recognise and celebrate their dedication and outstanding achievements in cancer research and awareness. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-former-students-are-leaders-in-cancer-research-across-the-uk-and-the-worldhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-former-students-are-leaders-in-cancer-research-across-the-uk-and-the-worldOur former students are leaders in cancer research across the UK and the worldA new regulatory system is challenging higher education institutions to demonstrate the value of the education they provide. For the ICR, argues Registrar Barbara Pittam, that value is shown by the impact of our students worldwide.https://www.icr.ac.uk/news-archive%2ficr-features-in-prestigious-report-on-university-business-collaborationhttps://www.icr.ac.uk/news-archive%2ficr-features-in-prestigious-report-on-university-business-collaborationICR features in prestigious report on university-business collaborationA new strategic partnership between The ICR, the pharma company Merck and Cancer Research UK features in a new report on effective collaborations between academics and industry partners.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-lgbt-representation-matters-in-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-lgbt-representation-matters-in-scienceWhy LGBT+ representation matters in scienceAs the ICR joins organisations worldwide in supporting LGBTSTEM Day, Conor McKeever, our Science Communications Officer, shares his thoughts on the importance of making science inclusive.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-nhs-at-70-how-three-icr-discoveries-have-helped-improve-the-lives-of-people-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-nhs-at-70-how-three-icr-discoveries-have-helped-improve-the-lives-of-people-with-cancerThe NHS at 70 – how three ICR discoveries have helped improve the lives of people with cancerThe NHS turns 70 this year, and we’re proud to be involved with three important research discoveries that have been highlighted in the #NHS70 campaign as having transformed the lives of cancer patients. https://www.icr.ac.uk/news-archive%2fnew-triple-therapy-could-boost-treatment-and-prevent-relapse-of-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2fnew-triple-therapy-could-boost-treatment-and-prevent-relapse-of-advanced-breast-cancerNew ‘triple therapy’ could boost treatment and prevent relapse of advanced breast cancerTreating advanced breast cancer with three drugs instead of one could boost the effectiveness of treatment and stop tumours developing resistance, a new study reports.https://www.icr.ac.uk/news-archive%2fteamwork-between-cells-fuels-aggressive-childhood-brain-tumourhttps://www.icr.ac.uk/news-archive%2fteamwork-between-cells-fuels-aggressive-childhood-brain-tumourTeamwork between cells fuels aggressive childhood brain tumourScientists have discovered that cancerous cells in an aggressive type of childhood brain tumour work together to infiltrate the brain, and this finding could ultimately lead to much needed new treatments, according to a new study.https://www.icr.ac.uk/news-archive%2fimmunotherapy-drug-for-skin-disease-could-boost-hormone-treatment-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fimmunotherapy-drug-for-skin-disease-could-boost-hormone-treatment-for-prostate-cancerImmunotherapy drug for skin disease could boost hormone treatment for prostate cancerA new form of immunotherapy reactivates the response to hormone treatment in advanced prostate cancer, a study in mice and human prostate cancer cells has found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2foutsmarting-cancer-staying-one-step-ahead-of-drug-resistancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2foutsmarting-cancer-staying-one-step-ahead-of-drug-resistanceOutsmarting cancer – staying one step ahead of drug resistanceCancer drug resistance is one of the biggest challenges of 21st century medicine – and a challenge that our researchers are facing up to. Rose Wu introduces how some of our researchers are aiming to outsmart cancer by tackling drug resistance.https://www.icr.ac.uk/news-archive%2ficr-and-partners-take-centre-stage-at-major-international-conferenceshttps://www.icr.ac.uk/news-archive%2ficr-and-partners-take-centre-stage-at-major-international-conferencesICR and partners take centre stage at major international conferencesClinical trials of promising cancer treatments discovered or developed at the ICR were among the highlights at this year’s American Society of Clinical Oncology (ASCO) meeting, the biggest international clinical cancer research gathering of the year.https://www.icr.ac.uk/news-archive%2fprofessor-mel-greaves-awarded-prestigious-society-of-memorial-sloan-kettering-prize-for-contributions-to-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fprofessor-mel-greaves-awarded-prestigious-society-of-memorial-sloan-kettering-prize-for-contributions-to-childhood-cancerProfessor Mel Greaves awarded prestigious Society of Memorial Sloan Kettering Prize for contributions to childhood cancerThe ICR’s Professor Mel Greaves has been awarded a prestigious prize from the Memorial Sloan Kettering Cancer Center in New York for his ground-breaking research and expertise in childhood leukaemia.https://www.icr.ac.uk/news-archive%2fhigher-bmi-is-associated-with-a-lower-risk-of-breast-cancer-before-the-menopausehttps://www.icr.ac.uk/news-archive%2fhigher-bmi-is-associated-with-a-lower-risk-of-breast-cancer-before-the-menopauseHigher BMI is associated with a lower risk of breast cancer before the menopauseHaving a higher body mass index (BMI) at a younger age is associated with a decreased risk of developing breast cancer before the menopause, major new research funded by Breast Cancer Now and other collaborators has found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-secrets-of-successful-industry-academic-partnershipshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-secrets-of-successful-industry-academic-partnershipsThe secrets of successful industry-academic partnershipsThe Institute of Cancer Research, London – the world’s leading academic centre for drug discovery – has announced a major new strategic partnership with science and technology company Merck, and Cancer Research UK. Here Dr Angela Kukula, Director of Enterprise at The Institute of Cancer Research (ICR) – and responsible for its interactions with industry – gives some tips on what makes a good collaboration between industry and academic researchers.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-research-is-making-radiotherapy-smarter-and-kinder-for-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-research-is-making-radiotherapy-smarter-and-kinder-for-cancer-patientsHow our research is making radiotherapy smarter and kinder for cancer patientsWe’ve come a long way from the early days of radiotherapy. Thanks to years of research, the treatment cures many patients, and we’re now working on ways to make it smarter, kinder and more convenient for them. https://www.icr.ac.uk/news-archive%2ficr-ranked-among-the-world-s-best-research-institutions-for-industry-collaborationhttps://www.icr.ac.uk/news-archive%2ficr-ranked-among-the-world-s-best-research-institutions-for-industry-collaborationICR ranked among the world’s best research institutions for industry collaborationThe ICR has ranked in the top 30 higher education institutions in the world for research in an independent evaluation funded by the European Commission.https://www.icr.ac.uk/news-archive%2fgene-testing-could-identify-men-with-prostate-cancer-who-may-benefit-from-immunotherapyhttps://www.icr.ac.uk/news-archive%2fgene-testing-could-identify-men-with-prostate-cancer-who-may-benefit-from-immunotherapyGene testing could identify men with prostate cancer who may benefit from immunotherapyScientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.https://www.icr.ac.uk/news-archive%2fblocking-energy-production-could-help-treat-lung-cancer-where-chemotherapy-has-limited-effecthttps://www.icr.ac.uk/news-archive%2fblocking-energy-production-could-help-treat-lung-cancer-where-chemotherapy-has-limited-effectBlocking energy production could help treat lung cancer where chemotherapy has limited effect Targeting an enzyme that helps cells to generate energy could trigger cell death and be a way to treat some forms of lung cancer, even where the effect of chemotherapy is limited.https://www.icr.ac.uk/news-archive%2fprostate-cancer-dna-test-identifies-men-with-six-fold-increased-riskhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-dna-test-identifies-men-with-six-fold-increased-riskProstate cancer DNA test identifies men with six-fold increased riskA major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2flight-sound-image!-photoacoustic-imaging-for-cancer-treatmenthttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2flight-sound-image!-photoacoustic-imaging-for-cancer-treatmentLight, sound… image! Photoacoustic imaging for cancer treatmentPhotoacoustic imaging is an emergent technology that uses a mixture of light and sound to generate images. PhD student Dr Márcia Costa, from the ICR’s Department of Radiotherapy and Imaging, gives an introduction to this exciting technology – and to our work to develop it for use in cancer treatment.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-abiraterone-as-first-line-treatment-for-advanced-prostate-cancerThe ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancerThe Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (brand name Zytiga) will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS. https://www.icr.ac.uk/news-archive%2fstunting-cell-antennae-could-make-cancer-drugs-work-againhttps://www.icr.ac.uk/news-archive%2fstunting-cell-antennae-could-make-cancer-drugs-work-againStunting cell ‘antennae’ could make cancer drugs work againScientists have uncovered a completely new way to make cancers sensitive to treatment – by targeting antenna-like structures on cells.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-how-we-re-using-the-immune-system-to-beat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-how-we-re-using-the-immune-system-to-beat-cancerImmunotherapy: How we’re using the immune system to beat cancerImmunotherapy is the latest revolution in cancer treatment. Bold claims have been made about its potential – but should you believe the headlines? And how does it work?https://www.icr.ac.uk/news-archive%2fasco-2018-major-trial-is-first-to-show-benefits-of-immunotherapy-in-some-men-with-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fasco-2018-major-trial-is-first-to-show-benefits-of-immunotherapy-in-some-men-with-prostate-cancerASCO 2018: Major trial is first to show benefits of immunotherapy in some men with prostate cancerA major clinical trial has become the first to show benefits of immunotherapy in prostate cancer – for some men with advanced, otherwise untreatable disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2018-world-s-largest-cancer-conference-seeks-to-expand-the-reach-of-precision-medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2018-world-s-largest-cancer-conference-seeks-to-expand-the-reach-of-precision-medicineASCO 2018: World’s largest cancer conference seeks to expand the reach of precision medicineLeading cancer researchers from across the world are travelling to Chicago for the ASCO 2018 Annual Meeting, the world’s biggest cancer conference. The conference is aiming to ensure as many patients as possible benefit from latest advances in precision medicine – and ICR researchers are at the forefront. https://www.icr.ac.uk/news-archive%2facclaimed-opera-singers-come-together-to-support-the-icrhttps://www.icr.ac.uk/news-archive%2facclaimed-opera-singers-come-together-to-support-the-icrAcclaimed opera singers come together to support the ICRA world-class group of opera singers united at the intimate setting of Spencer House this week to celebrate and support the ICR.https://www.icr.ac.uk/news-archive%2fleading-uk-scientist-reveals-likely-cause-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fleading-uk-scientist-reveals-likely-cause-of-childhood-leukaemiaLeading UK scientist reveals likely cause of childhood leukaemiaA major new analysis reveals for the first time the likely cause of most cases of childhood leukaemia and that the disease may be preventable.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-childhood-leukaemia-become-a-thing-of-the-pasthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-childhood-leukaemia-become-a-thing-of-the-pastCould childhood leukaemia become a thing of the past?The ICR’s Professor Mel Greaves has revealed the likely cause of the most common type of childhood leukaemia, and that it might be preventable. Dr Claire Hastings explains the research findings, and what it means for children and their families.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-fundraiser-named-nhs-hero-for-supporting-icr-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fchildhood-cancer-fundraiser-named-nhs-hero-for-supporting-icr-researchChildhood cancer fundraiser named NHS Hero for supporting ICR researchLynn Lucas co-founded the Chris Lucas Trust in memory of her son, who died from cancer of the soft tissues. Now she has received the NHS Hero Award for Fundraiser of the Year for her continued support for The Institute of Cancer Research, London. Lydia Brain, our Cancer Stories Officer, spoke with Lynn about her achievements and also met the ICR researcher whose lab has been supported for so long by the charity.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fhow-ai-technologies-can-learn-how-to-spot-and-visualise-cancerhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fhow-ai-technologies-can-learn-how-to-spot-and-visualise-cancerHow AI technologies can learn how to spot and visualise cancerProfessor Nandita de Souza, Professor of Translational Imaging at the ICR, argues that Deep Mind-style artificial intelligence is set to have a huge impact on the imaging technologies used to diagnose, monitor and treat cancer.https://www.icr.ac.uk/news-archive%2fstudy-picks-out-children-with-incurable-brain-cancer-who-could-benefit-from-adult-therapyhttps://www.icr.ac.uk/news-archive%2fstudy-picks-out-children-with-incurable-brain-cancer-who-could-benefit-from-adult-therapyStudy picks out children with incurable brain cancer who could benefit from adult therapyChildren with incurable brain tumours could benefit from potentially life-extending treatment if genetic testing was used to personalise therapy as it is in many adults, major new research reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-long-term-impact-of-cancer-enabling-patients-to-thrive-and-not-just-survivehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-long-term-impact-of-cancer-enabling-patients-to-thrive-and-not-just-surviveThe long term impact of cancer; enabling patients to thrive and not just surviveDr Olga Husson is researching the long-term impact of cancer on individuals who were treated for bowel cancer. Our Cancer Stories Officer, Lydia Brain, spoke to her and bowel cancer advocate Cara Hoofe on the importance of more research and better follow-up treatment pathways for patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-real-impact-on-the-lives-of-people-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-real-impact-on-the-lives-of-people-with-cancerMaking a real impact on the lives of people with cancerThe Institute of Cancer Research, London, is one of the world's most influential cancer research institutes. Our Internal Communications Manager Rose Wu writes about how we've helped to transform our understanding of cancer and how it can be treated in ever smarter, kinder ways to improve patient lives.https://www.icr.ac.uk/news-archive%2fscientists-identify-cause-of-resistance-to-breakthrough-breast-and-ovarian-cancer-drughttps://www.icr.ac.uk/news-archive%2fscientists-identify-cause-of-resistance-to-breakthrough-breast-and-ovarian-cancer-drugScientists identify cause of resistance to breakthrough breast and ovarian cancer drugThe study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcommunicating-cancer-research-my-experience-as-an-intern-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcommunicating-cancer-research-my-experience-as-an-intern-at-the-icrCommunicating cancer research: my experience as an intern at the ICRThe ICR’s Communications Directorate is responsible for maintaining our website and social media channels, both vital platforms for promoting our world-class research. Solomon Brown, our first ever Digital Communications Intern, gives a personal view on his six months at the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-test-for-ovarian-cancer-mutation-heads-into-clinical-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-test-for-ovarian-cancer-mutation-heads-into-clinical-trialsNew test for ovarian cancer mutation heads into clinical trialsToday, 8 May 2018, is the World Ovarian Cancer Day – and to mark the occasion our Communications Administrator, Tilly Haynes, spoke with Dr Rachael Natrajan and Dr Saira Khalique about innovative research which is driving the treatment of gynaecological cancers in the right direction.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fhow-many-mutations-does-it-takehttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fhow-many-mutations-does-it-takeHow many mutations does it take?For some time before we had the benefit of cancer genomics, it was generally believed that for a cancer to disseminate and become potentially lethal, it would have had to accrue several mutations that, collectively, would provide a kind of ‘full house’ for malignancy.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fncri-2015-evolutionary-tales-in-leukaemiahttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fncri-2015-evolutionary-tales-in-leukaemiaNCRI 2015 – Evolutionary tales in leukaemiaThis post is a synopsis of the lecture I gave at the National Cancer Research Institute (NCRI) conference in Liverpool on the 2nd November 2015 – minus some anecdotes about mentors and colleagues – you needed to be there to hear those.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fdrivers-and-passengers-who-s-in-chargehttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fdrivers-and-passengers-who-s-in-charge‘Drivers’ and ‘Passengers’: who’s in charge?Genome sequencing has revealed that a plethora of gene mutations can co-exist in individual cancers: thousands in some cases. Based on Darwinian theory, we assume that whilst most are irrelevant, buried in the background is a modest number of mutations (perhaps counted in single figures) that are functionally active in a way that contributes to cancer clonal development. https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fpredicting-evolutionary-futureshttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fpredicting-evolutionary-futuresPredicting evolutionary futuresOne of the striking achievements of cancer genomics and its allied bioinformatics has been to construct phylogenetic trees depicting the trajectories of sub-clones in cancers and their ancestral relationships. It’s like taking a peek back in time at the origin and prior evolutionary history of the malignancy.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fcancer-evolution-it-s-in-the-blood!https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fcancer-evolution-it-s-in-the-blood!Cancer Evolution – It’s in the Blood!In the first of our guest blog posts, Dr. Marco Gerlinger highlights some of the remarkable developments being made in ctDNA analysis, a powerful new technology with the potential to transform tumour predictions and treatment outcomes.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fcancer-versus-immunological-diversityhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fcancer-versus-immunological-diversityCancer versus immunological diversityWe are seeing a renaissance of optimism about immunotherapy for cancer – after many years of disappointment. Patients with advanced and clinically intransigent lung cancers and melanomas, treated in early clinical trials with antibodies to immune checkpoint inhibitors PD-1 and CTLA-4, have been surviving longer than would previously have been expected.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fconvergence-in-tumour-evolution-singing-the-same-tunehttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fconvergence-in-tumour-evolution-singing-the-same-tuneConvergence in tumour evolution: singing the same tuneCancer clone evolution, just like evolutionary speciation, is characterised by an extraordinary diversity of descendants derived from a common ancestor. Yet, paradoxically, some evolutionary trajectories are convergent on a common phenotype.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbig-bang-cancer-growthhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbig-bang-cancer-growth“Big Bang” cancer growthIn the second of our guest blog posts, Dr Andrea Sottoriva describes how a comparison between the expanding universe and the growth of cancers led him to formulate his “Big Bang” theory of tumour growth – a model with novel treatment implications.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fways-of-escapehttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fways-of-escapeWays of escapeCancers are life threatening because they migrate within the body, spreading far from their point of origin. This process – metastasis – hijacks tissues and compromises their critical functions.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2flessons-from-cancer-risk-in-animalshttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2flessons-from-cancer-risk-in-animalsLessons from cancer risk in animalsThink for a moment about a young girl, four years old, diagnosed with acute lymphoblastic leukaemia (ALL). This is not so unusual, and in fact, ALL is the most commonly diagnosed childhood cancer. However, only two years earlier, this young girl was also diagnosed with a grade II glioma in her brain, treated by surgical resection with no chemotherapy or radiation exposure.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fdo-mutations-cause-cancer-(or-the-dog-that-did-not-bark)https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fdo-mutations-cause-cancer-(or-the-dog-that-did-not-bark)Do mutations cause cancer? (or the dog that did not bark)Evolution is change over time, and it is well-accepted that cancers evolve through the stepwise accumulation of somatic mutations. Logically, mutations ‘cause’ cancer, and therefore, simplistically, the key to preventing cancer could be to avoid mutations.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fwhich-cancers-are-most-survivable-and-whyhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fwhich-cancers-are-most-survivable-and-whyWhich cancers are most survivable and why?Cancer is not a death sentence; there is a great deal of difference between a prostate and a pancreatic cancer diagnosis, and even differences between subtypes of cancer within any particular organ.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fhow-cancer-outsmarts-multicellularityhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fhow-cancer-outsmarts-multicellularityHow cancer outsmarts multicellularityThe transition from unicellularity to multicellularity was one of the most significant advances in the evolution of life on Earth. This allowed adaptation to a wide range of new ecological niches, rapidly accelerating the pace of evolution and creating an explosion of diversity across the plant, animal and fungal kingdoms.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2funderstanding-the-mutations-that-drive-myeloma-a-cancer-of-the-bone-marrowhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2funderstanding-the-mutations-that-drive-myeloma-a-cancer-of-the-bone-marrowUnderstanding the mutations that drive myeloma, a cancer of the bone marrowPhD student Phuc Hoang's work is exploring the genetic mutations that lead to development of the cancer multiple myeloma. Here, fellow PhD student Molly Went writes with Phuc about the work, and its implications for understanding and treating the disease.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2ftime-for-a-new-perspective-on-cancerhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2ftime-for-a-new-perspective-on-cancerTime for a new perspective on cancer?https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-what-has-evolution-got-to-do-with-cancerhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-what-has-evolution-got-to-do-with-cancerBackground: What has evolution got to do with cancer?What exactly is cancer? Can we capture its biological essence in a few words or a phrase? For the ancient Greeks, it was a manifestation of black bile, or constitutional melancholy. https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-the-principles-of-evolutionary-natural-selection-in-cancerhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-the-principles-of-evolutionary-natural-selection-in-cancerBackground: The principles of evolutionary natural selection in cancerCharles Darwin had it right, despite knowing nothing of genetics or the basis of inheritable variation.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-darwin-s-branching-tree-of-evolutionary-phylogenyhttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fbackground-darwin-s-branching-tree-of-evolutionary-phylogenyBackground: Darwin’s branching tree of evolutionary phylogenySince the turn of this century, cancer genomics has strongly endorsed the Darwinian view of cancer biology. Interrogation of the genomes of single cancer cells and multi-regional small biopsies of tumours have allowed us to construct evolutionary histories, or phylogenies, of cancer clones.https://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fwhen-normal-is-the-favoured-typehttps://www.icr.ac.uk/our-research%2fcentres-and-collaborations%2fcentres-at-the-icr%2fcentre-for-evolution-and-cancer%2fthe-darwin-cancer-blog%2fpage-details%2fwhen-normal-is-the-favoured-typeWhen normal is the favoured typeBefore we discuss cancer, let’s consider other sets of nasty characters – criminals, Nazis and terrorists. We know that the best way to limit crime is to create neighbourhoods that provide opportunities for education and jobs – a healthy infrastructure disfavours the criminal phenotype.https://www.icr.ac.uk/news-archive%2fmajor-study-gives-vital-new-understandings-of-how-cells-dividehttps://www.icr.ac.uk/news-archive%2fmajor-study-gives-vital-new-understandings-of-how-cells-divideMajor study gives vital new understandings of how cells divideThe ground-breaking research used mathematical models and pain-staking experiments to clarify the role of a key phase of cell division.https://www.icr.ac.uk/news-archive%2ftargeting-chemotherapy-with-genetic-testing-provides-effective-treatment-for-women-with-aggressive-breast-cancerhttps://www.icr.ac.uk/news-archive%2ftargeting-chemotherapy-with-genetic-testing-provides-effective-treatment-for-women-with-aggressive-breast-cancerTargeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancerWomen with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmore-on-chemical-probes-from-indiana-jones-to-open-sciencehttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmore-on-chemical-probes-from-indiana-jones-to-open-scienceMore on chemical probes – from Indiana Jones to open scienceProfessor Paul Workman reflects on what a swashbuckling archaeologist can teach us about the importance of choosing a chemical probe wisely – and how new initiatives to guide the selection can make cancer research more robust.https://www.icr.ac.uk/news-archive%2fresearchers-find-five-sub-types-of-the-brain-cancer-gliomahttps://www.icr.ac.uk/news-archive%2fresearchers-find-five-sub-types-of-the-brain-cancer-gliomaResearchers find five sub-types of the brain cancer gliomaThe findings come from the largest ever genetic study its kind on glioma and could help us understand the biological mechanisms that trigger the disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-time-out-from-cancer-research-to-meet-the-future-kinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-time-out-from-cancer-research-to-meet-the-future-kingTaking time out from cancer research to meet the future KingA team representing The Institute of Cancer Research, London, recently visited Buckingham Palace to receive a major honour from Prince Charles. Our Head of Media Relations, Ben Kolb, met two PhD students from the group to find out more about their experience of the day and life studying at the ICR.https://www.icr.ac.uk/news-archive%2fgood-luck-to-our-teamicr-2018-london-marathon-teamhttps://www.icr.ac.uk/news-archive%2fgood-luck-to-our-teamicr-2018-london-marathon-teamGood luck to our #teamICR 2018 London marathon teamThis year 22 people are joining #teamICR to run the London marathon to raise funds for cancer research. We wish all of our runners the best of luck!https://www.icr.ac.uk/news-archive%2fscans-could-guide-drug-treatment-in-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscans-could-guide-drug-treatment-in-breast-cancerScans could guide drug treatment in breast cancerA new scan could help doctors to spot when women with breast cancer stop responding to targeted drugs.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fputting-the-person-in-personalised-medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fputting-the-person-in-personalised-medicinePutting the person in personalised medicineDr Sam Dick, our Science Information and Policy Officer, considers the importance of assessing a patient’s views about their quality of life for the future of personalised medicine.https://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-given-aacr-award-for-outstanding-achievementhttps://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-given-aacr-award-for-outstanding-achievementProfessor Johann de Bono given 2018 AACR award for outstanding achievementThe ICR's Professor Johann de Bono has been chosen to receive the 2018 AACR–Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research.https://www.icr.ac.uk/news-archive%2fscientists-uncover-80-potential-lines-of-attack-against-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-uncover-80-potential-lines-of-attack-against-prostate-cancerScientists uncover 80 potential lines of attack against prostate cancerScientists have identified 80 molecular weaknesses in prostate cancer that could be targeted by drugs – in the largest, most comprehensive study ever conducted into the genes that drive the disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-attending-the-2018-aacr-annual-meeting-tomorrowhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-attending-the-2018-aacr-annual-meeting-tomorrowICR researchers attending the 2018 AACR Annual Meeting tomorrowAs many of our researchers attend the AACR Annual Meeting – ‘Driving innovative cancer science to patient care’ - between 14th - 18th April in Chicago, here’s a snapshot of the exciting science they will be presenting.https://www.icr.ac.uk/news-archive%2ficr-hosts-discussion-on-gender-equality-for-uk-research-instituteshttps://www.icr.ac.uk/news-archive%2ficr-hosts-discussion-on-gender-equality-for-uk-research-institutesICR hosts discussion on gender equality for UK research institutesThe Institute of Cancer Research, London, hosted a conference, specifically for research institutes, on how to improve gender equality within the workplace in Chelsea at the end of March.https://www.icr.ac.uk/news-archive%2fresearchers-discover-40-genes-involved-in-early-development-of-myelomahttps://www.icr.ac.uk/news-archive%2fresearchers-discover-40-genes-involved-in-early-development-of-myelomaResearchers discover 40 genes involved in early development of myelomaResearchers have revealed 40 genes involved in the development of myeloma, increasing our understanding of the complex genetics behind the incurable blood cancer.https://www.icr.ac.uk/news-archive%2ftwo-single-letter-dna-changes-could-raise-risk-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2ftwo-single-letter-dna-changes-could-raise-risk-of-childhood-leukaemiaTwo single-letter DNA changes could raise risk of childhood leukaemiaThe team analysed genetic data from almost 2,500 people with, and more than 14,500 without, the disease to identify the differences that are associated with a greater risk.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseeing-the-future-of-radiotherapy-in-the-mr-linachttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseeing-the-future-of-radiotherapy-in-the-mr-linacSeeing the future of radiotherapy in the MR LinacWe are currently calibrating a revolutionary new type of radiotherapy machine, which is set to transform cancer treatment by allowing radiation to be aimed at tumours with extreme precision. The ICR’s Helen Craig experienced the MR Linac from the inside.https://www.icr.ac.uk/news-archive%2fscientists-map-the-genetic-evolution-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fscientists-map-the-genetic-evolution-of-childhood-leukaemiaScientists map the genetic evolution of childhood leukaemia The key genetic events responsible for initiating the early stages of a type of childhood leukaemia have been identified by ICR scientists.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-darwin%27s-finches-may-help-us-treat-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-darwin%27s-finches-may-help-us-treat-cancerScience Writing Prize 2017 – How Darwin's finches may help us treat cancerIn his winning entry to the ICR's 2017 Science Writing Competition, Dr Benjamin Hunter discussed why an understanding of evolutionary biology matters to cancer researchers – and how the key principles of Darwin's great theory can be applied to create new ways of monitoring and treating cancer.https://www.icr.ac.uk/news-archive%2flung-cancer-drug-shows-promise-as-targeted-therapy-for-thousands-with-breast-cancerhttps://www.icr.ac.uk/news-archive%2flung-cancer-drug-shows-promise-as-targeted-therapy-for-thousands-with-breast-cancerLung cancer drug shows promise as targeted therapy for thousands with breast cancerA drug used in treating non-small cell lung cancer could offer a new targeted therapy for thousands of breast cancer patients, following the discovery that it can kill breast cancer cells with a particular genetic defect.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2faccelerating-returns-sequencing-our-genomeshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2faccelerating-returns-sequencing-our-genomesScience Writing Prize 2017 – Accelerating returns: sequencing our genomesIn his runner-up entry to 2017's Science Writing Competition, Matthew Beaney reflects on the speed of technological change and it's enormous impact on DNA sequencing.https://www.icr.ac.uk/news-archive%2f%27virtual-tumours%27-predict-success-of-tumour-heating-sound-waveshttps://www.icr.ac.uk/news-archive%2f%27virtual-tumours%27-predict-success-of-tumour-heating-sound-waves'Virtual tumours' predict success of tumour-heating sound wavesThe technology uses targeted sounds waves to destroy cancer cells and could be extra beneficial when used in combination with radiotherapy.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-be-satisfied-with-progress-on-children-s-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcan-we-be-satisfied-with-progress-on-children-s-cancerCan we be satisfied with progress on children’s cancer?A new analysis of the impact of European regulations designed to bring through new treatments for children with cancer has expressed disappointment at the speed of progress. The ICR’s Dr Eva Sharpe finds out more.https://www.icr.ac.uk/news-archive%2fwomen-report-fewer-adverse-side-effects-from-partial-or-reduced-breast-radiotherapy-reveals-major-studyhttps://www.icr.ac.uk/news-archive%2fwomen-report-fewer-adverse-side-effects-from-partial-or-reduced-breast-radiotherapy-reveals-major-studyWomen report fewer adverse side-effects from partial or reduced breast radiotherapy, reveals major studyThe latest results from a large study indicates over half of patients do not report moderate or marked side-effects at any point and that most side-effects reduce over time. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fdevelopment-of-cancer---the-luck-of-the-drawhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fdevelopment-of-cancer---the-luck-of-the-drawScience Writing Prize 2017 – Development of cancer: the luck of the draw?Dr Samantha Nimalasena is an oncology registrar at the ICR. In her runner-up entry to 2017's Science Writing Competition, she describes the difficulties in conveying the message that the risk of developing cancer is dependent on probabilities.https://www.icr.ac.uk/news-features%2flatest-features%2fsix-discoveries-that-greatly-improved-the-treatment-of-ovarian-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fsix-discoveries-that-greatly-improved-the-treatment-of-ovarian-cancerSix steps forward we've made in ovarian cancer treatmentOver the last few decades, our research into ovarian cancer has led to discoveries that greatly impact on its treatment. Today, this research is giving women with ovarian cancer a better quality of life and more time with their loved ones. Here are six of our discoveries.https://www.icr.ac.uk/news-features%2flatest-features%2fwinners-of-the-icr%27s-science-photography-and-imaging-competition-2017-announcedhttps://www.icr.ac.uk/news-features%2flatest-features%2fwinners-of-the-icr%27s-science-photography-and-imaging-competition-2017-announcedWinners of the ICR's Science Photography and Imaging Competition 2017 announcedThe annual competition, open to all researchers at the ICR and The Royal Marsden, aims to showcase the beauty often found in scientific and medical images and how they can be used to tell a story.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-power-of-precision-medicine-in-cancer-drug-discovery-and-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-power-of-precision-medicine-in-cancer-drug-discovery-and-treatmentThe power of precision medicine in cancer drug discovery and treatmentDr Olivia Rossanese is finding new ways to target cancer with drugs and previously, at GlaxoSmithKline, was in the team that discovered the targeted cancer treatment, and BRAF inhibitor, dabrafenib. Our Communications Administrator, Tilly Haynes, heard what she had to say about the future of precision medicine at The Economist’s ‘War on Cancer’ event.https://www.icr.ac.uk/news-archive%2fscientists-discover-exciting-new-line-of-attack-for-hard-to-treat-breast-cancershttps://www.icr.ac.uk/news-archive%2fscientists-discover-exciting-new-line-of-attack-for-hard-to-treat-breast-cancersScientists discover exciting new line of attack for hard-to-treat breast cancersThe identified gene was one of 37 new genes that the researchers found triple-negative breast cancers were 'addicted to'.https://www.icr.ac.uk/news-archive%2fscientists-find-treasure-trove-of-110-genes-linked-to-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-find-treasure-trove-of-110-genes-linked-to-breast-cancerScientists find treasure trove of 110 genes linked to breast cancerThe study used a pioneering genetic technique to analyse maps of DNA regions linked to an inherited risk of breast cancer and find the actual genes involved.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-tackling-gender-inequality-in-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-tackling-gender-inequality-in-scienceHow we’re tackling gender inequality in scienceProfessor Jessica Downs is our Professor of Epigenetics and Genome Stability, and an advocate for gender equality at the ICR. To coincide with International Women’s Day, here she gives a personal view on promoting equality for women in science.https://www.icr.ac.uk/news-archive%2fdrug-that-targets-on-switch-in-cancer-cells-moves-one-step-closerhttps://www.icr.ac.uk/news-archive%2fdrug-that-targets-on-switch-in-cancer-cells-moves-one-step-closerDrug that targets ‘on switch’ in cancer cells moves one step closerThe new targeted therapy which could combat drug resistance has been found to be safe in early trials, allowing it to move to the next stage of development.https://www.icr.ac.uk/news-archive%2fnew-class-of-drugs-effective-against-one-of-the-toughest-cancers-to-treathttps://www.icr.ac.uk/news-archive%2fnew-class-of-drugs-effective-against-one-of-the-toughest-cancers-to-treatNew class of drugs effective against one of the toughest cancers to treatScientists have discovered a promising new type of therapy for bile duct cancer – a deadly disease which in most cases is inoperable and incurable.https://www.icr.ac.uk/news-archive%2fnew-blood-test-could-quickly-predict-if-the-drug-palbociclib-will-help-breast-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-blood-test-could-quickly-predict-if-the-drug-palbociclib-will-help-breast-cancer-patientsNew blood test could quickly predict if the drug palbociclib will help breast cancer patientsScientists say the test could detect in two to three weeks whether the drug is working, compared to the two to three months that it currently takes.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-rare-cancers-deserve-a-greater-focus-and-a-more-targeted-approachhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-rare-cancers-deserve-a-greater-focus-and-a-more-targeted-approachWhy rare cancers deserve a greater focus and a more targeted approachThe theme of Rare Disease Day 2018 is research. We asked Professor Winette van der Graaf, Professor of Personalised Oncology at The Institute of Cancer Research, London, to share her experiences of research into rare cancers and how this can improve outcomes for patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdo-academic-organisations-make-enough-money-from-their-inventionshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdo-academic-organisations-make-enough-money-from-their-inventionsDo academic organisations make enough money from their inventions?Dr Angela Kukula asks whether academic organisations should gain financially from lucrative discoveries – and proposes some solutions to the high costs of new cancer drugs.https://www.icr.ac.uk/news-archive%2fcelebrating-courageous-patients-and-research-successhttps://www.icr.ac.uk/news-archive%2fcelebrating-courageous-patients-and-research-successCelebrating courageous patients and research successDiscovery Club members at our annual Discovery Club reception recently heard first-hand about ovarian cancer treatment from cancer survivor Sue Vincent.https://www.icr.ac.uk/news-archive%2fgrowing-replica-tumours-in-the-lab-could-personalise-drug-treatment-for-each-patienthttps://www.icr.ac.uk/news-archive%2fgrowing-replica-tumours-in-the-lab-could-personalise-drug-treatment-for-each-patientGrowing replica tumours in the lab could personalise drug treatment for each patientThe exciting new technique involves growing ‘mini tumours’ from biopsy samples – and could help end reliance on trial and error in selecting cancer treatments.https://www.icr.ac.uk/news-archive%2fcancer-researchers-visit-the-palace-to-receive-major-prize-for-pioneering-precision-medicine-discoverieshttps://www.icr.ac.uk/news-archive%2fcancer-researchers-visit-the-palace-to-receive-major-prize-for-pioneering-precision-medicine-discoveriesCancer researchers visit the Palace to receive major prize for pioneering precision medicine discoveriesThe award acknowledges the ICR's outstanding contribution to the discovery of new cancer drugs – including pioneering the transition from one-size-fits-all chemotherapy to targeted drug treatment.https://www.icr.ac.uk/news-archive%2ficr-childhood-brain-cancer-research-to-benefit-from-funding-boost-announced-by-the-department-of-health-and-social-care-and-cancer-research-ukhttps://www.icr.ac.uk/news-archive%2ficr-childhood-brain-cancer-research-to-benefit-from-funding-boost-announced-by-the-department-of-health-and-social-care-and-cancer-research-ukICR childhood brain cancer research to benefit from funding boost announced by the Department of Health and Social Care and Cancer Research UK Brain tumour research in the UK is set to be revolutionised with £45 million in funding by the Department of Health and Social Care and Cancer Research UK. The Institute of Cancer Research, London, will benefit from some of this new funding.https://www.icr.ac.uk/news-archive%2ficr-teams-up-with-merck-and-cancer-research-uk-on-strategic-drug-discovery-programmehttps://www.icr.ac.uk/news-archive%2ficr-teams-up-with-merck-and-cancer-research-uk-on-strategic-drug-discovery-programmeICR teams up with Merck and Cancer Research UK on strategic drug discovery programme The new alliance will take a strategic joint approach to drug discovery and build on previous successful collaborations on individual research projects.https://www.icr.ac.uk/news-archive%2fscientists-reveal-protein-that-all-cells-rely-on-to-divide-at-the-right-timehttps://www.icr.ac.uk/news-archive%2fscientists-reveal-protein-that-all-cells-rely-on-to-divide-at-the-right-timeScientists reveal protein that all cells rely on to divide at the right timeICR scientists have identified a cell cycle protein that is crucial to cell division, and whose location determines when cells begin to divide.https://www.icr.ac.uk/news-archive%2fsir-vince-cable-mp-visits-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fsir-vince-cable-mp-visits-the-london-cancer-hubSir Vince Cable MP visits The London Cancer HubLiberal Democrat leader Sir Vince Cable heard about exciting progress in delivery of The London Cancer Hub, and the challenges in taking advances in treatment to patients, during a visit to the ICR’s Sutton site.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-darwin-help-us-outsmart-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-darwin-help-us-outsmart-cancerCould Darwin help us outsmart cancer?To celebrate Darwin Day, we invited Professor Andrew Read from Pennsylvania State University to talk to us about why cancer researchers should care about the founder of evolutionary biology, and why his 150-year old findings might just be the most important weapon we have to defeat cancer.https://www.icr.ac.uk/news-archive%2fstudy-opens-up-new-way-of-treating-rare-cancer-of-arms-and-legshttps://www.icr.ac.uk/news-archive%2fstudy-opens-up-new-way-of-treating-rare-cancer-of-arms-and-legsStudy opens up new way of treating rare cancer of arms and legsThe disease, called synovial sarcoma, showed unusual sensitivity to drugs that stop cells from repairing damage to their DNA.https://www.icr.ac.uk/news-archive%2fdeal-doubles-land-purchased-for-new-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2fdeal-doubles-land-purchased-for-new-london-cancer-hubDeal doubles land purchased for new London Cancer HubA new £14.1 million investment sets the stage for a site in Sutton, south London, to become the world’s leading hub for cancer research and treatment.https://www.icr.ac.uk/news-archive%2fdiscovery-in-understanding-the-spread-of-breast-cancer-could-lead-to-new-treatments-to-slow-metastasishttps://www.icr.ac.uk/news-archive%2fdiscovery-in-understanding-the-spread-of-breast-cancer-could-lead-to-new-treatments-to-slow-metastasisDiscovery in understanding the spread of breast cancer could lead to new treatments to slow metastasisResearchers have discovered a certain amino acid is essential for breast cancer spread and restricting it in mice can stop cancer cells invading other parts of the body.https://www.icr.ac.uk/news-archive%2fcombination-treatment-blocks-cell-growth-and-triggers-cell-death-in-colon-cancerhttps://www.icr.ac.uk/news-archive%2fcombination-treatment-blocks-cell-growth-and-triggers-cell-death-in-colon-cancerCombination treatment blocks cell growth and triggers cell death in colon cancerDrugs that block cancer’s growth and survival could be used in a powerful one-two combination with death-triggering cancer drugs to treat colon cancer, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-genomics-approach-to-radiotherapy-could-improve-outcomes-for-prostate-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-genomics-approach-to-radiotherapy-could-improve-outcomes-for-prostate-cancer-patientsHow a genomics approach to radiotherapy could improve outcomes for prostate cancer patientsLast week saw The Festival of Genomics return to London. Dr Keith Bradnam reports on one of the exciting talks that took place in a special session of presentations from ICR early-career scientists.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-2018-five-ways-our-world-class-cancer-research-is-helping-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fworld-cancer-day-2018-five-ways-our-world-class-cancer-research-is-helping-patientsWorld Cancer Day 2018: five ways our world-class cancer research is helping patientsToday is <a href="https://www.icr.ac.uk/worldcancerday">World Cancer Day</a> – a growing, global movement which aims to unite the world to find better treatments against cancer. Graham Shaw introduces some of our world class research.https://www.icr.ac.uk/news-archive%2ficr-alumnus-professor-jacques-miller-awarded-the-japan-prizehttps://www.icr.ac.uk/news-archive%2ficr-alumnus-professor-jacques-miller-awarded-the-japan-prizeICR alumnus Professor Jacques Miller awarded the Japan PrizeProfessor Jacques Miller has been awarded the prestigious Japan Prize for his discovery of the role of the thymus and the two types of white blood cell involved in the adaptive immune system – a discovery that laid the groundwork for much of the field of immunology.https://www.icr.ac.uk/news-archive%2fblocking-cancer-stress-signal-shows-promise-in-bone-marrow-cancerhttps://www.icr.ac.uk/news-archive%2fblocking-cancer-stress-signal-shows-promise-in-bone-marrow-cancerBlocking cancer stress signal shows promise in bone marrow cancerPotential new drugs that block a safeguard used by cancer cells to stay alive in stressful conditions have shown promise against myeloma, a cancer of white blood cells made in the bone marrow, a new study reports.https://www.icr.ac.uk/news-archive%2fblood-test-could-indicate-which-patients-will-respond-to-immunotherapyhttps://www.icr.ac.uk/news-archive%2fblood-test-could-indicate-which-patients-will-respond-to-immunotherapyBlood test could indicate which patients will respond to immunotherapyThe test gives a measure of a patient’s immune system health by comparing the number of neutrophils with the number of lymphocytes.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frethinking-clinical-trials-how-tessa-jowell-s-intervention-could-benefit-people-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frethinking-clinical-trials-how-tessa-jowell-s-intervention-could-benefit-people-with-cancerRethinking clinical trials – how Tessa Jowell’s intervention could benefit people with cancerBaroness Tessa Jowell has helped to raise awareness of the need for patients to access the latest drugs and treatments more quickly on the NHS. The ICR’s Rose Wu looks at why increasing flexibility around clinical trials could bring benefit to patients.https://www.icr.ac.uk/news-archive%2fviral-gene-therapy-could-improve-results-from-breast-reconstruction-surgery-after-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fviral-gene-therapy-could-improve-results-from-breast-reconstruction-surgery-after-cancer-treatmentViral gene therapy could improve results from breast reconstruction surgery after cancer treatmentA new type of gene therapy delivered using a virus could protect healthy tissues from the harmful side-effects of radiotherapy after cancer treatment, a new study reports.https://www.icr.ac.uk/news-archive%2fexposure-to-light-at-night-does-not-increase-breast-cancer-risk-major-new-study-suggestshttps://www.icr.ac.uk/news-archive%2fexposure-to-light-at-night-does-not-increase-breast-cancer-risk-major-new-study-suggestsExposure to light at night does not increase breast cancer risk, major new study suggestsThe prospective analysis of 105,866 women provides evidence against the 40 year old proposal that night-time light levels and breast cancer risk are linked.https://www.icr.ac.uk/news-archive%2fnew-treatment-strategy-could-overcome-drug-resistance-in-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fnew-treatment-strategy-could-overcome-drug-resistance-in-testicular-cancerNew treatment strategy could overcome drug resistance in testicular cancerMen with testicular cancers called testicular germ cell tumours could benefit from a new combination of treatments if their chemotherapy stops working.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdelivering-on-the-promise-of-big-datahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdelivering-on-the-promise-of-big-dataDelivering on the promise of Big DataUsing Big Data effectively will allow us to answer key questions for cancer research and treatment, but there are challenges. The ICR’s Dr Eva Sharpe finds out more.https://www.icr.ac.uk/news-archive%2fscientists-zoom-in-to-watch-dna-code-being-readhttps://www.icr.ac.uk/news-archive%2fscientists-zoom-in-to-watch-dna-code-being-readScientists zoom in to watch DNA code being readScientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-cancer-research-leads-to-new-understandings-of-life-itselfhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-cancer-research-leads-to-new-understandings-of-life-itselfHow cancer research leads to new understandings of life itselfAs well as leading to cures and treatments, cancer research leads to completely new understandings of the fundamental processes of life. Henry French introduces some of the ICR’s recent discoveries.https://www.icr.ac.uk/news-archive%2fthe-icr-and-cancer-research-uk-join-forces-with-leading-science-and-technology-company-in-new-drug-discovery-alliancehttps://www.icr.ac.uk/news-archive%2fthe-icr-and-cancer-research-uk-join-forces-with-leading-science-and-technology-company-in-new-drug-discovery-allianceThe ICR and Cancer Research UK join forces with leading science and technology company in new drug discovery allianceThe deal follows previous drug discovery collaborations and a more recent successful target validation collaboration between Merck and Cancer Research UK’s Cancer Therapeutics Unit at the ICR.https://www.icr.ac.uk/news-archive%2ficr-phd-student-chosen-to-speak-at-joint-uk-india-conferencehttps://www.icr.ac.uk/news-archive%2ficr-phd-student-chosen-to-speak-at-joint-uk-india-conferenceICR PhD student chosen to speak at joint UK-India conferenceJonny Pettinger was one of just eight PhD students chosen from across the UK to speak, and was also given the chance to undertake a two-week research project.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-the-fda-approval-of-olaparib-for-women-with-brca-mutant-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-the-fda-approval-of-olaparib-for-women-with-brca-mutant-advanced-breast-cancerThe ICR responds to the FDA approval of olaparib for women with BRCA-mutant​​ advanced breast cancerThe Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-nerdy-kid-to-cancer-research-imaging-pioneer-profiling-the-icr-s-professor-jeff-bamberhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-nerdy-kid-to-cancer-research-imaging-pioneer-profiling-the-icr-s-professor-jeff-bamberFrom nerdy kid to cancer research imaging pioneer – profiling the ICR’s Professor Jeff BamberAt the end of last year, Professor Jeff Bamber was invited to give an inaugural lecture at the ICR celebrating his career in cancer imaging so far. Tilly Haynes, our Communications Administrator, spoke with Professor Bamber to get an insight into the man behind the research and learn some of his research highlights from 2017.https://www.icr.ac.uk/news-archive%2fscientists-bring-innovative-microbeam-radiation-therapy-for-cancer-treatment-a-step-closerhttps://www.icr.ac.uk/news-archive%2fscientists-bring-innovative-microbeam-radiation-therapy-for-cancer-treatment-a-step-closerScientists bring innovative microbeam radiation therapy for cancer treatment a step closerScientists have developed a new mathematical tool which will speed a smart new type of radiotherapy into the first patient trials.https://www.icr.ac.uk/news-archive%2fvirus-could-treat-brain-tumours-by-boosting-immune-systemhttps://www.icr.ac.uk/news-archive%2fvirus-could-treat-brain-tumours-by-boosting-immune-systemVirus could treat brain tumours by boosting immune systemA virus injected directly into the bloodstream could be used to treat people with aggressive brain tumours, a major new study reports.https://www.icr.ac.uk/news-archive%2ftest-reveals-which-breast-cancer-patients-may-benefit-from-targeted-therapyhttps://www.icr.ac.uk/news-archive%2ftest-reveals-which-breast-cancer-patients-may-benefit-from-targeted-therapyTest reveals which breast cancer patients may benefit from targeted therapyA new test could indicate which women with some breast cancer types are likely to benefit from targeted treatments, according to new research.https://www.icr.ac.uk/news-archive%2ffundraiser-hollywood-dave-runs-an-incredible-11-marathons-for-the-icr-this-yearhttps://www.icr.ac.uk/news-archive%2ffundraiser-hollywood-dave-runs-an-incredible-11-marathons-for-the-icr-this-yearFundraiser ‘Hollywood’ Dave runs an incredible 11 marathons for the ICR this yearInspirational fundraiser ‘Hollywood’ Dave Griffiths has finished a heroic 11 marathon challenge to raise money for the Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fdelay-in-reforming-european-rules-could-deny-thousands-of-children-access-to-latest-cancer-drugshttps://www.icr.ac.uk/news-archive%2fdelay-in-reforming-european-rules-could-deny-thousands-of-children-access-to-latest-cancer-drugsDelay in reforming European rules could deny thousands of children access to latest cancer drugsThousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.https://www.icr.ac.uk/news-archive%2fmri-could-detect-signs-of-more-aggressive-breast-cancershttps://www.icr.ac.uk/news-archive%2fmri-could-detect-signs-of-more-aggressive-breast-cancersMRI could detect signs of more aggressive breast cancersMagnetic resonance imaging (MRI) is able to detect indicators that a breast tumour is likely to be more aggressive, researchers have found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faddressing-career-inequalities-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faddressing-career-inequalities-in-cancer-researchAddressing career inequalities in cancer researchHenry French speaks to Dr Vanessa McKean, Equality, Diversity and Inclusion Manager, about the ICR’s work to embed equality in everything we do.https://www.icr.ac.uk/news-archive%2fimportant-step-towards-mr-linac-radiotherapy-for-lung-cancerhttps://www.icr.ac.uk/news-archive%2fimportant-step-towards-mr-linac-radiotherapy-for-lung-cancerImportant step towards MR Linac radiotherapy for lung cancerResearchers working with the MR Linac – a pioneering radiotherapy machine – have successfully developed treatment plans for patients with an advanced form of lung cancer.https://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2017-celebrities-gather-for-icr-flagship-fundraising-eventhttps://www.icr.ac.uk/news-archive%2fcarols-from-chelsea-2017-celebrities-gather-for-icr-flagship-fundraising-eventCarols from Chelsea 2017: celebrities gather for ICR flagship fundraising eventCelebrities including Jeremy Paxman, Edward Holcroft and Prue Leith joined us for this year's Carols from Chelsea concert – the ICR's flagship annual social and fundraising event.https://www.icr.ac.uk/news-features%2flatest-features%2fnew-simple-blood-tests-for-prostate-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fnew-simple-blood-tests-for-prostate-cancerNew, simple blood tests for prostate cancerConor McKeever introduces an exciting new technology, developed by researchers at The Institute of Cancer Research.https://www.icr.ac.uk/news-archive%2fcancer-causing-mutation-suppresses-immune-system-around-tumourshttps://www.icr.ac.uk/news-archive%2fcancer-causing-mutation-suppresses-immune-system-around-tumoursCancer-causing mutation suppresses immune system around tumoursMutations in ‘Ras’ genes, which drive 25 per cent of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study.https://www.icr.ac.uk/news-archive%2fnew-resource-to-challenge-widespread-poor-practice-in-biomedical-researchers-use-of-chemical-probeshttps://www.icr.ac.uk/news-archive%2fnew-resource-to-challenge-widespread-poor-practice-in-biomedical-researchers-use-of-chemical-probesNew resource to challenge widespread poor practice in biomedical researchers’ use of chemical probesDetails of a major new online resource designed to improve biomedical research by helping researchers choose the best chemical probes for their experiments – allowing drug targets to be validated much more effectively – have been published today.https://www.icr.ac.uk/news-features%2flatest-features%2ftop-10-scientific-achievements-of-2017https://www.icr.ac.uk/news-features%2flatest-features%2ftop-10-scientific-achievements-of-2017Top 10 scientific achievements of 2017We've selected our top 10 discoveries of 2016/17 – chosen because they best represent the breadth of our research and our ambitions set out in our research strategy.https://www.icr.ac.uk/news-archive%2ficr-researcher-wins-major-prize-at-san-antonio-breast-cancer-symposiumhttps://www.icr.ac.uk/news-archive%2ficr-researcher-wins-major-prize-at-san-antonio-breast-cancer-symposiumICR researcher wins major prize at 2017 San Antonio Breast Cancer SymposiumAn ICR researcher has been given a prestigious award at the San Antonio Breast Cancer Symposium, one of the world’s most important annual breast cancer research conferences.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finvesting-in-the-future-what-does-the-life-sciences-sector-deal-means-for-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finvesting-in-the-future-what-does-the-life-sciences-sector-deal-means-for-cancer-researchInvesting in the future – what does the life sciences sector deal mean for cancer research?This week the government announced the first of its sector deals – an agreement between the Government and the life sciences sector on how they will turn the recommendations in the Life Sciences Industrial Strategy into reality. Our Science Information and Policy Officer, Dr Sam Dick takes a closer look to see what it means for the future of cancer research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-data-modelling-will-transform-prostate-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-data-modelling-will-transform-prostate-cancer-treatmentHow data modelling will transform prostate cancer treatmentOur researchers have been at the forefront of major clinical trials that have dramatically improved prostate cancer treatment. Henry French explains how we now plan to use statistical modelling methods to learn more about the vast amount of data we’ve collected, to further benefit future patients.https://www.icr.ac.uk/news-archive%2fbreast-bowel-and-other-cancers-could-be-targeted-by-new-drug-typehttps://www.icr.ac.uk/news-archive%2fbreast-bowel-and-other-cancers-could-be-targeted-by-new-drug-typeBreast, bowel and other cancers could be targeted by new drug typeDrugs that target a ‘crutch’ used by cancer cells to keep on dividing and growing could help treat a range of cancer types, researchers have found. https://www.icr.ac.uk/news-archive%2ficr-joins-call-to-ensure-continued-recruitment-of-scientific-technicians-after-brexithttps://www.icr.ac.uk/news-archive%2ficr-joins-call-to-ensure-continued-recruitment-of-scientific-technicians-after-brexitICR joins call to ensure continued recruitment of technical scientists after BrexitThe Institute of Cancer Research has joined other influential UK research and higher education bodies to call for government recognition of the importance of international technicians in delivering world-leading research.https://www.icr.ac.uk/news-archive%2ficr-awarded-major-prize-for-pioneering-discoveries-in-precision-medicines-for-cancerhttps://www.icr.ac.uk/news-archive%2ficr-awarded-major-prize-for-pioneering-discoveries-in-precision-medicines-for-cancerICR awarded major prize for pioneering discoveries in precision medicines for cancerThe Institute of Cancer Research, London, has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery.https://www.icr.ac.uk/news-archive%2fgenetic-link-found-between-the-immune-system-and-lymphomahttps://www.icr.ac.uk/news-archive%2fgenetic-link-found-between-the-immune-system-and-lymphomaGenetic link found between the immune system and lymphomaPeople who inherit genetic changes which alter the function of their immune system are at increased risk of developing Hodgkin lymphoma, a major new study reports.https://www.icr.ac.uk/news-archive%2flocal-mp-scanned-as-healthy-volunteer-in-pioneering-new-mr-linac-radiotherapy-machinehttps://www.icr.ac.uk/news-archive%2flocal-mp-scanned-as-healthy-volunteer-in-pioneering-new-mr-linac-radiotherapy-machineLocal MP scanned as healthy volunteer in pioneering new MR Linac radiotherapy machineMP for Sutton and Cheam Paul Scully has volunteered to be scanned as part of research to help develop a revolutionary new type of radiotherapy machine. He is one of the first healthy volunteers to be scanned as part of the initial trials of the MR Linac.https://www.icr.ac.uk/news-archive%2feuropean-medicines-agency-approves-abiraterone-combined-with-hormone-therapy-as-first-line-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2feuropean-medicines-agency-approves-abiraterone-combined-with-hormone-therapy-as-first-line-treatment-for-advanced-prostate-cancerEuropean Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancerThe prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer. https://www.icr.ac.uk/news-archive%2fsmoking-particularly-if-started-during-adolescence-is-associated-with-an-increased-risk-of-breast-cancer-major-new-study-findshttps://www.icr.ac.uk/news-archive%2fsmoking-particularly-if-started-during-adolescence-is-associated-with-an-increased-risk-of-breast-cancer-major-new-study-findsSmoking – particularly if started during adolescence – is associated with an increased risk of breast cancer, major new study findsA major new prospective study funded by Breast Cancer Now has found that smoking is associated with an increased risk of breast cancer, particularly among those who began smoking during adolescence and those with a family history of the disease.https://www.icr.ac.uk/news-archive%2ficr-fundraisers-take-part-in-climb-of-life-30th-year-celebrations-to-raise-a-new-record-breaking-totalhttps://www.icr.ac.uk/news-archive%2ficr-fundraisers-take-part-in-climb-of-life-30th-year-celebrations-to-raise-a-new-record-breaking-totalICR fundraisers take part in Climb of Life 30th year celebrations to raise a new record-breaking totalThe 30th Climb of Life annual fundraiser has celebrated a landmark year – with an amazing total of over £900,000 raised for the ICR over the lifetime of the event.https://www.icr.ac.uk/news-features%2flatest-features%2four-world-leading-prostate-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2four-world-leading-prostate-cancer-researchOur world-leading prostate cancer researchResearchers at the ICR are known around the world for their success in improving treatments for men with prostate cancer. Henry French gives an overview of some of our more recent discoveries.https://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-approval-of-new-breakthrough-drugs-on-the-nhs-for-women-with-advanced-breast-cancerhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-nice-approval-of-new-breakthrough-drugs-on-the-nhs-for-women-with-advanced-breast-cancerICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancerThe Institute of Cancer Research, London, welcomes the approval by NICE of a new type of treatment for women with previously untreated advanced breast cancer.https://www.icr.ac.uk/news-archive%2fmr-linac-first-healthy-volunteer-scanned-in-pioneering-new-radiotherapy-machinehttps://www.icr.ac.uk/news-archive%2fmr-linac-first-healthy-volunteer-scanned-in-pioneering-new-radiotherapy-machineMR Linac: first healthy volunteer scanned in pioneering new radiotherapy machineThe first healthy volunteer has been scanned using a revolutionary new type of radiotherapy machine, which is set to transform cancer treatment by allowing radiation to be aimed at tumours with extreme precision.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-take-home-messages-from-the-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-take-home-messages-from-the-conferenceNCRI 2017: Take home messages from the conferenceWe consider what the 2017 NCRI conference tells us about the future of cancer treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fspecial-issue-of-biochemistry-journal-guest-edited-by-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fspecial-issue-of-biochemistry-journal-guest-edited-by-icrSpecial journal issue on structure-based drug design, edited by ICRProfessor Paul Workman, the ICR’s Chief Executive, and Dr Rob van Montfort, a structural biologist at the ICR, have guest edited a special edition of the journal Essays in Biochemistry focussing on structure-based drug design, published today. Here, we provide an overview of the issue and introduce some of the key articles it contains.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-understanding-cancer-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-understanding-cancer-evolutionNCRI 2017: Understanding cancer evolutionDr Andrea Sottoriva at the NCRI 2017 conference explained what we know about cancer evolution, what we don't know, and what questions we should be asking. Our Science Information and Policy Officer Dr Sam Dick takes a closer look in his latest Science Talk blog.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-how-3d-tumour-models-grown-from-patients-cell-samples-could-improve-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-how-3d-tumour-models-grown-from-patients-cell-samples-could-improve-drug-discoveryNCRI 2017: How 3D tumour models grown from patients’ cell samples could improve drug discoveryICR researchers at the NCRI 2017 conference presented new ways of studying tumour cells in the lab to more closely mimic features of cancer in patients. With these new models, they are working to improve drug discovery and help tackle drug resistance.https://www.icr.ac.uk/news-archive%2fncri-2017-big-data-analysis-predicts-risk-of-radiotherapy-effectshttps://www.icr.ac.uk/news-archive%2fncri-2017-big-data-analysis-predicts-risk-of-radiotherapy-effectsNCRI 2017: Big data analysis predicts risk of radiotherapy effectsAnalysing big data to predict men’s risk of side effects could help personalise radiotherapy treatment for prostate cancer, according to new research presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool, today.https://www.icr.ac.uk/news-archive%2fncri-2017-icr-researcher-wins-future-leaders-prizehttps://www.icr.ac.uk/news-archive%2fncri-2017-icr-researcher-wins-future-leaders-prizeNCRI 2017: Dr Gerhardt Attard wins Cancer Research UK Future Leaders PrizeDr Gert Attard has been awarded the Cancer Research UK Future Leaders in Cancer Research Prize at this week’s National Cancer Research Institute (NCRI) conference in Liverpool.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-world-class-research-on-show-in-liverpoolhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2017-world-class-research-on-show-in-liverpoolNCRI 2017: World-class research on show in LiverpoolThe National Cancer Research Institute (NCRI) Cancer Conference in Liverpool is the UK's largest meeting of cancer researchers and doctors. The ICR is there and we will be reporting on major findings from the conference and cutting-edge science.https://www.icr.ac.uk/news-archive%2fmore-breast-cancer-patients-should-be-offered-brca-gene-testing-new-research-showshttps://www.icr.ac.uk/news-archive%2fmore-breast-cancer-patients-should-be-offered-brca-gene-testing-new-research-showsMore breast cancer patients should be offered BRCA gene testing, new research showsMany more people with breast cancer could get tested for mutations in the BRCA1 and BRCA2 genes under new criteria, a study suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-difference-will-the-accelerated-access-review-make-for-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-difference-will-the-accelerated-access-review-make-for-cancer-patientsWhat difference will the Accelerated Access Review make for cancer patients?Today the Government released its report on how the recommendations of the Accelerated Access Review will be implemented in the UK. Our Science Information and Policy Officer, Dr Sam Dick, takes a look at what this means for the future of cancer treatment.https://www.icr.ac.uk/news-archive%2ficr-responds-to-government-report-produced-following-accelerated-access-reviewhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-government-report-produced-following-accelerated-access-reviewICR responds to Government report produced following Accelerated Access ReviewThe Institute of Cancer Research, London, today responds to the Government’s announcement of a new, fast-track route into the NHS for 'breakthrough' medicines and technologies. This announcement is a response to 2016's Accelerated Access Review.https://www.icr.ac.uk/news-archive%2fnew-blood-test-detects-early-resistance-to-brca-targeting-drugs-for-breast-and-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fnew-blood-test-detects-early-resistance-to-brca-targeting-drugs-for-breast-and-ovarian-cancerNew blood test detects early resistance to BRCA-targeting drugs for breast and ovarian cancerScientists have developed a new highly sensitive blood test to deliver precision medicine to women with BRCA mutations who have breast or ovarian cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpremenopausal-breast-cancer-how-the-icr-is-helping-get-to-grips-with-the-datahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpremenopausal-breast-cancer-how-the-icr-is-helping-get-to-grips-with-the-dataPremenopausal breast cancer – the challenge of research to help young womenYesterday marked the end of Breast Cancer Awareness Month. Our Communications Administrator Tilly Haynes explores some of the ICR’s work into premenopausal breast cancer, its associated risk factors and the challenges researchers face.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-cancer-tech-is-fighting-drug-resistancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-cancer-tech-is-fighting-drug-resistanceHow our cancer tech is fighting drug resistanceOur scientists are pioneering research that could help solve the challenge of drug resistance. Cancer is able to resist treatments by evolving over time, and picking up genetic changes that provide immunity to drugs. It is the biggest challenge in cancer research and treatment.https://www.icr.ac.uk/news-archive%2fspecial-device-facilitates-imaging-of-mice-on-clinical-mri-scanners-for-neuroblastoma-researchhttps://www.icr.ac.uk/news-archive%2fspecial-device-facilitates-imaging-of-mice-on-clinical-mri-scanners-for-neuroblastoma-researchSpecial device facilitates imaging of mice on clinical MRI scanners for neuroblastoma researchA special device for holding mice while they undergo magnetic resonance imaging (MRI) scans on clinical MRI machines – those used on humans – can enhance imaging investigations in mouse models of neuroblastoma, researchers have found.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhy-we-study-inherited-cancer-riskhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhy-we-study-inherited-cancer-riskWhy we study inherited cancer riskFollowing their <a href=http://www.nature.com/nrc/journal/vaop/ncurrent/full/nrc.2017.82.html>recent publication in Nature Reviews Cancer</a>, the ICR’s Dr Amit Sud and Dr Ben Kinnersley explain why studying genetic susceptibility is a crucial aspect of cancer research, and how their work fits into our mission to defeat cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finnovation-in-research-provides-benefits-to-society-and-the-economy-but-how-do-we-measure-ithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finnovation-in-research-provides-benefits-to-society-and-the-economy-but-how-do-we-measure-itInnovation in research provides benefits to society and the economy… but how do we measure it?Dr Angela Kukula, the ICR’s Director of Enterprise, says that innovation in academic research is key to unlocking benefits to society and the economy – but cautions that measuring it is much trickier than just counting patents or profits.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-we-re-commercialising-a-pioneering-cancer-drughttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-we-re-commercialising-a-pioneering-cancer-drugHow we’re commercialising a pioneering cancer drugIn advance of industry conference BIO-Europe, Henry French speaks to the Enterprise Unit’s Dr Toby Richardson about one of the most promising commercialisation opportunities in our partnering portfolio.https://www.icr.ac.uk/news-archive%2fthe-icr-named-uk-s-top-higher-education-institution-for-commercial-earningshttps://www.icr.ac.uk/news-archive%2fthe-icr-named-uk-s-top-higher-education-institution-for-commercial-earningsThe ICR named UK’s top higher education institution for commercial earningsThe Institute of Cancer Research, London, is now the most successful higher education institution in the UK at earning invention income from its research.https://www.icr.ac.uk/news-archive%2fnew-targeted-drug-shows-signs-of-effectiveness-in-first-clinical-trialhttps://www.icr.ac.uk/news-archive%2fnew-targeted-drug-shows-signs-of-effectiveness-in-first-clinical-trialNew targeted cancer drug shows signs of effectiveness in first clinical trialA new targeted cancer drug has a good safety profile and has led to responses in some patients with particular genetic characteristics in their tumours.https://www.icr.ac.uk/news-archive%2fpioneering-imaging-tech-measures-cell-changes-in-melanomahttps://www.icr.ac.uk/news-archive%2fpioneering-imaging-tech-measures-cell-changes-in-melanomaPioneering imaging tech measures cell changes in melanomaA cutting-edge form of non-invasive imaging technology can track the response of malignant melanoma cells to treatment, researchers have found.https://www.icr.ac.uk/news-archive%2flord-prior-minister-for-life-sciences-visits-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2flord-prior-minister-for-life-sciences-visits-the-london-cancer-hubGovernment minister Lord Prior visits The London Cancer HubTransport links in Sutton, and the potential for science to drive economic growth, were two of the themes of a visit by Government minister Lord Prior to The London Cancer Hub.https://www.icr.ac.uk/news-archive%2fcancer-relapse-linked-to-body-s-own-immune-systemhttps://www.icr.ac.uk/news-archive%2fcancer-relapse-linked-to-body-s-own-immune-systemCancer relapse linked to body’s own immune systemCancer cells that survive after treatment may use the body’s own immune system to wake themselves up and fuel their growth, a new study shows.https://www.icr.ac.uk/news-archive%2fbreakthrough-for-advanced-head-and-neck-cancer-patients-as-nivolumab-made-available-on-the-cancer-drugs-fundhttps://www.icr.ac.uk/news-archive%2fbreakthrough-for-advanced-head-and-neck-cancer-patients-as-nivolumab-made-available-on-the-cancer-drugs-fundBreakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs FundThe immunotherapy nivolumab has today been made available on the Cancer Drugs Fund (CDF) for patients with head and neck cancer if the disease progresses within six months of receiving platinum chemotherapy.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fwhat-the-humble-tardigrade-teaches-us-about-advanced-cancerhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fwhat-the-humble-tardigrade-teaches-us-about-advanced-cancerWhat the humble tardigrade teaches us about advanced cancerRoyal Medal winner Professor Mel Greaves argues that survival traits evolved by the likes of the tardigrade, or water bear, also keep cancer cells alive.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevidence-vs-access-addressing-the-balance-in-assessing-new-cancer-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevidence-vs-access-addressing-the-balance-in-assessing-new-cancer-drugsEvidence vs access – addressing the balance in assessing new cancer drugsA study in the BMJ last week has opened up a debate over the level of evidence needed before a drug is made available to patients. Here, our Science Information and Policy Officer, Dr Sam Dick, takes a look at the study in more detail.https://www.icr.ac.uk/news-archive%2fnew-myeloma-clinical-trial-launches-with-aim-to-transform-treatment-from-one-size-fits-all-approachhttps://www.icr.ac.uk/news-archive%2fnew-myeloma-clinical-trial-launches-with-aim-to-transform-treatment-from-one-size-fits-all-approachNew myeloma clinical trial launches with aim to transform treatment from one-size-fits-all approachPeople with newly diagnosed high risk myeloma will be treated based on the results of genetic testing as part of a new UK-first clinical trial.https://www.icr.ac.uk/news-archive%2fquick-cheap-genetic-test-could-help-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fquick-cheap-genetic-test-could-help-prostate-cancer-treatmentQuick, cheap genetic test could help prostate cancer treatmentIdentifying which men with advanced prostate cancer will benefit from targeted treatments could be made easier with a quick and cost-effective test, researchers have found.https://www.icr.ac.uk/news-archive%2fstate-of-immune-system-linked-to-worse-survival-in-biliary-tract-cancershttps://www.icr.ac.uk/news-archive%2fstate-of-immune-system-linked-to-worse-survival-in-biliary-tract-cancersState of immune system linked to worse survival in biliary tract cancersThe state of the immune system in the area around a biliary tract cancer tumour may be a good indicator of whether the cancer is likely to return following surgery, researchers have found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-chemistry-2017-how-revolutionary-cryo-electron-microscopy-underpins-vital-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnobel-prize-for-chemistry-2017-how-revolutionary-cryo-electron-microscopy-underpins-vital-cancer-researchNobel Prize for Chemistry 2017: how revolutionary cryo-electron microscopy underpins vital cancer researchA revolutionary form of technology has won the 2017 Nobel Prize for Chemistry. Henry French explains how it’s being used in cancer research.https://www.icr.ac.uk/news-archive%2foveractive-gene-associated-with-more-aggressive-forms-of-bone-marrow-cancer-myelomahttps://www.icr.ac.uk/news-archive%2foveractive-gene-associated-with-more-aggressive-forms-of-bone-marrow-cancer-myelomaOveractive gene associated with more aggressive forms of bone marrow cancer myelomaA gene which is overactive in some cases of myeloma has been linked, for the first time, with more aggressive forms of the disease.https://www.icr.ac.uk/news-archive%2fstudy-splits-incurable-childhood-brain-tumours-into-10-new-diseaseshttps://www.icr.ac.uk/news-archive%2fstudy-splits-incurable-childhood-brain-tumours-into-10-new-diseasesStudy splits incurable childhood brain tumours into 10 new diseasesScientists have found that deadly childhood brain tumours are actually 10 different diseases that should each be diagnosed and treated based on their specific genetic faults.https://www.icr.ac.uk/news-archive%2fno-evidence-for-genetic-link-between-height-and-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fno-evidence-for-genetic-link-between-height-and-testicular-cancerNo evidence for genetic link between height and testicular cancerThere is no evidence being tall causes an increased risk of testicular cancer, according to a new genetic analysis of more than 24,000 men.https://www.icr.ac.uk/news-archive%2fpioneering-precision-radiotherapy-boosts-prostate-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fpioneering-precision-radiotherapy-boosts-prostate-cancer-survivalPioneering ‘precision’ radiotherapy boosts prostate cancer survivalA high-tech form of radiotherapy that shapes radiation beams to tumours can dramatically improve outcomes for patients with prostate cancer, long-term clinical trial results show.https://www.icr.ac.uk/news-archive%2fnew-treatment-approach-for-rare-type-of-triple-negative-breast-cancers-identifiedhttps://www.icr.ac.uk/news-archive%2fnew-treatment-approach-for-rare-type-of-triple-negative-breast-cancers-identifiedNew treatment approach for rare type of ‘triple negative’ breast cancers identifiedLeading scientists funded by Breast Cancer Now have identified a potential new treatment approach for some ‘triple negative’ breast cancers (TNBCs).https://www.icr.ac.uk/news-archive%2fblood-test-could-predict-response-of-hpv-positive-head-and-neck-cancer-to-treatmenthttps://www.icr.ac.uk/news-archive%2fblood-test-could-predict-response-of-hpv-positive-head-and-neck-cancer-to-treatmentBlood test could predict response of HPV-positive head and neck cancer to treatmentResearchers have developed a blood test that can detect whether patients with a type of locally advanced (non-metastatic) head and neck cancer have residual tumours after chemotherapy and radiotherapy.https://www.icr.ac.uk/news-archive%2ficr-reacts-to-decision-to-make-the-immunotherapy-nivolumab-available-on-the-cancer-drugs-fund-for-non-small-cell-lung-cancershttps://www.icr.ac.uk/news-archive%2ficr-reacts-to-decision-to-make-the-immunotherapy-nivolumab-available-on-the-cancer-drugs-fund-for-non-small-cell-lung-cancersICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancersThe ICR responds to the announcement by NICE that the immunotherapy nivolumab (Opdivo) will now be made available on the Cancer Drugs Fund for non-small cell lung cancers.https://www.icr.ac.uk/news-archive%2fwhole-body-scans-benefit-people-with-highest-inherited-cancer-riskhttps://www.icr.ac.uk/news-archive%2fwhole-body-scans-benefit-people-with-highest-inherited-cancer-riskWhole-body scans benefit people with highest inherited cancer riskPeople with a gene mutation that confers a very high risk of cancer would benefit from a whole-body MRI scan to detect the disease early, a new study reports.https://www.icr.ac.uk/news-archive%2ftesting-metabolites-in-blood-predicts-success-of-skin-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2ftesting-metabolites-in-blood-predicts-success-of-skin-cancer-treatmentTesting metabolites in blood predicts success of skin cancer treatmentTesting for a panel of metabolites in the blood can pick out which patients are likely to respond to a drug for skin cancer, new research reports.https://www.icr.ac.uk/news-archive%2fthe-icr-pays-tribute-to-researcher-james-mordenhttps://www.icr.ac.uk/news-archive%2fthe-icr-pays-tribute-to-researcher-james-mordenThe ICR pays tribute to researcher James MordenThe Institute of Cancer Research, London, has paid tribute to the life of James Morden, a senior medical statistician in the Clinical Trials and Statistics Unit (ICR-CTSU), who was tragically killed at the weekend.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fexploring-the-future-of-genomics-and-technology-like-novaseqhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fexploring-the-future-of-genomics-and-technology-like-novaseqExploring the future of genomics – the potential of sequencing technologies like NovaSeqThe Institute of Cancer Research is the first institution in the UK to deploy the state-of-the-art NovaSeq genome sequencer from Illumina. We spoke to Nik Matthews, Genomics Manager in the ICR’s Tumour Profiling Unit and a member of the team that sequenced the first human genome, to find out more about this potentially revolutionary platform and explore what the future holds for sequencing technologies like NovaSeq.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhy-developing-treatments-into-rare-childhood-cancers-is-a-team-efforthttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhy-developing-treatments-into-rare-childhood-cancers-is-a-team-effortWhy developing treatments into rare childhood cancers is a team effortAs part of Childhood Cancer Awareness Month we invited Antonio Romo-Morales to write about his research into Ewing sarcoma – a form of cancer that mainly affects children. Antonio is a PhD student in a team that works closely with family-led charities and through his research he has gained a deeper appreciation for how such charities support our research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fscience-after-brexit-how-will-we-continue-to-collaborate-with-the-eu-on-medical-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fscience-after-brexit-how-will-we-continue-to-collaborate-with-the-eu-on-medical-researchScience after Brexit – how will we continue to collaborate with the EU on medical research?This week the Government released a position paper on collaboration in science and innovation as we leave the EU. Our Science Policy Officer Dr Sam Dick discusses some key points from the paper and what they mean for the future of UK medical research.https://www.icr.ac.uk/news-archive%2fnew-software-can-correct-systematic-%27batch-effects%27-error-in-research-datahttps://www.icr.ac.uk/news-archive%2fnew-software-can-correct-systematic-%27batch-effects%27-error-in-research-dataNew software can correct systematic 'batch effects' error in research dataResearchers have developed a new way to identify and correct for a type of systematic statistical error, known as 'batch effects', in large datasets.https://www.icr.ac.uk/news-archive%2ficr-responds-to-government-s-policy-paper-on-science-and-innovation-after-leaving-euhttps://www.icr.ac.uk/news-archive%2ficr-responds-to-government-s-policy-paper-on-science-and-innovation-after-leaving-euICR responds to Government’s policy paper on science and innovation after BrexitThe Institute of Cancer Research, London, has issued the following statement from Chief Executive Professor Paul Workman in response to a new policy paper by the Department for Exiting the European Union on the government's plans for science and innovation after Brexit.https://www.icr.ac.uk/news-archive%2fnew-approach-could-better-predict-breast-cancer-risk-due-to-family-historyhttps://www.icr.ac.uk/news-archive%2fnew-approach-could-better-predict-breast-cancer-risk-due-to-family-historyNew approach could better predict breast cancer risk due to family historyScientists funded by Breast Cancer Now and Cancer Research UK have demonstrated a more accurate method to assess a woman’s familial risk of breast cancer, which could one day be added to existing models to help better predict an individual’s overall risk of breast cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdefeating-childhood-cancer-fighting-on-multiple-frontshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdefeating-childhood-cancer-fighting-on-multiple-frontsDefeating childhood cancer – fighting on multiple frontsThis Childhood Cancer Awareness Month we’re reflecting on some recent research advances and developments made here at The Institute of Cancer Research, London, and considering what’s needed for continued progress to defeat children’s cancers.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2famerica-approves-revolutionary-car-t-cell-immunotherapy-what-does-it-mean-for-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2famerica-approves-revolutionary-car-t-cell-immunotherapy-what-does-it-mean-for-cancer-patientsAmerica approves ‘revolutionary’ CAR T cell immunotherapy — what does this mean for cancer patients?The decision by US regulators to approve this first-of-its-kind treatment has been hailed as ‘historic’ and ‘a new frontier’ in cancer treatment. But how significant is the announcement by US regulators – and will it make-it across the pond?https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fexploration-and-exploitation-of-potential-drug-space-using-computershttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fexploration-and-exploitation-of-potential-drug-space-using-computersExploration and exploitation of potential drug space using computersFor the last decade, Dr Nathan Brown has led the In Silico Medicinal Chemistry Team at The Institute of Cancer Research, London. Today, on his last day at the ICR, he writes about the current use of computer algorithms in the ongoing quest to design cancer drugs more efficiently. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-life-sciences-industrial-strategy-what-does-it-mean-for-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-life-sciences-industrial-strategy-what-does-it-mean-for-cancer-researchThe Life Sciences Industrial Strategy – what does it mean for cancer research?The outlook for medical research is looking positive this week as the Life Sciences Industrial Strategy is launched in the UK. Our Science Information and Policy Officer Dr Sam Dick considers his five highlights from the report and how these will benefit cancer research.https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-government-s-life-sciences-industrial-strategyhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-government-s-life-sciences-industrial-strategyThe ICR responds to Sir John Bell's Life Sciences Industrial StrategyThe Institute of Cancer Research, London, today responds to the publication of the Life Sciences Industrial Strategy. The ICR responded to the UK Government’s January 2017 green paper proposing how they intend to build a modern industrial strategy.https://www.icr.ac.uk/news-archive%2fbowel-cancer-study-reveals-impact-of-mutations-on-protein-networkshttps://www.icr.ac.uk/news-archive%2fbowel-cancer-study-reveals-impact-of-mutations-on-protein-networksBowel cancer study reveals impact of mutations on protein networksFor the first time, scientists have completed a detailed study of many of the proteins in bowel cancer cells.https://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-to-chair-ncri-cancer-conferencehttps://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-to-chair-ncri-cancer-conferenceProfessor Johann de Bono to chair NCRI Cancer ConferenceThe ICR’s Professor Johann de Bono will take the prestigious position of Chair of the Scientific Committee for the 2017 National Cancer Research Institute (NCRI) annual conference in Liverpool this November.https://www.icr.ac.uk/news-archive%2ftributes-for-pioneering-icr-radiotherapy-scientist-dr-roy-bentleyhttps://www.icr.ac.uk/news-archive%2ftributes-for-pioneering-icr-radiotherapy-scientist-dr-roy-bentleyTributes for pioneering ICR radiotherapy scientist Dr Roy BentleyResearchers at the Institute of Cancer Research, London, have paid tribute to their former colleague and radiotherapy pioneer Dr Roy Bentley, who sadly died last month.https://www.icr.ac.uk/news-archive%2fscientists-uncover-a-deadly-addiction-in-oesophageal-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-uncover-a-deadly-addiction-in-oesophageal-cancerScientists uncover a deadly ‘addiction’ in oesophageal cancerScientists have discovered a new way of attacking oesophageal cancer cells that could make use of an existing drug in a new approach to treatment.https://www.icr.ac.uk/news-archive%2fpatients-with-advanced-cancer-survive-10-years-on-first-targeted-cancer-wonder-drughttps://www.icr.ac.uk/news-archive%2fpatients-with-advanced-cancer-survive-10-years-on-first-targeted-cancer-wonder-drugPatients with advanced cancer survive 10 years on first targeted cancer wonder drugA significant minority of patients with advanced and aggressive cancer have survived more than 10 years after treatment with one of the first successful targeted cancer drugs.https://www.icr.ac.uk/news-archive%2fnon-invasive-imaging-test-could-predict-which-kidney-cancer-patients-will-benefit-from-anti-vascular-therapyhttps://www.icr.ac.uk/news-archive%2fnon-invasive-imaging-test-could-predict-which-kidney-cancer-patients-will-benefit-from-anti-vascular-therapyNon-invasive imaging test could predict which kidney cancer patients will benefit from anti-vascular therapyA magnetic resonance imaging test that measures the volume of blood in tumours could help select which patients will benefit from drugs that block blood vessel growth, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-next-generation-inspiring-the-cancer-researchers-of-the-futurehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-next-generation-inspiring-the-cancer-researchers-of-the-futureThe next generation – inspiring the cancer researchers of the futureThe ICR has published a new guide for young people thinking about their future careers.https://www.icr.ac.uk/news-archive%2fnew-tests-select-patients-who-could-live-for-nearly-a-year-longer-on-targeted-bowel-cancer-drughttps://www.icr.ac.uk/news-archive%2fnew-tests-select-patients-who-could-live-for-nearly-a-year-longer-on-targeted-bowel-cancer-drugNew tests select patients who could live for nearly a year longer on targeted bowel cancer drugGiving patients with bowel cancer an MRI scan and a blood test could pick out those who would benefit from a targeted cancer treatment, a new study reports.https://www.icr.ac.uk/news-archive%2fscientists-find-new-method-to-target-hard-to-treat-head-and-neck-cancershttps://www.icr.ac.uk/news-archive%2fscientists-find-new-method-to-target-hard-to-treat-head-and-neck-cancersScientists find new method to target hard-to-treat head and neck cancersAn MRI technique could help doctors predict survival and develop improved treatments by identifying areas of fluctuating oxygen levels in head and neck tumours.https://www.icr.ac.uk/news-archive%2ftesting-for-immune-hotspots-can-predict-risk-that-breast-cancer-will-returnhttps://www.icr.ac.uk/news-archive%2ftesting-for-immune-hotspots-can-predict-risk-that-breast-cancer-will-returnTesting for immune ‘hotspots’ can predict risk that breast cancer will returnScientists have developed a new test that can pick out women at high risk of relapsing from breast cancer within 10 years of diagnosis.https://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-limits-side-effects-of-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-limits-side-effects-of-breast-cancer-treatmentTargeted radiotherapy limits side effects of breast cancer treatmentBreast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, according to trial results published in The Lancet.https://www.icr.ac.uk/news-archive%2fstructure-of-key-complex-behind-dna-transcription-uncoveredhttps://www.icr.ac.uk/news-archive%2fstructure-of-key-complex-behind-dna-transcription-uncoveredStructure of key complex behind DNA transcription uncoveredResearchers have determined the structure of a molecular protein complex that helps DNA to be read and its instructions carried out.https://www.icr.ac.uk/news-archive%2fdiscovery-club-learns-of-lost-tribe-of-young-adult-cancer-patientshttps://www.icr.ac.uk/news-archive%2fdiscovery-club-learns-of-lost-tribe-of-young-adult-cancer-patientsDiscovery Club learns of “lost tribe” of young adult cancer patientsMembers of our Discovery Club gathered at Chelsea Physic Garden in London earlier this month to learn about the unique challenges posed in treating cancer in teens and young adults.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fprobe-miner-a-new-resource-for-objective-large-scale-assessment-of-chemical-toolshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fprobe-miner-a-new-resource-for-objective-large-scale-assessment-of-chemical-toolsProbe Miner: a new resource for objective, large-scale assessment of chemical toolsICR Chief Executive Professor Paul Workman talks about the launch of Probe Miner – the new web resource for objective, large-scale analysis of chemical probes.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2freflections-of-an-accidental-scientisthttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2freflections-of-an-accidental-scientistReflections of an accidental scientistProfessor Mel Greaves, winner this week of a Royal Society Royal Medal for outstanding research, looks back over his career and considers what has made him tick as a scientist.https://www.icr.ac.uk/news-archive%2fnew-computer-program-makes-it-easier-to-track-living-cellshttps://www.icr.ac.uk/news-archive%2fnew-computer-program-makes-it-easier-to-track-living-cellsNew computer program makes it easier to track living cellsResearchers have developed a computer program - NucliTrack - to more efficiently track the trajectory of moving cells.https://www.icr.ac.uk/news-archive%2fscientists-discover-new-line-of-attack-against-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-discover-new-line-of-attack-against-cancerScientists discover new line of attack against cancerScientists have made the surprise discovery of an exciting new way of blocking a crucial cancer protein that has proved extremely difficult to target.https://www.icr.ac.uk/news-archive%2fpioneering-leukaemia-and-evolution-researcher-professor-mel-greaves-wins-prestigious-royal-society-awardhttps://www.icr.ac.uk/news-archive%2fpioneering-leukaemia-and-evolution-researcher-professor-mel-greaves-wins-prestigious-royal-society-awardPioneering leukaemia and evolution researcher – Professor Mel Greaves – wins prestigious Royal Society awardProfessor Mel Greaves has been awarded The Royal Society’s prestigious Royal Medal in recognition of his research, which has dramatically improved our understanding of childhood leukaemia.https://www.icr.ac.uk/news-archive%2ficr-commended-for-plans-to-work-with-commercial-partnershttps://www.icr.ac.uk/news-archive%2ficr-commended-for-plans-to-work-with-commercial-partnersICR commended for plans to work with commercial partnersThe ICR has been commended for its approach to transforming its discoveries into new treatments for people with cancer by working with industry.https://www.icr.ac.uk/news-archive%2fworld-leading-cancer-researchers-first-in-uk-to-receive-novaseq---the-latest-genome-sequencing-technologyhttps://www.icr.ac.uk/news-archive%2fworld-leading-cancer-researchers-first-in-uk-to-receive-novaseq---the-latest-genome-sequencing-technologyWorld-leading cancer researchers first in UK to receive NovaSeq - the latest genome sequencing technologyUK scientists now have access to a new kind of next-generation genome sequencer - NovaSeq - which could revolutionise their research to defeat cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-making-radiotherapy-a-smarter-kinder-treatment-for-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we-re-making-radiotherapy-a-smarter-kinder-treatment-for-cancerHow we’re making radiotherapy a smarter, kinder treatment for cancerRadiotherapy is a crucial part of treatment for many cancers. Here at the ICR, we’re developing new ways to use radiotherapy to kill cancer cells with fewer side effects and fewer hospital visits.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fcall-to-bioscientists-choose-and-use-your-chemicai-probes-very-carefullyhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fcall-to-bioscientists-choose-and-use-your-chemicai-probes-very-carefullyCall to bioscientists: choose and use your chemicaI probes very carefullyICR Chief Executive Paul Workman blogs about a new article we have published in Cancer Cell that seeks to draw to the attention of the bioscience community the serious dangers of using flawed chemical probes – or tool compounds – in mechanistic investigations and target validation for translational research.https://www.icr.ac.uk/news-archive%2fscientists-call-for-better-use-of-chemical-tools-to-improve-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2fscientists-call-for-better-use-of-chemical-tools-to-improve-cancer-drug-discoveryScientists call for better use of chemical tools to improve cancer drug discoveryChemical tools used in cancer research need to be selected more carefully, researchers have warned.https://www.icr.ac.uk/news-archive%2ficr-awarded-30-million-towards-new-centre-for-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2ficr-awarded-30-million-towards-new-centre-for-cancer-drug-discoveryICR awarded £30 million towards new Centre for Cancer Drug DiscoveryThe Institute of Cancer Research has secured a £30 million grant from the Higher Education Funding Council for England (HEFCE) towards the costs of building a new, state-of-the-art drug discovery facility.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fexpanding-my-knowledge-a-q-a-with-one-of-our-msc-in-oncology-studentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fexpanding-my-knowledge-a-q-a-with-one-of-our-msc-in-oncology-students‘Expanding my knowledge’ – a Q&A with one of our MSc in Oncology studentsIn addition to offering PhD and MD(Res) opportunities, the ICR also runs a popular MSc in Oncology. This course is a day release modular programme designed for medically qualified candidates who intend to pursue a professional career in some aspect of clinical or medical oncology.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-teaching-excellence-and-why-we-don%27t-feature-in-the-teaching-excellence-framework-resultshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-teaching-excellence-and-why-we-don%27t-feature-in-the-teaching-excellence-framework-resultsOur teaching excellence – and why we don't feature in the Teaching Excellence Framework resultsDr Barbara Pittam, Registrar and Director of Academic Services at the ICR, explains why as a postgraduate research institute, we do not feature in recent rankings of University teaching excellence – despite our world-leading teaching environment.https://www.icr.ac.uk/news-archive%2ficr-awards-ceremony-celebrates-graduating-students-and-pioneering-researchershttps://www.icr.ac.uk/news-archive%2ficr-awards-ceremony-celebrates-graduating-students-and-pioneering-researchersICR Awards Ceremony celebrates graduating students and pioneering researchersThree internationally recognised cancer researchers have been honoured alongside graduating students and former staff members at the annual ICR Awards Ceremony.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fphd-students-reflect-on-life-at-the-icrhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fphd-students-reflect-on-life-at-the-icrPhD students reflect on life at the ICRWe asked some of our talented PhD students to reflect on all aspects of life at The Institute of Cancer Research, London, for our inaugural Teaching Week.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmore-than-your-average-spreadsheet---one-phd-student%27s-quest-to-understand-cancer-geneticshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmore-than-your-average-spreadsheet---one-phd-student%27s-quest-to-understand-cancer-geneticsMore than your average spreadsheet - one PhD student's quest to understand cancer geneticsAs part of our inaugural Teaching Week we hear from second-year PhD student Molly Went – who gives us a behind the scenes look at her research into the genetics of multiple myeloma, and provides general insights from working in a leading cancer research lab.https://www.icr.ac.uk/news-archive%2ffirst-ever-teaching-week-to-promote-the-icr-s-academic-excellencehttps://www.icr.ac.uk/news-archive%2ffirst-ever-teaching-week-to-promote-the-icr-s-academic-excellenceFirst ever Teaching Week to promote the ICR’s academic excellenceThe ICR will be underlining its credentials as a global leader in cancer research, education and training through a series of communication activities during its first ever Teaching Week.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseven-ways-we-are-outsmarting-cancer-by-overcoming-drug-resistancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseven-ways-we-are-outsmarting-cancer-by-overcoming-drug-resistanceSeven ways we are outsmarting cancer by overcoming drug resistanceDrug resistance is the single biggest challenge in cancer treatment today. Here’s how we’re rising to the challenge.https://www.icr.ac.uk/news-archive%2ftime-since-chemotherapy-may-predict-response-to-olaparib-in-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2ftime-since-chemotherapy-may-predict-response-to-olaparib-in-ovarian-cancerTime since chemotherapy may predict response to olaparib in ovarian cancerWomen with advanced ovarian cancer who begin treatment with olaparib are more likely to respond to the drug if it has been more than a year since their last round of chemotherapy, according to new research.https://www.icr.ac.uk/news-archive%2fimmunotherapy-kinder-than-chemotherapy-for-patients-with-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fimmunotherapy-kinder-than-chemotherapy-for-patients-with-head-and-neck-cancerImmunotherapy kinder than chemotherapy for patients with head and neck cancerThe immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the negative effects of the disease on patients’ quality of life.https://www.icr.ac.uk/news-archive%2ficr-scientist-dr-sebastian-guettler-awarded-prestigious-lister-prizehttps://www.icr.ac.uk/news-archive%2ficr-scientist-dr-sebastian-guettler-awarded-prestigious-lister-prizeICR scientist Dr Sebastian Guettler awarded prestigious Lister PrizeDr Sebastian Guettler, a Team Leader at The Institute of Cancer Research, London, has been recognised as one of the most promising young biomedical researchers in the UK and awarded a Lister Institute Research Prize Fellowship.https://www.icr.ac.uk/news-archive%2fseven-new-dna-regions-linked-to-kidney-cancer-riskhttps://www.icr.ac.uk/news-archive%2fseven-new-dna-regions-linked-to-kidney-cancer-riskSeven new DNA regions linked to kidney cancer riskResearchers have found seven new single-letter changes to DNA that are linked to an increased chance of developing renal cell carcinoma.https://www.icr.ac.uk/news-archive%2fnew-three-in-one-blood-test-opens-door-to-precision-medicine-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-three-in-one-blood-test-opens-door-to-precision-medicine-for-prostate-cancerNew three-in-one blood test opens door to precision medicine for prostate cancerScientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.https://www.icr.ac.uk/news-archive%2fbetter-treatment-for-high-risk-children-s-cancer-shown-in-major-trialhttps://www.icr.ac.uk/news-archive%2fbetter-treatment-for-high-risk-children-s-cancer-shown-in-major-trialBetter treatment for high-risk children’s cancer shown in major trialChildren with a high-risk, deadly form of neuroblastoma will benefit from a treatment regime that improves survival and reduces side-effects, following the publication of a major European trial.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-reasons-we-re-excited-by-how-structural-biology-is-advancing-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-reasons-we-re-excited-by-how-structural-biology-is-advancing-cancer-researchFive reasons we’re excited by how structural biology is advancing cancer researchWe are excited about the potential that structural biology has to enable the discovery of brand new cancer drugs. Here are five reasons why this field is of great interest to our researchers.https://www.icr.ac.uk/news-archive%2fgenetic-testing-can-pick-out-men-at-increased-risk-of-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-can-pick-out-men-at-increased-risk-of-testicular-cancerGenetic testing can pick out men at increased risk of testicular cancerTesting for large numbers of genetic changes can identify men with over a 10-fold increased risk of testicular cancer, a new study shows.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ftribute-to-patrick-johnston-a-true-leader-and-champion-of-cancer-research-and-cancer-patientshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ftribute-to-patrick-johnston-a-true-leader-and-champion-of-cancer-research-and-cancer-patientsTribute to Patrick (Paddy) Johnston – a true leader and champion of cancer research and cancer patientsOur Chief Executive pays tribute to Professor Patrick Johnston, Vice Chancellor of Queen's University Belfast and formerly Director of the Centre for Cancer Research and Cell Biology, who died this month.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2017-brca-targeting-drug-olaparib-offers-hope-for-women-with-advanced-breast-cancer-with-inherited-mutationhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2017-brca-targeting-drug-olaparib-offers-hope-for-women-with-advanced-breast-cancer-with-inherited-mutationASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutationResults presented at the ASCO 2017 Annual Meeting in Chicago show olaparib delays progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients?https://www.icr.ac.uk/news-archive%2fnew-chemotherapy-approach-offers-breast-cancer-patients-a-better-quality-of-lifehttps://www.icr.ac.uk/news-archive%2fnew-chemotherapy-approach-offers-breast-cancer-patients-a-better-quality-of-lifeNew chemotherapy approach offers breast cancer patients a better quality of lifeUsing a different chemotherapy drug to prevent the return of breast cancer is just as effective as the current standard approach and crucially means a better quality of life, according to a new clinical trial.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2017-using-targeted-cancer-drugs-earlier-in-treatment-abiraterone-benefits-prostate-cancer-patients-at-diagnosishttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-2017-using-targeted-cancer-drugs-earlier-in-treatment-abiraterone-benefits-prostate-cancer-patients-at-diagnosisASCO 2017: Using targeted cancer drugs earlier in treatment – abiraterone benefits prostate cancer patients at diagnosisSarah Wells reviews clinical trial data presented at ASCO showing that prostate cancer drug abiraterone – discovered at the ICR – could have even greater benefits when used at the start of treatment.https://www.icr.ac.uk/news-archive%2fadding-abiraterone-to-standard-treatment-improves-prostate-cancer-survival-by-almost-40https://www.icr.ac.uk/news-archive%2fadding-abiraterone-to-standard-treatment-improves-prostate-cancer-survival-by-almost-40ASCO 2017: Adding abiraterone to standard treatment improves prostate cancer survival by almost 40%Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37%, according to the results of one of the largest-ever clinical trials for prostate cancer.https://www.icr.ac.uk/news-archive%2fovarian-cancer-drug-delivers-very-promising-results-in-early-trialhttps://www.icr.ac.uk/news-archive%2fovarian-cancer-drug-delivers-very-promising-results-in-early-trialASCO 2017: Ovarian cancer drug delivers ‘very promising’ results in early trialA new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-annual-meeting-2017-to-highlight-advances-in-patient-and-survivor-carehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fasco-annual-meeting-2017-to-highlight-advances-in-patient-and-survivor-careASCO Annual Meeting 2017 to highlight advances in patient and survivor careAs leading ICR researchers head to Chicago for the world’s biggest cancer conference, we look forward to the latest advances they will be presenting.https://www.icr.ac.uk/news-features%2flatest-features%2fpioneering-genetic-research-into-myeloma-is-spearheading-our-search-for-new-treatmentshttps://www.icr.ac.uk/news-features%2flatest-features%2fpioneering-genetic-research-into-myeloma-is-spearheading-our-search-for-new-treatmentsPioneering genetic research into myeloma is spearheading our search for new treatmentsOur researchers are pioneering a new understanding of the genetic complexities of myeloma and the innovative use of existing drugs as treatments, as Conor McKeever finds out.https://www.icr.ac.uk/news-archive%2fnew-genetic-cause-of-kidney-cancer-in-children-discoveredhttps://www.icr.ac.uk/news-archive%2fnew-genetic-cause-of-kidney-cancer-in-children-discoveredNew genetic cause of kidney cancer in children discoveredScientists have identified a new genetic cause of a childhood kidney cancer called Wilms tumour – revealing insights into how loss of control of chromosome number can lead to cancer.https://www.icr.ac.uk/news-archive%2fnew-benchmarking-resource-for-tricky-type-of-gene-mutationhttps://www.icr.ac.uk/news-archive%2fnew-benchmarking-resource-for-tricky-type-of-gene-mutationNew benchmarking resource for tricky type of gene mutationResearchers have made available a vital resource that will allow labs throughout the world to assess how accurately they are detecting an important type of mutation.https://www.icr.ac.uk/news-archive%2fstudy-suggests-new-approach-to-assess-patients-cancer-geneticshttps://www.icr.ac.uk/news-archive%2fstudy-suggests-new-approach-to-assess-patients-cancer-geneticsStudy suggests new approach to assess patients’ cancer geneticsScientists have used mathematics to predict how many biopsy samples need to be taken from a patient to give an accurate picture of the genetic make-up of their cancer.https://www.icr.ac.uk/news-archive%2ffree-breathing-mri-scan-is-accurate-enough-for-clinical-trialshttps://www.icr.ac.uk/news-archive%2ffree-breathing-mri-scan-is-accurate-enough-for-clinical-trials‘Free-breathing’ MRI scan is accurate enough for clinical trialsA magnetic resonance imaging (MRI) technique that can measure tumours in the body could be an easy and reliable way to assess lung cancer’s response to treatment, a new study shows.https://www.icr.ac.uk/news-archive%2fpotent-targeted-cancer-drug-shows-promise-in-first-patient-trialshttps://www.icr.ac.uk/news-archive%2fpotent-targeted-cancer-drug-shows-promise-in-first-patient-trialsPotent targeted cancer drug shows promise in first patient trialsAn experimental cancer drug which targets cancer cells’ DNA repair could be an effective treatment for a range of cancers, the first clinical trial in patients has shown.https://www.icr.ac.uk/news-archive%2fscientists-build-molecule-to-disrupt-cancer-proteinhttps://www.icr.ac.uk/news-archive%2fscientists-build-molecule-to-disrupt-cancer-proteinScientists build molecule to disrupt cancer proteinResearchers have designed and built a molecule that blocks the action of a protein linked to tumour development.https://www.icr.ac.uk/news-archive%2frecord-breaking-christmas-appeal-raises-over-100-000https://www.icr.ac.uk/news-archive%2frecord-breaking-christmas-appeal-raises-over-100-000Record-breaking Christmas appeal raises over £100,000Our 2016 Christmas appeal raised a record-breaking £100,000, giving a huge boost to two of our research projects into breast cancer and sarcoma.https://www.icr.ac.uk/news-archive%2fscientists-carbon-date-cancer-and-unearth-secrets-about-what-could-help-make-it-deadlyhttps://www.icr.ac.uk/news-archive%2fscientists-carbon-date-cancer-and-unearth-secrets-about-what-could-help-make-it-deadlyScientists ‘carbon date’ cancer and unearth secrets about what could help make it deadlyScientists have put precise timings on the history of a patient’s cancer for the first time, effectively ‘carbon dating’ the different stages in the disease’s progression.https://www.icr.ac.uk/news-archive%2fparkinson-s-gene-mutation-discovered-in-one-third-of-cancershttps://www.icr.ac.uk/news-archive%2fparkinson-s-gene-mutation-discovered-in-one-third-of-cancersParkinson’s gene mutation discovered in one third of cancersA gene found in a hereditary form of Parkinson’s disease is mutated in a third of all human cancers – and helps regulate one of the disease’s most commonly activated cell signalling mechanisms, a new study reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsharing-success-how-team-science-is-helping-us-break-new-ground-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsharing-success-how-team-science-is-helping-us-break-new-ground-in-cancer-researchSharing success: how team science is helping us break new ground in cancer researchIn 2016, the winning project in the ICR’s first Team Science Competition aimed to bring together Big Data mathematicians and computational biologists with clinicians and physicists developing radiotherapy treatment. One year on, we spoke to team co-leader Dr Navita Somaiah about the secrets of successfully leading a large multidisciplinary team.https://www.icr.ac.uk/news-archive%2ficr-s-professor-richard-houlston-made-fellow-of-the-royal-societyhttps://www.icr.ac.uk/news-archive%2ficr-s-professor-richard-houlston-made-fellow-of-the-royal-societyICR’s Professor Richard Houlston made Fellow of the Royal SocietyProfessor Richard Houlston, a world-leading geneticist at the ICR, has been elected as a Fellow of the Royal Society in recognition of his outstanding contribution to cancer research.https://www.icr.ac.uk/news-archive%2fstudy-unravels-the-genetics-of-childhood-overgrowthhttps://www.icr.ac.uk/news-archive%2fstudy-unravels-the-genetics-of-childhood-overgrowthStudy unravels the genetics of childhood ‘overgrowth’Researchers have undertaken the world’s largest genetic study of childhood overgrowth syndromes – providing new insights into their causes and new recommendations for genetic testing.https://www.icr.ac.uk/news-archive%2fnew-blood-test-predicts-who-will-benefit-from-targeted-prostate-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-blood-test-predicts-who-will-benefit-from-targeted-prostate-cancer-treatmentsNew blood test predicts who will benefit from targeted prostate cancer treatmentsA new blood test could predict which men with advanced prostate cancer will respond to new targeted treatments for the disease.https://www.icr.ac.uk/news-features%2flatest-features%2fhow-our-26-dedicated-london-marathon-2017-runners-are-set-to-raise-over-90-000-for-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fhow-our-26-dedicated-london-marathon-2017-runners-are-set-to-raise-over-90-000-for-cancer-researchHow our 26 dedicated London Marathon 2017 runners are set to raise over £90,000 for cancer researchWith donations to our dedicated #teamICR London Marathon runners set to top £90,000, Laura Mulkerne looks back on a day of gruelling effort, raucous support and hard-won medals.https://www.icr.ac.uk/news-archive%2ficr-and-sutton-council-call-for-improved-transport-infrastructure-as-minister-for-london-visits-the-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2ficr-and-sutton-council-call-for-improved-transport-infrastructure-as-minister-for-london-visits-the-london-cancer-hubICR and Sutton Council call for improved transport infrastructure as Minister for London visits The London Cancer HubThe Minister for London, Gavin Barwell MP, heard calls for improved public transport in Sutton on a visit to The London Cancer Hub.https://www.icr.ac.uk/news-archive%2fexperimental-drug-could-lead-to-potent-combination-in-breast-and-other-cancershttps://www.icr.ac.uk/news-archive%2fexperimental-drug-could-lead-to-potent-combination-in-breast-and-other-cancersExperimental drug could lead to potent combination in breast and other cancersAn experimental drug could be used in combination with chemotherapy as a treatment for breast and other cancers, new research shows.https://www.icr.ac.uk/news-archive%2fscientists-identify-new-way-of-attacking-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-new-way-of-attacking-breast-cancerScientists identify new way of attacking breast cancerScientists have discovered a brand new way of attacking breast cancer that could lead to a new generation of drugs.https://www.icr.ac.uk/news-archive%2fweekly-radiotherapy-suitable-for-bladder-cancer-patients-too-frail-for-aggressive-treatment-study-findshttps://www.icr.ac.uk/news-archive%2fweekly-radiotherapy-suitable-for-bladder-cancer-patients-too-frail-for-aggressive-treatment-study-findsWeekly radiotherapy suitable for bladder cancer patients too frail for aggressive treatment, study findsOlder patients with bladder cancer who are too frail for aggressive treatment could benefit from weekly image-guided radiotherapy, new research reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-brought-our-science-to-the-public-and-found-out-that-everyone-has-a-research-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-brought-our-science-to-the-public-and-found-out-that-everyone-has-a-research-storyWe brought our science to the public – and found out that everyone has a research storyThe ICR’s Dr Anna Wilkins recently spoke to members of the public at two meetings of the University of the Third Age. Helen Craig blogs about the events.https://www.icr.ac.uk/news-archive%2fnivolumab-not-recommend-for-relapsed-or-metastatic-head-and-neck-cancer-on-the-nhshttps://www.icr.ac.uk/news-archive%2fnivolumab-not-recommend-for-relapsed-or-metastatic-head-and-neck-cancer-on-the-nhsNivolumab not recommended for relapsed or metastatic head-and-neck cancer on the NHSThe immunotherapy nivolumab will not be recommended for the treatment of patients with relapsed or metastatic head-and-cancer, under a new draft technology appraisal issued by NICE.https://www.icr.ac.uk/news-archive%2ficr-ranked-among-top-five-in-the-world-for-university-researchhttps://www.icr.ac.uk/news-archive%2ficr-ranked-among-top-five-in-the-world-for-university-researchICR ranked among top five in the world for university researchThe Institute of Cancer Research, London, has ranked in the top five higher education institutions in the world for research in a new independent evaluation funded by the European Commission.https://www.icr.ac.uk/news-archive%2fdrug-makes-head-and-neck-cancer-more-sensitive-to-radiotherapyhttps://www.icr.ac.uk/news-archive%2fdrug-makes-head-and-neck-cancer-more-sensitive-to-radiotherapyDrug makes head-and-neck cancer more sensitive to radiotherapyA drug that has shown promise in breast and lung cancer trials also makes the combination of chemotherapy and radiotherapy more successful at killing head-and-neck cancers, a new study has found.https://www.icr.ac.uk/news-features%2flatest-features%2fjennifer-s-running-for-the-icrhttps://www.icr.ac.uk/news-features%2flatest-features%2fjennifer-s-running-for-the-icrFind out why our supporter Jennifer is running the London Marathon for #teamICRIt’s nearly that time of year again, when runners from all over the world lace up their trainers and tackle one of the most famous marathons there is: the Virgin Money London Marathon. But why do our supporters do it? Heather Lacey caught up with one of our supporters, Jennifer Herbert, to find out why she decided to support our vital work by running 26.2 gruelling miles.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-rank-among-world-s-best-at-working-with-industry-to-take-discoveries-to-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-rank-among-world-s-best-at-working-with-industry-to-take-discoveries-to-patientsWhy we rank among world’s best at working with industry to take discoveries to patientsThe ICR was recently ranked among the world’s top universities for working with industry. Brad Gellert discusses what is needed for academic and business collaboration to turn research into breakthroughs for patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-to-succeed-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-to-succeed-in-cancer-researchHow to succeed in cancer researchThe AACR conference, one of the largest annual cancer research events, is getting underway. Dr Eva Sharpe spoke to our Chief Executive, Professor Paul Workman, beforehand about a discussion he will lead there tonight on supporting career development in cancer research. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-annual-meeting-kicks-off-tomorrow-in-washington-d.chttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2faacr-annual-meeting-kicks-off-tomorrow-in-washington-d.c2017 AACR Annual Meeting kicks off in Washington, D.C.As leading researchers from The Institute of Cancer Research head to the US we look forward to the latest advancements in cancer research they will be presenting.https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-combination-shows-promise-in-early-trialhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-combination-shows-promise-in-early-trialProstate cancer drug combination shows promise in early trialA combination of two drugs for prostate cancer is safe and shows signs of effectiveness in patients with advanced, aggressive disease, an early-stage trial reports.https://www.icr.ac.uk/news-archive%2fscientists-create-artificial-mini-tumours-to-study-cancer-geneshttps://www.icr.ac.uk/news-archive%2fscientists-create-artificial-mini-tumours-to-study-cancer-genesScientists create artificial ‘mini tumours’ to study cancer genesA new technique to screen clumps of cancer cells in the lab which act like miniature tumours could help scientists discover potential new cancer drugs.https://www.icr.ac.uk/news-archive%2fdiscovery-club-learns-how-maths-can-model-cancer-evolutionhttps://www.icr.ac.uk/news-archive%2fdiscovery-club-learns-how-maths-can-model-cancer-evolutionDiscovery Club learns how maths can model cancer evolutionMembers of our Discovery Club gathered at The Royal Society in London earlier this month to learn about the role mathematics plays in modern cancer research and treatment.https://www.icr.ac.uk/news-archive%2flargest-ever-brain-cancer-study-reveals-new-secrets-to-inherited-riskhttps://www.icr.ac.uk/news-archive%2flargest-ever-brain-cancer-study-reveals-new-secrets-to-inherited-riskLargest-ever brain cancer study reveals new secrets to inherited riskScientists have uncovered a treasure trove of information about the genetic causes of brain cancer in the largest-ever study of the disease.https://www.icr.ac.uk/news-archive%2ficr-scientists-awarded-1.5m-precision-medicine-funding-for-targeted-less-toxic-childhood-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2ficr-scientists-awarded-1.5m-precision-medicine-funding-for-targeted-less-toxic-childhood-cancer-treatmentsICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatmentsScientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdoing-more-for-deadly-cancers-new-push-to-improve-pancreatic-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdoing-more-for-deadly-cancers-new-push-to-improve-pancreatic-cancer-treatmentDoing more for deadly cancers: new push to improve pancreatic cancer treatmentWhile survival from breast and prostate cancer is increasing, there has been barely any improvement for patients with a lesser-known type of the disease – pancreatic cancer. But a new precision medicine initiative is looking to change that.https://www.icr.ac.uk/news-archive%2f14m-investment-marks-first-step-towards-new-london-cancer-hubhttps://www.icr.ac.uk/news-archive%2f14m-investment-marks-first-step-towards-new-london-cancer-hub£14m investment marks first step towards new London Cancer HubAmbitions to create the world’s leading hub for cancer research and treatment have taken an important first step forward as the London Borough of Sutton invests £14 million in NHS land needed to develop the site.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-ways-we-plan-to-inspire-the-next-generation-of-cancer-researchers-and-clinicianshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-ways-we-plan-to-inspire-the-next-generation-of-cancer-researchers-and-cliniciansThree ways we plan to inspire the next generation of cancer researchers and cliniciansHow a new strategy to develop learning and teaching at the ICR aims to educate and train the cancer research leaders of tomorrow.https://www.icr.ac.uk/news-archive%2fcells-retain-a-memory-of-dna-damage-as-part-of-the-repair-processhttps://www.icr.ac.uk/news-archive%2fcells-retain-a-memory-of-dna-damage-as-part-of-the-repair-processCells retain a memory of DNA damage as part of the repair processCells are able to remember that DNA damage has occurred as they pass through the process of cell division, a new study reveals.https://www.icr.ac.uk/news-archive%2fnew-genetic-link-to-acute-lymphoblastic-leukaemiahttps://www.icr.ac.uk/news-archive%2fnew-genetic-link-to-acute-lymphoblastic-leukaemiaNew genetic link to acute lymphoblastic leukaemiaA single letter change to DNA is linked to an increased risk of one of the most common forms of childhood leukaemia, a new study has revealed.https://www.icr.ac.uk/news-archive%2ffundraisers-celebrated-by-prime-minister-with-points-of-light-award-after-raising-over-1m-for-our-researchhttps://www.icr.ac.uk/news-archive%2ffundraisers-celebrated-by-prime-minister-with-points-of-light-award-after-raising-over-1m-for-our-researchFundraisers celebrated by Prime Minister with Points of Light Award after raising over £1m for our researchPrime Minister Theresa May has celebrated the devoted fundraising of Karen and Kevin Capel, who set up Christopher’s Smile in memory of their son who died of a brain tumour.https://www.icr.ac.uk/news-archive%2fhodgkin-lymphoma-survivors-at-high-risk-of-second-cancershttps://www.icr.ac.uk/news-archive%2fhodgkin-lymphoma-survivors-at-high-risk-of-second-cancersHodgkin lymphoma survivors at high risk of second cancersPatients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.https://www.icr.ac.uk/news-archive%2fmore-breast-cancer-patients-could-benefit-from-promising-new-treatment-genetic-study-revealshttps://www.icr.ac.uk/news-archive%2fmore-breast-cancer-patients-could-benefit-from-promising-new-treatment-genetic-study-revealsMore breast cancer patients could benefit from promising new treatment, genetic study revealsA greater number of breast cancers are genetically similar to rarer cases with faulty BRCA1 or BRCA2 genes, according to research from the Wellcome Trust Sanger Institute and The Institute of Cancer Research, London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-now-is-our-best-chance-to-change-rules-on-childhood-cancer-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-now-is-our-best-chance-to-change-rules-on-childhood-cancer-trialsWhy now is our best chance to change rules on childhood cancer trialsThe Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust are calling on the European Commission to update rules on testing new drugs in children. Dr Eva Sharpe, our Senior Policy and Engagement Manager, explains why.https://www.icr.ac.uk/news-archive%2fseize-chance-to-close-eu-loophole-in-childhood-cancer-treatments-say-cancer-expertshttps://www.icr.ac.uk/news-archive%2fseize-chance-to-close-eu-loophole-in-childhood-cancer-treatments-say-cancer-expertsSeize chance to close EU loophole in childhood cancer treatments, say cancer expertsCancer treatments are not being trialled in children because of outdated European regulations which are in urgent need of reform, say cancer experts.https://www.icr.ac.uk/news-archive%2four-joint-letter-calling-for-reform-of-european-regulations-on-clinical-trials-in-childrenhttps://www.icr.ac.uk/news-archive%2four-joint-letter-calling-for-reform-of-european-regulations-on-clinical-trials-in-childrenOur joint letter calling for reform of European regulations on clinical trials in childrenRead the letter written in support of calls from The Institute of Cancer Research, London and its partner signatories to reform European regulations around trials of cancer treatments in children.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fphd-insights-seeing-individual-atoms-using-structural-biologyhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fphd-insights-seeing-individual-atoms-using-structural-biologyPhD insights: ’Seeing’ individual atoms using structural biologyStudying the shapes and roles of proteins is vital in understanding how cells malfunction in cancer. But it’s easier said than done when these molecules are invisible to the naked eye…https://www.icr.ac.uk/news-archive%2fprotein-postcodes-point-to-new-targets-for-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fprotein-postcodes-point-to-new-targets-for-cancer-treatmentProtein ‘postcodes’ point to new targets for cancer treatmentScientists have devised a new technique that establishes the ‘postcode’ for proteins within cancer cells, as a faster, more accurate way of identifying signals that are driving cancer growth.https://www.icr.ac.uk/news-archive%2ficr-and-imperial-college-london-launch-the-cancer-research-centre-of-excellencehttps://www.icr.ac.uk/news-archive%2ficr-and-imperial-college-london-launch-the-cancer-research-centre-of-excellenceICR and Imperial College London launch the Cancer Research Centre of ExcellenceThe Institute of Cancer Research and Imperial College London have marked the start of a new joint partnership with the launch of the Cancer Research Centre of Excellence (CRCE) in London.https://www.icr.ac.uk/news-archive%2fgood-news-as-cancer-patients-will-get-access-to-more-treatments-after-price-dropshttps://www.icr.ac.uk/news-archive%2fgood-news-as-cancer-patients-will-get-access-to-more-treatments-after-price-dropsGood news as cancer patients will get access to more treatments after price dropsPharmaceutical companies have lowered the prices of 14 key cancer medicines as part of a review by NICE of the old Cancer Drugs Fund (CDF).https://www.icr.ac.uk/news-archive%2fexperimental-drug-could-prevent-cancer-dna-repair-to-boost-radiotherapy-effectshttps://www.icr.ac.uk/news-archive%2fexperimental-drug-could-prevent-cancer-dna-repair-to-boost-radiotherapy-effectsExperimental drug could prevent cancer DNA repair to boost radiotherapy effectsTreating bladder and head-and-neck cancers with an experimental drug called CCT244747 makes radiotherapy more successful at killing them, scientists have discovered.https://www.icr.ac.uk/news-archive%2ficr-partners-in-a-new--180-c-cryo-em-machinehttps://www.icr.ac.uk/news-archive%2ficr-partners-in-a-new--180-c-cryo-em-machineICR partners in a new -180°C ‘cryo-EM’ machineA new £3m grant from Wellcome to a consortium led by scientists at Imperial College London and The Institute of Cancer Research, London, will help to purchase a state-of-the-art cryo-electron microscopy machine.https://www.icr.ac.uk/news-features%2flatest-features%2ffive-stunning-scientific-images-of-our-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2ffive-stunning-scientific-images-of-our-cancer-researchFive stunning scientific images of our cancer researchResearchers at the ICR were challenged to capture in a single image their ground-breaking work making the discoveries that defeat cancer.https://www.icr.ac.uk/news-archive%2fnew-molecular-building-block-to-aid-drug-discoveryhttps://www.icr.ac.uk/news-archive%2fnew-molecular-building-block-to-aid-drug-discoveryNew molecular ‘building block’ to aid drug discoveryScientists have discovered how to make a synthetic molecule that could be a key building block in the production of future cancer drugs.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrca-targeting-drug-olaparib-could-offer-hope-for-women-with-advanced-breast-cancer-with-inherited-mutationhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrca-targeting-drug-olaparib-could-offer-hope-for-women-with-advanced-breast-cancer-with-inherited-mutationBRCA-targeting drug olaparib could offer hope for women with advanced breast cancer with inherited mutationAstraZeneca has issued a statement saying a phase III trial of the ovarian cancer drug olaparib significantly delayed progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients?https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fa-pioneer-of-cancer-drug-discovery-professor-ken-harrap-1931-2017https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fa-pioneer-of-cancer-drug-discovery-professor-ken-harrap-1931-2017A pioneer of cancer drug discovery – Professor Ken Harrap 1931–2017Our Chief Executive remembers Professor Ken Harrap, a pioneer of cancer research who was instrumental to the discovery of life saving treatments including carboplatin and raltitrexed, who died last week.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhat-can-cancer-research-learn-from-the-origin-of-lifehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhat-can-cancer-research-learn-from-the-origin-of-lifeWhat can cancer research learn from ‘the origin of life’?It was standing room only when UCL's Dr Nick Lane presented at the ICR's annual 'Darwin Lecture' last week. Dr Christopher Tape was in attendance to find out why cancer biologists should be interested in the 'evolutionary big bang' that gave rise to eukaryotic cells.https://www.icr.ac.uk/news-archive%2ficr-team-is-part-of-winning-consortium-for-cancer-research-uk-grand-challengehttps://www.icr.ac.uk/news-archive%2ficr-team-is-part-of-winning-consortium-for-cancer-research-uk-grand-challengeICR team is part of winning consortium for Cancer Research UK ‘Grand Challenge’Scientists from The Institute of Cancer Research, London, are part of a consortium that has won one of the first wave of ‘Grand Challenge’ grants from Cancer Research UK.https://www.icr.ac.uk/news-archive%2fnon-profit-drug-development-could-cut-cost-of-cancer-medicineshttps://www.icr.ac.uk/news-archive%2fnon-profit-drug-development-could-cut-cost-of-cancer-medicinesNon-profit drug development could cut cost of cancer medicinesUniversities should work with new forms of commercial partner to take their own cancer drugs to market and drive down the ‘spiralling’ cost of new medicines, leading experts propose.https://www.icr.ac.uk/news-archive%2fimmune-system-genes-linked-to-most-common-type-of-leukaemiahttps://www.icr.ac.uk/news-archive%2fimmune-system-genes-linked-to-most-common-type-of-leukaemiaImmune system genes linked to most common type of leukaemiaPeople who inherit genetic variants affecting the function of their immune system are at increased risk of developing the most common form of leukaemia, a major new study reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-genomics-revolution-opportunities-and-challenges-for-21st-century-healthcarehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-genomics-revolution-opportunities-and-challenges-for-21st-century-healthcareThe genomics revolution: opportunities and challenges for 21st century healthcareThe future of healthcare played a prominent part in discussion at the recent Festival of Genomics conference in London. Dr Keith Bradnam reports on what the genomics revolution means for routine medical care – and for cancer research in particular.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-knows-no-borders-and-nor-should-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-knows-no-borders-and-nor-should-scienceCancer knows no borders – and nor should scienceOn World Cancer Day, our researchers and some of their international collaborators explain why it is essential that science can operate as a global endeavour. https://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-palbociclibhttps://www.icr.ac.uk/news-archive%2fthe-icr-responds-to-decision-by-nice-not-to-recommend-palbociclibThe ICR responds to decision by NICE not to recommend palbociclibThe Institute of Cancer Research, London, has expressed disappointment that the breast cancer drug palbociclib will not be made available to patients and is calling for urgent discussions to reduce the price of the drug.https://www.icr.ac.uk/news-archive%2fcell-shape-maps-could-point-to-new-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fcell-shape-maps-could-point-to-new-cancer-treatmentsCell shape ‘maps’ could point to new cancer treatmentsScientists have created a ‘map’ linking the shape of breast cancer cells to the activation of their genes, which could point towards new treatments and help improve the effectiveness of immunotherapies.https://www.icr.ac.uk/news-features%2flatest-features%2fpresident-trump-the-cancer-moonshot-and-the-new-war-on-drug-pricinghttps://www.icr.ac.uk/news-features%2flatest-features%2fpresident-trump-the-cancer-moonshot-and-the-new-war-on-drug-pricingPresident Trump, the Cancer Moonshot and the new war on drug pricingWhat could the new US administration mean for drug discovery and development – in the US and the UK? Dr Angela Kukula, the ICR's Director of Enterprise, reports back from the world’s biggest life sciences conference, BioWeek SF.https://www.icr.ac.uk/news-archive%2ffundraiser-recognised-by-prime-minister-with-points-of-light-award-after-raising-millions-for-icr-researchhttps://www.icr.ac.uk/news-archive%2ffundraiser-recognised-by-prime-minister-with-points-of-light-award-after-raising-millions-for-icr-researchFundraiser recognised by Prime Minister with Points of Light Award after raising millions for ICR researchPrime Minister Theresa May has celebrated the dedicated fundraising of Lynn Lucas, who set up a Trust to fund research into a rare form of cancer in memory of her son Chris.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fcomputing-cancer-amidst-a-deluge-of-datahttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fcomputing-cancer-amidst-a-deluge-of-dataComputing cancer amidst a deluge of dataThe reams of data now being generated by genome sequencing provide challenges and opportunities in our hunt for better ways to understand and treat cancer, as ICR bioinformatician Dr Philip Law explains.https://www.icr.ac.uk/news-archive%2fscientists-discover-powerful-new-inhibitor-of-cancer-stress-signalhttps://www.icr.ac.uk/news-archive%2fscientists-discover-powerful-new-inhibitor-of-cancer-stress-signalScientists discover powerful new inhibitor of cancer stress signalScientists have discovered a powerful new chemical inhibitor that blocks a crucial system used by cancer cells to cope with stress.https://www.icr.ac.uk/news-archive%2fscientists-raise-warning-over-drugs-targeting-key-cancer-mechanismhttps://www.icr.ac.uk/news-archive%2fscientists-raise-warning-over-drugs-targeting-key-cancer-mechanismScientists raise warning over drugs targeting key cancer mechanismScientists have expressed concerns about developing drugs against two molecular targets that had been considered highly promising, after finding that specifically blocking their function adversely affected normal body systems.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-opened-our-labs-to-a-local-artist-the-piece-she-created-is-a-metaphor-for-hopehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-opened-our-labs-to-a-local-artist-the-piece-she-created-is-a-metaphor-for-hopeWe opened our labs to a local artist: the piece she created is a metaphor for hope What role does art have in communicating the essence of cancer research? We invited local artist Tia Arberry to the ICR's labs to create a piece of art inspired by our work: the result was an intriguing combination of art and science.https://www.icr.ac.uk/news-archive%2fscientists-find-how-cancer-cells-can-shrug-off-physical-constraints-on-growth-and-spreadhttps://www.icr.ac.uk/news-archive%2fscientists-find-how-cancer-cells-can-shrug-off-physical-constraints-on-growth-and-spreadScientists find how cancer cells can shrug off physical constraints on growth and spreadScientists have revealed how cancer cells are able to break free of the physical restraints imposed by their surroundings in order to grow and spread around the body.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fthe-acceptable-poison-drinking-alcohol-will-remain-a-personal-choice-despite-links-to-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fthe-acceptable-poison-drinking-alcohol-will-remain-a-personal-choice-despite-links-to-cancerThe acceptable poison: drinking alcohol will remain a personal choice despite links to cancerAlcohol is everywhere in modern Western society, but with growing evidence of a link to cancer, ICR PhD student Kevin Litchfield asks how long the status quo will last.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fteam-science-it-s-all-greek-to-mehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fteam-science-it-s-all-greek-to-meTeam Science? It’s all Greek to meScientists from different disciplines must take care with how they communicate if we are to deliver true team science.https://www.icr.ac.uk/news-archive%2fgene-test-could-pinpoint-patients-sensitive-to-new-type-of-cancer-drughttps://www.icr.ac.uk/news-archive%2fgene-test-could-pinpoint-patients-sensitive-to-new-type-of-cancer-drugGene test could pinpoint patients sensitive to new type of cancer drugTesting for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmore-than-one-way-to-skin-a-cat-at-least-in-our-geneshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmore-than-one-way-to-skin-a-cat-at-least-in-our-genesMore than one way to skin A CAT… at least in our genesFinding the harmful 'spelling mistakes' among our 20,000 genes is a gargantuan task, but one which could unlock the causes of genetic disorders.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-greater-understanding-of-cancer-s-metabolism-could-mean-better-treatments-for-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-greater-understanding-of-cancer-s-metabolism-could-mean-better-treatments-for-patientsA greater understanding of cancer’s metabolism could mean better treatments for patientsImproving our knowledge of the genetic, metabolic and molecular factors that affect tumour growth will help us develop and select the best treatments for patients.https://www.icr.ac.uk/news-archive%2fcancer-protein-steers-tumour-cells-and-could-help-them-spread-through-the-bodyhttps://www.icr.ac.uk/news-archive%2fcancer-protein-steers-tumour-cells-and-could-help-them-spread-through-the-bodyCancer protein ‘steers’ tumour cells and could help them spread through the bodyScientists have discovered a protein that helps steer cells to move in particular directions – which could help them to spread around the body.https://www.icr.ac.uk/news-features%2flatest-features%2fparent-led-charities-and-their-inspirational-support-for-the-icr-s-child-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fparent-led-charities-and-their-inspirational-support-for-the-icr-s-child-cancer-researchParent-led charities and their inspirational support for the ICR’s child cancer researchHow families are making a hugely valuable contribution towards our research to improve the outlook for children with cancer.https://www.icr.ac.uk/news-archive%2fannual-climb-of-life-event-in-the-lake-district-raises-a-record-102-000-for-the-icr-s-researchhttps://www.icr.ac.uk/news-archive%2fannual-climb-of-life-event-in-the-lake-district-raises-a-record-102-000-for-the-icr-s-researchAnnual Climb of Life event in the Lake District raises a record £102,000 for the ICR’s researchThe annual climbing fundraising event held in support of The Institute of Cancer Research, London has broken all previous records by raising £102,210.https://www.icr.ac.uk/news-features%2flatest-features%2ftop-10-scientific-achievements-of-2016https://www.icr.ac.uk/news-features%2flatest-features%2ftop-10-scientific-achievements-of-2016Top 10 scientific achievements of 2016We've selected our top 10 discoveries of 2015/16 – chosen because they best represent the breadth of our research and our ambitions under the new research strategy.https://www.icr.ac.uk/news-archive%2ficr-scientists-attend-10-downing-street-reception-with-prime-minister-theresa-may-for-sarcoma-researchhttps://www.icr.ac.uk/news-archive%2ficr-scientists-attend-10-downing-street-reception-with-prime-minister-theresa-may-for-sarcoma-researchICR scientists attend 10 Downing Street reception with Prime Minister Theresa May for sarcoma researchLeading researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust attended a reception at Number 10 Downing Street with Prime Minister Theresa May – to raise awareness of research into sarcoma, a rare cancer. https://www.icr.ac.uk/news-archive%2ftv-royalty-attend-icr-s-carols-from-chelsea-service-to-raise-money-for-our-cancer-researchhttps://www.icr.ac.uk/news-archive%2ftv-royalty-attend-icr-s-carols-from-chelsea-service-to-raise-money-for-our-cancer-researchTV royalty attend ICR’s Carols from Chelsea service to raise money for our cancer researchMonty Python star Michael Palin, The Crown’s Vanessa Kirby and Downton Abbey’s Elizabeth McGovern attended Carols from Chelsea, a major highlight of the ICR’s fundraising calendar.https://www.icr.ac.uk/news-archive%2fcancer-research-technology-pioneer-fund-announces-investment-in-blood-cancer-drugshttps://www.icr.ac.uk/news-archive%2fcancer-research-technology-pioneer-fund-announces-investment-in-blood-cancer-drugsCancer research technology pioneer fund announces investment in blood cancer drugsThe Cancer Research Technology (CRT) Pioneer Fund today (Thursday) announced an investment to develop a promising new class of drugs for blood cancer.https://www.icr.ac.uk/news-archive%2fscientists-reveal-safety-catch-within-all-dividing-cellshttps://www.icr.ac.uk/news-archive%2fscientists-reveal-safety-catch-within-all-dividing-cellsScientists reveal ‘safety catch’ within all dividing cellsResearchers have made a major discovery about how cells control when to divide – representing a step forward in scientists’ understanding of one of the most fundamental processes of life.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fteaching-pigeons-to-spot-gorillashttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fteaching-pigeons-to-spot-gorillasTeaching pigeons to spot gorillasWhy the future may be digital for detecting cancer in imaging scans – almost.https://www.icr.ac.uk/news-archive%2fmap-of-drugs-reveals-uncharted-waters-in-search-for-new-treatmentshttps://www.icr.ac.uk/news-archive%2fmap-of-drugs-reveals-uncharted-waters-in-search-for-new-treatmentsMap of drugs reveals uncharted waters in search for new treatmentsScientists have created a map of all 1,578 licensed drugs and their mechanisms of action – as a means of identifying ‘uncharted waters’ in the search for future treatments.https://www.icr.ac.uk/news-archive%2ficr-and-royal-marsden-secure-new-funding-for-cancer-research-uk-centrehttps://www.icr.ac.uk/news-archive%2ficr-and-royal-marsden-secure-new-funding-for-cancer-research-uk-centreICR and Royal Marsden secure new funding for Cancer Research UK CentreThe ICR and The Royal Marsden have successfully renewed our Cancer Research UK Centre and secured very substantial funding.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-women-in-science-computers-and-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-women-in-science-computers-and-drug-discoveryCelebrating women in science, drug discovery and computingDr Bissan Al-Lazakani recently spoke at Ada Lovelace Live 2016, an evening of scientific performances celebrating the woman who has been described as the world’s first computer programmer. https://www.icr.ac.uk/news-archive%2favoiding-penile-bulb-with-radiotherapy-could-save-men-with-prostate-cancer-from-harmful-side-effectshttps://www.icr.ac.uk/news-archive%2favoiding-penile-bulb-with-radiotherapy-could-save-men-with-prostate-cancer-from-harmful-side-effectsAvoiding penile bulb with radiotherapy could save men with prostate cancer from harmful side-effectsResearchers have found that avoiding the penile bulb when giving radiotherapy treatment to men with prostate cancer could reduce the severity of erectile dysfunction.https://www.icr.ac.uk/news-archive%2ftricky-gene-mutations-detected-by-new-easy-to-use-decon-softwarehttps://www.icr.ac.uk/news-archive%2ftricky-gene-mutations-detected-by-new-easy-to-use-decon-softwareTricky gene mutations detected by new easy-to-use DECoN softwareScientists have developed an easy-to-use software tool that can detect important genetic mutations that previously needed to be identified by a separate test. https://www.icr.ac.uk/news-archive%2fnew-research-uncovers-mechanism-for-genetic-risk-of-myelomahttps://www.icr.ac.uk/news-archive%2fnew-research-uncovers-mechanism-for-genetic-risk-of-myelomaNew research uncovers mechanism for genetic risk of myelomaResearchers have identified a mechanism that may explain how a key genetic variant acts to increase the risk of developing myeloma.https://www.icr.ac.uk/news-archive%2fnew-era-in-cancer-treatment-to-begin-as-sadiq-khan-opens-revolutionary-radiotherapy-machinehttps://www.icr.ac.uk/news-archive%2fnew-era-in-cancer-treatment-to-begin-as-sadiq-khan-opens-revolutionary-radiotherapy-machineNew era in cancer treatment to begin as Mayor of London Sadiq Khan opens revolutionary radiotherapy machineA pioneering new type of radiotherapy machine opened on Tuesday by Mayor of London Sadiq Khan has the potential to transform the care of cancer patients by directing radiation even at tumours that move during treatment.https://www.icr.ac.uk/news-archive%2fenhanced-mri-techniques-can-spot-brain-tumour-growthhttps://www.icr.ac.uk/news-archive%2fenhanced-mri-techniques-can-spot-brain-tumour-growthEnhanced MRI techniques can spot brain tumour growthA combination of functional imaging techniques can help determine which regions of a brain tumour are likely to spread undetected, according to a new study.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-icr-helps-to-%27shine-a-light-on-cancer%27-for-the-bbc-one-breakfast-showhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-icr-helps-to-%27shine-a-light-on-cancer%27-for-the-bbc-one-breakfast-showThe ICR helps to 'shine a light on cancer' for the BBC One Breakfast show Scientists from The Institute of Cancer Research, London took part in a week-long focus on cancer by BBC One's Breakfast show that aired on 14–18 November 2016.https://www.icr.ac.uk/news-archive%2fone-thousand-cancer-patients-have-gene-testing-through-efficient-affordable-new-processhttps://www.icr.ac.uk/news-archive%2fone-thousand-cancer-patients-have-gene-testing-through-efficient-affordable-new-processOne thousand cancer patients have gene testing through efficient, affordable new processA thousand breast and ovarian cancer patients have now benefited from a faster BRCA gene testing process that was developed in the UK and is being adopted around the globe.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-good-the-bad-and-the-immune-system-how-viruses-can-fight-cancer-and-each-otherhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-good-the-bad-and-the-immune-system-how-viruses-can-fight-cancer-and-each-otherThe good, the bad and the immune system — how viruses can fight cancer, and each otherThe ICR’s Professor Alan Melcher and colleagues at the University of Leeds have been pitting viruses against each other to treat cancer. https://www.icr.ac.uk/news-archive%2fcough-virus-kills-liver-cancer-cells-and-the-hepatitis-virus-that-causes-themhttps://www.icr.ac.uk/news-archive%2fcough-virus-kills-liver-cancer-cells-and-the-hepatitis-virus-that-causes-them'Cough virus' kills liver cancer cells — and the hepatitis virus that causes themA virus that causes childhood coughs and colds could help in the fight against primary liver cancer, according to a study.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-could-exciting-new-treatments-to-block-cancer-evolution-halt-drug-resistancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-could-exciting-new-treatments-to-block-cancer-evolution-halt-drug-resistanceNCRI 2016: Could exciting new treatments to block cancer evolution halt drug resistance?Cancer can evolve stubborn resistance to even our best therapies, threatening our ability to treat tumours effectively. But new research promises to solve this pressing problem and deliver better survival rates for patients.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-what-we-learned-from-the-uk-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-what-we-learned-from-the-uk-s-largest-cancer-conferenceNCRI 2016: What we learned from the UK’s largest cancer conferenceWe consider what the NCRI conference tells us about the future of cancer treatment. https://www.icr.ac.uk/news-archive%2ftake-multiple-biopsies-in-studies-of-personalised-breast-cancer-treatments-study-sayshttps://www.icr.ac.uk/news-archive%2ftake-multiple-biopsies-in-studies-of-personalised-breast-cancer-treatments-study-saysTake multiple biopsies in studies of personalised breast cancer treatments, study saysNew research finds taking single biopsy can miss key genetic mutations that could influence drug susceptibility and resistancehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-cancer-treatment-goes-viralhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-cancer-treatment-goes-viralNCRI 2016: Why viruses could be the next big thing in cancer treatmentAt the NCRI Conference 2016, ICR Professors Alan Melcher and Kevin Harrington, along with other UK experts, presented their recent advances in using viruses to treat cancer.https://www.icr.ac.uk/news-archive%2fdr-andrea-sottoriva-wins-cancer-research-uk-future-leaders-in-cancer-research-prizehttps://www.icr.ac.uk/news-archive%2fdr-andrea-sottoriva-wins-cancer-research-uk-future-leaders-in-cancer-research-prizeDr Andrea Sottoriva wins Cancer Research UK Future Leaders in Cancer Research PrizeDr Andrea Sottoriva has been awarded a Cancer Research UK Future Leaders in Cancer Research Prize at this year’s National Cancer Research Institute (NCRI) Conference in Liverpool.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fncri-2016-five-reasons-why-we-must-prioritise-innovative-drug-discovery-to-tackle-cancer-s-challengeshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fncri-2016-five-reasons-why-we-must-prioritise-innovative-drug-discovery-to-tackle-cancer-s-challengesNCRI 2016: Five reasons why we must prioritise innovative drug discovery to tackle cancer’s challenges ICR Chief Executive Professor Paul Workman took part in a debate at the NCRI conference on how to prioritise research spending — on creating new treatments or repurposing old ones. Here he outlines the arguments in favour of innovation.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-collaboration-and-communication-at-the-heart-of-future-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fncri-2016-collaboration-and-communication-at-the-heart-of-future-cancer-researchNCRI 2016: Collaboration and communication at the heart of future cancer researchThe National Cancer Research Institute (NCRI) Cancer Conference in Liverpool is the UK's largest meeting of cancer researchers and doctors. The Institute of Cancer Research, London, is there and we will be reporting on major findings from the conference and cutting-edge science from ICR researchers.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fbringing-science-and-art-togetherhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fbringing-science-and-art-togetherBringing science and art togetherFor the first time, The Institute of Cancer Research, London, took part in Sutton’s Imagine Festival of the Arts, hosting an evening of science and interactivity in Sutton Library. Molly Went, a PhD student at the ICR, writes about the experience. https://www.icr.ac.uk/news-archive%2frelish-is-pickled-to-protect-flies-from-immunogenic-havochttps://www.icr.ac.uk/news-archive%2frelish-is-pickled-to-protect-flies-from-immunogenic-havocRelish is pickled to protect flies from immunogenic havocTwo proteins called Pickle and Relish help to keep fruit flies healthy, a new study shows.https://www.icr.ac.uk/news-archive%2ficr-launches-new-phd-recruitment-drivehttps://www.icr.ac.uk/news-archive%2ficr-launches-new-phd-recruitment-driveICR launches new PhD recruitment driveThe Institute of Cancer Research, London, has begun its annual drive to recruit the best and brightest PhD students, as advertisements for 12 fully funded research projects go live.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-ways-the-icr-is-defeating-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-ways-the-icr-is-defeating-breast-cancerFive ways the ICR is defeating breast cancerWe look back at some of the many influential breakthroughs our scientists have made; breakthroughs that have not only aided our primary understanding of breast cancer but which have also helped in the development of new and improved treatments for this disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-new-drugs-are-helping-more-breast-cancer-patients-survive-longerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-new-drugs-are-helping-more-breast-cancer-patients-survive-longerHow new drugs are helping more breast cancer patients survive longerAs part of Breast Cancer Awareness Month, Graham Shaw looks at the trailblazing work by researchers at The Institute of Cancer Research, London, to bring some promising new drugs for breast cancer closer to the clinic. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fan-ambitious-plan-for-faster-access-to-innovative-treatmentshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fan-ambitious-plan-for-faster-access-to-innovative-treatmentsAn ambitious plan for faster access to innovative treatmentsProfessor Paul Workman comments on the recently published findings of the Accelerated Access Review and the importance of speeding up the adoption of innovative drugs and medical technologies.https://www.icr.ac.uk/news-archive%2fnew-drug-combination-could-target-incurable-infant-cancerhttps://www.icr.ac.uk/news-archive%2fnew-drug-combination-could-target-incurable-infant-cancerNew drug combination could target incurable infant cancerScientists have identified a drug combination that could be effective against a childhood cancer for which there is no current cure.https://www.icr.ac.uk/news-archive%2fpromising-drug-target-for-aggressive-triple-negative-breast-cancers-identifiedhttps://www.icr.ac.uk/news-archive%2fpromising-drug-target-for-aggressive-triple-negative-breast-cancers-identifiedPromising drug target for aggressive ‘triple-negative’ breast cancers identifiedScientists have identified a molecule crucial to the growth of triple-negative breast cancers that they believe could now be targeted by drugs to help treat patients resistant to chemotherapy.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseven-of-the-most-promising-new-approaches-in-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseven-of-the-most-promising-new-approaches-in-cancer-treatmentSeven of the most promising new approaches in cancer treatmentDr Angela Kukula, the ICR’s Director of Enterprise, was asked at a recent conference to give a rundown of innovative science in action — and where it will deliver real progress in our efforts to defeat cancer. Here, Dr Eva Sharpe reports on the seven areas she highlighted.https://www.icr.ac.uk/news-archive%2fsecondary-breast-and-bowel-cancers-found-to-grow-by-piggy-backing-on-patients-blood-vesselshttps://www.icr.ac.uk/news-archive%2fsecondary-breast-and-bowel-cancers-found-to-grow-by-piggy-backing-on-patients-blood-vesselsSecondary breast and bowel cancers found to grow by piggy-backing on patients’ blood vesselsNew research into breast and bowel cancers that have spread to the liver shows that some tumours power their growth using pre-existing blood vessels rather than developing new ones.https://www.icr.ac.uk/news-archive%2fstatement-about-abpi-report-into-the-changing-uk-drug-discovery-landscapehttps://www.icr.ac.uk/news-archive%2fstatement-about-abpi-report-into-the-changing-uk-drug-discovery-landscapeStatement about ABPI report into the changing UK drug discovery landscapeThe Institute of Cancer Research, London, has issued the following statement from Chief Executive Professor Paul Workman in response to a new report by the Association of the British Pharmaceutical Industry (ABPI) on the changing UK drug discovery landscape.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeating-the-house-how-mathematics-is-helping-beat-cancer-at-its-own-gamehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbeating-the-house-how-mathematics-is-helping-beat-cancer-at-its-own-gameBeating the house: how mathematics is helping beat cancer at its own gameThe ICR’s Dr Andrea Sottoriva recently spoke to BBC Radio 4 about the importance of mathematics to understand the biological processes driving cancer, and how it could help us come up with new ways to beat the disease.https://www.icr.ac.uk/news-features%2flatest-features%2fovercoming-the-evolution-of-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fovercoming-the-evolution-of-cancerOvercoming the evolution of cancerCancer evolution can lead to the emergence of drug resistance, so the ICR and The Royal Marsden are working to unravel cancer's complexity and open up new approaches to treatment.https://www.icr.ac.uk/news-archive%2ffaulty-molecule-offers-new-target-for-treating-liver-cancerhttps://www.icr.ac.uk/news-archive%2ffaulty-molecule-offers-new-target-for-treating-liver-cancerFaulty molecule offers new target for treating liver cancerBlocking a single faulty molecule in a biological process that drives the growth of advanced liver cancers could offer a new way to treat the disease, researchers have found.https://www.icr.ac.uk/news-archive%2f2d-building-blocks-can-build-better-3d-drugshttps://www.icr.ac.uk/news-archive%2f2d-building-blocks-can-build-better-3d-drugs2D building blocks can build better 3D drugsCreating cancer drugs that better resemble 3D structures in cells is all about how you put the building blocks together, a new study has shown. https://www.icr.ac.uk/news-archive%2fquarter-of-a-million-pound-icr-fundraiser-needs-your-vote-for-justgiving-awardshttps://www.icr.ac.uk/news-archive%2fquarter-of-a-million-pound-icr-fundraiser-needs-your-vote-for-justgiving-awardsQuarter-of-a-million-pound ICR fundraiser needs your vote for JustGiving AwardsBowel cancer patient and fundraiser Tim Morgan has been nominated for JustGiving’s Fundraising Team of the Year award after raising more than £250,000 for the ICR — and he needs your vote!https://www.icr.ac.uk/news-archive%2fgame-changing-immunotherapy-doubles-head-and-neck-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fgame-changing-immunotherapy-doubles-head-and-neck-cancer-survival‘Game-changing’ immunotherapy doubles head and neck cancer survivalAn immunotherapy drug has been hailed as a potential ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer — a disease which is notoriously difficult to treat.https://www.icr.ac.uk/news-archive%2ficr-chief-executive-professor-paul-workman-receives-award-from-spanish-cancer-foundationhttps://www.icr.ac.uk/news-archive%2ficr-chief-executive-professor-paul-workman-receives-award-from-spanish-cancer-foundationICR Chief Executive Professor Paul Workman receives award from Spanish Cancer FoundationProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, has been given a special award for his services to cancer research by the charity Cancer Research Innovation Spain (CRIS) at its annual gala ball. https://www.icr.ac.uk/news-archive%2fprofessor-stan-kaye-awarded-cancer-research-uk-lifetime-achievement-prizehttps://www.icr.ac.uk/news-archive%2fprofessor-stan-kaye-awarded-cancer-research-uk-lifetime-achievement-prizeProfessor Stan Kaye awarded Cancer Research UK lifetime achievement prizeProfessor Stan Kaye, one of The Institute of Cancer Research, London’s most eminent researchers, has been awarded the Lifetime Achievement in Cancer Research Prize by Cancer Research UK.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseeing-with-sound-how-ultrasound-is-helping-doctors-home-in-on-cancershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fseeing-with-sound-how-ultrasound-is-helping-doctors-home-in-on-cancersSeeing with sound: how ultrasound is helping doctors home in on cancersUltrasound is familiar to many as a way to monitor the health of foetuses during pregnancy, but this affordable, safe imaging technology could also improve radiotherapy for cancer.https://www.icr.ac.uk/news-archive%2fself-assembling-molecules-help-key-signalling-pathway-in-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fself-assembling-molecules-help-key-signalling-pathway-in-bowel-cancer‘Self-assembling’ molecules help key signalling pathway in bowel cancerA key protein in cancer ‘self-assembles’ into structures which help drive signalling processes that fuel bowel cancer growth, a new study shows.https://www.icr.ac.uk/news-archive%2fnew-treatment-approach-may-offer-hope-to-patients-with-aggressive-childhood-cancershttps://www.icr.ac.uk/news-archive%2fnew-treatment-approach-may-offer-hope-to-patients-with-aggressive-childhood-cancersNew treatment approach may offer hope to patients with aggressive childhood cancersTargeted treatments that attack cancer metabolism could treat some of the most aggressive childhood cancers caused by faulty activation of a gene called MYCN, new research outlines.https://www.icr.ac.uk/news-archive%2f3d-printed-abdoman-could-transform-radiotherapyhttps://www.icr.ac.uk/news-archive%2f3d-printed-abdoman-could-transform-radiotherapy3D-printed ‘AbdoMan’ could transform radiotherapyA 3D-printed human torso is helping doctors safely and reliably model ‘internal radiation’ treatments for cancer.https://www.icr.ac.uk/news-archive%2fstatement-about-nice-decision-on-t-vec-for-treating-inoperable-metastatic-melanomahttps://www.icr.ac.uk/news-archive%2fstatement-about-nice-decision-on-t-vec-for-treating-inoperable-metastatic-melanomaStatement about NICE decision on T-VEC for treating inoperable metastatic melanomaThe Institute of Cancer Research, London, has issued the following statement from Professor Kevin Harrington in response to the decision by NICE to approve the use of talimogene laherparepvec (T-VEC) for treating inoperable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.https://www.icr.ac.uk/news-archive%2fmen-with-high-genetic-chance-of-bowel-cancer-could-have-lower-risk-with-healthy-lifestyleshttps://www.icr.ac.uk/news-archive%2fmen-with-high-genetic-chance-of-bowel-cancer-could-have-lower-risk-with-healthy-lifestylesMen with high genetic chance of bowel cancer could have lower risk with healthy lifestylesMen with a high genetic risk of developing bowel cancer over the next 25 years could have a lower risk of developing the disease if they also have a healthy lifestyle, according to a study.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-this-icr-phd-student-is-helping-bring-personalised-medicine-to-children-with-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-this-icr-phd-student-is-helping-bring-personalised-medicine-to-children-with-cancerHow this ICR PhD student is helping bring personalised medicine to children with cancerAs we near the end of September’s Childhood Cancer Awareness Month, Elisa Izquierdo Delgado, a PhD student at The Institute of Cancer Research, London, talks to Gabriella Beer about a new test she’s developed that could transform treatment for children with cancer.https://www.icr.ac.uk/news-archive%2fpronai-licenses-oncology-drug-targeting-dna-damage-response-checkpoint-kinase-1-(chk1)-from-crt-pioneer-fund-ukhttps://www.icr.ac.uk/news-archive%2fpronai-licenses-oncology-drug-targeting-dna-damage-response-checkpoint-kinase-1-(chk1)-from-crt-pioneer-fund-ukProNAi licenses oncology drug targeting DNA damage response Checkpoint kinase 1 (Chk1) from CRT Pioneer Fund, UKProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1).https://www.icr.ac.uk/news-archive%2fhigh-tech-scan-after-chemotherapy-could-indicate-whether-head-and-neck-cancer-treatment-is-workinghttps://www.icr.ac.uk/news-archive%2fhigh-tech-scan-after-chemotherapy-could-indicate-whether-head-and-neck-cancer-treatment-is-workingHigh-tech scan after chemotherapy could indicate whether head and neck cancer treatment is workingAn advanced type of scan merging two imaging technologies could tell doctors whether treatment for head and neck cancer is working after just one cycle of chemotherapy.https://www.icr.ac.uk/news-archive%2fcancer-patients-optimism-exceeds-what-phase-i-trials-can-deliverhttps://www.icr.ac.uk/news-archive%2fcancer-patients-optimism-exceeds-what-phase-i-trials-can-deliverCancer patients’ optimism exceeds what phase I trials can deliverAround half of cancer patients referred for phase I clinical trials thought their tumours would shrink, even after their clinician explained that the trial might not have the desired outcome, a new study reveals.https://www.icr.ac.uk/news-archive%2fnew-triple-therapy-could-boost-treatment-and-prevent-relapse-in-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fnew-triple-therapy-could-boost-treatment-and-prevent-relapse-in-head-and-neck-cancerNew triple therapy could boost treatment and prevent relapse in head and neck cancerCombining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemo-radiotherapy for head and neck cancers and stop cells becoming resistant to treatment.https://www.icr.ac.uk/news-archive%2fnew-ecosystem-test-strongly-predicts-ovarian-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fnew-ecosystem-test-strongly-predicts-ovarian-cancer-survivalNew ‘ecosystem’ test strongly predicts ovarian cancer survivalAssessing the cell ‘ecosystems’ at sites where ovarian cancer has spread round the body strongly predicts the chances of surviving from the disease, a new study reports.https://www.icr.ac.uk/news-archive%2fstudy-shows-blood-vessel-cells-are-helping-breast-cancers-enter-bloodstream-and-spread-around-bodyhttps://www.icr.ac.uk/news-archive%2fstudy-shows-blood-vessel-cells-are-helping-breast-cancers-enter-bloodstream-and-spread-around-bodyStudy shows blood vessel cells are helping breast cancers enter bloodstream and spread around bodyScientists have discovered that non-cancer cells that wrap around blood vessels — called ‘pericytes’ — are helping breast cancer cells enter the bloodstream and spread around the body through the production of a key molecule called endosialin.https://www.icr.ac.uk/news-archive%2ficr-and-royal-marsden-awarded-43-million-for-biomedical-research-centrehttps://www.icr.ac.uk/news-archive%2ficr-and-royal-marsden-awarded-43-million-for-biomedical-research-centreICR and The Royal Marsden awarded £43 million for Biomedical Research CentreThe Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have successfully renewed their joint Biomedical Research Centre.https://www.icr.ac.uk/news-archive%2fcounting-cancer-cells-in-blood-could-be-key-to-telling-whether-prostate-cancer-treatment-is-workinghttps://www.icr.ac.uk/news-archive%2fcounting-cancer-cells-in-blood-could-be-key-to-telling-whether-prostate-cancer-treatment-is-workingCounting cancer cells in blood could be key to telling whether prostate cancer treatment is workingA drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-a-new-class-of-cancer-drugs-light-the-way-forward-for-treating-leukaemiahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-a-new-class-of-cancer-drugs-light-the-way-forward-for-treating-leukaemiaCould a new class of cancer drugs light the way forward for treating leukaemia?Targeting a group of malfunctioning components of cell division named after the Northern Lights may present a new way to treat leukaemia. Liz Burtally finds out the latest on this promising line of research.https://www.icr.ac.uk/news-archive%2ficr-secures-new-wellcome-trust-clinical-phdshttps://www.icr.ac.uk/news-archive%2ficr-secures-new-wellcome-trust-clinical-phdsICR secures new Wellcome Trust clinical PhDsThe Institute of Cancer Research, London, will host a new clinical PhD programme in cancer research, after being awarded funding from the Wellcome Trust.https://www.icr.ac.uk/news-archive%2ficr-chief-executive-paul-workman-named-one-of-london-s-most-influential-peoplehttps://www.icr.ac.uk/news-archive%2ficr-chief-executive-paul-workman-named-one-of-london-s-most-influential-peopleICR Chief Executive Paul Workman named one of London’s most influential peopleProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, has been named in the Evening Standard’s Progress 1000 list of the most influential people in London.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdiscovering-hope-the-future-of-drug-research-for-prostate-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdiscovering-hope-the-future-of-drug-research-for-prostate-cancerDiscovering hope: the future of drug research for prostate cancerTechnological advances are helping scientists to identify new drug targets for prostate cancer. Steve Robinson looks at some of the most exciting avenues for future treatment — and the challenges that must be overcome to make them a reality.https://www.icr.ac.uk/news-archive%2fsingle-letter-variation-in-dna-linked-to-longer-bowel-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fsingle-letter-variation-in-dna-linked-to-longer-bowel-cancer-survivalSingle-letter variation in DNA linked to longer bowel cancer survivalA single letter in a strand of DNA within tumours is linked to longer survival times for some patients treated for bowel cancer, a new study reveals.https://www.icr.ac.uk/news-archive%2ficr-s-microscope-appeal-raises-50-000-for-cutting-edge-researchhttps://www.icr.ac.uk/news-archive%2ficr-s-microscope-appeal-raises-50-000-for-cutting-edge-researchICR’s microscope appeal raises £50,000 for cutting-edge researchA new fundraising appeal by The Institute of Cancer Research, London, for research using a new type of high-tech microscope has raised an amazing £50,000. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-promise-of-liquid-biopsies-could-a-simple-blood-test-change-the-future-of-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-promise-of-liquid-biopsies-could-a-simple-blood-test-change-the-future-of-cancer-treatmentThe promise of liquid biopsies — could a simple blood test change the future of cancer treatment? Liquid biopsies could usher in a new era of personalised cancer treatment. Dr Claire Bithell explores the latest research in this fast-moving field.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fradioactive-cancer-drug-radium-223-offers-another-treatment-option-for-prostate-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fradioactive-cancer-drug-radium-223-offers-another-treatment-option-for-prostate-cancerRadioactive cancer drug radium-223 offers another treatment option for prostate cancerDr Eva Sharpe reflects on NICE’s decision to approve use of radium-223 pre-chemotherapy — and the impact it can have on the lives of patients.https://www.icr.ac.uk/news-archive%2fstatement-about-nice-decision-on-radium-223https://www.icr.ac.uk/news-archive%2fstatement-about-nice-decision-on-radium-223Statement about NICE decision on radium-223The Institute of Cancer Research, London, has issued a statement in response to the decision by NICE to approve the use of radium-223 for treating hormone-relapsed prostate cancer with bone metastases if docetaxel chemotherapy isn’t a suitable treatment option. https://www.icr.ac.uk/news-archive%2fblood-test-to-spot-new-breast-cancer-subtype-delays-progression-for-twice-as-longhttps://www.icr.ac.uk/news-archive%2fblood-test-to-spot-new-breast-cancer-subtype-delays-progression-for-twice-as-longBlood test to spot new breast cancer subtype delays progression for twice as longA blood test that detects when the most common form of breast cancer has become resistant to treatment could double the average time it takes for the disease to progress, from around two-and-a-half to around six months, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-summer-placement-in-cancer-research-could-open-doors-for-undergraduateshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-summer-placement-in-cancer-research-could-open-doors-for-undergraduatesThe ICR summer studentship scheme: introducing undergraduates to the world of cancer researchEvery year, the ICR invites applications for our summer studentship scheme allowing undergraduate students to sample life in a cancer research laboratory. In this post, Helen Craig explores the opportunities afforded by this scheme.https://www.icr.ac.uk/news-archive%2fscientists-discover-drug-combination-slows-lung-cancer-cell-growthhttps://www.icr.ac.uk/news-archive%2fscientists-discover-drug-combination-slows-lung-cancer-cell-growthScientists discover drug combination slows lung cancer cell growthScientists have shown that a drug combination slows cancer cell growth in a type of non-small cell lung cancer when tested in the lab, offering potential for developing new treatments in the future. https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fescape-from-reductionist-valleyhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fescape-from-reductionist-valleyEscape from reductionist valleyDr Christopher Tape, a Sir Henry Wellcome Postdoctoral Fellow at the ICR, ponders the limitations of a reductionist approach in cancer biology and looks at how new approaches might provide for a more holistic view of how tumours behave.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-should-women-know-about-the-new-hrt-and-breast-cancer-studyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-should-women-know-about-the-new-hrt-and-breast-cancer-studyHRT and breast cancer riskIn this Science Talk blog post, Claire Bithell looks at what our latest research about HRT and breast cancer means for women.https://www.icr.ac.uk/news-archive%2feffect-of-combined-hrt-on-breast-cancer-risk-likely-to-have-been-underestimated-new-study-findshttps://www.icr.ac.uk/news-archive%2feffect-of-combined-hrt-on-breast-cancer-risk-likely-to-have-been-underestimated-new-study-findsEffect of combined HRT on breast cancer risk likely to have been underestimated, new study findsThe effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published in the British Journal of Cancer.https://www.icr.ac.uk/news-features%2flatest-features%2finspired-by-the-olympicshttps://www.icr.ac.uk/news-features%2flatest-features%2finspired-by-the-olympicsInspired by the Olympics?If watching the stunning displays of athleticism in the Olympics inspired you to become more physically active, then why not consider becoming part of Team ICR? You could take part in one or more of our exciting sporting challenges — either here in the UK or around the worldhttps://www.icr.ac.uk/news-archive%2fstudy-links-two-genes-to-breast-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fstudy-links-two-genes-to-breast-cancer-survivalStudy links two genes to breast cancer survivalTesting for the activity of two genes could pick out women who are at increased risk of dying from their breast cancers, suggests a new study of almost 2,000 patients.https://www.icr.ac.uk/news-archive%2fresearch-reveals-insights-into-genetics-behind-common-blood-cancerhttps://www.icr.ac.uk/news-archive%2fresearch-reveals-insights-into-genetics-behind-common-blood-cancerResearch reveals insights into genetics behind common blood cancerScientists have identified how an inherited genetic variant, associated with an increased risk of developing the most common type of leukaemia, helps cancer cells survive. https://www.icr.ac.uk/news-archive%2fradiotherapy-supercharges-cancer-targeting-viruses-to-treat-deadly-skin-cancerhttps://www.icr.ac.uk/news-archive%2fradiotherapy-supercharges-cancer-targeting-viruses-to-treat-deadly-skin-cancerRadiotherapy supercharges cancer-targeting viruses to treat deadly skin cancerCombining radiotherapy with a virus that targets cancer cells kicks both treatments into overdrive to treat the deadliest form of skin cancer, a new study shows.https://www.icr.ac.uk/news-archive%2fgene-testing-in-rare-tumour-type-could-uncover-cancer-familieshttps://www.icr.ac.uk/news-archive%2fgene-testing-in-rare-tumour-type-could-uncover-cancer-familiesGene testing in rare tumour type could uncover ‘cancer families’Genetic testing of patients with a rare form of cancer that can affect children and young adults can pick out genetic errors hidden in their family tree which increase the risk of a wide variety of cancer types.https://www.icr.ac.uk/news-features%2flatest-features%2ffinding-new-ways-to-fight-cancer-by-targeting-the-stress-responsehttps://www.icr.ac.uk/news-features%2flatest-features%2ffinding-new-ways-to-fight-cancer-by-targeting-the-stress-responseFinding new ways to fight cancer by targeting the stress responseDespite major breakthroughs in creating innovative cancer drugs, there is still an urgent need to explore more treatment options. Liz Burtally finds out how researchers are now looking outside the historical, well-trodden cancer pathways usually targeted by cancer therapeutics.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-our-supporters-fund-phd-students-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-our-supporters-fund-phd-students-in-cancer-researchWhy our supporters fund PhD students in cancer researchThe Institute of Cancer Research, London, is committed to training the next generation of cancer researchers. But why do our supporters choose to fund our PhD students? Graham Shaw spoke to head and neck cancer charity Oracle Cancer Trust to find out. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fon-chris-marshall-s-wheel-a-celebration-of-his-scientific-achievementshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fon-chris-marshall-s-wheel-a-celebration-of-his-scientific-achievementsOn Chris Marshall’s Wheel – a celebration of his scientific achievements‘On Chris Marshall’s Wheel’ – gathered Professor Marshall’s friends, colleagues, peers and mentees to hear about some of the science around the world that his game-changing research had sparked or influenced. Liz Burtally picks out some of the highlights. https://www.icr.ac.uk/news-archive%2fstarting-gun-fired-in-race-against-cancer-evolutionhttps://www.icr.ac.uk/news-archive%2fstarting-gun-fired-in-race-against-cancer-evolutionStarting gun fired in race against cancer evolutionWorld-leading cancer researchers have revealed plans to create a new generation of ‘anti-evolution’ therapies, designed to combat cancer’s lethal ability to adapt and evade treatment.https://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-named-regius-professor-of-cancer-research-by-royal-decreehttps://www.icr.ac.uk/news-archive%2fprofessor-johann-de-bono-named-regius-professor-of-cancer-research-by-royal-decreeProfessor Johann de Bono named Regius Professor of Cancer Research by Royal DecreeThe Institute of Cancer Research, London, has named Professor Johann de Bono as Regius Professor of Cancer Research.https://www.icr.ac.uk/news-archive%2fceremony-welcomes-professors-paul-workman-and-jon-pines-as-royal-society-fellowshttps://www.icr.ac.uk/news-archive%2fceremony-welcomes-professors-paul-workman-and-jon-pines-as-royal-society-fellowsCeremony welcomes Professors Paul Workman and Jon Pines as Royal Society FellowsProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, and Professor Jon Pines, Head of Cancer Biology, will be admitted as Fellows to the Royal Society on Friday 15 July 2016 — the greatest honour in UK science.https://www.icr.ac.uk/news-archive%2fstress-and-adverse-life-events-unlikely-to-cause-breast-cancer-major-study-findshttps://www.icr.ac.uk/news-archive%2fstress-and-adverse-life-events-unlikely-to-cause-breast-cancer-major-study-findsStress and adverse life events unlikely to cause breast cancer, major study findsDay-to-day psychological stress and adverse life events are unlikely to increase a woman’s risk of developing breast cancer, according to a major new prospective study. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-clinical-trials-must-change-to-give-hope-to-children-with-brain-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-clinical-trials-must-change-to-give-hope-to-children-with-brain-cancerWhy clinical trials must change to give hope to children with brain cancerChildhood cancers can be very different from adult cancers, even if they look the same under the microscope. Henry French looks back on a recent research summit which looked to a future of smarter clinical trials for children.https://www.icr.ac.uk/news-archive%2fsimplifying-access-to-gene-testing-for-women-with-ovarian-cancer-improves-treatment-choices-and-could-save-liveshttps://www.icr.ac.uk/news-archive%2fsimplifying-access-to-gene-testing-for-women-with-ovarian-cancer-improves-treatment-choices-and-could-save-livesSimplifying access to gene testing for women with ovarian cancer improves treatment choices and could save livesA new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalised cancer management and their relatives to benefit from cancer prevention strategies.https://www.icr.ac.uk/news-archive%2fnew-test-predicts-breast-cancer-spread-faster-and-more-accurately-than-nhs-testhttps://www.icr.ac.uk/news-archive%2fnew-test-predicts-breast-cancer-spread-faster-and-more-accurately-than-nhs-testNew test predicts breast cancer spread faster and more accurately than NHS testA new test could predict the risk of a woman’s breast cancer spreading within 10 years of diagnosis more accurately than the current NICE-approved test, Oncotype DX, scientists have found.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-i-co-operate-with-scientists-across-disciplines-to-discover-new-cancer-drugshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-i-co-operate-with-scientists-across-disciplines-to-discover-new-cancer-drugsHow I co-operate with scientists across disciplines to discover new cancer drugsThe latest innovations in science often involve researchers working together across numerous disciplines. Katie Pollock, a PhD student at The Institute of Cancer Research, London, describes what it’s like working across different fields of cancer research.https://www.icr.ac.uk/news-archive%2fgenetic-testing-can-help-deliver-precision-medicine-to-men-with-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-can-help-deliver-precision-medicine-to-men-with-advanced-prostate-cancerGenetic testing can help deliver precision medicine to men with advanced prostate cancerGenetic testing in men with advanced prostate cancer could pick up a significant proportion whose disease may be caused by inherited mutations in genes involved in repairing DNA damage, a major new study reveals.https://www.icr.ac.uk/news-archive%2fnew-genetic-findings-help-explain-inherited-predisposition-to-myelomahttps://www.icr.ac.uk/news-archive%2fnew-genetic-findings-help-explain-inherited-predisposition-to-myelomaNew genetic findings help explain inherited predisposition to myelomaResearchers have identified eight new genetic variations in the human genome that could be linked to an increased risk of developing myeloma.https://www.icr.ac.uk/news-archive%2fleukaemia-drug-shows-potential-for-rarer-type-of-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fleukaemia-drug-shows-potential-for-rarer-type-of-ovarian-cancerLeukaemia drug shows potential for rarer type of ovarian cancerA drug already approved for leukaemia patients could also be used to treat a specific type of ovarian cancer, according to new research.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-ultrasound-to-navigate-the-path-of-cancer-treatmenthttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-ultrasound-to-navigate-the-path-of-cancer-treatmentUsing ultrasound to navigate the path of cancer treatmentSound waves that the human ear can’t detect help animals create a picture of unfamiliar environments. Now, researchers believe sound waves could be a surprising way of helping us select the best cancer therapy for an individual.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fa-day-in-the-life-of-an-icr-phd-studenthttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fa-day-in-the-life-of-an-icr-phd-studentA day in the life of an ICR PhD studentHave you ever wondered what it’s like to work in a scientific laboratory? Jamie Dean, a PhD student at The Institute of Cancer Research, London, gives us a glimpse into the day to day work of an early-career cancer scientist.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-kinesin-inhibitors-to-unmask-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-kinesin-inhibitors-to-unmask-cancerUsing kinesin inhibitors to unmask cancerKinesins are vital components in the mechanics of cell division, and are emerging as feasible targets for cancer drug development. Liz Burtally finds out more about kinesin inhibitors, and what challenges lie ahead.https://www.icr.ac.uk/news-archive%2flandmark-study-gives-clearest-picture-of-genetic-causes-of-bowel-cancerhttps://www.icr.ac.uk/news-archive%2flandmark-study-gives-clearest-picture-of-genetic-causes-of-bowel-cancerLandmark study gives clearest picture of genetic causes of bowel cancerA landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.https://www.icr.ac.uk/news-archive%2fnew-radiotherapy-regime-for-prostate-cancer-could-save-nhs-tens-of-millions-per-yearhttps://www.icr.ac.uk/news-archive%2fnew-radiotherapy-regime-for-prostate-cancer-could-save-nhs-tens-of-millions-per-yearNew radiotherapy regime for prostate cancer could save NHS tens of millions per yearA shorter course of prostate cancer radiotherapy, involving fewer hospital visits and higher individual doses of radiotherapy, is as effective as the current standard treatment for both survival and quality of life, a major new study reports.https://www.icr.ac.uk/news-features%2flatest-features%2fuk-first-microscope-uses-tractor-beams-to-peer-inside-cellshttps://www.icr.ac.uk/news-features%2flatest-features%2fuk-first-microscope-uses-tractor-beams-to-peer-inside-cellsUK first: microscope uses tractor beams to peer inside cellsThe Institute of Cancer Research, London, will be the first research organisation in the UK to receive a new type of high-tech microscope, allowing scientists to view dynamic cellular processes in real time. Liz Burtally finds out how this powerful machine will help researchers to design a new generation of drugs that target cell division.https://www.icr.ac.uk/news-archive%2fwhole-body-scans-could-track-cancer-in-patients-skeletonshttps://www.icr.ac.uk/news-archive%2fwhole-body-scans-could-track-cancer-in-patients-skeletonsWhole-body scans could track cancer in patients’ skeletonsMagnetic resonance imaging (MRI) could monitor aggressive cancer that has spread to the bone anywhere in the body, a new study reveals. https://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-for-head-and-neck-cancer-could-reduce-the-risk-of-dry-mouthhttps://www.icr.ac.uk/news-archive%2ftargeted-radiotherapy-for-head-and-neck-cancer-could-reduce-the-risk-of-dry-mouthTargeted radiotherapy for head and neck cancer could reduce the risk of dry mouthChanging the intensity of radiotherapy to protect the salivary glands could help treat a rare type of head and neck cancer and improve patients’ day-to-day lives, a new study shows. https://www.icr.ac.uk/news-archive%2fcbe-for-eminent-icr-researcher-in-queen-s-birthday-honourshttps://www.icr.ac.uk/news-archive%2fcbe-for-eminent-icr-researcher-in-queen-s-birthday-honoursCBE for eminent ICR researcher in Queen’s Birthday HonoursProfessor Nazneen Rahman, a world-leading scientist from The Institute of Cancer Research, London, has been awarded a CBE in the Queen's Birthday Honours list for services to medical sciences.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpersonalised-medicine-is-the-talk-of-chicago-at-the-asco-world-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpersonalised-medicine-is-the-talk-of-chicago-at-the-asco-world-cancer-conferencePersonalised medicine is the talk of Chicago at the ASCO world cancer conferenceCancer can be tough to treat but personalising medicine using targeted therapies and screening programmes could benefit patients with cancer, and this was a major talking point at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.https://www.icr.ac.uk/news-features%2flatest-features%2fprogress-with-radiotherapy-machine-promises-a-new-era-of-personalised-therapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fprogress-with-radiotherapy-machine-promises-a-new-era-of-personalised-therapyProgress with MR Linac radiotherapy machine promises a new era of personalised therapyFollowing the delivery of a giant magnet for the groundbreaking MR Linac machine, Dr Claire Bithell considers what its completion will mean for personalised cancer therapy.https://www.icr.ac.uk/news-archive%2fqueen-awards-prestigious-regius-professorship-to-the-icrhttps://www.icr.ac.uk/news-archive%2fqueen-awards-prestigious-regius-professorship-to-the-icrQueen awards prestigious Regius Professorship to the ICRThe Institute of Cancer Research, London, has been awarded a highly prestigious Regius Professorship by Her Majesty the Queen to mark her 90th Birthday. https://www.icr.ac.uk/news-archive%2ftesting-blood-metabolites-could-help-tailor-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2ftesting-blood-metabolites-could-help-tailor-cancer-treatmentTesting blood metabolites could help tailor cancer treatmentTesting for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-hits-the-headlines-againhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmunotherapy-hits-the-headlines-againImmunotherapy hits the headlines againAs further developments in immunotherapy-related cancer research are reported in the national media, Dr Claire Bithell reflects on the dramatic recent progress in this field.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-s-cancer-research-presented-at-the-asco-annual-meetinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-s-cancer-research-presented-at-the-asco-annual-meetingICR’s cancer research to be presented at the ASCO Annual MeetingRob Dawson looks at the wide range of cancer research being undertaken at the ICR that will be presented to an annual meeting of oncology experts in the US, which begins on 3 June 2016.https://www.icr.ac.uk/news-archive%2fcholesterol-production-could-drive-resistance-to-anti-hormone-treatment-in-er-positive-breast-cancerhttps://www.icr.ac.uk/news-archive%2fcholesterol-production-could-drive-resistance-to-anti-hormone-treatment-in-er-positive-breast-cancerCholesterol production could drive resistance to anti-hormone treatment in ER-positive breast cancerCommon breast cancers could be using a cholesterol-based molecule to evade standard anti-hormone treatments, causing patients’ disease to return, according to new research.https://www.icr.ac.uk/news-archive%2fblood-test-supports-use-of-potential-new-treatment-for-patients-with-stomach-cancerhttps://www.icr.ac.uk/news-archive%2fblood-test-supports-use-of-potential-new-treatment-for-patients-with-stomach-cancerBlood test supports use of potential new treatment for patients with stomach cancerTesting cancers for ‘addiction’ to a gene that boosts cell growth can pick out patients who may respond to a targeted drug under development, a major new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-science-of-team-science-how-working-together-helps-to-improve-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-science-of-team-science-how-working-together-helps-to-improve-cancer-researchThe science of team science: how working together helps to improve cancer researchAt the Science of Team Science conference in Phoenix, Arizona, US, two presentations from the ICR highlighted best practice in drawing on a diverse pool of academic minds to boost cancer research.https://www.icr.ac.uk/news-archive%2fnew-protein-test-predicts-survival-for-advanced-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-protein-test-predicts-survival-for-advanced-prostate-cancer-patientsNew protein test predicts survival for advanced prostate cancer patientsA protein linked to prostate cancer could predict which men are likely to develop resistance to current treatments and die earlier, a new study reveals.https://www.icr.ac.uk/news-archive%2fnew-hope-for-prostate-cancer-screeninghttps://www.icr.ac.uk/news-archive%2fnew-hope-for-prostate-cancer-screeningNew hope for prostate cancer screeningTaking samples of prostate cells from all men with a family history of prostate cancer could help to identify a significant number of new cases of the disease, according to new research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-gene-testing-for-cancer-patients-part-of-routine-carehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-gene-testing-for-cancer-patients-part-of-routine-careMaking gene testing for cancer patients part of routine careWe need to make gene testing for cancer part of routine care, says Professor Nazneen Rahman, Head of the Division of Genetics and Epidemiology at the ICR and Head of the Cancer Genetics Clinical Unit at The Royal Marsden.https://www.icr.ac.uk/news-archive%2ficr-and-imperial-college-london-set-out-partnership-planshttps://www.icr.ac.uk/news-archive%2ficr-and-imperial-college-london-set-out-partnership-plansICR and Imperial College London set out partnership plansThe Institute of Cancer Research, London, and Imperial College London have agreed plans to develop a strategic partnership through the creation of a virtual Cancer Research Centre of Excellence (CRCE).https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ficr-at-the-imperial-festival-2016-a-sunny-weekend-for-sciencehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2ficr-at-the-imperial-festival-2016-a-sunny-weekend-for-scienceICR at the Imperial Festival 2016: A sunny weekend for scienceThe ICR recently attended the annual Imperial Science Festival to explain to the public how Darwinian evolution can be applied to cancer research and treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-drug-development-unit-celebrates-its-10th-birthday-in-stylehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-drug-development-unit-celebrates-its-10th-birthday-in-styleOur Drug Development Unit celebrates its 10th birthday in styleAn open evening celebrated 10 years of the Drug Development Unit by bringing together patients, relatives, healthcare professionals and scientists.https://www.icr.ac.uk/news-archive%2ftest-for-six-key-genes-can-spot-aggressive-breast-cancerhttps://www.icr.ac.uk/news-archive%2ftest-for-six-key-genes-can-spot-aggressive-breast-cancerTest for six key genes can spot aggressive breast cancerTesting the activity of as few as six key genes is helping to identify women with particularly aggressive breast cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftissue-repair-and-cancer-how-not-to-inflame-the-neighbourshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftissue-repair-and-cancer-how-not-to-inflame-the-neighboursTissue repair and cancer: how not to inflame the neighboursThe human body has remarkable abilities to repair itself after illness and damage, but these same mechanisms could help cancer bounce back from treatments designed to kill cancer cells. Researchers at The Institute of Cancer Research, London, are studying what happens during tissue damage and repair to see if it can provide clues for treating cancer.https://www.icr.ac.uk/news-archive%2fnew-target-for-lung-cancer-identifiedhttps://www.icr.ac.uk/news-archive%2fnew-target-for-lung-cancer-identifiedNew target for lung cancer identifiedResearchers have uncovered a key part of a chain reaction of signals that tell some lung cancers to grow. This new insight into a major cancer signalling pathway could prioritise new drug targets. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fbiomarkers-offer-a-glimpse-into-the-future-of-personalised-cancer-treatmenthttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fbiomarkers-offer-a-glimpse-into-the-future-of-personalised-cancer-treatmentBiomarkers offer a glimpse into the future of personalised cancer treatmentThe pioneering use of biomarkers is opening up a new era of personalised treatment, explains Dr Irene Chong, Clinician Scientist at The Institute of Cancer Research, London, and a Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-researchers-gained-top-honour-in-uk-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-researchers-gained-top-honour-in-uk-scienceHow our researchers gained top honour in UK scienceLast week it was announced that two of our leading scientists have been elected as Fellows of the Royal Society. Henry French discusses their research – and the crucial role it is playing in the search for new cancer treatments.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-molecular-imaging-to-take-a-snapshot-of-cancer-and-its-treatmenthttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-molecular-imaging-to-take-a-snapshot-of-cancer-and-its-treatmentUsing molecular imaging to take a snapshot of cancer and its treatmentResearchers at The Institute of Cancer Research, London, are investigating new ways to use molecular imaging to predict how a person will respond to cancer treatment. Liz Burtally finds out how.https://www.icr.ac.uk/news-archive%2fcancer-research-technology-pioneer-fund-boosts-investment-in-drugs-that-block-cancer-defenceshttps://www.icr.ac.uk/news-archive%2fcancer-research-technology-pioneer-fund-boosts-investment-in-drugs-that-block-cancer-defencesCancer research technology pioneer fund boosts investment in drugs that block cancer defencesThe Cancer Research Technology (CRT) Pioneer Fund has today (Thursday) announced its investment in research to develop new drugs called heat-shock factor 1 (HSF1) pathway inhibitors, which have the potential to block a protective mechanism used by cancer cells.https://www.icr.ac.uk/news-archive%2fgruelling-cycle-raises-over-190-000-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fgruelling-cycle-raises-over-190-000-for-cancer-researchGruelling cycle ride raises almost £250,000 for cancer researchTim Morgan has faced an extraordinary challenge this month in a cycle ride pitched as the 'hardest event in the Cycling Weekly Sportive Series' to raise funds for cancer research. His amazing efforts have already raised almost £250,000.https://www.icr.ac.uk/news-archive%2fpioneering-cancer-researcher-takes-on-charity-cycle-in-memory-of-his-colleaguehttps://www.icr.ac.uk/news-archive%2fpioneering-cancer-researcher-takes-on-charity-cycle-in-memory-of-his-colleaguePioneering cancer researcher takes on charity cycle in memory of his colleaguePioneering cancer researcher Professor Richard Marais is taking on a 112-mile cycle challenge to raise funds in memory of Professor Chris Marshall – an outstanding and inspirational scientist whose work led to the development of new cancer treatments.https://www.icr.ac.uk/news-archive%2fnew-cancer-drugs-could-treat-lethal-resistant-prostate-cancershttps://www.icr.ac.uk/news-archive%2fnew-cancer-drugs-could-treat-lethal-resistant-prostate-cancersNew cancer drugs could treat lethal resistant prostate cancersMen with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmune-therapies-cause-big-reaction-at-aacr-2016https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fimmune-therapies-cause-big-reaction-at-aacr-2016Immune therapies cause big reaction at AACR 2016As American Vice President Joe Biden called for greater research collaboration at the AACR cancer conference, we look at the major themes emerging from the meeting.https://www.icr.ac.uk/news-archive%2feminent-cancer-researchers-elected-to-royal-society-fellowshiphttps://www.icr.ac.uk/news-archive%2feminent-cancer-researchers-elected-to-royal-society-fellowshipEminent cancer researchers elected to Royal Society FellowshipTwo world-leading scientists at The Institute of Cancer Research, London, have been made Fellows of the Royal Society – one of the greatest honours in UK science.https://www.icr.ac.uk/news-archive%2ftop-breast-cancer-scientist-recognised-by-the-academy-of-medical-scienceshttps://www.icr.ac.uk/news-archive%2ftop-breast-cancer-scientist-recognised-by-the-academy-of-medical-sciencesTop breast cancer scientist recognised by the Academy of Medical SciencesProfessor Clare Isacke has been elected to the Academy of Medical Sciences in recognition of her outstanding contribution to the advancement of cancer research.https://www.icr.ac.uk/news-archive%2ficr-gains-major-award-for-supporting-women-in-sciencehttps://www.icr.ac.uk/news-archive%2ficr-gains-major-award-for-supporting-women-in-scienceICR gains major award for supporting women in scienceThe Institute of Cancer Research, London, is committed to creating a supportive work environment, providing good career support for both women and men, and to remove any unnecessary barriers to career progression. Our efforts to address gender inequality have been recognised with a prestigious Athena SWAN Silver Award.https://www.icr.ac.uk/news-archive%2ficr-runners-success-at-the-london-marathonhttps://www.icr.ac.uk/news-archive%2ficr-runners-success-at-the-london-marathonICR runners’ success at the London MarathonAs in previous years, The Institute of Cancer Research, London, had an inspiring team of runners taking part in the prestigious London Marathon. This year, #teamICR comprised of 25 runners who are set to raise an outstanding amount of money that will help fund our research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fshould-science-only-be-reported-by-journalists-with-a-scientific-backgroundhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fshould-science-only-be-reported-by-journalists-with-a-scientific-backgroundShould science only be reported by journalists with a scientific background?When a room full of PhD students from The Institute of Cancer Research, London, held a debate about science journalism, most initially agreed that journalists covering science stories should have a science background. But would hearts and minds be swayed by a panel of experts on both sides of the debate?https://www.icr.ac.uk/news-archive%2fearly-blood-test-predicts-response-to-advanced-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fearly-blood-test-predicts-response-to-advanced-prostate-cancer-treatmentEarly blood test predicts response to advanced prostate cancer treatmentAn early blood test could help doctors identify which patients will benefit from treatment for advanced prostate cancer, according to a new study.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feight-ways-you-can-support-the-icr-s-groundbreaking-research-in-2016https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feight-ways-you-can-support-the-icr-s-groundbreaking-research-in-2016Eight ways you can support the ICR’s groundbreaking cancer research in 2016As our 25 runners prepare to take part in the Virgin Money London Marathon 2016 to fundraise for The Institute of Cancer Research, London, we look at eight more ways you can get involved and support our cutting-edge research this year.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffresh-excitement-about-cancer-immunotherapy-checkpoint-inhibitorshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffresh-excitement-about-cancer-immunotherapy-checkpoint-inhibitorsFresh excitement about cancer immunotherapy: checkpoint inhibitorsNew clinical data from immunotherapy trials involving researchers from the Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were presented at the AACR conference in New Orleans this week. Dr Claire Hastings looks at where this exciting research is headed.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffive-ways-we-can-harness-the-power-of-big-data-to-transform-cancer-research-and-treatmenthttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffive-ways-we-can-harness-the-power-of-big-data-to-transform-cancer-research-and-treatmentFive ways we can harness the power of Big Data to transform cancer research and treatmentProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, sets out what needs to happen for Big Data to deliver on its promise to revolutionise cancer research and care.https://www.icr.ac.uk/news-archive%2fimmunotherapy-is-first-to-show-survival-benefit-in-head-and-neck-cancerhttps://www.icr.ac.uk/news-archive%2fimmunotherapy-is-first-to-show-survival-benefit-in-head-and-neck-cancerImmunotherapy is first to show survival benefit in head and neck cancerThe immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.https://www.icr.ac.uk/news-archive%2fbreast-cancer-can-reprogram-its-metabolism-to-resist-hormone-therapyhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-can-reprogram-its-metabolism-to-resist-hormone-therapyBreast cancer can ‘reprogram’ its metabolism to resist hormone therapyCells from the most common form of breast cancer can reprogram their metabolism to help resist hormone treatments and become more aggressive, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-we-re-looking-forward-to-at-aacr-2016https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-we-re-looking-forward-to-at-aacr-2016What we’re looking forward to at AACR 2016As some of The Institute of Cancer Research's leading scientists head to the American Association for Cancer Research (AACR) Annual Meeting 2016 in the US, we look forward to some of the exciting research they will be presenting.https://www.icr.ac.uk/news-archive%2flondon-cancer-hub-cited-in-report-on-innovation-districts-in-capitalhttps://www.icr.ac.uk/news-archive%2flondon-cancer-hub-cited-in-report-on-innovation-districts-in-capitalLondon Cancer Hub cited in report on innovation districts in capitalA report into London’s new knowledge economy highlights plans for The London Cancer Hub – which aims to be one of the world’s top life-science campuses specialising in cancer – as a prime example of an ‘innovation district’.https://www.icr.ac.uk/news-archive%2fteam-icr-will-be-running-the-london-marathonhttps://www.icr.ac.uk/news-archive%2fteam-icr-will-be-running-the-london-marathonTeam ICR will be running the London MarathonA team of 25 runners will be representing The Institute of Cancer Research, London, in the 2016 London Marathon. Their inspiring efforts will help support our world-leading cancer research.https://www.icr.ac.uk/news-archive%2fcancer-cells-turn-healthy-cells-to-the-dark-sidehttps://www.icr.ac.uk/news-archive%2fcancer-cells-turn-healthy-cells-to-the-dark-sideCancer cells turn healthy cells to the ‘dark side’Cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread, a major new study reports.https://www.icr.ac.uk/news-features%2flatest-features%2fwatch-how-cancers-turn-healthy-cells-to-the-dark-sidehttps://www.icr.ac.uk/news-features%2flatest-features%2fwatch-how-cancers-turn-healthy-cells-to-the-dark-sideWatch: How cancers turn healthy cells to the ‘dark side’Through images and video, we explain new research that shows cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread.https://www.icr.ac.uk/news-archive%2fnew-insights-show-how-some-breast-cancers-resist-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-insights-show-how-some-breast-cancers-resist-treatmentNew insights show how some breast cancers resist treatmentBreast cancer cells can become resistant to a common anticancer drug in a variety of different ways — suggesting that tailored treatment combinations to overcome resistance may be required for each patient.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrcaness-going-beyond-the-brca-geneshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrcaness-going-beyond-the-brca-genesBRCAness – going beyond the BRCA genesMuch is known about the BRCA genes and how to target them, but what do we know about ‘BRCAness’? Liz Burtally finds out more.https://www.icr.ac.uk/news-archive%2fartificial-dna-could-build-new-generation-of-cancer-drugshttps://www.icr.ac.uk/news-archive%2fartificial-dna-could-build-new-generation-of-cancer-drugsArtificial DNA could build new generation of cancer drugsScientists have built the first 3D nano-sized objects using artificial DNA, which could be used to deploy cancer treatments inside tumour cells.https://www.icr.ac.uk/news-archive%2fcancer-thwarts-treatment-by-stealing-blood-vesselshttps://www.icr.ac.uk/news-archive%2fcancer-thwarts-treatment-by-stealing-blood-vesselsCancer thwarts treatment by ‘stealing’ blood vesselsCancers can resist treatment by ‘stealing’ blood vessels from nearby tissues, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-antibody-drug-conjugates-the-fabled-magic-bullets-against-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-antibody-drug-conjugates-the-fabled-magic-bullets-against-cancerAre antibody-drug conjugates the fabled magic bullets against cancer?Drugs that deliver cancer-killing compounds directly to the tumour could emerge as a serious contender in the fight against cancer. Liz Burtally explains how.https://www.icr.ac.uk/news-archive%2fstudy-predicts-rare-but-severe-side-effects-after-breast-cancer-radiotherapyhttps://www.icr.ac.uk/news-archive%2fstudy-predicts-rare-but-severe-side-effects-after-breast-cancer-radiotherapyStudy predicts rare but severe side-effects after breast cancer radiotherapySmall skin samples can be used to predict the likelihood of rare but severe side-effects that can occur years after radiotherapy for breast cancer, according to new research.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fan-exciting-step-for-childhood-cancer-researchhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fan-exciting-step-for-childhood-cancer-researchAn exciting step for childhood cancer research and targeted treatmentProfessor Paul Workman blogs about a new test for childhood cancer which hit the headlines yesterday — a multi-gene panel that should speed progress to targeted therapy.https://www.icr.ac.uk/news-archive%2fchildren-with-cancer-to-get-new-gene-testhttps://www.icr.ac.uk/news-archive%2fchildren-with-cancer-to-get-new-gene-testChildren with cancer to get new gene testChildren with cancer at leading hospitals across the UK will be offered testing for genetic mutations in their tumours as part of a new initiative to begin to personalise children’s cancer treatment. https://www.icr.ac.uk/news-archive%2fnew-blood-test-could-direct-pancreatic-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-blood-test-could-direct-pancreatic-cancer-treatmentNew blood test could direct pancreatic cancer treatmentScientists have developed a blood test that can pick out patients with pancreatic cancer who require different types of treatment to delay progression of the disease.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fabiraterone-s-approval-is-great-news-for-men-with-prostate-cancer-but-why-did-it-take-so-longhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fabiraterone-s-approval-is-great-news-for-men-with-prostate-cancer-but-why-did-it-take-so-longAbiraterone’s approval is great news for men with prostate cancer – but why did it take so long?Professor Paul Workman comments on the recent decision by NICE to approve abiraterone for men with advanced prostate cancer and offers thoughts on the drug approval process.https://www.icr.ac.uk/news-archive%2fscientists-identify-potential-treatment-options-for-rare-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-potential-treatment-options-for-rare-cancerScientists identify potential treatment options for rare cancerResearchers have found that a combination of chemotherapy and modern radiotherapy can benefit patients with advanced nasopharyngeal cancer – a cancer that starts at the back of the nose.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsneak-preview-inside-the-new-facility-that-hopes-to-revolutionise-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsneak-preview-inside-the-new-facility-that-hopes-to-revolutionise-radiotherapySneak preview: Inside the new facility that hopes to revolutionise radiotherapyDr Claire Bithell gives an update on the construction of the facility to house the new MR Linac machine, which is due to arrive in the next few months.https://www.icr.ac.uk/news-features%2flatest-features%2fseeking-kinder-ways-to-tackle-childhood-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fseeking-kinder-ways-to-tackle-childhood-cancerSeeking kinder ways to tackle childhood cancerOur research could reshape how we treat rhabdomyosarcoma, making huge, long-lasting improvements to young patients’ lives. Liz Burtally finds out how.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftesting-genes-today-and-sequencing-genomes-tomorrowhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftesting-genes-today-and-sequencing-genomes-tomorrowTesting genes today, and sequencing genomes tomorrowA special event for Genome Sequencing Week explored the implications of whole-genome sequencing for cancer patients, and touched on today’s challenges in widening access to gene testing.https://www.icr.ac.uk/news-archive%2ffrequent-mri-scans-help-to-target-bladder-cancerhttps://www.icr.ac.uk/news-archive%2ffrequent-mri-scans-help-to-target-bladder-cancerFrequent MRI scans help to target bladder cancerA new radiotherapy technique could help doctors to focus treatment more precisely on tumours in the bladder and reduce damage to surrounding healthy tissue.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2frevealing-the-world-of-cancer-research-through-playhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2frevealing-the-world-of-cancer-research-through-playRevealing the world of cancer research – through playCancer can be scary – so The Institute of Cancer Research, London, recently attended the Royal Holloway Science Festival to show an all-ages audience how we’re working to defeat it. https://www.icr.ac.uk/news-archive%2ficr-statement-on-nice%27s-abiraterone-recommendationhttps://www.icr.ac.uk/news-archive%2ficr-statement-on-nice%27s-abiraterone-recommendationNICE recommends abiraterone use before chemotherapyNICE has announced that abiraterone, the life-extending prostate cancer drug discovered at The Institute of Cancer Research, London, will be made available for men on the NHS earlier in the course of their treatment.https://www.icr.ac.uk/news-archive%2fusing-mathematical-models-to-guide-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fusing-mathematical-models-to-guide-cancer-treatmentUsing mathematical models to guide cancer treatmentResearchers have found a way to estimate the number of cells responsible for driving and maintaining a cancer’s growth, and the results could help to tailor treatments to each patient’s cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-the-next-decade-hold-for-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-does-the-next-decade-hold-for-cancer-researchWhat does the next decade hold for cancer research?For British Science Week 2016, researchers at The Institute of Cancer Research, London, share thoughts on where their research may be headed over the next 10 years.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fstem-ambassadors-inspiring-students-and-dispelling-mythshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fstem-ambassadors-inspiring-students-and-dispelling-mythsSTEM Ambassadors: inspiring students and dispelling mythsDuring British Science Week 2016, Dr Becky Cook looks at the role of science, technology, engineering and maths (STEM) Ambassadors at The Institute of Cancer Research, London, in enthusing young people in these subjects.https://www.icr.ac.uk/news-archive%2ficr-science-symposium-to-commemorate-legacy-of-chris-marshallhttps://www.icr.ac.uk/news-archive%2ficr-science-symposium-to-commemorate-legacy-of-chris-marshallICR science symposium to commemorate legacy of Chris MarshallThe Institute of Cancer Research, London, will celebrate the outstanding scientific achievements of the late Professor Chris Marshall, former Director of Research at the ICR, during a symposium at the Royal Society.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-next-for-the-breast-cancer-research-that-hit-the-front-pageshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-next-for-the-breast-cancer-research-that-hit-the-front-pagesWhat next for the breast cancer research that hit the front pages?News that researchers had shown a combination of two drugs could shrink breasts cancers within 11 days is exciting, but much more needs to happen before this treatment routinely reaches patients.https://www.icr.ac.uk/news-archive%2fnew-way-of-targeting-cancer-s-most-commonly-mutated-genehttps://www.icr.ac.uk/news-archive%2fnew-way-of-targeting-cancer-s-most-commonly-mutated-geneNew way of targeting cancer’s most commonly mutated geneBlocking a gene involved with cellular division and replication could provide clues in understanding how to target the most common mutation found in cancer, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsigns-of-hope-for-ovarian-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsigns-of-hope-for-ovarian-cancerSigns of hope for ovarian cancerA growing understanding of the genetics of ovarian cancer is helping scientists identify weak spots that could be targets for new drugs.https://www.icr.ac.uk/news-archive%2fdiscovery-club-members-learn-how-big-data-is-transforming-cancer-researchhttps://www.icr.ac.uk/news-archive%2fdiscovery-club-members-learn-how-big-data-is-transforming-cancer-researchDiscovery Club members learn how big data is transforming cancer researchMembers of The Discovery Club of The Institute of Cancer Research, London, gathered at the Royal Society on 8 March 2016 to learn how our scientists are using big data to help defeat cancer.https://www.icr.ac.uk/news-archive%2fdrug-combination-shrinks-her2-positive-breast-cancers-within-11-dayshttps://www.icr.ac.uk/news-archive%2fdrug-combination-shrinks-her2-positive-breast-cancers-within-11-daysDrug combination shrinks HER2-positive breast cancers within 11 daysA drug combination – of lapatinib and trastuzumab (Herceptin) – before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days, according to new research.https://www.icr.ac.uk/news-archive%2fgene-may-worsen-cancer-outcome-by-speeding-metabolism-of-drugshttps://www.icr.ac.uk/news-archive%2fgene-may-worsen-cancer-outcome-by-speeding-metabolism-of-drugsGene may worsen cancer outcome by speeding metabolism of drugsSome patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.https://www.icr.ac.uk/news-archive%2fpartial-breast-radiotherapy-cuts-breast-cancer-side-effectshttps://www.icr.ac.uk/news-archive%2fpartial-breast-radiotherapy-cuts-breast-cancer-side-effectsPartial breast radiotherapy cuts breast cancer side-effects Postoperative radiotherapy focused on the breast tissue that once contained tumours has fewer long-term side-effects and is just as effective as standard whole-breast radiotherapy, new trial results show.https://www.icr.ac.uk/news-archive%2fstudy-reveals-enzymes-that-cancers-depend-on-to-survivehttps://www.icr.ac.uk/news-archive%2fstudy-reveals-enzymes-that-cancers-depend-on-to-surviveStudy reveals enzymes that cancers depend on to surviveA new study has identified a catalogue of specific enzymes, known as kinases, that some types of cancer rely on to survive. https://www.icr.ac.uk/news-archive%2fnew-centre-for-cancer-imaging-to-open-window-onto-cancerhttps://www.icr.ac.uk/news-archive%2fnew-centre-for-cancer-imaging-to-open-window-onto-cancerNew Centre for Cancer Imaging to open window onto cancerThe Institute of Cancer Research, London, celebrated the opening of the new £20 million Centre for Cancer Imaging on its Sutton site this week. The state-of-the-art building is designed to drive collaboration between researchers from many different fields on pioneering approaches to cancer imaging.https://www.icr.ac.uk/news-archive%2fhealthy-cells-collaborate-with-tumours-to-help-build-new-blood-vesselshttps://www.icr.ac.uk/news-archive%2fhealthy-cells-collaborate-with-tumours-to-help-build-new-blood-vesselsHealthy cells ‘collaborate’ with tumours to help build new blood vesselsHealthy cells actively collaborate with tumours by creating a mesh of collagen that encourages cancer cells to build new blood vessels, a new study shows.https://www.icr.ac.uk/news-archive%2fdrug-combination-slows-breast-cancer-spreadhttps://www.icr.ac.uk/news-archive%2fdrug-combination-slows-breast-cancer-spreadDrug combination slows breast cancer spreadA combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months – working in all subsets of the most common type of breast cancer, research has shown.https://www.icr.ac.uk/news-archive%2fscientists-develop-new-way-to-view-bone-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-develop-new-way-to-view-bone-cancerNew way to view prostate cancer that has spread to the bonesA new imaging technique could allow doctors to assess accurately if cancer has spread into the bones of prostate cancer patients, and how severe it is.https://www.icr.ac.uk/news-features%2flatest-features%2fmoving-away-from-the-one-fraction-size-fits-all%27-approach-to-radiotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fmoving-away-from-the-one-fraction-size-fits-all%27-approach-to-radiotherapyMoving away from the ‘one fraction size fits all' approach to radiotherapyResearchers are discovering biological markers that can predict the sensitivity of tumours to radiotherapy, with the potential to tailor dosing to individual patients, finds Liz Burtally.https://www.icr.ac.uk/news-archive%2fprotein-key-to-cancer-spread-also-controls-tumour-growthhttps://www.icr.ac.uk/news-archive%2fprotein-key-to-cancer-spread-also-controls-tumour-growthProtein key to cancer spread also controls tumour growthA family of proteins known as 'ROCK' regulate the shape and movement of cells, and in doing so help to control tumour growth, a new study reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcar-t-cell-immunotherapy-on-the-road-towards-a-cancer-curehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcar-t-cell-immunotherapy-on-the-road-towards-a-cancer-cureCAR T cell immunotherapy: on the road towards a cancer cure?Cancer immunotherapy hit the headlines once again last week, but this latest therapy is still some years away from reaching patients, writes Dr Claire Hastings.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2ffinding-the-10-what-%27essential-genes%27-mean-for-cancerhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2ffinding-the-10-what-%27essential-genes%27-mean-for-cancerFinding the 10%: what 'essential genes' mean for cancerAre some genes more essential for cells to survive than others? Why is the recently discovered list of ‘essential’ genes important for developing new treatments for cancer? Dr Chris Lord, leader of the Gene Function Team at the Institute of Cancer Research, London, looks at the evidence.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-3-searching-for-cure-or-long-term-controlhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-3-searching-for-cure-or-long-term-controlThe death of cancer? Part 3: Searching for cure or long-term controlIn the last instalment of a three-part essay reflecting on five decades of cancer treatment advances, ICR CEO Professor Paul Workman explores the transition from classical chemotherapy drugs to new molecularly targeted treatments and immunotherapy, and discusses the attitudes and language used in the drive to defeat cancer.https://www.icr.ac.uk/news-features%2flatest-features%2flondon-students-gain-experience-of-life-in-a-breast-cancer-research-labhttps://www.icr.ac.uk/news-features%2flatest-features%2flondon-students-gain-experience-of-life-in-a-breast-cancer-research-labLondon students gain experience of life in a breast cancer research labStudents from Wembley High Technology College visited The Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, to learn how they could become the cancer researchers of the future. https://www.icr.ac.uk/news-archive%2fecologically-diverse-breast-cancers-more-likely-to-be-deadlyhttps://www.icr.ac.uk/news-archive%2fecologically-diverse-breast-cancers-more-likely-to-be-deadly‘Ecologically diverse’ breast cancers more likely to be deadlyBreast cancers which are particularly complex and diverse, as judged by a test used in ecology to analyse species of animals and plants, are particularly likely to progress and lead to death, a new study shows.https://www.icr.ac.uk/news-archive%2fnew-viral-radiotherapy-combination-could-treat-prostate-cancershttps://www.icr.ac.uk/news-archive%2fnew-viral-radiotherapy-combination-could-treat-prostate-cancersNew viral-radiotherapy combination could treat prostate cancersScientists have developed a new viral therapy that is capable of killing prostate cancer cells, and found it is even more effective when combined with a type of radiotherapy.https://www.icr.ac.uk/news-archive%2fresearchers-map-key-stage-in-cell-divisionhttps://www.icr.ac.uk/news-archive%2fresearchers-map-key-stage-in-cell-divisionResearchers map key stage in cell divisionScientists have developed a mathematical model that describes a key step in human cell division – and an important target for cancer treatment – in unprecedented detail.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-2-the-war-on-cancer-and-the-politics-of-drug-accesshttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-2-the-war-on-cancer-and-the-politics-of-drug-accessThe death of cancer? Part 2: the War on Cancer and the politics of drug accessIn a special, three-part essay, ICR Chief Executive Professor Paul Workman reflects on five decades of advances in cancer treatment – inspired by The Death of Cancer, an account by the clinical research pioneer Vincent DeVita. In part two, he explores the huge political repercussions of those early breakthroughs in treatment.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-the-laws-of-nature-to-predict-tumour-growthhttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-the-laws-of-nature-to-predict-tumour-growthUsing the laws of nature to predict tumour growthResearch is enabling scientists to anticipate how different cancers evolve in the body, opening up the possibility of being able to predict how cancers change with time.https://www.icr.ac.uk/news-archive%2fscientists-discover-how-breast-cancer-cells-spread-from-blood-vesselshttps://www.icr.ac.uk/news-archive%2fscientists-discover-how-breast-cancer-cells-spread-from-blood-vesselsScientists discover how breast cancer cells spread from blood vesselsResearchers have identified a protein that controls how breast cancer cells spread around the body, according to a new study.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhen-nostradamus-got-it-right-about-cancer-treatmenthttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwhen-nostradamus-got-it-right-about-cancer-treatmentWhen Nostradamus got it right about cancer treatmentThe French philosopher was right to predict that sound waves could be used as an innovative way of targeting tumours.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-phase-i-trials-should-be-opened-up-to-older-cancer-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-phase-i-trials-should-be-opened-up-to-older-cancer-patientsWhy phase I trials should be opened up to older cancer patientsThere is concern that older patients are missing out on the chance to join innovative clinical trials. Steve Robinson finds new research could at last signal a shift in thinking.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftransforming-drug-discovery-with-an-explosion-of-big-datahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftransforming-drug-discovery-with-an-explosion-of-big-dataTransforming drug discovery with an explosion of big dataBig data has the potential to transform the drug discovery landscape: Dr Eva Sharpe explains how.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmy-reflections-on-the-death-of-cancerhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmy-reflections-on-the-death-of-cancerMy reflections on The Death of CancerProfessor Paul Workman introduces his special three-part essay, inspired by the memoir The Death of Cancer, and reflecting on five decades of progress in cancer research and treatment.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-1-the-birth-of-effective-drug-therapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-death-of-cancer-part-1-the-birth-of-effective-drug-therapyThe death of cancer? Part 1: the birth of effective drug therapyIn a special, three-part essay to mark World Cancer Day, ICR Chief Executive Professor Paul Workman reflects on five decades of advances in cancer treatment – inspired by The Death of Cancer, an account by early pioneer Vincent DeVita. In part one, Professor Workman discusses the early days of chemotherapy.https://www.icr.ac.uk/news-features%2flatest-features%2fworld-cancer-dayhttps://www.icr.ac.uk/news-features%2flatest-features%2fworld-cancer-dayWorld Cancer Day 2016: a global perspective from the ICROn World Cancer Day, we wanted to recognise our many global collaborators who work with us to make the discoveries that defeat cancer.https://www.icr.ac.uk/news-archive%2fplans-unveiled-for-uk-s-new-global-hub-for-cancer-research-and-treatmenthttps://www.icr.ac.uk/news-archive%2fplans-unveiled-for-uk-s-new-global-hub-for-cancer-research-and-treatmentPlans unveiled for The London Cancer Hub – the UK’s new global centre for cancer research and treatmentA new global hub for cancer research and treatment is to be established in London with the aim of accelerating the discovery of new treatments.https://www.icr.ac.uk/news-archive%2ficr-sells-portion-of-its-projected-abiraterone-royaltieshttps://www.icr.ac.uk/news-archive%2ficr-sells-portion-of-its-projected-abiraterone-royaltiesICR sells portion of its projected abiraterone royaltiesThe Institute of Cancer Research, London, has sold a portion of its royalty entitlement for the prostate cancer drug abiraterone for an undisclosed sum.https://www.icr.ac.uk/news-archive%2fchemotherapy-drug-boosts-survival-for-newly-diagnosed-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fchemotherapy-drug-boosts-survival-for-newly-diagnosed-prostate-cancerChemotherapy drug boosts survival for newly diagnosed prostate cancerCombining a chemotherapy drug with first-line hormone therapy could help men diagnosed with prostate cancer live longer, according to research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-predictable-is-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-predictable-is-cancerHow predictable is cancer?An ICR researcher discusses the current limits of attempting to predict cancer’s next move, and how lessons from Darwin can help us find the best course of action to treat patients.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fobama-s-cancer-challenge-and-the-audacity-of-hopehttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fobama-s-cancer-challenge-and-the-audacity-of-hopeObama’s cancer challenge and the audacity of hopeUS President Barack Obama recently threw down the gauntlet of curing cancer ‘once and for all’. Professor Mel Greaves discusses whether, and how, this formidable challenge can be achieved.https://www.icr.ac.uk/news-archive%2fscientists-identify-genetic-cause-of-myeloma-bone-diseasehttps://www.icr.ac.uk/news-archive%2fscientists-identify-genetic-cause-of-myeloma-bone-diseaseScientists identify genetic cause of myeloma bone diseaseScientists have identified a change in the DNA of patients with myeloma that increases their risk of developing bone disease, a common and serious complication of this cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-genomics-revolution-and-why-we-need-to-be-smarter-in-our-use-of-genetic-datahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-genomics-revolution-and-why-we-need-to-be-smarter-in-our-use-of-genetic-dataThe genomics revolution and why we need to be smarter in our use of genetic dataProfessor Nazneen Rahman spoke about implementing genomic medicine at London’s first Festival of Genomics last week. Dr Eva Sharpe picks out some of the highlights from the talk.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-strange-case-of-the-self-curing-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-strange-case-of-the-self-curing-cancerThe strange case of the ‘self-curing’ cancerHenry French blogs on an unusual cancer – and a new theory that could explain why it spontaneously cures without treatment.https://www.icr.ac.uk/news-features%2flatest-features%2ficr-at-the-london-festival-of-genomicshttps://www.icr.ac.uk/news-features%2flatest-features%2ficr-at-the-london-festival-of-genomicsICR at the London Festival of GenomicsScientists from The Institute of Cancer Research, London, gave two talks at this exciting conference that ran from 19-21 January 2016. See some of the reaction to the presentations.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-changes-to-cancer-medicine-policy-on-the-horizonhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fare-changes-to-cancer-medicine-policy-on-the-horizonAre changes to cancer medicine policy on the horizon?Talks are underway on issues affecting access to cancer medicines in the UK, and The Institute of Cancer Research is at the discussion table.https://www.icr.ac.uk/news-archive%2flaws-of-nature-predict-cancer-evolutionhttps://www.icr.ac.uk/news-archive%2flaws-of-nature-predict-cancer-evolutionLaws of nature predict cancer evolutionCancers evolve over time in patterns governed by the same natural laws that drive physical and chemical processes as diverse as the flow of rivers or the brightness of stars, according to new research.https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fdoes-imaging-have-a-role-in-cancer-evolutionhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fdoes-imaging-have-a-role-in-cancer-evolutionDoes imaging have a role in cancer evolution?Professor Nandita deSouza discusses the value of imaging in predicting the evolution of cancer in the body - and what the latest developments in this field could mean for the future of treatment.https://www.icr.ac.uk/news-archive%2fscientists-identify-protein-used-by-breast-tumours-to-radicalise-normal-cells-and-spread-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-protein-used-by-breast-tumours-to-radicalise-normal-cells-and-spread-cancerScientists identify protein used by breast tumours to ‘radicalise’ normal cells and spread cancerWnt7a protein found to be key "rallying call" secreted by aggressive tumours to help recruit non-cancerous fibroblasts and enable growth.https://www.icr.ac.uk/news-archive%2ficr-donors-give-a-fantastic-12m-for-cancer-research-in-2015https://www.icr.ac.uk/news-archive%2ficr-donors-give-a-fantastic-12m-for-cancer-research-in-2015ICR donors give a fantastic £12m for cancer research in 2015Donors and supporters of The Institute of Cancer Research, London, contributed £12.3 million in charitable donations in 2015.https://www.icr.ac.uk/news-archive%2fdoubt-over-high-pressure-oxygen-for-radiotherapy-induced-gastrointestinal-symptomshttps://www.icr.ac.uk/news-archive%2fdoubt-over-high-pressure-oxygen-for-radiotherapy-induced-gastrointestinal-symptomsDoubt over high-pressure oxygen for radiotherapy-induced gastrointestinal symptomsPatients with chronic gastrointestinal complaints caused by pelvic radiotherapy may not benefit from the standard high-pressure oxygen therapy that has been used for decades, a study has suggested.https://www.icr.ac.uk/news-archive%2fmri-technique-offers-painless-follow-up-for-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fmri-technique-offers-painless-follow-up-for-prostate-cancer-patientsMRI technique offers painless follow-up for prostate cancer patientsSpecialised MRI could be an alternative to biopsies when deciding if prostate cancer patients should receive treatment or continue with surveillance. https://www.icr.ac.uk/news-archive%2fdose-finding-studies-for-some-targeted-drugs-need-to-be-refinedhttps://www.icr.ac.uk/news-archive%2fdose-finding-studies-for-some-targeted-drugs-need-to-be-refinedDose-finding studies for some targeted drugs need to be refinedEarly clinical trials of some targeted cancer drugs may underestimate their toxicity, according to a new analysis.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmore-better-new-drugs-five-ways-the-system-must-changehttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fmore-better-new-drugs-five-ways-the-system-must-changeMore, better new drugs: five ways the system must changeProfessor Paul Workman outlines five solutions to the challenge of the broken drug system of drug discovery and development, which is failing to deliver enough innovative new cancer drugs to those who need them.https://www.icr.ac.uk/news-archive%2fbiggest-database-for-cancer-drug-discovery-goes-3dhttps://www.icr.ac.uk/news-archive%2fbiggest-database-for-cancer-drug-discovery-goes-3dBiggest database for cancer drug discovery goes 3DThe world’s largest database for cancer drug discovery has been revolutionised by adding 3D structures of faulty proteins and maps of cancer’s communication networks, according to new research.https://www.icr.ac.uk/news-archive%2fa-quarter-of-common-brain-cancer-risk-comes-from-inherited-genetic-faultshttps://www.icr.ac.uk/news-archive%2fa-quarter-of-common-brain-cancer-risk-comes-from-inherited-genetic-faultsA quarter of common brain cancer risk comes from inherited genetic faultsAround 25 per cent of the risk of developing the most common type of brain cancer, known as glioma, comes from inherited DNA errors, new research shows.https://www.icr.ac.uk/news-archive%2fmapping-cancer-s-social-networks-opens-new-approaches-to-treatmenthttps://www.icr.ac.uk/news-archive%2fmapping-cancer-s-social-networks-opens-new-approaches-to-treatmentMapping cancer’s ‘social networks’ opens new approaches to treatmentScientists design a computer model that applies techniques used to analyse social networks to identify new ways of treating cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-year-in-cancer-research---we-look-back-at-some-of-the-highlights-of-2015https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-year-in-cancer-research---we-look-back-at-some-of-the-highlights-of-2015A year in cancer research - we look back at some of the highlights of 2015From new drug approvals to prestigious awards and a prime time documentary about cancer. We present some of our highlights from 2015https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevery-picture-tells-a-storyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevery-picture-tells-a-storyEvery picture tells a storyICR researchers were set the challenge of capturing in a single image the groundbreaking work they're doing to make the discoveries that defeat cancer.https://www.icr.ac.uk/news-archive%2ft-vec-becomes-first-viral-immunotherapy-approved-in-europehttps://www.icr.ac.uk/news-archive%2ft-vec-becomes-first-viral-immunotherapy-approved-in-europeT-VEC becomes first viral immunotherapy approved in EuropeA viral immunotherapy for cancer has become the first of its kind to be approved by the European Medicines Agency for use in adults with advanced melanoma.https://www.icr.ac.uk/news-archive%2fscientists-discover-how-tumours-hijack-body-s-wound-healing-processhttps://www.icr.ac.uk/news-archive%2fscientists-discover-how-tumours-hijack-body-s-wound-healing-processScientists discover how tumours hijack body’s wound healing processScientists have discovered how cells that usually help repair wounds can switch from friend to foe, escalating tumour growth and cancer spread. https://www.icr.ac.uk/news-archive%2ficr-recognised-as-a-top-spot-for-pharmacology-in-the-ukhttps://www.icr.ac.uk/news-archive%2ficr-recognised-as-a-top-spot-for-pharmacology-in-the-ukICR recognised as a top spot for pharmacology and drug discovery in the UKThe ICR wins a Pharmacology On The Map award from the British Pharmacological Society, to recognise our contribution to improving human health. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmock-trials-3d-printers-and-strawberry-dna-the-icr-opens-its-door-to-local-students-in-suttonhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmock-trials-3d-printers-and-strawberry-dna-the-icr-opens-its-door-to-local-students-in-suttonMock trials, 3D printers and strawberry DNA – the ICR opens its doors to local students in SuttonThe ICR gave local sixth formers across Sutton the chance to find out about our research and careers in science at an open evening recently. Public Engagement Officer, Helen Craig talks us through some of her highlights of the evening.https://www.icr.ac.uk/news-archive%2flocal-protein-factories-make-cancer-cells-motilehttps://www.icr.ac.uk/news-archive%2flocal-protein-factories-make-cancer-cells-motileLocal protein factories make cancer cells motileMaking key proteins at the driving edge of cancer cells is crucial for the spread of the disease around the body, new research concludes.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-announces-latest-drug-decisions-and-its-mixed-news-for-cancer-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-announces-latest-drug-decisions-and-its-mixed-news-for-cancer-drugsNICE announces latest drug decisions – and it's mixed news for cancer drugsThere are mixed feelings at the ICR today as NICE announces its latest decisions on cancer drugs. Our Science Information and Policy Manager, Dr Eva Sharpe, explains the latest announcement.https://www.icr.ac.uk/news-archive%2fnice-makes-decisions-on-use-of-three-innovative-cancer-drugs-on-nhs-icr-statementhttps://www.icr.ac.uk/news-archive%2fnice-makes-decisions-on-use-of-three-innovative-cancer-drugs-on-nhs-icr-statementNICE makes decisions on use of three innovative cancer drugs on NHS: ICR statementICR CEO Professor Paul Workman comments on decisions by NICE today to recommend the drugs olaparib and enzalutamide for use on the NHS, but reject the ICR-discovered prostate cancer drug abiraterone.https://www.icr.ac.uk/news-archive%2ficr-wins-prestigious-award-for-openness-in-animal-research-communicationhttps://www.icr.ac.uk/news-archive%2ficr-wins-prestigious-award-for-openness-in-animal-research-communicationICR wins prestigious award for openness in animal research communicationThe ICR has won a prestigious communications award that celebrates our success in communicating openly about animal research.https://www.icr.ac.uk/news-archive%2fimaging-test-detects-aggressive-and-treatment-resistant-cancershttps://www.icr.ac.uk/news-archive%2fimaging-test-detects-aggressive-and-treatment-resistant-cancersImaging test detects aggressive and treatment-resistant cancersICR Scientists have developed a new imaging test that could enable doctors to identify more dangerous tumours before they spread around the body – and tailor treatment accordingly.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year-2015https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year-2015Highlights of the year, 2015We look back at our researchers' scientific achievements to pick out ten of our most exciting discoveries from the past year. https://www.icr.ac.uk/news-archive%2fthe-icr-opens-its-doors-to-schools-across-suttonhttps://www.icr.ac.uk/news-archive%2fthe-icr-opens-its-doors-to-schools-across-suttonThe ICR opens its doors to schools across SuttonThe ICR gave local sixth formers across Sutton the chance to find out about our research at an open evening this week.https://www.icr.ac.uk/news-archive%2fmaster-switch-helps-cancer-cells-survive-stresshttps://www.icr.ac.uk/news-archive%2fmaster-switch-helps-cancer-cells-survive-stress‘Master switch’ helps cancer cells survive stressNew survival mechanism could be a target for future cancer drugshttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fwhat-s-luck-got-to-do-with-ithttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2fwhat-s-luck-got-to-do-with-itWhat’s luck got to do with it?Is cancer just down to bad luck or do the environment and inherited factors dictate whether we will develop the disease? Leading ICR researcher Professor Mel Greaves looks at the evidence. https://www.icr.ac.uk/news-archive%2fcarols-by-candlelighthttps://www.icr.ac.uk/news-archive%2fcarols-by-candlelightCarols by CandlelightThe stunning Wren Chapel of The Royal Hospital Chelsea was the setting for Carols from Chelsea – The Institute of Cancer Research’s flagship annual social and fundraising event.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeting-cancers-weak-spot-dna-repair-mechanismshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeting-cancers-weak-spot-dna-repair-mechanismsTargeting cancers’ weak spot: DNA repair mechanismsIn a session at the NCRI Cancer Conference, scientists – including the ICR’s Professor Johann de Bono – discussed the development of new cancer treatments targeting DNA damage and the importance of research that moves from bench to bedside and back again.https://www.icr.ac.uk/news-archive%2fnew-computational-test-predicts-ovarian-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fnew-computational-test-predicts-ovarian-cancer-survivalNew computational test predicts ovarian cancer survivalScientists have developed a new automated way of predicting the survival chances from ovarian cancer from routine biopsy samples, by looking at the cells in the environment around tumours.https://www.icr.ac.uk/news-archive%2ficr-donors-celebrate-a-year-of-scientific-discoveryhttps://www.icr.ac.uk/news-archive%2ficr-donors-celebrate-a-year-of-scientific-discoveryICR donors celebrate a year of scientific discoveryMembers of The Institute of Cancer Research, London’s Discovery Club gathered at the 4th Annual Reception to celebrate the scientific achievements made possible over the past year thanks to philanthropic investment from donors and supporters.https://www.icr.ac.uk/news-archive%2fnew-drug-combination-treats-kidney-cancershttps://www.icr.ac.uk/news-archive%2fnew-drug-combination-treats-kidney-cancersNew drug combination treats kidney cancersNew research shows that a combination of two existing drug types slows the growth of kidney cancer by suppressing the development of new tumour blood vessels more effectively than existing treatments. https://www.icr.ac.uk/news-archive%2fthe-climb-of-life-beats-100-000-targethttps://www.icr.ac.uk/news-archive%2fthe-climb-of-life-beats-100-000-targetThe Climb of Life beats £100,000 target The ICR's annual Climb of Life fundraising event has raised a fantastic £101,260, surpassing last year’s final total and raising more than £650,000 in a decade. https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhappigenetics-a-marriage-of-art-and-sciencehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhappigenetics-a-marriage-of-art-and-scienceHappigenetics – a marriage of art and scienceHappigenetics mixes science with art to explore our perceptions of genetics and genomic research. ICR research fellow Martina Mijuskovic explains what the project means to her. https://www.icr.ac.uk/news-archive%2fecological-technique-to-find-cancer-tracking-immune-cells-predicts-breast-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fecological-technique-to-find-cancer-tracking-immune-cells-predicts-breast-cancer-survivalEcological technique to find cancer-tracking immune cells predicts breast cancer survivalA system used by ecologists to study predator-prey interactions could predict breast cancer survival, according to ICR research.https://www.icr.ac.uk/news-archive%2ficr-video-celebrates-mel-greaves-s-lifetime-achievement-awardhttps://www.icr.ac.uk/news-archive%2ficr-video-celebrates-mel-greaves-s-lifetime-achievement-awardICR video celebrates Mel Greaves’ Lifetime Achievement AwardProfessor Mel Greaves discusses his 30 years at the ICR in a video about the science which recently won him Cancer Research UK’s Lifetime Achievement award. https://www.icr.ac.uk/news-archive%2fstatement-about-plans-to-reform-cancer-drugs-fundhttps://www.icr.ac.uk/news-archive%2fstatement-about-plans-to-reform-cancer-drugs-fundStatement about plans to reform Cancer Drugs FundICR CEO Professor Paul Workman comments on new plans to reform the Cancer Drugs Fund in England. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-inequality-in-science-isn-t-just-letting-women-down-but-science-toohttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-inequality-in-science-isn-t-just-letting-women-down-but-science-tooWhy inequality in science isn’t just letting women down, but science tooEquality of opportunity is a key objective for the ICR and underpins our aim to be the employer of choice for those working in cancer research. Our latest blog from CEO Professor Paul Workman explains our commitment to ensure women have the same opportunities to progress in their scientific careers as men, and what we're doing to achieve it.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-royal-visit-to-our-partner-hospitalhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-royal-visit-to-our-partner-hospitalA Royal visit to our partner hospitalHRH The Duke of Cambridge is visiting The Royal Marsden and will learn about some of the world-leading research carried out within our joint Biomedical Research Centre.https://www.icr.ac.uk/news-archive%2fmri-could-detect-head-and-neck-cancer-s-resistant-coreshttps://www.icr.ac.uk/news-archive%2fmri-could-detect-head-and-neck-cancer-s-resistant-coresMRI could detect head and neck cancer’s resistant coresGrouping magnetic resonance imaging data into clusters could detect treatment-resistant cores inside head and neck tumours, a new study shows.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-radiotracers-to-spy-on-cancer-s-secretshttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-radiotracers-to-spy-on-cancer-s-secretsUsing radiotracers to spy on cancer’s secretsScientists are developing new imaging techniques that track cancer’s metabolism using radiolabelled amino acidshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-centre-for-evolution-and-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-centre-for-evolution-and-cancerOur Centre for Evolution and Cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit%27s-time-drugs-regulation-caught-up-with-cancer-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit%27s-time-drugs-regulation-caught-up-with-cancer-scienceIt's time drugs regulation caught up with cancer sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbringing-together-germline-and-tumour-genetic-information-for-patient-benefithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbringing-together-germline-and-tumour-genetic-information-for-patient-benefitBringing together germline and tumour genetic information for patient benefitA fascinating session hosted by Professor Nazneen Rahman at the recent NCRI annual conference explored the potential value of integrating genetic information into the patient pathwayhttps://www.icr.ac.uk/news-archive%2fblood-test-detects-when-hormone-treatment-for-breast-cancer-stops-workinghttps://www.icr.ac.uk/news-archive%2fblood-test-detects-when-hormone-treatment-for-breast-cancer-stops-workingBlood test detects when hormone treatment for breast cancer stops workingScientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fset-back-for-off-patent-drugs-as-mps-fail-to-support-new-billhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fset-back-for-off-patent-drugs-as-mps-fail-to-support-new-billSet-back for off-patent drugs as MPs fail to support new BillDespite a bold campaign supported by the ICR, improving access to repurposed medicines has been dealt a setback in the House of Commonshttps://www.icr.ac.uk/news-archive%2fnew-genetic-cause-of-a-childhood-kidney-cancer-discoveredhttps://www.icr.ac.uk/news-archive%2fnew-genetic-cause-of-a-childhood-kidney-cancer-discoveredNew genetic cause of a childhood kidney cancer discoveredGenetic mutations in a gene called REST have been shown to cause Wilms tumour, a rare kidney cancer that occurs in children.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fas-the-2015-ncri-conference-draws-to-a-close-what-have-we-learnedhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fas-the-2015-ncri-conference-draws-to-a-close-what-have-we-learnedAs the 2015 NCRI conference draws to a close – what have we learned?The UK's largest cancer conference is over for another year. Our blog looks back at the key themes and highlights from the 4 day event. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-quiet-revolution-how-high-frequency-sound-waves-are-being-used-to-treat-cancer-painhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-quiet-revolution-how-high-frequency-sound-waves-are-being-used-to-treat-cancer-painThe quiet revolution: how high-frequency sound waves are being used to treat cancer painOur researchers are using powerful beams of ultrasound to burn away tissue around tumours. Find out more about this exciting new technology to treat cancer. https://www.icr.ac.uk/news-archive%2fblood-test-picks-out-prostate-cancer-drug-resistancehttps://www.icr.ac.uk/news-archive%2fblood-test-picks-out-prostate-cancer-drug-resistanceBlood test picks out prostate cancer drug resistanceScientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fon-the-path-to-personalising-radionuclide-therapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fon-the-path-to-personalising-radionuclide-therapyOn the path to personalising radionuclide therapy Senior ICR researcher Professor Nandita deSouza hosted a session at this year's NCRI conference on radionucleotide therapy. Our blog looks at the prospect of personalised treatment plans for molecular radiotherapy.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmentors-motivations-mutations-and-more-to-come-from-melhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmentors-motivations-mutations-and-more-to-come-from-melMentors, motivations, mutations – and more to come from MelProfessor Mel Greaves last night gave an inspirational overview of his 40-year career in cancer research as he received a major lifetime achievement award.https://www.icr.ac.uk/news-archive%2fchanges-urged-to-radiotherapy-practice-that-could-save-nhs-tens-of-millions-per-yearhttps://www.icr.ac.uk/news-archive%2fchanges-urged-to-radiotherapy-practice-that-could-save-nhs-tens-of-millions-per-yearChanges urged to radiotherapy practice that could save NHS tens of millions per yearMajor clinical trial finds new regime for prostate cancer at least as good, cheaper and more convenient than current practicehttps://www.icr.ac.uk/news-archive%2fprofessor-mel-greaves-wins-cancer-research-uk-lifetime-achievement-awardhttps://www.icr.ac.uk/news-archive%2fprofessor-mel-greaves-wins-cancer-research-uk-lifetime-achievement-awardProfessor Mel Greaves wins Cancer Research UK Lifetime Achievement AwardThe ICR’s Professor Mel Greaves has been awarded the Cancer Research UK Lifetime Achievement Award for his work investigating the causes and clonal evolution of childhood leukaemia.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-house-divided-should-we-be-focusing-on-the-causes-of-breast-cancer-or-action-to-prevent-ithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-house-divided-should-we-be-focusing-on-the-causes-of-breast-cancer-or-action-to-prevent-itA house divided: should we be focusing on the causes of breast cancer, or action to prevent it?A keenly contested debate at the NCRI conference asked whether it was time to move beyond research on causes of breast cancer to the implementation of strategies for prevention.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwelcome-to-the-uk-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwelcome-to-the-uk-s-largest-cancer-conferenceWelcome to the UK’s largest cancer conferenceThe ICR communications team is in Liverpool this week, reporting the highlights from the NCRI cancer conference 2015 #NCRI2015https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fputting-off-patent-drugs-back-to-workhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fputting-off-patent-drugs-back-to-workPutting off-patent drugs back to work We’re supporting a campaign to ensure off-patent drugs get licensed for new indications –providing patients with access to a wider range of treatmentshttps://www.icr.ac.uk/news-archive%2flandmark-clinical-trial-shows-gene-targeted-drug-can-treat-prostate-cancerhttps://www.icr.ac.uk/news-archive%2flandmark-clinical-trial-shows-gene-targeted-drug-can-treat-prostate-cancerLandmark clinical trial shows gene-targeted drug can treat prostate cancerFirst trial to show benefit of ‘precision medicine’ in prostate cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-it-like-to-study-at-the-uk-s-leading-academic-research-centrehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-is-it-like-to-study-at-the-uk-s-leading-academic-research-centreWhat is it like to study at the UK’s leading academic research centre?As we start to recruit our latest round of PhD students, we provide a window into student life at The Institute of Cancer Research.https://www.icr.ac.uk/news-archive%2fgenetic-testing-could-identify-men-at-a-10-fold-increased-risk-of-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-could-identify-men-at-a-10-fold-increased-risk-of-testicular-cancerGenetic testing could identify men at a 10-fold increased risk of testicular cancerA new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer.https://www.icr.ac.uk/news-archive%2fchemical-probe-to-dissect-role-of-potential-cancer-causing-proteinshttps://www.icr.ac.uk/news-archive%2fchemical-probe-to-dissect-role-of-potential-cancer-causing-proteinsChemical probe to dissect role of potential cancer-causing proteinsScientists have created a highly specific chemical probe to shed new light on the role two important proteins play in driving cancer cell proliferation.https://www.icr.ac.uk/news-archive%2ft-vec-becomes-first-viral-immunotherapy-recommended-for-approval-in-europehttps://www.icr.ac.uk/news-archive%2ft-vec-becomes-first-viral-immunotherapy-recommended-for-approval-in-europeT-VEC becomes first viral immunotherapy recommended for approval in EuropeA viral immunotherapy for cancer has become the first to be given the green light by European regulators.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-success-looks-like-in-the-war-on-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-success-looks-like-in-the-war-on-cancerWhat success looks like in the War on CancerMore basic cancer research, a braver approach to drug discovery and earlier use of targeted treatments were among the prescriptions for success made by the ICR’s Professor Kevin Harrington at a prestigious debate this week. Dr Claire Hastings went along to find out what he had to say.https://www.icr.ac.uk/news-archive%2fstudy-identifies-new-treatment-target-in-brca2-mutant-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fstudy-identifies-new-treatment-target-in-brca2-mutant-prostate-cancerStudy identifies new treatment target in BRCA2-mutant prostate cancerGenetic abnormalities associated with poor prognosis in prostate cancer are particularly common in men with germline mutations in the BRCA2 gene.https://www.icr.ac.uk/news-archive%2ftest-could-predict-whether-breast-cancer-will-spread-to-the-brainhttps://www.icr.ac.uk/news-archive%2ftest-could-predict-whether-breast-cancer-will-spread-to-the-brainTest could predict whether breast cancer will spread to the brainWomen with particularly aggressive forms of breast cancer could be identified by a test that predicts whether the disease is likely to spread to the brain.https://www.icr.ac.uk/news-archive%2fanother-successful-year-for-the-icr-team-at-the-royal-parks-half-marathonhttps://www.icr.ac.uk/news-archive%2fanother-successful-year-for-the-icr-team-at-the-royal-parks-half-marathonAnother successful year for the ICR team at the Royal Parks Half MarathonAll 24 of our runners in the Royal Parks Half Marathon completed the 13.1 mile course and together are set to raise £25,000 for our research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsounding-an-early-warning-of-cancer-s-returnhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsounding-an-early-warning-of-cancer-s-returnSounding an early warning of cancer’s returnTests for cancer DNA in the bloodstream can act as an early warning sign that drugs are no longer working, and could change the face of cancer treatment.https://www.icr.ac.uk/news-archive%2ficr-scientists-set-to-conquer-mount-snowdon-for-research-into-rare-teenage-cancerhttps://www.icr.ac.uk/news-archive%2ficr-scientists-set-to-conquer-mount-snowdon-for-research-into-rare-teenage-cancerICR scientists set to conquer Mount Snowdon for research into rare teenage cancerA team of scientists from The Institute of Cancer Research, London, are embarking on a series of fundraising challenges in support of two parent-led charities committed to funding the ICR’s research into teenage cancer.https://www.icr.ac.uk/news-archive%2fnew-test-to-predict-relapse-of-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fnew-test-to-predict-relapse-of-testicular-cancerNew test to predict relapse of testicular cancerAssessing just three features of a common kind of testicular cancer can identify those at most at risk of relapse.https://www.icr.ac.uk/news-archive%2fblood-test-could-match-cancer-patients-to-best-treatmentshttps://www.icr.ac.uk/news-archive%2fblood-test-could-match-cancer-patients-to-best-treatmentsBlood test could match cancer patients to best treatmentsScientists have developed a blood test that could match cancer patients with the most suitable therapy and track the tumour’s progress to see if the treatment is working.https://www.icr.ac.uk/news-archive%2fnew-test-could-help-personalise-treatment-for-common-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fnew-test-could-help-personalise-treatment-for-common-childhood-cancerNew test could help personalise treatment for common childhood cancerA new test that examines the activity of only five genes can identify which patients are likely to suffer more aggressive forms of the childhood cancer rhabdomyosarcoma.https://www.icr.ac.uk/news-archive%2fabiraterone-made-available-earlier-for-men-in-scotlandhttps://www.icr.ac.uk/news-archive%2fabiraterone-made-available-earlier-for-men-in-scotlandAbiraterone made available earlier for men in ScotlandAbiraterone has been made available on the NHS in Scotland for men with advanced prostate cancer before treatment with chemotherapy.https://www.icr.ac.uk/news-archive%2fscientists-uncover-four-different-types-of-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-uncover-four-different-types-of-bowel-cancerScientists uncover four different types of bowel cancerBowel cancer can be divided up into four distinct diseases, each with its own set of biological characteristics, a major new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-nobel-prize-winning-research-is-helping-us-to-treat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-nobel-prize-winning-research-is-helping-us-to-treat-cancerHow Nobel Prize winning research is helping us to treat cancerThe Nobel Prize in Chemistry has been awarded for discoveries into how cells repair DNA – mechanisms which are being exploited by ICR researchers in exciting new treatments for cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fputting-the-pieces-together-a-jigsaw-puzzle-approach-to-treating-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fputting-the-pieces-together-a-jigsaw-puzzle-approach-to-treating-cancerPutting the pieces together: a jigsaw puzzle approach to treating cancer Delegates at the European Cancer Congress in Vienna heard Professor Kevin Harrington talk on putting together the pieces of the puzzle – radiotherapy, immunotherapy and viral therapy – for each individual patient.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-elephant-got-less-cancer-(and-other-stories)https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-elephant-got-less-cancer-(and-other-stories)How the elephant got less cancer (and other stories)New research has come up with a plausible answer to one of the most celebrated riddles in evolutionary biology – why some big animals with lots of cells have low rates of cancer.https://www.icr.ac.uk/news-archive%2fgene-may-explain-elephants-surprisingly-low-cancer-ratehttps://www.icr.ac.uk/news-archive%2fgene-may-explain-elephants-surprisingly-low-cancer-rateGene may explain elephants’ surprisingly low cancer rateScientists believe they may be able to explain elephants’ low cancer rates – providing intriguing clues for preventing cancer in humans.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhpv-or-not-hpv-and-what-this-means-for-throat-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhpv-or-not-hpv-and-what-this-means-for-throat-cancer-treatmentHPV or not HPV, and what this means for throat cancer treatmentICR researchers are at the forefront of improving treatments for all patients with throat cancer, including those with the harder-to-treat HPV-negative throat cancer.https://www.icr.ac.uk/news-archive%2fnew-head-of-cancer-therapeutics-sets-sights-on-cancers-of-unmet-needhttps://www.icr.ac.uk/news-archive%2fnew-head-of-cancer-therapeutics-sets-sights-on-cancers-of-unmet-needNew Head of Cancer Therapeutics sets sights on cancers of unmet needDr Rajesh Chopra, a global leader in the development of molecularly targeted cancer drugs, will spearhead the ICR's world-leading work in cancer therapeutics.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-huge-hole-in-the-ground-that-is-set-to-revolutionise-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-huge-hole-in-the-ground-that-is-set-to-revolutionise-radiotherapyThe huge hole in the ground that is set to revolutionise radiotherapyDr Claire Bithell visited the site of our revolutionary new radiotherapy machine - the MR Linac.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-we-learned-from-europe-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-we-learned-from-europe-s-largest-cancer-conferenceWhat we learned from Europe’s largest cancer conferenceWe look back on some of the announcements from the European Cancer Conference in Vienna to highlight research which could make a big impact on cancer care and treatmenthttps://www.icr.ac.uk/news-archive%2fmajor-study-finds-five-new-genetic-variants-linked-to-brain-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-study-finds-five-new-genetic-variants-linked-to-brain-cancerMajor study finds five new genetic variants linked to brain cancerThe biggest ever study of DNA from the most common form of brain cancer has discovered five new genetic variants associated with the disease.https://www.icr.ac.uk/news-archive%2fhrt-safe-and-perhaps-beneficial-in-women-treated-for-ovarian-cancer-major-trial-showshttps://www.icr.ac.uk/news-archive%2fhrt-safe-and-perhaps-beneficial-in-women-treated-for-ovarian-cancer-major-trial-showsHRT safe and perhaps beneficial in women treated for ovarian cancer, major trial showsWomen with the commonest type of ovarian cancer can safely take hormone replacement therapy according to results from a 24-year, phase III international trial.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhormone-replacement-therapy-and-cancer-and-where-our-new-study-fits-inhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhormone-replacement-therapy-and-cancer-and-where-our-new-study-fits-inHormone replacement therapy and cancer – and where our new study fits inA new study suggests it’s safe for women with ovarian cancer to take HRT. Henry French places the results in context.https://www.icr.ac.uk/news-archive%2ffewer-larger-radiotherapy-doses-prove-effective-for-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2ffewer-larger-radiotherapy-doses-prove-effective-for-prostate-cancer-patientsFewer, larger radiotherapy doses prove effective for prostate cancer patientsGiving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to research presented at the 2015 European Cancer Congress.https://www.icr.ac.uk/news-features%2flatest-features%2funderstanding-why-some-men-still-die-from-testicular-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2funderstanding-why-some-men-still-die-from-testicular-cancerUnderstanding why some men still die from testicular cancerSince the early 1970s survival for testicular cancer has risen continuously, and current cure rates are a remarkable 96%. Research attention is now focused on the minority of patients who do not survive.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feurope-s-biggest-cancer-conference-takes-a-big-picture-view-of-cancer-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feurope-s-biggest-cancer-conference-takes-a-big-picture-view-of-cancer-drug-discoveryEurope’s biggest cancer conference takes a big picture view of cancer drug discoveryThousands of cancer researchers across the world are descending on Vienna for one of the biggest dates in the international cancer calendar – the European Cancer Congress (#ECC2015)https://www.icr.ac.uk/news-archive%2ftom-bowdidge-foundation-gives-250-000-for-rare-cancer-researchhttps://www.icr.ac.uk/news-archive%2ftom-bowdidge-foundation-gives-250-000-for-rare-cancer-researchTom Bowdidge Foundation gives £250,000 for rare cancer researchThe Tom Bowdidge Foundation has pledged to give more than £250,000 to support research into a rare form of cancer called desmoplastic small round cell tumour.https://www.icr.ac.uk/news-archive%2frare-variants-are-not-so-rare-after-all-new-study-findshttps://www.icr.ac.uk/news-archive%2frare-variants-are-not-so-rare-after-all-new-study-findsRare variants are not so rare after all, new study findsScientists from the ICR have shown that each person in the UK has an average of 160 rare genetic variants.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcollaborating-for-cancer-finding-common-ground-to-cure-childhood-cancershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcollaborating-for-cancer-finding-common-ground-to-cure-childhood-cancersCollaborating for cancer – finding common ground to cure childhood cancersGerm cell tumours are rare in children, but differing criteria to treat the disease around the world makes developing new therapies challenging. Now researchers are working together to ensure a common approach to test new treatments for children with germ cell tumours.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-simple-change-in-dosing-has-made-radiotherapy-for-breast-cancer-better-and-cheaperhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-a-simple-change-in-dosing-has-made-radiotherapy-for-breast-cancer-better-and-cheaperHow a simple change in dosing has made radiotherapy for breast cancer better and cheaperA new type of radiotherapy could help breast cancer patients by delivering more radiation in fewer sessions.https://www.icr.ac.uk/news-archive%2fsir-kenneth-stowe-former-icr-chairman-and-senior-civil-servant-dieshttps://www.icr.ac.uk/news-archive%2fsir-kenneth-stowe-former-icr-chairman-and-senior-civil-servant-diesSir Kenneth Stowe, former ICR Chairman and senior civil servant, diesSir Kenneth Stowe, who was Chairman of the ICR in the eighties and nineties, has died.https://www.icr.ac.uk/news-archive%2fprofessor-nazneen-rahman-featured-in-list-of-london-s-most-influential-peoplehttps://www.icr.ac.uk/news-archive%2fprofessor-nazneen-rahman-featured-in-list-of-london-s-most-influential-peopleProfessor Nazneen Rahman featured in list of London’s most influential peopleFor the second consecutive year, Professor Nazneen Rahman has featured in the London Evening Standard’s ‘Power1000’ list of the most influential people in London.https://www.icr.ac.uk/news-archive%2fcancer-genes-control-the-way-cells-get-fathttps://www.icr.ac.uk/news-archive%2fcancer-genes-control-the-way-cells-get-fatCancer genes control the way cells get fatScientists have shown that the tumour suppressor gene TP53 and genes in TOR family play a role in fat production during normal cell division, with important implications for cancer biology.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-key-points-on-cancer-drug-pricinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-key-points-on-cancer-drug-pricingFive key points on cancer drug pricingThe Cancer Drugs Fund in England will no longer pay for 16 medicines, used in 23 separate cancer treatments. Henry French provides some views on cancer drug pricing, and how to improve access to cancer drugs. https://www.icr.ac.uk/news-archive%2fnew-head-of-cancer-biology-to-target-cancer-cell-divisionhttps://www.icr.ac.uk/news-archive%2fnew-head-of-cancer-biology-to-target-cancer-cell-divisionNew Head of Cancer Biology to target cancer cell divisionWorld-leading cell biologist Dr Jonathon Pines joins the ICR as Head of the Division of Cancer Biology.https://www.icr.ac.uk/news-archive%2fnearly-half-of-testicular-cancer-risk-comes-from-inherited-genetic-faultshttps://www.icr.ac.uk/news-archive%2fnearly-half-of-testicular-cancer-risk-comes-from-inherited-genetic-faultsNearly half of testicular cancer risk comes from inherited genetic faultsAlmost half of the risk of developing testicular cancer comes from the DNA passed down from our parents, a greater proportion than for other cancers.https://www.icr.ac.uk/news-archive%2fbreast-cancer-test-could-spare-some-women-from-unnecessary-chemotherapyhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-test-could-spare-some-women-from-unnecessary-chemotherapyBreast cancer test could spare some women from unnecessary chemotherapyA prognostic tool for breast cancer could spare some women from unnecessary chemotherapy, a new study shows.https://www.icr.ac.uk/news-archive%2fshape-shifting-cells-can-take-detours-to-drive-skin-cancer-metastasishttps://www.icr.ac.uk/news-archive%2fshape-shifting-cells-can-take-detours-to-drive-skin-cancer-metastasisShape-shifting cells can take detours to drive skin cancer metastasisScientists have observed malignant melanoma cells shift between forms that each have the ability to invade different tissue types.https://www.icr.ac.uk/news-archive%2fnew-mutation-tracking-blood-test-could-predict-breast-cancer-relapse-months-in-advancehttps://www.icr.ac.uk/news-archive%2fnew-mutation-tracking-blood-test-could-predict-breast-cancer-relapse-months-in-advanceNew ‘mutation-tracking’ blood test could predict breast cancer relapse months in advanceScientists have developed a blood test for breast cancer to spot patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.https://www.icr.ac.uk/news-archive%2ficr-among-the-world-s-most-innovative-universities-in-new-league-tableshttps://www.icr.ac.uk/news-archive%2ficr-among-the-world-s-most-innovative-universities-in-new-league-tablesICR among the world’s most innovative universities in new league tablesThe ICR is the joint top institute in the world in the proportion of its academic papers cited in patent applications.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsummer-students-and-the-surprising-role-they-play-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsummer-students-and-the-surprising-role-they-play-in-cancer-researchSummer students, and the surprising role they play in cancer researchEvery year, a few undergraduate students gain a very special experience over their summer months – becoming a cancer researcher.https://www.icr.ac.uk/news-archive%2fimaging-probe-outperforms-the-best-external-detector-for-early-cervical-cancerhttps://www.icr.ac.uk/news-archive%2fimaging-probe-outperforms-the-best-external-detector-for-early-cervical-cancerImaging probe outperforms the best external detector for early cervical cancerAn endovaginal magnetic resonance imaging technique is more accurate at detecting early-stage cervical cancer than the best widely available method.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-i-value-being-a-patient-advocate-and-how-it-can-shape-clinical-trial-designhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-i-value-being-a-patient-advocate-and-how-it-can-shape-clinical-trial-designWhy I value being a patient advocate – and how it can shape clinical trial designInvolving patients and the public is an important and valuable aspect of clinical trial design argues the patient advocates group, the Independent Cancer Patients' Voice.https://www.icr.ac.uk/news-archive%2fgenetic-test-could-improve-blood-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fgenetic-test-could-improve-blood-cancer-treatmentGenetic test could improve blood cancer treatmentAs few as nine genetic features would need to be tested to help doctors identify patients at risk of developing more aggressive disease.https://www.icr.ac.uk/news-archive%2ficr-competes-in-university-challenge-for-the-first-timehttps://www.icr.ac.uk/news-archive%2ficr-competes-in-university-challenge-for-the-first-timeICR competes in University Challenge for the first timeFour students from The Institute of Cancer Research, London, will be hoping to answer their ‘Starter for 10’, as they spearhead the organisation’s first ever appearance on the BBC quiz programme University Challenge.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fa-step-forward-in-our-campaign-to-increase-children-s-access-to-new-drugshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fa-step-forward-in-our-campaign-to-increase-children-s-access-to-new-drugsA step forward in our campaign to increase children’s access to new drugsOne policy issue that the ICR is involved in is discussing the regulatory barriers that our researchers face in running clinical trials in children – we have been pushing for changes to the way EU regulations are implemented.https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-chris-marshall-1949-2015https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-chris-marshall-1949-2015Professor Chris Marshall, 1949–2015Professor Chris Marshall, who has very sadly died aged 66, was an inspirational scientist who will leave a lasting legacy of game-changing discoveries in cancer research and generous support for his younger colleagues.https://www.icr.ac.uk/news-archive%2ficr-mourns-loss-of-research-director-professor-chris-marshallhttps://www.icr.ac.uk/news-archive%2ficr-mourns-loss-of-research-director-professor-chris-marshallICR mourns loss of Research Director Professor Chris MarshallIt is with great sadness that we confirm that Professor Chris Marshall, inspirational scientist and esteemed colleague, friend and mentor, has died.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-displays-bringing-the-icr-s-history-and-the-role-played-in-it-by-women-back-to-lifehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-displays-bringing-the-icr-s-history-and-the-role-played-in-it-by-women-back-to-lifeThe displays bringing the ICR’s history – and the role played in it by women – back to lifeThe ICR is celebrating its history with a series of historical photo displays – the latest is devoted to some of the women who have made vital contributions to our researchhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-comments-on-further-draft-guidance-for-olaparibhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-comments-on-further-draft-guidance-for-olaparibProfessor Paul Workman comments on further draft guidance for olaparibProfessor Paul Workman, Cheif Executive of the ICR has commented on today’s decision on olaparib for women with BRCA mutated ovarian cancer in further draft guidance from NICE.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fjudging-at-the-teentech-finalshttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fjudging-at-the-teentech-finalsJudging at the TeenTech finalsAfter judging the electronic entries for the TeenTech Health category, Yvette Newbatt from the ICR’s Division of Cancer Therapeutics was delighted to be asked to judge the shortlisted entries as part of an event at the Royal Society.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftreating-testicular-cancer-in-men-with-down-syndromehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftreating-testicular-cancer-in-men-with-down-syndromeTreating testicular cancer in men with Down syndromeDr Shaista Hafeez argues in a new opinion piece that there is a need for a more holistic and personalised approach to make sure that patients with Down syndrome get the care they deservehttps://www.icr.ac.uk/news-features%2flatest-features%2fcreative-typeshttps://www.icr.ac.uk/news-features%2flatest-features%2fcreative-typesCreative typesIn the fifth and final essay short-listed for the ICR's Mel Greaves Science Writing Prize 2015, Dr Chris Tape discovers what it's like to communicate science to millions of people.https://www.icr.ac.uk/news-archive%2flucy-s-gratitude-walkhttps://www.icr.ac.uk/news-archive%2flucy-s-gratitude-walkLucy’s Gratitude Walk to raise funds for the ICRLucy O'Donnell, a mother of three teenagers, and her friend Lucinda will walk the South Downs Way in support of the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmr-linac-promises-to-revolutionise-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmr-linac-promises-to-revolutionise-radiotherapyMR Linac promises to revolutionise radiotherapyA new radiotherapy machine, known as MR Linac, promises to more accurately track and target tumours – how else is radiotherapy improving patients' lives?https://www.icr.ac.uk/news-archive%2fprofessor-kevin-harrington-to-star-in-bbc2-s-trust-me-i-m-a-doctorhttps://www.icr.ac.uk/news-archive%2fprofessor-kevin-harrington-to-star-in-bbc2-s-trust-me-i-m-a-doctorProfessor Kevin Harrington to star in BBC2’s Trust me, I’m a DoctorThe ICR’s Professor Kevin Harrington is to feature in the BBC2 programme Trust Me, I’m a Doctor on Wednesday 29 July.https://www.icr.ac.uk/news-archive%2fdrugs-for-worms-and-river-blindness-could-treat-breast-cancerhttps://www.icr.ac.uk/news-archive%2fdrugs-for-worms-and-river-blindness-could-treat-breast-cancerDrugs for worms and river blindness could treat breast cancerCheap drugs which treat parasitic worms and conditions such as river blindness could be used for women with a type of breast cancer that often fails to respond to standard therapies.https://www.icr.ac.uk/news-features%2flatest-features%2fsocrates-and-apoptosishttps://www.icr.ac.uk/news-features%2flatest-features%2fsocrates-and-apoptosisSocrates and apoptosisIn the fourth of five articles short-listed for the ICR's Mel Greaves Science Writing Prize 2015, Dr Daniel Nava Rodrigues offers similarities between our bodies and city-states – how are the cells in our bodies policed?https://www.icr.ac.uk/news-archive%2foestrogen-suppressing-drugs-substantially-reduce-breast-cancer-deathshttps://www.icr.ac.uk/news-archive%2foestrogen-suppressing-drugs-substantially-reduce-breast-cancer-deathsOestrogen-suppressing drugs substantially reduce breast cancer deathsA class of hormonal drugs – already used in the clinic – reduce the risk of death in postmenopausal women with the most common type of breast cancer.https://www.icr.ac.uk/news-archive%2fnew-chemotherapy-booster-could-treat-lung-and-pancreatic-cancerhttps://www.icr.ac.uk/news-archive%2fnew-chemotherapy-booster-could-treat-lung-and-pancreatic-cancerNew ‘chemotherapy booster’ could treat lung and pancreatic cancerA new drug that blocks cancer’s escape route from chemotherapy could be used to treat deadly lung and pancreatic cancers, new research reports.https://www.icr.ac.uk/news-archive%2fresistance-to-cancer-drug-found-to-occur-naturally-in-the-breasthttps://www.icr.ac.uk/news-archive%2fresistance-to-cancer-drug-found-to-occur-naturally-in-the-breastResistance to cancer drug found to occur naturally in the breastStudy finds the genetic mutations which drive resistance to some targeted cancer drugs are present in breast cancer cells right from the beginning of treatment.https://www.icr.ac.uk/news-archive%2fnew-tripadvisor-site-to-address-use-of-substandard-biomedical-research-toolshttps://www.icr.ac.uk/news-archive%2fnew-tripadvisor-site-to-address-use-of-substandard-biomedical-research-toolsNew ‘TripAdvisor’ site to address use of substandard biomedical research toolsA new 'TripAdvisor-style' website will help biomedical researchers pick the best chemical probes for the job – improving research and treatment of disease.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fensuring-biomedical-research-is-gold-standard-through-better-use-of-chemical-probeshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fensuring-biomedical-research-is-gold-standard-through-better-use-of-chemical-probesEnsuring biomedical research is gold standard – through better use of chemical probesChemical tools are essential to probe the function of proteins and validate them as drug targets, but loose standards in their design and use are leading to potentially serious errors in biomedical research studies.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-rocky-road-to-developing-new-children-s-cancer-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-rocky-road-to-developing-new-children-s-cancer-treatmentsThe rocky road to developing new children’s cancer treatmentsIt takes years to develop drugs that target a specific cancer-causing mutation. Dr Claire Bithell reflects on the promises of targeting ALK mutations in neuroblastoma – a common type of childhood cancer.https://www.icr.ac.uk/news-features%2flatest-features%2fword-processing-for-mankindhttps://www.icr.ac.uk/news-features%2flatest-features%2fword-processing-for-mankindWord processing for mankindIn the third of five articles short-listed for the ICR's Mel Greaves Science Writing Prize 2015, Kevin Litchfield discusses the potential consequences of cutting-edge genetics research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcomputational-chemistry-designing-drugs-by-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcomputational-chemistry-designing-drugs-by-evolutionComputational chemistry – designing drugs by evolutionIt’s a huge challenge for researchers to find effective drug molecules from the millions of potentials – but sophisticated software that mimics evolution can help them do so.https://www.icr.ac.uk/news-archive%2fprofessor-stan-kaye-honoured-with-students-at-annual-awardshttps://www.icr.ac.uk/news-archive%2fprofessor-stan-kaye-honoured-with-students-at-annual-awardsProfessor Stan Kaye honoured with students at annual awardsProfessor Stan Kaye, a pioneer in experimental clinical trials world-class translational research, was honoured alongside students and former staff members at our annual celebration, the ICR Awards Ceremony.https://www.icr.ac.uk/news-features%2flatest-features%2fplan-your-child-s-future-because-you-never-know-when-sci-fi-becomes-truehttps://www.icr.ac.uk/news-features%2flatest-features%2fplan-your-child-s-future-because-you-never-know-when-sci-fi-becomes-truePlan your child’s future – because you never know when sci-fi becomes trueIn the second of five articles short-listed for the ICR's Mel Greaves Science Writing Prize 2015, Marcia Costa delves into the science and ethics behind many of science fiction's greatest stem-cell inventions.https://www.icr.ac.uk/news-archive%2fgala-fundraising-dinner-raises-thousands-for-research-into-cancerhttps://www.icr.ac.uk/news-archive%2fgala-fundraising-dinner-raises-thousands-for-research-into-cancerICR gala fundraising dinner raises £250,000 for research into cancerGala fundraising event raises an impressive £250,000 for the ICR’s cancer research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fstructural-biology-mapping-the-intricate-configuration-of-proteins-provides-a-classic-example-of-the-benefits-of-basic-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fstructural-biology-mapping-the-intricate-configuration-of-proteins-provides-a-classic-example-of-the-benefits-of-basic-researchStructural biology – mapping the intricate configuration of proteins – provides a classic example of the benefits of basic researchOur Chief Executive, Professor Paul Workman, has written on his own blog about the critical importance of ‘basic research’ for understanding and treating cancer – and we’ve just seen a great example from the world of structural biology.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we%27re-fighting-neuroblastomahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-we%27re-fighting-neuroblastomaHow we're fighting neuroblastomaA new storyline in Coronation Street will help to raise awareness about neuroblastoma – a devastating cancer which often affects very young children. Henry French writes on how this awareness could improve treatment for this disease and other childhood cancers.https://www.icr.ac.uk/news-archive%2fscientists-advance-cancer-drug-design-with-image-of-one-of-key-proteins-of-lifehttps://www.icr.ac.uk/news-archive%2fscientists-advance-cancer-drug-design-with-image-of-one-of-key-proteins-of-lifeScientists advance cancer drug design with image of one of key proteins of lifeScientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life – a cellular recycling unit with a role in many diseases.https://www.icr.ac.uk/news-archive%2fhow-removing-a-protein-slows-blood-vessel-growth-in-tumourshttps://www.icr.ac.uk/news-archive%2fhow-removing-a-protein-slows-blood-vessel-growth-in-tumoursRemoving protein slows blood vessel growth in tumoursScientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumours which have spread to the brain, a common location which breast cancer can spread to.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-basic-research-is-critical-for-understanding-and-treating-cancerhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhy-basic-research-is-critical-for-understanding-and-treating-cancerWhy ‘basic research’ is critical for understanding and treating cancerCancer research often makes the biggest headlines when it begins to benefit patients – but in order to come up with innovative approaches to cancer treatment, we need first to make exciting scientific discoveries that illuminate our understanding of cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fre-inventing-the-fingerhttps://www.icr.ac.uk/news-features%2flatest-features%2fre-inventing-the-fingerRe-inventing the fingerIn the first of five articles short-listed for the ICR's Mel Greaves Science Writing Prize 2015, the winner Dr Hugh Harvey writes about re-inventing an age-old test for prostate cancer.https://www.icr.ac.uk/news-archive%2fnew-radiotherapy-technique-could-target-prostate-cancer-while-reducing-side-effectshttps://www.icr.ac.uk/news-archive%2fnew-radiotherapy-technique-could-target-prostate-cancer-while-reducing-side-effectsNew radiotherapy technique could target prostate cancer while reducing side-effectsA new technique for targeting radiotherapy at prostate cancer could improve treatment for aggressive disease that has spread into pelvic lymph nodes.https://www.icr.ac.uk/news-archive%2fnew-use-for-routine-test-could-improve-prediction-of-breast-cancer-recurrencehttps://www.icr.ac.uk/news-archive%2fnew-use-for-routine-test-could-improve-prediction-of-breast-cancer-recurrenceNew use for routine test could improve prediction of breast cancer recurrenceA leading research team has discovered an improved way of predicting risk of breast cancer recurrence following standard five-year hormone treatment using information from a test already being used within the NHS.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-nhs-bottleneck-for-new-cancer-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-nhs-bottleneck-for-new-cancer-drugsThe NHS ‘bottleneck’ for new cancer drugsTwo new cancer drugs have recently been 'turned down' by NICE. Henry French provides a summary of what we've said about this and how the system could be changed for the better.https://www.icr.ac.uk/news-archive%2fnew-charity-breast-cancer-now-acts-to-eradicate-deaths-from-breast-cancer-by-2050https://www.icr.ac.uk/news-archive%2fnew-charity-breast-cancer-now-acts-to-eradicate-deaths-from-breast-cancer-by-2050New charity Breast Cancer Now acts to eradicate deaths from breast cancer by 2050A new study analysing tissue from secondary breast cancer patients, collected just hours after they pass away, will open the door to understanding and ultimately stopping the spread of the disease.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffirst-comprehensive-map-of-breast-cancer-spread-may-help-find-new-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffirst-comprehensive-map-of-breast-cancer-spread-may-help-find-new-treatmentsFirst comprehensive map of breast cancer spread may help find new treatmentsA new study has been launched today which will help us understand why breast cancer that has spread around the body – also known as secondary or metastatic breast cancer – is so difficult to treat.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-ways-we-ve-been-talking-about-animal-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffive-ways-we-ve-been-talking-about-animal-researchFive ways we’ve been talking about animal research Our Science Information and Policy Manager, Dr Eva Sharpe, looks at how we are communicating about our research using animals.https://www.icr.ac.uk/news-archive%2fstudy-links-gene-to-aggressive-form-of-brain-cancerhttps://www.icr.ac.uk/news-archive%2fstudy-links-gene-to-aggressive-form-of-brain-cancerStudy links gene to aggressive form of brain cancerScientists have identified a gene mutation linked to the development of an aggressive form of brain cancer.https://www.icr.ac.uk/news-archive%2fstatement-about-nice-draft-guidance-on-enzalutamidehttps://www.icr.ac.uk/news-archive%2fstatement-about-nice-draft-guidance-on-enzalutamideStatement about NICE draft guidance on enzalutamide ICR CEO Professor Paul Workman comments on today’s rejection of enzalutamide for advanced prostate cancer before chemotherapy in draft guidance from NICE. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-glassful-of-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-glassful-of-scienceA glassful of scienceAfter a long Wednesday, many scientists at The Institute of Cancer Research might be longing for some well-deserved rest. But for three of our researchers, their work was just getting started as they prepared for Pint of Science.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fdisappointing-week-for-first-cancer-drug-targeted-at-an-inherited-genetic-faulthttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fdisappointing-week-for-first-cancer-drug-targeted-at-an-inherited-genetic-faultDisappointing week for first cancer drug targeted at an inherited genetic faultThis week we’ve had very disappointing news that the highly innovative cancer drug, olaparib, has been turned down by NICE. This decision is harder to bear as we found out last week that the drug will not be made available to patients via the Cancer Drugs Fund.https://www.icr.ac.uk/news-archive%2fmutations-disrupting-a-growth-controlling-enzyme-implicated-in-a-new-childhood-overgrowth-conditionhttps://www.icr.ac.uk/news-archive%2fmutations-disrupting-a-growth-controlling-enzyme-implicated-in-a-new-childhood-overgrowth-conditionMutations disrupting a growth-controlling enzyme implicated in a new childhood overgrowth conditionScientists have shown that mutations in three genes can alter the function of an important growth-controlling enzyme and cause increased growth and intellectual disability in childrenhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2filluminating-insights-and-innovative-ideas-at-the-world-s-largest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2filluminating-insights-and-innovative-ideas-at-the-world-s-largest-cancer-conferenceIlluminating insights and innovative ideas at the world’s largest cancer conferenceAfter an exhilarating five days sharing new research and ideas, researchers from The Institute of Cancer Research, London, are returning from the world’s largest cancer conference – the Annual Meeting of the American Society for Clinical Oncology (ASCO).https://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2flives-without-cancerhttps://www.icr.ac.uk/blogs%2fthe-bigger-picture%2fpage-details%2flives-without-cancerLives without cancerIn his first post for The Bigger Picture, Professor Mel Greaves offers insights into the evolution of cancer defence mechanisms in large animals – and what these might mean for human cancers.https://www.icr.ac.uk/news-archive%2fdrug-combination-controls-breast-cancer-for-over-twice-as-longhttps://www.icr.ac.uk/news-archive%2fdrug-combination-controls-breast-cancer-for-over-twice-as-longDrug combination controls breast cancer for over twice as longA new drug delays the progression of advanced breast cancer by over twice as long when used in combination with standard treatment, compared to standard treatment alone, a major clinical trial shows.https://www.icr.ac.uk/news-archive%2fstatement-about-rejection-of-olaparib-by-nicehttps://www.icr.ac.uk/news-archive%2fstatement-about-rejection-of-olaparib-by-niceStatement about rejection of olaparib by NICEICR CEO Professor Paul Workman comments on the decision by NICE to reject olaparib for women with BRCA mutated ovarian cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftop-cancer-conference-gives-icr-researchers-chance-to-share-and-learnhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftop-cancer-conference-gives-icr-researchers-chance-to-share-and-learnTop cancer conference gives ICR researchers chance to share and learnThe eyes of the cancer world turn to Chicago as the world’s largest cancer conference begins today in the windy city. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-infection-may-cause-childhood-leukaemia-and-prevent-ithttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-infection-may-cause-childhood-leukaemia-and-prevent-itWhy infection may cause childhood leukaemia – and prevent itA new study helps explain why early infection and vaccination could protect children against leukaemia – while later infection could raise the risk.https://www.icr.ac.uk/news-archive%2fsleeping-cancer-cells-can-wake-up-after-decadeshttps://www.icr.ac.uk/news-archive%2fsleeping-cancer-cells-can-wake-up-after-decadesSleeping cancer cells can ‘wake up’ after decadesScientists at the ICR have found genetic evidence that cancer cells can go to sleep – avoiding the effects of treatment – only to ‘wake up’ many years later.https://www.icr.ac.uk/news-archive%2fscientists-identify-key-to-preventing-secondary-cancershttps://www.icr.ac.uk/news-archive%2fscientists-identify-key-to-preventing-secondary-cancersScientists identify key to preventing secondary cancersExisting class of drugs for osteoporosis could stop the spread of the breast cancer to the bones, the most common site for the disease to spread. https://www.icr.ac.uk/news-archive%2fworld-first-as-viral-immunotherapy-for-skin-cancer-shows-patient-benefit-in-phase-iii-trialhttps://www.icr.ac.uk/news-archive%2fworld-first-as-viral-immunotherapy-for-skin-cancer-shows-patient-benefit-in-phase-iii-trialWorld first as viral immunotherapy for skin cancer shows patient benefit in Phase III trialA genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.https://www.icr.ac.uk/news-archive%2fscientists-unveil-prostate-cancer-s-rosetta-stonehttps://www.icr.ac.uk/news-archive%2fscientists-unveil-prostate-cancer-s-rosetta-stoneScientists unveil prostate cancer’s ‘Rosetta Stone’Landmark study hails new era of personalised treatment for cancers that have spread round the bodyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdelivering-a-step-change-in-children-s-cancer-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdelivering-a-step-change-in-children-s-cancer-trialsDelivering a step change in children’s cancer trialsGood research with children and young people is essential and must happen. That’s one of the two main messages from a report launch Dr Eva Sharpe, our Science Information and Policy Manager, went to last week, from the Nuffield Council on Bioethics. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-the-worry-out-of-cancer-screeninghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-the-worry-out-of-cancer-screeningTaking the worry out of cancer screeningCancer screening programmes offer a great opportunity to spot the disease early – making it easier to treat – but how can we avoid them causing unnecessary anxiety?https://www.icr.ac.uk/news-archive%2fcombining-targeted-cancer-drugs-is-best-when-used-to-the-maxhttps://www.icr.ac.uk/news-archive%2fcombining-targeted-cancer-drugs-is-best-when-used-to-the-maxCombining targeted cancer drugs is best when used to the maxCombining drugs that inhibit two signalling pathways critical to cancer growth could boost treatment outcomes for some types of cancer, but only when used together at maximum doses, a new study has found.https://www.icr.ac.uk/news-archive%2fuk-us-study-compares-radiotherapy-with-proton-therapy-in-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fuk-us-study-compares-radiotherapy-with-proton-therapy-in-childhood-cancerUK-US study compares radiotherapy with proton therapy in childhood cancerThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, are leading a collaborative international study looking at the potential benefits of proton radiotherapy for young patients with brain tumours. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fless-pain-more-gainhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fless-pain-more-gainLess pain, more gain?Cancer can be extremely painful, but as we begin to understand the complex reasons why, it may open up new avenues for pain control.https://www.icr.ac.uk/news-archive%2fscientists-identify-a-new-strategy-to-kill-cancer-cellshttps://www.icr.ac.uk/news-archive%2fscientists-identify-a-new-strategy-to-kill-cancer-cellsScientists identify a new strategy to kill cancer cellsScientists have discovered a new strategy to kill cancer cells with defects in genes responsible for DNA repair and cell division. https://www.icr.ac.uk/news-features%2flatest-features%2fthe-ongoing-battle-with-melanomahttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-ongoing-battle-with-melanomaThe ongoing battle with melanomaUntil recently there were no effective treatments for metastatic melanoma, but in the last decade we have seen a flurry of treatment breakthroughs, and scientists at the ICR have been at the heart of the fight against the disease.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fi-m-a-scientist-get-me-out-of-herehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fi-m-a-scientist-get-me-out-of-hereI’m a Scientist: Get me out of here!Poetry, cancer research and 3D-printing – Dr Hugh Harvey blogs about taking part in "I'm a Scientist: Get me out of here!".https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fras-proteins-common-cancer-causing-and-can-t-be-druggedhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fras-proteins-common-cancer-causing-and-can-t-be-druggedRAS proteins – common, cancer-causing, and can’t be drugged?Could indirect lines of attack be the key to hitting one of cancer’s most elusive targets?https://www.icr.ac.uk/news-archive%2fdrug-improves-quality-of-life-in-men-with-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fdrug-improves-quality-of-life-in-men-with-advanced-prostate-cancerDrug improves quality of life in men with advanced prostate cancerThe prostate cancer drug enzalutamide improves quality of life in men who haven’t previously received chemotherapy, a major Phase III clinical trial reports.https://www.icr.ac.uk/news-archive%2fnew-drugs-could-stop-skin-cancer-from-spreadinghttps://www.icr.ac.uk/news-archive%2fnew-drugs-could-stop-skin-cancer-from-spreadingNew drugs could stop skin cancer from spreadingTwo new drugs could stop melanoma from spreading to other parts of the body, a new study has found.https://www.icr.ac.uk/news-archive%2ficr-mourns-leading-molecular-biologist-alan-hall-1952-2015https://www.icr.ac.uk/news-archive%2ficr-mourns-leading-molecular-biologist-alan-hall-1952-2015ICR mourns leading molecular biologist Alan Hall, 1952–2015Professor Alan Hall, a key figure in the development of molecular oncology at The Institute of Cancer Research, London, died suddenly in New York on 3 May.https://www.icr.ac.uk/news-archive%2ftrial-of-new-resistance-busting-skin-cancer-drug-begins-as-first-patient-receives-treatmenthttps://www.icr.ac.uk/news-archive%2ftrial-of-new-resistance-busting-skin-cancer-drug-begins-as-first-patient-receives-treatmentTrial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatmentThe patient has received a new panRAF inhibitor – a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdifferent-worlds-but-one-event-to-drive-forward-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdifferent-worlds-but-one-event-to-drive-forward-drug-discoveryDifferent worlds, but one event to drive forward drug discovery'Horizons in Cancer Drug Discovery' is a different kind of conference – bringing together researchers, biotech and pharmaceutical companies, charity funders and investors to share ideas and build relationships. Liz Burtally spoke to our researchers who attended.https://www.icr.ac.uk/news-archive%2ficr%27s-children%27s-cancer-researchers-inspire-donors-and-fundraisershttps://www.icr.ac.uk/news-archive%2ficr%27s-children%27s-cancer-researchers-inspire-donors-and-fundraisersICR's children's cancer researchers inspire donors and fundraisersMembers of the ICR’s Discovery Club and parents leading children’s cancer charities gathered in the inspiring surroundings of The Royal Society to hear about the ICR’s pioneering children’s cancer research.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-opportunity-to-help-and-judge-the-scientists-and-entrepreneurs-of-tomorrowhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-opportunity-to-help-and-judge-the-scientists-and-entrepreneurs-of-tomorrowAn opportunity to help – and judge – the scientists and entrepreneurs of tomorrowOur Public Engagement Officer, Helen, caught up with Yvette Newbatt, who has been getting some unusual emails recently. Ideas for health gadgets were flooding into her inbox – the imaginative, impressive creations of around 13 teams of school children. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-some-childhood-cancers-are-examples-of-big-bang-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-some-childhood-cancers-are-examples-of-big-bang-evolutionWhy some childhood cancers are examples of ‘big bang’ evolutionNormally cancer occurs through the accumulation of mutations – but in some childhood cancers, it seems that a single mutation can be enough.https://www.icr.ac.uk/news-archive%2flondon-marathon-runners-raise-thousands-for-the-icrhttps://www.icr.ac.uk/news-archive%2flondon-marathon-runners-raise-thousands-for-the-icrLondon Marathon runners raise thousands for the ICRA team of runners is on target to raise more than £55,000 for the ICR at this year’s London Marathon on the 35th anniversary of the world-famous race. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-hot-as-one-of-cancer-s-biggest-events-draws-to-a-close-for-another-yearhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-hot-as-one-of-cancer-s-biggest-events-draws-to-a-close-for-another-yearWhat’s hot as one of cancer’s biggest events draws to a close for another year?Our researchers have been presenting their work at a massive, international conference this week. Liz Burtally caught up with some of them to discover what was discussed.https://www.icr.ac.uk/news-archive%2fgenetic-signature-points-to-poor-blood-cancer-outcomehttps://www.icr.ac.uk/news-archive%2fgenetic-signature-points-to-poor-blood-cancer-outcomeGenetic ‘signature’ points to poor blood cancer outcomeTesting for a DNA signature could predict which patients with myeloma – a cancer of immune cells in the blood and bone marrow – are likely to develop more serious disease, with a reduced chance of survival. https://www.icr.ac.uk/news-archive%2ficr-phd-student-wins-women-in-cancer-research-awardhttps://www.icr.ac.uk/news-archive%2ficr-phd-student-wins-women-in-cancer-research-awardICR PhD student wins Women in Cancer Research AwardPhD Student Dr Charlotte Pawlyn has won an award for her research presented at the prestigious international American Association of Cancer Research conference in Philadelphia.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-versatility-of-ultrasound-from-bats-to-battling-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-versatility-of-ultrasound-from-bats-to-battling-cancerThe versatility of ultrasound – from bats to battling cancerUltrasound as a medical application has been with us for more than 75 years, but it seems that it is only now that are we exploring its full potential for improving cancer treatment.https://www.icr.ac.uk/news-archive%2ftrial-shows-benefit-of-brca-targeting-drug-in-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ftrial-shows-benefit-of-brca-targeting-drug-in-prostate-cancerTrial shows benefit of ‘BRCA-targeting’ drug in prostate cancerMen with prostate cancer benefited from treatment with the pioneering drug olaparib – a drug which targets BRCA gene mutations.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-set-off-for-prestigious-international-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-set-off-for-prestigious-international-cancer-conferenceICR researchers set off for prestigious international cancer conferenceThe internationally renowned AACR cancer conference starts tomorrow in Philadelphia, and some of our leading researchers will be attending to present their cutting-edge research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-school-children-excited-about-sciencehttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fmaking-school-children-excited-about-scienceMaking school children excited about scienceDr Tatiana McHardy shares her experiences on a recent school's career day she attended in which she engaged young girls with her scientific career.https://www.icr.ac.uk/news-archive%2fover-drinks-three-icr-researchers-talk-sciencehttps://www.icr.ac.uk/news-archive%2fover-drinks-three-icr-researchers-talk-scienceOver drinks, three ICR researchers talk scienceJoin ICR scientists at the Somers Town Coffee House and learn about their research.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-the-seeds-of-cancer-to-guide-treatment-strategieshttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-the-seeds-of-cancer-to-guide-treatment-strategiesUsing the seeds of cancer to guide treatment strategiesCirculating tumour cells can act as ‘seeds’ – breaking away from the primary tumour and colonising other sites in the body. But they are also becoming an increasingly useful tool in cancer medicine – measuring a patient’s state of disease. https://www.icr.ac.uk/news-archive%2fgenetic-screening-could-improve-breast-cancer-preventionhttps://www.icr.ac.uk/news-archive%2fgenetic-screening-could-improve-breast-cancer-preventionGenetic screening could improve breast cancer preventionA test for a wide range of genetic risk factors could improve doctors’ ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-unusual-ethical-evening-at-the-science-museumhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-unusual-ethical-evening-at-the-science-museumAn unusual, ethical evening at the Science MuseumICR researcher Dr Udai Banerji visited the Science Museum to talk about a subject close to his heart – the ethics and realities of early clinical trials.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmapping-the-evolutionary-road-to-metastasishttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmapping-the-evolutionary-road-to-metastasisMapping the evolutionary road to metastasisNew research into advanced prostate cancer reveals that the evolutionary path to cancer spread isn’t just a one-way street.https://www.icr.ac.uk/news-archive%2fscientists-drill-down-to-genetic-root-of-prostate-tumour-developmenthttps://www.icr.ac.uk/news-archive%2fscientists-drill-down-to-genetic-root-of-prostate-tumour-developmentScientists drill down to genetic root of prostate tumour developmentResearch from an international collaboration of scientists has revealed new clues to the genetic causes of prostate cancer that has spread to other parts of the body.https://www.icr.ac.uk/news-archive%2fconsortium-signs-deal-with-basilea-to-develop-resistance-busting-cancer-drugshttps://www.icr.ac.uk/news-archive%2fconsortium-signs-deal-with-basilea-to-develop-resistance-busting-cancer-drugsConsortium signs deal with Basilea to develop resistance-busting cancer drugsThe cross-institution agreement with Basilea Pharmaceutica Ltd. will progress a new family of cancer drugs designed to tackle drug-resistant cancers.https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-to-co-host-horizons-in-cancer-drug-discoveryhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-to-co-host-horizons-in-cancer-drug-discoveryProfessor Paul Workman to co-host ‘Horizons in Cancer Drug Discovery’Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, is to co-host ‘Horizons in Cancer Drug Discovery’ – a meeting of minds of academia, the pharmaceutical industry and investors to discuss innovative methods of cancer drug discovery.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frevealed-secrets-of-an-80s-cancer-genehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2frevealed-secrets-of-an-80s-cancer-geneRevealed: secrets of an 80s cancer geneAs technology advances, researchers are finding there’s still a lot they don’t know about genes discovered almost 30 years ago – with important implications for cancer treatment.https://www.icr.ac.uk/news-archive%2fnew-role-uncovered-for-oldest-tumour-suppressor-genehttps://www.icr.ac.uk/news-archive%2fnew-role-uncovered-for-oldest-tumour-suppressor-geneNew role uncovered for ‘oldest’ tumour suppressor geneA new function has been found for one of the first cancer genes ever discovered.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhigh-hopes-for-hypofractionation-in-search-for-cheaper-better-radiotherapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhigh-hopes-for-hypofractionation-in-search-for-cheaper-better-radiotherapyHigh hopes for hypofractionation in search for cheaper, better radiotherapyGiving radiotherapy in fewer treatments but at higher doses could work just as well as standard regimes, but be cheaper and more convenient for patients. https://www.icr.ac.uk/news-archive%2fusing-multiple-imaging-measures-could-improve-prostate-cancer-diagnosishttps://www.icr.ac.uk/news-archive%2fusing-multiple-imaging-measures-could-improve-prostate-cancer-diagnosisUsing multiple imaging measures could improve prostate cancer diagnosisCombining a variety of different imaging parameters could be more accurate at diagnosing prostate cancer than an experienced radiologist.https://www.icr.ac.uk/news-archive%2fdetecting-cancer-cells-in-blood-can-give-an-early-warning-of-treatment-failurehttps://www.icr.ac.uk/news-archive%2fdetecting-cancer-cells-in-blood-can-give-an-early-warning-of-treatment-failureDetecting cancer cells in blood can give an early warning of treatment failureA blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.https://www.icr.ac.uk/news-archive%2fsperm-and-egg-gene-implicated-in-breast-cancerhttps://www.icr.ac.uk/news-archive%2fsperm-and-egg-gene-implicated-in-breast-cancerSperm and egg gene implicated in breast cancerA gene normally used in the development of sperm and egg cells has been shown to be active in some types of breast cancer, suggesting new treatments might be available.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-some-of-the-uncertainties-out-of-cancer-surgeryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftaking-some-of-the-uncertainties-out-of-cancer-surgeryTaking some of the uncertainties out of cancer surgeryThe London—Milan collaboration aiming to make operations for kidney cancer less riskyhttps://www.icr.ac.uk/news-archive%2fworld-first-cancer-drugs-could-work-in-larger-group-of-patientshttps://www.icr.ac.uk/news-archive%2fworld-first-cancer-drugs-could-work-in-larger-group-of-patientsWorld-first cancer drugs could work in larger group of patientsA pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.https://www.icr.ac.uk/news-archive%2fdiscovery-club-members-show-their-commitment-to-supporting-the-next-generation-of-cancer-researchershttps://www.icr.ac.uk/news-archive%2fdiscovery-club-members-show-their-commitment-to-supporting-the-next-generation-of-cancer-researchersDiscovery Club members supporting the next generation of cancer researchersMembers of The Discovery Club at The Institute of Cancer Research, London, met with PhD students last month to learn how they hope their research will transform the lives of cancer patients in the future.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fseven-things-you-learn-while-surrounded-by-datahttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fseven-things-you-learn-while-surrounded-by-dataSeven things you learn while surrounded by dataAs a data manager in the Clinical Trials and Statistics Unit, Lucy has changed the way she thinks about everyday events. She shares some of the more unexpected experiences and learning curves she's come across while ploughing through piles of data.https://www.icr.ac.uk/news-features%2flatest-features%2fphysics-unlocking-the-mysteries-of-tumourshttps://www.icr.ac.uk/news-features%2flatest-features%2fphysics-unlocking-the-mysteries-of-tumoursPhysics: unlocking the mysteries of tumoursResearch into ionising radiation takes us from the edges of the universe to treatment planning for cancerhttps://www.icr.ac.uk/news-archive%2f3d-drug-design-leads-to-potent-new-drug-candidatehttps://www.icr.ac.uk/news-archive%2f3d-drug-design-leads-to-potent-new-drug-candidate3D drug design leads to potent new drug candidateICR scientists have used structure-based drug design to identify a chemical probe that fits proteins implicated in some cancers like a 3D jigsaw puzzle. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdiscussing-personalised-cancer-medicine-with-the-aid-of-glitter-glue-jenga-and-some-locked-away-sweetshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdiscussing-personalised-cancer-medicine-with-the-aid-of-glitter-glue-jenga-and-some-locked-away-sweetsDiscussing personalised cancer medicine with the aid of glitter glue, Jenga, and some locked-away sweetsScientists, students and staff headed to the Royal Holloway Festival and encouraged local families and children to become 'DNA Detectives' – sharing our research with them.https://www.icr.ac.uk/news-archive%2fnew-scan-feels-stiffness-or-stretchiness-of-tumourshttps://www.icr.ac.uk/news-archive%2fnew-scan-feels-stiffness-or-stretchiness-of-tumoursNew scan ‘feels’ stiffness or stretchiness of tumoursA new type of scan that measures the stiffness or stretchiness of tissues could help to diagnose different types of brain cancer, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-children-miss-out-on-the-latest-cancer-drugs-and-a-year-in-childhood-cancer-researchttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-children-miss-out-on-the-latest-cancer-drugs-and-a-year-in-childhood-cancer-researcHow children miss out on the latest cancer drugs – and a year in childhood cancer researchOur call to change EU rules that allow companies to avoid testing promising new drugs in children featured prominently in the media last week – coinciding with the relaunch of two fundraising appeals that feature our childhood cancer research.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwounds-that-never-heal-cancer-the-immune-system-and-a-century-of-researchhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwounds-that-never-heal-cancer-the-immune-system-and-a-century-of-research‘Wounds that never heal’ – cancer, the immune system, and a century of researchDr Chris Bakal, Team Leader in Dynamical Cell Systems, gives a historical perspective on research into cancer and the immune system, and puts his own new study in context. https://www.icr.ac.uk/news-archive%2fmanipulating-cells-shapes-could-treat-breast-cancerhttps://www.icr.ac.uk/news-archive%2fmanipulating-cells-shapes-could-treat-breast-cancerManipulating cells’ shapes could treat breast cancerChanging the shapes of tumour cells could make them a target of the body’s own inflammatory response against a tumour, inhibiting cancer progression.https://www.icr.ac.uk/news-archive%2fstem-cell-test-could-identify-most-aggressive-breast-cancershttps://www.icr.ac.uk/news-archive%2fstem-cell-test-could-identify-most-aggressive-breast-cancers‘Stem cell’ test could identify most aggressive breast cancersBreast cancers cells that behave like adult stem cells are more likely to spread to other parts of the body, according to research.https://www.icr.ac.uk/news-archive%2fhealthy-looking-prostate-cells-mask-cancer-causing-mutationshttps://www.icr.ac.uk/news-archive%2fhealthy-looking-prostate-cells-mask-cancer-causing-mutationsHealthy-looking prostate cells mask cancer-causing mutationsProstate cells that look normal under the microscope may be hiding genetic mutations that could develop into cancer.https://www.icr.ac.uk/news-archive%2fcancer-targeting-virus-gives-surprising-boost-to-other-skin-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fcancer-targeting-virus-gives-surprising-boost-to-other-skin-cancer-treatmentsCancer-targeting virus gives surprising boost to other skin cancer treatmentsA virus specially designed to target skin cancer boosts the effectiveness of other cancer treatments in an unexpected way, a new study has foundhttps://www.icr.ac.uk/news-archive%2ficr-co-ordinates-sector-wide-sunday-telegraph-letter-on-childhood-cancer-drugs-ruleshttps://www.icr.ac.uk/news-archive%2ficr-co-ordinates-sector-wide-sunday-telegraph-letter-on-childhood-cancer-drugs-rulesICR co-ordinates sector-wide Telegraph letter on childhood cancer drugs rulesA letter written by The Institute of Cancer Research, London, and co-signed by more than 10 charities has been published in The Telegraph.https://www.icr.ac.uk/news-archive%2fnew-breast-cancer-test-links-immune-hotspots-to-better-survivalhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-test-links-immune-hotspots-to-better-survivalNew breast cancer test links immune ‘hotspots’ to better survivalFrom criminology to cancer research – a new test can predict the survival chances of women with breast cancer by analysing images of ‘hotspots’ where there has been a fierce immune reaction to a tumour.https://www.icr.ac.uk/news-archive%2fscientists-find-cancer-weak-spots-for-new-targeted-drugshttps://www.icr.ac.uk/news-archive%2fscientists-find-cancer-weak-spots-for-new-targeted-drugsScientists find cancer weak spots for new targeted drugsScientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.https://www.icr.ac.uk/news-archive%2fcancer-risk-linked-to-dna-wormholeshttps://www.icr.ac.uk/news-archive%2fcancer-risk-linked-to-dna-wormholesCancer risk linked to DNA ‘wormholes’Researchers found that DNA sequences within ‘gene deserts’ – so called because they are completely devoid of genes – can regulate gene activity elsewhere by forming DNA loops across relatively large distances. https://www.icr.ac.uk/news-features%2flatest-features%2fwhy-we-need-more-women-at-the-top-of-sciencehttps://www.icr.ac.uk/news-features%2flatest-features%2fwhy-we-need-more-women-at-the-top-of-scienceWhy we need more women at the top of scienceDespite making up 50% of students and postdoctoral researchers, not enough women progress to senior positions in science. The ICR is striving to ensure all researchers have the same opportunities to develop their scientific careers, regardless of gender.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fin-modern-cancer-treatment-are-two-drugs-better-than-onehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fin-modern-cancer-treatment-are-two-drugs-better-than-oneIn modern cancer treatment, are two drugs better than one?We are now armed with an extensive arsenal of targeted drugs, but drug resistance is inevitable. Researchers are realising that combining targeted therapies together might limit drug resistance. So are two drugs better than one?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsandwiches-the-pancreas-and-cancer-s-bullying-of-healthy-cellshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsandwiches-the-pancreas-and-cancer-s-bullying-of-healthy-cellsSandwiches, the pancreas and cancer’s bullying of healthy cellsDr Chris Tape, a cellular biochemist at The Institute of Cancer Research, and a Sir Henry Wellcome Postdoctoral Fellow, talked about his research as part of the Wellcome Trust Packed Lunch series of talks.https://www.icr.ac.uk/news-archive%2fscan-tunes-out-interference-to-detect-cancer-metabolismhttps://www.icr.ac.uk/news-archive%2fscan-tunes-out-interference-to-detect-cancer-metabolismScan tunes out interference to detect cancer metabolismA new type of scan uses a clever ‘noise cancelling’ technique to map cancer metabolism inside brain tumours, a new study shows.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpanorama-s-behind-the-scenes-glimpse-at-how-science-benefits-cancer-patients-and-vice-versahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpanorama-s-behind-the-scenes-glimpse-at-how-science-benefits-cancer-patients-and-vice-versaPanorama’s behind the scenes glimpse at how science benefits cancer patients – and vice versaThis week’s Panorama programme, Can you cure my cancer?, is a fantastic opportunity for us to talk about the ICR’s research and to get across how closely we work with our partner hospital, The Royal Marsden.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbbc-s-panorama-is-a-tale-of-partnership-patients-and-personalised-medicinehttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbbc-s-panorama-is-a-tale-of-partnership-patients-and-personalised-medicineBBC’s Panorama is a tale of partnership, patients and personalised medicineWe have been working with the BBC’s Panorama team for nearly two years. Over that time they have met scores of scientists and clinicians here at The Institute of Cancer Research, London, and our partner hospital, The Royal Marsden.https://www.icr.ac.uk/news-archive%2fpaul-workman-visits-boston-with-london-mayor-boris-johnsonhttps://www.icr.ac.uk/news-archive%2fpaul-workman-visits-boston-with-london-mayor-boris-johnsonPaul Workman visits Boston with London Mayor Boris JohnsonProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, visited the prestigious university town of Boston this week with Mayor of London Boris Johnson to promote the capital as a world-leading centre for life sciences.https://www.icr.ac.uk/news-archive%2fstatement-on-today-s-rejection-of-abiraterone-before-chemotherapy-by-the-scottish-medicines-consortiumhttps://www.icr.ac.uk/news-archive%2fstatement-on-today-s-rejection-of-abiraterone-before-chemotherapy-by-the-scottish-medicines-consortiumStatement on today’s rejection of abiraterone before chemotherapy by the Scottish Medicines ConsortiumThe ICR's CEO Professor Paul Workman reacts to the news that the Scottish Medicines Consortium has rejected the use of abiraterone before chemotherapy.https://www.icr.ac.uk/news-archive%2ficr-to-star-in-bbc-panorama-documentaryhttps://www.icr.ac.uk/news-archive%2ficr-to-star-in-bbc-panorama-documentaryICR and The Royal Marsden to star in BBC Panorama documentaryAn episode of Panorama focused entirely on the pioneering work of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust is to air on BBC One next week.https://www.icr.ac.uk/news-archive%2ftwo-major-studies-strengthen-case-for-prostate-cancer-drug-before-chemotherapyhttps://www.icr.ac.uk/news-archive%2ftwo-major-studies-strengthen-case-for-prostate-cancer-drug-before-chemotherapyTwo major studies strengthen case for prostate cancer drug before chemotherapyPioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown.https://www.icr.ac.uk/news-archive%2fmajor-study-links-two-new-genetic-variants-to-breast-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-study-links-two-new-genetic-variants-to-breast-cancerMajor study links two new genetic variants to breast cancerA worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer. The genetic variants are specifically linked to the most common form of breast cancer, oestrogen receptor positive, and provide important insights into how the disease develops.https://www.icr.ac.uk/news-archive%2fsimple-tweak-to-mri-could-sharpen-images-of-cancershttps://www.icr.ac.uk/news-archive%2fsimple-tweak-to-mri-could-sharpen-images-of-cancersSimple tweak to MRI could sharpen images of cancersA simple change in the processing of data from scans of cancer patients could sharpen images taken of tumours, a new study reveals.https://www.icr.ac.uk/news-archive%2funiversities-must-do-more-to-support-networking-for-women-in-science-says-research-leaderhttps://www.icr.ac.uk/news-archive%2funiversities-must-do-more-to-support-networking-for-women-in-science-says-research-leaderUniversities must support networking for women in science, says Professor Paul WorkmanUniversities must offer women more networking opportunities and training in leading large teams to help close the gender gap at the top of science – according to the head of the UK’s leading research centre. Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, urged more support for female scientists to lead ‘team science’ initiatives in a roundtable discussion at the Academy of Medical Sciences today (Monday).https://www.icr.ac.uk/news-archive%2fscientists-find-previously-unknown-survival-signals-that-can-keep-cancer-cells-alivehttps://www.icr.ac.uk/news-archive%2fscientists-find-previously-unknown-survival-signals-that-can-keep-cancer-cells-aliveScientists find previously unknown survival signals that can keep cancer cells aliveScientists have discovered that a key cancer protein can promote the survival of cancer cells – even when targeted by drugs designed to block its main function.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffor-rare-cancers-like-mine-research-has-to-go-internationalhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffor-rare-cancers-like-mine-research-has-to-go-internationalFor rare cancers like mine, research has to go international"As a patient with a rare tumour, I was interested to read a paper that presents challenges and methods available for conducting collaborative research into rare cancers." https://www.icr.ac.uk/news-archive%2fbad-genetic-changes-outweigh-good-for-patients-with-blood-cancerhttps://www.icr.ac.uk/news-archive%2fbad-genetic-changes-outweigh-good-for-patients-with-blood-cancer‘Bad’ genetic changes outweigh ‘good’ for blood cancer patientsPatients with myeloma whose cancer cells carry genetic changes associated with both good and bad prognosis have outcomes similar to those with bad risk changes alone, a new ICR study reports.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-sound-waves-to-zap-away-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-sound-waves-to-zap-away-cancerUsing sound waves to zap away cancerUltrasound can be used to supply focused energy in the form of heat in a technique called high-intensity focused ultrasound. The energy from this technique can be focused and used to selectively target tumour tissue. https://www.icr.ac.uk/news-archive%2fcancer-drugs-should-be-licensed-on-smaller-trials-to-cut-priceshttps://www.icr.ac.uk/news-archive%2fcancer-drugs-should-be-licensed-on-smaller-trials-to-cut-pricesCancer drugs should be licensed on smaller trials to cut pricesEarlier licensing could speed progress and reduce drug costs, global experts say.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeted-treatments-big-data-and-the-pros-and-cons-of-having-your-genomehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeted-treatments-big-data-and-the-pros-and-cons-of-having-your-genomeTargeted treatments, big data and the pros and cons of having your genome sequencedThe ICR’s Professor Nazneen Rahman took part in an international debate on genomics – and is keen to hear your views on knowing your sequence https://www.icr.ac.uk/news-archive%2fchris-lucas-trust-donates-300-000-to-rhabdomyosarcoma-researchhttps://www.icr.ac.uk/news-archive%2fchris-lucas-trust-donates-300-000-to-rhabdomyosarcoma-researchChris Lucas Trust donates £300,000 to rhabdomyosarcoma researchThe Chris Lucas Trust has made another generous pledge of £300,000 to support rhabdomyosarcoma research at the ICR.https://www.icr.ac.uk/news-archive%2fmajor-study-links-gene-to-drug-resistance-in-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-study-links-gene-to-drug-resistance-in-testicular-cancerMajor study links gene to drug resistance in testicular cancerA major research study has uncovered several new genetic mutations that could drive testicular cancer – and also identified a gene which may contribute to tumours becoming resistant to current treatments.https://www.icr.ac.uk/news-archive%2fsound-waves-being-used-to-heat-treat-cancer-painhttps://www.icr.ac.uk/news-archive%2fsound-waves-being-used-to-heat-treat-cancer-painSound waves being used to heat-treat cancer painA pioneering clinical trial is testing whether focusing high-frequency sound waves onto the surface of bone where cancer has spread can burn away the source of pain.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-micro-rnas-in-cancer-research-little-strands-of-genetic-material-with-big-promisehttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-micro-rnas-in-cancer-research-little-strands-of-genetic-material-with-big-promiseUsing micro-RNAs in cancer research: little strands of genetic material with big promise After the human genome project was completed, many people were surprised to learn that 98% of genome did not code for any functional genes. However, this ‘junk DNA’ holds surprising secrets, and is actually a hub of crucial gene-controlling activity.https://www.icr.ac.uk/news-archive%2fgrandfather-s-memory-inspires-challenge-to-mount-kilimanjarohttps://www.icr.ac.uk/news-archive%2fgrandfather-s-memory-inspires-challenge-to-mount-kilimanjaroGrandfather’s memory inspires challenge to Mount KilimanjaroFundraiser Sean Chinn embarked on the challenge of a lifetime when he set off to Tanzania to climb to the summit of Mount Kilimanjaro. He raised an impressive £3,800 for world-leading cancer research at the ICR.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2f3d-assays-genetic-tests-going-mainstream-and-new-epigenetic-drugs-icr-researchers-gaze-into-their-crystal-ballshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2f3d-assays-genetic-tests-going-mainstream-and-new-epigenetic-drugs-icr-researchers-gaze-into-their-crystal-balls3D assays, genetic tests going mainstream and new ‘epigenetic’ drugs – ICR researchers gaze into their crystal ballsWe asked some of our top researchers to take a look forward to what they expect for 2015. Here are their predictions about the upcoming year...https://www.icr.ac.uk/news-archive%2fnew-pathway-identified-for-debilitating-skin-conditionhttps://www.icr.ac.uk/news-archive%2fnew-pathway-identified-for-debilitating-skin-conditionNew pathway identified for debilitating skin conditionICR scientists have discovered that a type of signal within tumour cells is critical to the development of a rare and debilitating inherited skin condition.https://www.icr.ac.uk/news-archive%2fidentical-twins-reveal-new-clues-to-origins-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fidentical-twins-reveal-new-clues-to-origins-of-childhood-leukaemiaIdentical twins reveal new clues to origins of childhood leukaemiaA new study of identical twins with leukaemia has traced its earliest genetic changes all the way back to immature cells from the immune system, which develop before children are even born.https://www.icr.ac.uk/news-archive%2fresearch-identifies-new-system-for-predicting-treatment-outcome-in-breast-cancerhttps://www.icr.ac.uk/news-archive%2fresearch-identifies-new-system-for-predicting-treatment-outcome-in-breast-cancerResearch identifies new system for predicting treatment outcome in breast cancerCombining two measures of breast cancer’s response to treatment provides a better prediction of long-term outcome following chemotherapy than existing assessments, a new study reports. https://www.icr.ac.uk/news-archive%2ficr-now-top-in-clinical-medicine-too-in-new-ref-rankinghttps://www.icr.ac.uk/news-archive%2ficr-now-top-in-clinical-medicine-too-in-new-ref-rankingICR now top in clinical medicine too in new REF rankingA new league table ranking universities by both the excellence and ‘intensity’ of their research has again placed The Institute of Cancer Research, London, top in the UK.https://www.icr.ac.uk/news-archive%2ficr-donor-supports-pioneering-research-into-cancer-evolutionhttps://www.icr.ac.uk/news-archive%2ficr-donor-supports-pioneering-research-into-cancer-evolutionICR donor supports pioneering research into cancer evolutionA generous gift has provided the driving force behind new research at the ICR to explore how cancer occurs and why.https://www.icr.ac.uk/news-archive%2fscientists-develop-new-software-using-avatars-to-picture-the-complexity-of-cancer-cellshttps://www.icr.ac.uk/news-archive%2fscientists-develop-new-software-using-avatars-to-picture-the-complexity-of-cancer-cellsScientists develop new software using avatars to picture the complexity of cancer cellsNew software to visualise data generated by imaging of cells could help scientists understand more about cancer.https://www.icr.ac.uk/news-archive%2fscientists-discover-how-tumours-take-over-healthy-blood-vesselshttps://www.icr.ac.uk/news-archive%2fscientists-discover-how-tumours-take-over-healthy-blood-vesselsScientists discover how tumours take over healthy blood vessels ICR researchers have discovered how secondary cancers in the lung, called lung metastases, can take over healthy blood vessels in order to fuel their growth.https://www.icr.ac.uk/news-archive%2fstudy-makes-case-for-wider-gene-testing-in-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fstudy-makes-case-for-wider-gene-testing-in-bowel-cancerStudy makes case for wider gene testing in bowel cancerGene testing could identify the causes of cancer for up to a quarter of patients with bowel cancer who have a family history of the disease, a new study reports.https://www.icr.ac.uk/news-features%2flatest-features%2fmost-popular-news-of-2014https://www.icr.ac.uk/news-features%2flatest-features%2fmost-popular-news-of-2014Our most read news stories of 2014It’s been a very busy year here at the ICR. Here are the ten ICR news stories that have proved most popular with readers over the past 12 months.https://www.icr.ac.uk/news-features%2flatest-features%2fmost-popular-blogs-of-2014https://www.icr.ac.uk/news-features%2flatest-features%2fmost-popular-blogs-of-2014Our most read blogs of 2014Here we take a look back at the most read posts on the ICR’s blogs this year. From how personalised medicine could change the world to the babies who cure themselves of cancer – these are the stories that have most grabbed your attention in 2014.https://www.icr.ac.uk/news-archive%2ficr-donors-give-a-record-12m-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2ficr-donors-give-a-record-12m-for-cancer-researchICR donors give a record £12m for cancer researchThis year's donations income smashes last year’s achievement by more than £3 million. https://www.icr.ac.uk/news-archive%2ficr-welcomes-olaparib-approval-by-european-medicines-agencyhttps://www.icr.ac.uk/news-archive%2ficr-welcomes-olaparib-approval-by-european-medicines-agencyICR welcomes olaparib approval by European Medicines AgencyThe European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA1 or BRCA2 mutation.https://www.icr.ac.uk/news-archive%2fscientists-map-out-how-childhood-brain-tumours-relapsehttps://www.icr.ac.uk/news-archive%2fscientists-map-out-how-childhood-brain-tumours-relapseScientists map out how childhood brain tumours relapseResearchers have discovered the unique genetic paths that the childhood brain tumour medulloblastoma follows when the disease comes back.https://www.icr.ac.uk/news-archive%2fboris-johnson-hails-icr-as-creative-powerhouse-as-it-tops-university-tablehttps://www.icr.ac.uk/news-archive%2fboris-johnson-hails-icr-as-creative-powerhouse-as-it-tops-university-tableBoris Johnson hails ICR as ‘creative powerhouse’ as it tops university tableMayor of London Boris Johnson hailed the ICR as a ‘creative powerhouse’, after it was ranked top in the Government’s Research Excellence Framework.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2froad-to-the-refhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2froad-to-the-refHuge team effort on REF is rewarded by a fantastic result and memorable weekIt was an enormous undertaking from our research and support staff to submit to the REF process – Dr Barbara Pittam reflects on a memorable week for The Institute of Cancer Research.https://www.icr.ac.uk/news-archive%2fmayor-of-london-visits-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-archive%2fmayor-of-london-visits-the-institute-of-cancer-researchMayor of London visits The Institute of Cancer ResearchMayor of London Boris Johnson visited the ICR today to hear about plans to create one of the world’s top centres for cancer drug discovery and life sciences. https://www.icr.ac.uk/news-archive%2ficr-tops-league-table-of-university-excellencehttps://www.icr.ac.uk/news-archive%2ficr-tops-league-table-of-university-excellenceICR tops league table of university excellenceThe ICR is the top higher education institution in the country in the overall league table of academic performance, the Government’s Research Excellence Framework has revealed.https://www.icr.ac.uk/news-archive%2fscientists-use-3d-printing-to-make-replica-organs-for-enhanced-radiotherapyhttps://www.icr.ac.uk/news-archive%2fscientists-use-3d-printing-to-make-replica-organs-for-enhanced-radiotherapyScientists use 3D printing to make replica organs for enhanced radiotherapyICR researchers have used 3D printing to produce replica models of tumours and organs of patients with cancer, to help calculate precisely how much radiation has been delivered to the cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-patients-need-to-be-involved-in-using-data-to-transform-cancer-carehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-patients-need-to-be-involved-in-using-data-to-transform-cancer-careWhy patients need to be involved in using data to transform cancer careThis year’s Britain Against Cancer conference brought together MPs, policy makers, researchers, clinicians and patients to discuss cancer policy.https://www.icr.ac.uk/news-archive%2fcombination-therapy-could-be-effective-against-resistant-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fcombination-therapy-could-be-effective-against-resistant-childhood-cancerCombination therapy could be effective against resistant childhood cancerUsing two targeted drugs at once could be an effective treatment strategy for children with an aggressive form of cancer who develop resistance to a single targeted drug, a new study shows. https://www.icr.ac.uk/news-archive%2fmajor-trial-finds-better-treatment-for-some-women-with-familial-and-triple-negative-breast-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-trial-finds-better-treatment-for-some-women-with-familial-and-triple-negative-breast-cancerMajor trial finds better treatment for some women with familial and triple negative breast cancerInitial results from a major phase III clinical trial reveal that women with a type of breast cancer are much more likely to respond to chemotherapy drug carboplatin than standard treatment.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flooks-can-be-deceiving-high-grade-glioma-in-children-and-adultshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2flooks-can-be-deceiving-high-grade-glioma-in-children-and-adultsLooks can be deceiving: high grade glioma in children and adultsTwo diseases that look the same might be hiding different genetic mutations.https://www.icr.ac.uk/news-archive%2fnew-targeted-drugs-could-treat-drug-resistant-skin-cancerhttps://www.icr.ac.uk/news-archive%2fnew-targeted-drugs-could-treat-drug-resistant-skin-cancerNew targeted drugs could treat drug-resistant skin cancerA brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports. https://www.icr.ac.uk/news-archive%2fcelebrities-support-cancer-research-at-icr-s-carols-from-chelseahttps://www.icr.ac.uk/news-archive%2fcelebrities-support-cancer-research-at-icr-s-carols-from-chelseaCelebrities support cancer research at ICR’s ‘Carols from Chelsea’More than 400 people attended the sold-out event on Tuesday night which was hosted by the ICR in the beautiful Wren Chapel of the Royal Hospital, Chelsea. https://www.icr.ac.uk/news-archive%2ftest-assesses-whether-immune-system-is-holding-cancer-in-checkhttps://www.icr.ac.uk/news-archive%2ftest-assesses-whether-immune-system-is-holding-cancer-in-checkTest assesses whether immune system is holding cancer in checkICR scientists have developed a new high-tech system for measuring the body’s immune response to cancer: that combines computerised imaging of tumour samples with statistical analysis, and is the first objective method to measure the interaction between a patient’s immune system and their tumour.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-three-generations-of-precision-medicine-are-transforming-lung-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-three-generations-of-precision-medicine-are-transforming-lung-cancerHow three generations of precision medicine are transforming lung cancerLung cancer is the biggest killer in cancer, but treatments targeting specific mutations are now offering patients a lifeline, and displaying the power of precision medicine. https://www.icr.ac.uk/news-archive%2fnew-software-helps-radiotherapy-track-moving-tumourshttps://www.icr.ac.uk/news-archive%2fnew-software-helps-radiotherapy-track-moving-tumoursNew software helps radiotherapy track moving tumoursScientists have developed new software which can track cancers that undergo substantial movement during radiotherapy, such as lung or liver tumours.https://www.icr.ac.uk/news-archive%2ficr-s-scientific-creativity-celebrated-at-the-third-annual-reception-of-the-discovery-clubhttps://www.icr.ac.uk/news-archive%2ficr-s-scientific-creativity-celebrated-at-the-third-annual-reception-of-the-discovery-clubICR’s scientific creativity celebrated at the third annual reception of The Discovery ClubOur third annual gathering of the club celebrated the ICR's scientific creativity and achievements over the past year. https://www.icr.ac.uk/news-features%2flatest-features%2ffine-tuning-radiotherapy-for-breakthroughs-in-treating-bladder-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2ffine-tuning-radiotherapy-for-breakthroughs-in-treating-bladder-cancerFine tuning radiotherapy for breakthroughs in treating bladder cancerBladder shape, capacity and position vary between individuals, making radiotherapy in patients with bladder cancer a real challenge. But now researchers at ICR are working with the bladder’s unpredictability to deliver better radiotherapy for a type of cancer that has traditionally been hard-to-treat.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhat-we-need-to-be-successful-in-team-sciencehttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fwhat-we-need-to-be-successful-in-team-scienceWhat we need to be successful in team scienceMuch of modern-day science is a 'team-game' – so what are we doing at The Institute of Cancer Research to recognise this?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpicking-out-the-year%27s-10-most-exciting-discoveries-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpicking-out-the-year%27s-10-most-exciting-discoveries-in-cancer-researchPicking out the year's 10 most exciting discoveries in cancer researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year-2014https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year-2014Highlights of the year, 20142014 has been full of exciting research results for the ICR. We have selected ten of our discoveries from the past year, which we'll publish every day over the next two weekshttps://www.icr.ac.uk/news-archive%2fthe-climb-of-life-event-reaches-new-heightshttps://www.icr.ac.uk/news-archive%2fthe-climb-of-life-event-reaches-new-heightsThe Climb of Life event reaches new heightsThe annual fundraising event has raised more than £100,000, bringing the grand total raised by the team over the last eight years to over £600,000.https://www.icr.ac.uk/news-archive%2fblood-test-could-pick-up-genetic-echoes-of-lifestyle-risk-for-cancerhttps://www.icr.ac.uk/news-archive%2fblood-test-could-pick-up-genetic-echoes-of-lifestyle-risk-for-cancerBlood test could pick up genetic echoes of lifestyle risk for cancerA blood test could one day uncover the genetic ‘echoes’ from past activity such as smoking which could increase a person’s chance of developing cancer years laterhttps://www.icr.ac.uk/news-archive%2fscientists-discover-way-to-target-rare-breast-cancer-mutationhttps://www.icr.ac.uk/news-archive%2fscientists-discover-way-to-target-rare-breast-cancer-mutationScientists discover way to target rare breast cancer mutationUK scientists have identified a drug to target a rare breast cancer mutation that helps drive the disease in around 900 of the 50,000 new cases of breast cancer diagnosed in the UK each year. https://www.icr.ac.uk/news-archive%2ficr-supporters-take-on-the-berlin-marathonhttps://www.icr.ac.uk/news-archive%2ficr-supporters-take-on-the-berlin-marathonICR supporters take on the Berlin MarathonSupporters of The Institute of Cancer Research, London, raised more than £7,000 at the Berlin Marathon for research into cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-research-takes-a-step-closer-to-patients-as-olaparib-is-assessed-for-nhshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-research-takes-a-step-closer-to-patients-as-olaparib-is-assessed-for-nhsICR research takes a step closer to patients as olaparib is assessed for NHShttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-appointed-as-icr-chief-executivehttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-appointed-as-icr-chief-executiveProfessor Paul Workman appointed as ICR Chief ExecutiveProfessor Paul Workman has been appointed as Chief Executive and President of The Institute of Cancer Research, London, on a permanent basis.https://www.icr.ac.uk/news-archive%2fnew-research-leader-pledges-three-pronged-attack-on-cancer-evolution-and-drug-resistancehttps://www.icr.ac.uk/news-archive%2fnew-research-leader-pledges-three-pronged-attack-on-cancer-evolution-and-drug-resistanceNew research leader pledges three-pronged attack on cancer evolution and drug resistanceProfessor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, Londonhttps://www.icr.ac.uk/news-archive%2fstructural-study-reveals-clues-of-cancer-causing-proteinhttps://www.icr.ac.uk/news-archive%2fstructural-study-reveals-clues-of-cancer-causing-proteinStructural study reveals clues of cancer-causing proteinAdvanced modelling techniques have mapped the structure of a key protein for the development of the nervous system – and cancer, a new study reveals.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-solutions-to-cancer-s-drug-resistance-professor-paul-workman-visits-chinahttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthree-solutions-to-cancer-s-drug-resistance-professor-paul-workman-visits-china“Three solutions to cancer’s drug resistance” – Professor Paul Workman visits ChinaProfessor Paul Workman, Interim Chief Executive of The Institute of Cancer Research, London, took a global perspective on cancer in a high-profile talk this week.https://www.icr.ac.uk/news-archive%2fgenetic-testing-could-improve-breast-cancer-preventionhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-could-improve-breast-cancer-preventionGenetic testing could improve breast cancer preventionScreening women for a wide range of known genetic risk factors could improve strategies for breast cancer prevention, a new analysis shows.https://www.icr.ac.uk/news-features%2flatest-features%2fprostate-cancer-entering-the-golden-age-of-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2fprostate-cancer-entering-the-golden-age-of-researchProstate cancer: entering a golden age of researchOncologists are hailing this as the ‘golden age of prostate cancer research’ after new prostate cancer drugs reached the clinic. The ICR has played a major role in developing four new drugs that have been shown as effective in later-phase trials.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-i-convinced-my-audience-that-personalised-medicine-can-change-the-worldhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fhow-i-convinced-my-audience-that-personalised-medicine-can-change-the-worldHow I convinced my audience that personalised medicine can change the world"I never imagined I would be in central London, speaking at a debate about the importance of biological research." Laura Danielson reflects on her invitation to talk at an event hosted by the Society of Biology.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fday-three-at-the-uk-s-biggest-cancer-conference-clinical-trials-metabolomics-and-targeted-therapieshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fday-three-at-the-uk-s-biggest-cancer-conference-clinical-trials-metabolomics-and-targeted-therapiesDay three at the UK’s biggest cancer conference: clinical trials, metabolomics, and targeted therapieshttps://www.icr.ac.uk/news-archive%2fbrca-targeting-drugs-could-treat-prostate-cancer-leading-expert-sayshttps://www.icr.ac.uk/news-archive%2fbrca-targeting-drugs-could-treat-prostate-cancer-leading-expert-saysBRCA-targeting drugs could treat prostate cancer, leading expert saysA pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffinding-the-right-target-for-liver-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffinding-the-right-target-for-liver-cancer-treatmentFinding the right target for liver cancer treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhere-are-we-going-with-patient-care-genomics-and-targeted-therapieshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhere-are-we-going-with-patient-care-genomics-and-targeted-therapiesWhere are we going with patient care, genomics and targeted therapies?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbuzz-as-uk-s-biggest-cancer-conference-gets-underwayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbuzz-as-uk-s-biggest-cancer-conference-gets-underwayBuzz as UK’s biggest cancer conference gets underwayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgoodbye-flat-biologyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgoodbye-flat-biologyGoodbye flat biologyhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fturning-targets-into-effective-treatments-my-three-questions-to-the-world-oncology-forumhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fturning-targets-into-effective-treatments-my-three-questions-to-the-world-oncology-forumTurning targets into effective treatments – my three questions to the World Oncology ForumI welcomed the opportunity to give the opening presentation at the World Oncology Forum 2014, and to ask questions about what has to happen to translate the knowledge we now have about the genetics and biology of cancer into effective treatments.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-to-present-on-topics-from-evolution-to-imaging-at-uk-s-biggest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-researchers-to-present-on-topics-from-evolution-to-imaging-at-uk-s-biggest-cancer-conferenceICR researchers to present on topics from evolution to imaging at UK’s biggest cancer conferencehttps://www.icr.ac.uk/news-features%2flatest-features%2fbeating-brca-mutant-cancershttps://www.icr.ac.uk/news-features%2flatest-features%2fbeating-brca-mutant-cancersHow the ICR drove the science behind pioneering cancer drugOlaparib is set to become the first cancer drug for an inherited genetic fault. Here is the story of our crucial role in its development.https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-european-medicines-agency%27s-approval-of-olaparibhttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-european-medicines-agency%27s-approval-of-olaparibStatement in response to the European Medicines Agency's recommendation for approval of olaparib The Institute of Cancer Research, London, is issuing the following statement from Professor Alan Ashworth, whose work underpinned the development of olaparib.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmoke-signals-tracking-cancer-through-the-metabolic-signatures-it-gives-offhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmoke-signals-tracking-cancer-through-the-metabolic-signatures-it-gives-offSmoke signals – tracking cancer through the metabolic signatures it gives offCancer cells display many different characteristics to normal tissue. Research from a new ICR team leader could use cancer’s unique metabolism to diagnose and treat the disease.https://www.icr.ac.uk/news-archive%2fcancer-drug-discovery-system-is-broken-global-summit-hearshttps://www.icr.ac.uk/news-archive%2fcancer-drug-discovery-system-is-broken-global-summit-hearsCancer drug discovery system is broken, global summit hearsPaul Workman of the ICR calls for major changes to restock pipeline with innovative cancer treatments. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-to-beat-cancer-at-the-evolution-gamehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-to-beat-cancer-at-the-evolution-gameHow to beat cancer at the evolution gameThe evolution of cancer cells can cause tumours to become resistant to treatment – which is why we need to get smart to fight them effectively.https://www.icr.ac.uk/news-archive%2fleading-cancer-centre-receives-10-million-for-state-of-the-art-radiotherapy-machinehttps://www.icr.ac.uk/news-archive%2fleading-cancer-centre-receives-10-million-for-state-of-the-art-radiotherapy-machineLeading cancer centre receives £10 million for state-of-the-art radiotherapy machineThe ICR and The Royal Marsden will become the first institutions in the UK to own and develop world-leading MR Linac technology.https://www.icr.ac.uk/news-archive%2fsimple-blood-test-can-quantify-drug-effects-on-protein-signals-to-guide-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fsimple-blood-test-can-quantify-drug-effects-on-protein-signals-to-guide-cancer-treatmentSimple blood test can quantify drug effects on protein signals to guide cancer treatmentTaking a new cancer drug once a week could benefit patients by giving healthy tissues time to recover from the effects of treatment, as suggested by a simple blood test, according to a new clinical trial.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffive-ways-that-nice-could-help-bring-innovative-cancer-medicines-into-the-nhshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2ffive-ways-that-nice-could-help-bring-innovative-cancer-medicines-into-the-nhsFive ways that NICE could help bring innovative cancer medicines into the NHSEarlier this year, NICE released a complex and far-reaching set of proposals for redrawing how it evaluates drugs for use on the NHS – I reflect on these reforms.https://www.icr.ac.uk/news-archive%2fstudent-on-a-summer-placement-develops-new-way-of-visualising-genetics-datahttps://www.icr.ac.uk/news-archive%2fstudent-on-a-summer-placement-develops-new-way-of-visualising-genetics-dataStudent on a summer placement develops new way of visualising genetics dataA student on a short-term placement at The Institute of Cancer Research, London, has led development of a new tool to visualise and analyse complex genetics data sets.https://www.icr.ac.uk/news-archive%2ficr-team-scores-100-success-in-the-royal-parks-half-marathonhttps://www.icr.ac.uk/news-archive%2ficr-team-scores-100-success-in-the-royal-parks-half-marathonICR team scores 100% success in the Royal Parks Half MarathonAll 22 intrepid runners for The Institute of Cancer Research successfully completed Sunday’s gruelling 13-mile Royal Parks Half Marathon to raise vital funds for our research.https://www.icr.ac.uk/news-archive%2fnew-cancer-drug-shows-signs-of-promise-in-early-stage-trialhttps://www.icr.ac.uk/news-archive%2fnew-cancer-drug-shows-signs-of-promise-in-early-stage-trialNew cancer drug shows signs of promise in early-stage trialA drug which can block the activity of a common mutation in cancer has shown promise in its first patient trial, a new study reports. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-international-mix-of-phd-students-learn-at-the-front-line-of-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-international-mix-of-phd-students-learn-at-the-front-line-of-cancer-researchOur international mix of PhD students learn at the front line of cancer researchThe ICR is currently recruiting for a range of fully funded four-year PhD studentships. Read about how our PhD students contribute to our cutting-edge research and why the ICR is a great place to study. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fhitting-the-right-target-validating-new-approaches-for-innovative-cancer-drugshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fhitting-the-right-target-validating-new-approaches-for-innovative-cancer-drugsHitting the right target – validating new approaches for innovative cancer drugs Therapeutic innovation and clinical benefit require the discovery of truly novel drugs that act on previously unexploited molecular targets.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feuropean-commission-misses-a-chance-to-open-a-pipeline-of-cancer-drugs-to-childrenhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feuropean-commission-misses-a-chance-to-open-a-pipeline-of-cancer-drugs-to-childrenEuropean Commission misses a chance to open a pipeline of cancer drugs to childrenThe ICR has been campaigning for changes to the EU Paediatric Regulation, which we believe could make a real difference to the number of new cancer drugs which enter clinical trials in children. Here we look at a missed opportunity for change.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-crystals-to-cure-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-crystals-to-cure-cancerScience Writing Prize 2014 – Using crystals to cure cancerEach year, the ICR runs a science writing competition among our scientists and students – and here is 2014’s winning piece.https://www.icr.ac.uk/news-archive%2ficr-to-collaborate-with-merck-serono-and-wellcome-trust-to-co-develop-anti-cancer-drugshttps://www.icr.ac.uk/news-archive%2ficr-to-collaborate-with-merck-serono-and-wellcome-trust-to-co-develop-anti-cancer-drugsICR to collaborate with Merck Serono and Wellcome Trust to co-develop anti-cancer drugsMerck Serono, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-pauses-abiraterone-decision-for-further-price-discussionshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-pauses-abiraterone-decision-for-further-price-discussionsNICE pauses abiraterone decision for further price discussionsAfter first deciding to block earlier use of prostate cancer drug abiraterone, NICE has now suspended its appraisal, allowing more discussion on the price. Here Dr Eva Sharpe summarises what is new.https://www.icr.ac.uk/news-archive%2fchemotherapy-regimen-shows-promise-against-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fchemotherapy-regimen-shows-promise-against-testicular-cancerChemotherapy regimen shows promise against testicular cancerA combination of chemotherapy drugs has shown promise in a group of patients with testicular cancer and other germ cell tumours who currently have a poor prognosis. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-update-on-movember-s-london-centre-of-excellence-for-prostate-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fan-update-on-movember-s-london-centre-of-excellence-for-prostate-cancerAn update on Movember’s London Centre of Excellence for Prostate Cancer Our researchers spoke at the launch of Movember's London Centre of Excellence for Prostate Cancer. We talk about how the new centre is helping to drive new treatments for prostate cancer.https://www.icr.ac.uk/news-archive%2fdna-in-gene-deserts-linked-with-breast-cancerhttps://www.icr.ac.uk/news-archive%2fdna-in-gene-deserts-linked-with-breast-cancerDNA in ‘gene deserts’ linked with breast cancerLong stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftracing-a-new-treatment-for-skin-cancer-to-its-roots-in-icr-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftracing-a-new-treatment-for-skin-cancer-to-its-roots-in-icr-scienceTracing a new treatment for skin cancer to its roots in ICR scienceNICE has approved the skin cancer drug dabrafenib for use on the NHS. Much of the work characterising the function of the mutant protein it targets was carried out at the ICR and here we talk about the story of the research behind BRAF inhibitors.https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-approval-of-dabrafenib-for-the-treatment-of-certain-cases-of-advanced-melanomahttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-approval-of-dabrafenib-for-the-treatment-of-certain-cases-of-advanced-melanomaStatement in response to NICE approval of dabrafenib for the treatment of certain cases of advanced melanomaProfessor Paul Workman comments on final draft guidance from NICE recommending dabrafenib for the treatment of advanced melanoma which tests positive for the BRAF V600 mutation.https://www.icr.ac.uk/news-archive%2fblood-test-could-identify-when-cancer-treatment-has-become-detrimentalhttps://www.icr.ac.uk/news-archive%2fblood-test-could-identify-when-cancer-treatment-has-become-detrimentalBlood test could identify when cancer treatment has become detrimentalSome treatments for prostate cancer, while initially effective at controlling the disease, not only stop working over time but actually start driving tumour growth, a major new study shows.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fsniffing-out-cancerhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fsniffing-out-cancerSniffing Out CancerProfessor Mel Greaves, Director of the Centre for Evolution and Cancer at the ICR, talks about dogs' amazing sense of smell and how medical detection dogs can be trained to sniff out cancer in patients. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-the-icr-s-discoveries-from-the-thymus-gland-to-molecular-medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcelebrating-the-icr-s-discoveries-from-the-thymus-gland-to-molecular-medicineCelebrating the ICR’s discoveries… from the thymus gland to molecular medicineWe've launched a new project looking at the ICR’s greatest ever discoveries. Here we give more detail about some of our biggest achievements, how the discoveries were made, and why they have made such an impact on cancer research.https://www.icr.ac.uk/news-archive%2fgenetic-testing-can-identify-men-at-six-fold-increased-risk-of-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-testing-can-identify-men-at-six-fold-increased-risk-of-prostate-cancerGenetic testing can identify men at six-fold increased risk of prostate cancerScientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease.https://www.icr.ac.uk/news-archive%2flocation-of-cancer-s-growth-affects-treatment-effectivenesshttps://www.icr.ac.uk/news-archive%2flocation-of-cancer-s-growth-affects-treatment-effectivenessLocation of cancer’s growth affects treatment effectivenessA new study by scientists at the ICR, showed that mice with melanoma responded differently to a viral therapy depending on where in the body their tumours developed.https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-government%27s-decision-to-increase-the-cancer-drugs-fundhttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-government%27s-decision-to-increase-the-cancer-drugs-fundStatement in response to the Government's decision to increase the Cancer Drugs FundOur Interim Chief Executive, Professor Paul Workman, comments on the Government's decision to increase the Cancer Drugs Fund from £200m a year to £280m a year https://www.icr.ac.uk/news-archive%2fnew-tool-to-probe-cancer-s-molecular-make-uphttps://www.icr.ac.uk/news-archive%2fnew-tool-to-probe-cancer-s-molecular-make-upNew tool to probe cancer’s molecular make-upScientists have shown how to better identify and measure vital molecules that control cell behaviour – paving the way for improved tools for diagnosis, prediction and monitoring of cancer.https://www.icr.ac.uk/news-archive%2fscientists-map-risk-of-premature-menopause-after-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fscientists-map-risk-of-premature-menopause-after-cancer-treatmentRisk of premature menopause after cancer treatment mappedWomen treated for the cancer Hodgkin lymphoma will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments.https://www.icr.ac.uk/news-features%2flatest-features%2fexploiting-the-cell-cycle-to-improve-radiotherapy-outcomeshttps://www.icr.ac.uk/news-features%2flatest-features%2fexploiting-the-cell-cycle-to-improve-radiotherapy-outcomesExploiting the cell cycle to improve radiotherapy outcomesOne of the crucial signalling networks that often go awry in cancer are those that respond to DNA damage and regulate the cell cycle progression. But now researchers are turning this to their advantage, and are attacking cancer by targeting one of the very processes that drives it – a faulty DNA repair response.https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-rejection-of-abiraterone-before-chemotherapy-in-final-draft-guidance-from-nicehttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-rejection-of-abiraterone-before-chemotherapy-in-final-draft-guidance-from-niceStatement in response to rejection of abiraterone before chemotherapy in final draft guidance from NICEOur Interim Chief Executive, Professor Paul Workman, comments on today’s rejection of abiraterone before chemotherapy in final draft guidance from NICE. https://www.icr.ac.uk/news-archive%2fmutations-in-a-gene-essential-for-cell-regulation-cause-kidney-cancer-in-childrenhttps://www.icr.ac.uk/news-archive%2fmutations-in-a-gene-essential-for-cell-regulation-cause-kidney-cancer-in-childrenMutations in a gene essential for cell regulation cause kidney cancer in childrenMutations in a gene that helps regulate when genes are switched on and off in cells have been found to cause rare cases of Wilms tumour, the most common kidney cancer occurring in children.https://www.icr.ac.uk/news-archive%2fcancer-drug-improves-quality-of-life-in-men-with-incurable-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fcancer-drug-improves-quality-of-life-in-men-with-incurable-prostate-cancerCancer drug improves quality of life in men with incurable prostate cancerNew study shows enzalutamide improves the quality of life of patients with advanced, incurable prostate cancer. https://www.icr.ac.uk/news-archive%2fchildhood-brain-tumours-breakthrough-could-speed-new-treatmentshttps://www.icr.ac.uk/news-archive%2fchildhood-brain-tumours-breakthrough-could-speed-new-treatmentsChildhood brain tumours: breakthrough could speed new treatmentsImaging study raises hope for young patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdoing-cancer-research-in-pictureshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdoing-cancer-research-in-picturesDoing cancer research – In picturesDr Chris Bakal, head of the Dynamical Cell Systems Team at the ICR, has taken these stunning cells images to investigate the Endoplasmic Reticulum (ER), the factory in cells that makes the building blocks they need to grow.https://www.icr.ac.uk/news-archive%2fcause-of-rare-childhood-cancer-discoveredhttps://www.icr.ac.uk/news-archive%2fcause-of-rare-childhood-cancer-discoveredCause of rare childhood cancer discoveredScientists have made a breakthrough in understanding the cause of a rare childhood muscle cancer, called Rhabdomyosarcoma (RMS).https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-babies-who-cure-themselves-of-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-babies-who-cure-themselves-of-cancerThe babies who cure themselves of cancerNeuroblastoma can be a devastating childhood cancer, usually treated with chemotherapy but in many cases unresponsive to current treatments. Yet some babies are able to fight off the disease without medical help, even after it has spread. This incredible phenomenon sheds light on how our own immune systems protect us from cancer and might be supported by new therapies.https://www.icr.ac.uk/news-archive%2fviral-therapy-could-boost-limb-saving-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fviral-therapy-could-boost-limb-saving-cancer-treatmentViral therapy could boost limb-saving cancer treatmentViruses designed to target and kill cancer cells could boost the effectiveness of chemotherapy to the arms and legs and help avoid amputation, a new study reports.https://www.icr.ac.uk/news-archive%2fscientists-map-one-of-most-important-proteins-in-life-and-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-map-one-of-most-important-proteins-in-life-and-cancer Scientists map one of most important proteins in life – and cancerResearch carried out at the ICR has revealed the structure of one of the most important and complicated proteins in cell division – a fundamental process the development of cancer. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-new-website-will-open-a-window-to-the-icrs-sciencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-our-new-website-will-open-a-window-to-the-icrs-scienceHow our new website will open a window to the ICR's scienceIf you're a regular visitor to our website, you may have noticed that it looks a little different this week. I certainly hope you have.https://www.icr.ac.uk/news-archive%2fnew-website-to-showcase-icr-s-world-class-researchhttps://www.icr.ac.uk/news-archive%2fnew-website-to-showcase-icr-s-world-class-researchICR launches new website to showcase its world-class researchThe Institute of Cancer Research, London, today launches a sophisticated new website designed to use news and multimedia to provide the public with a window onto its world-leading cancer research.https://www.icr.ac.uk/news-features%2flatest-features%2fdarwinian-evolution-from-dinosaurs-to-cancer-drug-resistancehttps://www.icr.ac.uk/news-features%2flatest-features%2fdarwinian-evolution-from-dinosaurs-to-cancer-drug-resistanceDarwinian evolution: from dinosaurs to cancer drug resistanceBirds evolving from dinosaurs, fish emerging from the sea, and hominids adopting an upright posture – all are iconic examples of evolution. On the surface they don’t have a great deal to do with cancer, but the process underlying them both — natural selection — is identical.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-big-genetic-screens-are-finding-the-answers-to-resistance-to-cancer-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-big-genetic-screens-are-finding-the-answers-to-resistance-to-cancer-treatmentsHow ‘big’ genetic screens are finding the answers to resistance to cancer treatmentsTargeted cancer treatments are starting to make a big difference to the lives of cancer patients, but their effectiveness diminishes over time and for some patients, these treatments may not work at all. Now large-scale screening techniques are helping scientists to uncover the mechanisms that help cancer resist treatment.https://www.icr.ac.uk/news-archive%2fsignal-may-send-cancer-s-cellular-factories-into-overdrivehttps://www.icr.ac.uk/news-archive%2fsignal-may-send-cancer-s-cellular-factories-into-overdriveSignal may send cancer’s cellular factories into overdriveA network of signals active in almost all types of cancer sends the protein factories in our cells into overdrive, and may help fuel a tumour’s uncontrolled growth, Chelsea scientists have found.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatenting-not-always-black-and-whitehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatenting-not-always-black-and-whitePatenting – not always black and whiteHow big a role does business play in getting new diagnostics and treatments to patients?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-circulating-tumour-cells-be-the-swiss-army-knife-of-cancer-markershttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-circulating-tumour-cells-be-the-swiss-army-knife-of-cancer-markersCould circulating tumour cells be the swiss army knife of cancer markers?Circulating tumour cells exist in tiny numbers in the blood of cancer patients, but they could be one of the best ways to track a patient’s disease, and they could also help researchers to develop new treatments.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmapping-the-biodiversity-of-tumourshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmapping-the-biodiversity-of-tumoursMapping the biodiversity of tumoursJust as studying a single organism can’t tell you everything about the ecosystem it lives in, a single biopsy might not describe the diversity of cancer cells found within an individual tumour.https://www.icr.ac.uk/news-archive%2ficr-awards-ceremony-celebrates-achievements-of-new-cancer-research-graduateshttps://www.icr.ac.uk/news-archive%2ficr-awards-ceremony-celebrates-achievements-of-new-cancer-research-graduatesICR awards ceremony celebrates achievements of new cancer research graduatesStudents, public figures and academics were honoured during the annual awards ceremony for graduates of The Institute of Cancer Research, London. https://www.icr.ac.uk/news-archive%2ftuberculosis-protein-helps-spot-breast-cancer-s-signalshttps://www.icr.ac.uk/news-archive%2ftuberculosis-protein-helps-spot-breast-cancer-s-signalsTuberculosis protein helps spot breast cancer’s signalsScientists have used a protein from Mycobacterium tuberculosis – the bacterium that causes most cases of tuberculosis – to unravel the signals produced by cancer from those of healthy cells.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-icr-is-part-of-a-healthy-future-for-medical-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-icr-is-part-of-a-healthy-future-for-medical-researchThe ICR is part of a healthy future for medical researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-of-cancer-treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-future-of-cancer-treatmentThe future of cancer treatmenthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fresearchers-gather-to-discuss-hottest-topics-in-cancer-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fresearchers-gather-to-discuss-hottest-topics-in-cancer-researchResearchers gather to discuss hottest topics in cancer researchToday’s date has been ringed on our calendar for many months now as our researchers gather for the start of our annual conference.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-survival-the-legacy-of-charles-hugginshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fprostate-cancer-survival-the-legacy-of-charles-hugginsProstate cancer survival: the legacy of Charles HugginsUntil the middle of the 20th century, prostate cancer was perceived as a death sentence, and there was little understanding of the disease or its reliance on hormones. https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbeing-open-about-animal-researchhttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fbeing-open-about-animal-researchBeing open about animal researchBy signing the Concordat on Openness on Animal Research, we have reiterated our commitment to being transparent about when, how and why we use animals in our work.https://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fnhs-watchdog-changes-could-endanger-new-cancer-drugshttps://www.icr.ac.uk/blogs%2fthe-drug-discoverer%2fpage-details%2fnhs-watchdog-changes-could-endanger-new-cancer-drugsNHS watchdog changes could endanger new cancer drugsNew guidance from NICE could deny cancer patients access to life-extending drugs and dramatically reduce the likelihood of achieving the cancer cures of the future.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-blocks-earlier-use-of-abirateronehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnice-blocks-earlier-use-of-abirateroneNICE blocks earlier use of abirateronehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhave-a-pint-of-science!https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhave-a-pint-of-science!Have a Pint of Science!https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-viruses-to-treat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fusing-viruses-to-treat-cancerUsing viruses to treat cancerhttps://www.icr.ac.uk/news-archive%2ficr-researcher-shortlisted-for-prestigious-l-or%C3%A9al-unesco-fellowship-for-women-in-sciencehttps://www.icr.ac.uk/news-archive%2ficr-researcher-shortlisted-for-prestigious-l-or%C3%A9al-unesco-fellowship-for-women-in-scienceICR researcher shortlisted for prestigious L’Oréal-UNESCO Fellowship for Women in ScienceDr Chiara Braconi of the Division of Cancer Therapeutics at the ICR has been shortlisted for a prestigious award for women in science for her work on pancreatic cancer.https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-cell-kill-thyselfhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-cell-kill-thyselfCancer cell, kill thyselfhttps://www.icr.ac.uk/news-archive%2fnew-clues-to-skin-cancer-development-show-sunscreen-is-not-enoughhttps://www.icr.ac.uk/news-archive%2fnew-clues-to-skin-cancer-development-show-sunscreen-is-not-enoughNew clues to skin cancer development show sunscreen is not enoughScientists have shown that sunscreen cannot be relied upon alone to prevent malignant melanoma, the most deadly form of skin cancer. https://www.icr.ac.uk/news-archive%2ficr-tops-rankings-for-invention-income-earned-from-its-researchhttps://www.icr.ac.uk/news-archive%2ficr-tops-rankings-for-invention-income-earned-from-its-researchICR tops rankings for invention income earned from its researchA new analysis ranks the ICR first among UK higher education institutions for income from intellectual property in figures adjusted for size.https://www.icr.ac.uk/news-archive%2fhigh-tech-radiotherapy-drug-combinations-and-immunotherapy-showcased-as-future-of-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fhigh-tech-radiotherapy-drug-combinations-and-immunotherapy-showcased-as-future-of-cancer-treatmentHigh-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatmentHigh-tech radiotherapy, drug combinations, and immunotherapy are showcased as future of cancer treatment at Cheltenham Science Festival https://www.icr.ac.uk/news-archive%2fnew-technology-to-allow-simultaneous-tumour-imaging-and-radiotherapy-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-technology-to-allow-simultaneous-tumour-imaging-and-radiotherapy-treatmentNew technology to allow simultaneous tumour imaging and radiotherapy treatmentThe ICR has entered into a pioneering research collaboration with manufacturer Elekta which aims to develop a state-of-the-art radiotherapy system. https://www.icr.ac.uk/news-archive%2ficr-commits-to-openness-on-animal-researchhttps://www.icr.ac.uk/news-archive%2ficr-commits-to-openness-on-animal-researchICR commits to openness on animal researchThe Concordat on Openness on Animal Research will ensure members of the public have access to accurate information about when, how and why animals are used in research.https://www.icr.ac.uk/news-archive%2fsmokers-with-gene-defect-have-one-in-four-chance-of-developing-lung-cancerhttps://www.icr.ac.uk/news-archive%2fsmokers-with-gene-defect-have-one-in-four-chance-of-developing-lung-cancerSmokers with gene defect have one in four chance of developing lung cancerAround a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals.https://www.icr.ac.uk/news-archive%2fexposure-to-light-while-sleeping-linked-to-obesityhttps://www.icr.ac.uk/news-archive%2fexposure-to-light-while-sleeping-linked-to-obesityExposure to light while sleeping linked to obesityNew research co-funded by Breakthrough Breast Cancer has found that women who are exposed to greater levels of light while sleeping tend more often to be obese.https://www.icr.ac.uk/news-archive%2f50th-asco-conference-welcomes-presenters-from-the-icrhttps://www.icr.ac.uk/news-archive%2f50th-asco-conference-welcomes-presenters-from-the-icr50th ASCO conference welcomes presenters from the ICRResearchers from the ICR will be presenting their findings at the 2014 American Society of Clinical Oncology Annual Meeting, which opens today in Chicago. https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fshoot-the-messenger-micrornas-as-a-new-cancer-drug-targethttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fshoot-the-messenger-micrornas-as-a-new-cancer-drug-targetShoot the messenger: microRNAs as a new cancer drug targethttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-the-link-between-antibiotic-resistance-and-cancer-treatment-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhat-s-the-link-between-antibiotic-resistance-and-cancer-treatment-What’s the link between antibiotic resistance and cancer treatment?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fabiraterone-the-prostate-cancer-drug-that-s-going-from-strength-to-strengthhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fabiraterone-the-prostate-cancer-drug-that-s-going-from-strength-to-strengthAbiraterone, the prostate cancer drug that’s going from strength to strengthhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fconference-buzz-what-we%27re-taking-home-from-the-aacr-meetinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fconference-buzz-what-we%27re-taking-home-from-the-aacr-meetingConference buzz: what we're taking home from the AACR meetinghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fstone-man-syndrome-and-its-mysterious-link-to-childhood-brain-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fstone-man-syndrome-and-its-mysterious-link-to-childhood-brain-cancerStone man syndrome and its mysterious link to childhood brain cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2funcovering-cancer-s-rootshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2funcovering-cancer-s-rootsUncovering cancer’s rootshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-bedside-and-back-again-working-with-patients-to-develop-clinical-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fto-bedside-and-back-again-working-with-patients-to-develop-clinical-trialsTo bedside and back again – working with patients to develop clinical trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fguiding-kids%27-cancer-treatments-with-liquid-biopsieshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fguiding-kids%27-cancer-treatments-with-liquid-biopsiesGuiding kids' cancer treatments with liquid biopsieshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevery-cancer-is-different-our-research-on-bbc-bang-goes-the-theoryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fevery-cancer-is-different-our-research-on-bbc-bang-goes-the-theoryEvery cancer is different – our research on BBC Bang Goes the Theoryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-everyone-develop-a-hidden-cancer-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcould-everyone-develop-a-hidden-cancer-Could everyone develop a hidden cancer?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatently-obvious-the-icr-joins-the-gene-patenting-debatehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatently-obvious-the-icr-joins-the-gene-patenting-debatePatently obvious? The ICR joins the gene patenting debatehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fradiotherapy-and-the-microbiome-could-a-patient-s-gut-group-change-their-response-to-treatment-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fradiotherapy-and-the-microbiome-could-a-patient-s-gut-group-change-their-response-to-treatment-Radiotherapy and the microbiome: could a patient’s ‘gut group’ change their response to treatment?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fclinical-trials-for-children-with-cancer-the-latest-from-nicehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fclinical-trials-for-children-with-cancer-the-latest-from-niceClinical trials for children with cancer: the latest from NICEhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgene-testing-why-more-patients-need-it-and-how-to-bring-it-to-themhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgene-testing-why-more-patients-need-it-and-how-to-bring-it-to-themGene testing – why more patients need it and how to bring it to themhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit-s-time-for-change-to-eu-regulations-on-children-s-cancer-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fit-s-time-for-change-to-eu-regulations-on-children-s-cancer-trialsIt’s time for change to EU regulations on children’s cancer trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcommercial-link-ups-that-take-discoveries-to-patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcommercial-link-ups-that-take-discoveries-to-patientsCommercial link-ups that take discoveries to patientshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finfluencing-the-microenvironment-how-driving-cancer-evolution-could-lead-to-new-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2finfluencing-the-microenvironment-how-driving-cancer-evolution-could-lead-to-new-treatmentsInfluencing the microenvironment: how driving cancer evolution could lead to new treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgetting-nurses-up-to-speed-on-genomic-medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgetting-nurses-up-to-speed-on-genomic-medicineGetting nurses up to speed on genomic medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatient-records-the-key-to-future-cancer-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpatient-records-the-key-to-future-cancer-treatmentsPatient records – the key to future cancer treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-challenges-of-big-data-for-cancer-drug-discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-challenges-of-big-data-for-cancer-drug-discoveryThe challenges of big data for cancer drug discoveryhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-trials-and-tribulations-of-tackling-triple-negative-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-trials-and-tribulations-of-tackling-triple-negative-breast-cancerThe trials and tribulations of tackling triple-negative breast cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdeveloping-the-next-generation-of-cancer-drugs---we-need-to-work-together-to-succeed-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdeveloping-the-next-generation-of-cancer-drugs---we-need-to-work-together-to-succeed-Developing the next generation of cancer drugs - we need to work together to succeed https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdo-we-need-intensive-follow-ups-for-early-caught-breast-cancer-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fdo-we-need-intensive-follow-ups-for-early-caught-breast-cancer-Do we need intensive follow-ups for early caught breast cancer?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-new-recruits-and-their-exciting-new-avenues-for-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2four-new-recruits-and-their-exciting-new-avenues-for-researchOur new recruits and their exciting new avenues for researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-team-leaders-share-their-vision-for-future-research-(part-2)-cancer-imaginghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-team-leaders-share-their-vision-for-future-research-(part-2)-cancer-imagingNew team leaders share their vision for future research (Part 2): cancer imaginghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-team-leaders-share-their-vision-for-future-research-(part-1)-cancer-evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fnew-team-leaders-share-their-vision-for-future-research-(part-1)-cancer-evolutionNew team leaders share their vision for future research (Part 1): cancer evolutionhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffred-sanger-the-giant-of-genomicshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffred-sanger-the-giant-of-genomicsFred Sanger: the giant of genomicshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-need-smarter-clinical-trials-for-cancer-treatments-1https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-we-need-smarter-clinical-trials-for-cancer-treatments-1Why we need smarter clinical trials for cancer treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpenile-cancer-new-hope-for-a-rare-male-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpenile-cancer-new-hope-for-a-rare-male-cancerPenile Cancer – new hope for a rare male cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fartificial-intelligence-uses-biggest-disease-database-to-fight-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fartificial-intelligence-uses-biggest-disease-database-to-fight-cancerArtificial intelligence uses biggest disease database to fight cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-ncri-conference---what-we-have-learnedhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-ncri-conference---what-we-have-learnedThe NCRI conference - what we have learnedhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftackling-the-rarer-causes-of-breast-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftackling-the-rarer-causes-of-breast-cancerTackling the rarer causes of breast cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeting-the-epigenomehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftargeting-the-epigenomeTargeting the epigenomehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-chemistry-and-biology-work-together-to-make-drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-chemistry-and-biology-work-together-to-make-drugsHow chemistry and biology work together to make drugshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-uk-s-biggest-cancer-conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-uk-s-biggest-cancer-conferenceThe UK’s biggest cancer conferencehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fold-drugs-new-tricks-thalidomide-s-journey-back-from-the-wildernesshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fold-drugs-new-tricks-thalidomide-s-journey-back-from-the-wildernessOld drugs, new tricks: Thalidomide’s journey back from the wildernesshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffinding-the-right-bullet-against-breast-cancer-how-access-to-tumour-samples-could-save-liveshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffinding-the-right-bullet-against-breast-cancer-how-access-to-tumour-samples-could-save-livesFinding the right ‘bullet’ against breast cancer: how access to tumour samples could save liveshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feurope-s-biggest-cancer-conference-gets-underwayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feurope-s-biggest-cancer-conference-gets-underwayEurope’s biggest cancer conference gets underwayhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreaking-through-the-barriers-to-targeted-therapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbreaking-through-the-barriers-to-targeted-therapyBreaking through the barriers to targeted therapyhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feffective-action-needed-to-make-the-uk-a-more-attractive-location-for-clinical-trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2feffective-action-needed-to-make-the-uk-a-more-attractive-location-for-clinical-trialsEffective action needed to make the UK a more attractive location for clinical trialshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-drugs-will-we-find-a-cure-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcancer-drugs-will-we-find-a-cure-Cancer drugs – will we find a cure?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpaying-for-the-discoveries-that-defeat-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpaying-for-the-discoveries-that-defeat-cancerPaying for the discoveries that defeat cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftrials-and-tribulations-how-red-tape-is-stifling-development-of-targeted-treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ftrials-and-tribulations-how-red-tape-is-stifling-development-of-targeted-treatmentsTrials and tribulations: how red tape is stifling development of targeted treatmentshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fageing-genes-and-the-anti-cancer-clockhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fageing-genes-and-the-anti-cancer-clockAgeing genes and the anti-cancer clockhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcompetition-or-collaboration-where-s-the-best-science-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fcompetition-or-collaboration-where-s-the-best-science-Competition or collaboration: where’s the best science?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-difference-in-prostate-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fmaking-a-difference-in-prostate-cancerMaking a difference in prostate cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-testicular-cancer-survivors-aren%27t-just-living-long-lives---they%27re-living-normal-healthy-oneshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwhy-testicular-cancer-survivors-aren%27t-just-living-long-lives---they%27re-living-normal-healthy-onesWhy testicular cancer survivors aren't just living long lives - they're living normal healthy oneshttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffostering-business-university-collaboration-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffostering-business-university-collaboration-Fostering business-university collaboration https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-bench-to-bedside-the-importance-of-fundamental-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ffrom-bench-to-bedside-the-importance-of-fundamental-researchFrom bench to bedside: the importance of fundamental researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-icr-is-helping-to-realise-the-potential-of-stratified-medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fhow-the-icr-is-helping-to-realise-the-potential-of-stratified-medicineHow the ICR is helping to realise the potential of stratified medicinehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsequencing-mehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsequencing-meSequencing mehttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fscience-and-the-spending-reviewhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fscience-and-the-spending-reviewScience and the Spending Reviewhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-annual-conference-making-the-discoveries-that-defeat-cancer-1https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2ficr-annual-conference-making-the-discoveries-that-defeat-cancer-1ICR Annual Conference – Making the discoveries that defeat cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-supreme-court-gene-patenting-decision---sparking-questions-for-the-uk-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-supreme-court-gene-patenting-decision---sparking-questions-for-the-uk-The Supreme Court gene patenting decision – sparking questions for the UK?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-charity-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsupporting-charity-researchSupporting charity researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-biggest-event-in-the-cancer-calendarhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-biggest-event-in-the-cancer-calendarThe biggest event in the cancer calendarhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-tale-of-science-war-and-ciderhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fa-tale-of-science-war-and-ciderA tale of science, war and ciderhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmarter-drugs-to-outsmart-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fsmarter-drugs-to-outsmart-cancerSmarter drugs to outsmart cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrca-testing-what-does-it-all-mean-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fbrca-testing-what-does-it-all-mean-BRCA testing: what does it all mean?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2f-humphrey-helps-unravel-the-genetics-of-testicular-cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2f-humphrey-helps-unravel-the-genetics-of-testicular-cancer‘Humphrey’ helps unravel the genetics of testicular cancerhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpaul-burstow-mp-visits-the-institute-of-cancer-research-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fpaul-burstow-mp-visits-the-institute-of-cancer-research-Paul Burstow MP visits The Institute of Cancer Research https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-greatest-medical-innovation-in-the-last-100-years-https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fthe-greatest-medical-innovation-in-the-last-100-years-The greatest medical innovation in the last 100 years?https://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwider-legacy-for-headline-genetics-researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwider-legacy-for-headline-genetics-researchWider legacy for headline genetics researchhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-stand-on-the-shoulders-of-the-genome-gianthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwe-stand-on-the-shoulders-of-the-genome-giantWe stand on the shoulders of the genome gianthttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgovernment-staying-quiet-on-its-plans-for-science-spendhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fgovernment-staying-quiet-on-its-plans-for-science-spendGovernment staying quiet on its plans for science spendhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwelcome-to-the-icr-research-bloghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fwelcome-to-the-icr-research-blogWelcome to the ICR Research Bloghttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fin-the-lab-with-the-international-cancer-genome-consortiumhttps://www.icr.ac.uk/blogs%2fscience-talk%2fpage-details%2fin-the-lab-with-the-international-cancer-genome-consortiumIn the lab with the International Cancer Genome Consortiumhttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fparp-inhibitors-killing-cancer-cells-by-allowing-them-to-destroy-their-own-dnahttps://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fparp-inhibitors-killing-cancer-cells-by-allowing-them-to-destroy-their-own-dnaPARP inhibitors: killing cancer cells by allowing them to destroy their own DNADr Mariam Orme – a post-doctoral researcher – reflects on the life of former colleague Professor Julian Lewis, and one of the recent breakthroughs that has given men with prostate cancer more time and better quality of life.https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwelcome!https://www.icr.ac.uk/blogs%2ftales-from-the-lab%2fpage-details%2fwelcome!Welcome!Lizzie Coker – a second-year PhD student – offers insights into the world of a PhD student at The Institute of Cancer Research.https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-appointed-interim-chief-executive-of-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-appointed-interim-chief-executive-of-the-institute-of-cancer-researchProfessor Paul Workman appointed Interim Chief Executive of The Institute of Cancer ResearchProfessor Workman will take over responsibility for driving forward our world-class programme of research and education from 1 July. https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-draft-guidance-rejecting-the-use-of-abiraterone-for-prostate-cancer-before-chemotherapyhttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-draft-guidance-rejecting-the-use-of-abiraterone-for-prostate-cancer-before-chemotherapyStatement in response to NICE draft guidance rejecting the use of abiraterone for prostate cancer before chemotherapyProfessor Paul Workman expresses disappointment as NHS is advised against using ICR-developed drug earlier in the treatment of prostate cancer on grounds of cost.https://www.icr.ac.uk/news-features%2flatest-features%2fabiraterone-a-story-of-scientific-innovation-and-commercial-partnershiphttps://www.icr.ac.uk/news-features%2flatest-features%2fabiraterone-a-story-of-scientific-innovation-and-commercial-partnershipThe story of abirateroneAbiraterone is one of the ICR’s biggest success stories: the first treatment shown to be effective in men with advanced prostate cancer. But it took almost 20-years of hard work to take the drug from an initial idea to the clinic, where it now transforms the lives of more than 25,000 patients every year.https://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-final-draft-guidance-recommending-enzalutamide-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-nice-final-draft-guidance-recommending-enzalutamide-for-prostate-cancerStatement in response to NICE final draft guidance recommending enzalutamide for prostate cancerThe Institute of Cancer Research welcomes NICE draft guidance recommending patients with advanced prostate cancer who have had chemotherapy receive the life-extending drug on the NHS. https://www.icr.ac.uk/news-archive%2ficr-supports-petition-on-royal-brompton-redevelopment-planshttps://www.icr.ac.uk/news-archive%2ficr-supports-petition-on-royal-brompton-redevelopment-plansICR supports petition on Royal Brompton redevelopment plansChelsea plans could threaten ICR operations, while loss of site to residential development would dash hopes for once-in-a-lifetime opportunity to strengthen ties with The Royal Marsden hospital.https://www.icr.ac.uk/news-archive%2fscientists-find-new-exploitable-weakness-in-cancer-cellshttps://www.icr.ac.uk/news-archive%2fscientists-find-new-exploitable-weakness-in-cancer-cellsScientists find new exploitable weakness in cancer cellsScientists have discovered a new way to target cancer cells and prevent them from dividing properly, causing them to die.https://www.icr.ac.uk/news-archive%2f%27dustman%27-protein-helps-bin-cancer-cellshttps://www.icr.ac.uk/news-archive%2f%27dustman%27-protein-helps-bin-cancer-cells'Dustman' protein helps bin cancer cellsNew findings suggest a test could identify patients who would be most responsive to a new class of cancer drugs and also those who might develop resistance.https://www.icr.ac.uk/news-archive%2ffirst-genetic-link-discovered-to-difficult-to-diagnose-breast-cancer-sub-typehttps://www.icr.ac.uk/news-archive%2ffirst-genetic-link-discovered-to-difficult-to-diagnose-breast-cancer-sub-typeFirst genetic link discovered to difficult-to-diagnose breast cancer sub-typeScientists have identified the first genetic variant specifically associated with the risk of invasive lobular carcinoma, a difficult-to-diagnose cancer sub-type accounting for around 10-15% of all breast cancer cases.https://www.icr.ac.uk/news-archive%2fmicrorna-could-be-key-target-for-bowel-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fmicrorna-could-be-key-target-for-bowel-cancer-treatmentMicroRNA could be key target for bowel cancer treatmentA tiny genetic molecule called microRNA plays a central role in bowel cancer and could be key to developing new treatments for the disease, say ICR Researchers.https://www.icr.ac.uk/news-archive%2fprofessor-alan-ashworth-wins-genetics-society-medalhttps://www.icr.ac.uk/news-archive%2fprofessor-alan-ashworth-wins-genetics-society-medalProfessor Alan Ashworth wins Genetics Society medalProfessor Alan Ashworth, Chief Executive of The Institute of Cancer Research, London, has been awarded the 2015 Genetics Society medal. The prestigious award is given annually for outstanding contributions to the study of genetics. https://www.icr.ac.uk/news-archive%2ficr-professor-is-a-%27game-changer%27-in-woman-s-hour-power-listhttps://www.icr.ac.uk/news-archive%2ficr-professor-is-a-%27game-changer%27-in-woman-s-hour-power-listICR professor is a 'Game Changer' in Woman’s Hour Power ListProfessor Nazneen Rahman, head of the Division of Genetics and Epidemiology, has been announced as one of the top ten 'Game Changers' in the BBC Woman's Hour Power List of 2014.https://www.icr.ac.uk/news-archive%2ficr-researcher-wins-award-to-present-at-top-cancer-conferencehttps://www.icr.ac.uk/news-archive%2ficr-researcher-wins-award-to-present-at-top-cancer-conferenceICR researcher wins award to present at top cancer conferenceA young scientist at The Institute of Cancer Research, London, is presenting her work at a leading international cancer conference after winning a major award for early-career researchers.https://www.icr.ac.uk/news-archive%2fstopping-cancer-in-its-tracks-the-icr-s-discovery-club-tackles-cancer-metastasishttps://www.icr.ac.uk/news-archive%2fstopping-cancer-in-its-tracks-the-icr-s-discovery-club-tackles-cancer-metastasisStopping cancer in its tracks: the ICR’s Discovery Club tackles cancer metastasisOur latest Discovery Club event at the Royal Society gave members and guests an insight into a crucial area of our research: understanding how cancer cells spread around the body.https://www.icr.ac.uk/news-archive%2fvideo-dr-chris-jones-on-the-discovery-of-the-genetic-flaw-that-may-hold-the-key-to-devastating-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fvideo-dr-chris-jones-on-the-discovery-of-the-genetic-flaw-that-may-hold-the-key-to-devastating-childhood-cancerVideo: Dr Chris Jones on the discovery of the genetic flaw that may hold the key to devastating childhood cancerDr Chris Jones tells Henry French about his team's discovery of a genetic flaw driving the deadly childhood brain cancer DIPG, its surprising links to a developmental syndrome in which muscle turns to bone, and how the discovery could lead to new therapies for this hard-to-treat cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-flaw-may-hold-key-to-deadly-childhood-brain-tumourhttps://www.icr.ac.uk/news-archive%2fgenetic-flaw-may-hold-key-to-deadly-childhood-brain-tumourGenetic flaw may hold key to deadly childhood brain tumourICR researchers have found a surprising link between childhood glioma and rare genetic syndrome in which muscle turns to bone.https://www.icr.ac.uk/news-archive%2ficr-researchers-focus-on-smart-treatments-at-leading-cancer-conferencehttps://www.icr.ac.uk/news-archive%2ficr-researchers-focus-on-smart-treatments-at-leading-cancer-conferenceICR researchers focus on smart treatments at leading cancer conferenceICR scientists are making the trip to San Diego this weekend for one of the biggest dates in the cancer calendar – the American Association of Cancer Research (AACR) conference.https://www.icr.ac.uk/news-archive%2fblood-test-could-provide-a-representative-measure-of-long-term-hormone-levelshttps://www.icr.ac.uk/news-archive%2fblood-test-could-provide-a-representative-measure-of-long-term-hormone-levelsBlood test could provide a representative measure of long term hormone levelsA single blood sample could predict hormone levels known to be an indicator of breast cancer risk for years to come, according to ICR researchers.https://www.icr.ac.uk/news-archive%2fhow-cancer-evolves-sheds-light-on-origin-of-breast-cancer-subtypeshttps://www.icr.ac.uk/news-archive%2fhow-cancer-evolves-sheds-light-on-origin-of-breast-cancer-subtypesHow cancer evolves sheds light on origin of breast cancer subtypesICR researchers find that multiple forms of breast cancer can originate from a single cell type, which could change how we target and treat the disease.https://www.icr.ac.uk/news-archive%2fstatement-in-reaction-to-new-proposals-from-nice-on-end-of-life-criteriahttps://www.icr.ac.uk/news-archive%2fstatement-in-reaction-to-new-proposals-from-nice-on-end-of-life-criteriaStatement in reaction to new proposals from NICE on end of life criteriaThe ICR highlights the importance of the end of life criteria in the way NICE makes recommendations on new medicines, as it is important for cancer patients to access life-extending drugs.https://www.icr.ac.uk/news-archive%2fhigh-tech-ultrasound-scan-could-match-tumour-tracking-power-of-cyberknifehttps://www.icr.ac.uk/news-archive%2fhigh-tech-ultrasound-scan-could-match-tumour-tracking-power-of-cyberknifeHigh-tech ultrasound scan could match tumour tracking power of CyberKnifeA new type of ultrasound imaging could potentially follow tumour movements as well as the X-ray tracking used in the sophisticated radiotherapy technology CyberKnife, allowing precise targeting of radiation doses, new research concludes.https://www.icr.ac.uk/news-archive%2fgut-bacteria-clinical-study-could-help-reduce-radiotherapy-side-effectshttps://www.icr.ac.uk/news-archive%2fgut-bacteria-clinical-study-could-help-reduce-radiotherapy-side-effectsGut bacteria clinical study could help reduce radiotherapy side-effectsICR researchers will examine how gut bacteria influences the side-effects patients experience after radiotherapy, in the first clinical study of its type.https://www.icr.ac.uk/news-archive%2fprof-andrew-tutt-to-head-breakthrough-breast-cancer-research-centrehttps://www.icr.ac.uk/news-archive%2fprof-andrew-tutt-to-head-breakthrough-breast-cancer-research-centreProf Andrew Tutt to head Breakthrough Breast Cancer Research CentreLeading expert in clinical trials and targeted therapies for breast cancer joins the ICR as Centre Director for the Breakthrough Toby Robins Breast Cancer Research Centrehttps://www.icr.ac.uk/news-archive%2fgene-test-finds-breast-cancer-patients-who-may-benefit-from-longer-therapyhttps://www.icr.ac.uk/news-archive%2fgene-test-finds-breast-cancer-patients-who-may-benefit-from-longer-therapyGene test finds breast cancer patients who may benefit from longer therapySome postmenopausal women with ER+ breast cancer may benefit from ten years of hormone therapy instead of five, says ICR researcher. https://www.icr.ac.uk/news-archive%2fcancer-study-sheds-new-light-on-premature-menopausehttps://www.icr.ac.uk/news-archive%2fcancer-study-sheds-new-light-on-premature-menopauseCancer study sheds new light on premature menopauseAround two per cent of women with primary ovarian insufficiency – the medical term for a permanent halt in menstruation occurring naturally before the age of 40 – are affected by changes to a particular gene, a study has shown.https://www.icr.ac.uk/news-archive%2ficr-scientists-pioneer-new-skin-cancer-elastography-imaginghttps://www.icr.ac.uk/news-archive%2ficr-scientists-pioneer-new-skin-cancer-elastography-imagingICR scientists pioneer new skin cancer elastography imagingInstitute of Cancer Research scientists have developed a new technique to analyse skin lesions by looking at how tissues move when they are stretched.https://www.icr.ac.uk/news-archive%2fprof-alan-ashworth-appointed-director-of-ucsf-helen-diller-cancer-centerhttps://www.icr.ac.uk/news-archive%2fprof-alan-ashworth-appointed-director-of-ucsf-helen-diller-cancer-centerProf Alan Ashworth appointed Director of UCSF Helen Diller Cancer CenterChief exec who reinforced the ICR's position among the world's top cancer research centres will lead San Francisco Comprehensive Cancer Center from 2015.https://www.icr.ac.uk/news-archive%2fstudy-sheds-new-light-on-dna-repairhttps://www.icr.ac.uk/news-archive%2fstudy-sheds-new-light-on-dna-repairStudy sheds new light on DNA repairA major study has given a new insight into how DNA is repaired – a fundamentally important process in all forms of life and diseases including cancer.https://www.icr.ac.uk/news-archive%2ficr-researcher-wins-biochemical-society-centenary-awardhttps://www.icr.ac.uk/news-archive%2ficr-researcher-wins-biochemical-society-centenary-awardICR researcher wins Biochemical Society Centenary awardProfessor Chris Marshall, Head of the Division of Cancer Biology, has won the prestigious Biochemical Society Centenary Award 2015.https://www.icr.ac.uk/news-archive%2fnew-imaging-approach-fast-tracks-drug-testing-for-incurable-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-imaging-approach-fast-tracks-drug-testing-for-incurable-prostate-cancerNew imaging approach fast tracks drug testing for incurable prostate cancerScientists have developed a new way to test the effectiveness of a drug for prostate cancer that has spread to the bone, which is currently incurable. https://www.icr.ac.uk/news-features%2flatest-features%2ffunctional-imaging-providing-direction-in-the-fight-against-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2ffunctional-imaging-providing-direction-in-the-fight-against-cancerFunctional imaging: providing direction in the fight against cancerPeople have been exploring with the help of magnetic fields ever since the twelfth century, when explorers first started using compasses to guide ships on cloudy nights. https://www.icr.ac.uk/news-archive%2fmutations-in-leukaemia-gene-linked-to-new-childhood-growth-disorderhttps://www.icr.ac.uk/news-archive%2fmutations-in-leukaemia-gene-linked-to-new-childhood-growth-disorderMutations in leukaemia gene linked to new childhood growth disorderGenetic mutations associated with leukaemia cause a newly described condition that affects growth and intellectual development in children.https://www.icr.ac.uk/news-archive%2fnew-computer-software-could-spot-cancer-gene-mutationshttps://www.icr.ac.uk/news-archive%2fnew-computer-software-could-spot-cancer-gene-mutationsNew computer software could spot cancer gene mutationsScientists have developed a cutting-edge computer program that could be used to find as-yet undiscovered genetic mutations that cause cancer. https://www.icr.ac.uk/news-features%2flatest-features%2fbreaking-down-the-barriers-to-treating-childhood-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fbreaking-down-the-barriers-to-treating-childhood-cancerBreaking down the barriers to treating childhood cancerTreatments for childhood cancer have improved greatly in recent decades – over 80% of children with cancer now survive their disease. But that figure, on the surface encouraging, hides the alarming truth that many children who do survive cancer are left with lifelong side-effects. As many as 40% of children who survive cancer are still suffering serious or even life-threatening side-effects 30 years after diagnosis.https://www.icr.ac.uk/news-archive%2fscan-measures-cancer-metabolites-inside-the-bodyhttps://www.icr.ac.uk/news-archive%2fscan-measures-cancer-metabolites-inside-the-bodyScan measures cancer metabolites inside the bodyScientists have used a new scanning technique to measure the metabolites produced by tumours as a means of assessing their severity.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-smart-phone-technology-to-deliver-smart-cancer-treatmentshttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-smart-phone-technology-to-deliver-smart-cancer-treatmentsUsing smart phone technology to deliver smart cancer treatmentsWhen we pick up our smart phone and take a photo or video and share with our friends and family, most of us do not give a second thought about the technology we’re using. We owe this modern day given to something called a complementary metal-oxide-semiconductor (CMOS) sensor, also known as the active pixel sensor (APS). https://www.icr.ac.uk/news-archive%2fscans-of-tumour-stiffness-can-assess-response-to-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fscans-of-tumour-stiffness-can-assess-response-to-cancer-treatmentScans of tumour ‘stiffness’ can assess response to cancer treatmentA new type of scan measuring whether tissues are ‘stiff’ or elastic can assess whether they are responding to treatment, say ICR researchers. https://www.icr.ac.uk/news-archive%2fmore-intensive-radiotherapy-is-better-for-localised-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fmore-intensive-radiotherapy-is-better-for-localised-prostate-cancerMore intensive radiotherapy is better for localised prostate cancerResults from a 10-year trial have shown that a radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer. https://www.icr.ac.uk/news-archive%2fvideo-skin-cancer-risk-may-have-driven-evolution-of-black-skinhttps://www.icr.ac.uk/news-archive%2fvideo-skin-cancer-risk-may-have-driven-evolution-of-black-skinVideo: Skin cancer risk may have driven evolution of black skinEarly humans may have evolved black skin to protect against a very high risk of dying from ultraviolet light-induced skin cancer, a new analysis concludes.https://www.icr.ac.uk/news-archive%2fobesity-found-to-be-significantly-related-to-male-breast-cancer-risk-https://www.icr.ac.uk/news-archive%2fobesity-found-to-be-significantly-related-to-male-breast-cancer-risk-Obesity found to be significantly related to male breast cancer risk A study has found that obesity, and several other physical and hormone-related characteristics are associated with increased breast cancer risk in menhttps://www.icr.ac.uk/news-archive%2fnew-study-shows-snapshot-of-how-blood-cancer-evolveshttps://www.icr.ac.uk/news-archive%2fnew-study-shows-snapshot-of-how-blood-cancer-evolvesNew study shows snapshot of how blood cancer evolvesA new study is uncovering the evolutionary history of multiple myeloma for the first time, according to ICR researchers.https://www.icr.ac.uk/news-archive%2fscientists-target-children-s-brain-tumours-in-4-million-research-programmehttps://www.icr.ac.uk/news-archive%2fscientists-target-children-s-brain-tumours-in-4-million-research-programmeScientists target children’s brain tumours in £4 million research programmeScientists in London are at the forefront of a groundbreaking research programme aimed at beating childhood brain tumourshttps://www.icr.ac.uk/news-archive%2fstudy-shows-how-hpv-protein-helps-ovarian-cancer-cells-growhttps://www.icr.ac.uk/news-archive%2fstudy-shows-how-hpv-protein-helps-ovarian-cancer-cells-growStudy shows how HPV protein helps ovarian cancer cells growA protein produced by cancer cells infected with the human papillomavirus (HPV) could help them to survive and spread, say researchers. https://www.icr.ac.uk/news-archive%2fprostate-cancer-uk-and-movember-launch-london-centre-of-excellencehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-uk-and-movember-launch-london-centre-of-excellenceProstate Cancer UK and Movember launch London Centre of ExcellenceThe Movember Foundation and Prostate Cancer UK announce the launch of a Centres of Excellence programme in prostate cancer research.  https://www.icr.ac.uk/news-archive%2fdiscovery-may-help-to-explain-mystery-of-missing-genetic-riskhttps://www.icr.ac.uk/news-archive%2fdiscovery-may-help-to-explain-mystery-of-missing-genetic-riskDiscovery may help to explain mystery of ‘missing’ genetic riskA new study could help to answer an important riddle in our understanding of genetics. https://www.icr.ac.uk/news-archive%2fgene-prevents-breast-cancer-spread-by-stopping-cells-becoming-sticky-https://www.icr.ac.uk/news-archive%2fgene-prevents-breast-cancer-spread-by-stopping-cells-becoming-sticky-Gene prevents breast cancer spread by stopping cells becoming ‘sticky’Scientists have discovered a gene that prevents the spread of breast cancer by stopping tumour cells from becoming ‘sticky’.https://www.icr.ac.uk/news-archive%2ficr-scientists-call-for-changes-to-eu-rules-on-children%27s-cancer-drugshttps://www.icr.ac.uk/news-archive%2ficr-scientists-call-for-changes-to-eu-rules-on-children%27s-cancer-drugsICR scientists call for changes to EU rules on children's cancer drugsWhy we're worried that EU rules on drug trials are denying children with cancer new, potentially life-saving drugs.https://www.icr.ac.uk/news-archive%2fvideo-why-we-must-change-the-rules-on-children%27s-cancer-drugshttps://www.icr.ac.uk/news-archive%2fvideo-why-we-must-change-the-rules-on-children%27s-cancer-drugsVideo: Why we must change the rules on children's cancer drugsChanges to how EU rules are implemented could allow children access to a goldmine of potential cancer drugs which have currently only been tested in adults – by making it more difficult for pharma companies to avoid testing them in under-18s too.https://www.icr.ac.uk/news-archive%2fabbie%27s-army-fund-award-winning-childhood-cancer-researcherhttps://www.icr.ac.uk/news-archive%2fabbie%27s-army-fund-award-winning-childhood-cancer-researcherAbbie's Army fund award winning childhood cancer researcherA gift of £110,000 from charity Abbie's Army is helping to fund a talented young scientist, who recently won an award for her research into childhood brain cancer.https://www.icr.ac.uk/news-archive%2fmutations-link-common-immune-condition-with-blood-cancerhttps://www.icr.ac.uk/news-archive%2fmutations-link-common-immune-condition-with-blood-cancerMutations link common immune condition with blood cancerICR scientists find a genetic link between multiple myeloma and a mysterious but harmless condition affecting the blood.https://www.icr.ac.uk/news-archive%2ficr-researchers-present-method-to-dissect-paired-stem-cellshttps://www.icr.ac.uk/news-archive%2ficr-researchers-present-method-to-dissect-paired-stem-cellsICR researchers present method to dissect paired stem cellsScientists from The Institute of Cancer Research, London, have outlined their new method to separate paired embryonic stem cells. https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-receives-prestigious-raymond-bourgine-award-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-receives-prestigious-raymond-bourgine-award-for-cancer-researchProfessor Paul Workman receives prestigious Raymond Bourgine Award for cancer researchThe ICR's Deputy CEO has been honoured with an international award for excellence in cancer research.https://www.icr.ac.uk/news-archive%2fpromising-results-for-new-cancer-drughttps://www.icr.ac.uk/news-archive%2fpromising-results-for-new-cancer-drugPromising results for new cancer drugA new drug – combined with cytotoxic and targeted chemotherapies – has been shown to be safe for patients with advanced solid tumours.https://www.icr.ac.uk/news-archive%2fstudy-leads-to-new-understandings-of-rare-breast-cancer-typehttps://www.icr.ac.uk/news-archive%2fstudy-leads-to-new-understandings-of-rare-breast-cancer-typeStudy leads to new understandings of rare breast cancer typeA study into a unique breast cancer sub-type called micropapillary carcinoma of the breast has given new clues to its genetic make-up. https://www.icr.ac.uk/news-features%2flatest-features%2fthe-centre-for-evolution-and-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-centre-for-evolution-and-cancerThe Centre for Evolution and CancerDarwin’s theory of evolution by natural selection – a force of nature favouring those carrying advantageous traits and making those traits more common in the next generation – is the central paradigm of biology. Darwin developed this idea to explain the origins of the extraordinary diversity of species on the planet. But it turns out that exactly the same fundamental principle applies to many areas of health and disease, including antibiotic resistance, the emergence of new infectious diseases, the functioning of our immune systems and, not least, cancer.https://www.icr.ac.uk/news-archive%2fvideo-high-tech-whole-body-scan-could-improve-treatment-of-bone-marrow-cancerhttps://www.icr.ac.uk/news-archive%2fvideo-high-tech-whole-body-scan-could-improve-treatment-of-bone-marrow-cancerVideo: High-tech ‘whole body’ scan could improve treatment of bone marrow cancerICR researchers pioneer scanning technique that can image a patient’s entire body to reveal where cancer is affecting the bones.https://www.icr.ac.uk/news-archive%2fvideo-the-centre-for-evolution-and-cancerhttps://www.icr.ac.uk/news-archive%2fvideo-the-centre-for-evolution-and-cancerVideo: The Centre for Evolution and CancerProfessor Mel Greaves FRS talks to us about why The Institute of Cancer Research is launching The Centre for Evolution and Cancer.https://www.icr.ac.uk/news-archive%2fdeputy-chief-executive-elected-to-european-academyhttps://www.icr.ac.uk/news-archive%2fdeputy-chief-executive-elected-to-european-academyDeputy Chief Executive elected to European AcademyProfessor Paul Workman, has been elected as a Fellow of the European Academy of Cancer Scienceshttps://www.icr.ac.uk/news-archive%2fnew-insights-into-dna-repair-processhttps://www.icr.ac.uk/news-archive%2fnew-insights-into-dna-repair-processNew insights into DNA repair process

Researchers have shed new light on how DNA damage is repaired within cells, in work with important implications for cancer prevention and treatment.https://www.icr.ac.uk/news-archive%2finternational-deal-to-screen-potential-cancer-drugs-using-dna-barcodes-https://www.icr.ac.uk/news-archive%2finternational-deal-to-screen-potential-cancer-drugs-using-dna-barcodes-International deal to screen potential cancer drugs using DNA ‘barcodes’The Institute of Cancer Research enter drug discovery collaboration with Cancer Research Technology and Nuevolution A/S.https://www.icr.ac.uk/news-archive%2fa-new-pathway-for-cancer-gene-testing-successfully-completes-pilothttps://www.icr.ac.uk/news-archive%2fa-new-pathway-for-cancer-gene-testing-successfully-completes-pilotA new pathway for cancer gene testing successfully completes pilotResearchers have completed a pilot of a new ‘oncogenetic’ gene testing pathway which is much faster and less costly than standard gene testing pathwayshttps://www.icr.ac.uk/news-archive%2fcell-shape-study-gives-cancer-cluehttps://www.icr.ac.uk/news-archive%2fcell-shape-study-gives-cancer-clueCell shape study gives cancer clueThe transition from one cell shape to another can be largely explained by the actions of only two key proteins, researchers have found. The discovery could improve our understanding of cancer’s transformation from a localised, often manageable disease to a metastatic and deadly form that spreads to new parts of the body.https://www.icr.ac.uk/news-features%2flatest-features%2fdivide-and-rule-stratified-medicinehttps://www.icr.ac.uk/news-features%2flatest-features%2fdivide-and-rule-stratified-medicineDivide and rulePathologists have tended to take a fairly straightforward approach to understanding tumours – by simply cutting them into slices and examining them under the microscope. To some extent, they have succeeded in predicting how tumours might behave based on how they looked.https://www.icr.ac.uk/news-archive%2fimmune-system-development-linked-to-leukaemiahttps://www.icr.ac.uk/news-archive%2fimmune-system-development-linked-to-leukaemiaImmune system development linked to leukaemiaNew study shows how a genetic mutation can turn one of our defences against infection into a driver of cancer.https://www.icr.ac.uk/news-archive%2fdanny-alexander-visits-the-institute-of-cancer-research-and-the-royal-marsdenhttps://www.icr.ac.uk/news-archive%2fdanny-alexander-visits-the-institute-of-cancer-research-and-the-royal-marsdenDanny Alexander visits The Institute of Cancer Research and The Royal MarsdenThe Chief Secretary to the Treasury toured new state-of-the-art facilities, including the ICR's Centre for Cancer Imaging.https://www.icr.ac.uk/news-archive%2fnew-%27free-breathe%27-mri-scan-could-help-monitor-lung-cancerhttps://www.icr.ac.uk/news-archive%2fnew-%27free-breathe%27-mri-scan-could-help-monitor-lung-cancerNew 'free-breathe' MRI scan could help monitor lung cancerA new type of MRI scan of the lungs that is taken while patients are breathing normally could help track how patients with lung tumours respond to treatment. https://www.icr.ac.uk/news-archive%2fscans-on-day-of-treatment-could-improve-bladder-radiotherapyhttps://www.icr.ac.uk/news-archive%2fscans-on-day-of-treatment-could-improve-bladder-radiotherapyScans on day of treatment could improve bladder radiotherapyScanning bladder cancer patients on the day of treatment could lead to safer, more accurate radiotherapy, and could pave the way for fewer people to have their bladders removed, say researchers.https://www.icr.ac.uk/news-archive%2fgene-signatures-give-brain-cancer-cluehttps://www.icr.ac.uk/news-archive%2fgene-signatures-give-brain-cancer-clueGene signatures give brain cancer clueResearchers have shown that three different genetic fingerprints underlie three different forms of glioma, a cancer which accounts for around half of all brain tumours.https://www.icr.ac.uk/news-archive%2fradiotherapy-presents-risks-in-testicular-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fradiotherapy-presents-risks-in-testicular-cancer-treatmentRadiotherapy presents risks in testicular cancer treatmentRadiotherapy should be avoided for the treatment of testicular cancer after surgery because of an increased risk of developing secondary cancers, according to a new study by The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fcarols-from-chelseahttps://www.icr.ac.uk/news-archive%2fcarols-from-chelseaCarols from ChelseaOver 400 people gathered in the stunning surroundings of the Chapel of the Royal Hospital Chelsea for this year's 'Carols from Chelsea', raising nearly £100,000.https://www.icr.ac.uk/news-archive%2fresearch-shows-benefit-of-active-surveillance-for-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fresearch-shows-benefit-of-active-surveillance-for-prostate-cancer-patientsResearch shows benefit of active surveillance for prostate cancer patientsClosely monitoring prostate cancer patients could help thousands of men with less aggressive forms of the disease avoid unnecessary treatment, research shows.https://www.icr.ac.uk/news-features%2flatest-features%2fsaving-lives-by-changing-the-way-we-deliver-radiotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fsaving-lives-by-changing-the-way-we-deliver-radiotherapySaving lives by changing the way we deliver radiotherapyGerman physicist Professor Wilhelm Röentgen was the first person to report using X-rays back in 1896. His first X-ray picture was of his wife’s hand, and when she saw the picture, she exclaimed "I have seen my death!”. https://www.icr.ac.uk/news-archive%2fcomputer-controlled-table-could-direct-radiotherapy-to-tumourshttps://www.icr.ac.uk/news-archive%2fcomputer-controlled-table-could-direct-radiotherapy-to-tumoursComputer-controlled table could direct radiotherapy to tumoursSophisticated computer modelling could be used to deliver high doses of radiotherapy to tumours more quickly than current methodshttps://www.icr.ac.uk/news-archive%2ficr-research-team-wins-award-for-improving-quality-of-life-for-cancer-patientshttps://www.icr.ac.uk/news-archive%2ficr-research-team-wins-award-for-improving-quality-of-life-for-cancer-patientsICR research team wins award for improving quality of life for cancer patientsA clinical trials team at The Institute of Cancer Research, London, has won a top award for its work to improve quality of life for people with head and neck cancers.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-yearhttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-yearHighlights of 2013We review ten of the most exciting discoveries made in the past year.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fpinpointing-the-first-founder-mutations-that-lead-to-leukaemiahttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fpinpointing-the-first-founder-mutations-that-lead-to-leukaemiaPinpointing the first founder mutations that lead to leukaemiaProfessors Mel Greaves and Richard Houlston were able to identify the exact mutations that kick-start cancer, potentially enabling more effective targeted therapies.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fbeating-breast-cancer-s-resistance-to-hormone-treatmentshttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fbeating-breast-cancer-s-resistance-to-hormone-treatmentsBeating breast cancer’s resistance to hormone treatmentsProfessor Clare Isacke discovered that a signalling pathway in ER-positive breast cancer that is linked to resistance to aromatase inhibitors in some cancers.https://www.icr.ac.uk/news-archive%2fpioneering-cancer-drugs-could-treat-many-more-patients-by-targeting-new-gene-defecthttps://www.icr.ac.uk/news-archive%2fpioneering-cancer-drugs-could-treat-many-more-patients-by-targeting-new-gene-defectPioneering cancer drugs could treat many more patients – by targeting new gene defectA pioneering new class of targeted cancer drug could benefit many more patients than previously thought including some with ovarian, stomach, bladder, cervical and prostate cancer.https://www.icr.ac.uk/news-features%2flatest-features%2ficr-researchers-visit-westminster-to-see-science-policy-making-in-actionhttps://www.icr.ac.uk/news-features%2flatest-features%2ficr-researchers-visit-westminster-to-see-science-policy-making-in-actionICR researchers visit Westminster to see science policy making in actionLast week, two of our researchers here at The Institute of Cancer Research, London, spent a week in Westminster as part of the Royal Society MP Pairing Scheme.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fdiscovering-an-intriguing-gene-link-to-breast-and-ovarian-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fdiscovering-an-intriguing-gene-link-to-breast-and-ovarian-cancerDiscovering an intriguing gene link to breast and ovarian cancerProfessor Nazneen Rahman's team found gene mutations linked to an increased risk of breast and ovarian cancer, in what may be a new mechanism of cancer development.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fidentifying-the-genetic-driver-of-childhood-glioblastomahttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fidentifying-the-genetic-driver-of-childhood-glioblastomaIdentifying the genetic driver of childhood glioblastomaDr Chris Jones uncovered the genetic causes of a rare but lethal form of childhood brain cancer, improving our understanding of the development of the disease.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2funlocking-the-hidden-potential-of-cutting-edge-cancer-drugshttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2funlocking-the-hidden-potential-of-cutting-edge-cancer-drugsUnlocking the hidden potential of cutting-edge cancer drugsProfessor Paul Workman and collaborators uncovered a hidden mechanism revealing how a class of cutting-edge cancer drugs attack tumours.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fquantifying-breast-cancer-risk-after-lymphoma-treatmenthttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fquantifying-breast-cancer-risk-after-lymphoma-treatmentQuantifying breast cancer risk after lymphoma treatmentProfessor Tony Swerdlow and colleagues reported on the world’s largest cohort study into factors affecting the risk of breast cancer after treatment with radiotherapy for Hodgkin lymphoma.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fstopping-cancer-in-its-trackshttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fstopping-cancer-in-its-tracksStopping cancer in its tracksDr Chris Bakal and his team pinpointed a set of genes that allows melanoma cells to change rapidly between two shapes in order to escape from the skin and spread around the body.https://www.icr.ac.uk/news-archive%2fnew-cancer-protein-inhibitor-paves-way-for-research-into-new-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-cancer-protein-inhibitor-paves-way-for-research-into-new-treatmentsNew cancer protein inhibitor paves way for research into new treatmentshttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fusing-virtual-experiments-to-uncover-missing-cancer-targetshttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2fusing-virtual-experiments-to-uncover-missing-cancer-targetsUsing virtual experiments to uncover missing cancer targetsDr Bissan Al-Lazikani and her team identified 46 previously overlooked but potentially 'druggable' cancer targets, using a powerful new online knowledgebase developed here at the ICR.https://www.icr.ac.uk/news-archive%2ffrom-lab-bench-to-backbench-https://www.icr.ac.uk/news-archive%2ffrom-lab-bench-to-backbench-From lab bench to backbench Two ICR scientists will be swapping lab coats for legislation when they visit MP Paul Burstow for the Royal Society’s ‘Week in Westminster’ pairing scheme.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2ffinding-the-faulty-gene-with-a-domino-effect-on-cancer-riskhttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2ffinding-the-faulty-gene-with-a-domino-effect-on-cancer-riskFinding the faulty gene with a domino effect on cancer riskProfessors Richard Houlston and Gareth Morgan identified a brand new genetic mechanism that raises the risk of cancer via a domino effect on DNA.https://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2ficr%27s-pioneering-prostate-cancer-drug-found-to-be-effective-before-chemotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fhighlights-of-the-year%2ficr%27s-pioneering-prostate-cancer-drug-found-to-be-effective-before-chemotherapyICR's pioneering prostate cancer drug found to be effective before chemotherapyProfessor Johann de Bono and colleagues found that Abiraterone showed impressive benefits in a major clinical trial of men with early-stage prostate cancer.https://www.icr.ac.uk/news-archive%2fprevent-proteins-folding-and-you-may-stop-cancer-growinghttps://www.icr.ac.uk/news-archive%2fprevent-proteins-folding-and-you-may-stop-cancer-growingPrevent proteins folding and you may stop cancer growingA molecule that helps cancer cells to keep dividing could be a promising target for new treatmentshttps://www.icr.ac.uk/news-archive%2fnew-genetic-links-found-to-most-common-type-of-leukaemiahttps://www.icr.ac.uk/news-archive%2fnew-genetic-links-found-to-most-common-type-of-leukaemiaNew genetic links found to most common type of leukaemiaResearchers have identified four new regions of the genome linked with an increase in susceptibility to chronic lymphocytic leukaemia (CLL)https://www.icr.ac.uk/news-archive%2fnew-family-of-proteins-linked-to-major-role-in-cancerhttps://www.icr.ac.uk/news-archive%2fnew-family-of-proteins-linked-to-major-role-in-cancerNew family of proteins linked to major role in cancerScientists have described a new family of proteins that appear to play a key role in cancer https://www.icr.ac.uk/news-archive%2fcomputer-predictions-speed-up-search-for-potential-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fcomputer-predictions-speed-up-search-for-potential-cancer-treatmentsComputer predictions speed up search for potential cancer treatmentshttps://www.icr.ac.uk/news-archive%2fnew-mri-scan-could-help-improve-safety-of-brain-stem-cell-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-mri-scan-could-help-improve-safety-of-brain-stem-cell-treatmentsNew MRI scan could help improve safety of brain stem cell treatmentsAn MRI scan could one day help doctors check whether stem cells have transplanted effectively into the brain, say ICR researchers.https://www.icr.ac.uk/news-archive%2fcancer-researchers-find-new-%27helix-of-helix%27-structure-in-protein-foldinghttps://www.icr.ac.uk/news-archive%2fcancer-researchers-find-new-%27helix-of-helix%27-structure-in-protein-foldingCancer researchers find new 'helix of helix' structure in protein foldingScientists have discovered that units of a protein complex involved in cell division fit together in a 'helix of a helix' structure – an ordered spiral that turns left as it goes upwards, constantly twisting and turning.https://www.icr.ac.uk/news-archive%2fbody-s-natural-defence-carries-early-warning-system-for-recurring-cancershttps://www.icr.ac.uk/news-archive%2fbody-s-natural-defence-carries-early-warning-system-for-recurring-cancersBody’s natural defence carries early warning system for recurring cancersThe immune system can act as an early warning alarm for cancer recurrence, which could mean pre-emptive treatment before it takes hold again, say ICR scientistshttps://www.icr.ac.uk/news-archive%2fscientists-fingerprint-single-cancer-cells-to-map-cancer-s-family-tree-https://www.icr.ac.uk/news-archive%2fscientists-fingerprint-single-cancer-cells-to-map-cancer-s-family-tree-Scientists fingerprint single cancer cells to map cancer’s family tree A new method to take the DNA fingerprint of individual cancer cells is uncovering the true extent of cancer’s genetic diversity, new ICR research reveals. https://www.icr.ac.uk/news-archive%2fworld-s-largest-disease-database-will-use-artificial-intelligence-to-find-new-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fworld-s-largest-disease-database-will-use-artificial-intelligence-to-find-new-cancer-treatmentsWorld’s largest disease database will use artificial intelligence to find new cancer treatmentsICR database of 1.7 billion experiment results using A.I. like that for weather forecasts will find the cancer treatments of the future.https://www.icr.ac.uk/news-archive%2fvideo-updating-the-world%27s-largest-disease-databasehttps://www.icr.ac.uk/news-archive%2fvideo-updating-the-world%27s-largest-disease-databaseVideo: Updating the world's largest disease databaseDr Bissan Al-Lazikani tells us about the new version of CanSAR, and discusses the challenges of working with more data than would be generated by the Hubble space telescope in 1 million years.https://www.icr.ac.uk/news-archive%2fvideo-pioneering-cell-biologist-wins-young-scientist-awardhttps://www.icr.ac.uk/news-archive%2fvideo-pioneering-cell-biologist-wins-young-scientist-awardVideo: Pioneering cell biologist wins young scientist awardThe ICR's Dr Chris Bakal has won the 2013 British Association of Cancer Research/AstraZeneca Young Scientist Frank Rose Award for his groundbreaking research to understand the way cancer cells change shape and spread around the body. https://www.icr.ac.uk/news-archive%2fredirecting-our-immune-cells-to-help-fight-children%27s-cancerhttps://www.icr.ac.uk/news-archive%2fredirecting-our-immune-cells-to-help-fight-children%27s-cancerRedirecting our immune cells to help fight children's cancerThe ICR's Louis Chesler responds to news of a gene therapy approach to treating the childhood cancer neuroblastoma.https://www.icr.ac.uk/news-archive%2flatest-breast-cancer-treatment-advances-presented-at-ncri-conferencehttps://www.icr.ac.uk/news-archive%2flatest-breast-cancer-treatment-advances-presented-at-ncri-conferenceLatest breast cancer treatment advances presented at NCRI conferenceTwo researchers from The Institute of Cancer Research, London, have updated delegates at the UK's biggest cancer conference about the latest developments in breast cancer research.https://www.icr.ac.uk/news-archive%2ftop-award-for-discovery-of-resistance-busting-cancer-drugshttps://www.icr.ac.uk/news-archive%2ftop-award-for-discovery-of-resistance-busting-cancer-drugsTop award for discovery of resistance-busting cancer drugsICR scientists have won the 2013 Cancer Research UK Translational Cancer Research Prize for their pioneering work discovering how HSP90 works...https://www.icr.ac.uk/news-archive%2fvideo-top-award-for-discovery-of-resistance-busting-cancer-drugshttps://www.icr.ac.uk/news-archive%2fvideo-top-award-for-discovery-of-resistance-busting-cancer-drugsVideo: Top award for discovery of resistance-busting cancer drugsICR scientists have won the 2013 Cancer Research UK Translational Cancer Research Prize for their pioneering work discovering how HSP90 works, and a new class of drugs which can target it.https://www.icr.ac.uk/news-archive%2fexceptional-work-of-clinician-scientist-recognised-by-top-awardhttps://www.icr.ac.uk/news-archive%2fexceptional-work-of-clinician-scientist-recognised-by-top-awardExceptional work of clinician scientist recognised by top awardDr Nicola Valeri has received the 2013 AstraZeneca Student Prize Award, recognising the exceptional work of an early career cancer researcher.https://www.icr.ac.uk/news-archive%2fvideo-innovative-experiment-gives-new-understanding-of-key-cancer-proteinhttps://www.icr.ac.uk/news-archive%2fvideo-innovative-experiment-gives-new-understanding-of-key-cancer-proteinVideo: Innovative experiment gives new understanding of key cancer proteinA PhD project by an ICR student has made an important discovery about a protein involved in different types of cancer, using an innovative experimental technique for studying protein functions.https://www.icr.ac.uk/news-archive%2fdouble-pronged-attack-could-treat-common-children-s-cancerhttps://www.icr.ac.uk/news-archive%2fdouble-pronged-attack-could-treat-common-children-s-cancerDouble-pronged attack could treat common children’s cancerA dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growthhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-phd-panelhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-phd-panelThe PhD PanelOur big annual student recruitment drive has opened here at The Institute of Cancer Research, London. We're looking for the very best science students to take on our fully funded PhD projects in fields across the span of cancer research – in biology, chemistry, physics, computer science and mathematics.https://www.icr.ac.uk/news-archive%2fclinical-trial-moves-lung-cancer-drug-closer-to-uk-usehttps://www.icr.ac.uk/news-archive%2fclinical-trial-moves-lung-cancer-drug-closer-to-uk-useClinical trial moves lung cancer drug closer to UK useA recently approved lung cancer drug has moved closer to UK clinical use after ICR researchers provided the latest confirmation of its safety.https://www.icr.ac.uk/news-archive%2ficr-imaging-research-part-of-35m-funding-boosthttps://www.icr.ac.uk/news-archive%2ficr-imaging-research-part-of-35m-funding-boostICR imaging research part of £35m funding boostCANCER imaging is set to get a major boost from a £35 million initiative to develop cutting edge imaging technologies for cancer research.https://www.icr.ac.uk/news-archive%2fgene-discovery-points-to-immune-link-between-cancer-and-multiple-sclerosishttps://www.icr.ac.uk/news-archive%2fgene-discovery-points-to-immune-link-between-cancer-and-multiple-sclerosisGene discovery points to immune link between cancer and multiple sclerosisA genetic risk factor for multiple sclerosis (MS) has been linked to Hodgkin lymphoma, suggesting a common mechanism could be at work in the two diseases. https://www.icr.ac.uk/news-archive%2fnice-draft-guidance-recommends-new-prostate-cancer-drughttps://www.icr.ac.uk/news-archive%2fnice-draft-guidance-recommends-new-prostate-cancer-drugNICE draft guidance recommends new prostate cancer drugGuidance recommending ICR-developed drug enzalutamide for treating metastatic prostate cancer is welcomed as the latest in a drug development golden age.https://www.icr.ac.uk/news-archive%2finvading-cancers-secrete-enzyme-that-hijacks-healthy-tissuehttps://www.icr.ac.uk/news-archive%2finvading-cancers-secrete-enzyme-that-hijacks-healthy-tissueInvading cancers secrete enzyme that hijacks healthy tissueCancers secrete an enzyme allowing them to hijack the surrounding healthy tissue in order to create the right conditions for their invasion and spread, new research finds.https://www.icr.ac.uk/news-archive%2fthalidomide-therapy-effective-for-low-risk-myeloma-patientshttps://www.icr.ac.uk/news-archive%2fthalidomide-therapy-effective-for-low-risk-myeloma-patientsThalidomide therapy effective for low risk myeloma patientsThalidomide therapy can extend the lives of myeloma patients, but it isn’t suitable for everyone with the disease, ICR researchers have found.https://www.icr.ac.uk/news-archive%2f%27dna-tags%27-could-guide-treatment-for-advanced-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2f%27dna-tags%27-could-guide-treatment-for-advanced-ovarian-cancer'DNA tags' could guide treatment for advanced ovarian cancerChemical 'tags' on tumour DNA could help doctors decide which chemotherapy women with advanced ovarian cancer should get.https://www.icr.ac.uk/news-archive%2ftargeted-treatment-plus-chemotherapy-could-benefit-women-with-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2ftargeted-treatment-plus-chemotherapy-could-benefit-women-with-ovarian-cancerTargeted treatment plus chemotherapy could benefit women with ovarian cancerChemotherapy extends lives of women with ovarian cancer when used in tandem with a new type of targeted treatment, study shows.https://www.icr.ac.uk/news-archive%2fimaging-technique-could-assess-a-tumour-s-response-to-treatment-in-real-timehttps://www.icr.ac.uk/news-archive%2fimaging-technique-could-assess-a-tumour-s-response-to-treatment-in-real-timeImaging technique could assess a tumour’s response to treatment in real timeNew modelling technique could allow doctors to track metabolic reactions in tumours in real time, say ICR researchers. https://www.icr.ac.uk/news-archive%2fan-action-plan-to-tackle-critical-gaps-in-breast-cancer-research-https://www.icr.ac.uk/news-archive%2fan-action-plan-to-tackle-critical-gaps-in-breast-cancer-research-An action plan to tackle critical gaps in breast cancer research Research facilitated by Breast Cancer Campaign has identified the ten critical gaps that exist in breast cancer research.https://www.icr.ac.uk/news-archive%2fradiotherapy-could-spare-bladder-cancer-patients-surgeryhttps://www.icr.ac.uk/news-archive%2fradiotherapy-could-spare-bladder-cancer-patients-surgeryRadiotherapy could spare bladder cancer patients surgeryRadiotherapy is an effective treatment for aggressive bladder cancer and could improve quality of life by sparing patients surgery, according to an ICR study.https://www.icr.ac.uk/news-features%2flatest-features%2fultrasound-more-than-just-baby-pictureshttps://www.icr.ac.uk/news-features%2flatest-features%2fultrasound-more-than-just-baby-picturesUltrasound: more than just baby picturesFor many people, the word ‘ultrasound’ conjures up images of nurses and doctors showing grainy footage of foetuses to pregnant women. Although imaging unborn babies is undoubtedly important, the technology has an incredible array of clinical uses outside the obstetrician’s office.https://www.icr.ac.uk/news-archive%2finnovative-mri-scan-monitors-cancer-gene-therapyhttps://www.icr.ac.uk/news-archive%2finnovative-mri-scan-monitors-cancer-gene-therapyInnovative MRI scan monitors cancer gene therapyA new type of MRI scan could be used to monitor the effectiveness of an innovative new gene therapy for cancer, say scientists from The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fstudy-of-%27sister%27-stem-cells-uncovers-new-cancer-cluehttps://www.icr.ac.uk/news-archive%2fstudy-of-%27sister%27-stem-cells-uncovers-new-cancer-clueStudy of 'sister' stem cells uncovers new cancer clueUsing a new technique for examining stem cells, ICR scientists uncover dramatic differences in the gene expression levels between identical 'sister' pairs.https://www.icr.ac.uk/news-archive%2fbacit-limited-makes-first-investment-in-icr-drug-development-programmehttps://www.icr.ac.uk/news-archive%2fbacit-limited-makes-first-investment-in-icr-drug-development-programmeBACIT Limited makes first investment in ICR drug development programmeBACIT Limited, an innovative investment company with a financial model designed to help fund the battle against cancer has invested in its first drug development projecthttps://www.icr.ac.uk/news-archive%2fless-is-more-for-radiotherapy-in-early-breast-cancershttps://www.icr.ac.uk/news-archive%2fless-is-more-for-radiotherapy-in-early-breast-cancersLess is more for radiotherapy in early breast cancersLess is more for radiotherapy in early breast cancershttps://www.icr.ac.uk/news-archive%2fthe-wellcome-trust-award-4-million-to-the-icrhttps://www.icr.ac.uk/news-archive%2fthe-wellcome-trust-award-4-million-to-the-icrThe Wellcome Trust award £4 million to the ICRThe Institute of Cancer Research, London, has been awarded £4 million from the Wellcome Trust to continue their groundbreaking work developing cancer drugs that inhibit the PARP enzyme tankyrase.https://www.icr.ac.uk/news-archive%2fstatement-in-reaction-to-the-science-and-technology-committee-report-on-clinical-trialshttps://www.icr.ac.uk/news-archive%2fstatement-in-reaction-to-the-science-and-technology-committee-report-on-clinical-trialsStatement in reaction to the Science and Technology Committee report on clinical trialsThe ICR support wider registration and reporting of clinical trials, but explain that a more pressing issue is the burden of EU regulation which is holding up clinical trials to find better cancer treatments.https://www.icr.ac.uk/news-archive%2fnew-research-turns-cancer-s-own-weapons-against-itselfhttps://www.icr.ac.uk/news-archive%2fnew-research-turns-cancer-s-own-weapons-against-itselfNew research turns cancer’s own weapons against itselfScientists have discovered a potential new way of treating a type of blood cancer called myeloma that poisons cancer cells with their own secretions.https://www.icr.ac.uk/news-archive%2fadvanced-scan-looks-inside-tumours-to-tell-if-cancer-cells-have-diedhttps://www.icr.ac.uk/news-archive%2fadvanced-scan-looks-inside-tumours-to-tell-if-cancer-cells-have-diedAdvanced scan looks inside tumours to tell if cancer cells have diedA high-tech imaging technique can allow scientists to see into the middle of tumours and tell whether treatments are killing the cancer cells inside, new research reports.https://www.icr.ac.uk/news-archive%2fcollagen-clue-reveals-new-drug-target-for-untreatable-form-of-lung-cancerhttps://www.icr.ac.uk/news-archive%2fcollagen-clue-reveals-new-drug-target-for-untreatable-form-of-lung-cancerCollagen clue reveals new drug target for untreatable form of lung cancerCollagen, the stuff of ligaments and skin, and the most abundant protein in the human body, has an extraordinary role in triggering chemical signals that help protect the body from cancer, a new ICR study reveals.https://www.icr.ac.uk/news-archive%2ficr-scientists-find-genes-for-common-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2ficr-scientists-find-genes-for-common-childhood-leukaemiaICR scientists find genes for common childhood leukaemiaThe largest study of its kind has linked two inherited genetic variants with an increase in susceptibility to acute lymphoblastic leukaemia.https://www.icr.ac.uk/news-archive%2fresearchers-reveal-new-insights-into-drug-resistance-in-metastatic-renal-cancerhttps://www.icr.ac.uk/news-archive%2fresearchers-reveal-new-insights-into-drug-resistance-in-metastatic-renal-cancerResearchers reveal new insights into drug resistance in metastatic renal cancerResponses to treatment among metastatic renal cancers are closely linked with changes in tumour blood vessel supply, finds new research from The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fhighly-potent-new-drug-targets-cancer-cells%27-dna-repairhttps://www.icr.ac.uk/news-archive%2fhighly-potent-new-drug-targets-cancer-cells%27-dna-repairHighly potent new drug targets cancer cells' DNA repairA drug which has shown promise in early human trials for cancer could be up to 200 times more potent than others of its type, a study from The Institute of Cancer Research, London, has shown.https://www.icr.ac.uk/news-archive%2fnew-treatments-target-resistant-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fnew-treatments-target-resistant-bowel-cancerNew treatments target resistant bowel cancerTwo new drug classes appear to overcome resistance in colorectal cancer cells to one of our built in defences against the disease.https://www.icr.ac.uk/news-archive%2fnew-scan-could-help-in-treatment-planning-for-individual-patientshttps://www.icr.ac.uk/news-archive%2fnew-scan-could-help-in-treatment-planning-for-individual-patientsNew scan could help in treatment planning for individual patientsA type of non-invasive imaging method could help assess whether cancer patients are likely to respond to radiotherapy, a new study has shown.https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fof-ducks-and-tumourshttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fof-ducks-and-tumoursOf Ducks and Tumourshttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fcancerresearch-why-aren-t-we-trendinghttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fcancerresearch-why-aren-t-we-trending#CancerResearch: why aren’t we trending?https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fintermittent-drug-strategies-the-new-era-of-cancer-treatmenthttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fintermittent-drug-strategies-the-new-era-of-cancer-treatmentIntermittent drug strategies: the new era of cancer treatmentIn 2001, the Novartis drug imatinib revolutionised the treatment of chronic myeloid leukaemia, and so began a highly exciting era in cancer treatment: the era of targeted drug therapies. These differ from traditional chemotherapy drugs in their ability to knock down a specific biological pathway in a cancer cell that is essential for its malignant behaviour.https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2funravelling-the-complexity-of-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2funravelling-the-complexity-of-cancerUnravelling the complexity of cancerSo… when do you think they’ll find a cure for cancer?https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fcould-a-fly-save-your-lifehttps://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013%2fcould-a-fly-save-your-lifeCould a fly save your life?The answer to this seemingly absurd question is, quite definitely, yes. Now, I don’t mean that a fly is going to give you mouth-to-mouth or save you from a burning building. But if you ever have to take pharmaceutical drugs for a health condition such as cancer, it is quite possible that those drugs will have been developed with the help of research conducted using fruit flies – those same small flies that swarm around your compost heap in the summer.https://www.icr.ac.uk/news-features%2flatest-features%2filluminating-myelomahttps://www.icr.ac.uk/news-features%2flatest-features%2filluminating-myelomaIlluminating myelomaImagine you’re in a dark room trying to solve a puzzle, but your only source of light is a narrow slit that illuminates just a single piece at a time. That might give some idea what it’s like to look for signs that a cancer has recurred for patients with myeloma, a cancer of the bone marrow.https://www.icr.ac.uk/news-archive%2fmajor-study-links-ageing-gene-to-blood-cancerhttps://www.icr.ac.uk/news-archive%2fmajor-study-links-ageing-gene-to-blood-cancerMajor study links ageing gene to blood cancerICR scientists find four new genetic variants linked to myeloma, including a gene called TERC, previously linked to the ageing process.https://www.icr.ac.uk/news-archive%2fchemotherapy-reduces-testicular-cancer-relapse-and-side-effectshttps://www.icr.ac.uk/news-archive%2fchemotherapy-reduces-testicular-cancer-relapse-and-side-effectsChemotherapy reduces testicular cancer relapse and side effectsGiving men with stage 2 testicular cancer a single dose of carboplatin alongside radiotherapy could improve treatment effectiveness and reduce the risk of long-term side-effects, an ICR study reports.https://www.icr.ac.uk/news-archive%2ficr-researchers-in-new-international-trial-for-neuroblastomahttps://www.icr.ac.uk/news-archive%2ficr-researchers-in-new-international-trial-for-neuroblastomaICR researchers in new international trial for neuroblastomaNew 'BEACON' trial led by ICR scientists aims to tackle treatment-resistant form of childhood cancer neuroblastoma. https://www.icr.ac.uk/news-archive%2fexperimental-breast-cancer-drugs-could-treat-lung-cancer-toohttps://www.icr.ac.uk/news-archive%2fexperimental-breast-cancer-drugs-could-treat-lung-cancer-tooExperimental breast cancer drugs could treat lung cancer tooScientists discover that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer. https://www.icr.ac.uk/news-archive%2ftrial-compares-new-drug-combinations-for-breast-cancerhttps://www.icr.ac.uk/news-archive%2ftrial-compares-new-drug-combinations-for-breast-cancerTrial compares new drug combinations for breast cancerA combination of two hormone therapy drugs does not provide significant clinical benefit over single-drug treatments, according to a trial.https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013https://www.icr.ac.uk/news-features%2flatest-features%2fmel-greaves-science-writer-of-the-year-2013Science Writer of the Year 2013The ICR’s annual Mel Greaves Science Writing Prize – named in honour of the ICR Professor of Cell Biology and popular science author Professor Mel Greaves – aims to encourage imaginative writing about science that is engaging and understandable not only for fellow scientists but also for the wider public.https://www.icr.ac.uk/news-archive%2fluke-johnson-leading-entrepreneur-takes-the-helm-at-the-icrhttps://www.icr.ac.uk/news-archive%2fluke-johnson-leading-entrepreneur-takes-the-helm-at-the-icrLuke Johnson, leading entrepreneur, takes the helm at the ICRThis week, Luke Johnson, one of the UK’s most successful entrepreneurs and former Chairman of Channel 4, joins the ICR as Chairman.https://www.icr.ac.uk/news-archive%2fcancer-research-technology-the-institute-of-cancer-research-and-merck-serono-sign-licensing-deal-on-molecules-that-block-the-wnt-signalling-pathwayhttps://www.icr.ac.uk/news-archive%2fcancer-research-technology-the-institute-of-cancer-research-and-merck-serono-sign-licensing-deal-on-molecules-that-block-the-wnt-signalling-pathwayCancer Research Technology, The Institute of Cancer Research and Merck Serono sign licensing deal on molecules that block the WNT signalling pathwayThe Institute of Cancer Research, London, Cancer Research Technology, and Merck Serono have signed a licensing deal today extending an alliance to discover and develop anticancer drugs that block the WNT signalling pathway.https://www.icr.ac.uk/news-archive%2fmen-with-incurable-prostate-cancer-living-twice-as-long-as-decade-agohttps://www.icr.ac.uk/news-archive%2fmen-with-incurable-prostate-cancer-living-twice-as-long-as-decade-agoMen with incurable prostate cancer living twice as long as decade agoPatients with advanced prostate cancer treated with the latest therapies are living twice as long as a decade ago, a new ICR analysis reveals.https://www.icr.ac.uk/news-archive%2fvideo-men-with-advanced-prostate-cancer-are-living-longerhttps://www.icr.ac.uk/news-archive%2fvideo-men-with-advanced-prostate-cancer-are-living-longerVideo: Men with advanced prostate cancer are living longerPatients with advanced prostate cancer treated with the latest therapies are living on average for more than twice as long as a decade ago. Study leader Professor Johann de Bono told us why:https://www.icr.ac.uk/news-archive%2fstudy-shows-benefit-of-thalidomide-in-treatment-of-myelomahttps://www.icr.ac.uk/news-archive%2fstudy-shows-benefit-of-thalidomide-in-treatment-of-myelomaStudy shows benefit of thalidomide in treatment of myelomaThe controversial drug thalidomide could play an important role in treatment of myeloma by eradicating the final, residual traces of cancerous cells in patients.https://www.icr.ac.uk/news-archive%2flosing-weight-could-lower-women%27s-risk-of-breast-cancerhttps://www.icr.ac.uk/news-archive%2flosing-weight-could-lower-women%27s-risk-of-breast-cancerLosing weight could lower women's risk of breast cancerLosing weight could help women lower their risk of developing breast cancer by reducing levels of key sex hormones, a new study reports.https://www.icr.ac.uk/news-archive%2fnew-drug-that-targets-dna-packaging-passes-phase-i-trialhttps://www.icr.ac.uk/news-archive%2fnew-drug-that-targets-dna-packaging-passes-phase-i-trialNew drug that targets DNA packaging passes phase I trialA new potential cancer drug is due to move into trials to test its effectiveness in patients with cancer, after a successful phase I trial led by Institute of Cancer Research, London researchers at the Royal Marsden NHS Foundation Trust.https://www.icr.ac.uk/news-archive%2fnew-drug-targets-systems-protecting-cancer-from-dna-damagehttps://www.icr.ac.uk/news-archive%2fnew-drug-targets-systems-protecting-cancer-from-dna-damageNew drug targets systems protecting cancer from DNA damageA new drug that blocks the ability of tumours to repair their DNA has shown positive results in a phase I trial including patients with ovarian, breast, prostate and lung cancer.https://www.icr.ac.uk/news-features%2flatest-features%2fkinase-inhibitors-the-science-behind-a-revolutionhttps://www.icr.ac.uk/news-features%2flatest-features%2fkinase-inhibitors-the-science-behind-a-revolutionKinase inhibitors: the science behind a revolutionA little more than a decade ago, the prospects for people with chronic myelogenous leukaemia (CML) were rather bleak. Common treatments included high-risk bone marrow transplants, which required at least four weeks in hospital and often led to severe complications down the line. https://www.icr.ac.uk/news-archive%2fhigh-tech-scan-could-help-women-avoid-radical-cervical-cancer-surgeryhttps://www.icr.ac.uk/news-archive%2fhigh-tech-scan-could-help-women-avoid-radical-cervical-cancer-surgeryHigh-tech scan could help women avoid radical cervical cancer surgeryNew high-resolution MRI scan technology gives doctors and patients the detailed information they need to plan precisely targeted surgery.https://www.icr.ac.uk/news-archive%2fscientists-uncover-switch-flipping-stem-cell-mechanism-that-could-lead-to-new-breast-cancer-therapieshttps://www.icr.ac.uk/news-archive%2fscientists-uncover-switch-flipping-stem-cell-mechanism-that-could-lead-to-new-breast-cancer-therapiesScientists uncover ‘switch-flipping’ stem cell mechanism that could lead to new breast cancer therapiesThe discovery of a pathway that helps stem cells grow into different types of breast tissue could lead to new treatments for aggressive breast cancer.https://www.icr.ac.uk/news-archive%2fdouble-pronged-attack-overcomes-bladder-cancer-s-drug-resistancehttps://www.icr.ac.uk/news-archive%2fdouble-pronged-attack-overcomes-bladder-cancer-s-drug-resistanceDouble-pronged attack overcomes bladder cancer’s drug resistanceCombining two different targeted therapies could greatly increase the effectiveness of bladder cancer treatments by blocking a tumour’s path to drug resistance, a new study reports.https://www.icr.ac.uk/news-archive%2fpioneers-receive-honorary-icr-degreeshttps://www.icr.ac.uk/news-archive%2fpioneers-receive-honorary-icr-degreesPioneers receive honorary ICR degreesPostgraduate degrees have been awarded to over 80 students, while honours were received by Professor Dame Janet Husband, Professor Sir Mike Stratton and The Honourable Thomas Henderson for their contributions to cancer research.https://www.icr.ac.uk/news-archive%2f-homing-radioactive-injection-shows-benefit-in-prostate-cancer-trialhttps://www.icr.ac.uk/news-archive%2f-homing-radioactive-injection-shows-benefit-in-prostate-cancer-trial‘Homing’ radioactive injection shows benefit in prostate cancer trialA new treatment for advanced prostate cancer that homes in on tumours has shown significant patient benefit in clinical trials, say ICR researchers.https://www.icr.ac.uk/news-features%2flatest-features%2fusing-cancer-epidemiology-to-understand-the-causes-of-the-diseasehttps://www.icr.ac.uk/news-features%2flatest-features%2fusing-cancer-epidemiology-to-understand-the-causes-of-the-diseaseUsing cancer epidemiology to understand the causes of the diseaseThe roots of the modern-day study of cancer risk lie all the way back in the nineteenth century at a nunnery in Italy. It was here in 1842 that a doctor called Rigoni-Stern noticed that nuns virtually never suffered from cervical cancer but had a higher than usual incidence of breast cancer, and wondered whether the explanation might lie in the nuns’ celibacy.https://www.icr.ac.uk/news-archive%2fnew-report-pushes-for-stratified-medicinehttps://www.icr.ac.uk/news-archive%2fnew-report-pushes-for-stratified-medicineNew report pushes for stratified medicineRead the ICR response to the Academy of Medical Sciences report, which makes recommendations to remove barriers to the development and adoption of stratified medicine.https://www.icr.ac.uk/news-archive%2fmeasles-virus-improves-radiotherapy-treatmenthttps://www.icr.ac.uk/news-archive%2fmeasles-virus-improves-radiotherapy-treatmentMeasles virus improves radiotherapy treatmentA new combined treatment using the measles virus to target cancer could greatly improve bowel and head & neck cancer treatment, say ICR researchershttps://www.icr.ac.uk/news-archive%2fnew-tumour-tracker-could-target-moving-lung-tumours-as-patients-breathehttps://www.icr.ac.uk/news-archive%2fnew-tumour-tracker-could-target-moving-lung-tumours-as-patients-breatheNew tumour tracker could target moving lung tumours as patients breatheA new, targeted approach to radiotherapy could improve treatment of lung cancer by tracking a tumour’s movements as patients breathe in and out.https://www.icr.ac.uk/news-archive%2fscientists-identify-new-genetic-driver-for-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-identify-new-genetic-driver-for-breast-cancerScientists identify new genetic driver for breast cancerAn over-active gene called GNAS may help drive the growth of some types of difficult-to-treat breast cancers, ICR scientists have found.https://www.icr.ac.uk/news-features%2flatest-features%2fdesigning-precision-drugs-for-children-s-cancershttps://www.icr.ac.uk/news-features%2flatest-features%2fdesigning-precision-drugs-for-children-s-cancersDesigning precision drugs for children’s cancersOver the last decade, advances in technology have triggered an explosion in our knowledge about the biology of adult cancers – but we know far less about what causes cancers in children.https://www.icr.ac.uk/news-features%2flatest-features%2fbreast-cancer-patients-with-gene-fault-at-increased-risk-of-disease-returninghttps://www.icr.ac.uk/news-features%2flatest-features%2fbreast-cancer-patients-with-gene-fault-at-increased-risk-of-disease-returningBreast cancer patients with gene fault at increased risk of disease returningWomen with breast cancer who have inherited a damaged version of a gene called CHEK2 are at increased risk of dying from the disease, a major new study reports.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-promise-of-immunotherapy---and-bridging-the-funding-gaphttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-promise-of-immunotherapy---and-bridging-the-funding-gapThe promise of immunotherapy - and bridging the funding gapThe ICR's Professor Paul Workman, has featured in a BBC Newsnight investigation into promising new cancer treatment approaches including immunotherapy – and the financial stumbling blocks that could stop these advances reaching patients.https://www.icr.ac.uk/news-features%2flatest-features%2fclinical-trial-tests-new-combination-treatment-for-advanced-prostate-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fclinical-trial-tests-new-combination-treatment-for-advanced-prostate-cancerClinical trial tests new combination treatment for advanced prostate cancerScientists hope to reverse resistance that can develop to the next-generation prostate cancer treatment abiraterone by combining it with a promising experimental treatment, and believe the combination also has potential when given at an earlier stage to prevent resistance developing.https://www.icr.ac.uk/news-features%2flatest-features%2fhigh-quality-of-our-clinical-trials-confirmedhttps://www.icr.ac.uk/news-features%2flatest-features%2fhigh-quality-of-our-clinical-trials-confirmedHigh quality of our clinical trials confirmedThe Institute of Cancer Research, London, has successfully retained its status as one of the UK’s specialist centres for designing and running clinical trials.https://www.icr.ac.uk/news-archive%2fnew-breast-cancer-test-will-help-women-avoid-unnecessary-chemotherapyhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-test-will-help-women-avoid-unnecessary-chemotherapyNew breast cancer test will help women avoid unnecessary chemotherapyA new genetic test for breast cancer will help identify those women who should be considered for chemo, and those who can avoid it, say ICR researchers.https://www.icr.ac.uk/news-features%2flatest-features%2ffrom-caterpillars-to-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2ffrom-caterpillars-to-cancerFrom caterpillars to cancerHow researchers are beginning to exploit the mysterious phenomenon of epigeneticshttps://www.icr.ac.uk/news-archive%2freaction-to-the-comprehensive-spending-reviewhttps://www.icr.ac.uk/news-archive%2freaction-to-the-comprehensive-spending-reviewReaction to the Comprehensive Spending ReviewThe ICR's Chief Executive, Professor Alan Ashworth, comments on the potential impact of today's budget announcements on scientific research in the UK.https://www.icr.ac.uk/news-archive%2fnew-national-guidelines-on-breast-cancer-screeninghttps://www.icr.ac.uk/news-archive%2fnew-national-guidelines-on-breast-cancer-screeningNew national guidelines on breast cancer screeningRead our response to today’s launch by NICE of new national guidelines on familial breast cancer, which expand access to BRCA testing.https://www.icr.ac.uk/news-archive%2ffirst-stage-study-finds-potential-new-drugs-for-childhood-cancerhttps://www.icr.ac.uk/news-archive%2ffirst-stage-study-finds-potential-new-drugs-for-childhood-cancerFirst stage study finds potential new drugs for childhood cancerScientists at the ICR have made a step towards new targeted drugs for children with the highest-risk form of a childhood cancer called neuroblastoma.https://www.icr.ac.uk/news-archive%2ftesting-micro-rnas-could-aid-myeloma-diagnosishttps://www.icr.ac.uk/news-archive%2ftesting-micro-rnas-could-aid-myeloma-diagnosisTesting micro-RNAs could aid myeloma diagnosisTiny pieces of genetic material called micro-RNAs – miRNAs for short – could help improve diagnosis in people with myeloma, a study at The Institute of Cancer Research, London has shown.https://www.icr.ac.uk/news-archive%2fvideo-new-targeted-drugs-for-childhood-cancer-pass-first-hurdlehttps://www.icr.ac.uk/news-archive%2fvideo-new-targeted-drugs-for-childhood-cancer-pass-first-hurdleVideo: New targeted drugs for childhood cancer pass first hurdleScientists at The Institute of Cancer Research, London, have made huge progress towards testing two new targeted drugs for children with the highest-risk form of a childhood cancer called neuroblastoma. Pre-clinical study results show that the growth of cancerous neuroblastoma cells with an overactive MYCN gene were disrupted after treatment with two Aurora kinase inhibitors called MLN8054 and MLN8237. Dr Louis Chesler, who co-led of the study, tells us more about the difficulties in treating neuroblastoma, and how these new drugs may be used to treat children.https://www.icr.ac.uk/news-archive%2fnew-research-sheds-light-on-treatment-resistant-breast-cancershttps://www.icr.ac.uk/news-archive%2fnew-research-sheds-light-on-treatment-resistant-breast-cancersNew research sheds light on treatment-resistant breast cancersICR scientists have identified a new way of treating breast cancers that could overcome their resistance to a vitally important class of cancer drugs.https://www.icr.ac.uk/news-archive%2fvirus-combines-with-radiotherapy-to-kill-cancer-cellshttps://www.icr.ac.uk/news-archive%2fvirus-combines-with-radiotherapy-to-kill-cancer-cellsVirus combines with radiotherapy to kill cancer cellsA virus strain used to vaccinate people against smallpox could significantly improve treatment of aggressive skin cancer, an ICR study reports.https://www.icr.ac.uk/news-archive%2f-next-generation-cancer-drug-shows-promise-in-early-trialhttps://www.icr.ac.uk/news-archive%2f-next-generation-cancer-drug-shows-promise-in-early-trial‘Next generation’ cancer drug shows promise in early trialA new potential cancer drug has shown promising results in an early stage clinical trial. The drug, called AUY922, could help lead to a new way to treat a wide range of cancers including breast and lung cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2fchemistry-computers-and-cancer-drugshttps://www.icr.ac.uk/news-features%2flatest-features%2fchemistry-computers-and-cancer-drugsChemistry, computers and cancer drugsDrug discovery is a complex business – particularly in a field like cancer, where new-style treatments are increasingly aimed at specific molecular features of tumours. https://www.icr.ac.uk/news-archive%2fgenes-help-shape-shifting-skin-cancer-cells-to-spreadhttps://www.icr.ac.uk/news-archive%2fgenes-help-shape-shifting-skin-cancer-cells-to-spreadGenes help shape-shifting skin cancer cells to spreadScientists at the ICR have identified a set of genes that allow melanoma cells to change rapidly between two shapes in order to escape from the skin and spread around the body.https://www.icr.ac.uk/news-archive%2fsupreme-court-of-the-united-states-ruling-on-gene-patentinghttps://www.icr.ac.uk/news-archive%2fsupreme-court-of-the-united-states-ruling-on-gene-patentingSupreme Court of the United States ruling on gene patentingThe ICR's Chief Executive Professor Alan Ashworth has made a statement regarding gene patenting in advance of an upcoming Supreme Court decision.https://www.icr.ac.uk/news-archive%2fmechanism-of-cell-cycle-regulation-molecules-revealedhttps://www.icr.ac.uk/news-archive%2fmechanism-of-cell-cycle-regulation-molecules-revealedMechanism of cell cycle regulation molecules revealedKey insights into the workings of regulatory molecules that are implicated in the development of solid tumours have been revealed by scientists at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fnew-cancer-drug-shows-impressive-results-in-patients-with-brca-mutationshttps://www.icr.ac.uk/news-archive%2fnew-cancer-drug-shows-impressive-results-in-patients-with-brca-mutationsNew cancer drug shows impressive results in patients with BRCA mutationsA new potential cancer drug designed to fight tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.https://www.icr.ac.uk/news-archive%2ficr-researchers-present-at-global-cancer-conferencehttps://www.icr.ac.uk/news-archive%2ficr-researchers-present-at-global-cancer-conferenceICR researchers present at global cancer conferenceResearchers from the ICR will be presenting their findings at the 2013 American Society of Clinical Oncology Annual Meeting, which opens today in Chicago.https://www.icr.ac.uk/news-archive%2fflower-shape-and-new-treatments-for-myelomahttps://www.icr.ac.uk/news-archive%2fflower-shape-and-new-treatments-for-myelomaFlower shape and new treatments for myelomaICR scientists find a genetic process that determines a flower's shape could also underlie the development of blood cancer.https://www.icr.ac.uk/news-archive%2fa-new-model-for-genetic-testing-in-cancer-patientshttps://www.icr.ac.uk/news-archive%2fa-new-model-for-genetic-testing-in-cancer-patientsA new model for genetic testing in cancer patientsAn ICR research programme that will lay the foundations for anyone with cancer to have access to genetic testing has been launched with £2.7 million funding from the Wellcome Trust.https://www.icr.ac.uk/news-archive%2fhigh-tech-scans-monitor-activity-of-new-drug-treatmentshttps://www.icr.ac.uk/news-archive%2fhigh-tech-scans-monitor-activity-of-new-drug-treatmentsHigh-tech scans monitor activity of new drug treatmentsMonitoring lactate within tumours using high-tech scans could tell doctors whether or not cancer drugs are working, new research reveals.https://www.icr.ac.uk/news-archive%2fstatement-about-brca-genetic-research-and-testinghttps://www.icr.ac.uk/news-archive%2fstatement-about-brca-genetic-research-and-testingStatement about BRCA genetic research and testingStatement from the ICR about BRCA genetic research and testing, in the light of the announcement by Angelina Jolie that she has had a double mastectomy to reduce her BRCA1-associated risk of developing breast cancer.https://www.icr.ac.uk/news-archive%2flarge-study-identifies-nine-new-genomic-regions-linked-to-testicular-cancerhttps://www.icr.ac.uk/news-archive%2flarge-study-identifies-nine-new-genomic-regions-linked-to-testicular-cancerLarge study identifies nine new genomic regions linked to testicular cancerA study from the ICR involving over 2,000 men has identified nine new regions of the genome associated with testicular cancer.https://www.icr.ac.uk/news-archive%2ftiming-of-hodgkin-lymphoma-radiotherapy-to-women-s-first-period-critical-for-breast-cancer-risk-https://www.icr.ac.uk/news-archive%2ftiming-of-hodgkin-lymphoma-radiotherapy-to-women-s-first-period-critical-for-breast-cancer-risk-Timing of Hodgkin lymphoma radiotherapy to women’s first period critical for breast cancer risk ICR scientists find radiotherapy near a woman's first period increases breast cancer risk, but pregnancy doesn't increase danger.https://www.icr.ac.uk/news-features%2flatest-features%2fmapping-cancer-s-networkshttps://www.icr.ac.uk/news-features%2flatest-features%2fmapping-cancer-s-networksMapping cancer’s networksBuilding up a London Underground-style map of signalling pathways is pinpointing cancer’s weak pointshttps://www.icr.ac.uk/news-archive%2fresearchers-identify-indicator-for-drug-resistant-head-and-neck-cancershttps://www.icr.ac.uk/news-archive%2fresearchers-identify-indicator-for-drug-resistant-head-and-neck-cancersResearchers identify indicator for drug-resistant head and neck cancersScientists have uncovered a secret to why many tumours develop resistance to a class of targeted drug treatments.https://www.icr.ac.uk/news-archive%2fnew-dna-blood-test-could-increase-access-to-herceptinhttps://www.icr.ac.uk/news-archive%2fnew-dna-blood-test-could-increase-access-to-herceptinNew DNA blood test could increase access to HerceptinICR scientists believe a new blood test for women with breast cancer could identify more women who will benefit from the targeted treatment Herceptin without the need for uncomfortable biopsies.https://www.icr.ac.uk/news-archive%2fa-double-pronged-attack-on-testicular-seminomahttps://www.icr.ac.uk/news-archive%2fa-double-pronged-attack-on-testicular-seminomaA double-pronged attack on testicular seminomaGiving patients a single dose of chemotherapy alongside radiotherapy could improve outcomes for patients with a type of testicular cancer, a new study by The Institute of Cancer Research, London, suggests.https://www.icr.ac.uk/news-archive%2fnew-alliance-to-bring-lung-cancer-trials-to-population-of-six-millionhttps://www.icr.ac.uk/news-archive%2fnew-alliance-to-bring-lung-cancer-trials-to-population-of-six-millionNew Alliance to bring lung cancer trials to population of six millionLeading research institutions and hospitals across London today (Thursday, 25 April) unite to transform the care of lung cancer with plans to invite patients over a population of six million into a pioneering new programme of clinical trials.https://www.icr.ac.uk/news-archive%2fscientists-track-down-prostate-cancer-risk-to-key-ageing-genehttps://www.icr.ac.uk/news-archive%2fscientists-track-down-prostate-cancer-risk-to-key-ageing-geneScientists track down prostate cancer risk to key ageing geneResearchers have taken a step further in understanding prostate cancer genetics by fine-mapping an area of a chromosome associated with prostate cancer risk.https://www.icr.ac.uk/news-archive%2fprostate-cancer-patients-with-brca2-mutations-require-urgent-treatmenthttps://www.icr.ac.uk/news-archive%2fprostate-cancer-patients-with-brca2-mutations-require-urgent-treatmentProstate cancer patients with BRCA2 mutations require urgent treatmentMen with the faulty gene who develop prostate cancer need immediate surgery or radiotherapy, as their disease is more aggressive than other types, an ICR study has found.https://www.icr.ac.uk/news-archive%2fidentical-twins-genes-reveal-the-silent-beginnings-of-leukaemia-https://www.icr.ac.uk/news-archive%2fidentical-twins-genes-reveal-the-silent-beginnings-of-leukaemia-Identical twins’ genes reveal the ‘silent beginnings’ of leukaemia.A unique study sequencing the entire genomes of identical twins with leukaemia has identified the first mutations sparking the disease, which could be ideal targets for new cancer drugs.https://www.icr.ac.uk/news-archive%2ficr-scientists-present-at-aacr-conferencehttps://www.icr.ac.uk/news-archive%2ficr-scientists-present-at-aacr-conferenceICR scientists present at AACR conferencePromising results of clinical trials and the future direction of cancer research are amongst the topics that ICR scientists have been discussing at the American Association for Cancer Research conference this weekend.https://www.icr.ac.uk/news-archive%2fresearchers-discover-drug-target-for-incurable-childhood-brain-cancerhttps://www.icr.ac.uk/news-archive%2fresearchers-discover-drug-target-for-incurable-childhood-brain-cancerResearchers discover drug target for incurable childhood brain cancerICR scientists have uncovered the genetic causes of a rare but lethal form of childhood cancer – opening up the prospect of an effective treatment for the disease for the first time.https://www.icr.ac.uk/news-features%2flatest-features%2fcoordinating-the-global-hunt-for-prostate-cancer-geneshttps://www.icr.ac.uk/news-features%2flatest-features%2fcoordinating-the-global-hunt-for-prostate-cancer-genesCoordinating the global hunt for prostate cancer genesFor Professor Ros Eeles, her world-leading work in prostate cancer genetics is about much more than the thrill of scientific discovery. As not only a researcher but a practicing doctor, she is fired by a desire to turn the once theoretical world of cancer genetics into practical advances that have real benefits for patients.https://www.icr.ac.uk/news-archive%2fhuge-study-could-lead-to-genetic-screening-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fhuge-study-could-lead-to-genetic-screening-for-prostate-cancerHuge study could lead to genetic screening for prostate cancerGenetic screening for prostate cancer is now a real possibility following results from the largest-ever study into inherited risk factors for the disease. A clinical trial is likely to start this year as a result of the findings.https://www.icr.ac.uk/news-archive%2fground-breaking-discovery-into-the-genetic-causes-of-breast-cancerhttps://www.icr.ac.uk/news-archive%2fground-breaking-discovery-into-the-genetic-causes-of-breast-cancerGround-breaking discovery into the genetic causes of breast cancerScientists have discovered 49 new common genetic changes which can lead to the development of breast cancer, more than doubling the number previously known.https://www.icr.ac.uk/news-archive%2fluke-johnson-is-appointed-chairman-of-the-icr-https://www.icr.ac.uk/news-archive%2fluke-johnson-is-appointed-chairman-of-the-icr-Luke Johnson is appointed Chairman of the ICR Leading entrepreneur and former Chairman of Channel 4 will take the helm at the UK’s top academic research centre in August.https://www.icr.ac.uk/news-archive%2fcancer-research-technology-and-the-institute-of-cancer-research-enter-collaboration-with-janssen-to-discover-multiple-myeloma-drughttps://www.icr.ac.uk/news-archive%2fcancer-research-technology-and-the-institute-of-cancer-research-enter-collaboration-with-janssen-to-discover-multiple-myeloma-drugCancer Research Technology and The Institute of Cancer Research enter collaboration with Janssen to discover multiple myeloma drugA collaboration between the ICR, Cancer Research Technology and Janssen Biotech will seek to discover new multiple myeloma drugs by targeting a key protein on a cell-signalling route called the unfolded protein response (UPR) pathway.https://www.icr.ac.uk/news-archive%2fscientists-unlock-hidden-potential-of-cutting-edge-cancer-drugshttps://www.icr.ac.uk/news-archive%2fscientists-unlock-hidden-potential-of-cutting-edge-cancer-drugsScientists unlock hidden potential of cutting-edge cancer drugsA class of cutting-edge cancer drugs could keep patients alive for much longer than they do now following a major new discovery about exactly how they attack tumours.https://www.icr.ac.uk/news-archive%2fgene-fault-has-domino-effect-on-cancer-riskhttps://www.icr.ac.uk/news-archive%2fgene-fault-has-domino-effect-on-cancer-riskGene fault has domino effect on cancer riskA team at the ICR have found some cancer patients inherit a weak point in their DNA that appears to leave one of their chromosomes vulnerable to damage.https://www.icr.ac.uk/news-archive%2fawards-for-icr-researchers-maria-and-vickyhttps://www.icr.ac.uk/news-archive%2fawards-for-icr-researchers-maria-and-vickyAwards for ICR researchers, Maria and VickyVicky Bull, PhD student, was awarded the ‘BMUS Young Investigator's Award’ and Dr Maria Vinci, Post Doc Training Fellow, is nominated for a SET for BRITAIN Award.https://www.icr.ac.uk/news-archive%2fa-new-way-to-overcome-breast-cancer-drug-resistancehttps://www.icr.ac.uk/news-archive%2fa-new-way-to-overcome-breast-cancer-drug-resistanceA new way to overcome breast cancer drug resistanceScientists at the ICR have discovered a potential new way to overcome the resistance many women develop towards a treatment for breast cancer. https://www.icr.ac.uk/news-archive%2fnew-insights-into-molecular-mechanism-of-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fnew-insights-into-molecular-mechanism-of-childhood-cancerNew insights into molecular mechanism of childhood cancerA molecule's key role in the development of a childhood cancer has been discovered by scientists at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-features%2flatest-features%2ftumour-assassination-using-smart-targeted-treatments-to-enhance-anti-cancer-radiation-responseshttps://www.icr.ac.uk/news-features%2flatest-features%2ftumour-assassination-using-smart-targeted-treatments-to-enhance-anti-cancer-radiation-responsesTumour assassination – using smart targeted treatments to enhance anti-cancer radiation responsesProfessor Kevin Harrington has just been appointed joint head of the division of radiotherapy and imaging at The Institute of Cancer Research (ICR), London. Here, he talks about the novel approach his department will be taking to traditional radiotherapy treatment.https://www.icr.ac.uk/news-archive%2fgene-may-explain-why-some-breast-cancers-are-hard-to-treathttps://www.icr.ac.uk/news-archive%2fgene-may-explain-why-some-breast-cancers-are-hard-to-treatGene may explain why some breast cancers are hard to treatResearchers have identified a gene which some aggressive breast cancers rely on to survive, helping to explain why certain patients fail to benefit from targeted treatment.https://www.icr.ac.uk/news-archive%2fplan-for-action-to-fight-global-cancer-unveiledhttps://www.icr.ac.uk/news-archive%2fplan-for-action-to-fight-global-cancer-unveiledPlan for action to fight global cancer unveiledA 10-point plan to turn back the tide on cancer has been published to mark World Cancer Day. Developed by the World Oncology Forum, including the ICR's Professor Stan Kaye, the plan calls for more focus on research, and for governments around the world to invest in better healthcare systems to help reduce the number of people dying from the disease.https://www.icr.ac.uk/news-archive%2fnew-tumour-profiling-unit-signals-push-for-personalised-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-tumour-profiling-unit-signals-push-for-personalised-cancer-treatmentNew Tumour Profiling Unit signals push for personalised cancer treatmentA new Tumour Profiling Unit at the ICR will accelerate the development of personalised cancer treatments and their delivery to patients.https://www.icr.ac.uk/news-archive%2flaunch-of-trial-of-%27master-switch%27-drug-to-treat-several-cancer-typeshttps://www.icr.ac.uk/news-archive%2flaunch-of-trial-of-%27master-switch%27-drug-to-treat-several-cancer-typesLaunch of trial of 'master switch' drug to treat several cancer typesCancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The early-stage Phase I clinical trial of up to 40 patients will be carried out by the ICR, and The Royal Marsden Hospital.https://www.icr.ac.uk/news-archive%2fkey-driver-of-aggressive-prostate-cancer-foundhttps://www.icr.ac.uk/news-archive%2fkey-driver-of-aggressive-prostate-cancer-foundKey driver of aggressive prostate cancer foundA key driver for aggressive forms of prostate cancer has been uncovered by scientists at The Institute of Cancer Research, London. https://www.icr.ac.uk/news-archive%2f%27virtual-experiments%27-aid-scientists-to-find-missing-cancer-targetshttps://www.icr.ac.uk/news-archive%2f%27virtual-experiments%27-aid-scientists-to-find-missing-cancer-targets'Virtual experiments' aid scientists to find missing cancer targetsScientists have identified 46 previously overlooked but potentially ‘druggable’ cancer targets, using a powerful new online approach that allows researchers to carry out ‘virtual experiments’ to quickly prioritise which are the best targets for drug discovery. https://www.icr.ac.uk/news-archive%2fnew-partnership-model-needed-to-explore-kinases-for-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fnew-partnership-model-needed-to-explore-kinases-for-cancer-treatmentsNew partnership model needed to explore kinases for cancer treatmentsInternational leaders in drug discovery have warned that a huge reservoir of potential targets for cancer treatment will remain unexplored unless public funders, charities and pharmaceutical companies come together in a new model of large-scale partnership.https://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-discovery-cracks-mystery-of-families-with-a-strong-history-of-the-diseasehttps://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-discovery-cracks-mystery-of-families-with-a-strong-history-of-the-diseaseBowel cancer gene discovery cracks mystery of families with a strong history of the diseaseScientists have discovered that two gene faults increase the risk of bowel cancer in families with a strong history of developing the disease, who, until now, had no explanation as to why their risk was greater.https://www.icr.ac.uk/news-archive%2fscientists-discover-intriguing-new-gene-link-to-breast-and-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-discover-intriguing-new-gene-link-to-breast-and-ovarian-cancerScientists discover intriguing new gene link to breast and ovarian cancerA team of researchers led from the ICR, have found that mutations in a gene called PPM1D are linked to an increased risk of breast and ovarian cancer – through what may be a new mechanism of cancer development.https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-benefits-earlier-stage-diseasehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-benefits-earlier-stage-diseaseProstate cancer drug benefits earlier-stage diseaseProstate cancer drug benefits earlier-stage diseasehttps://www.icr.ac.uk/news-archive%2fthe-icr-welcomes-100m-investment-in-high-tech-genome-profiling-for-cancer-patients-https://www.icr.ac.uk/news-archive%2fthe-icr-welcomes-100m-investment-in-high-tech-genome-profiling-for-cancer-patients-The ICR welcomes £100m investment in high-tech genome profiling for cancer patients.The ICR welcomes £100m Government investment in high-tech genome profiling for cancer patients.https://www.icr.ac.uk/news-archive%2ffewer-bigger-doses-of-radiotherapy-benefit-breast-cancer-patientshttps://www.icr.ac.uk/news-archive%2ffewer-bigger-doses-of-radiotherapy-benefit-breast-cancer-patientsFewer, bigger doses of radiotherapy benefit breast cancer patientsWomen diagnosed with breast cancer can benefit from receiving fewer but higher doses of radiotherapy than is the international standard, according to long-term follow-up data of a major UK-wide trial led by the ICR.https://www.icr.ac.uk/news-archive%2fkidney-cancer-genetic-risk-discoveryhttps://www.icr.ac.uk/news-archive%2fkidney-cancer-genetic-risk-discoveryKidney cancer genetic risk discoveryScientists at the ICR have found a new genetic variation which increases a person’s risk of developing the most common type of kidney cancer.https://www.icr.ac.uk/news-archive%2fthe-icr-and-royal-marsden-open-groundbreaking-facility-bringing-smart-trials-to-the-nhs-https://www.icr.ac.uk/news-archive%2fthe-icr-and-royal-marsden-open-groundbreaking-facility-bringing-smart-trials-to-the-nhs-The ICR and Royal Marsden open groundbreaking facility bringing smart trials to the NHS Scientists will monitor whether new-generation cancer drugs are successfully hitting their targets by simply plucking samples from patients’ eyebrows following the opening of a new world-class research facility at The Royal Marsden and its academic research partner, The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-to-join-innovation-debate-2012https://www.icr.ac.uk/news-archive%2fprofessor-paul-workman-to-join-innovation-debate-2012Professor Paul Workman to join Innovation Debate 2012Professor Paul Workman, Deputy Chief Executive and head of cancer therapeutics at The Institute of Cancer Research, London, will join the distinguished panel of world-leading experts and chairman Professor Jim Al-Khalili for The Innovation Debate 2012, taking place on 20th November at 4pm at the Royal Society in London and webcast live.https://www.icr.ac.uk/news-archive%2f-1-2m-grant-to-develop-icr-discovered-drughttps://www.icr.ac.uk/news-archive%2f-1-2m-grant-to-develop-icr-discovered-drug£1.2m grant to develop ICR-discovered drugProfessor Paul Workman, deputy chief executive of The Institute of Cancer Research, has welcomed the news that a drug designed and synthesised in his unit will benefit from a £1.2m grant from the UK government’s Biomedical Catalyst programme that should help speed its progress towards clinical trials.https://www.icr.ac.uk/news-features%2flatest-features%2ftackling-cancer-s-biggest-challenge-combination-treatments-offer-hope-to-overcome-drug-resistancehttps://www.icr.ac.uk/news-features%2flatest-features%2ftackling-cancer-s-biggest-challenge-combination-treatments-offer-hope-to-overcome-drug-resistanceTackling cancer’s biggest challenge: Combination treatments offer hope to overcome drug resistanceThe huge genetic diversity within tumours is threatening efforts to create personalised cancer treatments – but, as an article in Nature Biotechnology reveals, scientists at The Institute of Cancer Research in London believe powerful new technology will bring a solution.https://www.icr.ac.uk/news-features%2flatest-features%2ffinding-the-right-combinationhttps://www.icr.ac.uk/news-features%2flatest-features%2ffinding-the-right-combinationFinding the right combinationThe dream of a single pill to cure cancer, a magic bullet that stops the disease in its tracks, is one that now looks a little outdated.https://www.icr.ac.uk/news-features%2flatest-features%2funtangling-the-evolution-of-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2funtangling-the-evolution-of-cancerUntangling the evolution of cancerAt The Institute of Cancer Research, London, Professor Mel Greaves applies evolutionary thinking to illuminate how cancers work.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-centre-for-molecular-pathologyhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-centre-for-molecular-pathologyThe Centre for Molecular PathologyCancers affecting a specific site are not single diseases, but rather a collection of diseases caused by alterations of distinct genes and molecular networks. Technological developments in the last decade have led to an increase in our understanding of which of these are required for cancer cells to grow and survive.https://www.icr.ac.uk/news-features%2flatest-features%2fhpc-super-computershttps://www.icr.ac.uk/news-features%2flatest-features%2fhpc-super-computersHPC Super-ComputersThe successful sequencing of the human genome in 2000 set in motion an explosion in our understanding of cancer. Some of the fruits of this research are already being incorporated into treatment and care of cancer patients, and much more is set to follow.https://www.icr.ac.uk/news-features%2flatest-features%2fbbc-world-highlights-the-future-of-personalised-medicine-in-the-ukhttps://www.icr.ac.uk/news-features%2flatest-features%2fbbc-world-highlights-the-future-of-personalised-medicine-in-the-ukBBC World highlights the future of personalised medicine in the UKA new programme on BBC World’s The Health Show revealed how doctors in the UK are tailoring cancer treatments to individual patients using samples of their DNA.https://www.icr.ac.uk/news-archive%2fzelboraf-recommended-for-nhs-patientshttps://www.icr.ac.uk/news-archive%2fzelboraf-recommended-for-nhs-patientsZelboraf recommended for NHS patientsProfessor Alan Ashworth, chief executive of The Institute of Cancer Research, London, comments on the announcement that vemurafenib (Zelboraf) has been recommended by NICE for NHS patients with advanced malignant melanoma and a mutated BRAF gene.https://www.icr.ac.uk/news-features%2flatest-features%2fcombining-imaging-and-gene-analysis-could-transform-breast-cancer-diagnosishttps://www.icr.ac.uk/news-features%2flatest-features%2fcombining-imaging-and-gene-analysis-could-transform-breast-cancer-diagnosisCombining imaging and gene analysis could transform breast cancer diagnosisScientists have developed a computer system that can automatically analyse images of breast cancer cells to look for telltale signs that the tumour will be aggressive. The technique, details of which were published this week in Science Translational Medicine, could be used to give women with breast cancer a more accurate prognosis and help tailor their treatment accordingly.https://www.icr.ac.uk/news-features%2flatest-features%2fmore-than-just-a-logo---the-icr-identity-storyhttps://www.icr.ac.uk/news-features%2flatest-features%2fmore-than-just-a-logo---the-icr-identity-storyMore than just a logo - the ICR identity storyThe Institute of Cancer Research, London, has an outstanding record of achievement going back over 100 years, and has been involved in some of the most important discoveries in the history of cancer research. But we need to do more to promote ourselves within the UK and globally to ensure we maintain our position as one of the world’s most influential cancer research institutes. Our new branding is an important part of our identity, and is designed to help get across to our various audiences the world class nature of our science, and its benefits for patients.https://www.icr.ac.uk/news-features%2flatest-features%2flarge-study-shows-benefits-of-single-agent-doxorubicin-therapy-for-sarcomahttps://www.icr.ac.uk/news-features%2flatest-features%2flarge-study-shows-benefits-of-single-agent-doxorubicin-therapy-for-sarcomaLarge study shows benefits of single agent doxorubicin therapy for sarcomaDoubts over the best standard treatment for metastatic soft tissue sarcoma have been put to rest thanks to a large international, randomised clinical trial led by a scientist at The Institute of Cancer Research, London.https://www.icr.ac.uk/news-archive%2fscientists-develop-barcode-blood-test-for-aggressive-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-develop-barcode-blood-test-for-aggressive-prostate-cancerScientists develop ‘barcode’ blood test for aggressive prostate cancerScientists have designed a blood test that reads genetic changes like a barcode – and can pick out aggressive prostate cancers by their particular pattern of gene activity.https://www.icr.ac.uk/news-archive%2ffibonacci-sequence-inspires-new-brand-identity-for-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-archive%2ffibonacci-sequence-inspires-new-brand-identity-for-the-institute-of-cancer-researchFibonacci sequence inspires new brand identity for The Institute of Cancer ResearchThe Fibonacci sequence and images inspired by science and medicine feature prominently in a bold rebranding of The Institute of Cancer Research, London. The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes, and its new visual identity is intended to help it develop the profile to match. https://www.icr.ac.uk/news-archive%2fmultimillion-pound-fund%27s-cancer-research-donations-should-help-deliver-real-benefits-to-cancer-patientshttps://www.icr.ac.uk/news-archive%2fmultimillion-pound-fund%27s-cancer-research-donations-should-help-deliver-real-benefits-to-cancer-patientsMultimillion pound fund's cancer research donations should help deliver real benefits to cancer patientsThe Institute of Cancer Research will be the main charitable beneficiary of an innovative multimillion pound investment fund. https://www.icr.ac.uk/news-archive%2ftargeted-therapy-may-benefit-men-whose-prostate-cancer-has-spread-to-their-boneshttps://www.icr.ac.uk/news-archive%2ftargeted-therapy-may-benefit-men-whose-prostate-cancer-has-spread-to-their-bonesTargeted therapy may benefit men whose prostate cancer has spread to their bonesA new-generation cancer drug could shrink prostate tumours that have spread to patients’ bones and help to relieve bone pain, trial results suggest.https://www.icr.ac.uk/news-features%2flatest-features%2fpaul-workman-features-in-bbc-radio-4-science-specialhttps://www.icr.ac.uk/news-features%2flatest-features%2fpaul-workman-features-in-bbc-radio-4-science-specialPaul Workman features in BBC Radio 4 science specialProfessor Paul Workman discusses the issues facing the pharmaceutical industry – and the role that non-profit and academic organisations like the ICR can play in driving drug discovery progress – in a BBC Radio 4 special. https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-philip-lawleyhttps://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-philip-lawleyProfessor Philip LawleyDistinguished ICR scientist Professor Philip Lawley died recently at the age of 84. His former ICR colleague Dr Stan Venitt, Emeritus Reader in Cancer Studies, reflects on an accomplished and dedicated man who gave the world the first convincing evidence that DNA damage was the basic cause of cancer.https://www.icr.ac.uk/news-features%2flatest-features%2ficr-scientific-image-competitionhttps://www.icr.ac.uk/news-features%2flatest-features%2ficr-scientific-image-competitionICR Scientific Image CompetitionThe annual ICR Scientific Image Competition provides our scientists and students an opportunity to share the importance of their research through the visual means of images gathered during the research process. Looking at the winning entries in this year's competition, it is hard not to feel that you are viewing artwork. https://www.icr.ac.uk/news-features%2flatest-features%2flonger-lives-for-multiple-myeloma-patientshttps://www.icr.ac.uk/news-features%2flatest-features%2flonger-lives-for-multiple-myeloma-patientsLonger Lives for Multiple Myeloma PatientsMultiple Myeloma affects around 4000 people each year. The average survival time after diagnosis is just three to five years, so new treatment options are urgently neededhttps://www.icr.ac.uk/news-archive%2fmale-breast-cancer-causing-gene-foundhttps://www.icr.ac.uk/news-archive%2fmale-breast-cancer-causing-gene-foundMale breast cancer-causing gene foundThe world’s largest study into the causes of male breast cancer has found a gene that can increase the risk of the disease by up to 50 per cent.https://www.icr.ac.uk/news-features%2flatest-features%2fnew-drug-type-could-boost-chemotherapyhttps://www.icr.ac.uk/news-features%2flatest-features%2fnew-drug-type-could-boost-chemotherapyNew drug type could boost chemotherapyScientists at The Institute of Cancer Research, in conjunction with cancer drug discovery company Sareum, have shown that a new type of drug could boost the effectiveness of chemotherapy treatments for many cancer types.https://www.icr.ac.uk/news-archive%2fwhole-genome-scan-helps-select-best-treatment-for-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fwhole-genome-scan-helps-select-best-treatment-for-childhood-cancerWhole-genome scan helps select best treatment for childhood cancerA whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, finds a study led by the ICR.https://www.icr.ac.uk/news-features%2flatest-features%2ffunding-injection-into-prostate-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2ffunding-injection-into-prostate-cancer-researchFunding injection into prostate cancer researchProstate cancer researchers at The Institute of Cancer Research, London, are launching two new collaborations that will make use of cutting-edge genetic technology to help improve patients’ treatment options, thanks to a $750,000 funding boost.https://www.icr.ac.uk/news-archive%2fepigenetic-drug-discovery-collaboration-announcedhttps://www.icr.ac.uk/news-archive%2fepigenetic-drug-discovery-collaboration-announcedEpigenetic drug discovery collaboration announcedAstex, CRT and the ICR have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.https://www.icr.ac.uk/news-archive%2fstop-start-hormone-therapy-better-than-continual-treatment-for-prostate-cancer-https://www.icr.ac.uk/news-archive%2fstop-start-hormone-therapy-better-than-continual-treatment-for-prostate-cancer-Stop-start hormone therapy better than continual treatment for prostate cancer Men with prostate cancer who receive hormone therapy intermittently respond as well as those who receive it over a continuous time period, and enjoy quality-of-life benefits, according to a study published in the New England Journal of Medicine today.https://www.icr.ac.uk/news-archive%2fgolden-age-of-prostate-cancer-treatment---fourth-drug-in-two-years-extends-lifehttps://www.icr.ac.uk/news-archive%2fgolden-age-of-prostate-cancer-treatment---fourth-drug-in-two-years-extends-lifeGolden age of prostate cancer treatment - fourth drug in two years extends lifeA study in the New England Journal of Medicine shows the drug enzalutamide can significantly extend life and improve quality of life in men with advanced prostate cancer – the fourth time in two years that a new drug has been shown to improve overall survival.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-institute-of-cancer-research-turns-up-the-heat-on-tumour-cellshttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-institute-of-cancer-research-turns-up-the-heat-on-tumour-cellsThe Institute of Cancer Research turns up the heat on tumour cellsResearchers at The Institute of Cancer Research (ICR) are investigating a new treatment that could destroy cancer cells in the abdomen by zapping them with intense soundwaves.https://www.icr.ac.uk/news-archive%2flower-risk-of-serious-side-effects-in-trials-of-new-targeted-drugshttps://www.icr.ac.uk/news-archive%2flower-risk-of-serious-side-effects-in-trials-of-new-targeted-drugsLower risk of serious side-effects in trials of new targeted drugsPatients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.https://www.icr.ac.uk/news-archive%2fthe-promise-of-immunotherapy---and-bridging-the-funding-gaphttps://www.icr.ac.uk/news-archive%2fthe-promise-of-immunotherapy---and-bridging-the-funding-gapThe promise of immunotherapy - and bridging the funding gapThe ICR’s Professor Paul Workman has featured in a BBC Newsnight investigation into promising new cancer treatment approacheshttps://www.icr.ac.uk/news-archive%2fnew-evidence-found-for-inheritability-of-common-leukaemiahttps://www.icr.ac.uk/news-archive%2fnew-evidence-found-for-inheritability-of-common-leukaemiaNew evidence found for inheritability of common leukaemiaScientists at The Institute of Cancer Research (ICR) in London have identified a heritable gene variant associated with an increased risk of developing chronic lymphocytic leukaemia (CLL).https://www.icr.ac.uk/news-archive%2fobesity-may-affect-response-to-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fobesity-may-affect-response-to-breast-cancer-treatmentObesity may affect response to breast cancer treatmentWomen who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.https://www.icr.ac.uk/news-features%2flatest-features%2fcancer-treatment-progress-two-promising-new-drugs-revealedhttps://www.icr.ac.uk/news-features%2flatest-features%2fcancer-treatment-progress-two-promising-new-drugs-revealedCancer treatment progress: Two promising new drugs revealedScientists at The Institute of Cancer Research have this week revealed promising early results from two exciting new targeted cancer drughttps://www.icr.ac.uk/news-archive%2fdrug-s-double-hit-overcomes-leukaemia-resistancehttps://www.icr.ac.uk/news-archive%2fdrug-s-double-hit-overcomes-leukaemia-resistanceDrug’s ‘double hit’ overcomes leukaemia resistanceA drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, led by the ICR, is published today in the journal Leukaemia. https://www.icr.ac.uk/news-archive%2fscientists-develop-new-strategy-to-overcome-drug-resistant-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-develop-new-strategy-to-overcome-drug-resistant-childhood-cancerScientists develop new strategy to overcome drug-resistant childhood cancerA new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment. https://www.icr.ac.uk/news-archive%2f%27master-switch%27-experimental-drug-could-treat-different-cancershttps://www.icr.ac.uk/news-archive%2f%27master-switch%27-experimental-drug-could-treat-different-cancers'Master switch' experimental drug could treat different cancersA unique multi-target experimental drug could treat a range of cancer types, according to research led by the ICR and published in Clinical Cancer Research today.https://www.icr.ac.uk/news-archive%2fpan-european-project-aims-to-screen-patients-for-hidden-cancer-cellshttps://www.icr.ac.uk/news-archive%2fpan-european-project-aims-to-screen-patients-for-hidden-cancer-cellsPan-European project aims to screen patients for hidden cancer cellsScientists across Europe are to collaborate on a €6m project to develop a technique of screening a patient’s entire blood volume for cancer cells that have evaded treatment.https://www.icr.ac.uk/news-archive%2fcancer-drug-discoverer-honoured-with-global-entrepreneurship-awardhttps://www.icr.ac.uk/news-archive%2fcancer-drug-discoverer-honoured-with-global-entrepreneurship-awardCancer drug discoverer honoured with global entrepreneurship awardProfessor Paul Workman has won a global award recognising his success at taking pioneering drugs out of the laboratory and into commercial development for the ultimate benefit of patients worldwide.https://www.icr.ac.uk/news-archive%2fnew-way-to-control-cancer-blood-supply-discoveredhttps://www.icr.ac.uk/news-archive%2fnew-way-to-control-cancer-blood-supply-discoveredNew way to control cancer blood supply discoveredAn entirely new way to control the development of blood vessels has been discovered by scientists, which could lead to improved treatment of cancer, heart disease and eye disease, with fewer side effects. The results are published today in the journal Blood.https://www.icr.ac.uk/news-archive%2flandmark-study-describes-long-term-risk-of-breast-cancer-from-lymphoma-treatmenthttps://www.icr.ac.uk/news-archive%2flandmark-study-describes-long-term-risk-of-breast-cancer-from-lymphoma-treatmentLandmark study describes long-term risk of breast cancer from lymphoma treatmentNew research from the ICR identifies the personalised breast cancer risk for women treated for Hodgkin lymphoma.https://www.icr.ac.uk/news-archive%2f-hitch-hiking-viral-therapy-deals-a-double-blow-to-cancerhttps://www.icr.ac.uk/news-archive%2f-hitch-hiking-viral-therapy-deals-a-double-blow-to-cancer‘Hitch-hiking’ viral therapy deals a double blow to cancerScientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumours undetected by hitching a ride on blood cells.https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-shown-to-extend-life-and-improve-quality-of-lifehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-shown-to-extend-life-and-improve-quality-of-lifeProstate cancer drug shown to extend life and improve quality of lifeThe drug enzalutamide has been shown to extend life for men with advanced prostate cancer and offers improved quality of life, according to new data from a Phase III clinical trial jointly led by the ICR and The Royal Marsden. https://www.icr.ac.uk/news-archive%2fabiraterone-acetate-shows-success-in-earlier-stage-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fabiraterone-acetate-shows-success-in-earlier-stage-prostate-cancer-patientsAbiraterone acetate shows success in earlier-stage prostate cancer patientsA large-scale international trial has shown that the ICR-discovered drug abiraterone acetate can benefit patients with earlier-stage prostate cancer, according to results being presented at the ASCO annual meeting today. https://www.icr.ac.uk/news-archive%2fbreakthrough-treatments-for-cancer-patients-are-presented-at-ascohttps://www.icr.ac.uk/news-archive%2fbreakthrough-treatments-for-cancer-patients-are-presented-at-ascoBreakthrough treatments for cancer patients are presented at ASCOClinicians and scientist from The Royal Marsden and the ICR will be presenting new pioneering research at the American Society of Clinical Oncology Annual Meeting.https://www.icr.ac.uk/news-archive%2fgene-link-to-higher-rates-of-bowel-cancer-in-menhttps://www.icr.ac.uk/news-archive%2fgene-link-to-higher-rates-of-bowel-cancer-in-menGene link to higher rates of bowel cancer in menScientists have shown for the first time that one of the sex chromosomes is involved in the development of a cancer that can afflict both genders, according to a study in Nature Genetics. https://www.icr.ac.uk/news-archive%2fnew-test-may-reduce-chemotherapy-use-in-breast-cancerhttps://www.icr.ac.uk/news-archive%2fnew-test-may-reduce-chemotherapy-use-in-breast-cancerNew test may reduce chemotherapy use in breast cancerA new test called IHC4 that is being considered for use on the NHS could identify patients at such low risk of their breast cancer returning after surgery that they may be spared chemotherapy.https://www.icr.ac.uk/news-archive%2fdrug-developers-welcome-nice-guidance-on-abirateronehttps://www.icr.ac.uk/news-archive%2fdrug-developers-welcome-nice-guidance-on-abirateroneDrug developers welcome NICE guidance on abirateroneThe Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust have welcomed the publication of guidance from the National Institute for Health and Clinical Excellence (NICE) recommending that patients with advanced prostate cancer receive abiraterone acetate on the NHShttps://www.icr.ac.uk/news-archive%2fnew-understanding-of-breast-cancer-genes-and-mutationshttps://www.icr.ac.uk/news-archive%2fnew-understanding-of-breast-cancer-genes-and-mutationsNew understanding of breast cancer genes and mutationsResearchers have identified nine new genes that drive the development of breast cancer, taking the tally associated with this type of cancer to 40. The study, which involved ICR scientists, published in the journal Nature.https://www.icr.ac.uk/news-archive%2fleading-prostate-cancer-researchers-elected-to-academy-of-medical-scienceshttps://www.icr.ac.uk/news-archive%2fleading-prostate-cancer-researchers-elected-to-academy-of-medical-sciencesLeading prostate cancer researchers elected to Academy of Medical SciencesTwo eminent researchers from the ICR and The Royal Marsden have been elected to the Academy of Medical Sciences in recognition of their efforts to defeat prostate cancer.https://www.icr.ac.uk/news-archive%2fnext-generation-epigenetic-cancer-pill-shown-to-be-safehttps://www.icr.ac.uk/news-archive%2fnext-generation-epigenetic-cancer-pill-shown-to-be-safeNext-generation “epigenetic” cancer pill shown to be safeScientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.https://www.icr.ac.uk/news-archive%2fcombining-prostate-cancer-drugs-could-delay-drug-resistance-study-findshttps://www.icr.ac.uk/news-archive%2fcombining-prostate-cancer-drugs-could-delay-drug-resistance-study-findsCombining prostate cancer drugs could delay drug resistance, study findsCombing two new prostate cancer drugs could increase the number of men who respond to treatment and the length of time they benefit, research led by the ICR has shown. https://www.icr.ac.uk/news-archive%2fscientists-find-dna-variants-linked-with-childhood-kidney-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-find-dna-variants-linked-with-childhood-kidney-cancerScientists find DNA variants linked with childhood kidney cancerAn international collaboration led by The Institute of Cancer Research (ICR) has found variations of the genetic code in two regions of the genome that increase the risk of developing Wilms tumour.https://www.icr.ac.uk/news-archive%2fexisting-drugs-could-treat-smokers-lung-cancerhttps://www.icr.ac.uk/news-archive%2fexisting-drugs-could-treat-smokers-lung-cancerExisting drugs could treat smokers’ lung cancerA common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC).https://www.icr.ac.uk/news-archive%2fprotein-block-kills-childhood-cancer-cellshttps://www.icr.ac.uk/news-archive%2fprotein-block-kills-childhood-cancer-cellsProtein ‘block’ kills childhood cancer cellsAn experimental drug that blocks an essential cell protein could be used to treat Wilms tumour, a childhood cancer that affects the kidneys.https://www.icr.ac.uk/news-archive%2fmen-with-breast-cancer-gene-four-times-more-likely-to-get-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fmen-with-breast-cancer-gene-four-times-more-likely-to-get-prostate-cancerMen with “breast cancer gene” four times more likely to get prostate cancerMen with a faulty gene known to increase the risk of breast cancer in women are four times more likely to develop prostate cancer, important new research published in the British Journal of Cancer today shows.https://www.icr.ac.uk/news-archive%2fadding-chemotherapy-to-radiotherapy-halves-risk-of-bladder-cancer-returninghttps://www.icr.ac.uk/news-archive%2fadding-chemotherapy-to-radiotherapy-halves-risk-of-bladder-cancer-returningAdding chemotherapy to radiotherapy halves risk of bladder cancer returningBladder cancer patients given low doses of chemotherapy combined with radiotherapy were nearly 50 per cent less likely to relapse with the most lethal form of the disease compared to patients given radiotherapy alone.https://www.icr.ac.uk/news-archive%2fgene-linked-to-oestrogen-levels-and-breast-cancer-risk-in-younger-womenhttps://www.icr.ac.uk/news-archive%2fgene-linked-to-oestrogen-levels-and-breast-cancer-risk-in-younger-womenGene linked to oestrogen levels and breast cancer risk in younger womenScientists have found the first direct link between breast cancer risk and genetically-determined levels of the hormone oestrogen in younger women, according to a paper published online this week in the Journal of the National Cancer Institute.https://www.icr.ac.uk/news-archive%2fmillion-boost-for-efforts-to-personalise-prostate-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fmillion-boost-for-efforts-to-personalise-prostate-cancer-treatment$10 million boost for efforts to personalise prostate cancer treatment Professor Johann de Bono from The Royal Marsden and The Institute of Cancer Research (ICR) will collaborate with other leading prostate cancer researchers in a $10 million global effort to drive the development of personalised treatment for this disease.https://www.icr.ac.uk/news-archive%2fbbc-documentary-horizon-takes-on-cancerhttps://www.icr.ac.uk/news-archive%2fbbc-documentary-horizon-takes-on-cancerBBC documentary Horizon takes on cancerBBC’s award winning documentary series, Horizon, will follow the work of The Royal Marsden and The Institute of Cancer Research (ICR) on Tuesday April 10 in their hour-long episode “Horizon: Defeating Cancer”.https://www.icr.ac.uk/news-archive%2ftrials-show-promise-of-human-virus-to-treat-head-and-neck-cancer-patientshttps://www.icr.ac.uk/news-archive%2ftrials-show-promise-of-human-virus-to-treat-head-and-neck-cancer-patientsTrials show promise of human virus to treat head and neck cancer patientsA naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published today in Clinical Cancer Researchhttps://www.icr.ac.uk/news-archive%2fscientists-honoured-at-the-aacr-conferencehttps://www.icr.ac.uk/news-archive%2fscientists-honoured-at-the-aacr-conferenceScientists honoured at the AACR conferenceScientists from The Institute of Cancer Research have received several major honours at the American Association for Cancer Research annual meeting this week.https://www.icr.ac.uk/news-archive%2fdiabetes-treatment-doubles-skin-cancer-drug%27s-effectivenesshttps://www.icr.ac.uk/news-archive%2fdiabetes-treatment-doubles-skin-cancer-drug%27s-effectivenessDiabetes treatment doubles skin cancer drug's effectivenessResearchers have found that using the diabetes drug metformin with Avastin (bevacizumab) to treat skin cancer almost doubles its ability to block tumour growth, according to a study in Cancer Discovery.https://www.icr.ac.uk/news-archive%2ftest-for-single-genetic-fault-can-predict-child-cancer-patient-survivalhttps://www.icr.ac.uk/news-archive%2ftest-for-single-genetic-fault-can-predict-child-cancer-patient-survivalTest for single genetic fault can predict child cancer patient survivalA study led by The Institute of Cancer Research (ICR) has shown that a simple genetic test could help predict the aggressiveness of rhabdomyosarcomas in children and should be introduced into clinical practice. https://www.icr.ac.uk/news-archive%2fteam-wins-prestigious-global-award-for-cancer-drug-successhttps://www.icr.ac.uk/news-archive%2fteam-wins-prestigious-global-award-for-cancer-drug-successTeam wins prestigious global award for cancer drug successA multidisciplinary team from The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, which receives funding from Cancer Research UK*, has won a prestigious global award for its success in taking new cancer drugs from concept to patients.https://www.icr.ac.uk/news-archive%2ftargeted-skin-cancer-drug-launches-in-ukhttps://www.icr.ac.uk/news-archive%2ftargeted-skin-cancer-drug-launches-in-ukTargeted skin cancer drug launches in UKA life-extending pill for advanced melanoma that The Institute of Cancer Research and The Royal Marsden Hospital helped develop is now available in the UK. https://www.icr.ac.uk/news-archive%2ficr-discovered-drug-abiraterone-shows-success-in-earlier-stage-prostate-patients-https://www.icr.ac.uk/news-archive%2ficr-discovered-drug-abiraterone-shows-success-in-earlier-stage-prostate-patients-ICR-discovered drug abiraterone shows success in earlier-stage prostate patients A large-scale international trial of abiraterone acetate in patients with earlier-stage prostate cancer has been stopped early due its effectiveness, so those on the placebo arm could be offered the drug.https://www.icr.ac.uk/news-archive%2fantidepressant-shows-promise-as-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fantidepressant-shows-promise-as-cancer-treatmentAntidepressant shows promise as cancer treatmentAn antidepressant combined with a drug derived from vitamin A could be used to treat a common adult form of leukaemia, according to laboratory research led by a team at the ICR.https://www.icr.ac.uk/news-archive%2fstudy-offers-reassurance-to-leukaemia-patientshttps://www.icr.ac.uk/news-archive%2fstudy-offers-reassurance-to-leukaemia-patientsStudy offers reassurance to leukaemia patientsA clinical trial into the most common form of adult leukaemia has established that patients taking an aggressive but effective drug combination can return to a normal quality of life once they complete treatment. https://www.icr.ac.uk/news-archive%2fhereditary-breast-cancer-genetic-code-unravelledhttps://www.icr.ac.uk/news-archive%2fhereditary-breast-cancer-genetic-code-unravelledHereditary breast cancer: genetic code unravelledScientists from the ICR's Breakthrough Breast Cancer Research Centre have become the first to fully sequence the DNA of two breast cancers caused by a faulty BRCA1 gene. Surprisingly, changes in the genetic code of the two tumours looked almost entirely different from one another. https://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-ian-judson-explores-new-research-into-the-safety-of-chemotherapy-during-pregnancyhttps://www.icr.ac.uk/news-features%2flatest-features%2fprofessor-ian-judson-explores-new-research-into-the-safety-of-chemotherapy-during-pregnancyProfessor Ian Judson explores new research into the safety of chemotherapy during pregnancyFinding out that you have cancer comes as a big shock to most people – but what if you are also pregnant? Do you delay treatment until the baby is born, carry on with treatment during pregnancy or have a termination? What impact does chemotherapy have on your unborn child?https://www.icr.ac.uk/news-features%2flatest-features%2fbuzz-grows-around-icr-discovered-drughttps://www.icr.ac.uk/news-features%2flatest-features%2fbuzz-grows-around-icr-discovered-drugBuzz grows around ICR-discovered drugThe discovery of a new type of cancer drug, a PI3K inhibitor, by scientists at The Institute of Cancer Research and collaborators is creating a stir in the cancer research community.https://www.icr.ac.uk/news-archive%2fnew-mri-technique-predicts-treatment-response-for-neuroendocrine-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-mri-technique-predicts-treatment-response-for-neuroendocrine-cancer-patientsNew MRI technique predicts treatment response for neuroendocrine cancer patientsScientists at the ICR and The Royal Marsden have shown that a specialist type of MRI scan can be used to predict which patients will respond to a targeted radiotherapy and monitor response to treatment. https://www.icr.ac.uk/news-archive%2fhundreds-more-breast-cancer-patients-should-be-tested-for-brca1-genehttps://www.icr.ac.uk/news-archive%2fhundreds-more-breast-cancer-patients-should-be-tested-for-brca1-geneHundreds more breast cancer patients should be tested for BRCA1 geneLeading breast cancer experts are calling for women under 50 who are diagnosed with triple-negative breast cancer to be offered testing for faults in the BRCA1 gene, according to a report published in the British Journal of Cancer today. https://www.icr.ac.uk/news-features%2flatest-features%2feducating-the-next-generation-of-researchers-at-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-features%2flatest-features%2feducating-the-next-generation-of-researchers-at-the-institute-of-cancer-researchEducating the Next Generation of Researchers at The Institute of Cancer ResearchIn the ICR’s mission to relieve suffering due to cancer, major strategies include both education and the furthering of knowledge through scientific advancement. The programme of postgraduate research and taught training at the ICR both reflects these strategies and forms part of a commitment to the current and future pursuit of excellence in the fight against cancer.https://www.icr.ac.uk/news-archive%2freport-reveals-year-of-research-successhttps://www.icr.ac.uk/news-archive%2freport-reveals-year-of-research-successReport reveals year of research successThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have launched their Joint Annual Research Report for 2010/11, highlighting a year of significant achievements. https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-shows-impressive-new-phase-iii-trial-resultshttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-shows-impressive-new-phase-iii-trial-resultsProstate cancer drug shows impressive new Phase III trial resultsPatients with advanced prostate cancer who were given a new type of hormonal treatment called MDV3100 lived an extra 4.8 months compared to men taking a placebo, according to the full analysis of a Phase III trial. https://www.icr.ac.uk/news-archive%2fwomen-with-faulty-brca-genes-more-likely-to-survive-ovarian-cancerhttps://www.icr.ac.uk/news-archive%2fwomen-with-faulty-brca-genes-more-likely-to-survive-ovarian-cancerWomen with faulty BRCA genes more likely to survive ovarian cancerOvarian cancer patients who carry BRCA1 or BRCA2 mutations are significantly more likely to survive the disease than women without these faulty genes, according to research published in the Journal of the American Medical Association.https://www.icr.ac.uk/news-archive%2fmusculoskeletal-side-effects-from-breast-cancer-treatment-not-long-termhttps://www.icr.ac.uk/news-archive%2fmusculoskeletal-side-effects-from-breast-cancer-treatment-not-long-termMusculoskeletal side–effects from breast cancer treatment not long termA drug regimen found to cut a women’s risk of dying from breast cancer gives a higher risk of carpal tunnel syndrome, but this can be managed and does not persist once treatment has finished. https://www.icr.ac.uk/news-archive%2fscientists-unravel-cause-of-second-cancer-arising-from-targeted-treatmenthttps://www.icr.ac.uk/news-archive%2fscientists-unravel-cause-of-second-cancer-arising-from-targeted-treatmentScientists unravel cause of second cancer arising from targeted treatmentScientists at The Institute of Cancer Research (ICR) have shown how to prevent new cancers which can occur when malignant melanoma patients are treated with drugs known as BRAF inhibitors, in a Cancer Research UK-funded study published today in the New England Journal of Medicine.https://www.icr.ac.uk/news-archive%2fscientist-wins-prestigious-fellowship-https://www.icr.ac.uk/news-archive%2fscientist-wins-prestigious-fellowship-Scientist wins prestigious fellowship A scientist from the ICR and The Royal Marsden has received one of four prestigious Cancer Research UK Clinical Scientist Fellowships for his research into new ways to detect and treat advanced prostate cancer. https://www.icr.ac.uk/news-archive%2ffewer-larger-radiotherapy-doses-prove-safe-for-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2ffewer-larger-radiotherapy-doses-prove-safe-for-prostate-cancer-patientsFewer, Larger Radiotherapy Doses Prove Safe For Prostate Cancer PatientsLess overall radiotherapy, delivered in fewer but higher doses, is as safe as standard, lower doses for treating prostate cancer, according to new research.https://www.icr.ac.uk/news-archive%2fscientists-discover-how-to-beat-resistance-to-standard-leukaemia-drughttps://www.icr.ac.uk/news-archive%2fscientists-discover-how-to-beat-resistance-to-standard-leukaemia-drugScientists Discover How To Beat Resistance To Standard Leukaemia DrugICR scientists have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cellhttps://www.icr.ac.uk/news-archive%2fscientist-recognised-with-cancer-charity-s-highest-honourhttps://www.icr.ac.uk/news-archive%2fscientist-recognised-with-cancer-charity-s-highest-honourScientist Recognised with Cancer Charity’s Highest HonourThe ICR's Professor Mel Greaves has become the first scientist honoured with leading blood cancer charity Leukaemia & Lymphoma Research's highest award. https://www.icr.ac.uk/news-archive%2ftopping-out-ceremony-marks-milestone-for-the-royal-marsden-and-the-icrhttps://www.icr.ac.uk/news-archive%2ftopping-out-ceremony-marks-milestone-for-the-royal-marsden-and-the-icrTopping out ceremony marks milestone for The Royal Marsden and the ICRProgress on The Royal Marsden and the ICR's new Centre for Molecular Pathology in Sutton, Surrey, has reached a major milestone with a topping out ceremony this week. https://www.icr.ac.uk/news-archive%2fglobal-award-for-prostate-cancer-blood-test-developerhttps://www.icr.ac.uk/news-archive%2fglobal-award-for-prostate-cancer-blood-test-developerGlobal Award for Prostate Cancer Blood Test DeveloperA scientist from the ICR and The Royal Marsden, Dr Timothy Yap, has received an award for ongoing work developing a blood test to predict how prostate cancer patients will respond to treatment.https://www.icr.ac.uk/news-archive%2ffirst-risk-genes-found-for-bone-marrow-cancerhttps://www.icr.ac.uk/news-archive%2ffirst-risk-genes-found-for-bone-marrow-cancerFirst Risk Genes Found for Bone Marrow CancerA team of scientists led by the ICR has shown for the first time that a person’s genes influences their risk of developing multiple myeloma, according to a paper publishing in the journal Nature Genetics.https://www.icr.ac.uk/news-archive%2ffirst-patients-enrolled-in-personalised-medicine-projecthttps://www.icr.ac.uk/news-archive%2ffirst-patients-enrolled-in-personalised-medicine-projectFirst patients enrolled in personalised medicine projectClinicians and scientists at The Royal Marsden and the ICR are taking part in a ground-breaking national project which could lead to personalised cancer treatment for individual patients. https://www.icr.ac.uk/news-archive%2ficr-scientists-at-forefront-of-high-tech-gene-sequencing-initiativehttps://www.icr.ac.uk/news-archive%2ficr-scientists-at-forefront-of-high-tech-gene-sequencing-initiativeICR Scientists at Forefront of High-Tech Gene Sequencing InitiativeThree new projects will use the latest sequencing machines to unravel the genetic secrets behind a range of cancers.https://www.icr.ac.uk/news-archive%2fgene-profiling-has-improved---but-not-yet-personalised---breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fgene-profiling-has-improved---but-not-yet-personalised---breast-cancer-treatmentGene Profiling Has Improved - But Not Yet Personalised - Breast Cancer TreatmentGenetic profiling has revolutionised our understanding of breast cancer, but more work is needed before we can deliver truly personalised medicine to patients, Professor Jorge Reis-Filho from the ICR writes in the prestigious journal The Lancet.https://www.icr.ac.uk/news-archive%2fskin-cancer-drug-development-boosted-with-3m-granthttps://www.icr.ac.uk/news-archive%2fskin-cancer-drug-development-boosted-with-3m-grantSkin Cancer Drug Development Boosted with £3m GrantThe ICR and The Royal Marsden are to progress into patient trials an experimental drug to combat the most deadly form of skin cancer. The BRAF-inhibitor has the potential to treat more sub-types of malignant melanoma than any other targeted treatments for this cancer. https://www.icr.ac.uk/news-features%2flatest-features%2ficr-drug-discovery-highlighted-for-patient-impacthttps://www.icr.ac.uk/news-features%2flatest-features%2ficr-drug-discovery-highlighted-for-patient-impactICR drug discovery highlighted for patient impactDrug discovery research by ICR scientists has been singled out by a leading cancer journal for the current and future impact it is having on patients, and will be the subject of a presentation at an international cancer conference.https://www.icr.ac.uk/news-archive%2fpositive-survival-data-from-interim-analysis-of-phase-iii-trial-of-prostate-cancer-drug-https://www.icr.ac.uk/news-archive%2fpositive-survival-data-from-interim-analysis-of-phase-iii-trial-of-prostate-cancer-drug-Positive Survival Data from Interim Analysis of Phase III Trial of Prostate Cancer Drug A new type of hormonal treatment has been shown to extend life for men with advanced prostate cancer, according to an interim analysis of a Phase III trial jointly led by Professor Johann de Bono from the ICR and The Royal Marsden Hospital.https://www.icr.ac.uk/news-archive%2fyoung-icr-scientists-win-european-research-award-https://www.icr.ac.uk/news-archive%2fyoung-icr-scientists-win-european-research-award-Young ICR scientists win European research awardTwo up-and-coming ICR scientists have taken first and third prize in a Europe-wide cancer research competition. https://www.icr.ac.uk/news-features%2flatest-features%2fnational-cancer-research-institute-(ncri)-cancer-conference-2011https://www.icr.ac.uk/news-features%2flatest-features%2fnational-cancer-research-institute-(ncri)-cancer-conference-2011National Cancer Research Institute (NCRI) Cancer Conference 2011The NCRI Cancer Conference is the UK’s major forum for showcasing the best British and international cancer research.https://www.icr.ac.uk/news-archive%2fswitching-drugs-improves-breast-cancer-survival-rates-long-term-trial-data-showshttps://www.icr.ac.uk/news-archive%2fswitching-drugs-improves-breast-cancer-survival-rates-long-term-trial-data-showsSwitching Drugs Improves Breast Cancer Survival Rates, Long-Term Trial Data ShowsChanging to an aromatase inhibitor called exemestane after two to three years of tamoxifen treatment can cut women’s risk of dying from breast cancer, according to long-term follow up data from the Intergroup Exemestane Study (IES) published today in the Journal of Clinical Oncology.https://www.icr.ac.uk/news-archive%2fbreast-cancer-breakthrough-could-predict-recurrence-risk-for-thousands-of-uk-women-https://www.icr.ac.uk/news-archive%2fbreast-cancer-breakthrough-could-predict-recurrence-risk-for-thousands-of-uk-women-Breast Cancer Breakthrough Could Predict Recurrence Risk for Thousands of UK Women ICR scientists have developed a cost effective test to help identify which of the 37,000 women diagnosed with ER positive breast cancer each year are at risk of the disease returning.https://www.icr.ac.uk/news-archive%2fgene-testing-young-prostate-cancer-patients-could-help-target-treatmenthttps://www.icr.ac.uk/news-archive%2fgene-testing-young-prostate-cancer-patients-could-help-target-treatmentGene Testing Young Prostate Cancer Patients Could Help Target TreatmentRoutinely testing for a faulty BRCA2 gene in under-65s with prostate cancer could help identify men who could benefit from new types of targeted treatment, research led by the ICR shows.https://www.icr.ac.uk/news-archive%2fhpv-testing-in-screening-programme-saves-3-500-women-from-unncessary-testshttps://www.icr.ac.uk/news-archive%2fhpv-testing-in-screening-programme-saves-3-500-women-from-unncessary-testsHPV Testing in Screening Programme Saves 3,500 Women From Unncessary TestsTesting for the human papillomavirus as part of cervical screening reduces the number of women unnecessarily going on for further tests by over a third, according to an analysis led by the ICR.https://www.icr.ac.uk/news-archive%2ficr-scientist-to-lead-manchester-s-paterson-institutehttps://www.icr.ac.uk/news-archive%2ficr-scientist-to-lead-manchester-s-paterson-instituteICR Scientist to Lead Manchester’s Paterson InstituteProfessor Richard Marais has been appointed as the next director of the Paterson Institute for Cancer Research in Manchester. https://www.icr.ac.uk/news-archive%2fuk-discovered-prostate-cancer-drug-launches-in-britainhttps://www.icr.ac.uk/news-archive%2fuk-discovered-prostate-cancer-drug-launches-in-britainUK-Discovered Prostate Cancer Drug Launches in BritainA life-extending new drug to treat patients with advanced prostate cancer, developed by the ICR and The Royal Marsden Hospital, has received its UK license.https://www.icr.ac.uk/news-archive%2finternational-award-for-prostate-cancer-drug-developerhttps://www.icr.ac.uk/news-archive%2finternational-award-for-prostate-cancer-drug-developerInternational Award for Prostate Cancer Drug DeveloperAn oncologist from the ICR and The Royal Marsden Hospital who played a leading role in developing important new prostate cancer drugs will this week be honoured with a prestigious European cancer award. https://www.icr.ac.uk/news-archive%2fbreakthrough-in-male-breast-cancerhttps://www.icr.ac.uk/news-archive%2fbreakthrough-in-male-breast-cancerBreakthrough in Male Breast CancerThe world’s largest study into the genes that cause breast cancer in men reveals similarities with the female disease but also identifies some differences that could potentially lead to tailored treatments. https://www.icr.ac.uk/news-archive%2flaunch-of-new-trial-to-treat-recurrent-brain-tumourshttps://www.icr.ac.uk/news-archive%2flaunch-of-new-trial-to-treat-recurrent-brain-tumoursLaunch of New Trial to Treat Recurrent Brain TumoursThe Phase I clinical trial at three centres including the Royal Marsden Hospital and The Institute of Cancer Research is testing a new combination of drugs for the treatment of patients with glioblastoma.https://www.icr.ac.uk/news-archive%2feuropean-approval-for-uk-discovered-prostate-cancer-drughttps://www.icr.ac.uk/news-archive%2feuropean-approval-for-uk-discovered-prostate-cancer-drugEuropean Approval for UK-Discovered Prostate Cancer DrugAbiraterone acetate, a drug that extends life for men with advanced prostate cancer and was developed at the ICR and The Royal Marsden Hospital, has today been approved for use throughout Europe.https://www.icr.ac.uk/news-archive%2fvital-funding-continues-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fvital-funding-continues-for-cancer-researchVital Funding Continues for Cancer ResearchThe Royal Marsden NHS Trust, and academic partner, The Institute of Cancer Research (ICR), have been successful in their bid to retain their status as the UK’s only Specialist Biomedical Research Centre (BRC) for Cancer.https://www.icr.ac.uk/news-archive%2fcancers-generate-muscle-like-contractions-to-spread-around-the-bodyhttps://www.icr.ac.uk/news-archive%2fcancers-generate-muscle-like-contractions-to-spread-around-the-bodyCancers Generate Muscle-Like Contractions to Spread Around the BodyProfessor Chris Marshall and colleagues have discovered that a protein called JAK triggers contractions in tumours that allow cancer cells to squeeze though tiny spaces and spread, raising the possibility of new drugs that could stop metastasis.https://www.icr.ac.uk/news-archive%2fpreclinical-development-candidate-selected-for-chk1-inhibitor-programmehttps://www.icr.ac.uk/news-archive%2fpreclinical-development-candidate-selected-for-chk1-inhibitor-programmePreclinical Development Candidate Selected for Chk1 Inhibitor ProgrammeThe ICR, specialist cancer drug discovery business Sareum and Cancer Research Technology Limited are pleased to announce the selection of a preclinical development candidate from their joint research collaboration. https://www.icr.ac.uk/news-archive%2fscan-predicts-chemotherapy-benefit-after-just-one-cyclehttps://www.icr.ac.uk/news-archive%2fscan-predicts-chemotherapy-benefit-after-just-one-cycleScan Predicts Chemotherapy Benefit After Just One CycleScientists at the ICR and The Royal Marsden have developed an advanced type of MRI scan that can detect whether late-stage ovarian cancers are responding to chemotherapy treatment after just one cycle, which should help doctors decide whether to continue or alter treatment.https://www.icr.ac.uk/news-archive%2flandmark-ovarian-cancer-discovery-as-scientists-unveil-high-risk-genehttps://www.icr.ac.uk/news-archive%2flandmark-ovarian-cancer-discovery-as-scientists-unveil-high-risk-geneLandmark Ovarian Cancer Discovery as Scientists Unveil High Risk GeneICR scientists have made the most significant ovarian cancer gene discovery for more than a decade, finding women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing the disease.https://www.icr.ac.uk/news-archive%2ffirst-encyclopaedia-of-breast-cancer-s-weaknesseshttps://www.icr.ac.uk/news-archive%2ffirst-encyclopaedia-of-breast-cancer-s-weaknessesFirst Encyclopaedia of Breast Cancer’s WeaknessesPioneering scientists at the ICR's Breakthrough Breast Cancer Research Centre have created the world’s first encyclopaedia of genes that drive breast cancer. It is hoped that new targeted treatments leading directly from this work will be in clinical trials in the next few years. https://www.icr.ac.uk/news-archive%2fgenetic-link-to-rare-brain-tumour-discoveredhttps://www.icr.ac.uk/news-archive%2fgenetic-link-to-rare-brain-tumour-discoveredGenetic Link to Rare Brain Tumour DiscoveredICR scientists have conducted the first whole-genome scan of the brain tumour meningioma and revealed a genetic region that increases the risk of developing the disease.https://www.icr.ac.uk/news-archive%2ficr-scientist-receives-cancer-research-uk-lifetime-achievement-prizehttps://www.icr.ac.uk/news-archive%2ficr-scientist-receives-cancer-research-uk-lifetime-achievement-prizeICR Scientist Receives Cancer Research UK Lifetime Achievement PrizeProfessor Chris Marshall has been named as the recipient of this year’s Cancer Research UK Lifetime Achievement Prize.https://www.icr.ac.uk/news-archive%2flife-extending-prostate-cancer-drug-in-sight-for-uk-menhttps://www.icr.ac.uk/news-archive%2flife-extending-prostate-cancer-drug-in-sight-for-uk-menLife-Extending Prostate Cancer Drug in Sight for UK MenThe ICR and The Royal Marsden welcome the European pharmaceutical regulator’s recommendation that abiraterone acetate, trade name Zytiga™, be approved for use in men with metastatic castration-resistant prostate cancer.https://www.icr.ac.uk/news-archive%2fcancer-research-uk-invests-in-future-world-leading-icr-scientisthttps://www.icr.ac.uk/news-archive%2fcancer-research-uk-invests-in-future-world-leading-icr-scientistCancer Research UK Invests in Future World-Leading ICR ScientistCancer Research UK has awarded Dr Claus Jorgensen from the ICR a prestigious award as part of a series of grants given to new investigators who are set to become the eminent cancer scientists of the future.https://www.icr.ac.uk/news-archive%2fprojects-launched-to-crack-the-cancer-codehttps://www.icr.ac.uk/news-archive%2fprojects-launched-to-crack-the-cancer-codeProjects Launched to Crack the Cancer CodeThe ICR is leading a project to create the most comprehensive genetic map of prostate cancer yet assembled, which will transform our understanding of the disease and pave the way to better and more targeted treatments. A second project aims to identify genetic faults driving oesophageal cancer.https://www.icr.ac.uk/news-archive%2fphysicists-team-up-to-focus-on-cancerhttps://www.icr.ac.uk/news-archive%2fphysicists-team-up-to-focus-on-cancerPhysicists Team up to Focus on CancerScientists from leading London research centres met this week to discuss new ways to help cancer patients by combining their strengths in physics, clinical activities and basic research.https://www.icr.ac.uk/news-archive%2fscientists-unlock-further-prostate-cancer-secretshttps://www.icr.ac.uk/news-archive%2fscientists-unlock-further-prostate-cancer-secretsScientists Unlock Further Prostate Cancer SecretsResearchers at the ICR and University of Cambridge led an international study that discovered seven new variants in the human genome that increase the chances of developing prostate cancer.https://www.icr.ac.uk/news-archive%2fnew-line-of-attack-in-fight-against-cancerhttps://www.icr.ac.uk/news-archive%2fnew-line-of-attack-in-fight-against-cancerNew Line of Attack in Fight Against CancerScientists have uncovered a new way of killing cancer cells, opening up a potentially highly effective avenue of attack in the fight against all forms of the disease.https://www.icr.ac.uk/news-archive%2fchemotherapy-protocol-proves-worth-for-high-risk-children-s-cancerhttps://www.icr.ac.uk/news-archive%2fchemotherapy-protocol-proves-worth-for-high-risk-children-s-cancerChemotherapy Protocol Proves Worth for High Risk Children’s CancerAn 18 country Europe-wide study has demonstrated the benefit of the new European high dose chemotherapy protocol. The research was led by the ICR, The Royal Marsden and Great Ormond Street Hospital in the UK, and international collaborators.https://www.icr.ac.uk/news-archive%2fexpert-independent-panel-reviews-mobile-phone-link-to-brain-tumourshttps://www.icr.ac.uk/news-archive%2fexpert-independent-panel-reviews-mobile-phone-link-to-brain-tumoursExpert Independent Panel Reviews Mobile Phone Link to Brain TumoursAccumulating scientific research is increasingly against the theory that mobile phone use causes brain tumours, an expert panel led by the ICR's Professor Tony Swerdlow has found.https://www.icr.ac.uk/news-archive%2fbreast-cancer-patients-could-benefit-from-fewer-radiotherapy-treatmentshttps://www.icr.ac.uk/news-archive%2fbreast-cancer-patients-could-benefit-from-fewer-radiotherapy-treatmentsBreast Cancer Patients Could Benefit from Fewer Radiotherapy TreatmentsA major new clinical trial coordinated by the ICR will determine whether people diagnosed with breast cancer could benefit from receiving fewer radiotherapy treatments than the current UK standard.https://www.icr.ac.uk/news-archive%2fstem-cell-time-bombs-cause-leukaemia-relapsehttps://www.icr.ac.uk/news-archive%2fstem-cell-time-bombs-cause-leukaemia-relapseStem Cell Time Bombs Cause Leukaemia RelapseLeukaemia “stem cells” can lie dormant in the body for a decade or more after a child achieves remission before being reactivated and causing a relapse, a new study shows.https://www.icr.ac.uk/news-archive%2fsimple-blood-test-could-speed-up-cancer-drug-developmenthttps://www.icr.ac.uk/news-archive%2fsimple-blood-test-could-speed-up-cancer-drug-developmentSimple Blood Test Could Speed up Cancer Drug DevelopmentCancer drug development could accelerate in the future thanks to a simple and quick blood test that can help reveal the effectiveness of a new treatment, according to research presented this week at the ASCO annual meeting in Chicago.https://www.icr.ac.uk/news-archive%2fnew-smart-pill-shown-to-extend-lives-of-patients-with-most-aggressive-skin-cancerhttps://www.icr.ac.uk/news-archive%2fnew-smart-pill-shown-to-extend-lives-of-patients-with-most-aggressive-skin-cancerNew ‘Smart’ Pill Shown to Extend Lives of Patients with Most Aggressive Skin CancerThe Institute of Cancer Research (ICR) was responsible for key research on the BRAF gene, which paved the way for the development of this first-of-its-kind personalised treatment for advanced melanoma.https://www.icr.ac.uk/news-archive%2ficr-scientist-to-receive-2-14m-share-of-inaugural-wellcome-trust-investigator-awardshttps://www.icr.ac.uk/news-archive%2ficr-scientist-to-receive-2-14m-share-of-inaugural-wellcome-trust-investigator-awardsICR Scientist to Receive £2.14m Share of Inaugural Wellcome Trust Investigator AwardsProfessor Dale Wigley of The Institute of Cancer Research (ICR) has been announced as a recipient of one of the inaugural Wellcome Trust Investigator Awards. https://www.icr.ac.uk/news-archive%2fgene-test-predicts-leukaemia-survivalhttps://www.icr.ac.uk/news-archive%2fgene-test-predicts-leukaemia-survivalGene Test Predicts Leukaemia SurvivalScientists at The Institute of Cancer Research (ICR) have found that a genetic test can be used to identify patients with the most common type of adult leukaemia who will not respond well to currently available drugs and should instead be considered for experimental treatments.https://www.icr.ac.uk/news-archive%2fgirls-ages-at-first-period-getting-younger-particularly-those-from-poorer-backgroundshttps://www.icr.ac.uk/news-archive%2fgirls-ages-at-first-period-getting-younger-particularly-those-from-poorer-backgroundsGirls’ Ages at First Period Getting Younger, Particularly Those From Poorer BackgroundsGirls from poorer backgrounds are more likely to start their periods at a younger age, potentially putting them at a higher risk of breast cancer, according to a collaboration between the ICR and Breakthrough Breast Cancer.https://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-developers-win-royal-society-of-chemistry-awardhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-drug-developers-win-royal-society-of-chemistry-awardProstate Cancer Drug Developers Win Royal Society of Chemistry AwardA team of scientists at the ICR has won a prestigious Royal Society of Chemistry (RSC) award for the discovery and clinical development of prostate cancer drug abiraterone.https://www.icr.ac.uk/news-features%2flatest-features%2ftesting-new-radiotherapy-techniques-for-breast-cancerhttps://www.icr.ac.uk/news-features%2flatest-features%2ftesting-new-radiotherapy-techniques-for-breast-cancerTesting new radiotherapy techniques for breast cancerRadiotherapy is one of the key treatments for cancer. More than 120,000 cancer patients in the UK are treated with radiotherapy each year and it continues to cure more people than all existing drugs combined. The Institute of Cancer Research founded its department of radiotherapy in the early 1940s and has been at the forefront of a number of important developments that have improved patient care. https://www.icr.ac.uk/news-features%2flatest-features%2fa-new-way-to-treat-prostate-cancer-the-story-of-abirateronehttps://www.icr.ac.uk/news-features%2flatest-features%2fa-new-way-to-treat-prostate-cancer-the-story-of-abirateroneA new way to treat prostate cancer: The story of abirateroneAbiraterone was designed and developed at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. First synthesised in the early 1990s, this year it completed the journey from an idea to life-extending treatment for men with advanced prostate cancer. The US Food and Drug administration (FDA) approved the use of abiraterone in men with castration resistant prostate cancer in April 2011, and European approval followed in September 2011.https://www.icr.ac.uk/news-archive%2fnew-type-of-hormone-therapy-extends-prostate-cancer-patients-lives-study-findshttps://www.icr.ac.uk/news-archive%2fnew-type-of-hormone-therapy-extends-prostate-cancer-patients-lives-study-findsNew Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives, Study FindsThe drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.https://www.icr.ac.uk/news-features%2flatest-features%2fnew-type-of-hormone-therapy-extends-prostate-cancer-patients-liveshttps://www.icr.ac.uk/news-features%2flatest-features%2fnew-type-of-hormone-therapy-extends-prostate-cancer-patients-lives New type of hormone therapy extends prostate cancer patients’ livesThe drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.https://www.icr.ac.uk/news-archive%2fworld-s-biggest-medical-imaging-microchip-heralds-better-treatment-for-cancer-patientshttps://www.icr.ac.uk/news-archive%2fworld-s-biggest-medical-imaging-microchip-heralds-better-treatment-for-cancer-patientsWorld’s Biggest Medical Imaging Microchip Heralds Better Treatment for Cancer PatientsA collaboration between scientists at four UK organisations including The Institute of Cancer Research (ICR) has created the world’s biggest microchip designed for medical imaging. https://www.icr.ac.uk/news-archive%2f-like-finding-gold-in-trafalgar-square-gene-breakthroughhttps://www.icr.ac.uk/news-archive%2f-like-finding-gold-in-trafalgar-square-gene-breakthrough‘Like Finding Gold in Trafalgar Square’: Gene BreakthroughIn a surprise finding, three new breast cancer genes have been discovered next to the oestrogen receptor gene, which has been intensively studied by scientists for decadeshttps://www.icr.ac.uk/news-archive%2fprostate-cancer-patients-to-benefit-from-drug-discovered-at-the-icrhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-patients-to-benefit-from-drug-discovered-at-the-icrProstate Cancer Patients to Benefit from Drug Discovered at the ICRA drug discovered at the ICR has today been approved in the US for use by men with metastatic prostate cancer.https://www.icr.ac.uk/news-archive%2fgenetics-are-key-to-age-at-which-girls-start-their-periodshttps://www.icr.ac.uk/news-archive%2fgenetics-are-key-to-age-at-which-girls-start-their-periodsGenetics are Key to Age at Which Girls Start their PeriodsGenetic makeup explains more than half of the variation between UK women’s ages at first period, according to a study of almost 26,000 UK women published today.https://www.icr.ac.uk/news-archive%2ffirst-patients-to-receive-new-cancer-drug-AZD5363https://www.icr.ac.uk/news-archive%2ffirst-patients-to-receive-new-cancer-drug-AZD5363First Patients To Receive New Cancer Drug AZD5363An experimental drug the ICR helped discover has started Phase I safety testing in a range of cancer types.https://www.icr.ac.uk/news-archive%2fblood-test-shows-potential-to-predict-treatment-responsehttps://www.icr.ac.uk/news-archive%2fblood-test-shows-potential-to-predict-treatment-responseBlood Test Shows Potential to Predict Treatment ResponseScientists at the ICR have shown evidence that a blood test can quickly identify patients who are responding to a new type of personalised cancer treatment. https://www.icr.ac.uk/news-archive%2fnew-radiotherapy-technique-may-save-more-healthy-breast-tissuehttps://www.icr.ac.uk/news-archive%2fnew-radiotherapy-technique-may-save-more-healthy-breast-tissueNew Radiotherapy Technique May Save More Healthy Breast TissueA new study will confirm whether an advanced radiotherapy technique that uses imaging of titanium clips implanted during surgery can reduce side-effects from breast cancer treatment.https://www.icr.ac.uk/news-archive%2fthe-icr-cancer-research-technology-and-zobio-bv-sign-deal-to-develop-cancer-drugshttps://www.icr.ac.uk/news-archive%2fthe-icr-cancer-research-technology-and-zobio-bv-sign-deal-to-develop-cancer-drugsThe ICR, Cancer Research Technology and Zobio BV Sign Deal to Develop Cancer DrugsThe three organisations are collaborating to discover and develop drugs to block a DNA repair target that may play a role in cancer cell survival.https://www.icr.ac.uk/news-archive%2ftwo-pronged-approach-brings-hope-for-bowel-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2ftwo-pronged-approach-brings-hope-for-bowel-cancer-treatmentTwo-pronged Approach Brings Hope For Bowel Cancer TreatmentCancer Research UK-funded scientists have discovered that blocking two cell DNA repair routes at once could provide a completely new way to treat bowel cancer and potentially other cancers.https://www.icr.ac.uk/news-archive%2fgene-test-to-predict-nerve-damage-from-bone-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fgene-test-to-predict-nerve-damage-from-bone-cancer-treatmentGene Test to Predict Nerve Damage from Bone Cancer TreatmentScientists have found a genetic test that predicts whether bone marrow cancer treatments including thalidomide are likely to give patients a debilitating side-effect.https://www.icr.ac.uk/news-archive%2fstudy-confirms-therapy-could-halt-breast-cancer-spreadhttps://www.icr.ac.uk/news-archive%2fstudy-confirms-therapy-could-halt-breast-cancer-spreadStudy Confirms Therapy Could Halt Breast Cancer SpreadICR scientists have for the first time shown that blocking a key enzyme can stop breast cancer spreading to distant organs.https://www.icr.ac.uk/news-features%2flatest-features%2fthe-art-of-structural-biology-modelling-the-apc-complexhttps://www.icr.ac.uk/news-features%2flatest-features%2fthe-art-of-structural-biology-modelling-the-apc-complexThe Art of Structural Biology: modelling the APC ComplexThe molecular machine controlling cell growth Professor David Barford leads a team within the Section of Structural Biology that has recently published work in the prestigious scientific journal Nature* examining the structure of a protein complex known as the anaphase-promoting complex (APC/C). https://www.icr.ac.uk/news-archive%2ffirst-national-data-on-breast-cancers-that-occur-between-screeningshttps://www.icr.ac.uk/news-archive%2ffirst-national-data-on-breast-cancers-that-occur-between-screeningsFirst National Data on Breast Cancers that Occur Between ScreeningsThe first UK-wide study into the rate of breast cancers diagnosed between scheduled screenings has been published today in the British Journal of Cancer. https://www.icr.ac.uk/news-archive%2fnew-targeted-treatment-strategy-could-help-bowel-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-targeted-treatment-strategy-could-help-bowel-cancer-patientsNew Targeted Treatment Strategy Could Help Bowel Cancer PatientsScientists at the ICR have found an important new drug target for advanced bowel cancerhttps://www.icr.ac.uk/news-archive%2fpill-brings-promise-for-patients-with-skin-cancerhttps://www.icr.ac.uk/news-archive%2fpill-brings-promise-for-patients-with-skin-cancerPill Brings Promise for Patients with Skin CancerStrength of early results means all 'placebo arm' trial patients will be offered treatment with RG7204.https://www.icr.ac.uk/news-archive%2fintensity-modulated-radiotheraphy-protects-saliva-function-and-improves-quality-of-lifehttps://www.icr.ac.uk/news-archive%2fintensity-modulated-radiotheraphy-protects-saliva-function-and-improves-quality-of-lifeIntensity-Modulated Radiotheraphy Protects Saliva Function and Improves Quality of LifeThese findings, from the largest randomised trial of IMRT in head and neck cancer https://www.icr.ac.uk/news-archive%2ffaulty-gene-behind-skin-cancer-also-triggers-spreadhttps://www.icr.ac.uk/news-archive%2ffaulty-gene-behind-skin-cancer-also-triggers-spreadFaulty Gene Behind Skin Cancer Also Triggers SpreadCancer Research UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked.https://www.icr.ac.uk/news-archive%2fspecialist-mri-detects-advancing-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fspecialist-mri-detects-advancing-prostate-cancerSpecialist MRI Detects Advancing Prostate CancerProstate cancer patients under Active Surveillance could be assessed by MRI instead of an invasive biopsy https://www.icr.ac.uk/news-archive%2fuk-scientists-reveal-cancer-s-dark-darwinian-secrethttps://www.icr.ac.uk/news-archive%2fuk-scientists-reveal-cancer-s-dark-darwinian-secretUK Scientists Reveal Cancer’s Dark Darwinian SecretA breakthrough study has shed light on the reason why advanced cancers are notoriously resistant to treatment and, remarkably, it may be as fundamental as evolution itself.https://www.icr.ac.uk/news-features%2flatest-features%2fdrug-discovery-database-launchedhttps://www.icr.ac.uk/news-features%2flatest-features%2fdrug-discovery-database-launchedDrug discovery database launchedSince the completion of the Human Genome Project in 2001 there has been an explosion in the amount of genetic information available to researchers involved in drug discovery. As faster technologies continue to fuel the growth of large datasets, researchers at the ICR and elsewhere must develop new methods for distilling useful information from an overwhelming amount of data.https://www.icr.ac.uk/news-archive%2foncovex-phase-iii-trial-for-head-and-neck-cancers-commenceshttps://www.icr.ac.uk/news-archive%2foncovex-phase-iii-trial-for-head-and-neck-cancers-commencesOncoVEX Phase III Trial for Head and Neck Cancers CommencesBiotechnology company BioVex Inc has announced the start of a Phase III study using the drug OncoVEX, a genetically engineered cold sore virus, to treat patients newly-diagnosed with locally advanced head and neck cancerhttps://www.icr.ac.uk/news-archive%2fdrug-can-extend-life-for-multiple-myeloma-patientshttps://www.icr.ac.uk/news-archive%2fdrug-can-extend-life-for-multiple-myeloma-patientsDrug Can Extend Life for Multiple Myeloma PatientsAdding a second drug to standard chemotherapy treatment can help patients diagnosed with an aggressive type of bone marrow cancer live longer.https://www.icr.ac.uk/news-archive%2ffinger-length-linked-to-prostate-cancer-riskhttps://www.icr.ac.uk/news-archive%2ffinger-length-linked-to-prostate-cancer-riskFinger Length Linked to Prostate Cancer RiskMen who have long index fingers are at lower risk of prostate cancer, a new study from the ICR has found.https://www.icr.ac.uk/news-archive%2fcancer-researcher-dr-janine-erler-recognised-as-pioneerhttps://www.icr.ac.uk/news-archive%2fcancer-researcher-dr-janine-erler-recognised-as-pioneerCancer Researcher Dr Janine Erler Recognised as PioneerDr Janine Erler from the ICR has been named as one of the UK’s most impressive professional women.https://www.icr.ac.uk/news-archive%2fpowerful-online-cancer-drug-discovery-database-unveiledhttps://www.icr.ac.uk/news-archive%2fpowerful-online-cancer-drug-discovery-database-unveiledPowerful Online Cancer Drug Discovery Database UnveiledA powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from ‘bench to bedside’.https://www.icr.ac.uk/news-archive%2fnew-study-reveals-factors-behind-age-of-girls-first-periodhttps://www.icr.ac.uk/news-archive%2fnew-study-reveals-factors-behind-age-of-girls-first-periodNew Study Reveals Factors Behind Age of Girls’ First PeriodLifestyle and health factors starting from before birth may affect the age at which a girl begins her periods, a major new study from the ICR shows.https://www.icr.ac.uk/news-archive%2fnew-study-evaluates-prostate-screening-for-higher-risk-menhttps://www.icr.ac.uk/news-archive%2fnew-study-evaluates-prostate-screening-for-higher-risk-menNew Study Evaluates Prostate Screening for Higher-risk MenA new study will determine whether existing genetic tests and family history profiling can be used to find men at higher risk of prostate cancer, so they can be targeted for screening.https://www.icr.ac.uk/news-archive%2fscientists-find-genes-that-make-brain-tumours-treatment-resistanthttps://www.icr.ac.uk/news-archive%2fscientists-find-genes-that-make-brain-tumours-treatment-resistantScientists Find Genes That Make Brain Tumours Treatment ResistantScientists at The Institute of Cancer Research (ICR) have pinpointed two genes that can predict whether patients with a deadly brain tumour will respond to the gold standard treatment.https://www.icr.ac.uk/news-archive%2fpooled-genome-data-reveals-four-bowel-cancer-risk-gene-variantshttps://www.icr.ac.uk/news-archive%2fpooled-genome-data-reveals-four-bowel-cancer-risk-gene-variantsPooled Genome Data Reveals Four Bowel Cancer Risk Gene VariantsScientists have discovered four new genetic variants linked to bowel cancer by combining data from three major genome studies.https://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-scientist-receives-cruk-future-leaders-prizehttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-scientist-receives-cruk-future-leaders-prizeInstitute of Cancer Research Scientist Receives CRUK Future Leaders PrizeProfessor Jorge Reis-Filho, a team leader at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, is one of two recipients of the inaugural Cancer Research UK Future Leaders in Cancer Research Prize.https://www.icr.ac.uk/news-archive%2fuk%27s-first-dedicated-prostate-cancer-virtual-biobank-launchedhttps://www.icr.ac.uk/news-archive%2fuk%27s-first-dedicated-prostate-cancer-virtual-biobank-launchedUK's First Dedicated Prostate Cancer Virtual Biobank LaunchedScientists from the ICR have helped develop the first virtual biobank dedicated to prostate cancer research.https://www.icr.ac.uk/news-archive%2fscientists-find-non-viral-pathway-of-blood-cancer-developmenthttps://www.icr.ac.uk/news-archive%2fscientists-find-non-viral-pathway-of-blood-cancer-developmentScientists Find Non-viral Pathway of Blood Cancer DevelopmentA study led by the ICR has found three new regions of DNA linked to the development of Hodgkin lymphoma.https://www.icr.ac.uk/news-archive%2ffour-in-10-men-with-prostate-cancer-may-avoid-radical-treatmenthttps://www.icr.ac.uk/news-archive%2ffour-in-10-men-with-prostate-cancer-may-avoid-radical-treatmentFour in 10 Men with Prostate Cancer May Avoid Radical TreatmentHundreds of UK men are opting to delay aggressive treatment for prostate cancer in favour of being monitoredhttps://www.icr.ac.uk/news-archive%2fscientists-report-first-step-towards-genetic-test-to-predict-early-menopausehttps://www.icr.ac.uk/news-archive%2fscientists-report-first-step-towards-genetic-test-to-predict-early-menopauseScientists Report First Step Towards Genetic Test to Predict Early MenopauseThe first Breakthrough Generations Study report could lead to a test to predict reproductive lifespan.https://www.icr.ac.uk/news-features%2flatest-features%2fprostate-cancer-progresshttps://www.icr.ac.uk/news-features%2flatest-features%2fprostate-cancer-progressProstate Cancer ProgressThe ICR’s focus on the deadly male cancer is paying offhttps://www.icr.ac.uk/news-archive%2furine-protein-could-pave-the-way-for-new-prostate-cancer-testhttps://www.icr.ac.uk/news-archive%2furine-protein-could-pave-the-way-for-new-prostate-cancer-testUrine Protein Could Pave the Way for New Prostate Cancer TestA new study has shown that a protein in urine could be a powerful indicator of prostate cancer risk.https://www.icr.ac.uk/news-archive%2ficr-discovered-drug-improved-prostate-cancer-patient-survivalhttps://www.icr.ac.uk/news-archive%2ficr-discovered-drug-improved-prostate-cancer-patient-survivalICR-Discovered Drug Improved Prostate Cancer Patient SurvivalPhase III trial results presented today show a drug developed by British scientists can significantly extend overall survival for men with advanced prostate cancer.https://www.icr.ac.uk/news-archive%2ftrial-helps-bring-new-prostate-cancer-drug-to-markethttps://www.icr.ac.uk/news-archive%2ftrial-helps-bring-new-prostate-cancer-drug-to-marketTrial Helps Bring New Prostate Cancer Drug to MarketA drug that the ICR and The Royal Marsden helped develop extends the life of men with advanced prostate cancer.https://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-names-professor-alan-ashworth-frs-as-new-ceohttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-names-professor-alan-ashworth-frs-as-new-ceoThe Institute of Cancer Research names Professor Alan Ashworth FRS as new CEOEurope’s leading cancer research centre, The Institute of Cancer Research (ICR), has named eminent scientist Professor Alan Ashworth as its new Chief Executive. Professor Ashworth will take up the appointment in January. https://www.icr.ac.uk/news-archive%2fscientists-unravel-genetic-risk-of-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-unravel-genetic-risk-of-bowel-cancerScientists Unravel Genetic Risk of Bowel CancerAn international study led by scientists at the ICR has shown how a single variant in a person’s DNA can promote bowel cancer development. https://www.icr.ac.uk/news-archive%2ffirst-major-study-supports-screening-in-men-at-higher-genetic-risk-of-prostate-cancerhttps://www.icr.ac.uk/news-archive%2ffirst-major-study-supports-screening-in-men-at-higher-genetic-risk-of-prostate-cancerFirst Major Study Supports Screening in Men at Higher Genetic Risk of Prostate CancerMen at higher risk of prostate cancer due to genetic changes may benefit from regular screening, according to preliminary results from the first multinational study of patients.https://www.icr.ac.uk/news-archive%2fscientists-make-major-discovery-in-finding-origins-of-aggressive-breast-cancerhttps://www.icr.ac.uk/news-archive%2fscientists-make-major-discovery-in-finding-origins-of-aggressive-breast-cancerScientists Make Major Discovery in Finding Origins of Aggressive Breast CancerScientists have made a major step towards answering one of the fundamental questions in breast cancer research – where the disease originates. This raises hope of new targeted treatments for women with breast cancer in the future.https://www.icr.ac.uk/news-archive%2fresearch-opens-door-to-new-drugs-that-will-counter-tamoxifen-resistancehttps://www.icr.ac.uk/news-archive%2fresearch-opens-door-to-new-drugs-that-will-counter-tamoxifen-resistanceResearch Opens Door to New Drugs That Will Counter Tamoxifen ResistanceA discovery by Professor Clare Isacke and her team at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR) could open the door to new treatments for those who have developed a resistance to tamoxifenhttps://www.icr.ac.uk/news-archive%2fnew-test-could-reveal-chemotherapy-benefit-in-24-hourshttps://www.icr.ac.uk/news-archive%2fnew-test-could-reveal-chemotherapy-benefit-in-24-hoursNew Test Could Reveal Chemotherapy Benefit in 24 HoursScientists have developed a new test to indicate whether the most commonly-used chemotherapy drug will benefit a breast cancer patient within 24 hours of taking it. The test also identifies patients who may benefit from PARP inhibitors, a promising new class of cancer treatment.https://www.icr.ac.uk/news-archive%2ficr-and-horizon-discovery-to-collaborate-on-genome-wide-synthetic-lethality-screenshttps://www.icr.ac.uk/news-archive%2ficr-and-horizon-discovery-to-collaborate-on-genome-wide-synthetic-lethality-screensICR and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality ScreensThe ICR and Horizon Discovery (Horizon) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.https://www.icr.ac.uk/news-archive%2fherpes-virus-treats-head-and-neck-cancer-patientshttps://www.icr.ac.uk/news-archive%2fherpes-virus-treats-head-and-neck-cancer-patientsHerpes Virus Treats Head and Neck Cancer PatientsA genetically engineered cold sore virus has been used to treat head and neck cancer patients in a Phase I/II clinical trial.https://www.icr.ac.uk/news-archive%2ficr-chief-executive-to-become-deputy-chairman-of-the-wellcome-trusthttps://www.icr.ac.uk/news-archive%2ficr-chief-executive-to-become-deputy-chairman-of-the-wellcome-trustICR Chief Executive to Become Deputy Chairman of the Wellcome TrustHe will take up the position at the independent, global biomedical charity in October. https://www.icr.ac.uk/news-archive%2ftherapy-reduces-dangerous-side-effectshttps://www.icr.ac.uk/news-archive%2ftherapy-reduces-dangerous-side-effectsTherapy Reduces Dangerous Side-effectsChildren given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect.https://www.icr.ac.uk/news-archive%2fbreast-cancer-drugs-may-treat-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-drugs-may-treat-prostate-cancerBreast Cancer Drugs May Treat Prostate CancerThe way prostate cancer develops in men who have an altered ‘breast cancer gene’ is the same route by which breast cancer develops in women with the same mutation.https://www.icr.ac.uk/news-archive%2fcancer-centres-launch-academic-partnershiphttps://www.icr.ac.uk/news-archive%2fcancer-centres-launch-academic-partnershipCancer Centres Launch Academic PartnershipA new academic partnership will be officially launched next week when Mount Vernon Cancer Centre joins the long-standing collaboration between The Royal Marsden and The Institute of Cancer Research (ICR).https://www.icr.ac.uk/news-archive%2fthree-new-testicular-cancer-risk-variantshttps://www.icr.ac.uk/news-archive%2fthree-new-testicular-cancer-risk-variantsThree New Testicular Cancer Risk VariantsA study led by The Institute of Cancer Research (ICR) has identified three new genetic risk factors for testicular cancer.https://www.icr.ac.uk/news-archive%2fmutation-confirmed-as-melanoma-drug-targethttps://www.icr.ac.uk/news-archive%2fmutation-confirmed-as-melanoma-drug-targetMutation Confirmed as Melanoma Drug TargetA mutation present in around half of malignant melanomas has been confirmed as a strong drug target, according to research published today in Science Translation Medicine. https://www.icr.ac.uk/news-archive%2ftesticular-cancer-chemo-risk-examinedhttps://www.icr.ac.uk/news-archive%2ftesticular-cancer-chemo-risk-examinedTesticular Cancer Chemo Risk ExaminedLong-term side-effects including nerve pain, hearing loss and discoloured fingers and toes are a risk for men given chemotherapy treatment for testicular cancer, new research shows.https://www.icr.ac.uk/news-archive%2fcancer-drug-researcher-receives-royal-society-of-chemistry-awardhttps://www.icr.ac.uk/news-archive%2fcancer-drug-researcher-receives-royal-society-of-chemistry-awardCancer Drug Researcher Receives Royal Society of Chemistry AwardProfessor Paul Workman from The Institute of Cancer Research (ICR) has received a prestigious award from the Royal Society of Chemistry for his work in discovering exciting new anti-cancer drugs.https://www.icr.ac.uk/news-archive%2fgenetic-mutation-shown-to-trigger-melanomahttps://www.icr.ac.uk/news-archive%2fgenetic-mutation-shown-to-trigger-melanomaGenetic Mutation Shown to Trigger MelanomaResearchers have discovered that a genetic mutation found in some malignant melanomas can initiate development of this most deadly form of skin cancer, according to a study published today in the journal Cancer Research.https://www.icr.ac.uk/news-archive%2fplanning-the-future-of-personalised-medicinehttps://www.icr.ac.uk/news-archive%2fplanning-the-future-of-personalised-medicinePlanning the Future of Personalised Medicinehttps://www.icr.ac.uk/news-archive%2ficr-s-chief-executive-elected-fellow-of-the-royal-societyhttps://www.icr.ac.uk/news-archive%2ficr-s-chief-executive-elected-fellow-of-the-royal-societyICR’s Chief Executive Elected Fellow of the Royal Societyhttps://www.icr.ac.uk/news-archive%2fhuman-virus-helps-to-treat-cancer-patientshttps://www.icr.ac.uk/news-archive%2fhuman-virus-helps-to-treat-cancer-patientsHuman Virus Helps to Treat Cancer Patientshttps://www.icr.ac.uk/news-archive%2fgenetics-of-children-s-brain-tumour-unlockedhttps://www.icr.ac.uk/news-archive%2fgenetics-of-children-s-brain-tumour-unlockedGenetics of Children’s Brain Tumour Unlockedhttps://www.icr.ac.uk/news-archive%2fbrain-tumour-and-mobile-phone-study-reportshttps://www.icr.ac.uk/news-archive%2fbrain-tumour-and-mobile-phone-study-reportsBrain Tumour and Mobile Phone Study Reportshttps://www.icr.ac.uk/news-archive%2fthe-iarc-medal-of-honour-award-2010https://www.icr.ac.uk/news-archive%2fthe-iarc-medal-of-honour-award-2010The IARC Medal of Honour Award 2010https://www.icr.ac.uk/news-archive%2ficr-hosts-meeting-of-top-network-biologistshttps://www.icr.ac.uk/news-archive%2ficr-hosts-meeting-of-top-network-biologistsICR Hosts Meeting of Top Network Biologistshttps://www.icr.ac.uk/news-archive%2fscientists-find-areas-of-genome-that-increase-breast-cancer-riskhttps://www.icr.ac.uk/news-archive%2fscientists-find-areas-of-genome-that-increase-breast-cancer-riskScientists Find Areas of Genome that Increase Breast Cancer Riskhttps://www.icr.ac.uk/news-archive%2ftwo-eminent-geneticists-elected-to-academy-of-medical-scienceshttps://www.icr.ac.uk/news-archive%2ftwo-eminent-geneticists-elected-to-academy-of-medical-sciencesTwo Eminent Geneticists Elected to Academy of Medical Scienceshttps://www.icr.ac.uk/news-archive%2f-5-8-million-grant-awarded-to-investigate-intelligent-cancer-imaginghttps://www.icr.ac.uk/news-archive%2f-5-8-million-grant-awarded-to-investigate-intelligent-cancer-imaging£5.8 Million Grant Awarded to Investigate Intelligent Cancer Imaginghttps://www.icr.ac.uk/news-archive%2fdrug-benefits-patients-with-inherited-ovarian-cancer-https://www.icr.ac.uk/news-archive%2fdrug-benefits-patients-with-inherited-ovarian-cancer-Drug Benefits Patients with Inherited Ovarian Cancer https://www.icr.ac.uk/news-archive%2fgrant-worth-4-million-awarded-to-develop-new-cancer-drughttps://www.icr.ac.uk/news-archive%2fgrant-worth-4-million-awarded-to-develop-new-cancer-drugGrant Worth £4 Million Awarded to Develop New Cancer Drughttps://www.icr.ac.uk/news-archive%2fgene-discovery-could-lead-to-new-treatments-for-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fgene-discovery-could-lead-to-new-treatments-for-childhood-cancerGene Discovery Could Lead to New Treatments for Childhood Cancerhttps://www.icr.ac.uk/news-archive%2fyounger-women-choose-breast-screenshttps://www.icr.ac.uk/news-archive%2fyounger-women-choose-breast-screensYounger Women Choose Breast Screenshttps://www.icr.ac.uk/news-archive%2fpotential-to-reduce-children-s-side-effects-from-cancer-treatment-https://www.icr.ac.uk/news-archive%2fpotential-to-reduce-children-s-side-effects-from-cancer-treatment-Potential to Reduce Children’s Side-effects from Cancer Treatment https://www.icr.ac.uk/news-archive%2ffirst-patient-treated-in-phase-ii-trial-of-anticancer-hsp90-inhibitorhttps://www.icr.ac.uk/news-archive%2ffirst-patient-treated-in-phase-ii-trial-of-anticancer-hsp90-inhibitorFirst Patient Treated in Phase II Trial of Anticancer Hsp90 Inhibitorhttps://www.icr.ac.uk/news-archive%2ficr-to-collaborate-on-cancer-drug-development-programmehttps://www.icr.ac.uk/news-archive%2ficr-to-collaborate-on-cancer-drug-development-programmeICR to Collaborate on Cancer Drug Development Programmehttps://www.icr.ac.uk/news-archive%2fexploiting-cancer-s-double-agent-could-lead-to-new-treatments-for-bowel-cancerhttps://www.icr.ac.uk/news-archive%2fexploiting-cancer-s-double-agent-could-lead-to-new-treatments-for-bowel-cancerExploiting Cancer’s ‘Double Agent’ Could Lead To New Treatments For Bowel Cancerhttps://www.icr.ac.uk/news-archive%2fmethods-for-classifying-patients-produce-inaccurate-and-inconsistent-resultshttps://www.icr.ac.uk/news-archive%2fmethods-for-classifying-patients-produce-inaccurate-and-inconsistent-resultsMethods for Classifying Patients Produce Inaccurate and Inconsistent Resultshttps://www.icr.ac.uk/news-archive%2fscientists-unlock-key-to-tamoxifen-resistancehttps://www.icr.ac.uk/news-archive%2fscientists-unlock-key-to-tamoxifen-resistanceScientists Unlock Key to Tamoxifen Resistancehttps://www.icr.ac.uk/news-archive%2fnew-drug-benefits-late-stage-prostate-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-drug-benefits-late-stage-prostate-cancer-patientsNew Drug Benefits Late-Stage Prostate Cancer Patientshttps://www.icr.ac.uk/news-archive%2fradiotherapy-regimen-safe-for-breast-patientshttps://www.icr.ac.uk/news-archive%2fradiotherapy-regimen-safe-for-breast-patientsRadiotherapy Regimen Safe for Breast Patientshttps://www.icr.ac.uk/news-archive%2ficr-receives-environmental-honourhttps://www.icr.ac.uk/news-archive%2ficr-receives-environmental-honourICR Receives Environmental Honourhttps://www.icr.ac.uk/news-archive%2fgenetic-abnormalities-predict-prostate-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fgenetic-abnormalities-predict-prostate-cancer-survivalGenetic Abnormalities Predict Prostate Cancer Survivalhttps://www.icr.ac.uk/news-archive%2ficr-selects-world%27s-fastest-supercomputerhttps://www.icr.ac.uk/news-archive%2ficr-selects-world%27s-fastest-supercomputerICR Selects World's Fastest Supercomputerhttps://www.icr.ac.uk/news-archive%2fdiscovery-could-help-refine-advanced-melanoma-treatmenthttps://www.icr.ac.uk/news-archive%2fdiscovery-could-help-refine-advanced-melanoma-treatmentDiscovery Could Help Refine Advanced Melanoma Treatmenthttps://www.icr.ac.uk/news-archive%2fmolecules-increase-the-effectiveness-of-certain-therapieshttps://www.icr.ac.uk/news-archive%2fmolecules-increase-the-effectiveness-of-certain-therapiesMolecules Increase the Effectiveness of Certain Therapieshttps://www.icr.ac.uk/news-archive%2fgenetic-factors-can-increase-leukaemia-risk-7-foldhttps://www.icr.ac.uk/news-archive%2fgenetic-factors-can-increase-leukaemia-risk-7-foldGenetic Factors Can Increase Leukaemia Risk 7-Foldhttps://www.icr.ac.uk/news-archive%2fdna-helps-identify-genes-that-drive-cancerhttps://www.icr.ac.uk/news-archive%2fdna-helps-identify-genes-that-drive-cancerDNA Helps Identify Genes that Drive Cancerhttps://www.icr.ac.uk/news-archive%2fclinical-candidate-selected-by-astrazenecahttps://www.icr.ac.uk/news-archive%2fclinical-candidate-selected-by-astrazenecaClinical Candidate Selected by AstraZenecahttps://www.icr.ac.uk/news-archive%2fdrug-can-curb-ewing-s-sarcoma-growthhttps://www.icr.ac.uk/news-archive%2fdrug-can-curb-ewing-s-sarcoma-growthDrug Can Curb Ewing’s Sarcoma GrowthAn early study of the drug figitumumab has found that in some patients it can curb the growth of Ewing’s sarcoma - a cancer which affects mainly teenage boys. The study was led by Dr Johann de Bono, from The Institute of Cancer Research and The Royal Marsden Hospital, and funded by Pfizer, who developed the drug.https://www.icr.ac.uk/news-archive%2fbroken-genomes-behind-breast-cancershttps://www.icr.ac.uk/news-archive%2fbroken-genomes-behind-breast-cancersBroken Genomes Behind Breast Cancershttps://www.icr.ac.uk/news-archive%2ffarewell-to-jonathan-kiplinghttps://www.icr.ac.uk/news-archive%2ffarewell-to-jonathan-kiplingFarewell to Jonathan Kiplinghttps://www.icr.ac.uk/news-archive%2fscientists-hear-cell-conversation-for-first-timehttps://www.icr.ac.uk/news-archive%2fscientists-hear-cell-conversation-for-first-timeScientists Hear Cell Conversation for First Timehttps://www.icr.ac.uk/news-archive%2fstudent-s-award-for-study-into-cancer-drug-target-https://www.icr.ac.uk/news-archive%2fstudent-s-award-for-study-into-cancer-drug-target-Student’s Award for Study into Cancer Drug Target https://www.icr.ac.uk/news-archive%2ftissue-stiffness-is-key-to-aggressive-cancershttps://www.icr.ac.uk/news-archive%2ftissue-stiffness-is-key-to-aggressive-cancersTissue Stiffness is Key to Aggressive Cancershttps://www.icr.ac.uk/news-archive%2finnovative-national-clinical-trial-network-launchedhttps://www.icr.ac.uk/news-archive%2finnovative-national-clinical-trial-network-launchedInnovative National Clinical Trial Network Launchedhttps://www.icr.ac.uk/news-archive%2ftelomere-targeting-agents-licenced-to-pharminox-https://www.icr.ac.uk/news-archive%2ftelomere-targeting-agents-licenced-to-pharminox-Telomere Targeting Agents Licenced to Pharminox https://www.icr.ac.uk/news-archive%2fscientists-solve-100-year-cancer-puzzlehttps://www.icr.ac.uk/news-archive%2fscientists-solve-100-year-cancer-puzzleScientists Solve 100-year Cancer Puzzlehttps://www.icr.ac.uk/news-archive%2ficr-and-marsden-honoured-with-oncology-awardhttps://www.icr.ac.uk/news-archive%2ficr-and-marsden-honoured-with-oncology-awardICR and Marsden Honoured with Oncology Awardhttps://www.icr.ac.uk/news-archive%2frare-genetic-mutations-increase-bowel-cancer-risk-https://www.icr.ac.uk/news-archive%2frare-genetic-mutations-increase-bowel-cancer-risk-Rare Genetic Mutations Increase Bowel Cancer Risk https://www.icr.ac.uk/news-archive%2fchild-brain-tumour-gene-foundhttps://www.icr.ac.uk/news-archive%2fchild-brain-tumour-gene-foundChild brain tumour gene foundhttps://www.icr.ac.uk/news-archive%2flaunch-of-joint-annual-research-reporthttps://www.icr.ac.uk/news-archive%2flaunch-of-joint-annual-research-reportLaunch of Joint Annual Research Reporthttps://www.icr.ac.uk/news-archive%2fprofessor-alan-ashworth-to-receive-prestigious-awardhttps://www.icr.ac.uk/news-archive%2fprofessor-alan-ashworth-to-receive-prestigious-awardProfessor Alan Ashworth to Receive Prestigious Awardhttps://www.icr.ac.uk/news-archive%2fscientists-in-major-prostate-cancer-gene-discoveryhttps://www.icr.ac.uk/news-archive%2fscientists-in-major-prostate-cancer-gene-discoveryScientists in Major Prostate Cancer Gene Discoveryhttps://www.icr.ac.uk/news-archive%2fnew-potential-for-targeted-cancer-treatment-uncoveredhttps://www.icr.ac.uk/news-archive%2fnew-potential-for-targeted-cancer-treatment-uncoveredNew Potential for Targeted Cancer Treatment Uncoveredhttps://www.icr.ac.uk/news-archive%2fkey-molecules-in-cancer-spread-uncoveredhttps://www.icr.ac.uk/news-archive%2fkey-molecules-in-cancer-spread-uncoveredKey Molecules in Cancer Spread Uncoveredhttps://www.icr.ac.uk/news-archive%2f60-year-old-drug-shows-new-promise-for-cancerhttps://www.icr.ac.uk/news-archive%2f60-year-old-drug-shows-new-promise-for-cancer60-Year-Old Drug Shows New Promise for Cancerhttps://www.icr.ac.uk/news-archive%2fnew-solid-tumour-drug-trial-commenceshttps://www.icr.ac.uk/news-archive%2fnew-solid-tumour-drug-trial-commencesNew Solid Tumour Drug Trial Commenceshttps://www.icr.ac.uk/news-archive%2ftreatment-for-footballers-could-help-cancer-patientshttps://www.icr.ac.uk/news-archive%2ftreatment-for-footballers-could-help-cancer-patientsTreatment for Footballers Could Help Cancer Patientshttps://www.icr.ac.uk/news-archive%2fevidence-that-genes-increase-lung-cancer-riskhttps://www.icr.ac.uk/news-archive%2fevidence-that-genes-increase-lung-cancer-riskEvidence that Genes Increase Lung Cancer Riskhttps://www.icr.ac.uk/news-archive%2fgender-equality-award-for-the-icrhttps://www.icr.ac.uk/news-archive%2fgender-equality-award-for-the-icrGender Equality Award for the ICRhttps://www.icr.ac.uk/news-archive%2finherited-susceptibility-to-childhood-leukaemia-identifiedhttps://www.icr.ac.uk/news-archive%2finherited-susceptibility-to-childhood-leukaemia-identifiedInherited Susceptibility to Childhood Leukaemia Identifiedhttps://www.icr.ac.uk/news-archive%2fdrug-increases-survival-in-advanced-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fdrug-increases-survival-in-advanced-prostate-cancerDrug Increases Survival in Advanced Prostate Cancerhttps://www.icr.ac.uk/news-archive%2ffuture-treatments-may-target-shared-biological-networkshttps://www.icr.ac.uk/news-archive%2ffuture-treatments-may-target-shared-biological-networksFuture Treatments May Target Shared Biological Networkshttps://www.icr.ac.uk/news-archive%2fmore-women-to-benefit-from-herceptinhttps://www.icr.ac.uk/news-archive%2fmore-women-to-benefit-from-herceptinMore Women to Benefit from Herceptinhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-dna-vaccine-shows-significant-responsehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-dna-vaccine-shows-significant-responseProstate Cancer DNA Vaccine Shows Significant Responsehttps://www.icr.ac.uk/news-archive%2fnew-13-million-imaging-centre-launchedhttps://www.icr.ac.uk/news-archive%2fnew-13-million-imaging-centre-launchedNew £13 Million Imaging Centre Launchedhttps://www.icr.ac.uk/news-archive%2ficr-collaborates-to-develop-oncology-softwarehttps://www.icr.ac.uk/news-archive%2ficr-collaborates-to-develop-oncology-softwareICR Collaborates to Develop Oncology Softwarehttps://www.icr.ac.uk/news-archive%2ficr-collaborates-to-create-state-of-the-art-proteomics-laboratoryhttps://www.icr.ac.uk/news-archive%2ficr-collaborates-to-create-state-of-the-art-proteomics-laboratoryICR Collaborates to Create State-of-the-Art Proteomics Laboratoryhttps://www.icr.ac.uk/news-archive%2fnew-drug-blocks-common-cancer-pathwayhttps://www.icr.ac.uk/news-archive%2fnew-drug-blocks-common-cancer-pathwayNew Drug Blocks Common Cancer Pathwayhttps://www.icr.ac.uk/news-archive%2falliance-for-discovery-of-wnt-pathway-inhibitorshttps://www.icr.ac.uk/news-archive%2falliance-for-discovery-of-wnt-pathway-inhibitorsAlliance for Discovery of WNT Pathway Inhibitorshttps://www.icr.ac.uk/news-archive%2fhuman-cells-evolved-to-reduce-cancer-riskhttps://www.icr.ac.uk/news-archive%2fhuman-cells-evolved-to-reduce-cancer-riskHuman Cells Evolved to Reduce Cancer Riskhttps://www.icr.ac.uk/news-archive%2fgenetic-risks-found-for-common-brain-tumourhttps://www.icr.ac.uk/news-archive%2fgenetic-risks-found-for-common-brain-tumourGenetic Risks Found for Common Brain Tumourhttps://www.icr.ac.uk/news-archive%2fnew-drug-targeting-cancer-weakness-shows-great-promisehttps://www.icr.ac.uk/news-archive%2fnew-drug-targeting-cancer-weakness-shows-great-promiseNew Drug Targeting Cancer Weakness Shows Great Promisehttps://www.icr.ac.uk/news-archive%2fpartnership-targets-cancer-causing-%27chaperones%27-https://www.icr.ac.uk/news-archive%2fpartnership-targets-cancer-causing-%27chaperones%27-Partnership Targets Cancer-causing 'Chaperones' https://www.icr.ac.uk/news-archive%2ftesticular-cancer-risk-genes-foundhttps://www.icr.ac.uk/news-archive%2ftesticular-cancer-risk-genes-foundTesticular Cancer Risk Genes Foundhttps://www.icr.ac.uk/news-archive%2fabiraterone-phase-ii-resultshttps://www.icr.ac.uk/news-archive%2fabiraterone-phase-ii-resultsAbiraterone Phase II Resultshttps://www.icr.ac.uk/news-archive%2fcervical-cancer-risk-for-women-over-50https://www.icr.ac.uk/news-archive%2fcervical-cancer-risk-for-women-over-50Cervical Cancer Risk for Women over 50https://www.icr.ac.uk/news-archive%2fscientists-shed-light-on-bowel-cancer-linkhttps://www.icr.ac.uk/news-archive%2fscientists-shed-light-on-bowel-cancer-linkScientists Shed Light On Bowel Cancer Linkhttps://www.icr.ac.uk/news-archive%2fscientists-unravel-skin-cancer-switchhttps://www.icr.ac.uk/news-archive%2fscientists-unravel-skin-cancer-switchScientists Unravel Skin Cancer Switchhttps://www.icr.ac.uk/news-archive%2finfection-link-found-to-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2finfection-link-found-to-childhood-leukaemiaInfection Link Found to Childhood Leukaemiahttps://www.icr.ac.uk/news-archive%2fearlier-bowel-screening-needed-for-high-risk-groupshttps://www.icr.ac.uk/news-archive%2fearlier-bowel-screening-needed-for-high-risk-groupsEarlier Bowel Screening Needed for High-risk Groupshttps://www.icr.ac.uk/news-archive%2fnew-clue-to-why-cancer-treatments-failhttps://www.icr.ac.uk/news-archive%2fnew-clue-to-why-cancer-treatments-failNew Clue to Why Cancer Treatments Failhttps://www.icr.ac.uk/news-archive%2fdomainex-collaboration-on-drug-targetshttps://www.icr.ac.uk/news-archive%2fdomainex-collaboration-on-drug-targetsDomainex Collaboration on Drug Targetshttps://www.icr.ac.uk/news-archive%2fprostate-cancer-screening-controversy-continues-https://www.icr.ac.uk/news-archive%2fprostate-cancer-screening-controversy-continues-Prostate Cancer Screening Controversy Continues https://www.icr.ac.uk/news-archive%2fsarah-brown-joins-generations-studyhttps://www.icr.ac.uk/news-archive%2fsarah-brown-joins-generations-studySarah Brown Joins Generations Studyhttps://www.icr.ac.uk/news-archive%2fkey-enzyme-found-for-cancer-spreadhttps://www.icr.ac.uk/news-archive%2fkey-enzyme-found-for-cancer-spreadKey Enzyme Found for Cancer Spreadhttps://www.icr.ac.uk/news-archive%2fnew-cancer-imaging-software-launchedhttps://www.icr.ac.uk/news-archive%2fnew-cancer-imaging-software-launchedNew Cancer Imaging Software Launchedhttps://www.icr.ac.uk/news-archive%2ffewer-treatments-for-infants-with-cancerhttps://www.icr.ac.uk/news-archive%2ffewer-treatments-for-infants-with-cancerFewer treatments for infants with cancerhttps://www.icr.ac.uk/news-archive%2fcarpenters%27-asbestos-cancer-riskhttps://www.icr.ac.uk/news-archive%2fcarpenters%27-asbestos-cancer-riskCarpenters' Asbestos Cancer Riskhttps://www.icr.ac.uk/news-archive%2fcancer-relapse-test-for-uk-childrenhttps://www.icr.ac.uk/news-archive%2fcancer-relapse-test-for-uk-childrenCancer Relapse Test for UK Childrenhttps://www.icr.ac.uk/news-archive%2fnetwork-tool-predicts-cancer-survivalhttps://www.icr.ac.uk/news-archive%2fnetwork-tool-predicts-cancer-survivalNetwork Tool Predicts Cancer Survivalhttps://www.icr.ac.uk/news-archive%2finstitute-named-top-research-organisationhttps://www.icr.ac.uk/news-archive%2finstitute-named-top-research-organisationInstitute Named Top Research Organisationhttps://www.icr.ac.uk/news-archive%2fscientists-win-award-for-patient-carehttps://www.icr.ac.uk/news-archive%2fscientists-win-award-for-patient-careScientists Win Award for Patient Carehttps://www.icr.ac.uk/news-archive%2fnew-wilms-tumour-discoveryhttps://www.icr.ac.uk/news-archive%2fnew-wilms-tumour-discoveryNew Wilms Tumour Discoveryhttps://www.icr.ac.uk/news-archive%2fglobal-blueprint-to-treat-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fglobal-blueprint-to-treat-childhood-cancerGlobal Blueprint to Treat Childhood Cancerhttps://www.icr.ac.uk/news-archive%2frights-granted-for-anti-cancer-agenthttps://www.icr.ac.uk/news-archive%2frights-granted-for-anti-cancer-agentRights Granted for Anti-cancer Agenthttps://www.icr.ac.uk/news-archive%2finvestigator-award-for-institute-scientisthttps://www.icr.ac.uk/news-archive%2finvestigator-award-for-institute-scientistInvestigator Award for Institute Scientisthttps://www.icr.ac.uk/news-archive%2fnew-genetic-risk-of-lung-cancer-identifiedhttps://www.icr.ac.uk/news-archive%2fnew-genetic-risk-of-lung-cancer-identifiedNew Genetic Risk of Lung Cancer Identifiedhttps://www.icr.ac.uk/news-archive%2fmechanism-behind-cancer-spread-explainedhttps://www.icr.ac.uk/news-archive%2fmechanism-behind-cancer-spread-explainedMechanism Behind Cancer Spread Explainedhttps://www.icr.ac.uk/news-archive%2fnew-technique-detects-early-cervical-cancerhttps://www.icr.ac.uk/news-archive%2fnew-technique-detects-early-cervical-cancerNew Technique Detects Early Cervical Cancerhttps://www.icr.ac.uk/news-archive%2fcancer-weaknesses-exposed-by-computinghttps://www.icr.ac.uk/news-archive%2fcancer-weaknesses-exposed-by-computingCancer Weaknesses Exposed by Computinghttps://www.icr.ac.uk/news-archive%2fantisoma-collaborate-on-novel-approachhttps://www.icr.ac.uk/news-archive%2fantisoma-collaborate-on-novel-approachAntisoma Collaborate on Novel Approachhttps://www.icr.ac.uk/news-archive%2fnew-cause-of-childhood-kidney-cancer-discoveredhttps://www.icr.ac.uk/news-archive%2fnew-cause-of-childhood-kidney-cancer-discoveredNew Cause of Childhood Kidney Cancer Discoveredhttps://www.icr.ac.uk/news-archive%2fnew-blood-test-to-evaluate-prostate-cancer-https://www.icr.ac.uk/news-archive%2fnew-blood-test-to-evaluate-prostate-cancer-New Blood Test to Evaluate Prostate Cancer https://www.icr.ac.uk/news-archive%2fanti-smoking-measure-welcomedhttps://www.icr.ac.uk/news-archive%2fanti-smoking-measure-welcomedAnti-smoking Measure Welcomedhttps://www.icr.ac.uk/news-archive%2fwelcome-end-to-prescription-chargeshttps://www.icr.ac.uk/news-archive%2fwelcome-end-to-prescription-chargesWelcome End to Prescription Chargeshttps://www.icr.ac.uk/news-archive%2fworking-to-identify-proteins-inside-cellshttps://www.icr.ac.uk/news-archive%2fworking-to-identify-proteins-inside-cellsWorking to Identify Proteins Inside Cellshttps://www.icr.ac.uk/news-archive%2fartists-unite-against-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fartists-unite-against-prostate-cancerArtists Unite Against Prostate Cancerhttps://www.icr.ac.uk/news-archive%2fneglected-protein-may-help-fight-cancerhttps://www.icr.ac.uk/news-archive%2fneglected-protein-may-help-fight-cancerNeglected Protein May Help Fight Cancerhttps://www.icr.ac.uk/news-archive%2fstudy-reveals-genetic-link-to-leukaemiahttps://www.icr.ac.uk/news-archive%2fstudy-reveals-genetic-link-to-leukaemiaStudy Reveals Genetic Link to Leukaemiahttps://www.icr.ac.uk/news-archive%2fcompact-disc-pain-relief-for-scotshttps://www.icr.ac.uk/news-archive%2fcompact-disc-pain-relief-for-scotsCompact Disc Pain Relief for Scotshttps://www.icr.ac.uk/news-archive%2finstitute-scientist-receives-global-awardhttps://www.icr.ac.uk/news-archive%2finstitute-scientist-receives-global-awardInstitute Scientist Receives Global Awardhttps://www.icr.ac.uk/news-archive%2fabiraterone-aggressive-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fabiraterone-aggressive-prostate-cancerAbiraterone Aggressive Prostate Cancerhttps://www.icr.ac.uk/news-archive%2finstitute-professor-wins-science-awardhttps://www.icr.ac.uk/news-archive%2finstitute-professor-wins-science-awardInstitute Professor Wins Science Awardhttps://www.icr.ac.uk/news-archive%2fgenes-cause-deadly-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fgenes-cause-deadly-prostate-cancerGenes Cause Deadly Prostate Cancerhttps://www.icr.ac.uk/news-archive%2finstitute-supports-human-gene-advancehttps://www.icr.ac.uk/news-archive%2finstitute-supports-human-gene-advanceInstitute Supports Human Gene Advancehttps://www.icr.ac.uk/news-archive%2fnew-drug-therapy-attacks-cancershttps://www.icr.ac.uk/news-archive%2fnew-drug-therapy-attacks-cancersNew Drug Therapy Attacks Cancershttps://www.icr.ac.uk/news-archive%2froche-s-acquisition-of-piramed-welcomedhttps://www.icr.ac.uk/news-archive%2froche-s-acquisition-of-piramed-welcomedRoche’s Acquisition of PIramed Welcomedhttps://www.icr.ac.uk/news-archive%2fthree-scientists-elected-to-royal-societyhttps://www.icr.ac.uk/news-archive%2fthree-scientists-elected-to-royal-societyThree Scientists Elected to Royal Societyhttps://www.icr.ac.uk/news-archive%2fneuroblastoma-genetic-risks-foundhttps://www.icr.ac.uk/news-archive%2fneuroblastoma-genetic-risks-foundNeuroblastoma: Genetic Risks Foundhttps://www.icr.ac.uk/news-archive%2fmolecular-pathology-expert-joins-institutehttps://www.icr.ac.uk/news-archive%2fmolecular-pathology-expert-joins-instituteMolecular Pathology Expert Joins Institutehttps://www.icr.ac.uk/news-archive%2ffellowship-awarded-to-prof-richard-maraishttps://www.icr.ac.uk/news-archive%2ffellowship-awarded-to-prof-richard-maraisFellowship Awarded to Prof. Richard Maraishttps://www.icr.ac.uk/news-archive%2fcancer-managing-the-painhttps://www.icr.ac.uk/news-archive%2fcancer-managing-the-painCancer: Managing the Painhttps://www.icr.ac.uk/news-archive%2finstitute-in-disease-genetics-studyhttps://www.icr.ac.uk/news-archive%2finstitute-in-disease-genetics-studyInstitute in Disease Genetics Studyhttps://www.icr.ac.uk/news-archive%2fkey-appointments-for-institute-staffhttps://www.icr.ac.uk/news-archive%2fkey-appointments-for-institute-staffKey appointments for Institute staffhttps://www.icr.ac.uk/news-archive%2f%27homing-in%27-on-lung-cancer-geneshttps://www.icr.ac.uk/news-archive%2f%27homing-in%27-on-lung-cancer-genes'Homing In' on Lung Cancer Geneshttps://www.icr.ac.uk/news-archive%2fgenetic-variants-increase-bowel-cancer-riskhttps://www.icr.ac.uk/news-archive%2fgenetic-variants-increase-bowel-cancer-riskGenetic Variants Increase Bowel Cancer Riskhttps://www.icr.ac.uk/news-archive%2fcancer-awareness-campaign-triumphhttps://www.icr.ac.uk/news-archive%2fcancer-awareness-campaign-triumphCancer Awareness Campaign Triumphhttps://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-for-breast-cancerhttps://www.icr.ac.uk/news-archive%2fshorter-radiotherapy-for-breast-cancerShorter Radiotherapy for Breast Cancerhttps://www.icr.ac.uk/news-archive%2fnew-marker-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-marker-for-prostate-cancerNew Marker for Prostate Cancerhttps://www.icr.ac.uk/news-archive%2ffaster-chemo-increases-neuroblastoma-survivalhttps://www.icr.ac.uk/news-archive%2ffaster-chemo-increases-neuroblastoma-survivalFaster Chemo Increases Neuroblastoma Survivalhttps://www.icr.ac.uk/news-archive%2fbrain-tumour-gene-link-foundhttps://www.icr.ac.uk/news-archive%2fbrain-tumour-gene-link-foundBrain Tumour Gene Link Foundhttps://www.icr.ac.uk/news-archive%2fclue-to-cancer-drug-resistance-uncoveredhttps://www.icr.ac.uk/news-archive%2fclue-to-cancer-drug-resistance-uncoveredClue to Cancer Drug Resistance Uncoveredhttps://www.icr.ac.uk/news-archive%2fnew-prostate-cancer-genetic-risk-factorshttps://www.icr.ac.uk/news-archive%2fnew-prostate-cancer-genetic-risk-factorsNew Prostate Cancer Genetic Risk Factorshttps://www.icr.ac.uk/news-archive%2fprotein%27s-role-in-drug-resistancehttps://www.icr.ac.uk/news-archive%2fprotein%27s-role-in-drug-resistanceProtein's Role in Drug Resistancehttps://www.icr.ac.uk/news-archive%2fleukaemia-stem-cells-foundhttps://www.icr.ac.uk/news-archive%2fleukaemia-stem-cells-foundLeukaemia Stem Cells Foundhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-trial-launchedhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-trial-launchedNew Breast Cancer Trial Launchedhttps://www.icr.ac.uk/news-archive%2fknighthood-for-ex-deputy-chairmanhttps://www.icr.ac.uk/news-archive%2fknighthood-for-ex-deputy-chairmanKnighthood for Ex-deputy Chairmanhttps://www.icr.ac.uk/news-archive%2faward-for-radiological-physicisthttps://www.icr.ac.uk/news-archive%2faward-for-radiological-physicistAward for Radiological Physicisthttps://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-triples-riskhttps://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-triples-riskBowel Cancer Gene Triples Riskhttps://www.icr.ac.uk/news-archive%2faward-for-breast-cancer-professorhttps://www.icr.ac.uk/news-archive%2faward-for-breast-cancer-professorAward for Breast Cancer Professorhttps://www.icr.ac.uk/news-archive%2fprestigious-appointment-for-ceohttps://www.icr.ac.uk/news-archive%2fprestigious-appointment-for-ceoPrestigious Appointment for CEOhttps://www.icr.ac.uk/news-archive%2ftop-award-for-institute-physicisthttps://www.icr.ac.uk/news-archive%2ftop-award-for-institute-physicistTop Award for Institute Physicisthttps://www.icr.ac.uk/news-archive%2findustry-leader-joins-the-institutehttps://www.icr.ac.uk/news-archive%2findustry-leader-joins-the-instituteIndustry Leader Joins The Institutehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-markers-the-way-forwardhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-markers-the-way-forwardProstate Cancer Markers: The Way Forwardhttps://www.icr.ac.uk/news-archive%2fnew-discovery-to-fight-cancerhttps://www.icr.ac.uk/news-archive%2fnew-discovery-to-fight-cancerNew Discovery to Fight Cancerhttps://www.icr.ac.uk/news-archive%2ftip60-gene-role-in-breast-cancer-discoveredhttps://www.icr.ac.uk/news-archive%2ftip60-gene-role-in-breast-cancer-discoveredTip60 Gene: Role in Breast Cancer Discoveredhttps://www.icr.ac.uk/news-archive%2fspin-out-companies-win-prestigious-awardshttps://www.icr.ac.uk/news-archive%2fspin-out-companies-win-prestigious-awardsSpin-Out Companies Win Prestigious Awardshttps://www.icr.ac.uk/news-archive%2fnew-marker-for-prostate-cancer-aggressivenesshttps://www.icr.ac.uk/news-archive%2fnew-marker-for-prostate-cancer-aggressivenessNew Marker for Prostate Cancer Aggressivenesshttps://www.icr.ac.uk/news-archive%2finsights-into-deadly-form-of-leukaemiahttps://www.icr.ac.uk/news-archive%2finsights-into-deadly-form-of-leukaemiaInsights into Deadly Form of Leukaemiahttps://www.icr.ac.uk/news-archive%2fannual-research-report-launchedhttps://www.icr.ac.uk/news-archive%2fannual-research-report-launchedAnnual Research Report Launchedhttps://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-locatedhttps://www.icr.ac.uk/news-archive%2fbowel-cancer-gene-locatedBowel Cancer Gene Locatedhttps://www.icr.ac.uk/news-archive%2fcd-rom-provides-a-breath-of-fresh-airhttps://www.icr.ac.uk/news-archive%2fcd-rom-provides-a-breath-of-fresh-airCD ROM Provides a Breath of Fresh Airhttps://www.icr.ac.uk/news-archive%2fthe-institute-congratulates-sir-ara-darzihttps://www.icr.ac.uk/news-archive%2fthe-institute-congratulates-sir-ara-darziThe Institute Congratulates Sir Ara Darzihttps://www.icr.ac.uk/news-archive%2fsmoking-ban-welcomedhttps://www.icr.ac.uk/news-archive%2fsmoking-ban-welcomedSmoking Ban Welcomedhttps://www.icr.ac.uk/news-archive%2fprofessor-janet-husband-appointed-dbehttps://www.icr.ac.uk/news-archive%2fprofessor-janet-husband-appointed-dbeProfessor Janet Husband Appointed DBEhttps://www.icr.ac.uk/news-archive%2fgene-therapy-kills-bowel-cancer-cellshttps://www.icr.ac.uk/news-archive%2fgene-therapy-kills-bowel-cancer-cellsGene Therapy Kills Bowel Cancer Cellshttps://www.icr.ac.uk/news-archive%2fhsp90-inhibitors-biological-properties-revealedhttps://www.icr.ac.uk/news-archive%2fhsp90-inhibitors-biological-properties-revealedHSP90 Inhibitors: Biological Properties Revealedhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-awareness-weekhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-awareness-weekProstate Cancer Awareness Weekhttps://www.icr.ac.uk/news-archive%2fprestigious-prize-for-former-directorhttps://www.icr.ac.uk/news-archive%2fprestigious-prize-for-former-directorPrestigious Prize for Former Directorhttps://www.icr.ac.uk/news-archive%2fno-smoking-dayhttps://www.icr.ac.uk/news-archive%2fno-smoking-dayNo Smoking Dayhttps://www.icr.ac.uk/news-archive%2fnovel-drug-sequence-improves-survivalhttps://www.icr.ac.uk/news-archive%2fnovel-drug-sequence-improves-survivalNovel Drug Sequence Improves Survivalhttps://www.icr.ac.uk/news-archive%2fstar-status-awarded-to-the-institutehttps://www.icr.ac.uk/news-archive%2fstar-status-awarded-to-the-instituteStar Status Awarded to The Institutehttps://www.icr.ac.uk/news-archive%2fhodgkin-disease-therapy-and-heart-attack-riskhttps://www.icr.ac.uk/news-archive%2fhodgkin-disease-therapy-and-heart-attack-riskHodgkin Disease Therapy and Heart Attack Riskhttps://www.icr.ac.uk/news-archive%2fprestigious-new-protein-initiative-announcedhttps://www.icr.ac.uk/news-archive%2fprestigious-new-protein-initiative-announcedPrestigious New Protein Initiative Announcedhttps://www.icr.ac.uk/news-archive%2ftop-prize-for-study-skills-bookhttps://www.icr.ac.uk/news-archive%2ftop-prize-for-study-skills-bookTop Prize for Study Skills Bookhttps://www.icr.ac.uk/news-archive%2fgene-linked-to-breast-and-childhood-cancerhttps://www.icr.ac.uk/news-archive%2fgene-linked-to-breast-and-childhood-cancerGene Linked to Breast and Childhood Cancerhttps://www.icr.ac.uk/news-archive%2fvital-funding-for-cancer-research-announcedhttps://www.icr.ac.uk/news-archive%2fvital-funding-for-cancer-research-announcedVital Funding for Cancer Research Announcedhttps://www.icr.ac.uk/news-archive%2fnew-company-london-genetics-launchedhttps://www.icr.ac.uk/news-archive%2fnew-company-london-genetics-launchedNew Company, London Genetics, Launchedhttps://www.icr.ac.uk/news-archive%2fmilestone-payment-for-hsp90-programmehttps://www.icr.ac.uk/news-archive%2fmilestone-payment-for-hsp90-programmeMilestone Payment for Hsp90 Programmehttps://www.icr.ac.uk/news-archive%2fresults-of-breast-screening-trialhttps://www.icr.ac.uk/news-archive%2fresults-of-breast-screening-trialResults of Breast Screening Trialhttps://www.icr.ac.uk/news-archive%2fnew-hope-for-children-with-cancerhttps://www.icr.ac.uk/news-archive%2fnew-hope-for-children-with-cancerNew Hope for Children with Cancerhttps://www.icr.ac.uk/news-archive%2fexperts-gather-for-impact-study-conferencehttps://www.icr.ac.uk/news-archive%2fexperts-gather-for-impact-study-conferenceExperts Gather for IMPACT Study Conferencehttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-risk-gene-discoveredhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-risk-gene-discoveredNew Breast Cancer Risk Gene Discoveredhttps://www.icr.ac.uk/news-archive%2fnew-genetic-route-to-skin-cancer-confirmedhttps://www.icr.ac.uk/news-archive%2fnew-genetic-route-to-skin-cancer-confirmedNew Genetic Route to Skin Cancer Confirmedhttps://www.icr.ac.uk/news-archive%2fstate-of-the-art-new-mri-scannerhttps://www.icr.ac.uk/news-archive%2fstate-of-the-art-new-mri-scannerState-of-the-art New MRI Scannerhttps://www.icr.ac.uk/news-archive%2fnovel-compounds-discoveredhttps://www.icr.ac.uk/news-archive%2fnovel-compounds-discoveredNovel Compounds Discoveredhttps://www.icr.ac.uk/news-archive%2fanti-cancer-drug-discovery-alliance-announcedhttps://www.icr.ac.uk/news-archive%2fanti-cancer-drug-discovery-alliance-announcedAnti-Cancer Drug Discovery Alliance Announcedhttps://www.icr.ac.uk/news-archive%2foncolytics-gains-approval-for-phase-ii-trialhttps://www.icr.ac.uk/news-archive%2foncolytics-gains-approval-for-phase-ii-trialOncolytics Gains Approval for Phase II Trialhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-risk-gene-mystery-unravelledhttps://www.icr.ac.uk/news-archive%2fbreast-cancer-risk-gene-mystery-unravelledBreast Cancer Risk Gene: Mystery Unravelledhttps://www.icr.ac.uk/news-archive%2foncolytics-commences-ib-reolysin-trialhttps://www.icr.ac.uk/news-archive%2foncolytics-commences-ib-reolysin-trialOncolytics Commences Ib REOLYSIN® Trialhttps://www.icr.ac.uk/news-archive%2frotary-launches-partnership-with-institutehttps://www.icr.ac.uk/news-archive%2frotary-launches-partnership-with-instituteRotary Launches Partnership with Institutehttps://www.icr.ac.uk/news-archive%2fjoint-annual-research-report-launchedhttps://www.icr.ac.uk/news-archive%2fjoint-annual-research-report-launchedJoint Annual Research Report Launchedhttps://www.icr.ac.uk/news-archive%2fthe-institute-awarded-ecmc-fundinghttps://www.icr.ac.uk/news-archive%2fthe-institute-awarded-ecmc-fundingThe Institute Awarded ECMC Fundinghttps://www.icr.ac.uk/news-archive%2fenrolment-complete-in-reolysin-trialhttps://www.icr.ac.uk/news-archive%2fenrolment-complete-in-reolysin-trialEnrolment Complete in REOLYSIN® Trialhttps://www.icr.ac.uk/news-archive%2fgenetic-susceptibility-to-lung-cancerhttps://www.icr.ac.uk/news-archive%2fgenetic-susceptibility-to-lung-cancerGenetic Susceptibility to Lung Cancerhttps://www.icr.ac.uk/news-archive%2fconcentrated-radiotherapy-better-for-breast-cancerhttps://www.icr.ac.uk/news-archive%2fconcentrated-radiotherapy-better-for-breast-cancerConcentrated Radiotherapy Better for Breast Cancerhttps://www.icr.ac.uk/news-archive%2fprof-naz-rahman-wins-professional-of-the-year-https://www.icr.ac.uk/news-archive%2fprof-naz-rahman-wins-professional-of-the-year-Prof Naz Rahman wins ‘Professional of The Year’https://www.icr.ac.uk/news-archive%2fnew-research-on-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-research-on-prostate-cancerNew Research on Prostate Cancerhttps://www.icr.ac.uk/news-archive%2fdermot-o%27leary-launches-everyman-monthhttps://www.icr.ac.uk/news-archive%2fdermot-o%27leary-launches-everyman-monthDermot O'Leary launches Everyman Monthhttps://www.icr.ac.uk/news-archive%2fprofessor-david-barford-elected-to-royal-societyhttps://www.icr.ac.uk/news-archive%2fprofessor-david-barford-elected-to-royal-societyProfessor David Barford elected to Royal Societyhttps://www.icr.ac.uk/news-archive%2ficr-announces-fellowships-for-2006https://www.icr.ac.uk/news-archive%2ficr-announces-fellowships-for-2006ICR announces Fellowships for 2006https://www.icr.ac.uk/news-archive%2fcall-for-uptake-of-new-imaging-technologyhttps://www.icr.ac.uk/news-archive%2fcall-for-uptake-of-new-imaging-technologyCall for Uptake of New Imaging Technologyhttps://www.icr.ac.uk/news-archive%2ffirst-clinical-trial-for-hereditary-breast-cancerhttps://www.icr.ac.uk/news-archive%2ffirst-clinical-trial-for-hereditary-breast-cancerFirst Clinical Trial for Hereditary Breast Cancerhttps://www.icr.ac.uk/news-archive%2fskin-cancer-men-not-getting-the-messagehttps://www.icr.ac.uk/news-archive%2fskin-cancer-men-not-getting-the-messageSkin Cancer: Men Not Getting the Messagehttps://www.icr.ac.uk/news-archive%2fscientists-reveal-structure-of-hsp90https://www.icr.ac.uk/news-archive%2fscientists-reveal-structure-of-hsp90Scientists Reveal Structure of HSP90https://www.icr.ac.uk/news-archive%2fillumina-to-conduct-large-scale-genotypinghttps://www.icr.ac.uk/news-archive%2fillumina-to-conduct-large-scale-genotypingIllumina To Conduct Large-Scale Genotypinghttps://www.icr.ac.uk/news-archive%2fillumina-to-conduct-large-scale-genotyping-forhttps://www.icr.ac.uk/news-archive%2fillumina-to-conduct-large-scale-genotyping-forIllumina to Conduct Large-Scale Genotyping for UK-Based Research Groups Studying Molecular Basis of Prostate CancerStudy designed to understand genetic susceptibility, mechanisms of disease progression, and cancer therapy management; new agreement mirrors one signed in Novemberhttps://www.icr.ac.uk/news-archive%2freolysin-presentation-at-ascohttps://www.icr.ac.uk/news-archive%2freolysin-presentation-at-ascoREOLYSIN® Presentation at ASCOhttps://www.icr.ac.uk/news-archive%2fthe-institute-launches-its-new-websitehttps://www.icr.ac.uk/news-archive%2fthe-institute-launches-its-new-websiteThe Institute Launches its New Websitehttps://www.icr.ac.uk/news-archive%2freolysin-radiation-abstract-on-aacr-websitehttps://www.icr.ac.uk/news-archive%2freolysin-radiation-abstract-on-aacr-websiteREOLYSIN®/Radiation Abstract on AACR Websitehttps://www.icr.ac.uk/news-archive%2fgloucester-pharma-reports-on-clinical-study-https://www.icr.ac.uk/news-archive%2fgloucester-pharma-reports-on-clinical-study-Gloucester Pharma Reports on Clinical Study https://www.icr.ac.uk/news-archive%2fmaking-sense-of-the-psa-test-for-prostate-cancer-https://www.icr.ac.uk/news-archive%2fmaking-sense-of-the-psa-test-for-prostate-cancer-Making Sense of the PSA Test for Prostate Cancer https://www.icr.ac.uk/news-archive%2fbiovex-begins-phase-ii-clinical-trialshttps://www.icr.ac.uk/news-archive%2fbiovex-begins-phase-ii-clinical-trialsBiovex Begins Phase II Clinical Trialshttps://www.icr.ac.uk/news-archive%2fmobile-phones-not-linked-to-increased-risk-of-brain-tumourshttps://www.icr.ac.uk/news-archive%2fmobile-phones-not-linked-to-increased-risk-of-brain-tumoursMobile Phones Not Linked To increased Risk Of Brain Tumourshttps://www.icr.ac.uk/news-archive%2fmilestone-reached-in-oncology-collaborationhttps://www.icr.ac.uk/news-archive%2fmilestone-reached-in-oncology-collaborationMilestone Reached in Oncology Collaborationhttps://www.icr.ac.uk/news-archive%2fnew-chair-for-top-academic-surgeonhttps://www.icr.ac.uk/news-archive%2fnew-chair-for-top-academic-surgeonNew Chair for Top Academic Surgeonhttps://www.icr.ac.uk/news-archive%2fcougar-biotechnology-announces-initiation-of-phase-i-ii-trial-for-cb7630-(abiraterone-acetate)https://www.icr.ac.uk/news-archive%2fcougar-biotechnology-announces-initiation-of-phase-i-ii-trial-for-cb7630-(abiraterone-acetate)Cougar Biotechnology Announces Initiation of Phase I/II Trial for CB7630 (Abiraterone Acetate)https://www.icr.ac.uk/news-archive%2fpromising-new-anti-cancer-drug-targets-malignant-melanoma-proteinhttps://www.icr.ac.uk/news-archive%2fpromising-new-anti-cancer-drug-targets-malignant-melanoma-proteinPromising New Anti-Cancer Drug Targets Malignant Melanoma Proteinhttps://www.icr.ac.uk/news-archive%2fpiramed-signs-collaboration-with-genentech-to-develop-new-class-of-anti-cancer-drugshttps://www.icr.ac.uk/news-archive%2fpiramed-signs-collaboration-with-genentech-to-develop-new-class-of-anti-cancer-drugsPIramed Signs Collaboration with Genentech to Develop New Class of Anti-Cancer Drugshttps://www.icr.ac.uk/news-archive%2fncri-informatics-initiative-wins-award-https://www.icr.ac.uk/news-archive%2fncri-informatics-initiative-wins-award-NCRI Informatics Initiative Wins Award https://www.icr.ac.uk/news-archive%2fbreathe-easy---international-lung-cancer-awareness-dayhttps://www.icr.ac.uk/news-archive%2fbreathe-easy---international-lung-cancer-awareness-dayBreathe Easy - International Lung Cancer Awareness Dayhttps://www.icr.ac.uk/news-archive%2foncolytics-biotech-webcasthttps://www.icr.ac.uk/news-archive%2foncolytics-biotech-webcastOncolytics Biotech Webcasthttps://www.icr.ac.uk/news-archive%2flove-your-mouth---mouth-cancer-awareness-weekhttps://www.icr.ac.uk/news-archive%2flove-your-mouth---mouth-cancer-awareness-weekLove Your Mouth - Mouth Cancer Awareness Weekhttps://www.icr.ac.uk/news-archive%2fncri-informatics-initiative-nominationhttps://www.icr.ac.uk/news-archive%2fncri-informatics-initiative-nominationNCRI Informatics Initiative Nominationhttps://www.icr.ac.uk/news-archive%2fgene-increases-risk-in-breast-cancer-familieshttps://www.icr.ac.uk/news-archive%2fgene-increases-risk-in-breast-cancer-familiesGene Increases Risk in Breast Cancer Familieshttps://www.icr.ac.uk/news-archive%2flord-ryder-appointed-as-chairman-of-the-institute-https://www.icr.ac.uk/news-archive%2flord-ryder-appointed-as-chairman-of-the-institute-Lord Ryder Appointed as Chairman of The Institute https://www.icr.ac.uk/news-archive%2fcougar-biotechnology-announcementhttps://www.icr.ac.uk/news-archive%2fcougar-biotechnology-announcementCougar Biotechnology Announcementhttps://www.icr.ac.uk/news-archive%2fscientists-discover-scaramanga-genehttps://www.icr.ac.uk/news-archive%2fscientists-discover-scaramanga-geneScientists Discover Scaramanga Genehttps://www.icr.ac.uk/news-archive%2fmobile-phone-use-and-risk-of-cancerhttps://www.icr.ac.uk/news-archive%2fmobile-phone-use-and-risk-of-cancerMobile Phone Use and Risk of Cancerhttps://www.icr.ac.uk/news-archive%2fskin-cancer-development-pathwayhttps://www.icr.ac.uk/news-archive%2fskin-cancer-development-pathwaySkin Cancer Development Pathwayhttps://www.icr.ac.uk/news-archive%2fcruk-scientists-develop-stealth-anti-cancer-drugshttps://www.icr.ac.uk/news-archive%2fcruk-scientists-develop-stealth-anti-cancer-drugsCRUK Scientists Develop Stealth Anti-Cancer Drugshttps://www.icr.ac.uk/news-archive%2fnew-advance-in-prostate-cancer-managementhttps://www.icr.ac.uk/news-archive%2fnew-advance-in-prostate-cancer-managementNew Advance in Prostate Cancer Managementhttps://www.icr.ac.uk/news-archive%2fastrazeneca-and-astex-form-new-strategic-alliancehttps://www.icr.ac.uk/news-archive%2fastrazeneca-and-astex-form-new-strategic-allianceAstraZeneca and Astex Form New Strategic Alliancehttps://www.icr.ac.uk/news-archive%2fmajor-cancer-drug-discovery-collaborationhttps://www.icr.ac.uk/news-archive%2fmajor-cancer-drug-discovery-collaborationMajor Cancer Drug Discovery Collaborationhttps://www.icr.ac.uk/news-archive%2fkudos-pharmaceuticals-first-patient-treated-with-new-anti-cancer-agenthttps://www.icr.ac.uk/news-archive%2fkudos-pharmaceuticals-first-patient-treated-with-new-anti-cancer-agentKuDOS Pharmaceuticals: First Patient Treated with New Anti-cancer Agenthttps://www.icr.ac.uk/news-archive%2ffertility-boost-for-testicular-cancer-patientshttps://www.icr.ac.uk/news-archive%2ffertility-boost-for-testicular-cancer-patientsFertility Boost for Testicular Cancer Patientshttps://www.icr.ac.uk/news-archive%2fearly-trials-of-cancer-drug-show-promise-https://www.icr.ac.uk/news-archive%2fearly-trials-of-cancer-drug-show-promise-Early Trials of Cancer Drug Show Promise https://www.icr.ac.uk/news-archive%2frachel-stevens-%27gets-fruity%27-for-everymanhttps://www.icr.ac.uk/news-archive%2frachel-stevens-%27gets-fruity%27-for-everymanRachel Stevens 'Gets Fruity' For Everymanhttps://www.icr.ac.uk/news-archive%2feveryman-scientists-bridge-major-gap-in-prostate-cancer-researchhttps://www.icr.ac.uk/news-archive%2feveryman-scientists-bridge-major-gap-in-prostate-cancer-researchEveryman Scientists Bridge Major Gap in Prostate Cancer Researchhttps://www.icr.ac.uk/news-archive%2fmagnetic-resonance-imaging-more-sensitive-than-mammograms-in-detecting-breast-cancer-in-high-risk-under-50%27shttps://www.icr.ac.uk/news-archive%2fmagnetic-resonance-imaging-more-sensitive-than-mammograms-in-detecting-breast-cancer-in-high-risk-under-50%27sMagnetic Resonance Imaging More Sensitive than Mammograms in Detecting Breast Cancer in High Risk Under 50'shttps://www.icr.ac.uk/news-archive%2fgood-news-for-prostate-cancer---avoid-the-need-for-treatmenthttps://www.icr.ac.uk/news-archive%2fgood-news-for-prostate-cancer---avoid-the-need-for-treatmentGood News for Prostate Cancer - Avoid the Need for Treatmenthttps://www.icr.ac.uk/news-archive%2fexperts-chart-pathway-leading-to-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fexperts-chart-pathway-leading-to-childhood-leukaemiaExperts Chart Pathway Leading to Childhood Leukaemiahttps://www.icr.ac.uk/news-archive%2fpossible-cancer-link-of-newly-discovered-protein-interactionhttps://www.icr.ac.uk/news-archive%2fpossible-cancer-link-of-newly-discovered-protein-interactionPossible Cancer Link of Newly Discovered Protein Interactionhttps://www.icr.ac.uk/news-archive%2fscientific-breakthrough-signals-brand-new-approach-to-breast-cancer-treatmenthttps://www.icr.ac.uk/news-archive%2fscientific-breakthrough-signals-brand-new-approach-to-breast-cancer-treatmentScientific Breakthrough Signals Brand New Approach To Breast Cancer Treatmenthttps://www.icr.ac.uk/news-archive%2fthe-england-football-team-urge-all-men-to-keep-your-eye-on-the-ball!-https://www.icr.ac.uk/news-archive%2fthe-england-football-team-urge-all-men-to-keep-your-eye-on-the-ball!-The England Football Team Urge All Men to “Keep Your Eye on the Ball!”https://www.icr.ac.uk/news-archive%2fnew-research-into-diesel-fume-cancer-riskhttps://www.icr.ac.uk/news-archive%2fnew-research-into-diesel-fume-cancer-riskNew research into Diesel Fume Cancer Riskhttps://www.icr.ac.uk/news-archive%2fsmoking-quitting-makes-sensehttps://www.icr.ac.uk/news-archive%2fsmoking-quitting-makes-senseSmoking – Quitting Makes Sensehttps://www.icr.ac.uk/news-archive%2fscientists-shed-light-on-tamoxifen-riskshttps://www.icr.ac.uk/news-archive%2fscientists-shed-light-on-tamoxifen-risksScientists Shed Light on Tamoxifen Riskshttps://www.icr.ac.uk/news-archive%2fthe-institute-s-groundbreaking-cancer-research-centre-reaches-structural-completionhttps://www.icr.ac.uk/news-archive%2fthe-institute-s-groundbreaking-cancer-research-centre-reaches-structural-completionThe Institute’s Groundbreaking Cancer Research Centre Reaches Structural Completionhttps://www.icr.ac.uk/news-archive%2fentente-cordiale-recognises-scientific-excellencehttps://www.icr.ac.uk/news-archive%2fentente-cordiale-recognises-scientific-excellenceEntente Cordiale Recognises Scientific Excellencehttps://www.icr.ac.uk/news-archive%2fchildren-with-rare-disorder-lead-scientists-to-cancer-related-genehttps://www.icr.ac.uk/news-archive%2fchildren-with-rare-disorder-lead-scientists-to-cancer-related-geneChildren with Rare Disorder Lead Scientists to Cancer Related Genehttps://www.icr.ac.uk/news-archive%2fcharities-launch-unique-study-to-pinpoint-causes-of-breast-cancer-for-future-generationshttps://www.icr.ac.uk/news-archive%2fcharities-launch-unique-study-to-pinpoint-causes-of-breast-cancer-for-future-generationsCharities Launch Unique Study To Pinpoint Causes Of Breast Cancer For Future Generationshttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-receives-top-markshttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-receives-top-marksThe Institute of Cancer Research Receives Top Markshttps://www.icr.ac.uk/news-archive%2fthe-freemasons-grand-charity-donates-1million-to-male-cancer-research-https://www.icr.ac.uk/news-archive%2fthe-freemasons-grand-charity-donates-1million-to-male-cancer-research-The Freemasons’ Grand Charity Donates £1million To Male Cancer Research https://www.icr.ac.uk/news-archive%2fupdate-of-the-interactive-education-unit-websitehttps://www.icr.ac.uk/news-archive%2fupdate-of-the-interactive-education-unit-websiteUpdate of the Interactive Education Unit Websitehttps://www.icr.ac.uk/news-archive%2fprostate-cancer-gene-detectedhttps://www.icr.ac.uk/news-archive%2fprostate-cancer-gene-detectedProstate Cancer Gene Detectedhttps://www.icr.ac.uk/news-archive%2fmen-behaving-safely!https://www.icr.ac.uk/news-archive%2fmen-behaving-safely!Men Behaving Safely!https://www.icr.ac.uk/news-archive%2fwhat-s-in-your-pants-https://www.icr.ac.uk/news-archive%2fwhat-s-in-your-pants-What’s in your Pants?https://www.icr.ac.uk/news-archive%2finadequate-cancer-test-puts-men-s-health-at-riskhttps://www.icr.ac.uk/news-archive%2finadequate-cancer-test-puts-men-s-health-at-riskInadequate Cancer Test Puts Men’s Health at Riskhttps://www.icr.ac.uk/news-archive%2ffootball-mad-rory-runs-for-englandhttps://www.icr.ac.uk/news-archive%2ffootball-mad-rory-runs-for-englandFootball Mad Rory Runs for Englandhttps://www.icr.ac.uk/news-archive%2fscientists-point-the-way-to-a-new-generation-of-cancer-drugshttps://www.icr.ac.uk/news-archive%2fscientists-point-the-way-to-a-new-generation-of-cancer-drugsScientists point the way to a new generation of cancer drugshttps://www.icr.ac.uk/news-archive%2fdon-t-let-your-resolve-go-up-in-a-puff-of-smoke!https://www.icr.ac.uk/news-archive%2fdon-t-let-your-resolve-go-up-in-a-puff-of-smoke!Don’t Let Your Resolve Go Up In a Puff of Smoke!https://www.icr.ac.uk/news-archive%2fnew-drug-sequence-reduces-breast-cancer-recurrencehttps://www.icr.ac.uk/news-archive%2fnew-drug-sequence-reduces-breast-cancer-recurrenceNew drug sequence reduces breast cancer recurrencehttps://www.icr.ac.uk/news-archive%2fbladder-cancer-gene-detected-by-scientists-at-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-archive%2fbladder-cancer-gene-detected-by-scientists-at-the-institute-of-cancer-researchBladder Cancer Gene Detected by Scientists at The Institute of Cancer Researchhttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-announces-fellowships-for-2004https://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-announces-fellowships-for-2004The Institute of Cancer Research Announces Fellowships for 2004https://www.icr.ac.uk/news-archive%2finvading-cancer-cells-are-targeted-by-scientists-at-the-institute-of-cancer-researchhttps://www.icr.ac.uk/news-archive%2finvading-cancer-cells-are-targeted-by-scientists-at-the-institute-of-cancer-researchInvading Cancer Cells are Targeted by Scientists At The Institute of Cancer Researchhttps://www.icr.ac.uk/news-archive%2fhair-today-gone-tomorrow-it-s-the-tacheback-finale-party!!!https://www.icr.ac.uk/news-archive%2fhair-today-gone-tomorrow-it-s-the-tacheback-finale-party!!!Hair Today, Gone Tomorrow – It’s The Tacheback Finale Party!!!https://www.icr.ac.uk/news-archive%2fcelebrities-prove-that-the-tache-is-backhttps://www.icr.ac.uk/news-archive%2fcelebrities-prove-that-the-tache-is-backCelebrities Prove That The Tache Is Backhttps://www.icr.ac.uk/news-archive%2flancashire-essex-nottinghamshire-sussex-county-cricket-club-knock-male-cancers-for-six-as-they-go-sports-mad!https://www.icr.ac.uk/news-archive%2flancashire-essex-nottinghamshire-sussex-county-cricket-club-knock-male-cancers-for-six-as-they-go-sports-mad!Lancashire, Essex, Nottinghamshire & Sussex County Cricket Club knock male cancers for six as they Go Sports Mad!https://www.icr.ac.uk/news-archive%2fcop-a-feel-and-a-copy---aware-magazinehttps://www.icr.ac.uk/news-archive%2fcop-a-feel-and-a-copy---aware-magazineCop a Feel and a Copy - AWARE Magazinehttps://www.icr.ac.uk/news-archive%2fcelebrity-fundraising-ball-puts-everyman-in-the-spotlighthttps://www.icr.ac.uk/news-archive%2fcelebrity-fundraising-ball-puts-everyman-in-the-spotlightCelebrity Fundraising Ball puts Everyman in the spotlighthttps://www.icr.ac.uk/news-archive%2fshaving-lives!https://www.icr.ac.uk/news-archive%2fshaving-lives!Shaving Lives!https://www.icr.ac.uk/news-archive%2fnational-call-up-to-find-the-genes-for-prostate-and-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fnational-call-up-to-find-the-genes-for-prostate-and-testicular-cancerNational Call Up to Find The Genes for Prostate and Testicular Cancerhttps://www.icr.ac.uk/news-archive%2fphillip-schofield-gets-shirty-to-support-everyman-male-cancer-awareness-monthhttps://www.icr.ac.uk/news-archive%2fphillip-schofield-gets-shirty-to-support-everyman-male-cancer-awareness-monthPhillip Schofield gets shirty to support Everyman Male Cancer Awareness monthhttps://www.icr.ac.uk/news-archive%2fpioneering-cancer-scanner-is-launchedhttps://www.icr.ac.uk/news-archive%2fpioneering-cancer-scanner-is-launchedPioneering cancer scanner is launchedhttps://www.icr.ac.uk/news-archive%2fa-close-shave-for-everymanhttps://www.icr.ac.uk/news-archive%2fa-close-shave-for-everymanA Close Shave for Everymanhttps://www.icr.ac.uk/news-archive%2fscientists-find-that-folic-acid-may-reduce-risk-of-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fscientists-find-that-folic-acid-may-reduce-risk-of-childhood-leukaemiaScientists find that folic acid may reduce risk of childhood leukaemiahttps://www.icr.ac.uk/news-archive%2fnew-findings-show-that-men-cured-of-testicular-cancer-are-more-likely-to-suffer-from-heart-disease-later-in-lifehttps://www.icr.ac.uk/news-archive%2fnew-findings-show-that-men-cured-of-testicular-cancer-are-more-likely-to-suffer-from-heart-disease-later-in-lifeNew findings show that men cured of testicular cancer are more likely to suffer from heart disease later in lifehttps://www.icr.ac.uk/news-archive%2fhigh-tech-radiotherapy-trial-seeks-to-reduce-treatment-timeshttps://www.icr.ac.uk/news-archive%2fhigh-tech-radiotherapy-trial-seeks-to-reduce-treatment-timesHigh-tech Radiotherapy Trial Seeks to Reduce Treatment Timeshttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-bring-cutting-edge-science-to-the-classroom-for-national-science-weekhttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-bring-cutting-edge-science-to-the-classroom-for-national-science-weekInstitute of Cancer Research Bring Cutting Edge Science to the Classroom for National Science Weekhttps://www.icr.ac.uk/news-archive%2fscientists-warn-smokers-that-giving-up-their-habit-will-reduce-their-risk-of-dying-of-cancer-by-60-per-centhttps://www.icr.ac.uk/news-archive%2fscientists-warn-smokers-that-giving-up-their-habit-will-reduce-their-risk-of-dying-of-cancer-by-60-per-centScientists warn smokers that giving up their habit will reduce their risk of dying of cancer by 60 per centhttps://www.icr.ac.uk/news-archive%2fnew-treatment-leads-to-dramatic-improvement-in-cure-rate-for-testicular-cancer-patientshttps://www.icr.ac.uk/news-archive%2fnew-treatment-leads-to-dramatic-improvement-in-cure-rate-for-testicular-cancer-patientsNew Treatment Leads To Dramatic Improvement In Cure Rate For Testicular Cancer Patientshttps://www.icr.ac.uk/news-archive%2finteractive-education-unit-website-updated-https://www.icr.ac.uk/news-archive%2finteractive-education-unit-website-updated-Interactive Education Unit Website Updated https://www.icr.ac.uk/news-archive%2fstars-get-funky-for-charityhttps://www.icr.ac.uk/news-archive%2fstars-get-funky-for-charityStars Get Funky For Charityhttps://www.icr.ac.uk/news-archive%2ffootballers-framed-to-help-tackle-testicular-cancerhttps://www.icr.ac.uk/news-archive%2ffootballers-framed-to-help-tackle-testicular-cancerFootballers Framed to Help Tackle Testicular Cancerhttps://www.icr.ac.uk/news-archive%2fresearchers-develop-method-to-predict-the-success-of-cancer-treatmentshttps://www.icr.ac.uk/news-archive%2fresearchers-develop-method-to-predict-the-success-of-cancer-treatmentsResearchers develop method to predict the success of cancer treatmentshttps://www.icr.ac.uk/news-archive%2fshirtless-celebrities-help-raise-funds-for-male-cancershttps://www.icr.ac.uk/news-archive%2fshirtless-celebrities-help-raise-funds-for-male-cancersShirtless Celebrities Help Raise Funds for Male Cancershttps://www.icr.ac.uk/news-archive%2fhrh-the-princess-royal-opens-new-cancer-research-centrehttps://www.icr.ac.uk/news-archive%2fhrh-the-princess-royal-opens-new-cancer-research-centreHRH The Princess Royal Opens New Cancer Research Centrehttps://www.icr.ac.uk/news-archive%2fhave-you-got-the-balls-to-join-in-https://www.icr.ac.uk/news-archive%2fhave-you-got-the-balls-to-join-in-Have You Got The Balls To Join In?https://www.icr.ac.uk/news-archive%2fexperts-from-the-institute-of-cancer-research-in-cutting-edge-venturehttps://www.icr.ac.uk/news-archive%2fexperts-from-the-institute-of-cancer-research-in-cutting-edge-ventureExperts from The Institute of Cancer Research in cutting edge venturehttps://www.icr.ac.uk/news-archive%2fchildhood-growth-in-girls-could-hold-key-to-identifying-risk-of-developing-cancerhttps://www.icr.ac.uk/news-archive%2fchildhood-growth-in-girls-could-hold-key-to-identifying-risk-of-developing-cancerChildhood growth in girls could hold key to identifying risk of developing cancerhttps://www.icr.ac.uk/news-archive%2fbreathlessness-cd-rom-wins-international-awardhttps://www.icr.ac.uk/news-archive%2fbreathlessness-cd-rom-wins-international-awardBreathlessness CD Rom Wins International Awardhttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-drug-shows-early-promisehttps://www.icr.ac.uk/news-archive%2fnew-breast-cancer-drug-shows-early-promiseNew Breast Cancer Drug Shows Early Promisehttps://www.icr.ac.uk/news-archive%2fmajor-advance-which-will-affect-future-of-cancer-drug-developmenthttps://www.icr.ac.uk/news-archive%2fmajor-advance-which-will-affect-future-of-cancer-drug-developmentMajor Advance Which Will Affect Future Of Cancer Drug Developmenthttps://www.icr.ac.uk/news-archive%2fnew-genetic-difference-link-to-prostate-cancer-developmenthttps://www.icr.ac.uk/news-archive%2fnew-genetic-difference-link-to-prostate-cancer-developmentNew Genetic Difference Link to Prostate Cancer Developmenthttps://www.icr.ac.uk/news-archive%2fbrookside-stars-blow-the-final-whistle-on-male-cancershttps://www.icr.ac.uk/news-archive%2fbrookside-stars-blow-the-final-whistle-on-male-cancersBrookside Stars Blow The Final Whistle On Male Cancershttps://www.icr.ac.uk/news-archive%2fmillwall-raise-thousands-for-charityhttps://www.icr.ac.uk/news-archive%2fmillwall-raise-thousands-for-charityMillwall Raise Thousands For Charityhttps://www.icr.ac.uk/news-archive%2fprostate-set-to-become-the-most-common-men%27s-cancer-within-three-yearshttps://www.icr.ac.uk/news-archive%2fprostate-set-to-become-the-most-common-men%27s-cancer-within-three-yearsProstate Set To Become The Most Common Men's Cancer Within Three Yearshttps://www.icr.ac.uk/news-archive%2ffrank-skinner-reveals-the-truth-about-male-cancershttps://www.icr.ac.uk/news-archive%2ffrank-skinner-reveals-the-truth-about-male-cancersFrank Skinner Reveals The Truth About Male Cancershttps://www.icr.ac.uk/news-archive%2fstars-step-out-in-the-male-cancer-awareness-badgehttps://www.icr.ac.uk/news-archive%2fstars-step-out-in-the-male-cancer-awareness-badgeStars Step Out In The Male Cancer Awareness Badgehttps://www.icr.ac.uk/news-archive%2feverton-footballers-line-up-to-tackle-male-cancershttps://www.icr.ac.uk/news-archive%2feverton-footballers-line-up-to-tackle-male-cancersEverton Footballers line-up to tackle Male Cancershttps://www.icr.ac.uk/news-archive%2fnew-research-to-study-health-effects-of-nuclear-weapons-testshttps://www.icr.ac.uk/news-archive%2fnew-research-to-study-health-effects-of-nuclear-weapons-testsNew Research to Study Health Effects of Nuclear Weapons Testshttps://www.icr.ac.uk/news-archive%2fdermot-o%27leary-drafted-up-in-the-fight-against-male-cancerhttps://www.icr.ac.uk/news-archive%2fdermot-o%27leary-drafted-up-in-the-fight-against-male-cancerDermot O'Leary drafted up in the fight against male cancerhttps://www.icr.ac.uk/news-archive%2fsmoking-linked-to-14-types-of-cancer-https://www.icr.ac.uk/news-archive%2fsmoking-linked-to-14-types-of-cancer-Smoking Linked to 14 Types of Cancer https://www.icr.ac.uk/news-archive%2fsven-calls-on-all-players-keep-your-eye-on-the-ball!-https://www.icr.ac.uk/news-archive%2fsven-calls-on-all-players-keep-your-eye-on-the-ball!-Sven Calls On All Players: "Keep Your Eye On The Ball!"https://www.icr.ac.uk/news-archive%2fclimbers-take-fundraising-to-new-heightshttps://www.icr.ac.uk/news-archive%2fclimbers-take-fundraising-to-new-heightsClimbers Take Fundraising To New Heightshttps://www.icr.ac.uk/news-archive%2finternational-study-gives-an-authoritative-view-on-health-risks-from-electricity-power-lineshttps://www.icr.ac.uk/news-archive%2finternational-study-gives-an-authoritative-view-on-health-risks-from-electricity-power-linesInternational Study Gives an authoritative view on Health Risks from Electricity Power Lineshttps://www.icr.ac.uk/news-archive%2fcelebrities-pull-on-their-pyjamas-in-aid-of-everymanhttps://www.icr.ac.uk/news-archive%2fcelebrities-pull-on-their-pyjamas-in-aid-of-everymanCelebrities pull on their pyjamas in aid of everymanhttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-announces-fellowships-for-2001https://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-announces-fellowships-for-2001The Institute of Cancer Research announces Fellowships for 2001https://www.icr.ac.uk/news-archive%2fmillwall-striker-goes-green-to-help-raise-funds-for-cancer-researchhttps://www.icr.ac.uk/news-archive%2fmillwall-striker-goes-green-to-help-raise-funds-for-cancer-researchMillwall Striker Goes Green To Help Raise Funds For Cancer Researchhttps://www.icr.ac.uk/news-archive%2finteractive-education-unit-launches-websitehttps://www.icr.ac.uk/news-archive%2finteractive-education-unit-launches-websiteInteractive Education Unit launches websitehttps://www.icr.ac.uk/news-archive%2fbowel-cancer-screening-success-in-the-falkland-islands-https://www.icr.ac.uk/news-archive%2fbowel-cancer-screening-success-in-the-falkland-islands-Bowel Cancer Screening Success in the Falkland Islands https://www.icr.ac.uk/news-archive%2fvanity-fair-gieves-hawkes-charity-auction-evening-https://www.icr.ac.uk/news-archive%2fvanity-fair-gieves-hawkes-charity-auction-evening-Vanity Fair / Gieves & Hawkes charity auction evening https://www.icr.ac.uk/news-archive%2fkeep-your-eye-on-the-ball!https://www.icr.ac.uk/news-archive%2fkeep-your-eye-on-the-ball!Keep your eye on the ball!https://www.icr.ac.uk/news-archive%2fpolicemen-take-to-the-streets-of-shrewsbury-in-aid-of-everymanhttps://www.icr.ac.uk/news-archive%2fpolicemen-take-to-the-streets-of-shrewsbury-in-aid-of-everymanPolicemen take to the streets of Shrewsbury in aid of everymanhttps://www.icr.ac.uk/news-archive%2fmet-commissioner-joins-everyman-as-he-leads-his-officers-into-battle-against-male-cancershttps://www.icr.ac.uk/news-archive%2fmet-commissioner-joins-everyman-as-he-leads-his-officers-into-battle-against-male-cancersMET Commissioner joins everyman as he leads his officers into battle against male cancershttps://www.icr.ac.uk/news-archive%2fnew-method-of-breast-cancer-diagnosis-will-eventually-help-thousandshttps://www.icr.ac.uk/news-archive%2fnew-method-of-breast-cancer-diagnosis-will-eventually-help-thousandsNew method of breast cancer diagnosis will eventually help thousandshttps://www.icr.ac.uk/news-archive%2ftopping-out-of-internationally-important-new-cancer-research-centrehttps://www.icr.ac.uk/news-archive%2ftopping-out-of-internationally-important-new-cancer-research-centreTopping-Out of Internationally Important New Cancer Research Centrehttps://www.icr.ac.uk/news-archive%2fhitting-the-right-target--new-drug-success-against-rare-tumourshttps://www.icr.ac.uk/news-archive%2fhitting-the-right-target--new-drug-success-against-rare-tumoursHitting The Right Target- New Drug Success Against Rare Tumourshttps://www.icr.ac.uk/news-archive%2factor-simon-callow-relieves-himself-for-everymanhttps://www.icr.ac.uk/news-archive%2factor-simon-callow-relieves-himself-for-everymanActor Simon Callow Relieves Himself for everymanhttps://www.icr.ac.uk/news-archive%2f%27they-think-its-all-over%27-ask-is-male-cancer-research-getting-the-attention-it-deserves-it-is-nowhttps://www.icr.ac.uk/news-archive%2f%27they-think-its-all-over%27-ask-is-male-cancer-research-getting-the-attention-it-deserves-it-is-now'They Think Its All Over' ask: "Is male cancer research getting the attention it deserves? It is nowhttps://www.icr.ac.uk/news-archive%2fjune-2001-everyman---male-cancer-awareness-monthhttps://www.icr.ac.uk/news-archive%2fjune-2001-everyman---male-cancer-awareness-monthJune 2001: everyman - male cancer awareness monthhttps://www.icr.ac.uk/news-archive%2fcelebrity-chefs-join-in-fight-against-male-cancershttps://www.icr.ac.uk/news-archive%2fcelebrity-chefs-join-in-fight-against-male-cancersCelebrity chefs join in fight against male cancershttps://www.icr.ac.uk/news-archive%2fyoung-men-prefer-to-suffer-in-silencehttps://www.icr.ac.uk/news-archive%2fyoung-men-prefer-to-suffer-in-silenceYoung men prefer to suffer in silencehttps://www.icr.ac.uk/news-archive%2foriginal-it-girl-tara-palmer-tomkinson-and-british-windsurfing-champion-tristan-boxford-support-the-everyman-campaignhttps://www.icr.ac.uk/news-archive%2foriginal-it-girl-tara-palmer-tomkinson-and-british-windsurfing-champion-tristan-boxford-support-the-everyman-campaignOriginal it girl, Tara Palmer-Tomkinson and British windsurfing champion, Tristan Boxford support the Everyman campaignhttps://www.icr.ac.uk/news-archive%2fmajor-new-male-nudes-exhibition-supports-fight-against-male-cancershttps://www.icr.ac.uk/news-archive%2fmajor-new-male-nudes-exhibition-supports-fight-against-male-cancersMajor New Male Nudes Exhibition Supports Fight Against Male Cancershttps://www.icr.ac.uk/news-archive%2finternational-footballers-get-their-pants-off-for-charity!https://www.icr.ac.uk/news-archive%2finternational-footballers-get-their-pants-off-for-charity!International Footballers get their pants off for charity!https://www.icr.ac.uk/news-archive%2fsex-smoking-and-cervical-cancerhttps://www.icr.ac.uk/news-archive%2fsex-smoking-and-cervical-cancerSex, Smoking and Cervical Cancerhttps://www.icr.ac.uk/news-archive%2fpioneering-medical-scanner-developed-for-cancer-detectionhttps://www.icr.ac.uk/news-archive%2fpioneering-medical-scanner-developed-for-cancer-detectionPioneering Medical Scanner Developed for Cancer Detectionhttps://www.icr.ac.uk/news-archive%2fevent-after-birth-major-factor-in-childhood-leukaemiahttps://www.icr.ac.uk/news-archive%2fevent-after-birth-major-factor-in-childhood-leukaemiaEvent After Birth Major Factor in Childhood Leukaemiahttps://www.icr.ac.uk/news-archive%2fwar-declared-on-%27undercover-cancer%27-dame-stella-rimington-and-bob-champion-open-europe%27s-first-dedicated-male-cancer-research-centrehttps://www.icr.ac.uk/news-archive%2fwar-declared-on-%27undercover-cancer%27-dame-stella-rimington-and-bob-champion-open-europe%27s-first-dedicated-male-cancer-research-centreWar Declared On 'Undercover Cancer' Dame Stella Rimington and Bob Champion open Europe's first dedicated Male Cancer Research Centrehttps://www.icr.ac.uk/news-archive%2fa-statement-from-the-institute-of-cancer-research-and-the-royal-marsden-nhs-trust-in-response-to-the-government%27s-nhs-cancer-planhttps://www.icr.ac.uk/news-archive%2fa-statement-from-the-institute-of-cancer-research-and-the-royal-marsden-nhs-trust-in-response-to-the-government%27s-nhs-cancer-planA Statement from The Institute of Cancer Research and The Royal Marsden NHS Trust in Response to the Government's NHS Cancer Planhttps://www.icr.ac.uk/news-archive%2fscreening-leads-to-reduction-in-breast-cancer-deathshttps://www.icr.ac.uk/news-archive%2fscreening-leads-to-reduction-in-breast-cancer-deathsScreening Leads to Reduction in Breast Cancer Deathshttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-government-announcement-of-extra-resources-for-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fstatement-in-response-to-the-government-announcement-of-extra-resources-for-prostate-cancerStatement in response to the government announcement of extra resources for prostate cancerhttps://www.icr.ac.uk/news-archive%2fclubbing-against-cancer---top-djs-help-fight-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fclubbing-against-cancer---top-djs-help-fight-testicular-cancerClubbing against cancer - top DJs help fight testicular cancerhttps://www.icr.ac.uk/news-archive%2fleading-expert-is-given-top-cancer-jobhttps://www.icr.ac.uk/news-archive%2fleading-expert-is-given-top-cancer-jobLeading Expert Is Given Top Cancer Jobhttps://www.icr.ac.uk/news-archive%2fjoint-response-to-the-science-technology-select-committee-enquiry-into-cancer-researchhttps://www.icr.ac.uk/news-archive%2fjoint-response-to-the-science-technology-select-committee-enquiry-into-cancer-researchJoint response to the Science & Technology Select Committee enquiry into cancer researchhttps://www.icr.ac.uk/news-archive%2fnew-high-precision-radiosurgery-developed-for-brain-tumourshttps://www.icr.ac.uk/news-archive%2fnew-high-precision-radiosurgery-developed-for-brain-tumoursNew High-Precision Radiosurgery Developed for Brain Tumourshttps://www.icr.ac.uk/news-archive%2ffootballers-put-prostate-cancer-awareness-into-the-premier-leaguehttps://www.icr.ac.uk/news-archive%2ffootballers-put-prostate-cancer-awareness-into-the-premier-leagueFootballers put prostate cancer awareness into the Premier Leaguehttps://www.icr.ac.uk/news-archive%2ffirst-survey-of-gps-proves-that-men-put-off-going-to-the-doctorhttps://www.icr.ac.uk/news-archive%2ffirst-survey-of-gps-proves-that-men-put-off-going-to-the-doctorFirst Survey of GPs Proves That Men Put Off Going to the Doctorhttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-builds-europe%27s-first-dedicated-male-cancer-research-centrehttps://www.icr.ac.uk/news-archive%2fthe-institute-of-cancer-research-builds-europe%27s-first-dedicated-male-cancer-research-centreThe Institute of Cancer Research Builds Europe's First Dedicated Male Cancer Research Centrehttps://www.icr.ac.uk/news-archive%2fdisfiguring-tumour-gene-discoveredhttps://www.icr.ac.uk/news-archive%2fdisfiguring-tumour-gene-discoveredDisfiguring Tumour Gene Discoveredhttps://www.icr.ac.uk/news-archive%2flord-lichfield-snaps-top-sports-stars-to-help-the-fight-against-male-cancershttps://www.icr.ac.uk/news-archive%2flord-lichfield-snaps-top-sports-stars-to-help-the-fight-against-male-cancersLord Lichfield snaps top sports stars to help the fight against male cancershttps://www.icr.ac.uk/news-archive%2feveryman-month---june-2000https://www.icr.ac.uk/news-archive%2feveryman-month---june-2000everyman month - June 2000https://www.icr.ac.uk/news-archive%2fnew-high-tech-radiotherapy-to-halt-the-spread-of-prostate-cancerhttps://www.icr.ac.uk/news-archive%2fnew-high-tech-radiotherapy-to-halt-the-spread-of-prostate-cancerNew High Tech Radiotherapy to Halt the Spread of Prostate Cancerhttps://www.icr.ac.uk/news-archive%2ffirst-gene-located-for-testicular-cancerhttps://www.icr.ac.uk/news-archive%2ffirst-gene-located-for-testicular-cancerFirst Gene Located for Testicular Cancerhttps://www.icr.ac.uk/news-archive%2fpublic-willing-to-support-cancer-charities-at-christmashttps://www.icr.ac.uk/news-archive%2fpublic-willing-to-support-cancer-charities-at-christmasPublic Willing to Support Cancer Charities at Christmashttps://www.icr.ac.uk/news-archive%2fmajor-new-cancer-labs-opened-by-hrh-the-prince-of-wales-and-public-say-cancer-research-is-top-priorityhttps://www.icr.ac.uk/news-archive%2fmajor-new-cancer-labs-opened-by-hrh-the-prince-of-wales-and-public-say-cancer-research-is-top-priorityMajor New Cancer Labs Opened by HRH The Prince of Wales and Public Say Cancer Research is Top Priorityhttps://www.icr.ac.uk/news-archive%2fnew-drug-developed-to-block-cancer-geneshttps://www.icr.ac.uk/news-archive%2fnew-drug-developed-to-block-cancer-genesNew Drug Developed to Block Cancer Geneshttps://www.icr.ac.uk/news-archive%2f-20-million-invested-by-the-institute-of-cancer-research-and-the-public-say-cancer-is-top-priorityhttps://www.icr.ac.uk/news-archive%2f-20-million-invested-by-the-institute-of-cancer-research-and-the-public-say-cancer-is-top-priority£20 Million Invested by the Institute of Cancer Research and the Public Say Cancer is Top Priorityhttps://www.icr.ac.uk/news-archive%2fpose-in-your-pants-and-help-the-fight-against-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fpose-in-your-pants-and-help-the-fight-against-testicular-cancerPose in your pants and help the fight against testicular cancerhttps://www.icr.ac.uk/news-archive%2ffirst-steps-to-childhood-leukaemia-occur-in-the-wombhttps://www.icr.ac.uk/news-archive%2ffirst-steps-to-childhood-leukaemia-occur-in-the-wombFirst steps to childhood leukaemia occur in the wombhttps://www.icr.ac.uk/news-archive%2fcancer-genome-project-revolutionises-search-for-cancer-geneshttps://www.icr.ac.uk/news-archive%2fcancer-genome-project-revolutionises-search-for-cancer-genesCancer Genome Project Revolutionises Search for Cancer Geneshttps://www.icr.ac.uk/news-archive%2fnew-test-predicts-how-breast-cancer-patients-will-respond-to-treatmenthttps://www.icr.ac.uk/news-archive%2fnew-test-predicts-how-breast-cancer-patients-will-respond-to-treatmentNew Test Predicts How Breast Cancer Patients Will Respond to Treatmenthttps://www.icr.ac.uk/news-archive%2fgene-therapy-offers-new-hope-in-the-treatment-of-brain-tumourshttps://www.icr.ac.uk/news-archive%2fgene-therapy-offers-new-hope-in-the-treatment-of-brain-tumoursGene Therapy Offers New Hope in the Treatment of Brain Tumourshttps://www.icr.ac.uk/news-archive%2frobbie-williams%27-debut-commercial-raises-awareness-of-testicular-cancerhttps://www.icr.ac.uk/news-archive%2frobbie-williams%27-debut-commercial-raises-awareness-of-testicular-cancerRobbie Williams' Debut Commercial Raises Awareness of Testicular Cancerhttps://www.icr.ac.uk/news-archive%2fmale-cancer-campaign-invites-sons-and-daughters-to-send-an-e-card-this-father%27s-dayhttps://www.icr.ac.uk/news-archive%2fmale-cancer-campaign-invites-sons-and-daughters-to-send-an-e-card-this-father%27s-dayMale Cancer Campaign Invites Sons and Daughters to Send an E-Card This Father's Dayhttps://www.icr.ac.uk/news-archive%2fadvertising-campaign-for-testicular-cancerhttps://www.icr.ac.uk/news-archive%2fadvertising-campaign-for-testicular-cancerAdvertising Campaign for Testicular Cancerhttps://www.icr.ac.uk/news-archive%2fmen-don%27t-talk-to-each-other-about-their-healthhttps://www.icr.ac.uk/news-archive%2fmen-don%27t-talk-to-each-other-about-their-healthMen don't talk to each other about their healthhttps://www.icr.ac.uk/news-archive%2fit%27s-small-it%27s-rubber-and-it-aims-to-save-lives-https://www.icr.ac.uk/news-archive%2fit%27s-small-it%27s-rubber-and-it-aims-to-save-lives-It's Small, It's Rubber and It Aims to Save Lives https://www.icr.ac.uk/news-archive%2fnurses-develop-treatment-for-breathlessnesshttps://www.icr.ac.uk/news-archive%2fnurses-develop-treatment-for-breathlessnessNurses Develop Treatment for Breathlessnesshttps://www.icr.ac.uk/news-archive%2fcancer-chip-revolutionises-search-for-cancer-genes-https://www.icr.ac.uk/news-archive%2fcancer-chip-revolutionises-search-for-cancer-genes-Cancer Chip Revolutionises Search for Cancer Genes https://www.icr.ac.uk/news-archive%2fprince-of-wales-accepts-patron%27s-role-for-gala-concert-in-aid-of-male-cancer-researchhttps://www.icr.ac.uk/news-archive%2fprince-of-wales-accepts-patron%27s-role-for-gala-concert-in-aid-of-male-cancer-researchPrince of Wales Accepts Patron's Role for Gala Concert in Aid of Male Cancer Researchhttps://www.icr.ac.uk/news-archive%2fleading-musician-uses-testicular-cancer-experience-to-raise-funding-and-awarenesshttps://www.icr.ac.uk/news-archive%2fleading-musician-uses-testicular-cancer-experience-to-raise-funding-and-awarenessLeading Musician Uses Testicular Cancer Experience to Raise Funding and Awarenesshttps://www.icr.ac.uk/news-archive%2fcancer-victim-tackles-britain%27s-longest-pathhttps://www.icr.ac.uk/news-archive%2fcancer-victim-tackles-britain%27s-longest-pathCancer victim tackles Britain's longest pathhttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-appoints-a-new-chief-executivehttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-appoints-a-new-chief-executiveInstitute of Cancer Research Appoints A New Chief Executivehttps://www.icr.ac.uk/news-archive%2fhollyoaks-actors-lend-support-to-testicular-cancer-campaignhttps://www.icr.ac.uk/news-archive%2fhollyoaks-actors-lend-support-to-testicular-cancer-campaignHollyoaks Actors Lend Support to Testicular Cancer Campaignhttps://www.icr.ac.uk/news-archive%2fcancer-nursing-centre-secures-5-years-fundinghttps://www.icr.ac.uk/news-archive%2fcancer-nursing-centre-secures-5-years-fundingCancer nursing centre secures 5 years fundinghttps://www.icr.ac.uk/news-archive%2fcancer-nurses-take-part-in-unique-theatrical-experiencehttps://www.icr.ac.uk/news-archive%2fcancer-nurses-take-part-in-unique-theatrical-experienceCancer nurses take part in unique theatrical experiencehttps://www.icr.ac.uk/news-archive%2fmps-to-address-concerns-about-male-cancershttps://www.icr.ac.uk/news-archive%2fmps-to-address-concerns-about-male-cancersMPs to Address Concerns About Male Cancershttps://www.icr.ac.uk/news-archive%2fmen-take-part-in-aerobathon-for-male-cancer-weekhttps://www.icr.ac.uk/news-archive%2fmen-take-part-in-aerobathon-for-male-cancer-weekMen Take Part In Aerobathon For Male Cancer Weekhttps://www.icr.ac.uk/news-archive%2fcarcinogens-in-healthy-breast-tissue-damage-dna-https://www.icr.ac.uk/news-archive%2fcarcinogens-in-healthy-breast-tissue-damage-dna-Carcinogens in Healthy Breast Tissue Damage DNA https://www.icr.ac.uk/news-archive%2fcity-event-reinforces-serious-message-of-everyman-male-cancer-awareness-monthhttps://www.icr.ac.uk/news-archive%2fcity-event-reinforces-serious-message-of-everyman-male-cancer-awareness-monthCity Event Reinforces Serious Message of everyman male cancer awareness monthhttps://www.icr.ac.uk/news-archive%2ffirst-everyman-male-cancer-awareness-monthhttps://www.icr.ac.uk/news-archive%2ffirst-everyman-male-cancer-awareness-monthFirst everyman Male Cancer Awareness Monthhttps://www.icr.ac.uk/news-archive%2fresearch-shows-men-are-still-dangerously-ignorant-about-male-cancershttps://www.icr.ac.uk/news-archive%2fresearch-shows-men-are-still-dangerously-ignorant-about-male-cancersResearch shows men are still dangerously ignorant about male cancershttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-opens-new-fulham-road-labshttps://www.icr.ac.uk/news-archive%2finstitute-of-cancer-research-opens-new-fulham-road-labsInstitute of Cancer Research opens new Fulham Road Labshttps://www.icr.ac.uk/news-archive%2fleading-sociologist-joins-palliative-care-centrehttps://www.icr.ac.uk/news-archive%2fleading-sociologist-joins-palliative-care-centreLeading Sociologist Joins Palliative Care Centre